We help the world breathe®
PULMONARY • CRITICAL CARE • SLEEP

ATS Review for the PULMONARY BOARDS

- Concise topic summaries ideal for quick review
- Hundreds of color images and tables that enhance study
- Key facts and mnemonics for easy memorization
- Embedded flashcards to test critical concepts

TAO **LE**
SUNNY **KHOSA**
SUSAN **PASNICK**
TISHA **WANG**

ATS Review for the **PULMONARY BOARDS**

TAO LE, MD, MHS
Associate Clinical Professor of Medicine and Pediatrics
Chief, Section of Allergy and Immunology
Department of Medicine
University of Louisville School of Medicine, Kentucky

SANDEEP KHOSA, MD
Consultant
Division of Pulmonary and Critical Care Medicine
Mayo Clinic Health System
Mankato, Minnesota

SUSAN PASNICK, MD
Clinical Instructor
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine
Department of Medicine
University of California, San Francisco

TISHA WANG, MD
Assistant Clinical Professor
Associate Chief of Inpatient Services
Fellowship Program Director
Division of Pulmonary, Critical Care, and Sleep Medicine
Department of Medicine
Ronald Reagan UCLA Medical Center, Los Angeles

American Thoracic Society
New York

ATS Review for the Pulmonary Boards, First Edition

Copyright © 2015 by American Thoracic Society. All rights reserved.

Notice

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

DEDICATION

To our families, friends, and loved ones, who encouraged and assisted us in the task of assembling this guide.

CONTENTS

Contributing Authors viii

Senior Reviewers x

Preface xii

Acknowledgements xiii

How to Contribute xiv

Chapter 1. Sleep Medicine and Neuromuscular/Skeletal Disorders 1

Sharon De Cruz, MD & Wajahat Khan, MD

Respiratory Sleep Medicine
Nonrespiratory Sleep Disorders
Neuromuscular Disorders and Diseases of the Chest Wall

Chapter 2. Critical Care 47

Anthony F. Arredondo, MD, Stephanie Young Clough, MD, Nandita R. Nadig MD, & Diana H. Yu, MD

Non-lung Critical Care
Lung Critical Care

Chapter 3. Obstructive Lung Disease 131

Nidhi Aggarwal MD, Anthony F. Arredondo, MD, & Abhay Vakil, MBBS

Asthma
COPD Basic Science
Comparison of Asthma and COPD
COPD
Bronchiectasis
Primary Ciliary Dyskinesia
Cystic Fibrosis

Chapter 4. Diffuse Parenchymal Lung Disease 221

Puneet S. Garcha, MD, Sachin Gupta, MD, & Carlos E. Kummerfeldt, MD

Interstitial Lung Disease
Sarcoidosis
Pulmonary Alveolar Proteinosis
Pulmonary Amyloidosis
Birt-Hogg-Dube
Lipoid Pneumonia
Drug-Induced Lung Disease
Occupational and Environmental Lung Disease

Chapter 5. Quality, Safety, and Ethics 305

Diana H. Yu, MD

Ethical Considerations in Pulmonary and Critical Care Medicine
Principles of Medical Ethics
Quality Improvement/Patient Care
Staffing Issues
Physician Well-Being/Impairment

Chapter 6. Epidemiology and Statistics 313

Nazir Ahmad Lone MD MPH

Epidemiology
Biostatistics
Data Distribution and Type of Variables

Chapter 7. Anatomy and Physiology of the Respiratory System 337

Muhammad Nouman Iqbal MD & Sandeep Khosa, MD

Structure and Functional Relationships of the Lung
Pulmonary Gas Exchange
Lung Mechanics and Lung Volumes
Respiratory Control
Acid-Base Disorders

Chapter 8. Common Respiratory Symptoms, Pulmonary Imaging, and Procedures 355

Stephanie Young Clough, MD

Common Respiratory Symptoms
Pulmonary Imaging
Procedures

Chapter 9. Lung Transplantation 395

Tessy Paul, MD

Indications and Patient Selection
Pretransplant Evaluation
Donor Selection and Organ Allocation
Transplant Immunosuppression
Complications after Transplantation
Outcome of Lung Transplantation

Chapter 10. Pulmonary Vascular Diseases 415

Jeffrey Albores, MD, Sachin Gupta, MD, Tessy Paul, MD, & Sandeep Sahay, MD

Pulmonary Vasculitis and Alveolar Hemorrhage Syndromes
Venous Thromboembolism
Pulmonary Hypertension
Other Pulmonary Vascular Disease

Chapter 11. Infections 457

Ariffin Alam, MD, Sugeet K. Jagpal, MD, Jimmy Johannes, MD, & Naresh Nagella, MD

Bronchial and Bronchiolar Infections
Fungal Infections
HIV
Lung Abscess
Mycobacterium tuberculosis
Pneumonia
Nosocomial Pneumonia
Nontuberculous Mycobacteria

Chapter 12. Lung Neoplasms **515**

Sujith V Cherian MD & Fayez Kheir, MD, MSCR

Introduction
Benign Lung Neoplasms
Malignant Lung Neoplasms
Techniques for Diagnosis and Staging
Mediastinal Neoplasms
Metastatic Lung Tumors
Lung Nodules
Paraneoplastic Syndromes
Pleural Neoplasms
Preoperative Assessment

Chapter 13. Pleural Disease **565**

Jeffrey Albores, MD

Pleural Effusion
Pleural Asbestosis
Pleural Other
Pneumothorax

About the Editors **593**

CONTRIBUTING AUTHORS

Nidhi Aggarwal, MD
Department of Internal Medicine, Division of Pulmonary and Critical Care, Maimonides Medical Center, New York

Ariffin Alam, MD
Fellow, Clinical Instructor, University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Cincinnati

Jeffrey Albores, MD
Pulmonary Critical Care Fellow, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Anthony F. Arredondo, MD
Pulmonary Critical Care Fellow, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Sujith V. Cherian, MD
Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas Health Science Center at Houston

Stephanie Young Clough, MD
Pulmonary and Critical Care Fellow, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland

Sharon De Cruz, MD
Clinical Instructor, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Puneet S. Garcha, MD
Associate Staff Physician, Respiratory Institute, Cleveland Clinic Foundation

Sachin Gupta, MD
Fellow, Department of Medicine, Division of Pulmonary and Critical Care Medicine, UT Southwestern, Dallas, Texas

Muhammad Nouman Iqbal, MD
Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland

Sugeet K. Jagpal, MD
Fellow, Pulmonary and Critical Care Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey

Jimmy Johannes, MD
Pulmonary Critical Care Fellow, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Wajahat Khan, MD
Fellow, Sleep Medicine, Division of Sleep Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

Fayez Kheir, MD, MSCR
Assistant Professor of Medicine, Department of Medicine, Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Tulane University, New Orleans

Carlos E. Kummerfeldt, MD
Pulmonary and Critical Care Fellow, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Medical University of South Carolina, Charleston

Nazir Ahmad Lone MD MPH
Pulmonary Critical Care Fellow, Department of Medicine, Division of Pulmonary, Critical Care and Environmental Medicine, University of Missouri, Columbia

Nandita R. Nadig MD
Clinical instructor, Department of Medicine, Division of Pulmonary and Critical care Medicine, Medical University of South Carolina, Charleston

Naresh Nagella, MD
Fellow, Pulmonary and Critical Care Medicine, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School New Brunswick, New Jersey

Tessy Paul, MD
Pulmonary Critical Care Fellow, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Sandeep Sahay, MD
Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas, Health Science Center at Houston

Abhay Vakil, MBBS
Pulmonary Fellow, Department of Internal Medicine, Division of Pulmonary Medicine, Jamaica Hospital Medical Center, New York

Diana H. Yu, MD
Pulmonary and Critical Care Fellow, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles Medical Center

SENIOR REVIEWERS

Diwakar D. Balachandran, MD
Associate Professor, Department of Pulmonary Medicine, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston

Igor Barjaktarevic, MD
Assistant Clinical Professor, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Tanaya Bhowmick, MD
Assistant Professor, Department of Medicine Division of Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

Charles R. Cantor, MD
Professor of Clinical Neurology, Associate Professor of Medicine, Perelman School of Medicine at the University of Pennsylvania; Medical Director, Penn Sleep Centers, Center for Sleep and Circadian Neurobiology, Philadelphia

Marina Duran Castillo, MD
Assistant Professor of Medicine, Case Western Reserve University, MetroHealth Medical Center Cleveland

Steven Chang, MD, PhD
Associate Clinical Professor, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Ousama Dabbagh, MD, MS
Staff Physician, Blount Memorial Hospital, Maryville, Tennessee; Adjunct Associate Professor of Clinical Medicine, Pulmonary, Critical Care and Environmental Medicine, University of Missouri, Columbia

Ariss Derhovanessian, MD
Assistant Professor, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Alan Fein, MD
Clinical Professor of Medicine, Hofstra Northshore-LIJ School of Medicine, Hempstead, New York; Associate Program Director of Pulmonary Medicine, Jamaica Hospital Medical Center, New York

Dee W. Ford, MD, MSCR
Associate Professor of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine; Medical Director, Medical Intensive Care Unit, Medical University of South Carolina, Charleston

John T. Huggins, MD
Associate Professor, Department of Medicine, Division of Pulmonary and Critical Care, Medical University of South Carolina, Charleston

Sabiha Hussain, MD
Assistant Professor, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey

Thanh Huynh, MD
Clinical Instructor, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Ronald Reagan UCLA Medical Center, Los Angeles

Corey Kershaw, MD
Associate Professor, Department of Internal Medicine, UT Southwestern Medical Center, Dallas

Yizhak Kupfer, MD
Clinical Professor of Medicine, Albert Einstein School of Medicine; Program Director, Division of Critical Care Medicine, Maimonides Medical Center; Associate Director, Division of Pulmonary Medicine, Maimonides Medical Center, Brooklyn, New York

Peter Lenz, MD
Assistant Professor, Fellowship Program Director of Pulmonary and Critical Care Medicine, University of Cincinnati Medical Center

Yuji Oba, MD
Associate Professor, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Missouri School of Medicine, Columbia

Scott Oh, DO, FCCP
Assistant Clinical Professor, Division of Pulmonary and Critical Care Medicine David Geffen School of Medicine at UCLA, Los Angeles

Jaime Palomino, MD
Assistant Professor, Director Pulmonary Diseases/Critical Care Medicine Fellowship Program, Tulane University, New Orleans

Joseph Parambil, MD
Staff Physician, Respiratory Institute, Cleveland Clinic

Silverio Santiago, MD
Director, Division of Pulmonary, Critical Care, and Sleep Medicine, VA Greater Los Angeles Area Medical Center

Ziad S. Shaman, MD, RDMS
Assistant Professor, Case Western Reserve University, Cleveland; Program Director, Pulm/CCM Fellowship, MetroHealth Medical Center

Donald Tashkin, MD
Emeritus Professor of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles

J. Daryl Thornton, MD, MPH
Associate Professor of Medicine, Case Western Reserve University; Director, Medical Intensive Care Unit; Researcher, Center for Reducing Health Disparities, MetroHealth Medical Center, Cleveland

Adriano Tonelli, MD
Staff Physician, Respiratory Institute, Cleveland Clinic

Edward Warren, MD
Associate Professor of Medicine, Director, and Vice Chair, Department of Internal Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland

PREFACE

With this first edition of *ATS Review for the Pulmonary Boards,* we attempt to provide fellows-in-training and pulmonologists with the most high-yield and up-to-date preparation guide for the ABIM Pulmonary Disease Certification exam. This text was written like other publications in the *First Aid* board review series and is designed to fill the need for a high-quality, in-depth, conceptually driven study guide for ABIM Pulmonary Disease Certification exam preparation. This resource is designed to be used either alone, or in conjunction with other texts.

This book would not have been possible without the help of the many fellows-in-training, physicians, and faculty members who contributed their feedback and suggestions. We invite you to share your thoughts and ideas to help us improve *ATS Review for the Pulmonary Boards,* (see How to Contribute, p. xiv.)

Tao Le, MD, MHS
Louisville, Kentucky

Sandeep (Sunny) Khosa, MD
Mankato, Minnesota

Susan Pasnick, MD
San Francisco

Tisha Wang, MD
Los Angeles

ACKNOWLEDGMENTS

This has been a collaborative project from the start. We gratefully acknowledge the thoughtful comments and advice of the fellows-in-training, pulmonologists, and faculty who have supported the authors in the development of *ATS Review for the Pulmonary Boards.*

Thanks to the American Thoracic Society for their support and the funding necessary to undertake this project. In particular, we would like to thank Eileen Larsson and Jennifer Siegel-Gasiewski for their encouragement, organizational assistance, and guidance throughout this process. We thank Drs. Vikas Bhatara and John C. Williams for their contributions to the text. We also thank Drs. Ariss Derhovanessian, David Ross, and John Belperio for their image contributions. For outstanding editorial work, we thank Karla Schroeder, Linda Bradford, Susan Brownstein, and Isabel Nogueira. We thank Louise Petersen for her project editorial support. A special thanks to Thomson Digital for their excellent illustration work.

Tao Le, MD, MHS
Louisville, Kentucky

Sandeep (Sunny) Khosa, MD
Mankato, Minnesota

Susan Pasnick, MD
San Francisco

Tisha Wang, MD
Los Angeles

HOW TO CONTRIBUTE

To continue to produce a current review source for the ABIM Pulmonary Disease Certification exam, you are invited to submit any suggestions or corrections. Please send us your suggestions for:

- Study and test-taking strategies
- New facts, mnemonics, diagrams, and illustrations
- Relevant topics that are likely to be tested in the future

For each entry incorporated into the next edition, you will receive a personal acknowledgment in the next edition. Also let us know about material in this edition that you feel is low yield and should be deleted.

The preferred way to submit entries, suggestions, or corrections is via our email address:

education@thoracic.org

NOTE TO CONTRIBUTORS

All submissions become property of the ATS and are subject to editing and reviewing. Please verify all data and spellings carefully. Include a reference to a standard textbook to facilitate verification of the fact. Please follow the style, punctuation, and format of this edition if possible.

1 Sleep Medicine and Neuromuscular/Skeletal Disorders

Sharon De Cruz, MD & Wajahat Khan, MD

RESPIRATORY SLEEP MEDICINE

SLEEP PHYSIOLOGY

Review of the physiologic changes that occur during sleep.

Regulation of Sleep and Wake

Sleep latency, quality and duration of sleep, and alertness are regulated by two components (sleep homeostasis and circadian rhythm) with a third process (sleep inertia) responsible for the transitional period of relative confusion between sleep and wake.

SLEEP HOMEOSTASIS—Dependent on the sleep–wake cycle.

- Sleep pressure increases as the duration of wakefulness increases and declines after sufficient sleep.
- Constant sleep throughout the sleep period is maintained because of a falling circadian alertness opposing any decrease in homeostatic sleep drive.

CIRCADIAN SYSTEM—Biologic alerting rhythm that consists of one oscillation every 24.2 hours (called "tau").

- Independent of sleep–wake cycle
- Entrainment of the circadian system occurs when environmental cues called zeitgebers; zeitgebers synchronize the circadian rhythm to the external 24-hour period, and can be photic (light) or nonphotic (eating times).
- Constant alertness throughout the waking period occurs because of rising circadian alertness opposing an increase in homeostatic sleep pressure.

SLEEP INERTIA—Refers to the cognitive impairment present immediately on awakening from sleep.

- Most pronounced in the first 15–30 minutes after wakening.
- May be relevant in occupations involving shift work (i.e., physicians being awakened by a page).

Flash Card Q1

What is the most powerful zeitgeber entraining the sleep–wake rhythm?

Flash Card Q2

What structure in the brain acts as the master circadian rhythm generator in mammals, and where is it located?

Suprachiasmatic nucleus is master circadian rhythm generator in mammals located in the anterior hypothalamus:

- Activity greatest during daytime
- Promotes wake during the day, and consolidates sleep at night
- Two circadian peaks of alertness—late morning and early evening
- Two circadian troughs of alertness—early morning and early afternoon
- Main afferent connection is the retinohypothalamic tract, which is most sensitive to blue–blue-green wavelength light
- Ablation of the suprachiasmatic nucleus causes sleep to be randomly distributed throughout the day and night, and it leads to a decrease in wake period duration

Neurotransmitters in Sleep and Wake

Sleep and wake cycles are generated and regulated by central nervous system (CNS) networks that exist in specific areas of the brain using specific neurotransmitters (Table 1-1).

Table 1-1. Neurotransmitters Responsible for Sleep and Wake

Sleep Neurotransmitters	Clinical Associations
GABA	Major CNS inhibitory neurotransmitter Example: Benzodiazepines, alcohol (see below)
Glutamate	Major CNS excitatory neurotransmitter Example: Alcohol is a GABA agonist and inhibits glutamate; high doses are sedating, but suppress REM sleep
Serotonin	Major CNS excitatory neurotransmitter Activity increases during wake and decreases during sleep
Norepinephrine	Major CNS excitatory neurotransmitter Activity increases during wake and decreases during sleep
Dopamine	Agonists promote wakefulness Haldol is an antagonist Example: Amphetamines (agonists)
Histamine	First-generation receptor antagonists promote sleep Example: Diphenhydramine
Acetylcholine	REM sleep neurotransmitter
Hypocretin	Hypocretin deficiency results in narcolepsy with cataplexy
Adenosine	Decrease in adenosine activity promotes wakefulness Example: Caffeine blocks adenosine receptors

GABA, gamma-aminobutyric acid; CNS, central nervous system; REM sleep, rapid eye movement sleep

Key Fact

Stimulants such as amphetamines and modafinil promote wakefulness by increasing excitatory neurotransmitters (norepinephrine, dopamine, and hypocretin).

Flash Card A1

Light

Flash Card A2

Suprachiasmatic nucleus; anterior hypothalamus

MELATONIN—Synthesized and released by the pineal gland, it influences circadian sleep–wake rhythms, and as such, secretion is greatest at night. Melatonin secretion is inhibited by light exposure.
Actions of melatonin:

- Causes phase advance circadian sleep–wake rhythm when given in early evening
- Causes phase delay circadian sleep–wake rhythm when given in early morning
- Less effective than light exposure in shifting of circadian rhythms

Key Fact

Caffeine increases wakefulness by blocking the receptors of adenosine, a CNS neurotransmitter.

Physiologic Changes During Sleep

Sleep has a significant effect on many organ systems and physiologic processes in the body (Table 1-2).

Sleep Deprivation

Sleep deprivation can affect cognition and performance.

PHYSIOLOGIC EFFECTS OF SLEEP DEPRIVATION

- ↑sleepiness, sympathetic activity, cortisol and ghrelin hormones, insulin resistance, medical errors, and motor vehicle accidents
- ↓cognition, seizure threshold, growth hormone, leptin activity, resistance to infection, and response to vaccines

Table 1-2. Physiologic Processes During Sleep

System	Physiologic Processes
Autonomic nervous system	During NREM sleep compared to wake: ↓sympathetic activity ↑parasympathetic activity
Respiratory system	Compared to wake: ↓Pa_{O_2}, ↓Sa_{O_2}, ↑Pa_{CO_2} ↓during NREM sleep ↓V_T↔RR, ↓minute ventilation During REM sleep: ↓↓UA dilator muscle tone Diaphragm activity remains intact Irregular respirations
Cardiovascular system	NREM sleep compared to wake: ↓HR, ↓CO, ↓BP REM sleep compared to NREM sleep and wake: ↑HR, ↑CO, ↑BP
Renal	Decrease in urine output: ↑water reabsorption, renin, ADH ↓GFR

Flash Card Q3

Which neurotransmitter is responsible for rapid eye movement sleep generation?

Flash Card Q4

When is melatonin secreted? What is its function?

Flash Card Q5

A 19-year-old woman sleeps from 3 am until 11 am daily. She starts college in 1 month and has 7 am classes. What circadian rhythm sleep disorder does she have? When would you give her melatonin?

Flash Card Q6

A 76-year-old man sleeps from 7 pm until 4 am once a day. He wants to join his local Bingo group that meets at 8 pm, and he would like to stay up longer at night. What circadian rhythm sleep disorder does he have, and when would you give him melatonin to treat it?

Table 1-2. Physiologic Processes During Sleep, cont.

System	Physiologic Processes
Endocrine	Increasing levels during sleep: GH, prolactin, parathyroid hormone, testosterone Decreasing levels during sleep: Cortisol, insulin, TSH
Immune system	Proinflammatory cytokines (↑sleepiness): ↑IL-1β, ↑TNFα Anti-inflammatory cytokines (↓sleepiness): ↑IL-4, ↑IL-10
Thermoregulation	Core body temperature: Peaks early evening (6–8 pm) Falls at onset of sleep Nadir is 2 hours prior to usual wake time (4–5 am) Sleep occurs during falling phase of temperature rhythm, and wake occurs during rising phase of temperature rhythm

ADH, antidiuretic hormone; BP, blood pressure; CO, cardiac output; GFR, glomerular filtration rate; GH, growth hormone; HR, heart rate; IL-1β, interleukin 1β; IL-4, interleukin 4; IL-10, interleukin 10; NREM, non-rapid eye movement; $PaCO_2$, partial pressure of carbon dioxide in blood; PaO_2, partial pressure of oxygen in blood; REM, rapid eye movement; SaO_2, saturation level of oxygen in hemoglobin; TNFα, tumor necrosis factor alpha; TSH, thyroid-stimulating hormone; V_T, tidal volume; RR, respiratory rate; UA, upper airway

Key Fact

Ghrelin stimulates appetite, and leptin inhibits appetite.
Ghrelin = **G**row
Leptin = **L**ean

POLYSOMNOGRAPHY (PSG)

Flash Card A3

Acetylcholine

Records physiologic variables during sleep using electroencephalography/-gram (EEG), electrooculography/-gram (EOG), chin electromyography/-gram (EMG), electrocardiography/-gram (ECG), oxygenation, snoring, respiratory effort, and leg (anterior tibialis) EMG (Figure 1-1).

Indications for PSG

Flash Card A4

Secreted at night; promotes sleep by causing drowsiness and lowering body temperature (think of melatonin as the darkness signal.)

Flash Card A5

She has a delayed sleep phase disorder; should receive melatonin early in the night to help her fall asleep earlier.

Flash Card A6

He has advanced sleep phase disorder, and he should receive melatonin in the early morning, after being cautioned that melatonin can cause drowsiness

PSG is used for:

- Diagnosis of sleep-disordered breathing (SDB)
- Testing efficacy after treatment for SDB with oral appliances or upper airway (UA) surgery
- Positive airway pressure (PAP) titration
- Diagnosis of nonrespiratory sleep disorders:
  - Periodic limb movement disorders (PLMDs)
  - Narcolepsy
  - Parasomnias
  - Nocturnal seizures
  - Rapid eye movement (REM) sleep behavior disorder


Sensor at nose to measure air flow
Sensors on face and scalp measure eye movement and brain activity
Wires transmit data to a computer. A technician in a nearby room monitors the data.
Elastic belt sensors around chest and belly measure amount of effort to breath
Sensor on finger measures amount of oxygen in blood

Figure 1-1. Polysomnography setup where patient lies in bed with EEG, EOG, chin EMG, ECG, airflow, oxygenation, snoring, respiratory effort, and leg EMG (some not pictured).
(Reproduced courtesy of the National Institutes of Health, Department of Health and Human Services.)

EEG Wave Frequencies

- Beta waves (Figure 1-2A): Alert and awake (> 13 Hz)
- Alpha waves (Figure 1-2B): Drowsy with eyes closed (8–13 Hz)
- Theta waves (Figure 1-2C): Characteristic of N1 and N2 sleep and REM sleep (4–7 Hz)
- Delta waves (Figure 1-2D): Characteristic of N3 sleep (< 4 Hz)

Flash Card Q7

What is/are the effect(s) of REM sleep compared to NREM sleep on the autonomic nervous system?

Flash Card Q8

How are hormones ghrelin and leptin affected by sleep deprivation?



Figure 1-2. One-second sample EEG tracings showing (A) beta, (B) alpha, (C) theta, and (D) delta waves.
(Reproduced courtesy of Hugo Gamboa, Wikimedia Commons, CC BY-SA 3.0.)

EEG WAVEFORMS—Important in the staging of sleep.

- Vertex waves:
  - Sharp negative waves in the theta range frequency
  - Usually occurs during latter part of sleep stage 1
- K-complex (Figure 1-5):
  - Sharp negative wave, followed by slower positive component
  - Usually seen in sleep stage 2
  - Premature ventricular contraction (PVC) waveforms of the EEG
- Sleep spindles (Figure 1-5):
  - Short rhythmic waveform clusters in the 12–14 Hz frequency range

Flash Card A7

A transient increase in sympathetic activity during phasic REM sleep

Flash Card A8

Ghrelin increases, and leptin decreases

  - Characteristic of sleep stage 2
- Sawtooth waves (Figure 1-7):
  - Low amplitude with notched/sawtooth appearance
  - Characteristic of REM sleep

Wake and Stages of Sleep

WAKE (Figure 1-3)

- > 50% of an epoch has alpha rhythm when eyes are closed
- Chin EMG tone is high
- Presence of any of the following, in the absence of alpha waves:
  - Fast eye movements and eye blinks when eyes open
  - Low voltage, mixed frequency pattern



Figure 1-3. PSG showing wake state. Alpha rhythm with frequency 8−13 Hz occupies > 50% of epoch *(red arrow)*; high chin EMG tone characteristic of wake state *(black arrow)*.

NREM SLEEP (Figures 1-4, 1-5, and 1-6)

- Sleep stage N1:
  - Alpha activity diminished or disappeared
  - Low amplitude, mixed frequency (4–7 Hz) waves that occupy > 50% of the epoch
  - Slow rolling eye movements
  - Vertex waves may be present
  - Chin EMG levels lower than stage wake
- Sleep stage N2:
  - Low amplitude, mixed frequency waves

- Presence of K-complexes and/or sleep spindles
- Sleep stage N3:
  - ≥ 20% of epoch occupied by low frequency, high amplitude delta waves (0.5–2 Hz and > 75 μV)



Figure 1-4. PSG showing NREM sleep stage N1. Slow rolling eye movements *(red arrow)*; chin EMG has decreased compared to wake stage *(green arrow)*; alpha activity diminished or disappeared and replaced by low amplitude *(black arrow)*, mixed frequency waves (4–7 Hz) that occupy > 50% of epoch.



Figure 1-5. PSG showing NREM sleep stage N2. Sleep spindles diagnostic of sleep stage N2 *(black arrow)*; K-complex diagnostic of sleep stage N2 *(red arrow)*.



Figure 1-6. PSG showing NREM sleep stage N3. Low frequency, high amplitude delta waves (0.5–2 Hz and > 75 μV) occupying ≥ 20% of epoch *(arrow)*.

REM sleep (Figure 1-7)

- Low amplitude, mixed frequency waves
- Low chin EMG tone
- Rapid eye movements

Figure 1-7. PSG showing REM sleep. Low amplitude, mixed frequency (sawtooth) waves *(black arrow)*; rapid eye movements *(red arrow)*; low chin EMG tone *(green arrow)*.

Flash Card Q9

What characteristic EEG waveforms define sleep stage N2?

Scoring

PSG data are divided into 30-second intervals or epochs, and an epoch is given a sleep stage based on whichever stage comprises the largest percentage of that epoch.

APNEA—Decrease in thermal sensor amplitude by ≥ 90% of baseline for ≥ 10 seconds.

- Obstructive apnea: Inspiratory effort present throughout apnea (Figure 1-10)
- Central apnea: Inspiratory effort absent throughout apnea (Figure 1-12)
- Mixed apnea: Central apnea followed by obstructive apnea (Figure 1-14)

HYPOPNEA—Decrease in nasal pressure by ≥ 30% for ≥ 10 seconds with a ≥ 4% drop in oxygen saturation (Figure 1-8).



Figure 1-8. Ambulatory sleep study showing hypopnea. Decrease in nasal pressure by ≥ 30% for ≥ 10 seconds with 4% oxygen desaturation *(arrow)*.

PLM (Figure 1-9)

- ≥ 4 consecutive leg movements, for 0.5–10 seconds each
- 5–90 seconds between movements

Flash Card A9

K-complex and sleep spindles



Figure 1-9. PSG showing PLMs. PLMs as defined by ≥ 4 consecutive leg movements, for 0.5–10 seconds each with periods of 5–90 seconds between movements *(arrow)*.

APNEA–HYPOPNEA INDEX (AHI)—Measure of the severity of sleep apnea.

- Number of apneas + hypopneas per hour of sleep:
  - AHI 0–5, normal
  - AHI 5–15, mild SDB
  - AHI 15–30, moderate SDB
  - AHI > 30, severe SDB

RESPIRATORY DISTURBANCE INDEX (RDI)

- Number of apneas + number of hypopneas + respiratory effort-related arousals per hour of sleep:
  - RDI 0–5, normal
  - RDI 5–15, mild
  - RDI 15–30, moderate
  - RDI > 30, severe

Epworth Sleepiness Scale

Eight-item questionnaire that evaluates the chances of dozing off to sleep on a scale of 0 (never) to 3 (high chance) under the following conditions:

- Sitting and reading
- Watching television
- Sitting inactive in a public place

- As a passenger in a car for an hour without a break
- Lying down to rest in the afternoon
- Sitting and talking to someone
- Sitting quietly after lunch without drinking alcohol
- Stopped in a car for a few minutes in traffic

An aggregate score of ≥ 10 indicates excessive daytime sleepiness.

Multiple Sleep Latency Test (MSLT)

- Measures tendency to fall asleep in quiet settings
- Patients instructed to try to fall asleep
- Indications:
  - Diagnose narcolepsy
  - Evaluate unexplained hypersomnia
- Requires PSG on the night prior to test and discontinuation of any medications that could affect sleep
- Consists of four or five 20-minute nap opportunities at 2-hour intervals with focus on sleep latency and presence or absence of REM sleep onset periods

SHORT SLEEP-ONSET LATENCY (SOL)—Test suggestive of excessive daytime sleepiness if there is short SOL (< 8 minutes)

- Causes of short SOL:
  - Narcolepsy
  - Idiopathic hypersomnia (IH)
  - Sleep deprivation
  - Obstructive sleep apnea
  - PLMD
  - Acute stimulant agent withdrawal

REM SLEEP ONSET—Test suggestive of narcolepsy if there are ≥ two sleep-onset REM sleep periods (SOREMPs).

- Causes of SOREMPs:
  - Narcolepsy
  - Sleep deprivation
  - OSA
  - Alcohol withdrawal
  - REM sleep suppressant withdrawal (e.g., antidepressants)

Maintenance of Wakefulness Test (MWT)

- Measures ability to stay awake in quiet settings
- Patients instructed to try to stay awake

- Consists of four 40-minute nap opportunities at 2-hour intervals
- Less sensitive than MSLT in detecting sleepiness and has variable predictive accuracy for sleepiness; patients may have normal MWT and still be sleepy
- SOL interval correlates with ability to stay awake:
  - SOL < 8 minutes—abnormal
  - SOL > 8 minutes and < 40 minutes—intermediate
  - SOL = 40 minutes (no sleep) —normal

SLEEP-DISORDERD BREATHING (SDB)

In this section, we will discuss respiratory causes of SDB including obstructive sleep apnea, central sleep apnea (CSA), and nocturnal hypoventilation.

Obstructive Sleep Apnea (OSA)

Common and underdiagnosed, with a prevalence of 5–10%, which increases with age.

RISK FACTORS

- Age
- Gender: Male subjects (up to age 50 years) and postmenopausal women (risk between genders similar after menopause)
- Obesity
- Ethnicity: Greater risk in African-American, Asian, Hispanic groups
- Obstructive UA anatomy
- Medical comorbidities: Heart failure, history of cerebrovascular accident, renal failure

SIGNS AND SYMPTOMS

- Unexplained daytime sleepiness
- Witnessed nocturnal apneas
- Frequent nocturnal awakenings
- Insomnia
- Morning headaches
- Nocturia
- Difficult concentrating and mood disorders

Key Fact

Absence of daytime sleepiness does not rule out sleep apnea, as > 50% of patients with OSA will not have daytime sleepiness.

DIAGNOSIS—History and physical exam alone often are nondiagnostic as > 50% of patients do not have daytime sleepiness. Witnessed snoring and apneas have a high positive predictive value of 64%, with witnessed apneas being the best historic predictor.

Flash Card Q10

What are two defining characteristics of narcolepsy on PSG with MSLT?

Key Fact

Sleep apnea is uncommon as the sole etiology for significant pulmonary hypertension; when present, other etiologies should be considered.

- In-laboratory PSG and portable home sleep testing are the main methods of diagnosing OSA.
- PSG is the gold standard for the diagnosis of SDB (Figure 1-10).
- Portable sleep studies are used for patients with a high pretest probability for OSA and without comorbid medical conditions such as cardiovascular disease, stroke, chronic obstructive pulmonary disease (COPD), and hypoventilation syndromes.



Figure 1-10. PSG showing obstructive apneas, characterized by presence of inspiratory effort throughout each apnea. Apnea as defined by decrease in thermal sensor amplitude by ≥ 90% of baseline for ≥ 10 seconds *(black arrow)*; presence of inspiratory effort throughout the apnea as indicated by persistent oscillations in both chest and abdomen channels (*green arrow*); note oxygen desaturations following apneas *(red arrow)*.

CONSEQUENCES

- Increases risk of:
  - Myocardial infarctions
  - Cerebrovascular accidents
  - Pulmonary hypertension
  - Hypertension
  - Sudden death
- May worsen diabetes and decrease GH and testosterone secretion
- May worsen heart failure
- Increases proinflammatory immune mediators CRP, IL-6, TNFα
- Causes daytime sleepiness with resultant motor vehicle accidents
- May cause neurocognitive deficits and memory and cognitive problems, and may increase risk of depression and mood disorders

TREATMENT—Continuous positive airway pressure (CPAP) is the mainstay of OSA treatment (Figure 1-11).

Flash Card A10

Decreased SOL and ≥ two SOREMPs on MSLT

Patients who need treatment:

- Moderate-to-severe OSA (AHI > 15) regardless of the presence or absence of symptoms
- Mild OSA (AHI > 5) with symptoms/comorbidities:
  - Symptoms/comorbidities are excessive daytime sleepiness, insomnia, cardiovascular disease, stroke, hypertension, depression, memory and mood problems
- Patients with OSA who have other concurrent sleep-related disorders (PLMs, insomnia, bradycardia, nocturia, etc.) should pursue CPAP therapy first, as these conditions often resolve with treatment of OSA.

Treatment recommendations are listed in Table 1-3.

CPAP use and cardiovascular disease:

- CPAP improves left ventricular ejection fraction (LVEF) modestly in patients with heart failure.
- CPAP reduces blood pressure and may improve mortality in patients with SDB.

CPAP compliance:

- Defined as use > 4 hours on at least 70% of observed nights.
- CPAP compliance is generally in the range of 50–60% when measured objectively.
- Patients commonly overestimate their subjective compliance.
- Compliance patterns are determined early.



Figure 1-11. PSG showing resolution of obstructive apneas from Figure 1-10, with CPAP use. CPAP pressure *(red arrow)*; presence of nasal flow with CPAP use *(black arrow)*; presence of effort *(green arrow)*.

Key Fact

Increased risk for cardiovascular disease in the context of OSA is tied more to degree of oxygen desaturation than to AHI.

Key Fact

The Joint National Committee (JNC) guidelines now lists OSA as a secondary cause of hypertension.

Flash Card Q11

Which patients should not undergo a portable home sleep study?

Flash Card Q12

What is the best historic predictor of OSA?

Flash Card Q13

What is the #1 reason for residual daytime sleepiness in patients who are on CPAP therapy for SDB?

Table 1-3. Treatment of OSA

Therapy	Indications
CPAP	First-line therapy Mild, moderate, and severe OSA Improves AHI, daytime sleepiness, quality of life
Oral device (mandibular advancement device or tongue retaining device)	Second-line therapy Snoring and mild-to-moderate OSA intolerant of CPAP
UA surgery	Alternative therapy Intolerant of CPAP and oral devices Uvulopalatopharyngoplasty generally is unsuccessful in resolving OSA and is not recommended Maxillomandibular advancement is successful in resolving OSA
Nasal EPAP (Provent)	Alternative therapy Mild OSA intolerant of CPAP and oral devices
Adjuvant therapies	Avoidance of alcohol and narcotics Positioning belts and pillows helps patients to sleep laterally, as OSA is generally is worse in the supine position Weight loss and bariatric surgery improve but rarely resolve OSA

AHI, apnea–hypopnea index; CPAP, continuous positive airway pressure; EPAP, expiratory positive airway pressure; OSA, obstructive sleep apnea

Key Fact

Nocturia associated with OSA improves with CPAP use.

Interventions proven to improve CPAP compliance:

- Heated humidification
- Education and early frequent contact with health care providers after CPAP initiation
- Cognitive behavioral therapy (CBT)
- Small studies indicate that use of eszopiclone once during CPAP titration study, and for the initial 14 nights of CPAP therapy, may be beneficial

Oral appliances for treating OSA:

- May use for snoring and mild-to-moderate OSA
- If patient has more severe disease and fails CPAP, may use oral appliance as second-line therapy
- Testing with sleep study should be performed to assess efficacy
- Outcomes:
  - Oral appliances as effective as CPAP for improving daytime sleepiness
  - Oral appliances less effective than CPAP for improving oxygenation and AHI

Flash Card A11

Patients with cardiovascular disease, stroke, COPD, and hypoventilation syndromes

Flash Card A12

Witnessed apneas—daytime sleepiness is the most common symptom

Flash Card A13

CPAP noncompliance

SURGERY FOR TREATING OSA

- Bariatric surgery for obese patients improves SDB but generally does not result in resolution of the sleep apnea.

- Uvulopalatopharyngoplasty, the reduction or removal of portions of the soft palate and uvula, generally is unsuccessful in resolving OSA, and it is not recommended.
- Maxillomandibular advancement, surgery to move the upper and lower jaw forward, has been noted to be successful in resolving OSA.
- Tracheostomy is used as a last resort for severe refractory symptomatic OSA in patients intolerant of CPAP.
- Adenotonsillectomy is effective in children and infants.

EPAP (PROVENT) TO TREAT OSA

- Only small studies available showing some benefit in positional OSA and mild OSA
- May be used for patients intolerant of CPAP and oral devices
- Testing with sleep study should be performed to assess efficacy

RESIDUAL SLEEPINESS

- First confirm compliance with CPAP
- Evaluate for other etiologies of excessive daytime sleepiness that may require alternative treatment, such as narcolepsy, IH, sleep deprivation, and shift work disorder
- Once compliance is confirmed and no other diagnoses are found, consider a trial of modafinil, which acts as a stimulant by inhibiting dopamine and hypocretin reuptake

Central Sleep Apnea (CSA)

Loss of ventilatory effort during sleep resulting in repetitive cessation of airflow.

NONHYPERCAPNIC CSA—Normal or low partial pressure of carbon dioxide ($PaCO_2$) and increased ventilatory response to hypercapnia.

Cheyne–Stokes respirations (CSRs) are characterized by crescendo–decrescendo periodic breathing (Figure 1-12).

- Pathophysiology:
  - Increased chemoreceptor sensitivity to carbon dioxide (CO_2)
  - Increased ventilatory drive
  - Increased circulatory time secondary to decreased cardiac output from heart failure
  - Decreased oxygen reserve

- Characteristics:
  - Occur predominantly in sleep stages N1 and N2

Flash Card Q14

Which outcome is the most likely to improve with use of CPAP in OSA?

Flash Card Q15

A 74-year-old man with heart failure (LVEF 20%) and atrial fibrillation is referred for frequent nocturnal desaturations noted during a recent hospitalization. What type of SDB would you be concerned about?

Flash Card Q16

Would a patient with CSRs be hypercapnic, hypocapnic, or eucapnic on a daytime arterial blood gas?

- Occur in about 30% of patients with heart failure, and is associated with increased morbidity and mortality
- Cycle duration is about 40–90 seconds
- Cycle duration is directly related to blood circulation time, and is inversely related to LVEF
- Oxygen desaturation and hypercarbia are delayed and occur during hyperpnea; arousal therefore occurs during peak hyperpnea
- Persistent awakenings related to apneic episodes may result in sleep fragmentation and excessive daytime sleepiness, though patients often are asymptomatic.

- Treatment:
  - There are limited data on the best therapy for CSR related to heart failure.
  - First step in management is to optimize heart failure (i.e., angiotensin-converting enzyme [ACE] inhibitors).
  - Adaptive servo-ventilation (ASV) has shown promising outcomes in the treatment of CSA, mainly CSR and complex sleep apnea; ASV adjusts respiratory rate and tidal volume to target a set minute ventilation, and reacts to periodic breathing by increasing inspiratory pressure during periods of apneas or hypopneas.
  - Oxygen may improve AHI and oxygen saturation in patients with CSR.
  - CANPAP trial: CPAP does not improve survival in patients with heart failure who have predominantly CSA, but CPAP does have a modest benefit in improving LVEF.
  - Auto-CPAP is **not** recommended for CSA.



Figure 1-12. Ambulatory sleep study showing Cheyne-Stokes respirations, characterized by the classic crescendo–decrescendo periodic breathing (shown in air flow channel). Apnea *(black arrow)*; crescendo–decrescendo periodic breathing *(red arrow)*; inspiratory effort absent throughout the apnea as shown by lack of oscillations in the chest and abdomen leads (*blue arrows*).

Flash Card A14
Daytime sleepiness

Flash Card A15
CSRs

Flash Card A16
Typically hypocapnic

Complex Sleep Apnea

- Central apneas emerge on application of CPAP treatment for OSA
- Pathophysiology not well defined
- Occurs mainly in NREM sleep and in supine position.
- Optimal treatment is not well defined:
  - In most patients, there is spontaneous resolution of complex sleep apnea with continued CPAP treatment of the obstructive apneas.
  - If complex apnea occurs during in-laboratory CPAP titration, attempt reduction of PAP as this may resolve the complex apnea.
  - ASV has been used successfully for those with persistent complex sleep apnea.

High-altitude periodic breathing:
- Occurs predominantly during NREM sleep
- Usually occurs above 2500 meters, with increased prevalence at higher altitudes
- Mechanism is related to enhanced ventilatory response to hypoxemia
- Period length of each breath cycle is shorter than CSR
- Treatment:
  - Oxygen
  - Acetazolamide

Idiopathic CSA:
- Rare, and cause is unknown
- Middle aged males are most commonly affected

Sleep-onset central sleep apnea:
- Thought to be related to fluctuations in $PaCO_2$ above and below the apneic threshold as sleep onset occurs
- Resolves as sleep progresses and respirations stabilize
- No therapy needed

HYPERCAPNIC CSA—Elevated $PaCO_2$ during sleep caused by decreased ventilatory response to hypercapnia.

- **Opioid-induced apnea** is induced most commonly by long-acting opioids, mainly methadone.
- Dose-dependent relationship with narcotics
- Patterns of SDB:
  - Biot respirations (Figure 1-13), CSA characterized by irregular periods of apnea (in contrast to CSR, which is characterized by regular periods of apnea)
  - Obstructive apnea

Flash Card Q17

What is the first step in the management of CSRs in the setting of heart failure?

  - Mixed apneas (CSA followed by OSA)
  - Prolonged obstructive hypoventilation
- Optimal treatment not clear:
  - Disease generally does not resolve spontaneously
  - Condition may improve with reduced opioid dose
  - ASV has been used, but data are lacking



Figure 1-13. Ambulatory sleep study showing Biot respirations, CSA characterized by irregular periods of apnea. Apnea *(black arrow)*; inspiratory effort absent throughout apnea as shown by lack of oscillations in chest and abdomen leads (*blue arrows*). Contrast this with regular periods of apnea found in CSRs.

Mixed Apnea

CSA followed by obstructive apnea (Figure 1-14). Etiology unclear, but may occur in patients who have CSA whereby loss of ventilatory effort and air flow results in collapse of the UA and subsequent obstruction. Treatment consists of management of the CSA, as discussed.

Flash Card A17

Optimize heart failure (i.e., ACE inhibitors)



Figure 1-14. PSG showing mixed apnea, characterized by CSA followed by obstructive apnea. Apnea *(black arrow)*; inspiratory effort absent during initial part of apnea as shown by lack of oscillations in chest and abdomen leads, characteristic of central apnea *(red arrows)*; presence of inspiratory effort during second part of apnea as indicated by persistent oscillations in both chest and abdomen channels, characteristic of obstructive apnea *(green arrows)*; note oxygen desaturation following apnea (*blue arrow*).

Nocturnal Hypoventilation

- Findings in adults:
  - Sleep-related oxygen desaturation
  - Increase in $PaCO_2$ during sleep to > 45 mmHg, or < 45 mmHg but increased relative to wake time (during normal sleep, $PaCO_2$ increases 3–5 mmHg as a result of ↓minute ventilation)
- Diagnostic studies:
  - Arterial $PaCO_2$, end tidal CO_2

OBESITY HYPOVENTILATION SYNDROME (OHS)

- Pathophysiology unclear (as most obese patients are unaffected):
  - Decreased chest wall compliance related to obesity
  - Elevated leptin levels that are associated with hypercapnia
  - Increased airway resistance related to obesity
- OSA occurs in 90% of patients with OHS.
- Pulmonary hypertension is more common in OHS than in OSA.
- Diagnosis:
  - Elevated awake $PaCO_2$ > 45 mmHg
  - Body mass index (BMI) > 30 kg/m^2
- Treatment:
  - CPAP ± oxygen is first-line therapy
  - Bilevel PAP (BPAP) may be beneficial for persistent hypoxemia

CONGENITAL CENTRAL HYPOVENTILATION

- Failure of breathing control center resulting in lack of responsiveness to O_2 and CO_2 that leads to hypoxemia and hypercapnia during sleep
- Onset during infancy
- Associated conditions: Autonomic dysfunction, Hirschsprung disease, neural crest tumors
- Pathophysiology unclear but associated with mutations in the *PHOX2B* gene

PAP THERAPY

Treatment of choice for patients with SDB.

Characteristics (Table 1-4)

Table 1-4. PAP Therapy

PAP	Pressure	Indication	Cautions	Alternatives
CPAP	One constant pressure throughout inspiration and expiration	OSA, CSA	Caution in patients with heart failure as may decrease preload	Oral appliance for mild-to-moderate OSA UA surgery EPAP (Provent)
CPAP (C Flex) machine	Similar to CPAP except allows transiently reduced pressure during expiratory phase	OSA, CSA	Similar to CPAP	Similar to CPAP
BPAP	Two distinct pressures, with a higher IPAP and lower EPAP	Patients who need very high CPAP pressures and have difficulty expiring Patients with hypoventilation syndromes	Does not improve compliance in patients with uncomplicated OSA No difference in efficacy in patients with uncomplicated OSA	Similar to CPAP
APAP	Automatically and constantly adjusts PAP to maintain UA patency	Treatment of uncomplicated OSA, in the setting of a home PAP titration	Not recommended in OSA with HF, hypoventilation, COPD	Similar to CPAP
ASV	Pressure support (IPAP - EPAP) increases with hypoventilation and decreases with hyperventilation	Complex sleep apnea Cheyne Stokes breathing	None	Oxygen CPAP Oxygen + CPAP

PAP, positive airway pressure; CPAP, continuous positive airway pressure; OSA, obstructive sleep apnea; CSA, central sleep apnea; UA, upper airway; EPAP, expiratory positive airway pressure; BPAP, bilevel positive airway pressure; IPAP, inspiratory positive airway pressure; APAP, autotitrating positive airway pressure; HF, heart failure; COPD, chronic obstructive pulmonary disease; ASV, adaptive servo-ventilation.

Benefits of PAP

- May reduce mortality
- Decrease in sleepiness
- Decrease or elimination of snoring
- Reduction in AHI
- Improvement in Sa_{O_2}
- Improvement in blood pressure control
- Improved LVEF in patients with heart failure
- Improvement in pulmonary artery pressures
- Decrease in proinflammatory immune mediators (i.e., CRP, IL-6, TNFα)
- Reduction in healthcare consumption

NOCTURNAL ASTHMA

Nocturnal asthma symptoms indicate poorly controlled asthma and generally occur in the early morning hours (3–6 am).

Mechanisms

Sleep-related changes are systemic changes that occur during sleep and may precipitate nocturnal asthma symptoms.

- Autonomic nervous system:
  - Increased vagus nerve tone and cholinergic activity
  - Decreased serum epinephrine levels
- Lung capacity:
  - Circadian variability in airflow occurs with decreased forced expiratory volume in 1 second (FEV_1), and peak flow rates with trough pulmonary function occur between 3–6 am
- Inflammatory agents:
  - Increased inflammatory agents during early morning hours, especially circulating eosinophils

Diagnosis and Treatment

- Decreased peak flow, symptomatic worsening, and increased rescue inhaler use, as in regular asthma
- Treatment consists of optimizing asthma medical management.

Flash Card Q18

What is the most important determinant of sleep-related hypoxemia in COPD?

- Concurrent sleep apnea should be treated, and PAP can improve nocturnal asthma symptoms, in this setting.

COPD

Obstructive lung disease related to tobacco use characterized by FEV_1/FVC ratio < 70% of predicted.

Causes of Sleep Disturbance and Frequent Arousals

- Nocturnal wheezing, coughing, dyspnea
- Increased work of breathing
- Hypoxemia

NOCTURNAL HYPOXEMIA IN COPD

Mechanism:

- Hypoventilation (REM sleep > NREM sleep > awake)
- Blunted respiratory center response to hypoxemia and hypercapnia (REM sleep > NREM sleep > awake)
- Increased UA resistance
- Decreased functional residual capacity (FRC) during sleep and in supine position (flattened diaphragms)
- Loss of accessory respiratory muscle use during REM sleep

Causes of sleep-related hypoxemia in COPD:

- ↓wake Sa_{O_2} and ↑wake Pa_{CO_2} are major predictors of hypoxemia during sleep
- Presence of concurrent OSA
- Increased severity of obstructive lung disease
- Elevated BMI
- Increased REM sleep duration

Diagnosis:

- Polysomnogram should be used to diagnose sleep apnea in patients with COPD.
- Overnight oximetry to evaluate for nocturnal hypoxemia is indicated for COPD patients with daytime hypercapnia, daytime hypoxemia, pulmonary hypertension, concern for right heart failure, or symptoms suggestive of nocturnal hypoxemia (i.e., fragmented sleep).

Key Fact

PSG, and not ambulatory sleep tests, should be used for the diagnosis of SDB in patients with COPD.

Flash Card A18

Hypoventilation

Treatment:

- Medical management per GOLD guidelines
- Indications for nocturnal oxygen therapy in patients with signs or symptoms of nocturnal hypoxemia, such as cognitive impairment, insomnia, and restlessness:
  - $Pa_{O_2} \leq 55$ mmHg, or
  - $Sa_{O_2} \leq 88\%$, or
  - Fall of $Pa_{O_2} > 10$ mmHg during sleep, or
  - Fall of $Sa_{O_2} > 5\%$ during sleep

OVERLAP SYNDROME

Coexistence of OSA and COPD in the same patient.

Characteristics

- Prevalence of OSA in the COPD population is similar to that in the general population
- In COPD patients with untreated OSA, there is an increased risk of death and severe COPD exacerbation leading to hospitalization, compared to COPD patients without OSA; this risk is reduced with CPAP therapy

NONRESPIRATORY SLEEP DISORDERS

HYPERSOMNIAS

Many conditions can result in excessive daytime somnolence or hypersomnia. Hypersomnia can be primary or secondary. Primary hypersomnia refers to hypersomnia originating in the CNS. Secondary hypersomnia occurs as a result of another medical condition or a drug. The most common primary hypersomnias are narcolepsy and IH.

Narcolepsy

> ***Key Fact***
>
> The hallmark of narcolepsy is daytime sleepiness. If a patient is not sleepy, the diagnosis of narcolepsy is highly unlikely.

A clinical syndrome characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and sleep hallucinations. Although all of these symptoms may be present, hypersomnia is the hallmark of narcolepsy, whereas cataplexy is a very specific finding. In contrast, sleep paralysis and sleep hallucinations are nonspecific and can occur in a variety of sleep disorders and even in normal individuals.

EPIDEMIOLOGY—Relatively uncommon disorder with prevalence in the United States of 1:2000. Patients typically present in the second or third decade of life. The disorder is distributed equally among male and female populations, and tends to persist throughout an individual's life.

ETIOLOGY—Exact etiology remains unknown. The prevailing hypotheses are listed below.

Orexin (also known as hypocretin):

- Neurotransmitter implicated in the pathogenesis of narcolepsy
- Involved in signal transduction within the lateral hypothalamus, and orexin-mediated nerve conduction is associated with heightened alertness and inhibition of REM sleep
- In autopsy studies, the brains of narcoleptic patients have gliosis in the lateral hypothalamus, with loss of hypocretin containing neurons; narcoleptic patients have low hypocretin levels in cerebrospinal fluid.

Genetic:

- Human leukocyte antigen DQB1*0602 has been shown to confer susceptibility in some patients, though it is nonspecific and often also present in patients without narcolepsy.

Autoimmune:

- In China, there is an increase in the incidence of narcolepsy during the spring, suggesting a possible association between winter month viral illnesses and an autoimmune response
- Narcoleptic patients also have higher levels of anti-streptolysin O titers, further raising suspicion of an immune etiology

CLINICAL FEATURES

Excessive daytime sleepiness:

- Often severe and unremitting
- Some patients may experience some degree of sleepiness throughout their lives, despite appropriate therapy

- Sleep and daytime naps are refreshing, and help to distinguish narcolepsy from IH, a condition in which sleep is not refreshing

Cataplexy**:**
- Pathognomonic of narcolepsy in any individual who complains of excessive daytime sleepiness
- Sudden loss of muscle tone, usually triggered by strong emotions
- Typically, patients will complain of muscle weakness during laughter; the episode is usually very brief, and the patient remains completely conscious

Sleep paralysis:
- Occurs while the patient is waking from sleep
- Although the episodes are brief in duration, they can be terrifying to the patient
- Sleep paralysis is common and nonspecific and can occur in normal individuals, especially in the setting of sleep deprivation

Sleep hallucinations usually occur at sleep onset (hypnagogic) and less commonly on awakening (hypnopompic), and may be visual, auditory, or tactile.

Sleep fragmentation:
- Narcolepsy can be thought of as a discontinuity in wakefulness, with features of REM sleep intruding into wakefulness
- Cataplexy, sleep paralysis, and sleep hallucinations represent these disruptions into wake periods
- Similarly, wakefulness also intrudes into sleep with frequent complaints of sleep fragmentation and poor sleep quality

DIAGNOSIS—Diagnosing narcolepsy often can be difficult. In evaluating a patient with suspected narcolepsy, it is important to distinguish narcolepsy with or without cataplexy, as management differs between the two groups.

The key to diagnosis is a thorough history, paying close attention to sleep patterns, daytime somnolence, and associated symptoms.

An MSLT, consisting of 4–5 20-minute naps, is recommended for the vast majority of patients with suspected narcolepsy. A diagnosis of narcolepsy can be made if the mean sleep latency is < 8 minutes for the sum of naps, and if there are ≥ two naps with REM sleep periods, termed sleep-onset REM periods (or SOREMPs).

Mnemonic

Sleep hallucinations—**GO** to sleep. **PO**p awake.

Hypna**GO**gic
Hypno**PO**mpic

Mnemonic

Clinical features of narcolepsy—**S**ome **P**atients **C**an **F**all **H**ard

Sleepiness
Paralysis
Cataplexy
Fragmentation of sleep
Hallucinations

Key Fact

An MSLT is suggestive of narcolepsy if the mean sleep latency is < 8 minutes and if there are at least two SOREMPs.

Flash Card Q19

What clinical feature is virtually pathognomonic for narcolepsy?

The MSLT should be preceded by an all-night PSG to rule out other sleep disorders such as OSA (though the two disorders can coexist). Notably, up to 20% of the general population can have an abnormal MSLT. Furthermore, patients with severe OSA or sleep deprivation can have a shortened mean sleep latency on MSLT.

TREATMENT—The goals of treatment are to alleviate daytime sleepiness and eliminate cataplexy, if present.

- Nonpharmacologic treatment can be very beneficial in managing daytime sleepiness; patients should be encouraged to have a structured sleep schedule, with consistent bedtimes and wake times; scheduled naps should be included in the treatment regimen of most patients with narcolepsy.
- Pharmacologic treatment (Table 1-5):
  - Excessive daytime sleepiness:
    - Stimulants (i.e., modafinil and armodafinil) are considered first-line therapy for narcolepsy
    - Amphetamines (i.e., methylphenidate, dextroamphetamine) are second-line therapies
  - Cataplexy:
    - Serotonin selective reuptake inhibitors (SSRIs; i.e., fluoxetine, venlafaxine, clomipramine) for mild cases
    - Sodium oxybate (gamma-hydroxybutyrate, GHB) is approved to treat both cataplexy and excessive daytime sleepiness, and is the drug of choice for difficult-to-manage cataplexy; though GHB has gained notoriety as the "date rape" drug, the risk for abuse in narcoleptics is extremely low

Table 1-5. Treatment of Narcolepsy

Clinical Feature	Treatment
Hypersomnolence	Stimulants (modafinil, armodafinil) Amphetamines (methylphenidate, dextroamphetamine) Structured sleep schedule, scheduled naps
Cataplexy	SSRIs (fluoxetine, venlafaxine, clomipramine) Sodium oxybate
Sleep fragmentation	Hypnotics (zolpidem, eszopiclone, etc) Sodium oxybate

SSRIs, serotonin selective reuptake inhibitors

Flash Card A19

Cataplexy

Idiopathic hypersomnia (IH)

IH is a condition of CNS origin that causes excessive daytime sleepiness. The etiology is unknown. Patients with IH often have severe daytime sleepiness, despite sleeping through the night. The pattern of sleepiness can help to distinguish IH from narcolepsy (Table 1-6). Whereas sleep is generally refreshing to narcoleptics, patients with IH remain sleepy after waking up from sleep or naps.

Key Fact

Sleep and naps are refreshing to patients with narcolepsy. This is in contrast to IH, in which sleep is not refreshing.

Epidemiology—Onset of symptoms is usually in the second to fourth decades of life. Patients may report a remote history of head trauma. Approximately 10% of patients will experience a spontaneous remission.

Diagnosis—Making the diagnosis requires a compatible history and an MSLT revealing a mean sleep latency of < 8 minutes and no more than one SOREMP.

Treatment—Pharmacologic treatment with either modafinil or armodafinil.

Table 1-6. Differentiating Narcolepsy from IH

Feature	Narcolepsy	IH
Sleepiness	Intermittent throughout the day	Continuous throughout the day
Naps/sleep	Refreshing	Not refreshing
Cataplexy	Often present but not required for diagnosis	No
Natural course	Persists for a lifetime	~10% of cases remit spontaneously
Treatment	Various treatments	Modafinil or armodafinil

IH, idiopathic hypersomnia

Mnemonic

Clinical features of RLS—**URGE**

Urge to move legs
Rest precipitates symptoms
Getting up and moving alleviates symptoms
Evening and nighttime worsening of symptoms

PERIODIC LIMB MOVEMENT DISORDERS (PLMD)

Restless legs syndrome (RLS) occurs during wakefulness, typically in the evening or at night. It is characterized by uncomfortable sensations in the legs at rest which are relieved with movement. Approximately 85% of patients who have RLS also have PLMs on PSG.

Flash Card Q20

What is the treatment of choice for IH?

Flash Card Q21

Decreased levels of which neurotransmitter is implicated in narcolepsy?

PLMs are interval, stereotypic movements of the lower extremities during sleep. They are very common and can occur in normal individuals or in SDB. The patient does not feel any noxious sensations, and the PLMs usually do not affect

sleep. When PLMs do cause sleep disruption, however, the condition is termed periodic limb movement disorder (PLMD).

Key Fact

Although RLS and PLMD are similar, they are two different conditions. RLS is a clinical diagnosis and does not require a PSG. However, if a PSG is performed, PLMs usually are found.

Epidemiology

About 3–15% of the general population suffers from RLS. It typically presents in the first to third decades of life, but diagnosis is usually delayed until the fifth to sixth decades. Women are at higher risk.

Etiology

Key Fact

RLS is related to low CNS iron stores, which disrupt dopamine synthesis. Dopamine agonists relieve RLS.

RLS is felt to be related to low CNS iron stores. Iron is a cofactor for tyrosine hydroxylase, the rate-limiting step in dopamine synthesis. Low CNS iron is felt to disrupt CNS dopamine levels, leading to RLS. Consequently, pharmacologic enhancement of dopamine levels relieves the condition. Iron supplements may also alleviate symptoms but are not as effective as dopamine agonists.

Associations include:

- Iron deficiency anemia
- End stage renal disease
- Pregnancy
- Medications: Dopamine antagonists (antipsychotics), SSRIs, TCAs

Diagnosis

Diagnosis requires an appropriate clinical history for RLS. A diagnosis of PLMD requires a PSG demonstrating frequent leg movements resulting in sleep disruption in a patient with sleep complaints.

Treatment

PHARMACOLOGIC—First-line medications are dopamine agonists (i.e., pramipexole and ropinirole). A well-known side effect of both medications is an increase in compulsive behaviors. Patients also may complain of augmentation, which is an occurrence of RLS symptoms earlier in the day.

Flash Card A20

Orexin (hypocretin)

Second-line medications include gabapentin, opioids, and carbidopa/levodopa.

Flash Card A21

Modafinil or armodafinil

Treatment in pregnant women can be challenging due to lack of medication safety data for the developing fetus. Mild RLS can be managed with massage and warm

compresses. More severe cases may require short courses of opioids. Folic acid and iron supplementation may also alleviate symptoms.

SECONDARY CAUSES—Treat iron deficiency anemia (i.e., iron replacement), renal disease, etc.

PARASOMNIAS

A parasomnia is any abnormal or complex body movement during sleep. The most common parasomnias include sleep terrors, sleep walking, sleep talking, and sleep eating. They occur primarily during non-REM sleep (NREM sleep).

Key Fact

Parasomnias typically occur during NREM sleep and thus are more often present during the first half of the night.

Night Terrors

- Usually present in early childhood
- The child often will sit up screaming or mumbling.
- There is a significant autonomic response, and the child may appear to be in a panic and thrashing.
- These dramatic episodes are often very distressing for parents/caregivers; the child, however, is completely unaware and amnestic to the event.
- Attempts to wake the child are unsuccessful and often result in increased confusion.

Mnemonic

Clinical features of night terrors—**SCREAMS**

Sit up screaming
Confusion/disorientation
Respond poorly to parents
Elevated arousal
Amnesia to event
Mumbling
Supportive care

TREATMENT—Supportive treatment unless the episodes are very frequent and disruptive, in which case benzodiazepines or TCAs may be beneficial.

REM Sleep Behavior Disorder (RBD)

Occurs during REM sleep, thereby distinguishing it from the other parasomnias.

In RBD, the normal muscle atonia of REM sleep is lost. Thus, the patient is susceptible to act out dreams. This puts the patient at risk for falls and self-harm, and the bed partner is also susceptible to injury. It occurs primarily in older men and in contrast to the other parasomnias, the patient is awakened easily and is rapidly alert (Table 1-7).

Approximately 40% of patients with RBD will go on to develop neuro-degenerative disorders, the most common being Parkinson disease.

Flash Card Q22

Patients with RBD are at high risk of developing which condition?

Table 1-7. Distinguishing Characteristics of RBD vs. Night Terrors

Feature	RBD	Night Terrors
Patients	Older male patients	Children
Stage	REM sleep	NREM sleep (N3)
Clinical features	Acting out dreams Easily aroused Memory of events present	Screaming and panic Cannot arouse Amnesia to events
Treatment	Clonazepam	Supportive
Sequelae	Parkinson disease in 40%	Benign

REM, rapid eye movement; NREM, non-rapid eye movement

DIAGNOSIS—An appropriate history of dream enactment in the right clinical setting makes the diagnosis. PSG demonstrating abnormal movements/lack of muscle atonia during REM sleep supports the diagnosis.

TREATMENT—The goal of **nonpharmacologic treatmen**t is to ensure safety for both the patient and bed partner. This may include putting the mattress on the floor, sleeping in separate beds or rooms, etc.

Pharmacologic treatment with clonazepam is preferred. Melatonin can be used for those who cannot tolerate clonazepam. Treatment of RBD has not been shown to decrease the risk of developing Parkinson disease.

CIRCADIAN RHYTHM DISORDERS

Although there are variations (Figure 1-15), most human beings sleep at a similar hour at night, sleep for a similar duration, and thus wake at similar times in the morning. Taking into account age, cultural norms, and various other factors, we can also observe different sleeping patterns i.e., “late sleepers,” “early risers,” etc.

Circadian and metabolic hypotheses are two leading hypotheses describing the conformity of our sleep patterns.

In the **circadian hypothesis**, melatonin is released by the pineal gland and sets the circadian rhythm. Melatonin promotes sleep and its production is inhibited by light. During the day, natural sunlight inhibits melatonin production, which results in wakefulness. With less sunlight at night, melatonin levels rise to promote sleep. Therefore, the sleep–wake cycle is entrained by light.

Flash Card A22

Parkinson disease



Figure 1-15. Sleep phases.

The **metabolic hypothesis** describes sleep as a physiologic need, serving a restorative function. The most active parts of the brain during wakefulness have higher levels of adenosine, a breakdown product of adenosine triphosphate (ATP). Adenosine levels return back to baseline after sleep, presumably replenishing ATP.

A circadian rhythm disorder occurs when an individual's sleep–wake pattern does not conform to accepted norms. This misalignment results in insomnia, excessive sleepiness, or both.

For all circadian rhythm disorders, the diagnosis is generally made by history. Sleep diaries and actigraphy also can assist with the diagnosis.

Delayed Sleep Phase Syndrome

Delayed sleep phase is a persistent, involuntary sleep pattern in which the individual falls asleep later and wakes up later. It is very common in adolescents and young adults. This is not a behavioral trait, but rather a true delay in the patient's normal circadian rhythm. When this sleep pattern causes daytime sleepiness or impairment, it is termed delayed sleep phase syndrome.

DIAGNOSIS—Often first diagnosed in high school, when children have to wake up earlier. Typically parents and teachers will complain that the child is falling asleep during the day.

TREATMENT—Consists of using bright light therapy in the morning to suppress melatonin release. Exogenous melatonin can also be used at night to help promote sleep. Chronotherapy refers to the use of light therapy to systematically shift the patient's delayed sleep phase to a more acceptable time.

Advanced Sleep Phase Syndrome (ASPS)

ASPS occurs most commonly in the elderly. The patient will often complain of waking up in the middle of the night and the inability to fall back asleep. An appropriate history will reveal that they are also going to sleep very early in the day. Treatment is only warranted if the sleep–wake cycle is causing distress in the patient's life. Treatment includes bright-light therapy at night to prevent falling asleep until a more acceptable time.

Shift Work Sleep Disorder

Because the normal circadian rhythm is not easily reversed, many individuals who work night shifts find it difficult to stay awake at night. Alternatively, they find it difficult to sleep or remain asleep during the day. This is termed shift work sleep disorder (SWSD).

TREATMENT—If switching to a daytime job is not feasible, treatment includes bright light while at the job to suppress melatonin. Both modafinil and armodafinil are stimulants approved for the treatment of SWSD.

During the day, the patient should wear dark sunglasses while driving home. The bedroom should be kept dark with conditions conducive to sleep.

Jet Lag Syndrome

A temporary misalignment between the individual's internal circadian rhythm and external time cues. This results in insomnia, daytime sleepiness, or both.

- East travel: Difficulty falling asleep
- West travel: Difficulty maintaining sleep

TREATMENT—Short-term use of sleep aids. Light exposure during the day.

Free Running Disorder

Also known as nonentrained or non-24-hour syndrome. Typically occurs in blind patients. As mentioned, light entrains the normal circadian rhythm.

In about 40% of blind patients, the circadian rhythm is not entrained by light. The result is a sleep–wake cycle which is progressively delayed each night.

TREATMENT—Exogenous melatonin at night to promote sleep. Other environmental cues such as alarm clocks or meal times also can be used to entrain the circadian rhythm.

INSOMNIA

Inability to initiate or maintain sleep despite adequate time and opportunity to do so. It can also be described as poor sleep quality or chronically nonrestorative sleep. The diagnosis can only be made if the sleep limitation causes impairment or distress to the individual's life.

There are seven types of insomnia:

- Psychophysiologic insomnia (primary or chronic insomnia)
- Acute insomnia (adjustment or short-term insomnia)
- Inadequate sleep hygiene
- Paradoxical insomnia (also called sleep-state misperception)
- Idiopathic insomnia (also called lifelong insomnia)
- Insomnia associated with a medical condition (or psychiatric disorder, neurologic disease, sleep disorder, medication, or drug use)
- Unspecified insomnia

EPIDEMIOLOGY—Depending on the study population, the prevalence of insomnia varies widely from about 20–70% of individuals. The prevalence increases with age, and women complain of insomnia 50% more often than men.

DIAGNOSIS—Patients typically present complaining of the inability to sleep, daytime sleepiness, or both. Good history taking will reveal limited sleep, daytime sleepiness or impairment, and the **inability to sleep** when time permits. The history also should eliminate other medical conditions or drugs as the source of insomnia. A formal sleep study generally is not required unless other sleep disorders are also suspected.

Flash Card Q23

What inhibits melatonin production?

Flash Card Q24

A 32-year-old woman reports sleeping only 3 hours per night for many years. She reports good sleep quality, denying any daytime impairment, sleepiness, or distress. Does this patient have insomnia?

Key Fact

The gold standard treatment of insomnia of long duration is CBT.

TREATMENT—Insomnia of short duration (i.e., acute insomnia) can be treated effectively with sedatives/hypnotics. The gold standard treatment of insomnia of long duration, such as psychophysiologic insomnia, is CBT. Sleep hygiene should be encouraged in both groups but is insufficient as a primary therapy for insomnia.

CBT is a systematic approach that addresses cognitive stress that exacerbates insomnia, and the maladaptive behaviors that perpetuate further sleep disturbances. When administered by experienced personnel, CBT is nearly equivalent in efficacy to pharmacologic treatment in the short term and has better sustained efficacy than pharmacologic sleep aids in the long term.

Pharmacologic treatment includes various hypnotics used for the treatment of short-duration insomnia. These include zolpidem, temazepam, eszopiclone, ramelteon, zaleplon, and doxepin (Table 1-8).

Table 1-8. Pharmacologic Sleep Aids

Drug	Mechanism of Action	Duration of Action	Indications	Side effects
Zolpidem	Selective GABA agonist	4–5 hours	Sleep initiation insomnia (a controlled release formulation is used for both sleep initiation and maintenance insomnia)	Complex behaviors during sleep such as sleep eating, depression, headaches, fatigue
Temazepam	Benzodiazepine	6–8 hours	Short-term (7–10 days) treatment of sleep initiation insomnia	Respiratory depression, fatigue, dependency/abuse, dizziness
Eszopiclone	Selective GABA agonist	6–8 hours	Sleep initiation and sleep maintenance insomnia	Depression, headaches, dizziness, unpleasant metallic taste
Ramelteon	Melatonin receptor agonist	4–5 hours	Sleep initiation insomnia	Depression, headaches, fatigue
Zaleplon	Selective GABA agonist	1–2 hours	Sleep initiation insomnia	Depression, headaches, dizziness, amnesia
Doxepin	SNRI	3–5 hours	Sleep maintenance insomnia	Fatigue, nausea, depression

GABA, gamma-aminobutyric acid; SNRI, serotonin–norepinephrine reuptake inhibitor

Flash Card A23

Light

Flash Card A24

No because the patient is not experiencing impairment or distress as a result of the short sleep duration.

NEUROMUSCULAR DISORDERS AND DISEASES OF THE CHEST WALL

NEUROMUSCULAR DISORDERS

Neuromuscular weakness of the diaphragm and accessory muscles of respiration can impair the ability of the lungs to ventilate. Bulbar weakness can affect muscles that aid in swallowing and clearance of secretions. Thus, neuromuscular disorders can result in respiratory failure due to inability to ventilate the lungs or inability to protect the airway or both (Table 1-9).

The fundamentals of respiratory management in neuromuscular disorders involve:

- Noninvasive positive pressure ventilation (NIPPV) to decrease work of breathing
- Clinical assessment of bulbar function, cough, and clearance of secretions
- Decision making surrounding initiation of mechanical ventilation (MV) when NIPPV is no longer working or not an option.

The diaphragm is the main muscle of respiration. Contraction moves the diaphragm downward and results in negative pressure ventilation of the lungs. The accessory muscles of respiration include:

- Abdominal muscles
- Intercostal muscles
- Sternocleidomastoids
- Scalene muscles

Respiratory muscle strength is assessed most often by measurement of negative inspiratory force (NIF), which is also known as the maximum inspiratory pressure (MIP), and the vital capacity (VC). Airway clearance by cough can be assessed using the maximum expiratory pressure (MEP).

Principles of NIPPV

Noninvasive ventilation plays a major role in the respiratory management of most neuromuscular disorders. Although evidence is lacking to address mode selection, most clinicians utilize bilevel positive airway pressure (BPAP).

There are two pressures the clinician sets in BPAP:

- Inspiratory airway pressure (IPAP)

- Expiratory airway pressure (EPAP)

The EPAP splints the airway, and the IPAP helps ventilation by providing pressure support. Typical starting pressures are:

- IPAP, 10–12 cm H_2O
- EPAP, 5–6 cm H_2O

Pressures can be adjusted based on the clinical situation. In many cases, overnight PSG is used to help adjust BPAP pressures.

Key Fact

Nocturnal NIPPV is the cornerstone of respiratory management in patients with neuromuscular disorders.

Minute ventilation decreases in all people during sleep due to a decrease in tidal volume. This physiologic decrease in ventilation can have especially deleterious effects in patients with neuromuscular disorders. Furthermore, the accessory muscles of respiration are paralyzed normally during REM sleep, which compounds respiratory insufficiency at night. Therefore, nocturnal NIPPV is the cornerstone of respiratory management in patients with neuromuscular disorders.

Table 1-9. Comparison of Neuromuscular Disorders

Disorder	Distinguishing Features	Features of Weakness	Supportive Respiratory Care	Treatment
GBS	Neuropathic pain Dysautonomia	Ascending paralysis	NIPPV or MV	Plasmapheresis or IVIG
Myasthenia gravis	Ptosis is classic	Often descending and worse as day progresses	NIPPV or MV during crises	Pyridostigmine Immunosuppression Plasmapheresis or IVIG Thymectomy
Lambert–Eaton	Associated with SCLC	Improves with repetitive muscle use	NIPPV early MV late	IVIG
ALS	Cognitive impairment and frontotemporal dementia	Signs of upper and lower motor neuron involvement	NIPPV or MV	Riluzole
Botulism	GI symptoms	Bilateral CNS involvement	MV, often prolonged	Antitoxin

ALS, amyotrophic lateral sclerosis; CNS, central nervous system; GBS, Guillain-Barré syndrome; ; IVIG; intravenous immunoglobulin; MV, mechanical ventilation; NIPPV, noninvasive positive pressure ventilation; SCLC, small cell lung cancer

Guillain-Barré Syndrome (GBS)

Acute inflammatory demyelinating polyneuropathy.

CHARACTERISTICS

- Classically an ascending paralysis starting in the lower extremities
- Progressive symmetric muscle weakness
- Can involve only lower extremities, or can ascend to involve all muscles (including respiratory and bulbar muscles)
- Often preceded by an infection, classically *Campylobacter jejuni* enteritis
- 40–50% have neuropathic pain
- 10–30% will advance to ventilator-dependent respiratory failure
- Dysautonomia occurs in up to 70% of patients (urinary retention, blood pressure fluctuations, diaphoresis)

Key Fact

Features that distinguish GBS from other neuromuscular disorders include neuropathic pain, autonomic dysfunction, and diminished deep tendon reflexes on physical exam.

DIAGNOSIS

- Clinical diagnosis:
  - Symmetric muscle weakness
  - Diminished deep tendon reflexes
- Confirmed with lumbar puncture (elevated protein, normal white blood cell count) and neurophysiologic testing:
  - EMG
  - Nerve conduction studies (NCS)

TREATMENT/MANAGEMENT

- Respiratory failure can occur rapidly
- Initial monitoring should include frequent measurements of VC and NIF

Factors associated with impending respiratory failure requiring MV are:

- VC < 20 mL/kg
- Reduction in VC > 30%
- MIP less negative than -30 cm H_2O, MEP < 40 cm H_2O
- Rapid disease progression
- Bulbar dysfunction
- Bilateral facial muscle weakness
- Dysautonomia

Weaning from MV should be guided by VC, NIF, and rapid shallow breathing index.

Plasmapheresis or intravenous immunoglobulin (IVIG) is most effective within 7 days of symptom onset, but benefits are seen even after 30 days. Treatment results in earlier recovery from MV and more complete recovery of muscle strength.

There is no role for steroids, and they may slow recovery of muscle strength.

Flash Card Q25

What are the only disease-modifying treatment options for GBS?

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

When GBS progresses past 8 weeks, it is termed chronic inflammatory demyelinating polyneuropathy. The course of CIDP can be slowly progressive or relapsing/remitting.

As opposed to GBS, the neuromuscular weakness of CIDP responds to glucocorticoids. Other treatments include plasmapheresis and IVIG.

Amyotrophic Lateral Sclerosis (ALS)

Progressive neurodegenerative disorder of unknown etiology. Invariably fatal due to progressive respiratory muscle weakness.

CLINICAL FEATURES—Signs of upper and lower motor neuron involvement.

- Upper: Slowness of movement, hyperreflexia, spasticity
- Lower: Weakness, atrophy, fasciculations

Key Fact

Signs of upper and lower motor neuron involvement are very characteristic of ALS. Spasticity, atrophy, and fasciculations will help distinguish ALS from other neuromuscular disorders.

- Respiratory involvement includes bulbar, diaphragm, and accessory muscles. Asymmetric limb weakness is the most common presentation of ALS (80%).
- There is also cognitive involvement in a majority of patients; up to 15% have overt frontotemporal dementia.
- The course is progressive, rather than relapsing/remitting, with a median survival of 3–5 years.

DIAGNOSIS—Mainly by history and physical; EMG and NCS can be helpful also.

TREATMENT

- **Comprehensive supportive care** by a multidisciplinary team is necessary throughout the course of ALS; respiratory management is central to supportive care
- **NIPPV** increases quality of life in patients with ALS; the optimal patient is one who has more nocturnal symptoms and minimal bulbar weakness (allowing for adequate handling of secretions); consider use in patients with:
  - Nocturnal hypoxemia or orthopnea
  - VC < 50% predicted
  - MIP < -60 cm H_2O
- NIPPV is not an alternative to **MV**; all patients will progress to respiratory failure requiring MV; patients who wish to continue treatment require tracheostomy and MV support; fewer than 10% of ALS patients choose invasive ventilation.
- Pharmacologic treatment with riluzole is the only drug treatment shown to increase survival.

Flash Card A25

Plasmapheresis or IVIG

Myasthenia Gravis

An autoimmune disorder involving the neuromuscular junction (NMJ) characterized by ocular, bulbar, limb, and respiratory muscle weakness. The weakness tends to worsen as the day progresses.

PATHOPHYSIOLOGY—Autoimmune process secondary to antibody-mediated T-cell destruction of acetylcholine receptors on the postsynaptic membrane of the NMJ.

DIAGNOSIS—Myasthenia gravis is a clinical diagnosis, but tests can be ordered for confirmation:

- Edrophonium test:
  - A positive edrophonium test will display improved muscle strength when administered to patients with myasthenia gravis.
  - Sensitivity is 80–90%, but specificity is low.
- Antibody testing: Serologic testing for autoantibodies to acetylcholine receptor or the receptor-associated protein, muscle specific tyrosine kinase, can be performed.
- Neurophysiologic studies: Repetitive nerve stimulation results in a decrease in action potential.

> ***Key Fact***
>
> Classically, the muscle weakness of myasthenia gravis worsens as the day progresses.

TREATMENT—Rarely, patients may simply need symptomatic treatment. Most, however, will need immunosuppression at some point in their course.

- Pyridostigmine provides short-term symptomatic relief.
- Glucocorticoids, azathioprine, cyclosporine, rituximab, cyclophosphamide can be used for maintenance therapy.
- All myasthenia gravis patients with a thymoma should undergo thymectomy.
- Myasthenia crises should be treated aggressively with:
  - Plasmapheresis or IVIG, or
  - High-dose steroids or alternative immunosuppressive therapy, or
  - Close monitoring of respiratory status with consideration for elective intubation if VC < 20 mL/kg or if MIP is worse than -30 cm H_2O

Lambert–Eaton Syndrome

A disorder of the NMJ that results in symmetric proximal muscle weakness. The syndrome is strongly associated with small cell lung cancer and can occur at any point in the course of small cell lung cancer.

> ***Key Fact***
>
> Lambert–Eaton syndrome is strongly associated with small cell lung cancer.

In contrast to myasthenia gravis, repetitive nerve stimulation results in increased amplitude of action potentials. This is mirrored clinically by increasing muscle strength with mild-to-moderate muscle activity. IVIG is the most common

therapy utilized and treatment of the underlying malignancy can also improve symptoms of weakness.

Respiratory failure due to muscle weakness tends to occurs late in the course. Mild respiratory muscle weakness in the earlier stages of the disease can be managed with NIPPV.

Botulism

A potentially fatal paralytic illness, caused by a neurotoxin produced by *Clostridium botulinum*.

CHARACTERISTICS

- Classically described as a symmetric, descending weakness.
- Exposure can result from ingestion of the preformed toxin or from wounds (most commonly "black tar" injection drug users).
- Upon entry into the body via a wound or the gastrointestinal (GI) tract, the toxin spreads hematogenously and irreversibly binds to the presynaptic membrane of cholinergic synapses.
- Symptoms can vary in severity from mild nonspecific GI symptoms to severe illness and death.

TREATMENT

- MV: Intubation and MV should be considered for those with worsening bulbar symptoms, VC < 30% of predicted, or rapidly declining pulmonary function; a long course of MV should be expected in these patients, often several months.
- Equine serum heptavalent botulism antitoxin (Pharmacologic treatment) is available through the CDC and should be given in severe illness.

Critical Illness Myopathy (CIM) and Critical Illness Polyneuropathy (CIP)

CIM occurs in patients who have been in the intensive care unit (ICU) for more than several days. Both glucocorticoids and neuromuscular blockade are risk factors for developing CIM.

- Most common presentation of muscle weakness is flaccid quadriparesis
- May also manifest as failure to wean from MV
- The myopathy is characterized by loss of myosin in muscle fibers
- It is reversible over weeks to months
- Treatment is mostly supportive, and aimed at minimizing glucocorticoids along with aggressive physical rehabilitation

CIP is associated with sepsis. The axonal injury to nerves is thought to be a manifestation of the systemic inflammatory response.

- Occurs in patients who have been in the ICU for weeks.
- Characterized by limb muscle weakness, diminished deep tendon reflexes, distal sensory loss.
- Muscle strength recovers over several months in mild-to-moderate cases.

Organophosphate Poisoning

Poisoning occurs most commonly from pesticide exposure. The classic presentation of acute toxicity is that of cholinergic excess: salivation, lacrimation, urination, defecation, emesis, bronchospasm, and bradycardia.

A subset of patients will develop a distinct neuromuscular weakness, sometimes termed intermediate syndrome. It is characterized by proximal muscle weakness, respiratory insufficiency, neck flexion weakness, and decreased deep tendon reflexes.

Patients will recover spontaneously, but often require supportive MV for several weeks.

Mnemonic

Symptoms of organophosphate poisoning—**SLUDGE**

Salivation
Lacrimation
Urination
Defecation
GI upset
Emesis

DISEASES OF THE CHEST WALL

Pectus Excavatum

Anterior chest wall deformity consisting of a concave depression (Figure 1-16.)



Figure 1-16. Pectus excavatum.
(Reproduced from Wikimedia Commons, CC BY-SA 3.0.)

CLINICAL CHARACTERISTICS—Most commonly occurs in men. Usually asymptomatic but may be associated with dyspnea on exertion, exercise limitation, local chest pain, and anxiety regarding the appearance of the defect.

The deformity occasionally can limit right ventricular filling, thus limiting cardiac output. Cardiopulmonary exercise testing may show cardiovascular limitation and decreased aerobic capacity. Pulmonary function tests (PFTs) can be normal or show mild restriction.

TREATMENT—Corrective surgery is available and is performed predominantly for cosmetic reasons. Surgery may or may not improve exercise capacity. PFTs generally remain unchanged after surgery.

Pectus Carinatum

- Protrusion of sternum from anterior chest wall (Figure 1-17).
- Less common than pectus excavatum
- Male subjects more commonly affected
- Usually discovered during growth spurt of puberty
- Associated conditions include congenital heart disease and scoliosis; pulmonary function typically normal in the absence of concurrent scoliosis
- Growing children and teens can be treated with customized braces, whereas adults require surgery for definitive treatment.
- As with pectus excavatum, benefits of surgery are mostly cosmetic

Figure 1-17. Pectus carinatum.
(Reproduced courtesy of Wikimedia Commons, CC BY-SA 3.0.)

Kyphoscoliosis

- Kyphosis refers to the normal anterior angulation of the thoracic spine.
- Scoliosis refers to an abnormal lateral curvature of the spine.
- Excess kyphosis or scoliosis can result in rib traction.
- Cobb angle measures the severity of hyperkyphosis or scoliosis (Figure 1-18); the degree of spinal deformity is related to the degree of respiratory compromise; ventilation-perfusion mismatch occurs when the scoliosis angle is > 65 degrees.

CLINICAL CHARACTERISTICS—Begins in childhood and typically is idiopathic.

- Both aging and progressive curvature add to decreased chest wall compliance, which increases work of breathing. The patient compensates with low tidal volume (V_T) and increased respiratory rate to minimize work of breathing. However, this can increase dead-space ventilation, and the resultant alveolar hypoventilation results in hypercapnia.
- PFT: Restrictive pattern with low TLC and VC but preserved RV (RV:TLC ratio increased) and FRC usually decreased due to reduced chest wall compliance.
- Low chest wall compliance results in lower V_T and subsequent atelectasis. The atelectasis then contributes to decreased lung compliance.

Key Fact

PFT findings in severe kyphoscoliosis include low TLC and VC, with preserved RV. This results in an increased RV:TLC ratio.



Figure 1-18. Cobb angle measurement of dextroscoliosis.
(Reproduced from Skoliose-Info-Forum.de, GNU Free Documentation License 1.2)

TREATMENT

- Supportive care in mild cases
- Treat other comorbid lung conditions.
- Surgery: Probably of limited value in adults but can be considered in select children
- Pulmonary rehabilitation
- NIPPV, particularly at night to reduce work of breathing and prevent hypoventilation
- Persistent hypercapnia despite NIPPV is a predictor of mortality

Obesity

The World Health Organization categorizes obesity as follows:

- Class I (moderate obesity): BMI 30–35
- Class II (severe obesity): BMI 35–40
- Class III (very severe obesity): BMI > 40

Severely obese patients tend to breathe at lower tidal volumes. Both chest wall and lung compliance often are reduced. As weight increases, progressive airway narrowing at low volumes can result in intrinsic positive end-expiratory pressure and air trapping. Atelectasis occurs at the lung bases.

Mild hypoxia can be seen in the awake, upright patient. Sleep and supine positions both independently worsen hypoxia. Obese patients tend to be eucapnic except the subset of patients with OHS.

PFT findings in severely obese patients:

- TLC, VC, and FRC are decreased
- FEV_1 and FVC are decreased with a preserved FEV_1:FVC ratio
- Residual volume (RV) usually is spared (RV:total lung capacity [TLC] ratio is elevated) except in rare severe cases
- DLCO is elevated when adjusted for alveolar volume

2 Critical Care

Anthony F. Arredondo, MD, Stephanie Young Clough, MD, Nandita R. Nadig MD, & Diana H. Yu, MD

NON-LUNG CRITICAL CARE

SHOCK

Shock is end-organ hypoperfusion as a result of circulatory failure. Mechanisms of circulatory failure:

- Compromised vascular tone (distributive shock)
- Low cardiac output (CO; cardiogenic or obstructive shock)
- Low plasma volume in blood vessels (hypovolemic shock)

Diagnosis

See Table 2-1.

Table 2-1. Diagnosis of Shock

Clinical Findings	Measured Parameters
Hypotension (systemic arterial hypotension)	Systolic blood pressure < 90 mm Hg or mean arterial pressure < 65−70 mm Hg Tachycardia
Hypoperfusion	Urine output < 0.5 mL/kg/h Cold and clammy skin; cyanosis Obtundation, disorientation, confusion Elevated lactate level

Mechanisms

See Table 2-2.

Table 2-2. Mechanisms of Shock

Type of Shock	Pathophysiology	Differential
Distributive	Decreased systemic vascular resistance	Severe sepsis Anaphylaxis Spinal cord injury (neurogenic)
Cardiogenic	Decreased CO due to "pump failure"	Acute myocardial infarction (right ventricular/left ventricular failure) End-stage cardiomyopathy Severe valvular disease Myocarditis Cardiac arrhythmias
Obstructive	Decreased CO due to external forces that change ventricular size and function	Pulmonary embolism Cardiac tamponade Tension pneumothorax Tension hydrothorax/pleural effusion Abdominal compartment syndrome[a]
Hypovolemic	Decreased CO due to loss of plasma or blood volume that reduces venous return	Acute hemorrhage Dehydration from vomiting, diarrhea, sweating, or insensible losses

CO, cardiac output.
[a]Leads to decreased venous return and cardiac output.

Evaluation and Treatment

Three general principles in the evaluation and treatment of shock:
- Volume resuscitation
- Vasoactive support
- Ventilatory support when needed

Rapid recognition of the type of shock can often be achieved with a bedside echocardiogram. However, shock is often multifactorial in a given patient.

ECHOCARDIOGRAPHIC FINDINGS

Distributive shock:
- Normal cardiac chambers and contractility
- In sepsis, ventricles often dilated to maintain stroke volume

Hypovolemic shock:
- Small cardiac chambers and normal to high contractility

Cardiogenic shock:
- Large ventricles and poor contractility with ventricular failure
- Wall motion abnormalities with ischemia
- Mechanical defects: Valvulopathy, ventricular septal defect, ventricular free wall rupture

Obstructive shock:

- Tamponade
  - Pericardial effusion with small right and left ventricles
  - Dilated inferior vena cava (IVC)
- Pulmonary embolism with right ventricular failure

VENTILATORY SUPPORT—Supplemental oxygen: Avoid hyperoxia.
Mechanical ventilation: Invasive and noninvasive

- Invasive mechanical ventilation:
  - Used for severe dyspnea, hypoxemia, or acidemia
  - Allows patient to rest, increasing oxygen delivery and reducing oxygen demand
  - Decreases left ventricular afterload
- Noninvasive mechanical ventilation:
  - Two types: Continuous positive airway pressure (CPAP) and bilevel positive airway pressure
  - Used cautiously because failure can lead to rapid cardiopulmonary arrest

VOLUME RESUSCITATION—Objective is to improve CO by optimizing preload.
Volume responsiveness:

- Accurate assessment of volume responsiveness can help to identify patients who will benefit from volume therapy. Even in septic shock, only ~ 50% of patients are considered volume responsive.
- Defined as > 15% increase in CO after fluid challenge.
- Many surrogates are available for CO, including stroke volume variation, pulse pressure variation, aortic blood flow, and IVC variation.

Dynamic assessment of volume responsiveness:

- Variation in intrathoracic pressure during respiratory cycle determines intravascular depletion and fluid responsiveness.
- Pulse pressure variation, stroke volume variation, aortic blood flow, and IVC variation are measurements determined by changes in intrathoracic pressure during the respiratory cycle:
  - Limitations of Pulse pressure variation, stroke volume variation, and IVC variation: Patient must be mechanically ventilated while receiving high tidal volumes (8–12 mL/kg) with no spontaneous respiratory effort, no arrhythmias, and normal right ventricular function.
- Passive leg raise:
  - Induced changes in stroke volume or CO with passive leg raise predict fluid responsiveness, regardless of mechanical ventilation, underlying arrhythmias or technique of measurement.
  - CO is measured with bioreactance, pulse contour analysis, or esophageal Doppler.
- Fluid challenge:

> ***Key Fact***
>
> Pulmonary artery catheterization can help to diagnose and guide treatment of shock, but has not been shown to improve survival or any other patient-related outcomes.

  - Intravenous fluids (crystalloids) to infuse 300–500 mL over 20–30 minutes
  - Positive test result: Increased arterial pressure, increased urine output, or decreased heart rate

Static assessment of volume responsiveness:

- Static measurements, such as central venous pressure, pulmonary capillary wedge pressure, and left ventricular end-diastolic area index, are unreliable.

VASOACTIVE DRUGS—Vasoconstrictors are indicated if the patient remains hypotensive despite adequate fluid resuscitation. Initiation of vasoactive therapy during fluid resuscitation may be indicated in severe hypotension with rapid weaning if hypovolemic shock is the primary cause (Table 2-3).

Adrenergic agonists (e.g., norepinephrine):

- First-line vasoconstrictor because of the rapid onset of action, high potency, and short half-life
  - β-adrenergic agonist: Increases blood flow as a result of increased heart rate and contractility; increases risk of myocardial ischemia.
  - α-adrenergic agonist: Increases vascular tone and blood pressure; can also decrease CO and impair blood flow to hepatosplanchnic region.

Inotropic agents:

- Dobutamine is considered first-line therapy for increasing CO.
  - Predominantly has β-adrenergic properties.
  - Blood pressure can decrease when patients are not well volume resuscitated.
  - Peripheral vasoconstriction can occur at high doses, given α-agonist properties.
- Phosphodiesterase type III inhibitors (milrinone and enoximone) decrease the metabolism of cyclic adenosine monophosphate and combine inotropic and vasodilating properties.
  - Long half-lives (4–6 hours).
  - Milrinone is known to cause hypotension via vasodilation.

Table 2-3. Vasoconstrictors

Vasoconstrictor	Receptors	Cardiovascular Effects	Indication	Notes
Norepinephrine (NE)	Mostly α-adrenergic; modest β-adrenergic effects	Increases vascular tone and maintains CO	First-line vasoconstrictor for most cases of shock, regardless of cause	Arrhythmias, bradycardia, peripheral ischemia
Epinephrine (E)	Mostly β_1- and β_2-adrenergic effects at low doses Increasing α-adrenergic effects at high doses	Inotropic with β-adrenergic effects Vasoconstriction with α-adrenergic effects	Alternative or add-on therapy to NE	Arrhythmias Reduction in gut blood flow Increases lactate
Dopamine (DA)	Mostly β-adrenergic effects at low doses Mostly α-adrenergic effects at high doses, but weak	No protective renal effects at very low doses (< 3 μg/kg/min) Inotropic with β_1 effects (5–10 μg/kg/min) Vasoconstriction with alpha effects (> 10 μg/kg/min)	Symptomatic bradycardia Not considered an alternative first-line vasoconstrictor to NE	More arrhythmogenic than NE May be associated with increased 28-day mortality in cardiogenic shock May be associated with higher death rates in patients with septic shock
Phenylephrine (PE)	Almost purely α-adrenergic effects	Increases vascular tone Can reduce CO and limit blood flow to gut	Rarely indicated as monotherapy May be used when other agents are contraindicated OR When shock persists despite > 2 agents	Used in neurologic disorders, anesthesia-induced shock Side effects: Reflex bradycardia
Vasopressin (V)	V1 receptors (vascular smooth muscle) V2 receptors (renal collecting duct system)	Direct vasoconstriction +/- inotropic or chronotropic effects	Not indicated as a single, titratable, vasoconstrictor Fixed dose: 0.03 or 0.04 units/min Higher doses associated with cardiac and peripheral ischemia	VASST Study: NE vs. NE + V No overall mortality benefit NE + V group: Large decrease in NE requirement Subgroup: NE < 15 μg/min + V associated mortality benefit

CO, cardiac output.

Key Fact

The VASST Study comparing norepinephrine with norepinephrine + vasopressin in septic shock showed no overall difference in survival between the treatment groups. The norepinephrine + vasopressin group had decreased norepinephrine requirement. Mortality benefit was seen in the subgroup of patients with less severe septic shock receiving both norepinephrine+ vasopressin when the norepinephrine dose was < 15 μg/min.

Key Fact

In a 2012 meta-analysis, norepinephrine was compared with dopamine for septic shock. The results suggested an increased risk of death for dopamine compared with norepinephrine.

Key Fact

Phenylephrine can reduce CO and induce reflex bradycardia.

MECHANICAL SUPPORT—Intra-aortic balloon counterpulsation:

- Increases mean arterial pressure (MAP), reduces left ventricular afterload, and increases coronary blood flow.
- Offers no survival benefit in patients with cardiogenic shock.
- Difficult to use in arrhythmias and contraindicated in significant aortic regurgitation.

Key Fact

Intra-aortic balloon counterpulsation has not shown a mortality benefit in patients with cardiogenic shock.

Venoarterial extracorporeal membrane oxygenation:

- Used as temporary lifesaving measure in patients with reversible cardiogenic shock or as a bridge to heart transplantation.

Key Fact

Norepinephrine is the first-line vasoconstrictor for most forms of shock.

GOALS OF THERAPY—MAP goals:

- Baseline healthy patient
  - MAP goal ≥ 65–70 mm Hg.
  - Purely hypovolemic patients may tolerate MAP < 65 mm Hg.
- Baseline uncontrolled hypertension
  - May require higher MAP goal.

Perform volume resuscitation and vasoactive support:

- Monitoring: Mental status, skin appearance, temperature, and urine output

Perform lifesaving measures:

- Surgery, pericardial drainage, revascularization for acute myocardial infarction, etc.

Correct hypoxemia and severe anemia:

- Target hemoglobin 7 g/dL for euvolemic patients who are not actively bleeding

Optimize CO: After hypoxemia and anemia are corrected, CO is the main determinant of oxygen delivery.

- The goal is to achieve adequate CO to maintain tissue perfusion.
- Mixed venous oxygen saturation (S_{VO2}):
  - Integrates oxygen supply and demand; requires pulmonary artery catheter.
  - Used to interpret CO.
  - Typically decreased in low-flow states (cardiogenic shock) or anemia.
  - Normal to high in distributive shock (normal, 60–80%).
- Central venous oxygen saturation (S_{CVO2}) for septic shock:
  - Used as a surrogate for S_{VO2}; measured with central venous catheter.
  - Reflects O_2 saturation of venous blood from upper half of the body.
  - Normally, S_{CVO2} is slightly < S_{VO2}.
  - In the critically ill, S_{CVO2} is often > S_{VO2}.
  - A recent article brought into question the efficacy and mortality benefit of early goal-directed therapy in sepsis using target $S_{CVO2} \geq 70\%$ in the first 6 hours.

Blood lactate level:

- Lactate ≥ 3 mmol/L: Targeting decrease ≥ 20% associated with reduced in-hospital mortality rate.
- Reduced lactate clearance seen with impaired liver function.

> ***Key Fact***
>
> S_{VO2} is typically decreased in low flow states (cardiogenic shock) or anemia, but is normal or high in distributive shock.

TYPES OF SHOCK

Distributive Shock

Distributive shock is characterized by decreased systemic vascular resistance with a high CO state.

SEPTIC SHOCK—Most common type of shock. It is sepsis with circulatory failure despite adequate volume resuscitation.

> ***Mnemonic***
>
> Causes of distributive shock—**SLAM D ANT**
>
> **S**ystemic inflammatory response syndrome (pancreatitis, burns, trauma)
> **L**iver failure
> **A**naphylaxis
> **M**yxedema coma
>
> **D**rugs or toxins (insect bites, transfusion reactions, heavy metal poisoning)
>
> **A**drenal insufficiency
> **N**eurogenic shock (central nervous system or spinal cord injury)
> **T**oxic shock syndrome

Principles of treatment:

- Control of source of infection with rapid administration of intravenous (IV) antibiotics and removal of infectious source
- Respiratory support
- Early goal-directed therapy: Treatment algorithm focused on resuscitation in the first 6 hours:
  - Volume resuscitation with goal central venous pressure 8–12 mm Hg and urine output ≥ 0.5 mL/kg/h
  - Vasoconstrictors started if MAP ≥ 65 not reached after fluid resuscitation
  - Goal S_{CVO2} ≥ 70% or S_{VO2} ≥ 65%
  - Blood transfusions: Goal hematocrit > 30%; controversial because packed red blood cell transfusions have potential harm in critical illness
  - Dobutamine: Potential therapy if MAP and hematocrit are at goal and low central/mixed venous oxygen saturation persists
- Early interventions in sepsis, not necessarily specifics of early goal-directed therapy is a possible cause of improved outcomes

Cardiogenic Shock

Caused by cardiac pump failure characterized as decreased CO and increased systemic vascular resistance.

TYPES—General categories of pump failure:

- Cardiomyopathies
- Arrhythmias
- Mechanical abnormalities

Cardiomyopathies:

- Post-myocardial infarction ventricular failure:
  - Left ventricular failure: Most common cause of post-myocardial infarction shock; occurs when infarction involves > 40% of left ventricular myocardium.
  - Right ventricular failure: Acute inferior myocardial infarction and hypotension raises suspicion for right ventricular infarct, with the right coronary artery the usual culprit. Right-sided electrocardiogram (ECG) is obtained if suspected.
  - 30–50% of inferior myocardial infarctions involve the right ventricle.
  - SHOCK Trial: Emergent revascularization (percutaneous coronary intervention or coronary artery bypass grafting) for post-myocardial infarction cardiogenic shock improved mortality at 6 and 12 months compared with stabilization with medical management and intra-aortic balloon counterpulsation.
- Nonischemic cardiomyopathy (alcohol, drugs, viral)
- Takotsubo cardiomyopathy:
  - Stress-induced cardiomyopathy or transient apical ballooning syndrome
  - Related to extreme emotional or physical stress (~ 70% of cases)
  - Hyperdynamic cardiac base and akinetic cardiac apex on ultrasound
  - Coronary angiography without stenosis to explain cardiomyopathy

Key Fact

Left ventricular failure is the most common cause of post-myocardial infarction shock.

Arrhythmias:

- Atrial fibrillation and flutter decrease CO by interrupting coordinated atrial filling of the ventricles.
- Ventricular tachycardia: Ventricular fibrillation abolishes CO.
- Bradyarrhythmias and complete heart block

Key Fact

Hypotension and inferior myocardial infarction should raise suspicion for right ventricular infarct with associated cardiogenic shock, especially if hypotension occurs after nitroglycerin or vasodilators. Obtain right-sided ECG. ST elevation > 1 mm in lead V_4R or V_5R is specific for right ventricular infarct.

Mechanical abnormalities:

- Valvular defects:
  - Rupture of papillary muscle or chordae tendineae
  - Aortic insufficiency from retrograde aortic dissection into aortic valve ring
  - Critical aortic stenosis
- Ventricular septal defects or rupture:
  - Post-myocardial infarction bimodal occurrence at 24 hours and 3–5 days
  - Pansystolic heart murmur, parasternal thrill, left-to-right intracardiac shunt
  - Treatment: Intra-aortic balloon counterpulsation, inotropes, afterload reduction, percutaneous occluding device with definitive surgical repair within 48 hours

Obstructive Shock

Usually the result of extracardiac forces that lead to cardiogenic shock.

CAUSES

- Massive pulmonary embolism: Treat with thrombolytics.
- Tension pneumothorax: Treat with needle decompression and/or chest tube.
- Cardiac tamponade: Treat with pericardiocentesis.
- Severe constrictive pericarditis: Treat underlying cause; often requires surgical intervention.

Hypovolemic Shock

- Two types: Hemorrhage and fluid losses.
- The mainstay of therapy is volume resuscitation with blood, crystalloids, or colloids.

Multiple Organ Dysfunction Syndrome

In the critically ill patient, multiple organ dysfunction syndrome represents progressive organ dysfunction in which homeostasis cannot be obtained without intervention. It is the most severe entity in the spectrum of systemic inflammatory response syndrome/sepsis.

PRIMARY AND SECONDARY CAUSES

- Primary:
  - Organ dysfunction directly attributed to a specific insult
  - Example: Renal failure from rhabdomyolysis
- Secondary:
  - Organ dysfunction attributed to the host's response to the insult
  - Example: Acute respiratory distress syndrome (ARDS) as a result of pancreatitis

CARDIOVASCULAR DISORDERS

Advanced Cardiac Life Support/Arrhythmias

In the intensive care setting, arrhythmias commonly occur in the setting of metabolic disturbances, myocardial infarction, sepsis, and respiratory failure.

BRADYARRHYTHMIAS AND TACHYARRHYTHMIAS IN THE INTENSIVE CARE UNIT (ICU)

Bradyarrhythmias:

- Sinus bradycardia: Rhythm arising from sinus node at a rate < 60 beats/min. Treatment is indicated only for symptomatic severe cases and involves temporary transvenous or transcutaneous cardiac pacing, isoproterenol, dopamine, epinephrine, or atropine.
- **Atrioventricular block (Figure 2-1):** Disturbance of normal conduction between the atria and ventricles.
- **Bradycardia after acute myocardial infarction:** Caused by disruption of blood flow to sinus node, atrioventricular node, His-Purkinje system, or increased vagal tone (seen in inferior myocardial infarction). Treatment recommended in patients with hemodynamic instability, sinus pauses ≥ 3 seconds, or heart rate < 40 beats/min.



Figure 2-1. Types of atrioventricular blocks.
(Reproduced, with permission, from USMLE-Rx.com.)

Tachyarrhythmias: Caused by abnormal automaticity, re-entry, or triggered automaticity.

- **Regular narrow QRS complex tachyarrhythmias:**
  - Supraventricular tachycardia (Figure 2-2): Caused by re-entrant mechanism.
    - Treat with adenosine 6–12 mg intravenously.
    - If not converted, provide rate control with β blocker or calcium channel blocker (nondihydropyridine).



Figure 2-2. Supraventricular tachycardia.

- **Irregular narrow QRS complex tachyarrhythmias:**
  - Atrial fibrillation and atrial flutter (Figure 2-3):
    - Provide rate control with β blocker or calcium channel blocker.
    - If hypotensive, consider loading with digoxin or amiodarone.
    - Perform cardioversion if hemodynamically unstable.

Figure 2-3. (A) Atrial fibrillation. (B) Atrial flutter.

- **Regular wide QRS complex tachyarrhythmias:**
  - Supraventricular tachycardia with aberrancy and monomorphic ventricular tachycardia (Figure 2-4):
    - Manage clinically stable patient with elective synchronized cardioversion or antiarrhythmics: Adenosine, procainamide, amiodarone, or sotalol.

Figure 2-4. (A) Supraventricular tachycardia with aberrancy. (B) Monomorphic ventricular tachycardia.

- **Irregular wide QRS complex tachyarrhythmias.**
  - Polymorphic ventricular tachycardia/Torsade de pointes (Figure 2-5A and B):
    - Manage with emergent defibrillation and magnesium sulfate.
  - Ventricular fibrillation (Figure 2-5C):
    - Manage with emergent defibrillation.
    - If persistent after defibrillation and cardiopulmonary resuscitation (CPR), give epinephrine (1 mg IV every 3–5 minutes) with option of vasopressin (40 units IV) as substitution for first or second dose of epinephrine.
    - No survival benefit is seen with antiarrhythmic drugs.



A



B

C

Figure 2-5. (A) Polymorphic ventricular tachycardia. (B) Torsade de pointes. (C) Ventricular fibrillation.

Hypertensive Emergency

Severe hypertension is defined as systolic blood pressure > 180 mm Hg and/or diastolic blood pressure > 120 mm Hg. Hypertensive emergency is severe hypertension in the presence of end-organ damage.

END-ORGAN DAMAGE

- **Neurologic:** Papilledema, hypertensive encephalopathy, intracerebral hemorrhage, subarachnoid hemorrhage
- **Cardiac:** Acute aortic dissection, acute myocardial infarction, acute left ventricular failure
- **Renal:** Acute kidney injury

Key Fact

Common secondary causes of hypertensive emergencies: (1) renal crisis from collagen vascular disease, (2) severe hypertension after renal transplantation, (3) pheochromocytoma, (4) cocaine, (5) rebound hypertension, and (6) preeclampsia/eclampsia.

TREATMENT

- **Acute aortic dissection:** Goal systolic blood pressure < 120 mm Hg. Initial management is β blockers (esmolol, labetalol) followed by vasodilators (nicardipine, nitroprusside).
- **Acute hemorrhagic stroke:** Goal systolic blood pressure < 140 mm Hg. Reduce expansion of hematoma with nicardipine or labetalol.
- **Acute ischemic stroke:** Goal systolic blood pressure < 220 mm Hg with permissive hypertension. Manage with nicardipine or labetalol.
- **Hypertensive encephalopathy:** Goal is initial decrease in MAP of 20–25%. Manage with labetalol, nicardipine, or nitroprusside.
- **Pre-eclampsia:** Goal is diastolic blood pressure < 110 mm Hg. Manage with magnesium, IV labetalol, nicardipine, or hydralazine. Definitive management is delivery.

Cardiac Tamponade

Pericardial effusion may develop acutely or gradually and can be complicated by tamponade. Cardiac tamponade is a clinical diagnosis.

- Acute cardiac tamponade can occur as a result of rupture of the heart or aorta secondary to trauma or procedural complications.
- Subacute cardiac tamponade can occur with underlying malignancy, infections, uremia, or pericarditis.

CLINICAL PRESENTATION

- Signs and symptoms: Dyspnea, chest pain, syncope/presyncope, hypotension, elevated jugular venous pressure, pulsus paradoxus, pericardial rub, and edema
- ECG: Sinus tachycardia, low QRS voltage, and electrical alternans
- Chest x-ray: Possible enlarged cardiac silhouette
- Transthoracic echocardiogram: Moderate to large pericardial effusion, diastolic collapse of right atrium/ventricle, and dilated IVC

TREATMENT

Both pericardiocentesis and surgical drainage are effective for relief of symptoms associated with hemodynamic compromise.

- Catheter pericardiocentesis is often preferred over surgical drainage because of lower complication and mortality rates.
- Surgical drainage has the advantage of accessibility for pericardial biopsy.

GASTROINTESTINAL DISORDERS

Acute Gastrointestinal Hemorrhage

UPPER GASTROINTESTINAL BLEED—Peptic ulcer disease accounts for ~ 50% of patients with upper gastrointestinal bleed. Esophageal/gastric variceal bleeds account for 5–10%.

Evaluation: Emphasis on stabilization and appropriate triage

- Urea/creatinine ratio ≥ 100 may suggest an upper gastrointestinal source.
- Nasogastric lavage can help to identify a potential upper gastrointestinal source and may indicate high-risk lesions if positive.

Treatment: Hemodynamic resuscitation, risk stratification for rebleed or mortality, pre-endoscopic medications, and endoscopy

- Recent data suggest that a restrictive transfusion threshold (transfuse when hemoglobin < 7 g/dL) in upper gastrointestinal bleed has a significantly lower mortality rate (6% versus 9%) at 45 days compared with a liberal transfusion threshold (transfuse when hemoglobin < 9 g/dL).
- High-risk clinical criteria:
  - Age > 65 years, comorbidities, anemia, melena, fresh blood on rectal examination, hematemesis, bloody nasogastric aspirate, and transfusion requirements
- Proton pump inhibitors neutralize gastric acid, leading to stabilization of clots and promotion of hemostasis.
- Vasoactive medications, such as vasopressin, somatostatin, and their analogs (octreotide), decrease portal blood flow in acute variceal hemorrhage.
- Prophylactic antibiotics (e.g., quinolone or cephalosporin) in cirrhotic patients result in reduction of infectious complications and risk of recurrent esophageal variceal bleeding.
- Esophagogastroduodenoscopy:
  - Specific findings are associated with subsequent risk of recurrent bleed:
    - Clean ulcer base (3–5%)
    - Flat spot (7–10%)
    - Adherent clot (25–30%)
    - Nonbleeding visible vessel (50%)
    - Active arterial bleed (90%)
  - High-risk endoscopic stigmata are treated with cauterization with bipolar probes or mechanical therapy with hemostatic clips, with or without epinephrine.
  - Band ligation is preferred over sclerotherapy for esophageal varices.

Key Fact

Early decompression with transjugular intrahepatic portosystemic shunt within 24–48 hours in high-risk patients results in reduction of treatment failure and mortality rate in severe variceal bleeds

Key Fact

Indications for stress ulcer prophylaxis in critically ill patients: mechanical ventilation > 48 hours, coagulopathy, and two or more of the following: sepsis, ICU admission > 1 week, occult gastrointestinal bleed > 6 days, steroid therapy.

Mnemonic

Scoring system for mortality in upper gastrointestinal bleed: **AIMS65**

Albumin < 3.0 g/dL
INR > 1.5
Altered **M**ental status
Systolic blood pressure < 90 mm Hg
Age > **65** years

- Balloon tamponade is reserved as a temporizing measure for severe hemorrhage with hemodynamic instability.
- Transjugular intrahepatic portosystemic shunt is reserved for unsuccessful endoscopic therapy or recurrent variceal bleed.
- Prophylactic intubation before endoscopy has not been shown to reduce the risk of aspiration pneumonia.

LOWER GASTROINTESTINAL BLEED—The most common etiology is diverticulosis. Bleeding from angiodysplasia or inflammatory bowel disease is more common in young patients. Malignancy or mesenteric ischemia is more common in older patients.

Treatment:

- Colonoscopy is diagnostic and can be therapeutic.
- Hemoclips, epinephrine injections, or bipolar coagulation are used for bleeding vessels.
- Persistent bleeding without identifiable lesions may require further diagnostic modalities such as radionuclide scanning (detects bleeding at rates 0.1–0.5 mL/min) or mesenteric angiography (detects bleeding at rates > 0.5 mL/min).
- Surgical intervention (colectomy) may be warranted in patients with rapid deterioration despite resuscitation.

Acute Hepatic Failure

Severe acute injury to the liver parenchyma related to exposure to hepatotoxins (e.g., alcohol, acetaminophen) or infectious agents (e.g., viruses) with encephalopathy and coagulopathy (INR > 1.5) in the absence of preexisting liver disease.

ACUTE LIVER FAILURE IN THE ICU—Given the poor prognosis, patients with acute liver failure should be managed in an ICU at a facility with the capability for liver transplantation.

Etiology:

- Drugs and toxins: Acetaminophen, alcohol, *Amanita phalloides* (mushroom poisoning), idiosyncratic drug reactions, toxin exposure
- Infections: Hepatitis viruses (B, C, D, E), cytomegalovirus, Epstein-Barr virus
- Hypoperfusion: Ischemic hepatitis, sepsis with shock liver, veno-occlusive disease, HELLP syndrome, hemophagocytic lymphohistiocytosis
- Genetic: Wilson disease, autoimmune hepatitis
- Infiltration: Malignant infiltration of tumor, typically metastatic

Clinical presentation:

- Hepatic encephalopathy:
  - Grade I: Mild confusion, slurred speech
  - Grade II: Lethargy, moderate confusion
  - Grade III: Incoherence, somnolence
  - Grade IV: Coma
- Cerebral edema: Increased intracranial pressure (ICP), which can cause hypertension, bradycardia, respiratory depression, and seizures

Diagnosis:

- Laboratory findings: Elevated aminotransferases (with elevated bilirubin and alkaline phosphatase levels), prolonged prothrombin time (INR $\geq$ 1.5)
- Imaging: Abdominal ultrasound, computed tomography (CT), magnetic resonance imaging (MRI)/magnetic resonance venography (MRV), liver biopsy in select cases

Treatment:

- Supportive care: IV fluids, infection surveillance, and stress ulcer prophylaxis
- Treatment of underlying cause:
  - N-acetylcysteine for acetaminophen toxicity and other causes of acute liver failure
  - Antiviral therapy for hepatitis B infection
  - Transjugular intrahepatic portosystemic shunt placement or surgical decompression for Budd-Chiari syndrome
- Liver transplantation:
  - Decision hinges on probability of spontaneous recovery, with significant emphasis on degree of encephalopathy.
  - King's College Criteria are widely used for referral for liver transplantation:
    - Acetaminophen-induced liver failure: Arterial pH < 7.3, regardless of grade of encephalopathy, or grade III/IV encephalopathy, with both prothrombin time > 100 seconds and serum creatinine > 3.4 mg/dL
    - Other causes of liver failure: prothrombin time > 100 or any three of the following criteria (age < 10 or > 40 years; unfavorable etiology [i.e., non-A or B viral hepatitis, drug reaction, or Wilson disease]; prothrombin time > 50 seconds; serum bilirubin > 18 mg/dL; > 7 days of jaundice before encephalopathy develops)

Key Fact

Hyperventilation for increased ICP is only useful if there is a planned intervention within 6–24 hours because it may eventually result in rebound elevation of ICP.

Management of complications:

- Hepatic encephalopathy: Lactulose is controversial, with no difference in severity of encephalopathy or overall outcome
- Cerebral edema with possible sequelae of elevated ICP, cerebral ischemia, and brain stem herniation

  - Treatment of elevated ICP: Hyperosmotic agents (e.g., mannitol), hyperventilation (Pa_{CO2} 25–30 mm Hg) for cerebrovascular vasoconstriction, barbiturates (pentobarbital)

Key Fact

Cerebral edema is the most common cause of death in acute liver failure.

- Seizures: Phenytoin is recommended over benzodiazepines, given the poor liver clearance of sedatives.
- Respiratory failure: Positive end-expiratory pressure (PEEP) should be used with caution because it can exacerbate cerebral edema.

Acute Pancreatitis

Gallstones and chronic alcohol abuse account for ~ 75% of cases of acute pancreatitis in the U.S.

Mnemonic

Etiology of acute pancreatitis—**I GET SMASHED**

Idiopathic

Gallstones
Ethanol
Trauma

Steroids
Mumps
Autoimmune (PAN)
Scorpion stings
Hyperlipidemia.
  Hypercalcemia
ERCP
Drugs (including azathioprine and diuretics)

ACUTE PANCREATITIS IN THE ICU—Overall mortality rate in all hospitalized patients with acute pancreatitis is ~ 10% (range, 2–22%). Those with severe acute pancreatitis requiring ICU care have a mortality rate of up to 30%.

Poor prognostic factors and complications:
- Elevated C-reactive protein level
- Respiratory complications of hypoxemia, atelectasis, pleural effusion, pneumonia, or ARDS
- Multiple organ system failure
- Pancreatic pseudocysts with necrosis and abscesses
- Splenic vein thrombosis with development of gastric varices
- Gastrointestinal bleed as a result of stress ulcers

Treatment:
- Aggressive fluid resuscitation and pain control
- Nutrition:
  - Mild pancreatitis: Oral feeding is initiated within 24–48 hours after onset.
  - Moderate to severe pancreatitis: Enteral feeding within 24–48 hours is preferred. Parenteral nutrition is initiated if enteral feeding is not tolerated.
- Antibiotic therapy for necrotizing pancreatitis, with consideration of interventional drainage or surgical debridement

Nutrition

Sepsis, trauma, and other causes of critical illness result in a hypercatabolic state, with subsequent immune dysfunction, skeletal muscle atrophy, peripheral and central weakness, and nutritional deficiencies.

NUTRITIONAL SUPPORT IN THE ICU

Indications:

- In patients without contraindications to enteral nutrition, early enteral feeding (within 48 hours of ICU admission) is recommended.
- In patients who are adequately nourished, early parenteral nutrition (within 1 week of ICU admission) is avoided, given increased risks of infection and prolonged mechanical ventilation.
- In patients who are malnourished and have contraindications to enteral nutrition, parenteral nutrition is considered. However, the timeline for initiation of parenteral nutrition remains uncertain, given the associated risks.

Contraindications:

- Contraindications to enteral nutrition:
  - Hemodynamic instability in underresuscitated patients who may be predisposed to bowel ischemia
  - Bowel obstruction, bowel ischemia, ileus, upper gastrointestinal bleed, intractable vomiting, or diarrhea
- Contraindications to parenteral nutrition:
  - Hyperosmolality, hypervolemia
  - Severe hyperglycemia or electrolyte abnormalities

Potential complications:

- Overfeeding syndrome:
  - Excessive (particularly parenteral) nutritional support can result in azotemia from excess protein, hypertriglyceridemia, metabolic acidosis, hyperglycemia, hepatic steatosis, and increased CO_2 production.
- Refeeding syndrome:
  - Patients with chronic malnourishment who receive excessive nutritional support can have hypokalemia, hypophosphatemia, and hypomagnesemia as a result of rapid intracellular shifts, with subsequent respiratory failure, heart failure, or arrhythmias.

Glucose control in the ICU: Aggressive glucose control (80–108 mg/dL) associated with increased mortality rate compared with glucose control target ≤ 180 mg/dL.

Key Fact

Enteral feeds are often held in ICU patients with a large gastric residual volume. However, two recent trials showed that gastric residual volume up to 500 mL could be safely tolerated and not measuring gastric residual volume improved caloric intake without increasing the incidence of pneumonia.

RENAL DISEASE

Acute Renal Failure

ACUTE KIDNEY INJURY IN THE ICU—Independent risk factors for hospital mortality:

- Vasopressors
- Mechanical ventilation
- Septic shock
- Cardiogenic shock
- Hepatorenal syndrome

The need for continuous renal replacement therapy for acute kidney injury is also associated with a high in-hospital mortality rate.

Continuous renal replacement therapy:

- Better tolerated in hemodynamically unstable patients, but does not improve mortality or renal recovery compared with intermittent hemodialysis.

ELECTROLYTE ABNORMALITIES—See Table 2-4.

Table 2-4. Electrolyte Derangement

Electrolyte	Hypo/Hyper	Clinical Manifestations	Common Disease Associations	Management Notes
Potassium	Hypokalemia	Muscle weakness that can progress to respiratory failure and colonic pseudo-obstruction	Metabolic alkalosis, diabetic ketoacidosis	Potassium replacement
	Hyperkalemia	Muscle weakness, peaked-T waves, shortened QT progressing to PR/QRS widening and asystole	Succinylcholine, trauma, rhabdomyolysis, tumor lysis, **acute kidney injury**	If electrocardiogram changes, treatment with calcium Sodium bicarbonate ineffective in dialysis-dependent patients
Sodium	Hyponatremia	When acute, can cause cerebral edema, altered mental status, seizures, and death	Diuretics, heart failure, cirrhosis, SIADH, low solute intake	Hypertonic saline solution for severe cases (≤ 10 mEq correction over 24 h)
	Hypernatremia	Polydipsia, muscle weakness, confusion, coma	Dehydration, diabetes insipidus	Repletion of free water deficit
Calcium	Hypocalcemia	Prolonged QT, tetany, seizures, hypotension, papilledema	s/p parathyroidectomy, thyroidectomy, head and neck surgery	Calcium chloride or gluconate Avoid calcium and dialyze if hyperphosphatemia is the cause (tumor lysis, rhabdomyolysis, **acute kidney injury**)
	Hypercalcemia	Constipation, fatigue, polyuria, polydipsia, anorexia, nausea, mood changes	Hyperparathyroidism, malignancy, milk alkali syndrome	IV fluids + furosemide, calcitonin, bisphosphonates, hemodialysis for severe cases
Phosphate	Hypophosphatemia	Respiratory muscle weakness	Alcoholism, anorexia nervosa, refeeding	IV phosphate
Magnesium	Hypomagnesemia	Muscle weakness, ↓ deep tendon reflexes, nausea, flushing, bradycardia, tetany, polymorphic ventricular tachycardia with prolonged QT	Hypokalemia and hypocalcemia	IV magnesium
	Hypermagnesemia	Muscle weakness, ↓deep tendon reflexes, flushing, bradycardia, heart block, and paralysis	Exogenous intake, renal failure, treatment of eclampsia	IV calcium or hemodialysis

IV, intravenous; SIADH, syndrome of inappropriate antidiuretic hormone secretion; s/p, status post

ENDOCRINE EMERGENCIES

See Table 2-5.

Table 2-5. Endocrine Emergencies

Disease	Clinical Findings	Risk Factors or Clues	Laboratory Findings	Treatment
DKA/HHS	DKA: Hyperglycemia, AGMA, ketonemia HHS: No ketoacidosis	Precipitating event: Infection most common	DKA: AGMA, ketonemia Hyperglycemia Total body potassium deficit Elevated lipase and amylase	Treatment of underlying cause Intravenous fluids + insulin Hourly glucose checks to avoid drops > 100 mg/dL/h Repletion of electrolytes (K and phosphorus)
Thyroid storm	Tachycardia, congestive heart failure, arrhythmia, hyperpyrexia, altered mentation, liver failure, vomiting, diarrhea Ophthalmopathy Lid lag Tremor Warm/moist skin	Thyroid or nonthyroid surgery Trauma Infection Acute iodine load Parturition	Suppressed thyroid-stimulating hormone Elevated T3 and free T4 Leukocytosis, hyperglycemia	Mortality rate 10–30% Treatment of precipitating factors (i.e., infection) Treatment of heart failure Control of fever Propranolol Thionamide (propylthiouracil or methimazole) Hydrocortisone Thyroidectomy if patient cannot take thionamide
Myxedema coma	Central nervous system: Psychosis, confusion, lethargy, coma, seizure Hypothermia, hypoventilation, bradycardia, low CO	Thyroidectomy scar History of iodine-131 therapy Hypothyroidism	Low T4 Thyroid-stimulating hormone level depends on etiology (primary vs. secondary) Hyponatremia, hypoglycemia	Mortality rate 40% Combined T4 and T3 IV Hydrocortisone Rewarming and supportive care
Adrenal crisis	Shock, nausea, vomiting, abdominal pain, weakness, fatigue, lethargy, fever, confusion, or coma	Undiagnosed primary adrenal insufficiency + serious illness Bilateral adrenal infarction or hemorrhage Pituitary infarction Abrupt withdrawal of glucocorticoids	Hypoglycemia: Rare for acute adrenal insufficiency Chronic adrenal insufficiency: Hyponatremia, hyperkalemia, hypercalcemia, azotemia	Intravenous fluids and correction of electrolytes Adrenocorticotropic hormone and cortisol obtained without delay in treatment Dexamethasone in patient without prior diagnosis; otherwise hydrocortisone Treatment of concurrent infections

DKA, diabetic ketoacidosis; HHS, hyperosmolar hyperglycemic state; AGMA, anion gap metabolic acidosis; CO, cardiac output; IV, intravenous

HEMATOLOGY AND ONCOLOGY

One third of patients admitted to the ICU have baseline hemoglobin < 10 g/dL. Most patients have anemia by ICU day 3. Anemia and red blood cell transfusions are associated with worse ICU outcomes.

> ***Key Fact***
>
> Initial treatment of myxedema coma requires an IV bolus of T4 and T3. IV hydrocortisone is also given for potential concurrent adrenal insufficiency.

> ***Key Fact***
>
> Initial management of thyroid storm includes administration of propranolol, thionamide (propylthiouracil or methimazole), and hydrocortisone.

Anemia and Red Blood Cell Transfusion in the ICU

THREE PRIMARY ETIOLOGIES

Underproduction of red blood cells:

- Anemia of chronic disease
- Iron deficiency
- Chronic kidney disease
- Toxin-related causes (drugs, chemotherapy)
- Myelodysplastic syndrome

Intravascular red blood cell destruction:

- Microangiopathic hemolytic anemia
- Immune-related hemolysis
- Hemoglobinopathy

Extravascular red blood cell loss: Active blood loss

RED BLOOD CELL TRANSFUSION GUIDELINE—Transfusion Requirement in Critical Care Study: Prospective randomized trial of restrictive transfusion practice (transfuse if hemoglobin < 7 g/dL) versus liberal transfusion practice (transfuse if hemoglobin < 10 g/dL) showed no difference in 30-day mortality rate between the two groups.

Platelet/Plasma/Cryoprecipitate Transfusion in the ICU

PLATELET TRANSFUSION

- Indications include acute bleed and prevention of bleed before procedures in the setting of thrombocytopenia.
- Each unit can increase platelet count by 5,000–10,000/μL, and each pheresis unit (containing platelets from 1 unit of whole blood) can increase platelet count by 30,000–60,000/μL.

FRESH-FROZEN PLASMA TRANSFUSION

Indications:

- Factor deficiency
- Reversal of warfarin therapy

- Thrombotic thrombocytopenic purpura
- Coagulopathy in an acute bleed

No consistent clinical evidence of benefit is seen for prophylactic or therapeutic use.

CRYOPRECIPITATE TRANSFUSION—Indications include hypofibrinogenemia secondary to dilution or consumptive coagulopathy.

Contains fibrinogen, fibronectin, von Willebrand factor, factor XIII, and factor VIII.

FACTOR VII INFUSION—Increased risk of thromboembolic complications has been shown in studies of recombinant activated factor VII for life-threatening bleeds.

Indicated for treatment of bleeding in patients with hemophilia A or B with inhibiting antibodies to coagulation factor VIII or IX.

Indications expanded to include management of other life-threatening bleeds:
- Severe traumatic injury
- Bleeding during surgery and transplantation
- Intracerebral hemorrhage and bleeds in the setting of anticoagulation

Transfusion-Related Acute Lung Injury (TRALI)

Clinical diagnosis that occurs when patients have acute hypoxemic respiratory failure during or within 6 hours after blood product transfusion. It occurs with all types of blood products, but the risk is highest with plasma-containing blood products (i.e., fresh-frozen plasma).

DIAGNOSTIC CRITERIA—All must be present.
- Acute onset (during or within 6 hours of transfusion)
- Hypoxemia ($Pa_{O_2}/Fi_{O_2} < 300$ or $Sp_{O2} < 90\%$ on room air)
- Bilateral infiltrates on chest radiograph without evidence of systemic fluid overload or pre-existing risk factors for ARDS

TRANSFUSION-ASSOCIATED CIRCULATORY OVERLOAD (TACO)—Another cause of transfusion-related respiratory insufficiency with clinical features similar to those of TRALI.

TRALI versus TACO:

- TRALI is more likely to be associated with fever, hypotension, and pulmonary infiltrates and less likely to respond to diuresis.
- TACO is more likely to be associated with volume overload.

TREATMENT—Immediate discontinuation of transfusion followed by supportive care (respiratory/hemodynamic support; diuresis; corticosteroids not indicated)

Hemostatic Failure and Disorders

HEPARIN-INDUCED THROMBOCYTOPENIA—Clinical syndrome characterized by thrombocytopenia and arterial-venous thrombosis resulting from an immune response, with antibody formation to endogenous platelet factor 4 complexed to heparin

Definition:

- Type I: Mild transient thrombocytopenia occurs within the first 2 days of heparin exposure, with gradual normalization of platelet level. Non-immune-mediated mechanism has a direct effect of heparin on platelets.
- Type II: Immune-mediated mechanism results in thrombosis and thrombocytopenia.

Treatment:

- Immediate discontinuation of heparin followed by initiation of nonheparin anticoagulant/direct thrombin inhibitor:
  - Argatroban is first-line therapy. Bivalirudin is approved for percutaneous coronary intervention in patients at increased risk for heparin-induced thrombocytopenia.
  - Fondaparinux is used clinically, but data are limited.

Key Fact

Anticoagulation is recommended for 4–6 weeks for patients with heparin-induced thrombocytopenia without thrombosis and for at least 3 months for patients with thrombosis. Vitamin K antagonists (warfarin) are avoided because they can exacerbate the prothrombotic state.

THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)-HEMOLYTIC UREMIC SYNDROME (HUS)—TTP and HUS form a thrombotic microangiopathy that results from abnormal activation and intravascular aggregation of platelets accompanied by intravascular hemolysis.

Diagnosis:

- Microangiopathic hemolytic anemia and thrombocytopenia
- Other clinical features: Acute kidney injury, neurologic symptoms, fever
- Reduced ADAMTS13 (von Willebrand factor–cleaving protease) activity

Treatment: Mortality rate before the use of plasma exchange was ~ 90%.

- Immediate plasma exchange until resolution of thrombocytopenia and hemolysis (evaluated by lactate dehydrogenase level)

Key Fact

Most cases of TTP-HUS are idiopathic, but known associations include bloody diarrhea caused by Shiga toxin-producing bacteria (e.g., *Escherichia coli* 0157:H7), pregnancy in patients with congenital or acquired ADAMTS13 deficiency, and drugs (chemotherapy, immunosuppression).

- Adjunctive glucocorticoid therapy if no evidence of drug-induced etiology or acute kidney injury in patients with persistent thrombocytopenia despite plasma exchange
- Rituximab (anti-CD20 antibody), with or without cyclophosphamide, in refractory or recurrent TTP-HUS
- No benefit from plasma exchange in thrombotic microangiopathy associated with chemotherapy or stem cell transplantation

DISSEMINATED INTRAVASCULAR COAGULATION—Systemic activation of the clotting cascade, fibrin deposition throughout the microvasculature, fibrinolysis, and consumption of clotting factors result in systemic thrombosis and hemorrhage.

Clinical features:
- Bleeding
- Acute kidney injury
- Hepatic dysfunction
- Pulmonary hemorrhage
- Central nervous system involvement (coma, delirium, focal neurologic deficits)

Diagnosis:
- History of sepsis, trauma, or malignancy
- Moderate to severe thrombocytopenia or microangiopathic hemolytic anemia
- Laboratory evidence of increased thrombin generation (decreased fibrinogen, prolonged prothrombin time/activated partial thromboplastin time) and increased fibrinolysis (elevated D-dimer; Table 2-6)

Treatment:
- Platelet and fresh-frozen plasma transfusion
- Protein C concentrate in patients with homozygous or acquired protein C deficiency

Table 2-6. Features of Coagulopathy

Coagulopathy	Prothrombin Time, Activated Partial Thromboplastin Time	Platelets	Fibrinogen	D-Dimer
Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome	Normal	↓	Normal	Normal
Disseminated intravascular coagulation	↑	↓	↓	↑

Hematologic and Oncologic Emergencies

TUMOR LYSIS SYNDROME—Oncologic emergency caused by massive tumor cell lysis with sequelae of hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia.

Clinical manifestations: Gastrointestinal symptoms (nausea, vomiting, abdominal pain, diarrhea), lethargy, hematuria, heart failure, seizures, tetany, syncope, and possible death

Diagnosis:
- Cairo-Bishop definition: Two or more laboratory changes within 3 days before or 7 days after cytotoxic therapy
- Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia

Prevention:
- Aggressive hydration, urinary alkalinization in patients with metabolic acidosis, and hypouricemic agents (allopurinol, rasburicase)

Treatment:
- Correction of electrolyte abnormalities
- Rasburicase, loop diuretics, and IV fluids
- Emergent dialysis in patients with severe oliguria or anuria, persistent hyperkalemia, or hyperphosphatemia-induced symptomatic hypocalcemia

ACUTE CHEST IN SICKLE CELL DISEASE—See Chapter 10.

BLAST CRISIS—Defined as one or more of the following:
- ≥ 20% peripheral blood or bone marrow blasts
- Bone marrow biopsy showing large foci or clusters of blasts
- Extramedullary blast infiltrates

Treatment:
- Urgent chemotherapy, with or without hematopoietic stem cell transplantation, in eligible patients
- Emergent stabilization of white blood cell count with chemotherapy and concomitant leukapheresis for symptomatic hyperleukocytosis (unclear survival benefit, but improves neurologic and pulmonary symptoms)

INFECTION

Infections other than pneumonia and sepsis that commonly require ICU admission include central nervous system infections, endocarditis, severe *Clostridium difficile,* and severe soft tissue infections. Other common infections seen in the intensive care setting include catheter-related infections.

Central Nervous System Infections

Infections that are of interest in the intensive care setting include meningitis, encephalitis, and brain abscess.

Meningitis: Inflammation of the leptomeninges. Symptoms include stiff neck, headache, and photophobia.

Encephalitis: Disturbance of cerebral function accompanied by cerebrospinal fluid pleocytosis. Symptoms include seizures and coma.

MENINGITIS

Diagnosis:

- Lumbar puncture: White blood cell count > 1000 cells/mm^3, glucose < 40 mg/dL, protein > 100 mg/dL. Contraindications include intracranial mass with localized edema or epidural abscess. Before lumbar puncture, head CT should be obtained in patients with a history of central nervous system disease, immunosuppressive disorder, seizures, moderate to severe impairment of consciousness, papilledema, or focal neurologic findings. Antibiotic therapy should not be delayed to obtain cultures.

Etiology: Table 2-7 shows potential organisms and the associated population.

- *Streptococcus pneumoniae* is the most common cause of bacterial meningitis in adults, accounting for 60–70% of cases. *Neisseria meningitidis* accounts for ~ 10%, *Haemophilus influenzae* 6%, and *Listeria monocytogenes* 4% (with increasing incidence in the older population).
- Nosocomial meningitis primarily affects neurosurgical patients. Most cases are caused by gram-negative bacilli with streptococci, *Staphylococcus aureus,* and coagulase-negative staphylococcus, all accounting for ~ 10% of cases.
- Given increasing concern with bioterrorism, it is important to note that hemorrhagic meningitis develops in 50% of patients who inhale *Bacillus anthracis* spores.

- The spores germinate and release toxins that cause hemorrhagic mediastinitis (evident by widened mediastinum on chest x-ray).
- Typically, initial symptoms are flu-like, with rapid progression in respiratory symptoms, hypoxia, shock, and then death.
- Antibiotic therapy is beneficial only when initiated during the initial prodrome of flu-like symptoms and thus should be initiated when inhalation anthrax is suspected. Recommended empirical treatment is ciprofloxacin or doxycycline plus one or two of the following: meropenem/imipenem, rifampin, vancomycin, penicillin/ampicillin, or clindamycin.

Table 2-7. Potential Organisms in Meningitis

Organism	Population at Risk
Streptococcus pneumonia	All
Pneumococcus	Head trauma Cerebrospinal fluid leak Hypogammaglobulinemia Asplenia Alcoholism
Neisseria	Older children and young adults
Listeria	Malignancy Organ transplantation Immunosuppression Debilitation Alcoholism > 50 years old
Haemophilus influenzae type B	Head trauma Cerebrospinal fluid leak Defect in humoral immunity
Gram-negative bacilli	Neurosurgery Trauma Complication of bacteremia in patients with cancer or alcohol-induced liver disease
Staphylococcus aureus	Neurosurgery Trauma Associated with endocarditis or soft tissue infection Cerebrospinal fluid shunt
Anaerobic and other streptococci	Brain abscess Chronic otitis Sinusitis
Amebic	Freshwater swimming
Bacillus anthracis	Bioterrorism ~ half of patients with inhalation anthrax have hemorrhagic meningitis (associated also with the other forms: cutaneous and gastrointestinal)

Flash Card Q1

A 47-year-old woman who worked in a textile mill with wool had malaise, fever, and myalgia 5 days ago is now presenting with severe hypoxia and delirium. Chest radiography shows widened mediastinum. What type of exposure is suggested?

Treatment: See Table 2-8 for recommendations on empiric antibiotics for certain clinical situations.

Table 2-8. Therapy for Bacterial Meningitis

Clinical Situation	Recommended Antibiotics
Age < 50 years	Ceftriaxone + vancomycin
Age > 50 years Immunosuppression, alcoholism, debilitation	Ceftriaxone + vancomycin + ampicillin
After neurosurgery Penetrating cranial trauma	Ceftazidime + vancomycin

Key Fact

In suspected bacterial meningitis, to be beneficial, dexamethasone is given before or simultaneously with the first dose of antibiotic.

Dexamethasone: Beneficial in bacterial meningitis if given before or simultaneously with the first antimicrobial dose. Reduces mortality and neurologic sequelae. Recommended dose is 0.15 mg/kg every 6 hours for 4 days.

ENCEPHALITIS—Causes of encephalitis are predominantly viral.

- The prognosis depends on the particular organisms, with herpes simplex and rabies carrying the highest risk of death.
- Magnetic resonance imaging and electroencephalogram can be beneficial in showing focal encephalitis, which could suggest herpes simplex encephalitis.
- Microorganisms at risk for producing neurologic deficits and a low risk of death include West Nile virus, measles, and smallpox vaccination.
- Treatment is mainly supportive. Options for some forms of encephalitis are outlined in Table 2-9.

Table 2-9. Treatment Options for Encephalitis

Organism	Treatment
Rocky Mountain spotted fever	Doxycycline
Neurosyphilis	Penicillin G
Lyme disease	Penicillin or third-generation cephalosporin
Herpes simplex	Acyclovir
Varicella zoster	Acyclovir

Flash Card A1

Bacillus anthracis inhalation

BRAIN ABSCESS—Most commonly caused by streptococci and anaerobes from chronic infection of the paranasal sinuses, middle ear, or mastoid.

- Staphylococci and gram-negative bacilli are associated with spread from penetrating trauma or surgery.
- Another potential etiology is hematogenous spread from *S. aureus* endocarditis. Fungi or mycobacteria can be seen in immunosuppressed patients.

Treatment: Empiric antibiotics with ceftriaxone + metronidazole and surgery.

SPINAL EPIDURAL ABSCESS—Can be secondary to bacteremia or a complication of vertebral osteomyelitis or surgery. Most cases are caused by *S. aureus*. Clinical course is back pain or nerve root pain → weakness → paralysis. Treatment is antibiotics and surgery.

Endocarditis

Infective endocarditis is infection of the endothelial lining of the heart, characterized by vegetation.

- It usually affects valves but also can affect mural thrombi or heart defects.
- Most cases (80%) are caused by *Staphylococcus* and *Streptococcus* species. Enterococci and negative cultures occur 8% of the time. Fungi and HACEK (*Haemophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae*) occur in ~ 2% of cases.
- Prosthetic valves have similar organisms, with slightly higher occurrences of gram-negative bacilli and fungi.

DIAGNOSIS—Based on the modified Duke criteria.

Definitive infective endocarditis: 2 major OR 1 major + 3 minor OR 5 minor

Possible infective endocarditis: 1 major + 1 minor OR 3 minor

Major criteria:

- Positive blood cultures
  - Typical microorganism from two separate blood cultures
  - Persistently positive blood culture
  - Single blood culture for *Coxiella burnetii* or antiphase I immunoglobulin G antibody titer > 1:800
- Evidence of endocardial involvement
  - Positive findings on echocardiogram
  - New valvular regurgitation

Minor criteria:

- Predisposition (heart condition, IV drug use)
- Fever
- Vascular phenomena
  - Major arterial emboli
  - Septic pulmonary infarct
  - Mycotic aneurysm
  - Intracranial hemorrhage
  - Conjunctival hemorrhage
  - Janeway lesions
- Immunologic phenomena
  - Glomerulonephritis
  - Osler nodes
  - Roth spots
  - Rheumatoid factor
- Positive blood cultures that do not meet the major criteria

TREATMENT

- Intravenous antibiotics are given for 4 weeks for infection in native valves and 6 weeks for infection in prosthetic valves (counted from the first day of negative culture results).
- If aortic or mitral valves are involved, serial electrocardiograms are obtained to look for PR interval prolongation or other conduction abnormalities that signal invasion of the interventricular septum.
- Main indications for valve surgery are heart failure (severe acute regurgitation with cardiogenic shock), uncontrolled infection (abscess, enlarging vegetation, dehiscence of prosthetic valve, persistent fever and blood cultures > 7 days), or prevention of embolic event (vegetation > 15 mm or > 10 mm + complication).

Catheter-Related Infections

INTRAVASCULAR CATHETERS

- Cellulitis or abscess at the site of exit of the catheter
- Infection along the tract of the tunneled catheter (tunnel infection)
- Catheter-related bacteremia (isolation of the same organism from tip and blood)

The most common organisms that cause line infections are *Staphylococcus aureus, Staphylococcus epidermidis,* and *Enterococcus*. *Candida* is more often seen in patients who are receiving multiple antibiotics as well as parental nutrition.

Treatment: Local infection without bacteremia usually responds to line removal.

In bacteremia, duration of antibiotic treatment depends on complications and organisms:

- Uncomplicated, with an organism other than *S. aureus*: 5–10 days after line removal
- Uncomplicated *S. aureus* bacteremia: 14 days
- Complicated cases: Individually tailored
- Candidemia: Treatment for 14 days, with recommendation of ophthalmologic examination because of the risk of endophthalmitis

Surgically implanted, long-term indwelling catheters are commonly left in place unless complications occur.

Prevention:
- Maximal sterile barriers during insertion of central catheters
- Chlorhexidine at the insertion site for antisepsis
- Chlorhexidine-impregnated patch
- Catheters coated with antimicrobial agents
- Use of dressings at the insertion site

Other recommendations:
- Specific site (subclavian > internal jugular > femoral) and use of minimal amount of ports
- Replacement of catheters placed during an emergency within 48 hours
- Removal of central lines when no longer necessary
- Routinely changing central intravascular catheters and using systemic antibiotics as prophylaxis have not been shown to reduce infections.

CATHETER-RELATED URINARY TRACT INFECTION—As with intravascular catheter infections, guidelines for prevention of catheter-related urinary tract infections include insertion for appropriate reasons with removal as soon as possible and use of aseptic catheter insertion techniques.

Appropriate reasons for insertion:
- Acute urinary retention
- Need for accurate measurement of output in critically ill patients
- Prolonged immobilization
- Assistance with healing of sacral or perineal wounds in incontinent patients
- Perioperatively during urologic or prolonged surgeries or with the use of large-volume infusions or diuretics

Asymptomatic bacteriuria in patients with indwelling catheters does not require treatment unless the patient is severely neutropenic. The most important therapy is to remove the catheter. If bacteriuria persists 48 hours after catheter removal, a 3-day course of an appropriate antimicrobial agent is appropriate. If bacteriuria persists, upper urinary tract infection is assumed and warrants a 14-day course.

Candiduria treatment is based on symptoms. Asymptomatic patients should be treated only if they are neutropenic or if they will undergo urinary tract manipulation. A short course of fluconazole (14 days) is recommended when treatment is necessary.

Clostridium difficile Colitis

Clinical manifestations of *C. difficile* colitis include fever, leukocytosis, and watery diarrhea.

- Often temporally associated with administration of antibiotics
- Ranges from simple self-limited diarrhea to severe pseudomembranous colitis, resulting in sepsis and toxic megacolon
- Strain NAP1/BI/027 associated with severe disease and increased production of toxins A and B

TREATMENT—Depends on severity. There is no consensus definition for severe *C. difficile* infection, but some definitions include:

- White blood cell count > 15,000 cells/μL
- Elevated serum creatinine level
- > 10 bowel movements per day

In severe disease, the recommended treatment is oral vancomycin (metronidazole in nonsevere cases). If ileus develops, oral antibiotic passage is delayed and addition of IV metronidazole may be beneficial. In case of profound ileus and progression to megacolon, vancomycin enemas should be added.

Reasons for surgical invention:

- Toxic megacolon
- Perforation or impending perforation
- Necrotizing colitis
- Rapidly progressive or refractory disease with systemic inflammatory response syndrome and multiple organ system failure

Severe Soft Tissue Infections

Severe soft tissue infections include necrotizing cellulitis, necrotizing fasciitis, pyomyositis, and myonecrosis (Table 2-10).

- These conditions cannot be differentiated by physical examination or laboratory findings.
- If not recognized early, they can lead to significant mortality.
- Definitive diagnosis can be made only by surgical exploration.
- Typically, initial antibiotic treatment is a carbapenem or third-generation cephalosporin + methicillin-resistant *S. aureus* coverage + clindamycin for added toxin inhibition (against strains of streptococci and staphylococci) and anaerobic activity.

Table 2-10. Severe Soft Tissue Infections

Disease	Clinical Features
Necrotizing cellulitis	Caused by *Clostridium* species or nonclostridial anaerobes mixed with gram-negative organisms Skin: Thin, dark, sometimes foul-smelling wound drainage, with tissue gas formation Mild pain and crepitus
Necrotizing fasciitis	Usually on extremities, perineum, and abdominal wall (involvement of male genitalia is called Fournier's gangrene) Type I: Mixed, usually gram-positive, negative aerobe, anaerobe, or *Vibrio* species Type II: Group A streptococci Predisposing factors: Cirrhosis, diabetes, immunocompromise Cellulitis that does not improve and spreads quickly, pain, elevated creatine phosphokinase, and crepitus
Necrotizing myositis	Caused by group A *Streptococcus* Predisposing factors: skin abrasions, blunt trauma, or heavy exercise Severe pain and swelling and induration of affected muscle
Clostridial myonecrosis	Predisposing factors: Contaminated wounds and surgery in immunocompromised patients Acute, sudden onset of painful and swollen area, severe sepsis, serosanguineous drainage with sweet odor Skin: Progression to red/yellow/green/black discoloration and bullae with crepitus

Key Fact

Clindamycin is included in the empiric antibiotic treatment of severe soft tissue infection because of its antitoxin effects against streptococci and staphylococci species.

OBSTETRIC EMERGENCIES

The rate of ICU admission for pregnant or peripartum women is low at < 2%. The two most common indications are hypertensive disorders and postpartum hemorrhage.

Preeclampsia and Eclampsia

Preeclampsia and eclampsia are multisystem diseases that develop during pregnancy. Eclampsia is the convulsive end phase of preeclampsia. Although controversial, HELLP syndrome may be a form of severe preeclampsia.

PREECLAMPSIA—Proteinuria (> 300 mg/d) and hypertension (>140/90 mm Hg) after the 20th week of gestation are typical features.

Diagnosis: Made in two ways: Either hypertension and proteinuria or hypertension and end-organ damage

- End-organ damage:
  - Platelets < 100,000/μL
  - Serum creatinine doubled or > 1.1 mg/dL
  - Liver transaminase twice the normal value
  - Pulmonary edema
  - Cerebral or visual symptoms

Key Fact

Single most important predictor of hemorrhagic stroke in patients with preeclampsia is systolic blood pressure > 160 mm Hg.

Treatment:
- Prompt delivery
- Seizure prevention with magnesium sulfate
- Antihypertensive therapy when diastolic blood pressure ≥ 105 mm Hg
  - Labetalol, nicardipine, and hydralazine preferred; nitroprusside and angiotensin-converting enzyme inhibitors contraindicated
  - Goal blood pressure 140–160/90–105 mm Hg; systolic blood pressure > 160 mm Hg associated with hemorrhagic stroke

HELLP Syndrome—Constellation of hemolysis (H), elevated liver enzymes (EL), and low platelet (LP) count. Typically presents at week 28–36, but can present as late as 7 days postpartum.

Diagnosis:
- Microangiopathic hemolytic anemia, elevated liver enzymes, and low platelets:
  - Prevalence: < 1% of pregnancies; 10–20% in severe preeclampsia
  - Elevated indirect bilirubin, low haptoglobin, platelet count < 100,000/μL
  - Clinical features: Abdominal pain, nausea, vomiting, and malaise

Management: Indications for prompt delivery:
- Disseminated intravascular coagulation
- Pulmonary edema
- Liver hemorrhage or infarction
- Renal failure
- Placental abruption
- Nonreassuring fetal status

Hemorrhage

POSTPARTUM HEMORRHAGE (PPH)

Diagnosis: Excessive bleeding that results in symptomatic anemia and/or hypovolemia
- Primary PPH: Excessive bleeding within first 24 hours after delivery
- Secondary PPH: Excessive bleeding 24 hours to 12 weeks postpartum

Signs and symptoms: May or may not have vaginal bleeding

Risk factors:
- Retained placenta
- Placenta accreta
- Lacerations
- Instrumental delivery

Etiologies:
- Uterine atony (80% of cases)
- Trauma (uterine rupture, lacerations)
- Coagulopathy (preeclampsia, HELLP syndrome, placental abruption)

Management: Early recognition of PPH needed to prevent shock and lethal triad of hypothermia, acidosis, and coagulopathy

General principles:
- In an observational study, an established protocol showed faster resolution of maternal bleeding, use of fewer blood products, and reduced disseminated intravascular coagulation.
- Standardized massive transfusion protocol is used for labor and delivery.
- Fundal massage and intrauterine tamponade are used.
- Uterotonic drugs: Oxytocin and misoprostol are given.
- Laparotomy, surgical exploration, and hysterectomy should not be delayed in disseminated intravascular coagulation, severe bleed, or large uterine rupture.

Flash Card Q2

What is the most common etiology of postpartum hemorrhage?

Complication: Sheehan syndrome: Panhypopituitarism secondary to pituitary necrosis

- Timing: Typically presents 2–12 months postpartum
- Risk factor: PPH with hypotension and multiple blood transfusions
- Panhypopituitarism: Adrenal insufficiency, hypothyroidism, and prolactin deficiency
- Symptoms: Fatigue, lethargy, secondary amenorrhea, and hyponatremia
- Treatment: Hydrocortisone (immediately if hypotensive); thyroid and reproductive hormone replacement

Pulmonary Edema

NONCARDIOGENIC PULMONARY EDEMA—Tocolytics are the most common cause of noncardiogenic peripartum pulmonary edema. Other causes include aspiration, preeclampsia, TRALI, and aggressive volume resuscitation.

Tocolytic pulmonary edema: β-adrenergic tocolytic therapy for preterm labor. Toxicity develops in up to 4% of pregnant women.

- β-adrenergic agents: Terbutaline and ritodrine most commonly used
- Risk factors: Prolonged therapy > 24–48 hours; large-volume resuscitation
- Clinical features: Pulmonary edema within 24–48 hours of therapy
- Supportive care: Discontinuation of tocolytics, supplemental oxygen, diuresis
- Alternative diagnosis sought if symptoms persist 12–24 hours after stopping therapy

CARDIOGENIC PULMONARY EDEMA—Cardiogenic pulmonary edema during pregnancy or the postpartum period can be caused by pre-existing or new cardiac disease.

Peripartum cardiomyopathy: New-onset cardiomyopathy (LVEF < 45%) that develops during the last month of pregnancy or up to 5 months postpartum.

- Etiology: Unclear; likely multifactorial and related to virus, nutrition, drugs, and/or connective tissue disease
- Echocardiogram findings: Four-chamber enlargement, global hypokinesis, and decreased left ventricular function
- Treatment: Standard heart failure therapy (avoid angiotensin-converting enzyme inhibitors in pregnancy)
- Prognosis: Recovery in one third of patients, residual cardiac failure in one third, and heart transplant required in one third

Flash Card A2

Uterine atony

ACQUIRED HEART DISEASE—Pre-existing heart disease (valvular disease, cardiomyopathy) may be undiscovered until pregnancy. Increase in CO during pregnancy can lead to decompensation of a previously asymptomatic condition and pulmonary edema.

Embolic Disease In Pregnancy

Three forms of pulmonary embolic events occur in women who are pregnant or peripartum:

- Pulmonary embolism
- Amniotic fluid embolism
- Air embolism

PULMONARY EMBOLISM—Venous thromboembolism in the form of an acute pulmonary embolism is relatively common during pregnancy, with an occurrence of 2–5/1,000 deliveries. Pulmonary embolisms account for ~ 9% of maternal deaths.

Diagnosis (see Chapter 10, "Vascular Disease."):

- V/Q scan is preferred in many centers, especially if chest x-ray findings are normal.
- CT pulmonary angiography is typically performed if the V/Q scan is not available or indeterminate or if chest x-ray findings are abnormal.
- CT pulmonary angiography is associated with higher radiation exposure to the mother than V/Q scanning, but slightly lower radiation exposure to the fetus. This is generally an accepted risk because the maternal mortality rate is high.

Treatment:

- Subcutaneous low-molecular-weight heparin is preferred, or subcutaneous or IV unfractionated heparin may be used:
  - Warfarin is teratogenic and contraindicated in pregnancy.
  - Anticoagulation is discontinued 24 hours before delivery if possible for epidural catheter placement and/or cesarean surgery.
  - Patients at high risk for recurrent venous thromboembolism may discontinue subcutaneous low-molecular-weight/unfractionated heparin and start IV unfractionated heparin until 4–6 hours before delivery.
  - Patients with poor cardiopulmonary reserve and pulmonary embolism may benefit from an IVC filter before delivery. Another option is to deliver while the patient is fully anticoagulated.
- Duration: For venous thromboembolism in pregnancy, therapy is continued for the duration of pregnancy and for ≥ 6 weeks postpartum (minimum 3–6 months).
- Systemic thrombolysis is used for massive pulmonary embolism:
  - Bleeding risk is highest peripartum, but thrombolysis is used in life-threatening massive pulmonary embolism with shock.

Flash Card Q3

What is the biggest risk factor for tocolytic-associated pulmonary edema?

- Surgical or mechanical clot removal is a potential alternative therapy.

AMNIOTIC FLUID EMBOLISM—Rare but catastrophic complication of pregnancy, most commonly occurring during labor or immediately postpartum.

Clinical presentation:
- Abrupt shock with acute cardiopulmonary collapse
- Profound hypoxemia and shortness of breath
- Disseminated intravascular coagulation (common and can cause hemorrhage after surgery)
- Pulmonary edema (common)
- Coma or seizures

Pathophysiology: Fetal cells and debris cause mechanical obstruction in the pulmonary arteries and an immune-mediated inflammatory response.
- Early phase: Pulmonary artery obstruction leading to pulmonary hypertension and right ventricular failure
- Later phase: Left ventricular dysfunction and cardiogenic pulmonary edema
- Immune-mediated inflammation: Activation of clotting cascade, capillary leak, and myocardial depression

Transthoracic echocardiography:
- Severe right ventricular dilation and decreased function (within minutes of onset of shock)
- Left ventricular dysfunction secondary to right ventricular enlargement

Key Fact

Venous thromboembolism related to pregnancy is treated with low-molecular-weight heparin for a minimum of 3–6 months, including the duration of the pregnancy and at least 6 weeks postpartum.

Treatment:
- Aggressive supportive care for blood pressure and hypoxemia, including inhaled nitric oxide. Case reports show improved shock and hypoxemia with this treatment.
- Hemorrhage control is provided with blood products and Factor VIIa.

AIR EMBOLISM—Venous air embolism is an uncommon complication of pregnancy that occurs when air enters the systemic venous system.

Clinical presentation: Typically occurs in the peripartum period as a result of cesarean delivery, uterine manipulation, or central venous catheterization. Severe cases present as acute cardiopulmonary or neurologic decompensation.

Diagnosis: Confirmed by the finding of air in the intravascular space.

Treatment:
- Initial management: Placement in the left lateral decubitus position
- Cardiac, pulmonary, or neurologic deficits: Supportive care and hyperbaric oxygen therapy

Flash Card A3

Prolonged tocolytic therapy > 24–48 hours

Ovarian Hyperstimulation Syndrome

Serious complication of excessive ovarian stimulation from fertility treatment.

- Ovarian enlargement because of multiple ovarian cysts and acute fluid shifts out of the intravascular space
- Severe cases: Ascites, pleural/pericardial effusions, hypovolemic shock, venous thromboembolism, disseminated intravascular coagulation and ARDS

Treatment: Supportive. Oophorectomy is reserved for torsion, cyst rupture, or hemorrhage.

NEUROLOGY

Disorders of Consciousness

Delirium and confusional states are among the most common neurologic disorders in patients in the ICU.

> ***Key Fact***
>
> Delirium is a risk factor for death in the ICU.

DELIRIUM

- Disturbance of consciousness with reduced ability to focus attention:
- Changes in cognition or development of perceptual disturbances that fluctuate throughout the day
- Etiology: Mostly multifactorial, although risk increased by:
  - Age
  - Neurodegenerative disease (stroke, Parkinson's, sensory impairment)
  - Polypharmacy
  - Malignancy
  - Postoperative setting
  - Uncontrolled pain
- Treatment: Avoidance of exacerbating factors (including sedation and benzodiazepines) and treatment of underlying illness. Antipsychotic agents reduce the severity and duration of episodes, although reduction in incidence has not been observed.

Status Epilepticus

DEFINITION—No standard definition but often refers to seizures lasting longer than 5–10 minutes without an intervening period of consciousness.

- Etiology: Noncompliance with anti-epileptic medication, drug or alcohol withdrawal syndrome, acute brain injury or infection, metabolic derangement

- Diagnosis: Neurologic examination, electroencephalogram
- Treatment in ICU patients:
  - Use midazolam infusion in place of barbiturates or propofol, which exacerbate hemodynamic instability.
  - Consider propofol in patients with increased risk of respiratory failure and prolonged mechanical ventilation to minimize duration of sedation.
  - Concomitant phenytoin or fosphenytoin is warranted if seizures persist.
  - Refractory status epilepticus: Phenobarbital and pentobarbital infusions.
  - Antiepileptic drugs: Topiramate, levetiracetam and valproic acid are second-line therapies.

Ischemic and Hemorrhagic Stroke

Intracranial hemorrhage, vertebrobasilar ischemia, or bihemispheric ischemia can result in increased ICP and respiratory failure because of diminished respiratory drive or airway obstruction.

ELEVATED ICP—A potentially devastating complication of neurologic injury that can result from severe traumatic brain injury, obstructive hydrocephalus, stroke, and acute liver failure.

Key Fact

Use of glucocorticoids in moderate to severe head injury was associated with worsened outcomes in a large randomized clinical trial.

- Clinical manifestations: Cushing's triad of bradycardia, respiratory depression and hypertension. Headaches, cranial nerve VI palsy, papilledema, and spontaneous periorbital bruising can also occur.
- ICP Monitoring: Intraventricular (gold standard) with surgically placed catheter into the ventricular system
- Management:
  - Treat the underlying cause of elevated ICP.
  - Elevate head of bed.
  - Hyperventilation to rapidly reduce ICP through vasoconstriction and decreasing the volume of intracranial blood (Pa_{CO2} goal 25–30 mm Hg)
  - IV mannitol or hypertonic saline.
  - Intubate with careful positioning and pretreatment with lidocaine (shown to decrease the rise in ICP associated with intubation).
  - Sedation: Propofol preferred given short half-life and ability to frequently assess neurologic status.

Brain Death

Irreversible and complete loss of cerebral and brainstem function. In the U.S., brain death is equivalent to cardiopulmonary death.

DIAGNOSIS

- Neurologic examination: Coma, absent brain-originating motor responses (painful stimuli), absent papillary light reflex/corneal reflexes/oculovestibular reflexes/jaw jerk/gag reflex.
- Drug intoxication or poisoning, metabolic derangements, hypothermia, and neuromuscular paralysis because of neuropathy or medications must be ruled out.
- Apnea test:
  - Performed after all other criteria for brain death are met and cannot have concurrent hypothermia, hypercapnia, hypotension, or hypoxia
  - 8–10 minutes without observable respiratory effort – Pa_{CO2} measured just before reconnection to ventilator > 60 mm Hg or 20 mm Hg greater than baseline.
  - Ancillary testing: Applied only when clinical criteria cannot be applied and includes cerebral angiography, transcranial Doppler, magnetic MRA, CT angiography, or electrophysiologic tests.

Therapeutic Hypothermia

Therapeutic hypothermia has been recommended for unconscious survivors of out-of-hospital cardiac arrest. A recent study found that targeting a temperature of 36°C had similar mortality and neurologic outcomes compared with a temperature of 33°C.

DRUG AND ENVIRONMENTAL EMERGENCIES

Overdoses and Withdrawal Syndromes

Table 2-11 shows drug classes and clinical features.

Table 2-11. Toxidrome

Drugs	Pupils	Temp.	BP	HR	RR	Others
Cocaine, amphetamines, pseudoephedrine, caffeine, theophylline	↑	↑	↑	↑	↑	Agitation, hallucinations, paranoia
MAOI, SSRI, TCA, dextromethorphan	↑	↑	↑	↑	↑	Myoclonus, hyperreflexia, diaphoresis, flushing, tremors, trismus, rigidity, confusion, agitation
Hallucinogens (LSD, ecstasy, phencyclidine)	↑	↑	↑	↑	↑	Nystagmus, perceptual distortions, hallucinations, agitation
Sedatives (benzodiazepines, alcohol, barbiturates)	↓	↓	↓	↓	↓	CNS depression, confusion, stupor, coma, hyporeflexia
Opioids (morphine, methadone, oxycodone, hydromorphone, heroin)	↓	↓	↓	↓	↓	CNS depression, coma, hyporeflexia, pulmonary edema
Cholinergic (organophosphate, nicotine, nerve agents, physostigmine, edrophonium)	↓	↔	↑	↓	↑↓	Salivation, urinary/fecal incontinence, diarrhea, emesis, diaphoresis, lacrimation
Anticholinergics (antihistamines, atropine, scopolamine, Jimson weed, TCA)	↑	↑	↑	↑	↑	Dry, flushed skin and mucous membranes; urinary retention; myoclonus; hypervigilance; agitation; delirium

BP, blood pressure; CNS, central nervous system; HR, heart rate; MAOI: monoamine oxidase inhibitor; RR, respiratory rate; SSRI: serotonin reuptake inhibitor; TCA: tricyclic antidepressant; Temp., temperature; LSD: lysergic acid diethylamide

Neuroleptic Malignant Syndrome/Serotonin Syndrome

Key Fact

NMS is associated with all classes of neuroleptic agents, including the newer atypical antipsychotic meds such as risperidone and olanzapine.

A life-threatening condition presenting as altered mental status, high fevers, dysautonomia, and rigidity.

DIFFERENTIAL DIAGNOSIS

- Serotonin syndrome: Similar clinical presentation as NMS but more likely to present with shivering, hyperreflexia, myoclonus, and ataxia. Rigidity and hyperthermia are less severe than in NMS.
- Malignant hyperthermia: Distinguished from NMS by exposure to halogenated inhalation anesthetic agents and succinylcholine.

TREATMENT—Supportive care along with specific medications: Dantrolene (direct-acting skeletal muscle relaxant), Bromocriptine (dopamine agonist), Amantadine (dopaminergic and anticholinergic effect).

Anaphylaxis

Rapid onset of serious allergic or hypersensitivity reaction that can be life-threatening when symptoms progress to respiratory distress (stridor, wheezing, dyspnea, cyanosis), and cardiovascular collapse.

ACUTE MANAGEMENT

- IM epinephrine: Inject 0.3–0.5 mg intramuscularly. May repeat every 5–15 minutes
- IV epinephrine continuous infusion for refractory symptoms
- Nebulized albuterol for epinephrine refractory bronchospasm
- Diphenhydramine 20–50 mg IV with or without methylprednisolone 125 mg IV
- Glucagon 1–5 mg IV for patients taking β blockers

Near Drowning

CLINICAL MANIFESTATIONS

- Pulmonary: Fluid aspiration that can result in hypoxemia because of noncardiogenic pulmonary edema
- Neurologic: Cerebral edema and increased ICP.
- Cardiovascular: Arrhythmias secondary to hypothermia and hypoxemia
- Hemolysis and coagulopathy are rare complications.

In critically ill patients, the therapeutic focus is to reduce the risk of brain injury. The role of glucocorticoids or prophylactic antibiotics is unclear.

Heat Stroke

Nonexertional heat stroke typically occurs in elderly patients with chronic medical conditions and impaired thermoregulation. Exertional heat stroke occurs in healthy, young patients with prolonged exposure to high ambient temperature. Managed with adequate fluid resuscitation and cooling measures.

Key Fact

Dantrolene, acetaminophen, and aspirin are ineffective and are not indicated in the treatment of heat stroke.

COMPLICATIONS

- Pulmonary: Hypoxemia caused by noncardiogenic pulmonary edema or bronchospasm.
- Neurologic: Seizures.
- Cardiovascular: Myocardial injury with ST-elevation, heart failure, arrhythmias.
- Rhabdomyolysis with acute kidney injury
- Acute liver failure
- Disseminated intravascular coagulation

Flash Card Q4

Concomitant use of which antibiotic with serotonergic agents can cause serotonin syndrome?

Bioterrorism

ORGANISMS OF CONCERN

- Category A: Highest priority agents easily grown in large quantities and difficult to destruct - anthrax and smallpox
- Category B: Second highest priority agents generally less lethal than category A: Q fever and brucellosis
- Category C: Pathogens that can be engineered for mass dissemination: multiple-drug-resistant tuberculosis, hantavirus.

TREATMENT OF ANTHRAX

- Bioterrorism-related cutaneous anthrax: Ciprofloxacin or doxycycline.
- Adjuvant therapy: Glucocorticoids for meningoencephalitis or extensive edema involving head/neck; Raxibacumab (human IgG1-gamma monoclonal antibody against protective antigen).

LUNG CRITICAL CARE

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

ARDS was first described in 1967 in a case series of 12 patients. The American-European Consensus Conference published a definition of ARDS in 1994 that remained the standard until it was replaced in 2012 by the Berlin definition.

The Berlin criteria are superior to the American-European Consensus Conference criteria because it improved reliability and validity of the definition by better defining the variables. Table 2-12 outlines the important changes made in the 2012 definition.

Flash Card A4

Linezolid

Table 2-12. Revised Definition of Acute Respiratory Distress Syndrome

American-European Consensus Conference 1994	Berlin Definition 2012
Acute onset	Addition of time frame to define acute Developing within 1 week of known clinical insult or new/worsening respiratory symptoms
Bilateral infiltrates on chest radiograph	Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules
Pulmonary capillary wedge pressure ≤ 18 mm Hg	Removal of pulmonary capillary wedge pressure criterion Respiratory failure not fully explained by cardiac failure or fluid overload If no known etiologic risk factor for ARDS (Table 2-13), objective evaluation of cardiac function with echocardiography or cardiac output measurement
Pa_{O_2}/FiO_2 < 300: ALI	Removal of ALI term
Pa_{O_2}/FiO_2 < 200: ARDS	Addition of PEEP to definition and severity categories: Mild: 200 < Pa_{O_2}/FiO_2 ≤ 300 + PEEP/CPAP ≥ 5 Moderate: 100 < P_aO_2/FiO_2 ≤ 200 + PEEP/CPAP ≥ 5 Severe: P_aO_2/FiO_2 ≤ 100 + PEEP/CPAP ≥ 5

ARDS, acute respiratory distress syndrome; ALI, acute lung injury; PEEP, positive end-expiratory pressure; CPAP, continuous positive airway pressure

Key Fact

With the new Berlin definition of ARDS in 2012, the pulmonary capillary wedge pressure criterion was removed. If there is no known etiologic risk factor for ARDS, cardiac function should be assessed objectively with echocardiography.

Etiology

Causes of ARDS are typically classified by direct (epithelial) versus indirect (vascular) modes of injury (Table 2-13). Regardless of the etiology, the pathologic finding is diffuse alveolar damage. Pathology of exudative phase is discussed in Table 2-14 and in Figure 2-6.

Table 2-13. Common Causes of Acute Respiratory Distress Syndrome

Direct Injury	Indirect Injury
Pneumonia	Sepsis
Aspiration	Shock
Near drowning	Trauma
Inhalation (smoke, toxin)	Multiple blood transfusions
Pulmonary contusion	Cardiopulmonary bypass
Embolism	Anaphylaxis
Re-expansion injury	Medications (opioids, salicylates, amiodarone, tocolytics, chemotherapy)
Reperfusion injury (after lung transplant)	Pancreatitis

Flash Card Q5

What condition is associated with the pathologic finding of diffuse alveolar damage with no known cause?

Pathophysiology

See Table 2-14.

Table 2-14. The Three Pathologic Stages of Acute Respiratory Distress Syndrome

Exudative	Proliferative	Fibrotic
Characterized by release of inflammatory markers, resulting in injury to epithelium and endothelium that leads to increased permeability and leakage of fluid into interstitial space and alveoli (Figure 2-6) Diffuse alveolar damage on pathology	Characterized by resolution of pulmonary edema, proliferation of type II alveolar cells, squamous metaplasia, interstitial infiltration by myofibroblasts, early deposition of collagen, and obliteration of pulmonary capillaries	Subset of patients Characterized by obliteration of normal lung architecture, diffuse fibrosis, and cyst formation
< 7–10 d	7 d–2 wk	> 2 wk


Insult
• Release of TNF α, IL-1, IL-6, IL-8 by alveolar macrophages
• Neutrophil recruitment
• Release of inflammatory mediators, proteases, and oxidants
Injury to alveolar epithelium and alveolar capillary endothelium
Increased alveolar–capillary permeability
Injury to type I pneumocytes results in impaired transport of sodium, chloride, and water from alveoli
Accumulation of protein-rich edema fluid within lung interstitial spaces and alveoli
Decreased surfactant production and function
Pulmonary hypertension
• Hypoxic vasoconstriction
• Intravasular fibrin deposition in pulmonary capillaries
• Compression of blood vessels with positive pressure ventilation
Results:
Stiff, poorly compliant lung
Alveoli prone to collapse, resulting in shuntlike gas exchange

Figure 2-6. Pathogenesis of acute respiratory distress syndrome and resulting syndrome.
TNF, tumor necrosis factor; IL, interleukin.

Flash Card A5

Acute interstitial pneumonia (Hamman-Rich syndrome)

Mortality

Since ARDS was first described, the mortality rate has steadily decreased, with recent reports estimating 30- to 60-day mortality rates of 25–30%. Several studies have considered factors that predict mortality (Table 2-15).

Table 2-15. Predictors of Mortality in Acute Respiratory Distress Syndrome

Patient-Related Factors	Disease-Related Factors	Treatment-Related Factors
Older age	Severe hypoxemia (P_aO_2/FiO_2)	Treatment with glucocorticoid before onset of acute respiratory distress syndrome
African-American race	Pulmonary vascular dysfunction (elevated transpulmonary gradient or pulmonary vascular resistance index)	Administration of packed red blood cell transfusion
Hispanic ethnicity	Dead space (determined by exhaled carbon dioxide levels)	Ventilation with tidal volumes ≥ 12 mL/kg predicted body weight
Female sex	Infection	
	Multiple organ dysfunction	
	Severity of illness score	
	Underlying cause of acute respiratory distress syndrome (lower mortality rate if trauma is etiology)	

Management

Management of ARDS is focused on treatment of the inciting event. Specific ventilator strategies, fluid management, and efforts to reduce inflammation have been studied and are described later.

VENTILATORY STRATEGIES—Ventilator-induced lung injury results from both mechanical and biochemical injury. Mechanical mechanisms include:

- Volutrauma: Overdistention of lung units as a result of high tidal volume
- Atelectrauma: Shear stress from repetitive opening and closing of terminal lung units

Mechanical ventilation can also induce release of inflammatory cytokines. Furthermore, high FiO_2 causes toxicity through formation of reactive oxygen and nitrogen species.

Patients with ARDS are especially vulnerable to ventilator-induced lung injury because of the heterogenesis of the lung damage, resulting in regional differences in lung compliance.

Key Fact

The key in mechanical ventilator management of ARDS is to prevent volutrauma, atelectrauma, and oxygen toxicity.

The main strategy of mechanical ventilation is to reduce the mechanisms of ventilator-induced lung injury by preventing volutrauma and atelectrauma and reducing oxygen toxicity. The principle is derived from the static inspiratory pressure–volume curve of the respiratory system. In ARDS, the curve is a sigmoid shape with a lower inflection point at lower lung volumes (atelectrauma) and an upper inflection point at higher lung volumes (volutrauma) (Figure 2-7).

Key Fact

A low tidal volume strategy improves outcomes in ARDS. However, increases in respiratory rate may be insufficient to compensate for low tidal volumes. Permissive hypercapnia is allowed if there are no contraindications.

As a result of the ARDS Network investigation, the current recommendations include:

- Goal tidal volume 4–6 mL/kg predicted body weight
- Plateau pressure < 30 cm H_2O
- Adjustment of FiO_2 and PEEP to achieve PaO_2 of 55–80 mm Hg or SpO_2 of 88–95%.
- Adjustment of respiratory rate to reach a goal pH of 7.3–7.45 with a maximum of 35 breaths/min



Figure 2-7. Volume–pressure relationship of the respiratory systems showing the lower and upper inflection points where atelectrauma and volutrauma occur. Positive end-expiratory pressure (PEEP) is applied to prevent atelectrauma. Low tidal volumes are used to prevent volutrauma.

PEEP: The goal is to reduce oxygen toxicity and avoid atelectrauma and volutrauma while preventing increases in dead space ventilation, barotrauma, and cardiovascular consequences. The Lung Open Ventilation Study looked at techniques to "open" collapsed alveoli through recruitment maneuvers and the use of PEEP.

The ideal PEEP is not yet known. Three large multicenter studies have evaluated high-PEEP versus low-PEEP strategies that showed no change in mortality rate among all patients with ARDS. However, in patients with severe ARDS, higher PEEP may lead to decreased mortality. The studies showed conflicting findings on whether the high-PEEP group had a reduction in ventilator days, refractory hypoxia, and the need for rescue therapy. Using esophageal pressures to adjust PEEP may also lead to improved outcomes, particularly in oxygenation and respiratory system compliance. Large clinical trials are underway.

Recruitment maneuvers have been postulated to open alveoli and keep them open with a lower amount of PEEP by applying higher inflation pressures initially for a certain amount of time. The technique of recruitment (degree and duration of PEEP) has not been standardized and has not shown mortality benefit.

Volume versus pressure control: The Lung Open Ventilation Study showed that pressure-controlled ventilation had similar patient outcomes compared with volume-controlled ventilation.

FLUID MANAGEMENT—The ARDS Network investigators also studied fluid management approaches by comparing a protocol-directed conservative approach with the conventional liberal approach. The conservative treatment group had:

- More ventilator-free days
- More ICU-free days
- Similar renal function
- Similar mortality rate
- More electrolyte disorders and metabolic alkalosis (but no associated arrhythmias)

The protocol-directed conservative approach involves assessing central venous pressure ranges, with or without shock, and urinary output. In the absence of shock, target goals were central venous pressure < 4 mm Hg in the conservative group and central venous pressure 10–14 mm Hg in the liberal group.

NUTRITION—The ARDS Network investigators compared full enteral feeding with trophic enteral feeding in the first 6 days of mechanical ventilation. The full feeding group had more gastrointestinal complications, with vomiting, high gastric residual volume, and constipation. No difference was found in mortality rate, length of days on the ventilator or in the ICU, or secondary infection.

Flash Card Q6

A patient presents with ARDS. You want to follow evidence-based ventilatory management strategies. What are the goals?

Varying the fatty acid components of lipids has been studied because metabolites can promote inflammation. However, the use of enteral feeds containing eicosapentaenoic acid, gamma-linoleic acid, and antioxidants is not recommended because the studies had methodologic errors and varying results.

CORTICOSTEROIDS—Because of the importance of inflammation in the pathophysiology of ARDS, the use of corticosteroids has been studied. The general guidelines provide a weak recommendation for use of corticosteroids. However, studies have been criticized because of small sample size and crossover between groups.

If corticosteroids are used:

- Dose should be moderate (methylprednisolone 1–2 mg/kg/d) and of longer duration (≤ 28 days) because of earlier studies showing benefits < risks with high doses for short duration secondary to higher infection rates.
- Do not use in patients with ARDS > 13 days. ARDS Network investigators found increased 60- and 180-day mortality rate in this subset of patients.

Refractory Hypoxia

Despite initiation of the lung-protective ventilator strategies and application of PEEP, some patients may continue to have severe hypoxia (refractory hypoxia). Vasodilators, neuromuscular blockade, prone positioning, high-frequency oscillatory ventilation, inverse-ratio ventilation, liquid ventilation, and extracorporeal membrane oxygenation have been considered for the treatment of ARDS with refractory hypoxia.

The principles behind the use of these modalities are outlined in Table 2-16 along with specific considerations and recommendations. Most randomized controlled trials of these modalities found improvements in initial oxygenation with no change in mortality rate. These modalities can be considered for patients with severe ARDS and refractory, life-threatening hypoxia. The exception is proning, with recent studies showing a potential mortality benefit with initiation early in severe ARDS. With these emerging studies, proning may no longer be considered only as rescue therapy for refractory hypoxia at appropriate facilities.

Flash Card A6

Tidal volume 6 mL/kg predicted body weight and plateau pressure < 30 cm H_2O

Table 2-16. Rescue Therapy for Refractory Hypoxia

Rescue Therapy	Proposed Mechanism	Benefits	Risks
Vasodilators Prostacyclin nitric oxide	Increased perfusion by dilation of pulmonary vessels Inhaled: Proposed benefit of being delivered only to ventilated areas, which should improve ventilation–perfusion matching	Randomized controlled trials: Initial improvement in oxygenation but no change in mortality and ventilator-free days	Intravenous: Can worsen shunt and oxygenation by increasing perfusion to unventilated alveoli
Neuromuscular blockade	Improved oxygenation in patients with ventilator asynchrony Possible reduction in inflammation from ventilator-induced lung injury	With cisatracurium in patients with severe ARDS: Lower mortality rate More ventilator-free days Fewer instances of pneumothorax No increase in intensive care unit–acquired paresis	Risk of myopathy: Use lowest effective dose Avoid corticosteroids Monitor nerve stimulation Periodically discontinue Brief duration < 48 h
Proning	Improved distribution of ventilation by reducing compression caused by heart and fixation of anterior chest by bed (less compliant) Promotion of drainage of secretions	Initial studies: Improved oxygenation and trend toward decreased mortality in severe ARDS More recent studies: Mortality benefit in severe ARDS when initiated early	Increased pressure sores Endotracheal tube obstruction Dislodgement of lines/tubes
High-frequency oscillatory ventilation	Reduced volutrauma by delivering tidal volume < 150 mL at rates > 180 breaths/min Reduced atelectrauma by maintaining constant mean airway pressure (inspiratory bias flow and limitation of gas outflow)	Improvement in oxygenation but possible increase in in-hospital mortality	Complex to manage: Frequency amplitude Airway pressure Bias gas flow Inspiratory time Counterintuitive targets Barotrauma Studies discontinued because of no improvement in mortality

Table 2-16. Rescue Therapy for Refractory Hypoxia, continued

Rescue Therapy	Proposed Mechanism	Benefits	Risks
Inverse ratio ventilation	Airway pressure release ventilation: Long inspiratory time with brief expiratory time Spontaneous breaths on top of long inspiratory phase: Better ventilation of lung fields by diaphragm	No adequately powered randomized clinical trials to address outcomes	Because of short exhalation time, avoided in patients with: Bronchospasm Obstructing secretions
Liquid ventilation	Use of perfluorocarbons to improve oxygen- and carbon dioxide–carrying capacity Improved recruitment because of lower surface tension of liquid Improved ventilation–perfusion matching by diverting perfusion to better ventilated areas from weight of liquid itself	No known benefits Therapy not recommended	Randomized clinical trials: Trend toward: Increased mortality Barotrauma Hypoxia Hypotension
ECMO	Artificial heart and lung Venovenous connection for respiratory failure Venoarterial connection for heart failure	CESAR trial: Trend toward improved mortality Criticism of trial: Only 76% of those referred for ECMO received it Comparison was with conventional centers, which had lower rates of low-tidal-volume ventilation Better outcomes in patients with: Reversible cause Limited duration of mechanical ventilation before ECMO No major comorbidities No contraindications to anticoagulation	Bleeding (secondary to need for heparin) Heparin-induced thrombocytopenia Thromboembolism Vessel perforation Arterial dissection

ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation

HYPOXEMIC RESPIRATORY FAILURE

Hypoxemia is low oxygen tension in the blood. Tissue hypoxia occurs by various mechanisms that impair oxygen delivery or use. For instance:

- Reduced oxygen content secondary to hypoxemic respiratory failure
- Reduced oxygen-carrying capacity secondary to anemia
- Impairment in oxygen delivery secondary to low cardiac output

Hypoxemic respiratory failure is a clinically significant reduction in Pa_{O_2}. The usual cutoff is Pa_{O_2} of 60 mm Hg because at this level (based on the sinusoidal shape of the oxygen–hemoglobin dissociation curve), hemoglobin saturation begins to fall rapidly with further decreases in Pa_{O_2}.

Hypoxemia has five mechanisms (discussed later). Clinical history, alveolar–arterial gradient, and response to administration of oxygen can help to differentiate among them. Oxygen is typically administered to patients with hypoxemia, so the Pa_{O_2}/Fi_{O_2} ratio can help to determine the degree of shunting if present.

Mechanisms of Hypoxemia

Hypoxia has five mechanisms:

- Decreased inspired oxygen pressure
- Alveolar hypoventilation
- Impaired diffusion
- Ventilation–perfusion mismatch
- Shunt

Table 2-17 summarizes the differences in the four common mechanisms. Decreased inspiratory oxygen pressure is not included but can occur at higher altitudes, reducing driving pressure across the alveolar–capillary membrane. For more details, see Chapter 4, “Diffuse Parenchymal Lung Disease.”

Table 2-17. Summary of Mechanisms of Hypoxia

Mechanism	A-a gradient	P_{CO2}	Corrects With Oxygen	Clinical Situation
Alveolar hypoventilation	Normal	Increased[a]	Easily	Insufficient ventilator drive (opiates) Neuromuscular disorders Chest wall restriction Airway obstruction
Impaired diffusion	Increased	Normal	Yes	Interstitial lung disease Acute respiratory distress syndrome
Ventilation–perfusion mismatch	Increased	Normal	Yes, units with moderate mismatch	Asthma Chronic obstructive pulmonary disease Pulmonary embolus Pulmonary edema
Shunt	Increased	Normal	No	Intrapulmonary: Pulmonary arteriovenous malformation Hepatopulmonary syndrome Atelectasis Pneumonia Extrapulmonary: Intracardiac communication

[a]See Hypercapnic Respiratory Failure

Management of Hypoxic Respiratory Failure

Initial evaluation:

- Chest x-ray
- Electrocardiogram
- Arterial blood gas

It is important to obtain both PaO_2 and $PaCO_2$ to calculate the arterial–alveolar gradient and PaO_2/FiO_2 to help to differentiate among the mechanisms. Ventilation–perfusion mismatch and shunt are distinguished by response to the addition of oxygen. The gold standard for treatment of severe hypoxemic respiratory failure is mechanical ventilation. Noninvasive ventilation can be considered for patients with cardiogenic pulmonary edema and exacerbation of chronic obstructive pulmonary disease (see Noninvasive Ventilation).

Common etiologies of acute hypoxemic respiratory failure:

- Cardiac dysfunction

- ARDS
- Pneumonia
- Pulmonary embolus
- Obstructive lung disease
- Pneumothorax
- Hemothorax
- Pulmonary contusion

ENDOTRACHEAL INTUBATION AND AIRWAY ASSESSMENT

Indications for Intubation

Table 2-18 outlines the indications for intubation; however, this is only a guide. The physician must consider each situation in the appropriate clinical context.

The following questions must be considered when deciding to intubate:

- What is the expected clinical course?
- What are the patient's goals of care?
- Does the patient have a failure of airway patency or protection?
- Does the patient have a failure of oxygenation?
- Does the patient have a failure of ventilation?

Table 2-18. Indications for Intubation

Indication	Examples
Airway patency or protection	Glasgow Coma Scale score < 8 Inability to swallow secretions Upper airway instability after trauma Depressed airway reflexes
Oxygenation	Clinically agitated or restless, cyanosis Pa_{O_2}/Fi_{O_2} < 200
Ventilation	Hyperventilation to reduce increased intracranial pressure Neuromuscular disorders: F**orced vital capacity** < 15 mL/kg body weight, maximal inspiratory pressure < -20 cm H2O pH < 7.25 Increasing $PaCO_2$ Respiratory rate > 35 breaths/min
Clinical course	Sepsis Smoke inhalation injury Need for sedation in the setting of poor airway control Imaging and transportation of an unstable patient Flail chest: Internal stabilization of thorax with positive end-expiratory pressure

Assessment of the Difficult Airway

Mnemonic

Assessing a difficult airway—**LEMON**

Look externally: Abnormal facie, abnormal anatomy, trauma
Evaluate 3-3-2 rule (3 fingers mouth opening, 3 fingers along floor of mandible, 2 fingers superior to laryngeal notch): Predicts difficult visualization for direct laryngoscopy
Mallampati score (Figure 2-8): Score of I or II predicts easy laryngoscopy, and score of III or IV predicts difficultly
Obstruction/obesity
Neck mobility: Ideally, patient should be in the sniff position for intubation.

The LEMON mnemonic has been validated for evaluation of the difficult airway in the emergency department. It provides information about the risk of difficult intubation under direct laryngoscopy.



Figure 2-8. Mallampati scoring.
(Reproduced from Wikimedia Commons; permission granted per the GNU Free Documentation License.)

Mnemonic

Predictors of difficult bag-mask ventilation—**MOANS**

Mask seal: Abnormal anatomy and facial hair
Obstruction/obesity
Age > 55 years, loss of elasticity, increased incidence of restrictive and obstructive lung disease
No teeth
Stiffness: Lung conditions that decrease lung compliance

Predictors for difficulty in bag-mask ventilation have also been studied and are summarized by the mnemonic MOANS.

If a difficult airway is anticipated, options include:

- Use of direct laryngoscopy
- Fiberoptic bronchoscopy
- Fiberoptic rigid intubating stylet with topical anesthesia and minimal procedural sedation

If those methods are unsuccessful, intubation with a laryngeal mask, blind nasotracheal intubation, or cricothyrotomy should be considered (Figure 2-9).



Figure 2-9. Airway management.

MECHANICAL VENTILATION

Modes of Ventilation

Classification:

- What initiates the breath (trigger)?
- What controls the delivery (target volume or pressure)?
- What terminates the breath (cycling)?

See Table 2-19 for comparison of volume-targeted versus pressure-targeted breaths.

Table 2-19. Volume-Targeted Versus Pressure-Targeted Breaths

Volume-Targeted Breaths	Pressure-Targeted Breaths
Set tidal volume	Set inspiratory pressure
Set inspiratory flow rate (typically 30–80 L/min) Higher flow rates: Shorter inspiratory time but higher peak inspiratory pressure	Inspiratory time: Determined by clinician on mandatory breaths Determined by patient on assisted breaths
Set pattern of delivery (square, sine, or decelerating/ramp pattern) Square pattern: Shorter inspiratory time, but higher peak inspiratory pressure Decelerating pattern: Longer inspiratory time and lower peak inspiratory pressure	
Airway pressures vary depending on lung and chest wall mechanics	Tidal volume varies depending on compliance

Key Fact

In pressure-targeted breaths, tidal volume may vary depending on lung compliance (and patient assistance) and therefore will be affected by changes in clinical state. For example, with resolution of pulmonary edema or ARDS, lung compliance improves and results in larger tidal volume for the same set inspiratory pressure and time.

Flash Card Q7

A patient requires intubation. He is obese and has a Mallampati class IV airway. Current saturation is 90% on a high-flow mask. What is the best next step?

Different modes can provide either mandatory or spontaneous breaths:

- Mandatory breath is an assured breath that occurs at a minimum respiratory rate and preset volume or pressure.
- Spontaneous breath is determined by patient effort for initiation and duration and is only pressure targeted.

Table 2-20 shows a summary of the different modes of ventilation.

Table 2-20. Modes of Mechanical Ventilation

		Trigger			Type of Breath		
Mode	**Target**	**Ventilator**	**Patient**	**Termination**	**Mandatory**	**Assisted**	**Spontaneous**
AC	Volume-limited	Yes	Yes	Volume	Yes	Yes	No
	Pressure-limited	Yes	Yes	Time	Yes	Yes	No
SIMV	Volume-limited	Yes	Yes	Volume	Yes	Yes	Yes
	Pressure-limited	Yes	Yes	Time	Yes	Yes	Yes
PSV	Pressure-limited	No	Yes	Flow, pressure, or time	No	Yes	No
PCV	Pressure-limited	Yes	No	Time	Yes	No	No
APRV	Pressure-limited	Yes	Yes	Time (very long inspiratory, short expiratory)	Yes	Yes	Yes throughout the respiratory cycle
PRVC	Pressure-limited with goal tidal volume	Yes	Yes	Time	Yes	Yes	No
VAPSV	Pressure-limited and volume-assured	No	Yes	Flow, pressure, or time	No	Yes (inspiratory pressure varies to achieve goal tidal volume)	No
PAV	Work of breathing	No	Yes	% of assistance set to give	No	Yes (pressure and volume vary depending on pulmonary compliance and resistance)	No

AC, assist control; SIMV, synchronized intermittent mandatory ventilation; PSV, pressure support ventilation; PCV, pressure-controlled ventilation; APRV, airway pressure release ventilation; PRVC, pressure-regulated volume control; VAPSV, volume-assured pressure support ventilation; PAV, proportional assist ventilation

Flash Card A7

Perform awake intubation with fiberoptic guidance.

ASSIST CONTROL—Additional breaths initiated by the patient above the minimum respiratory rate trigger the ventilator to supply an additional mandatory breath to the set volume or pressure (Figure 2-10). Potential complications include hyperventilation and breath stacking.



Figure 2-10. Assist control mode. Example of flow and pressure versus time graphics.

SYNCHRONIZED INTERMITTENT MANDATORY VENTILATION—Differs from assist control in that each additional breath above the set generated by the patient is either spontaneous or mandatory, depending on an algorithm (Figure 2-11).

Three potential types of breath:
- Mandatory
- Assisted
- Pressure-supported spontaneous

PRESSURE-SUPPORTED VENTILATION—All breaths are initiated by the patient. Delivered volume varies from breath to breath. Duration is determined by the patient's inspiratory effort and terminated when inspiratory flow decreases to a preset level, usually 25% of peak flow (Figure 2-12).



SIMV differs from assist control in that each additional breath above the set rate generated by the patient is either spontaneous or mandatory, depending on an algorithm.

3 potential breaths:
Mandatory
Assisted
Pressure-supported spontaneous

Figure 2-11. Tracings for volume-targeted synchronized intermittent mandatory ventilation (SIMV). Note the negative deflection and smaller tidal volume for the spontaneous breath.



In pressure-supported ventilation, all breaths are patient initiated and delivered volumes vary from breath to breath. Duration is determined by the patient's inspiratory effort and terminated when the inspiratory flow decreases to a preset level, usually 25% of peak flow.

Figure 2-12. Tracings for pressure support ventilation.

PRESSURE-CONTROLLED VENTILATION—See Figure 2-13.

- Inspiratory pressure is set.
- Duration of inspiratory time is set by adjusting inspiratory time or the inspiratory/expiratory ratio.
- Lung volumes vary, depending on lung compliance.
- Uncomfortable and requires heavy sedation because spontaneous breaths are not being supported.
- Used in ARDS.


Volume (mL) Pressure (cm H2O) Flow (L/min)
Time (s)
• Inspiratory pressure is set
• Duration of inspiratory time is set by adjusting Ti or I:E ratio
• Lung volumes, vary depending on lung compliance
• Disadvantages are that it is uncomfortable and patients require heavy sedation because spontaneous breaths are not supported
• Used in ARDS

Figure 2-13. Tracings for pressure control ventilation. Ti, inspiratory time; I:E, inspiratory/expiratory ratio; ARDS, acute respiratory distress syndrome.

BILEVEL VENTILATION AND AIRWAY PRESSURE RELEASE VENTILATION—See Figure 2-14.

Key Fact

Airway pressure release ventilation is an option for patients with refractory hypoxemia as a result of ARDS. It is best used in patients who are breathing spontaneously and are without bronchospasms or copious amounts of secretions that would put them at high risk for auto-PEEP.


Used as rescue therapy for refractory hypoxia in ARDS, although no supporting clinical trials show beneficial outcomes.
Spontaneous breaths can occur anywhere in the respiratory cycle, resulting in better ventilation of the lung fields by the diaphragm.
T high
P high
Pressure (cm H_2O)
P low
T low
Time (s)
Clinicians set P high, P low, T high, and T low; long inspiration with brief expiration (inverse ratio ventilation).
Given the short duration of exhalation, the risk of autou-PEEP is increased. This therapy is cautioned in patients with bronchospasm.

Figure 2-14. Airway pressure release ventilation pressure-time graphic. ARDS, acute respiratory distress syndrome; PEEP, positive end-expiratory pressure.

PRESSURE-REGULATED VOLUME CONTROL—Also referred to as Volume Control Plus (Puritan Bennett 840), AutoFlow **(**Dräger**)**, adaptive pressure control, and adaptive support ventilation, depending on the ventilator manufacturer. Clinician sets a goal tidal volume and inspiratory time, and with each breath the ventilator adjusts the pressure to achieve the goal tidal volume.

VOLUME-ASSURED PRESSURE SUPPORT VENTILATION—Pressure limited but volume guaranteed. Similar to pressure-regulated volume control, the only difference is that the patient is breathing spontaneously and there is no set mandatory breath.

PROPORTIONAL-ASSIST VENTILATION—Another spontaneous mode similar to pressure-supported ventilation. However, in this case, there is real-time feedback so that pressure support can be adjusted based on respiratory resistance and compliance breath to breath. No target flow, volume, or pressure is set.

NEURALLY ADJUSTED VENTILATORY ASSIST—Initiation of a breath is determined by the electrical activity of the diaphragm, which is sensed by a nasogastric tube with electrodes.

Monitoring Patients on Mechanical Ventilation

Monitoring airway pressure, volume, and flow can help to determine the etiology of changes in respiratory status. Resistance can be determined by the following equation:

$$\text{Resistance} = \text{Peak inspiratory pressure} - \text{Plateau pressure/flow}$$

The difference in peak inspiratory pressure and plateau pressures can generate a specific differential diagnosis for the etiology of respiratory distress (Figure 2-15).



Figure 2-15. Difference in peak inspiratory pressure (PIP) and plateau to aid with determination of the etiology of respiratory distress. PEEP, positive end-expiratory pressure.

Flash Card Q8

A patient with a severe exacerbation of COPD is having ineffective triggering because of auto-PEEP. You increase the applied PEEP. What parameter would you follow to determine whether excessive PEEP is being applied?

Static compliance = Tidal volume/Plateau – PEEP

Dynamic compliance = Tidal volume/Peak inspiratory pressure – PEEP

PATIENT–VENTILATOR ASYNCHRONY—Asynchrony with the ventilator can occur during:

- Triggering of a breath
- Inspiratory flow
- Cycling

Triggering of a breath: Three problems can occur with triggering:

- Ineffective triggering
- Double triggering
- Auto-triggering

Ineffective triggering can occur when the patient does not create sufficient change in airway pressure or flow to initiate a positive pressure breath (Figure 2-16).

The most common cause of ineffective triggering is auto-PEEP. With auto-PEEP, increased intrathoracic pressure raises the pressure drop needed for the patient to trigger a breath.

Other causes of ineffective triggering are low respiratory drive, weak inspiratory muscles, partially blocked endotracheal tube, alkaline pH, high trigger sensitivity, and expiratory asynchrony with delayed opening of the exhalation valve.



Figure 2-16. Ineffective triggering. Patient inspiratory effort does not trigger a breath *(arrows)*.

Flash Card A8

A rise in peak pressure. As long as applied PEEP is less than auto-PEEP, peak pressures will not change. However, once applied PEEP is greater than auto-PEEP, peak and plateau pressures will increase, placing the patient at risk for ventilator-induced lung injury.

Double triggering occurs when two positive pressure breaths occur with a limited expiratory phase between them that can result in large tidal volumes (Figure 2-17). Double triggering occurs when ventilator inspiratory time is shorter than the patient's inspiratory time. Ventilator adjustments to reduce double triggering include increasing tidal volume, inspiratory time, or sedation and switching to a variable flow setting.



Figure 2-17. Double triggering. Two breaths with limited expiration time between them (*arrows*).

Auto-triggering occurs when the ventilator is triggered without the patient initiating a breath (Figure 2-18). This typically occurs because of circuit leaks, fluid in the circuit, chest tube leaks, vibration from the ventilator tubing, and cardiogenic oscillations. Exhaled tidal volumes are reduced, and respiratory rate increases.



Figure 2-18. Auto-triggering. Note the increase in respiratory rate without triggering by the patient (absence of negative deflection on pressure-time graphic).

Inspiratory flow: Asynchrony occurs when the set flow rate is lower than the patient's desired flow rate. The pressure–time graphic shows a concave deflection because the patient creates negative pressure to pull more flow (Figure 2-19).



Figure 2-19. Pressure–time graphic of normal decelerating ramp versus flow starvation showing the concave deflection.

Key Fact

A patient who is receiving mechanical ventilation because of ARDS has increased work of breathing and a concave deflection on the pressure–time graphic. Increasing the flow rate improves the inspiratory flow asynchrony and relieves the work of breathing.

Cycling: Asynchrony occurs when the duration of breath delivered by the ventilator does not match the duration of the patient's desired breath. If the duration of breath is longer than the patient desires, an increase in airway pressure is seen on the pressure–time graphic at the end of inspiration, with an increase in expiratory flow on the flow–time graphic (Figure 2-20). Ventilator adjustments to correct this cycling asynchrony include shortening inspiratory time and increasing flow. If the duration of breath is shorter than the patient desires, because of persistent patient effort, the airway pressure curve is pulled downward and there is reversal of expiratory flow after breath termination (not pictured). This persistent effort may trigger a second breath.

Table 2-21 summarizes patient-ventilator asynchrony.

Key Fact

Cycling asynchrony caused by duration of breath longer than the patient desires is seen on the flow–time graphic with variation in expiratory flow and is seen as pressure spikes on the pressure–time graphic. Increasing the flow should improve cycling asynchrony.



Figure 2-20. Cycling asynchrony with delayed termination. Flow–time graphic (top) and pressure–time graphic (bottom). Variation in expiratory flow on the flow–time graphic (green arrows). Pressure spike caused by the patient's expiratory effort during inspiratory time *(blue arrows).*

Table 2-21. Summary of Patient–Ventilator Asynchrony

Asynchrony	Etiology	Graphics	Adjustments
Triggering Ineffective	Inadequate pressure change or flow	Inspiratory effort that does not trigger a breath	Auto-PEEP most common cause: ↑ PEEP
Double	Inadequate inspiratory time	Two subsequent breaths with limited expiratory time between them	↑ tidal volume, inspiratory time, sedation Switch to variable flow setting
Auto	Ventilator triggering without patient initiation	Increase in respiratory rate without patient triggering	Evaluate for leak in circuit, leak in cuff, and condensation in tube
Flow	Inadequate flow rate	Concave deflection on pressure–time graphic	↑ flow rate
Cycling	Duration of breath is too short/long	Variation in expiratory flow Pressure spike on pressure–time graphic	↓ inspiratory time ↑ flow

AUTO-PEEP—When a patient cannot fully exhale between breaths, breath stacking occurs, with resulting overinflation and auto-PEEP.

Key Fact

Auto-PEEP is apparent on the flow–time graphic when expiratory flow does not return to baseline before the next inspiratory cycle.

Overinflation → risk of alveoli rupture → compression of alveoli capillaries → ↑ dead space → flattened diaphragm → ↓ tidal volume and ↑ respiratory rate

Auto-PEEP → ↓ venous return → ↓ right and left heart filling → ↑ right ventricular overload secondary to ↑ intrathoracic pressures

Uncorrected, auto-PEEP can progress to hypotension, shock, and pulseless electrical activity. Prompt disconnection of the patient from the ventilator until exhalation is complete results in dramatic improvement in blood pressure and oxygenation.

Ventilator adjustments to reduce auto-PEEP include reducing respiratory rate, reducing tidal volume, and increasing inspiratory flow rate. Bronchodilator administration can assist exhalation in patients with bronchospasm.

If auto-PEEP is causing ineffective triggered breaths, the PEEP setting on the ventilator can be increased to reduce the amount of pressure drop needed for the patient to trigger a breath.

Auto-PEEP can be detected on the flow–time graphic by failure of expiratory flow to return to baseline before the next inspiratory cycle (Figure 2-21).



Figure 2-21. Auto-PEEP. Flow–time graphic shows failure of expiratory flow to return to baseline (*arrows*).

Airflow obstruction: Patients with exacerbation of COPD or status asthmaticus have severe overflow obstruction that increases the risk of auto-PEEP and barotrauma. Adequate sedation is needed to control tachypnea, bronchodilators administered to reduce airflow obstruction, and reduced minute ventilation set to provide sufficient expiratory time. Elevations of $PaCO_2$, known as permissive hypercapnia, are tolerated in this population unless otherwise contraindicated. Contraindications include intracranial hypertension, pulmonary hypertension, and cardiac arrhythmia.

PEEP has less of a role in respiratory failure from parenchymal lung disease. FiO_2 is increased to treat hypoxemia unless the patient has ineffective triggering as a consequence of auto-PEEP. In this case, increasing PEEP can help (see earlier section on ineffective triggering).

Because flow is determined by gas density, reduction in gas density increases flow. The use of helium has been proposed in severe airflow obstruction. Heliox comes in 80:20, 70:30, or 60:40 mixtures of helium to oxygen.

Complications of Positive Pressure Ventilation

Table 2-22 shows complications with specific prevention and treatment options.

Table 2-22. Complications Positive Pressure Ventilation

Complication	Symptoms	Prevention	Treatment
Laryngeal injury: Laryngeal edema Mucosal ulceration Granulomas Vocal cord paralysis	Laryngeal edema: Extubation failure Granulomas: Hoarseness 7–10 days after extubation Vocal cord paralysis: Hoarseness immediately after extubation (unilateral) or extubation failure (bilateral)	Avoidance of large and excessive movement of endotracheal tube	Laryngeal edema: Corticosteroids Granulomas: Fiberoptic laryngoscopy
Dysphagia	Swallowing impairment	Cause unknown	Typically resolves, no treatment necessary
Tracheal stenosis	Dyspnea within 5 wk of extubation	Cuff pressure 18–25 mm Hg	Surgery, stenting, laser therapy
Tracheoesophageal fistula	Recurrent aspiration pneumonias	Cuff pressure 18–25 mm Hg	Surgery
Sinusitis	Purulent nasal drainage and fever	No statistical difference found between treatment with nasal α-adrenergic agonist and glucocorticoid	Endoscopic-guided middle meatal aspiration for culture (gold standard) vs. empiric antibiotics (in practice, empiric
Ventilator-associated pneumonia	Fever, leukocytosis, purulent tracheal secretion, radiographic infiltrate	Chlorhexidine mouth scrubs and keep height of bed equal to or greater than 30 degrees	Antibiotics
Barotrauma	Extra-alveolar air leaks (pneumomediastinum, pneumopericardium, subcutaneous emphysema, pneumothorax, air emboli)	Reduction in ventilator pressure	Chest tube

Flash Card Q9

What are the specific ventilator strategies in a patient with severe airflow obstruction?

Heart and Lung Interactions on Mechanical Ventilation

Table 2-23 shows the changes to the heart and lung when positive pressure ventilation is applied.

Flash Card Q10

A 78-year-old woman is evaluated in your clinic for exertional dyspnea that started 1 week ago. She was recently intubated for 10 days for ARDS and was extubated successfully 4 weeks ago. Spirometry is performed and shows flattening of both the inspiratory and expiratory flow loops. What is the most appropriate next step in evaluation of this patient's dyspnea?

Table 2-23. Effects of Positive Pressure Ventilation on the Heart and Lung

Heart	Lung
↓ venous return	Distention of alveoli results in compression of alveolar blood vessels, ↑ in pulmonary vascular resistance, ↓ right ventricular stroke volume
↑ in pulmonary vascular resistance may cause leftward shift of interventricular septum, narrowing lumen of left ventricle, and worsening diastolic function	↓ normal intrapleural pressure gradient
↓ left ventricular afterload	Better ventilation of nondependent regions of lung (poorly perfused areas), resulting in ↑ alveolar dead space
	In ventilator modes that do not have active contraction of diaphragm, regional closure of alveoli at lung bases results in ↑ shunt

Key Fact

Depending on the clinical situation, it is common to see hypotension in a patient who is given positive pressure ventilation because of the effects of a decrease in venous return. This phenomenon is further exacerbated with PEEP administration and hypovolemia.

The reduction in venous return is partially counteracted by the decrease in left ventricular afterload. In left-sided heart failure, the reduction in afterload from positive pressure ventilation may improve cardiac output and impede ventilator liberation.

Liberation from the Ventilator

PROTOCOL-BASED LIBERATION—Protocol-based liberation administered daily by respiratory therapists can reduce the duration of ventilation with fewer complications compared with gradual reduction in pressure support or decreasing mandatory breaths on synchronized intermittent mandatory ventilation. These protocols incorporate daily screenings to answer important questions outlined in Table 2-24.

Table 2-24. Protocol-Based Liberation

Parameter	Measure
Hemodynamic stability	Absence of vasopressors
Mental status	Daily sedation interruptions Intermittent sedation
Oxygenation	Positive end-expiratory pressure ≤ 5 FiO_2 ≤ 50%
Lung mechanics	Respiratory frequency/tidal volume < 105
Ventilatory endurance	Passes spontaneous breathing trial
Secretion clearance	Good cough Suction frequency < every 2 h
Airway patency	Cuff leak

Flash Card A9

Smaller tidal volume and lower respiratory rate to decrease administered minute ventilation to reduce the risk of auto-PEEP. If there are no contraindications, permissive hypercapnia is tolerated in this subset of patients.

Flash Card A10

Fiberoptic laryngoscopy to evaluate for tracheal stenosis

Sedation plays an important role in liberation from the ventilator. Studies have shown the benefit of daily interruptions of sedation and intermittent sedation over continuous infusion.

The rapid shallow index has been shown in some studies to delay the weaning process. Some centers have removed this criterion from the liberation protocol.

Once certain criteria are met, patients are placed on a spontaneous breathing trial for 30–120 minutes on either CPAP 5 cm H_2O, T-tube, or automated tube compensation (use of pressure support to overcome the resistance of breathing through an endotracheal tube).

The percentage of cuff leak is determined by giving a breath with a tidal volume of 10 mL/kg of predicted body weight with the cuff inflated and then with the cuff deflated.

$$\% \text{ cuff leak} = \frac{V_T \text{ exhaled (cuff inflated)} - V_T \text{ exhaled (cuff deflated)}}{V_T \text{ exhaled (cuff inflated)}}$$

If cuff leak is < 25%, one study showed a reduction in postextubation stridor (6% versus 30%) with methylprednisolone 40 mg every 6 h × 4 doses.

TRACHEOSTOMY—For long-term mechanical ventilation, tracheostomy is considered a more stable and comfortable (with less use of sedatives) alternative to the endotracheal tube. However, the optimal timing for tracheostomy is unknown. A meta-analysis study found a shorter duration of mechanical ventilation and shorter ICU length of stay with "early" tracheostomy but no change in the rate of pneumonia or mortality. In this meta-analysis, "early" was defined as < 7 days on mechanical ventilation and "late" was defined as 8–16 days on mechanical ventilation.

Key Fact

Depending on the clinical The optimal timing for tracheostomy is unknown.

Noninvasive Ventilation

APPROPRIATE CANDIDATES—When determining whether a patient will be successful on noninvasive positive-pressure ventilation (NPPV), factors to consider are mental status, ability to protect the airway, and severity of the acid–base disorder. Table 2-25 shows which patients are not appropriate for NPPV. Patients who show improvement in mental status, P_{CO_2}, pH, and respiratory rate within the first few hours of NPPV are likely to be more successful.

Flash Card Q11

A 67-year-old man who is being treated for pneumonia is receiving mechanical ventilation with a current setting of pressure support of 18 cm H_2O with PEEP of 5 cm H_2O and FiO_2 40%. He is placed on a spontaneous breathing trial but becomes anxious, tachycardic, and hypertensive, with oxygen saturation dropping to 89%. He is returned to his baseline ventilator settings and stabilizes. What is the strategy to successfully liberate him from the ventilator?

Table 2-25. Contraindications for Noninvasive Ventilation

Overt respiratory distress	Cardiopulmonary arrest
Hemodynamic instability	Glasgow Coma Scale score < 10
Facial trauma or deformity	Gastrointestinal bleed

NPPV has been studied in multiple populations and was found to be beneficial in certain circumstances (Table 2-26).

Other considerations include post-lung resection and thoracoabdominal surgery. A randomized trial of patients after lung resection also found a reduction in intubations, ICU length of stay, and mortality rate when NPPV was used. NPPV has also been used prophylactically to reduce atelectasis and hypoxemia in thoracoabdominal surgery.

Key Fact

Good candidates for NPPV include those with exacerbation of COPD, cardiogenic pulmonary edema, or immunocompromised state with minimal secretions, mild to moderate acidosis, nonsomnolence, and hemodynamic stability.

Table 2-26. Indications Noninvasive Positive-Pressure Ventilation

Specific Patient Population	Considerations
Exacerbation of COPD	Severity of acidosis: Initial 7.1 < pH < 7.35 Initial P_{CO_2} < 92 mm Hg
Cardiogenic pulmonary edema	Absence of: Shock Acute coronary syndrome requiring acute coronary revascularization
Fever and pulmonary infiltrates in immunocompromised host	Avoidance of intubation because this population is at increased risk for ventilator-associated pneumonia and alveolar hemorrhage while receiving mechanical ventilation
Liberation from ventilator	Beneficial in patients with COPD Can consider if patient: Is receiving < 15 cm H_2O pressure support Can sustain 10 minutes of unassisted breathing Has adequate cough with minimal secretions Has COPD
"Rescue" postextubation	Considered in patients with COPD or hypercapnic respiratory failure Prompt reintubation if noninvasive positive-pressure ventilation fails

COPD, chronic obstructive pulmonary disease.

Flash Card A11

Repeat spontaneous breathing trials daily.

HYPERCAPNIC RESPIRATORY FAILURE

Hypercapnic respiratory failure is primarily caused by problems with ventilation Table 2-27). Hypercapnia is caused by increased production of CO_2 or reduced alveolar ventilation. Their relationship is illustrated by the following formula:

$$PaCO_2 = K(VCO_2/VA)$$

K = 0.863, which is a constant
VCO_2 = CO_2 ventilation
VA = alveolar ventilation

The most common causes of hypercapnia are disorders of alveolar ventilation. Examples are shown in Table 2-28. Methods of monitoring for hypercapnia and reduced alveolar ventilation are discussed later.

Table 2-27. Mechanisms of Hypercapnia

Increased CO_2 Production	Reduced Alveolar Ventilation
Fever, exercise	See Table 2-28
Overfeeding with carbohydrates	

Table 2-28. Disorders of Alveolar Ventilation

Organ System	Examples
Central nervous system	Overdose of narcotics and sedatives Medullary infarct or tumor Spinal cord injury above C3 Amyotrophic lateral sclerosis Central sleep apnea Congenital central hypoventilation Tetanus Rabies
Peripheral nervous system	Guillain-Barré syndrome Critical illness polyneuropathy and myopathy Tick paralysis Myasthenia gravis Lambert-Eaton syndrome Organ phosphorous poisoning
Disorders of airways	Status asthmatics Exacerbation of chronic obstructive pulmonary disease Bronchiectasis flare
Disorders of alveoli	Adult respiratory distress syndrome Pulmonary edema Pneumonia
Disorders of chest wall, diaphragm, and muscles	Kyphoscoliosis Flail chest Diaphragmatic paralysis/paresis Dermatomyositis, polymyositis Severe electrolyte abnormalities (e.g., hypokalemia, hypophosphatemia, hypomagnesemia)

Capnography

Capnography is noninvasive monitoring of partial pressure of carbon dioxide (CO_2) in exhaled breath and is expressed as CO_2 concentration over time (capnogram). End tidal CO_2 (Et_{CO2}) is the CO_2 concentration at the end of each tidal breath. The normal value is 35–45 mm Hg.

Capnogram has four phases Figure 2-22:

- Phase 1 (a) is the beginning of expiration, where the dead space is cleared from the airways.
- Phase 2 (a–b) is the rapid rise in CO_2 concentration as the CO_2 from the alveoli reaches the upper airway.
- Phase 3 (b–c) occurs when the CO_2 concentration reaches a plateau. Point c, occurring at the end of the plateau, is the maximum CO_2 concentration at the end of the tidal breath and is the Et_{CO2}.
- Phase 4 (c–d) is the start of inspiration.

Changes in the shape of the capnography curve are diagnostic of disease conditions, and changes in Et_{CO2} can be used to assess disease severity and response to treatment. Et_{CO2} in patients with lung disease is only useful for assessing trends over time, and isolated Et_{CO2} values may not correlate with $PaCO_2$. Patients with normal lung function have characteristic rectangular capnograms, as shown in Figure 2-23 (with a narrow gradient of 0–5 mm Hg difference between $PaCO_2$ and Et_{CO2}). Patients with obstructive lung disease have impaired expiratory flow and show a more rounded ascending phase (phase 2) and an upward slope in the alveolar plateau, as shown in Figure 2-23, denoted by the blue arrows. Caution must be exercised in patients with ventilation–perfusion mismatch because the Et_{CO2} and $PaCO_2$ gradient widens, depending on the severity of lung disease.



Figure 2-22. Normal capnography pattern.



Figure 2-23. Comparison of normal capnography wave form and wave form in chronic obstructive pulmonary disease (COPD). In COPD, a more rounded ascending phase (phase 2) is seen as well as an upward slope in the alveolar plateau (blue arrows).

The most important clinical use of capnography is endotracheal intubation. It is a reliable indicator for tube placement in the trachea. In addition, the current Advanced Cardiac Life Support guidelines recommend quantitative capnography during chest compressions to assess quality of chest compressions (Et_{CO2} < 10 mm Hg, indicating poor quality of CPR). Perfusion is reestablished immediately, accompanied by a dramatic increase in Et_{CO2}.

Key Fact

During CPR, the Advanced Cardiac Life Support provider can use Et_{CO2}:

- To evaluate the effectiveness of CPR, denoted by an increase in Et_{CO2} (Et_{CO2} increases with increased cardiac output)
- To determine resumption of spontaneous circulation, which is accompanied by a dramatic increase in Et_{CO2} (first indicator because of increased cardiac output)
- Et_{CO2} < 10 mm Hg indicates poor quality of CPR.

Hypercapnia and Neuromuscular Disorders

Respiratory muscle weakness causing hypercapnia and leading to mechanical ventilation is a common scenario in the ICU. Common disorders include Guillain-Barré syndrome, myasthenia gravis, dermatomyositis, polymyositis, and amyotrophic lateral sclerosis.

No single abnormality is diagnostic of neuromuscular weakness. However, several objective measures can be used in combination to identify abnormalities.

- Maximal inspiratory pressure reflects the strength of the diaphragm and other inspiratory muscles. It is synonymous with negative inspiratory force and indicates a high risk of hypercapnia.
- Maximal expiratory pressure reflects the strength of the abdominal muscles and other expiratory muscles and indicates inadequate cough strength and risk of retention of secretions.
- Restrictive pattern is seen on pulmonary function tests.
- Reduction is seen in supine forced vital capacity compared with upright forced vital capacity.
- Reduction is seen in maximal voluntary ventilation.

Maximal inspiratory pressure and maximal expiratory pressure measured in an individual patient are compared with a reference range or the lower limit of normal and are rarely used alone. Rather, they are considered in conjunction with other measures, such as vital capacity and forced vital capacity. The "20-30-40 rule" has been proposed and advocates the initiation of ventilatory support when vital capacity is < 20 mL/kg, maximal inspiratory pressure is less negative than −30 cm H_2O, or MEP is < 40 cm H_2O.

Serial measurements can be used as a rough guideline to predict the need for elective intubation. However, patients who have severe respiratory distress, marked blood gas abnormalities, high risk of aspiration, or impaired consciousness need immediate mechanical ventilation. In most cases, clinical findings and objective physiologic tests are used together to determine when mechanical ventilation is indicated.

PULMONARY COMPLICATIONS OF CARDIOTHORACIC SURGERY AND TRAUMA

Pulmonologists must be aware of common complications associated with cardiothoracic surgery and trauma (Table 2-29). They are frequently seen by intensivists and pulmonologists.

Table 2-29. Common Complications of Computed Tomography Surgery and Trauma

Computed Tomography Surgery	Trauma
Postoperative atelectasis, diaphragmatic paresis	Trauma and pain leading to atelectasis and diaphragmatic injury and paralysis
Postoperative pleural effusion, postcardiotomy syndrome	Hemothorax, pneumothorax, hemopneumothorax
Bronchopleural fistula after pneumonectomy	Bronchopleural fistula because of flail chest and blunt chest trauma

Postoperative Atelectasis and Diaphragmatic Dysfunction

POSTOPERATIVE ATELECTASIS—Atelectasis is one of the most common postoperative pulmonary complications, particularly after abdominal surgery. An example is shown in Figure 2-24. It is caused by decreased compliance of lung tissue, decreased regional ventilation, excessive secretions, and postoperative pain

that interferes with deep breathing, leading to hypoxia. Proven therapies that help with prevention include chest physiotherapy, incentive spirometry, and CPAP.



Figure 2-24. Postoperative atelectasis of the right lower lobe.
(Image reproduced from Wikimedia Commons, permission granted per the GNU Free Documentation License.)

DIAPHRAGMATIC DYSFUNCTION—The diaphragms are innervated by the ipsilateral phrenic nerves, which derive from nerve roots C3, C4, and C5. Injury to one of the phrenic nerves results in diaphragmatic paralysis that is usually unilateral but can be bilateral. Patients with unilateral paralysis are usually asymptomatic at rest, but may have symptoms on exertion.

Unilateral paralysis is usually suggested by an elevated hemidiaphragm on chest x-ray. This can be confirmed by fluoroscopy that shows paradoxical elevation of the paralyzed hemidiaphragm compared with rapid descent of the normal hemidiaphragm on inspiration (sniff test). The sniff test is positive in > 90% of patients with unilateral paralysis. Pulmonary function testing, forced vital capacity, and maximal inspiratory pressure are usually decreased in setting of normal maximal expiratory pressure.

Most patients with unilateral diaphragmatic paralysis are asymptomatic and require no treatment; however, a small percentage of patients require surgical plication, depending on the severity of symptoms. Patients with bilateral

diaphragmatic paralysis are more likely to require ventilatory support. Diaphragmatic pacing can also be considered in patients with intact phrenic nerve function.

Postoperative Pleural Effusion

Postoperative pleural effusion is common after abdominal and cardiothoracic surgery. Most cases resolve spontaneously within a few days. However, atypical characteristics of either the pleural effusion or the patient's clinical condition warrant further evaluation. Pleural effusion after cardiac surgery may be early (< 30 days) or late (> 30 days).

Common causes of pleural effusion after cardiac surgery are shown in Table 2-30.

Table 2-30. Etiology of Pleural Effusions After Cardiac Surgery

Early	Pleural Fluid Analysis	Late	Pleural Fluid Analysis
Surgical damage of mediastinal lymphatic channels	Chylous and exudative	Constrictive pericarditis	Exudative or transudate
Topical cardiac cooling leading to pleural injury	Transudate or exudate	Trapped lung	Transudate
Postpericardiotomy syndrome	Exudative with high neutrophil and eosinophil count	Heart failure	Transudate
Pleurotomy	Exudative and hemorrhagic	Unresolved postpericardiotomy syndrome	Exudative with lymphocytic predominance

Postpericardiotomy syndrome typically occurs ≥ 1 week after myocardial injury.

Characteristics:

- Fever
- Leukocytosis
- Elevated erythrocyte sedimentation rate
- Pulmonary infiltrate
- Pericardial effusion
- Pleural effusion

Physiologically, postpericardiotomy syndrome is hypothesized to be an immunologic response to damaged cardiac tissue because of the time lag of onset, response to steroids, and presence of antimyocardial antibodies. Pleural fluid

analysis shows an exudative effusion with normal pH and glucose levels. The cell count differential shows a predominance of polymorphonuclear cells during the acute phase and mononuclear cells later in the course. Various trials have evaluated empiric treatment with aspirin, prednisone, colchicine, and nonsteroidal antiinflammatory drugs to prevent postpericardiotomy syndrome. However, there is no consensus and the treatment depends on clinician preference.

Bronchopleural Fistula

Bronchopleural fistula is a patent sinus tract between the bronchus and the pleural space that may result from a variety of causes:

- Necrotizing pneumonia/empyema
- Lung neoplasm
- Blunt and penetrating chest injury
- Complication of a procedure (lung biopsy, chest tube drainage, thoracocentesis, pneumonectomy)
- Complication of radiation therapy

Bronchopleural fistula may occur after pneumonectomy if bronchial stump healing does not occur and may be noted in 1–20% of cases. It is diagnosed by a persistent air leak from a chest tube for > 24 hours and can present 7–14 days after the procedure. In patients with no chest tube, bronchopleural fistula can present as a steady increase in the size of the pneumothorax or as a tension pneumothorax.

Risk factors:

- Right-sided procedure
- Large bronchial stump
- Residual tumor
- Radiation therapy
- Age > 60 years
- Prolonged postoperative mechanical ventilation

Fiber optic bronchoscopy with selective instillation of methylene blue into the segmental bronchi, with its subsequent appearance in the chest drainage, can confirm the location of a bronchopleural fistula.

Management options are shown in Table 2-31.

Table 2-31. Management of Bronchopleural Fistula

Management/Procedure	Comments
Medical management	Dependent drainage, antibiotics, nutritional supplementation
Mechanical ventilation	Significant therapeutic challenge because of insufficient healing Ventilator modes that can be used: Single lung ventilation High-frequency oscillation ventilation Airway pressure release ventilation Tube occlusion during inspiration Low-positive end-expiratory pressure ventilation Short inspiration times
Bronchoscopy	Bronchoscopic placement of gel foam, autologous blood patch, fibrin glue Use of intrabronchial valves Placement of stents Bronchoscopic submucosal injection of absolute ethanol Closure of small fissure with Nd:YAG laser
Surgical options	Surgical closure by muscle flap to fill pleural space Pleurodesis for management of peripheral air leaks Surgical decortication an option in intractable cases

Flail Chest and Blunt Chest Trauma

Flail chest occurs in when three or more consecutive ribs are fractured in two or more places, creating a floating segment in the chest wall. It occurs as a complication of trauma and is seen in ~ 10% of patients with chest wall injury.

Flail chest is clinically diagnosed by paradoxical motion of the chest wall. The detached segment of the chest wall is pulled into the chest cavity during inspiration and pushed outward during expiration. This abnormal motion increases the work of breathing and compromises respiratory function.

Conservative management with pain control and prevention of atelectasis should be the primary goal of treatment, but intubation and ventilatory support may be needed for internal stabilization through positive pressure. Patients who cannot be weaned from mechanical ventilation may benefit from operative rib fracture fixation.

Hemothorax

Hemothorax is diagnosed when pleural fluid hematocrit is > 50% of total body hematocrit. Causes include aortic rupture, myocardial rupture, and injury to the intercostal or mammary blood vessels postsurgery. Hemothorax is treated with

tube thoracostomy using a large (minimum 36 French) chest tube. Immediate bloody drainage > 1.5 L fluid is generally considered an indication for surgical exploration.

MASSIVE HEMOPTYSIS

Massive hemoptysis is 100–1000 mL of expectorated blood in a 24-hour period. Identifying the source of bleeding, minimizing contamination of nonaffected areas of lung via positioning, and securing the airway are the most important factors. Common causes of massive hemoptysis are listed in Table 2-32.

Table 2-32. Causes of Massive Hemoptysis

Local Causes	Diffuse Causes
Pulmonary: Bronchiectasis Pulmonary embolism Cystic fibrosis Necrotic pneumonias Mycetoma Lung abscess Tuberculosis Lung cancer Bronchial adenoma	Hematologic: Coagulopathy Disseminated intravascular coagulation
Vascular: Arteriovenous malformation Aortic aneurysm Endocarditis causing septic emboli Tracheal innominate artery fistula	Systemic disease: Goodpasture syndrome Granulomatosis with polyangiitis Systemic lupus erythematosus Rheumatoid arthritis Microscopic polyangiitis Churg-Strauss syndrome Mixed connective tissue disease Primary antiphospholipid syndrome
Bronchoscopy Pulmonary catheter placement	Drugs: Anticoagulants Crack cocaine Thrombolytic agents
Trauma: Ruptured bronchus Penetrating chest trauma Foreign body	Miscellaneous: Lymphangioleiomyomatosis Idiopathic pulmonary hemosiderosis

Flash Card Q12

What is the optimal position for a patient who is bleeding from the right lung?

PATHOPHYSIOLOGY—Bronchial artery circulation is the first area evaluated via angiography in massive hemoptysis. The pulmonary arteries are generally studied only if bronchial arteriography does not identify a bleeding source because it is responsible for < 10% of cases of massive hemoptysis.

MANAGEMENT—Management of all patients includes airway management, correction of coagulopathy, and either nonsurgical or surgical intervention to achieve hemostasis (Table 2-33).

Table 2-33. Management of Massive Hemoptysis and Associated Risks

Intervention	Comments
Airway management	Bleeding side down Double-lumen endotracheal tube placement vs. selective main stem intubation
Bronchoscopy	Flexible bronchoscopy to evaluate source of bleeding Rigid bronchoscopy also can be done Application of iced saline, epinephrine 1:20,000, and thrombin Single-lumen endotracheal tube placement under flexible bronchoscopy Use of a bronchial blocker or balloon catheter If lesion identified: Laser therapy, argon plasma coagulation, electrocautery, and cryotherapy
Arteriography	Bronchial arteries: First vessels studied because they are most common source of bleeding Complication: Paraplegia (anterior spinal artery may arise from bronchial artery) Bronchial wall necrosis
Surgery	Unilateral, uncontrollable bleeding: Evaluation by thoracic surgeon early in the course of presentation Emergent surgery for massive hemoptysis: Mortality rate of ~ 20% and surgical morbidity rate of 25–50% Contraindications to surgery: Diffuse alveolar hemorrhage (DAH), multiple arteriovenous malformations, multifocal bronchiectasis, poor baseline lung function

Flash Card A12

The patient should be placed in the right-side-down (bleeding side down) decubitus position.

3 Obstructive Lung Disease

Nidhi Aggarwal MD, Anthony F. Arredondo, MD, & Abhay Vakil, MBBS

ASTHMA

Asthma is characterized by airway hyperresponsiveness that leads to an exaggerated contractile response of the airways to a variety of stimuli, resulting in variable airflow limitation.

PATHOPHYSIOLOGY

Airway inflammation plays an important role in the pathophysiology of asthma. In many cases, inflammation is triggered by an immune response to allergens. Exposure to an allergen leads to sensitization. Subsequent exposure to the allergen starts a cascade of cellular and immune response, leading to airway hyperactivity and symptoms of asthma.

Atopy

Atopy is defined as a state of having immunoglobulin E (IgE) antibodies to specific allergens. Total serum levels of IgE are linked to airway hyperresponsiveness, and elevated IgE levels suggest allergic sensitization. The correlation between atopy and asthma varies between populations. On average, the proportion of asthma cases that are attributable to atopy is usually less than one half. The association between wheezing and atopy is stronger in countries with higher socioeconomic status. IgE levels correlate with asthma severity; patients with higher IgE levels tend to have lower 1-second forced expiratory volumes (FEV_1).

Common allergen triggers in sensitized individual include:

- Dust mites
- Pollen
- Domestic pets
- Molds
- Cockroaches

Cellular Response and Inflammatory Mediators Associated With Asthma

Asthma is mainly an inflammatory disease related to Type 2 T helper (T_h2) cells. T_h2 cytokines such as IL-4, IL-5, and IL-13 play a major role in its pathophysiology.

INITIAL SENSITIZATION—Initial exposure of antigen-presenting cells (also known as dendritic cells) to an allergen in the airway leads to activation of T lymphocytes (CD4+). T helper cells develop into the T_h2 subtype and secrete T_h2 cytokines such as IL-4 and IL-13. This cytokine release then stimulates B cells to synthesize IgE, which causes allergic sensitization (Figure 3-1).

SUBSEQUENT EXPOSURE—Subsequent exposure to the allergen in a sensitized individual leads to a cellular immune response and release of mediators, causing both the early and late phases of asthma (Table 3-1).

Early phase/reaction: Antigen-specific IgE antibodies are bound to receptors on mast cells.

- Within minutes of exposure to antigen, sensitized mast cells degranulate and release inflammatory mediators, including histamine, tryptase, prostaglandin D2, leukotrienes, and cytokines (Figure 3-1). These mediators cause bronchoconstriction.
- Clinical significance: Mast cell membranes are stabilized by ß-receptor agonists and cromones such as sodium cromoglycate.

Late phase/reaction: The late phase of the immune response is characterized by an influx of inflammatory and immune cells, particularly eosinophils, basophils, neutrophils, and T cells, to sites of allergen exposure.

- Eosinophils:
  - The most characteristic cell of allergic asthma.
  - Attracted to the bronchial walls by IL-3, IL-5, and granulocyte–monocyte colony-stimulating factor (GM-CSF) secreted by the T_h2 cells.
  - Release a large number of proinflammatory mediators, including leukotrienes and basic proteins (Figure 3-1).
  - Clinical significance: Corticosteroids decrease number of eosinophils in circulation, decrease their penetration in the bronchial walls, and prevent activation of eosinophils that have entered the bronchial walls.

- Basophils secrete IL-4 and IL-13.

- T helper cells:
  - T_h2 cells infiltrating the airways secrete IL-3, Il-4, IL-5, IL-13, and GM-CSF.
  - T_h1 cells cause tissue inflammation and remodeling through release of interferon γ (IFNγ) and tumor necrosis factor (TNF).
  - T_h17 cells secrete IL-17 and are associated with neutrophilic inflammation during acute exacerbation and with tissue remodeling

Table 3-1. Cellular Responses and Mediators in Asthma

Phase of Asthma	Major Cell Types	Major Mediators in Each Phase
Early phase	Mast cells	Histamine PGD_2 LTC4, LTD4, LTE4
Late phase	Eosinophils Basophils Neutrophils Helper T cells Memory T cells	IL-4, IL-5, IL-13 MBP GM-CSF

GM-CSF, granulocyte–monocyte colony-stimulating factor; IL, interleukins; LT, leukotrienes; MBP, major basic protein; PG, prostaglandin.

INHIBITORY CELLS AND MEDIATORS—CD4-regulatory T cells inhibit T_h2 cells by secreting IL-10 and transforming growth factor beta (TGFβ) (Figure 3-1, Table 3-2).

Table 3-2. Inhibitory Cells and Mediators

Inhibitory Cell	Inhibitory Mediators
Regulatory T cells	IL-10 TGFβ

IL, interleukin; TGF, transforming growth factor.

Key Fact

IL-4 directs B lymphocytes to synthesize IgE.

IL-5 regulates eosinophil production and maturation.

IL-13 leads to airway eosinophilia, mucous gland hyperplasia, airway fibrosis, and remodeling.

Flash Card Q1

What are the primary T lymphocytes involved in the pathogenesis of asthma?



Figure 3-1. Antigen is presented to APC, leading to activation of a helper T cell. This activation leads predominantly to T_h2 response as well as to T_h1 response. Subsequent recruitment of multiple cell types and release of multiple mediators causes the asthma response.

APC, antigen presenting cell; GM-CSF, granulocyte–monocyte colony-stimulating factor; IFN, interferon; IFN Y, interferon-gamma; Ig, immunoglobulin; IL, interleukin; LT, leukotriene; PG, prostaglandin; TH1, T helper 1 cells; TH2, T helper 2 cells; Treg, regulatory T cells; Treg, regulatory T cells; TGFβ, transforming growth factor β.

Flash Card A1

T_h2 CD4+ T lymphocytes

Nonimmune-Related Asthma

Not all airway hyperresponsiveness is mediated by immune responses. Nonimmune-related asthma can be seen in reactive airway dysfunction syndrome (RADS), a subtype of occupational asthma. In RADS, a single exposure to an irritant renders the patient sensitive to subsequent exposures to similar compounds. This sensitivity may last for years.

The mechanism of nonimmune airway hyperresponsiveness involves the denudation of respiratory epithelium, direct inhibition of β-2 receptors, and the release of substance P by injury to sensory nerves.

Airway Remodeling

Although asthma is classically thought of as a reversible disorder, many patients with a history of moderate-to-severe allergic asthma develop airway remodeling and irreversible lung function deficits.

Airway remodeling leads to alterations in structural cells and tissues, causing persistent airflow obstruction (Figure 3-2).



Figure 3-2. Links between pathologic mechanisms and clinical consequences in asthma.
(Reproduced, with permission, from Bousquet J et al. Asthma. From bronchoconstriction to Airways inflammation and remodeling. *Am J Respir Crit Care Med* 2000;161:1720-1745, Fig 12. doi:10.1164/ajrccm.161.5.9903102)

MEDIATORS AND FACTORS

- T_h1 and IL-13 play an important role in airway remodeling.
- Increased production of epidermal growth factor (EGF), TGFβ, fibrogenic growth factor (FGF), insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF) lead to cellular and structural damage.

PATHOLOGIC FEATURES—Characteristic features are listed below and shown in Figures 3-3 and 3-4:

- Smooth muscle hyperplasia
- Subepithelial fibrosis
- Basement membrane thickening
- Increased vascular permeability
- Goblet cell hyperplasia



Figure 3-3. Clinical consequences of airway remodeling in asthma.
(Reproduced, with permission, from Bousquet J et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. *Am J Respir Crit Care Med* 2000;161:1720-1745, Fig 11. doi: 10.1164/ajrccm.161.5.9903102)



Figure 3-4. Airway changes in asthma remodeling.

EPIDEMIOLOGY

The age-adjusted prevalence of asthma in the United States increased from 7.3 to 8.2 percent between 2001 and 2009. Higher prevalence and death rates in blacks than in whites have been attributed to socioeconomic factors and differences in access to medical care. Genetic polymorphisms may also play a role.

Genetic Susceptibility

Several asthma-related genes and genetic variations have been identified using linkage analysis in families with asthma, case-control or family-based association studies, and animal models of asthma traits. However, as of yet, there is no established clinical utility for these findings.

Environmental Risk Factors (See Table 3-3.)

Table 3-3. Environmental Risk Factors for Asthma

Risk Factor	Comments
Perinatal factors	Prematurity: increased risk with shorter gestational age Low birth weight: increased risk independent of prematurity Maternal diet: maternal vitamin E and zinc intake may confer protective effect; conflicting data about vitamin D intake Neonatal jaundice Mode of delivery: cesarean section increases risk Maternal smoking
Indoor and outdoor allergens	Animals (cats, dogs, rodents); insects (mites, cockroaches); fungi; plant matter (trees, grass, weeds, pollens)
Smoking and environmental tobacco smoke	
Other pollutants	Occupational exposures, endotoxin exposure, indoor gas stove smoke
Race/ethnicity and socioeconomic status	Morbidity and mortality higher in blacks than whites as well as in patients with low socioeconomic status
Obesity	
Early menarche	
Gender	Childhood asthma more common in boys Incidence increases in females by puberty Equal prevalence in both sexes by age 40 More common in females than males after 40
Medication use	Acetaminophen Antibiotic use during infancy Postmenopausal hormone replacement therapy

Flash Card Q2

A 22-year-old male is seen for evaluation of his asthma. He was born at a gestational age of 42 weeks by planned cesarean section to a 19-year-old mother. During pregnancy his mother took herbal pills containing vitamin K. Which of these perinatal factors is associated with the development of childhood asthma?

DIAGNOSIS OF ASTHMA IN ADOLESCENTS AND ADULTS

Clinical Features

Key Fact

There is no gold standard for the diagnosis of asthma. It is a clinical diagnosis based on history, patient characteristics, physical findings, and the results of other evaluations.

HISTORY—Although most patients experience wheezing, coughing, and shortness of breath in varying degrees during acute episodes, there is no single symptom that is specific for asthma. Sometimes cough is the only presenting symptom. More severe episodes are accompanied by chest tightness.

Key Fact

New-onset asthma, although possible, is rare in older adults. The majority of cases are diagnosed in childhood, with most of the remaining cases diagnosed in their teens and twenties.

Historical features that increase the probability of an asthma diagnosis:

- Episodic nature of symptoms that may worsen at night, with seasonal changes in weather, or after exposure to a trigger or allergen, and may resolve spontaneously after removal of triggering stimulus.
- Presence of characteristic triggers, including cold air, exercise, environmental allergens, chemical irritants, viral and bacterial infections, or exposure to certain medications (aspirin).
- Symptoms usually occur within 30 minutes after exposure and resolve either with treatment or cessation of exposure.
- Personal history of environmental allergies, including presence of runny nose or watery eyes with changes in seasons or exposure to allergens.
- Family history of allergies or asthma.
- History of asthmatic symptoms as a child.

Historical features that decrease the likelihood of asthma include:

- Late age of onset (after 50 years)
- Lack of improvement following inhaled bronchodilator or oral steroid therapy
- History of smoking; these patients are more likely to have chronic obstructive pulmonary disease (COPD) or a combination of COPD and asthma.

PHYSICAL FINDINGS—Expiratory wheezing is a characteristic feature but is not specific for the diagnosis of asthma.

Flash Card A2

Delivery by cesarean section. Prematurity (birth between 23-27 weeks gestational age), neonatal jaundice, and prenatal exposure to maternal smoking are other risk factors. Maternal age and vitamin K use have not been shown to be risk factors.

Characteristics of wheezing in asthma:

- High-pitched and widespread; most commonly present during expiration but can also occur during inspiration.
- May be absent between exacerbations.
- Not predictive of the severity of airflow obstruction in asthma. Patients with severe obstruction may not wheeze due to very poor air movement.
- Should be differentiated from localized monophasic wheezing caused by bronchial narrowing or a foreign body.
- Should be differentiated from other sounds such as rhonchi (low-pitched, usually clears with cough, present due to increased airway secretions) and stridor (high-pitched inspiratory sound caused by upper airway narrowing).

Physical findings suggestive of severe airflow obstruction in asthma:
- Hemodynamic instability: tachypnea, tachycardia, pulsus paradoxus
- Use of accessory muscles of respiration
- Prolonged expiratory phase of respiration

However, the absence of any of these findings does not exclude the possibility of severe airflow obstruction during an exacerbation.

Extrapulmonary physical findings that increase the probability of asthma include clinical signs suggestive of:
- Allergic rhinitis
- Sinusitis
- Nasal polyps
- Atopic dermatitis

Extrapulmonary physical findings that decrease the probability of asthma include:
- Marked weight loss or severe wasting
- Clubbing

Evaluation

PULMONARY FUNCTION TESTING—In addition to a detailed clinical history and physical examination, evaluation of functional airflow limitation is important in making the diagnosis of asthma. Measurement of lung volumes is helpful to exclude restrictive ventilatory dysfunction. Measurement of diffusion lung capacity for carbon monoxide (DLCO) is helpful in differentiating asthma (normal or supranormal DLCO) from emphysema (low DLCO).

Key Fact

Baseline spirometry should be obtained in all patients with a suspected diagnosis of asthma.

- **Spirometry** can be used to determine the following:
  - Presence of baseline obstructive ventilatory dysfunction (FEV_1/forced vital capacity [FVC] ratio < 0.70) or restrictive ventilatory dysfunction (normal FEV_1/FVC ratio, FVC < 80% predicted).
  - Severity of airflow limitation.
  - Differential for the etiology of airflow obstruction based on the shape of the flow-volume loop (Figure 3-5).

Key Fact

Spirometry can be normal in a patient with asthma.



Figure 3-5. Spirometry showing obstruction on flow-volume loop.
(Reproduced, with permission, from Dr. Hinesh Upadhyay.)

- **Bronchodilator response:**
  - If airflow obstruction is present on baseline spirometry, bronchodilator response is assessed by administering 2–4 puffs of a short-acting bronchodilator, then repeating the tests after 10–15 minutes.
  - A positive bronchodilator response is defined as an increase in FEV_1 or FVC by 12% or more (Figure 3-6A), along with an absolute increase in FEV_1 or FVC by at least 200 mL (Figure 3-6B).

The presence of bronchodilator responsiveness in isolation is not sufficient for making the diagnosis of asthma, because a positive response can be seen in other conditions such as COPD, bronchiectasis, bronchiolitis, and cystic fibrosis. However, the increase in FEV_1 in patients with asthma is generally larger than in those with other conditions.

- Causes for false-negative bronchodilator response include:
  - Inadequate dose of short-acting bronchodilator
  - Use of bronchodilator before starting the test, resulting in maximal bronchodilation at baseline
  - Presence of minimal airflow obstruction at the time of testing
  - Concomitant presence of irreversible airway obstruction due to airway remodeling or fibrosis



Figure 3-6. (A) Positive bronchodilator response. The dotted blue line shows the expiratory loop at baseline (the slight concavity is suggestive of obstruction); the solid red line shows the expiratory loop 10 minutes after administration of bronchodilators. (B) Positive bronchodilator response. The dotted blue line shows FEV_1 of 2.3 L at baseline; the solid red line shows FEV_1 increasing to 3.2 L, 10 minutes after administration of bronchodilators.

- **Bronchoprovocation testing:**
  - Used in patients with high strong clinical suspicion of asthma and normal spirometry; or in patients with unexplained respiratory symptoms, particularly cough or nocturnal awakening; or for individuals who require an asthma screening test for occupational reasons. Test results should be interpreted in the context of clinical history (Table 3-4).

Table 3-4. Interpretation of Bronchoprovocation Challenge Testing

Test Result	History Suggestive of Asthma	History Not Suggestive of Asthma
Positive	Diagnosis of asthma confirmed	Up to 10% of nonatopic, nonasthmatic subjects (26% of all smokers) have reactive airways but are asymptomatic
Negative	Atopic patient with seasonal asthma symptoms tested "out of season" Patient with occupational asthma tested long after exposure to the etiologic agent Recent glucocorticoid use Other conditions mimicking asthma such as vocal cord dysfunction and central airway obstruction	Diagnosis of asthma ruled out

Mnemonic

Absolute contraindications to bronchoprovocation testing—**SMUK:**

Severe airflow limitation (FEV_1 < 50% predicted or < 1 L)
Myocardial infarction or stroke in last 3 months
Uncontrolled hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 100 mm Hg)
Known aortic aneurysm

Mnemonic

A false-positive bronchoprovocation test can occur in patients with: **ABCs**

Allergic rhinitis
Bronchitis
Congestive heart failure, **C**OPD, **c**ystic fibrosis

- Relative contraindications: moderate airflow limitation (FEV_1 < 60% predicted or < 1.5 L), inability to perform acceptable spirometry, pregnancy, breastfeeding.
- The most commonly used provocative stimulus is inhaled methacholine.
- Inhaled mannitol, exercise, or hyperventilation of cold, dry air can also be used.
- PC20 is defined as the concentration of drug causing a 20% drop in FEV_1 (Figure 3-7).
- When a diagnostic threshold PC20 of ≥ 8 mg/mL is used, the test has a very high negative predictive value; however, it lacks specificity for the diagnosis of asthma.

Specialized provocation tests can be used for the evaluation of asthma variants such as exercise-induced asthma (measuring lung function before and after exercise) and occupational asthma (measuring FEV_1 or PEF before and after the work shift).



Figure 3-7. Positive methacholine bronchoprovocation testing. Blue line shows FEV_1 values obtained at baseline, after administering nebulized saline, followed by FEV_1 values obtained after administering increasing concentrations of methacholine. The methacholine dose required to cause a 20% decrease in FEV_1 (demonstrated by solid red line) is the PC20. The test is terminated when PC20 is reached.
(Reproduced, with permission, from Dr. Khalid Sherani.)

- **Peak expiratory flow (PEF):**
  - Easily measured with a handheld meter and can be measured at home by patients (Figure 3-8).
  - Not used for primary diagnosis of asthma.
  - Used to monitor clinical status of patients with asthma and to assess the role of particular exposures or triggers.
  - Reduced peak flow is not specific for airflow obstruction and can be seen with other pulmonary processes.
  - In asymptomatic asthma patients and in individuals without asthma, PEF measurements vary up to 15–20% from one measurement to the next.
  - PEF measurements that vary little over time do not support the diagnosis of asthma.
  - PEF measurements that repeatedly fall below 20% of the individual's baseline when symptoms are present and return to baseline with the resolution of symptoms are consistent with the diagnosis of asthma.
  - Improvement in PEF by more than 20%, 10–20 minutes after administration of a short-acting bronchodilator, favors the diagnosis of asthma.

Figure 3-8. Monitoring peak expiratory flow.
(Reproduced, with permission, from Dr. Aashir Shah and Dr. Hemant Raval.)

- **Exhaled nitric oxide (eNO):**
  - A noninvasive biomarker of eosinophilic airway inflammation.
  - Patients with asthma are known to have higher concentration of NO in their exhaled air as compared to nonasthmatics.
  - Exposure to asthma triggers, viral respiratory tract infections, elevated sputum eosinophil count, and parameters associated with poor asthma control have been associated with rising NO concentrations in exhaled air.
  - Research is ongoing to define role of eNO in the diagnosis and treatment of asthma.

Key Fact

Total serum IgE levels should be measured in patients with moderate-to-severe persistent asthma who are being considered for omalizumab therapy or in patients suspected of having ABPA.

BLOOD TESTS—There is no specific blood test to diagnose asthma. Complete blood count can help to rule out other causes of dyspnea, such as anemia. Increased eosinophil count (>4% or 300–400 per mL) may support the diagnosis of asthma. However, asthma cannot be excluded in the absence of peripheral blood eosinophilia. Very high eosinophil count (>15% or 800 per mL) is suggestive of the presence of other disorders like allergic bronchopulmonary aspergillosis (ABPA), Churg-Strauss syndrome, parasitic infections, tropical eosinophilia, and Loeffler's syndrome.

ALLERGY TESTING—Not used to diagnose asthma, but can identify specific triggers and allergens.

- Allergic testing includes blood tests for allergen-specific IgE and allergy skin tests.
- Identification of specific allergens is useful for development of avoidance treatment strategies and immunotherapy regimens.

IMAGING

- Chest radiograph is recommended to rule out other conditions that can mimic asthma.
- Patients with uncomplicated asthma generally have unremarkable imaging findings.
- Hyperinflation seen less commonly in patients with asthma compared to patients with more chronic obstructive lung disease.

SPUTUM EXAMINATION—Several studies have suggested that sputum eosinophil count can be used to predict clinical outcomes; however, more research is needed before this is a useful clinical tool.

DIFFERENTIAL DIAGNOSIS

The differential diagnosis for episodic shortness of breath is broad. It is important to consider other conditions (Table 3-5), including those that can cause an obstructive pattern on pulmonary function tests (PFTs; see Table 3-6). In addition, a variety of comorbid conditions can exacerbate asthma symptoms (Table 3-7). Patients should be evaluated and treated for these conditions in order to optimize asthma control.

Table 3-5. Other Conditions in the Differential Diagnosis of Asthma

Condition	Comments
CHF	Dyspnea is usually exertional and not at rest Presence of elevated JVP, S3 gallop, and peripheral edema favor CHF Echocardiography, imaging studies, and BNP help differentiate between CHF and asthma
Hypersensitivity pneumonitis	History of exposure to particular allergens PFTs show obstructive, restrictive, or a mixed pattern with a reduced DLCO Imaging studies show reticular, nodular, or ground glass opacities
Parasitic lung infections	History of travelling or residing in an area where parasites are endemic Presence of peripheral blood eosinophilia and elevated serum IgE levels Presence of IgG antibodies specific to particular parasitic antigens
Asthmatic granulomatosis	Presence of peripheral blood eosinophilia and chronic rhinosinusitis PFTs may show a reduced DLCO
Endobronchial sarcoidosis	Imaging studies may show hilar adenopathy with or without reticular or nodular opacities

BNP, B-type natriuretic peptide; CHF, congestive heart failure; DLCO, diffusion lung capacity for carbon monoxide; Ig, immunoglobulin; JVP, jugular venous pressure; PFTs, pulmonary function testing.

Table 3-6. Conditions Producing Obstructive Pattern on Spirometry

Diagnosis	Clinical Features	Testing
COPD[a]	Significant smoking history. Family history of alpha-1 antitrypsin deficiency.	PFTs show irreversible or minimally reversible airflow obstruction; emphysema shows reduced DLCO. Check alpha-1 antitrypsin levels, particularly in young nonsmokers or those with positive family history.
Bronchiectasis	Excessive, chronic sputum production. History of recurrent infections	HRCT of the chest shows mucous plugging, tram-tracking, and dilated airways. Work up for etiology of bronchiectasis.
Constrictive bronchiolitis	History of viral illness, inhalation injury, lung transplant, rheumatoid lung disease, or inflammatory bowel disease.	PFTs show progressively worsening, irreversible airflow obstruction with reduced DLCO. HRCT of the chest shows mosaic attenuation with air trapping on expiratory view.
Central airway obstruction	Stridor and monophonic or localized wheezing may be present. Minimal or no response to inhaled bronchodilator therapy.	PFTs show characteristic flattening of flow-volume loop (Figure 3-9A and B). CT of the chest may show narrowing or obstruction of the airways. Direct visualization of the airways is usually diagnostic.

Table 3-6. Conditions Producing Obstructive Pattern on Spirometry, continued

Diagnosis	Clinical Features	Testing
Laryngeal dysfunction[a]	Stridor and/or hoarseness + wheezing Symptoms occur in response to exercise or exposure to irritants (perfumes) History of intubation, trauma, or surgery causing potential injury to laryngeal nerve	PFTs (performed when patient is symptomatic) show flattening of flow-volume loop during inspiration (Figure 3-9C). Direct laryngoscopy usually performed during exercise or after exposure to methacholine shows abnormal cord motion.
Reactive airways viral syndrome	Recent history of upper respiratory tract infection Transient, usually resolves in weeks	None.

[a]Conditions can co-occur with asthma.
COPD, chronic obstructive pulmonary disease; CT, computed tomography; DLCO, diffusion lung capacity for carbon monoxide; HRCT, high-resolution computed tomography; PFTs, pulmonary function testing.



Figure 3-9. (A) Flow-volume loop in fixed upper airway obstruction; note the flattening during inspiration and expiration. (B) Flow-volume loop in variable intrathoracic obstruction; note the flattening during expiration (red line) and normal inspiration. Blue line denotes a normal flow-volume loop. (C) Flow-volume loop in variable extrathoracic obstruction; note the flattening during inspiration (red line) and normal expiration. Blue line denotes a normal flow-volume loop.
(Figure A reproduced, with permission, from Dr. Hinesh Upadhyay and Dr. Khalid Sehrani.)

Table 3-7. Co-morbid and Contributing Conditions

Condition	Comments
Allergic rhinosinusitis	Common comorbid condition and an independent risk factor for asthma. Patients with rhinitis symptoms and asthma should be evaluated for nasal polyps and aspirin sensitivity. Sinus CT is recommended in patients with severe asthma.
GERD	Mimics or worsens asthma. Patients with reflux symptoms and asthma should be given a trial of PPI therapy. In patients without any reflux symptoms and moderate-to-severe asthma, consider diagnostic testing for GERD.
Obesity and deconditioning	Worsens asthma severity. Associated with increased asthma incidence in women.
OSA	Increased daytime sleepiness in patients with asthma may be associated with coexistent OSA. Polysomnography is recommended for asthma patients with predominantly nocturnal symptoms, increased daytime sleepiness, and difficult-to-control asthma.

BNP, B-type natriuretic peptide; CT, computed tomography; GERD, gastroesophageal reflux disease; JVP, jugular venous pressure; OSA, obstructive sleep apnea; PPI, proton pump inhibitor.

Other Conditions That Co-Exist with Asthma

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA)—ABPA is an inflammatory lung disease, primarily affecting patients with asthma or cystic fibrosis. It is caused by a hypersensitivity reaction to chronic airway colonization by *Aspergillus* species (most common) or other fungi. Clinical presentation usually includes recurrent episodes of airway obstruction with pneumonias that have no culture-identified source and fail to respond to standard therapy. In addition, patients may complaint of worsening sputum production with thick, brown mucus plugs, fever, malaise, wheezing, dyspnea, hemoptysis, and extremely poor asthma control. Table 3-8 summarizes the diagnostic criteria for ABPA.

Treatment of ABPA:

- Glucocorticoids (slowly tapered over 3–6 months) are the mainstay of therapy.
- Recent Infectious Diseases Society of America (IDSA) guidelines recommend combined therapy with glucocorticoids and itraconazole, with voriconazole serving as a potential alternative agent.

Flash Card Q3

A 55-year-old patient with asthma had three episodes of fever with worsening dyspnea as well as sputum production with brownish mucus plugs in the last 2 months. Chest radiographs show fleeting infiltrates and an HRCT shows central bronchiectasis. Serum IgE levels are elevated (1200 ng/mL) with peripheral blood eosinophilia (700/mL).
What is the most likely diagnosis? Which test should be done next?

Table 3-8. Criteria for the Diagnosis of ABPA

Condition	Diagnostic Criteria
ABPA central bronchiectasis (ABPA-CB)	History of asthma (mostly cases are poorly controlled) Immediate skin test reactivity to *Aspergillus fumigatus* Elevated serum total IgE (commonly > 1000 IU/mL) Elevated serum specific IgE to *A fumigatus* Serum precipitins present or elevated serum-specific IgG to *A fumigatus* Presence of central bronchiectasis on HRCT
Seropositive ABPA (ABPA-S)	Same as above, except no bronchiectasis seen on HRCT
Other findings that support the diagnosis	Elevated eosinophil count (usually > 500 mL) on peripheral blood smear Presence of patchy, fleeting infiltrates on chest radiograph Worsening cough with brown mucoid sputum production Positive sputum culture for *A fumigatus* Imaging studies showing bronchi filled with mucus

ABPA, allergic bronchopulmonary aspergillosis; HRCT, high-resolution computed tomography; Ig, immunoglobulin.

Mnemonic

Medications associated with EGPA:
COIL

Cocaine
Omalizumab
Inhaled glucocorticoids
Leukotriene-modifying agents

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGITIS (CHURG-STRAUSS) (EGPA)—Vasculitis of small- and medium-sized arteries with multisystem involvement, most commonly involving the lungs, and characterized by the presence of allergic rhinitis, asthma, and prominent eosinophilia in peripheral blood. Some 40–60% of patients with EGPA are found to have antineutrophil cytoplasmic antibodies (ANCA) in their blood. Treatment includes glucocorticoid therapy with or without other immunosuppressive agents like cyclophosphamide and azathioprine.

ASTHMA VARIANTS

Exercise-Induced Asthma

Many patients with asthma experience worsening symptoms with exercise. However, a subset of patients experience only post-exercise asthma symptoms and are asymptomatic at other times. Inhalation of large volumes of relatively cool, dry air during vigorous exercise is thought to trigger changes in airway physiology, resulting in exercise-induced bronchoconstriction.

Flash Card A3

Allergic bronchopulmonary aspergillosis.
A skin-prick test checking reactivity to *Aspergillus fumigatus* should be performed.

CLINICAL MANIFESTATIONS—Patients typically experience cough, chest tightness, and shortness of breath after an episode of exercise or during prolonged exercise. During the first 6–8 minutes of exercise, patients experience bronchodilation. This is followed by bronchoconstriction that peaks 10–15 minutes after onset of exercise. Symptoms generally resolve 60 minutes after

exercise. Bronchoconstriction is followed by a refractory period, lasting generally < 4 hours, during which release of inhibitory prostaglandins protect against bronchoconstriction, even if exercise is continued. Simple shortness of breath resulting from deconditioning usually resolves within 5 minutes after stopping exercise.

DIAGNOSIS—In patients with a clinical history suggestive of exercise-induced asthma, the diagnosis can be confirmed by an exercise challenge test with spirometric measurements before and after exercise. In patients with a known diagnosis of asthma who develop typical symptoms following exercise, exercise testing is not indicated. In patients with no associated findings or symptoms suggestive of asthma, in highly trained athletes, and in adults with new-onset exercise-associated symptoms, testing should first be done to rule out other causes. These include heart failure, coronary heart disease, central airway obstruction, vocal cord dysfunction, laryngotracheomalacia, parenchymal lung disease, and gastroesophageal reflux disorder.

Key Fact

The most direct way to establish the diagnosis of exercise-induced asthma is via exercise challenge testing.

TREATMENT—Therapy for exercise-induced asthma is aimed at maintaining the patient's ability to exercise regularly (Table 3-9).

Key Fact

In patients with poorly controlled asthma who experience frequent episodes of exercise-induced bronchoconstriction, the most important strategy is to improve overall asthma control.

Table 3-9. Management of Exercise-Induced Asthma

	Comments
Goal	Ensure that exercise is not avoided by patients with exercise-induced asthma by controlling exercise-induced symptoms.
General Measures	Improve cardiovascular fitness to reduce minute ventilation requirement for a given level of exercise, thereby reducing the stimulus for bronchoconstriction. Improve patient education regarding the disease and appropriate and timely use of medications. Reduce the temperature and humidity of inspired air by using a scarf or mask when exercising in cold, dry conditions.
Preventive Pharmacotherapy	Rapid-acting bronchodilators initiated about 10 minutes before exercise. Cromoglycates[a] (inhaled), initiated 15–20 minutes before exercise, can be used with rapid-acting bronchodilators for exercise in extreme conditions or for strenuous exercise.
Control of Refractory Exercise-Induced Asthma	Inhaled glucocorticoids, with or without inhaled long-acting bronchodilators, taken daily regardless of exercise. Antileukotriene agents, taken daily regardless of exercise.
Dietary Modifications	Diet rich in omega 3 fatty acids may be helpful.
Breakthrough Symptoms	Rapid-acting bronchodilators (inhaled).

[a]Available only as nebulizer solution in the US.

Work-Related Asthma

Occupational exposures can cause or exacerbate asthma symptoms. Work-related asthma is divided into several categories depending on the type and timeline of exposures and symptoms (Table 3-10).

Table 3-10. Types of Work-Related Asthma

Type	Comments
Occupational asthma (OA)	Adult onset Triggered by immunologic or nonimmunologic stimuli found only at the workplace
Work-exacerbated asthma	Presence of pre-existing or concurrent asthma Subjective worsening at the workplace
Irritant induced asthma	New-onset asthma in adulthood Induced by exposure to an irritant, nonimmunologic stimulus at a high level of intensity Considered a subset of OA if exposure happens at workplace, but physiologically different from immunologic OA
Reactive airways dysfunction syndrome (RADS)	Similar to irritant-induced asthma, except that an acute, single, high-intensity exposure to a nonimmunologic substance triggers symptoms within minutes Episode followed by bronchial hyperresponsiveness and ongoing asthma-like symptoms for a prolonged period of time
Occupational nonasthmatic eosinophilic bronchitis	Adult onset Symptoms mimic asthma Develops at workplace Absence of bronchial hyperresponsiveness but elevated sputum eosinophil count

Occupational Asthma (OA)

Key Fact

In the development of OA, the most important factor is the intensity of exposure.

OA is one of the most common work-related pulmonary diseases in developed countries, with >350 reported causative agents. Exposure to an immunologic stimulus is followed by a latency period during which sensitization develops. This period is followed by the development of airway inflammation, resulting in clinical symptoms. The time period between stimulus exposure and the development of symptoms is highly variable. Depending on the intensity of ongoing exposure to the stimulus and the initiation of treatment, immunologic OA can worsen, persist, subjectively improve, or resolve. Exposure to nonimmunologic stimuli leads to the development of either irritant-induced asthma or RADS, and usually does not have a latency period.

CLINICAL MANIFESTATIONS—Patients typically experience asthma-like symptoms at work or within a few hours after completion of their shift. They usually report subjective improvement in their symptoms during holidays or vacation. However, the absence of such a pattern does not exclude OA. Exposure to certain causative agents can cause rhinoconjunctivitis, allergic contact dermatitis, or urticaria in addition to OA.

DIFFENTIAL DIAGNOSIS—See Table 3-11.

Table 3-11. Differential Diagnosis of Occupational Asthma

Condition	Comments
COPD	Can occur due to personal use of tobacco and/or exposure to tobacco smoke or other pollutants at work. PFTs show irreversible or minimally reversible airflow obstruction and reduced DLCO.
Work-related irritable larynx syndrome	Sensory stimuli at workplace trigger hyperkinetic laryngeal symptoms. Includes vocal cord dysfunction, sensation of fullness/tension in throat and neck, dysphonia, and chronic cough.
Hyperventilation syndrome	Accompanied by other somatic symptoms. Symptoms can be reproduced completely or partially by voluntary hyperventilation.
Hypersensitivity pneumonitis	PFTs show obstructive, restrictive, or mixed pattern with reduced DLCO. Imaging studies show reticular, nodular, or ground glass opacities.

COPD, chronic obstructive pulmonary disease; DLCO, diffusion lung capacity for carbon monoxide; PFTs, pulmonary function testing.

DIAGNOSIS—The initial approach to patients suspected of having OA is similar to the workup of other adults suspected of having asthma. However, more focus is placed on occupation/exposure history, time course of symptoms, and specific testing that establishes an occupational contribution.

Key Fact

In a symptomatic patient with ongoing exposure, normal spirometry, and a negative nonspecific bronchoprovocation test excludes the possibility of OA.

History:

- Detailed information regarding current and previous occupations, including job description and exposure to potential causative agents, should be obtained.
- In case of an unclear cause, it is essential to obtain the list of all chemicals used and present at the workplace. (This information can be obtained from Material Safety Data Sheets.)

Stepwise approach to confirm OA diagnosis:

- Gather detailed occupational/exposure history as mentioned above.
- Confirm the diagnosis of asthma using an approach similar to that used for diagnosing asthma in adolescents and adults.
- Perform testing to establish occupational relationship of the symptoms (see Table 3-12).
- If the diagnosis is still unclear, specific bronchoprovocation testing to sensitizing agents at the work place is indicated.

Table 3-12. Tests for Establishing Occupational Relationship

Test	Comments
Serial PEFR measurements	Record 4 times a day for at least 2 weeks at work and for a similar period away from work. Compare values to check for work-related decrease in PEFR.
Serial spirometry	Perform on exposed and non-exposed days and compare the values. Change in FEV_1 is more reliable than changes in FVC. A single pre- and post-shift measurement of FEV_1 lacks sensitivity to examine relationship between asthma and work.
Nonspecific bronchoprovocation testing	After exposure to the causative agent, increased nonspecific bronchial responsiveness is seen in patients with OA. If normal spirometry and normal initial nonspecific bronchoprovocation testing, repeat the test after 2 weeks away from work and again after exposure to the workplace. The absence of bronchial hyperresponsiveness in a symptomatic patient, tested within 24 hours of exposure, rules out OA.
Skin and immunologic testing	In the presence of appropriate history, symptoms, and documented evidence of changes in airway physiology due to exposure, positive skin testing supports the diagnosis of OA being caused by that specific antigen. Blood testing for IgE antibodies to certain sensitizers can also be done.
Markers of airway inflammation	Increases in sputum eosinophil count (>1% increase) and eNO at the end of work period are suggestive of airway inflammation and are indirect evidence of OA. In a symptomatic patient, the presence of elevated eosinophil count in induced sputum (>2%) in the absence of bronchial hyperresponsiveness is suggestive of nonasthmatic eosinophilic bronchitis.
Specific bronchoprovocation testing	Performed only at specialized centers. Indicated in patients with suspected but uncertain diagnosis of OA. Patients are exposed to specific occupational agents, following which bronchial hyperresponsiveness is assessed. False negative results are possible if the patient has become desensitized to the specific agent or if the wrong agent is used.

eNO, exhaled nitric oxide; FEV_1, 1-second forced expiratory volume; FVC, forced vital capacity; Ig, immunoglobulin; OA, occupational asthma; PEFR, peak expiratory flow rate.

TREATMENT—The mainstay of therapy for OA is to avoid exposure to the causative agent. If the agent cannot be avoided, other steps can be taken to control symptoms (Table 3-13).

> ***Key Fact***
>
> The cornerstone of therapy for OA is to avoid further exposure to the sensitizing agent.

Table 3-13. Management of OA

Treatment Modalities	Comments
Exposure avoidance	Continued exposure leads to progressive deterioration in lung function.
Exposure reduction	Consider in patients with mild OA who are unable or unwilling to change work. Consider use of respiratory protection devices.
Pharmacotherapy	Same regimen as that for nonoccupational asthma. Treat associated occupational rhinitis, if present.
Subcutaneous immunotherapy	Consider in patients who are unable or unwilling to change work. Has no role in managing OA caused by LMW allergens, corrosives, or irritant substances.
Anti-IgE therapy	In patients with poorly controlled asthma secondary to continued occupational exposure, consider complete exposure avoidance rather than anti-IgE therapy.

Ig, immunoglobulin; LMW, low molecular weight; OA, occupational asthma.

> ***Key Fact***
>
> After complete avoidance of exposure, OA improves gradually then plateaus after about 2 years.

Reactive Airways Dysfunction Syndrome (RADS) and Irritant-Induced Asthma (IrIA)

CLINICAL MANIFESTATIONS—RADS is usually characterized by abrupt onset of symptoms following irritant exposure. However, in some cases, symptoms develop as late as 7 days after exposure. Initially patients complain of a burning sensation in the throat and nose (also called respiratory upper airway distress syndrome, or RUDS) without any respiratory symptoms. This is followed by the development of asthma-like symptoms. In most cases the symptoms are severe enough to warrant an emergency room visit. The time course of symptoms differs in RADS and IrIA. Due to multiple low-level exposures, patients with IrIA are unable to identify a particular date or time of exposure. In addition to asthma-like symptoms, patients with IrIA might also present with symptoms of mucosal irritation like nasal congestion, nasal pruritus, increased secretions, and rhinoconjunctivitis.

> ***Key Fact***
>
> RADS and IrIA symptoms are not reproduced by inhalation challenge with low levels of offending workplace agents, while symptoms of immunologic OA are reproduced in those conditions.

DIAGNOSIS—The approach to patients suspected of having RADS or IrIA is similar to that of occupational asthma. However, more focus is placed on looking for an exposure that led to the acute development of symptoms. Specific bronchoprovocation testing is not performed for the agents known to cause RADS and IrIA.

Criteria for establishing the diagnosis of RADS:

- No history of previous respiratory symptoms.
- Presence of a single, specific exposure leading to the onset of symptoms.
- Irritant substance present in high concentrations.
- Asthma-like symptoms begin within 24 hours of exposure and last for at least 3 months.
- Nonspecific bronchoprovocation testing positive.
- Other pulmonary diseases ruled out.

TREATMENT—Management of RADS and IrIA is similar to that of nonoccupational asthma and OA (Table 3-14).

Key Fact

After complete cessation of exposure, RADS and IrIA usually improve with time, but some patients continue to have symptoms for at least 1 year and residual physiologic abnormalities like bronchial hyperreactivity can last for several years.

Table 3-14. Management of RADS and IrIA

Condition	Comments
Acute RADS	Evaluation and treatment is the same as that for acute asthma exacerbation. No formal trials have been performed to evaluate the role of glucocorticoid therapy in RADS. For patients with moderate-to-severe symptoms and FEV_1 < 70% predicted, systemic steroid therapy is used. For patients with less severe symptoms and FEV_1 > 70% predicted, inhaled steroid therapy and/or inhaled ß-agonist therapy is used.
Persistent symptoms due to RADS and IrIA	Management is similar to OA.

FEV_1, forced expiratory volume in 1 second; IrIA, irritant-induced asthma; OA, occupational asthma; RADS, reactive airways dysfunction syndrome.

Nocturnal Asthma

CLINICAL MANIFESTATIONS —Many patients with asthma experience worsening of their symptoms at night. However, some patients present with asthma-like symptoms only at night. This condition is thought to be due to circadian variations in lung function that contribute to increased airway inflammation at night, including changes in neurohormonal activation, changes in lung volume, airway inflammation, blood volume of the pulmonary capillaries, glucocorticoid receptor affinity, and $ß_2$-adrenergic receptor function.

DIAGNOSIS—The evaluation and diagnostic approach is similar to that of asthma. For patients with predominantly nocturnal symptoms, alternative diagnoses like heart failure, GERD, and OSA should be ruled out. If patients fail to respond to asthma therapy, peak flows should be measured at bedtime, upon waking up, and during all nocturnal awakenings. A 15% or greater variability in measurements favors the diagnosis of asthma.

TREATMENT—See Table 3-15.

Table 3-15. Management of Nocturnal Asthma

Condition	Comments
Treatment of contributing factors	Avoid nocturnal exposure to allergens. Treat rhinitis and sinusitis, GERD, or OSA appropriately, if present.
Treatment of acute nocturnal symptoms	Inhaled short-acting ß agonists.
Refractory nocturnal asthma	Check if patient is compliant with medications, especially evening dose. Check for exposure to inhalants or irritants at night. Rule out alternative diagnoses. Consider adding/changing to an alternate long-acting controller medication. Switch to inhaled glucocorticoid. Consider chronotherapy (changing medication dosing time to optimize its effect), especially for oral glucocorticoid therapy. Re-evaluate for the presence of contributing factors, especially OSA.

GERD, gastroesophageal reflux disorder; OSA, obstructive sleep apnea.

Cough-Variant Asthma

For some patients, cough is the only presenting manifestation of asthma. Most such patients eventually develop wheezing, dyspnea, and other asthma-like symptoms.

Elements in clinical history that suggest cough-variant asthma:

- Seasonal nature of cough
- Occasional wheezing and dyspnea
- Personal history of environmental allergies, atopy, or childhood asthma
- Family history of allergies and/or asthma
- Worsening of cough after exposure to dust, cold, dry air, mold, fumes, and strong fragrances

The diagnostic approach, evaluation, and management of such patients are similar to that of patients with general asthma. However, other causes of cough, such as medication use (ACE inhibitors), GERD, upper airway cough syndrome, bronchiectasis, chronic bronchitis, COPD, lung cancer, acute infections, and chronic aspiration, should be ruled out. For patients with severe disabling cough, a 1–2 week course of oral glucocorticoids results in marked improvement.

Aspirin-Exacerbated Respiratory Disease (AERD)

AERD is clinically characterized by the presence of asthma, chronic rhinosinusitis (CRS) with nasal polyposis, and reactions such as bronchospasm and nasal congestion to aspirin and other COX-1–inhibiting nonsteroidal anti-inflammatory drugs (NSAIDs). Aspirin and other COX-1–inhibiting NSAIDs are not the actual cause of the disease. Rather, their use exacerbates and/or worsens the underlying asthma and CRS. Complete avoidance of these agents does not lead to resolution of the condition.

Mnemonic

Symptoms that typically begin within 30 minutes to 3 hours following NSAID use: **ABCDEF**

Asthma-like symptoms (acute asthma exacerbation)
Bronchospasm and laryngospasm (might be severe enough to require intubation)
Congestion and conjunctival redness
Diffuse abdominal cramps (less common)
Epigastric pain (less common) and **e**dema (usually periorbital)
Facial **f**lushing

Pathophysiologically, the reactions are not IgE-mediated and are labeled "pseudoallergic," representing an abnormal biochemical response to the pharmacologic actions of NSAIDs. Previous NSAID use is not required to develop sensitivity.

CLINICAL MANIFESTATIONS—It often takes years for all three components of the disorder to develop. Refractory chronic rhinosinusitis is usually the first manifestation, followed by development of nasal polyps and impaired sense of smell. In most patients the symptoms are severe and disabling, requiring frequent sinus surgeries and polypectomies. Eventually patients develop asthma-like symptoms. The exact time period for the appearance of aspirin/NSAID sensitivity remains unclear. However, if aspirin/NSAID sensitivity appears prior to the development of asthma-like symptoms, it is considered an independent risk factor for the development of asthma. Even with aspirin/NSAID avoidance, progressive worsening of AERD-related asthma and CRS is usually seen.

Key Fact

The only way to definitively diagnose NSAID sensitivity is via aspirin challenge testing. However, it is rarely used clinically for establishing the diagnosis of AERD. It is mostly performed as a part of a protocol when aspirin desensitization is indicated.

Hives, angioedema (in about 15% of patients), and hypotension can also be seen along with respiratory symptoms. All symptoms are dose related and usually resolve slowly.

DIAGNOSIS—The initial evaluation and diagnostic approach is similar to that of asthma. However, more focus is placed on the history of NSAID sensitivity and the type of symptoms experienced after NSAID use. If a history of NSAID sensitivity is present, attempts should be made to check if the patient has shown reactivity to more than one COX-1–inhibiting agent. If all three characteristic clinical features of AERD are present, it is easy to make the diagnosis clinically. It might be challenging to make the diagnosis in patients who only have one or two features. Even in such cases, challenge testing is indicated only if desensitization therapy is planned. In patients with severe asthma who have empirically avoided NSAID use, consider challenge testing to establish or rule out the diagnosis of AERD.

TREATMENT—See Table 3-16.

Table 3-16. Management of AERD

Condition	Comments
Treatment of asthma-like symptoms	Treatment principles similar to chronic asthma management except when considering early use of LTMAs in AERD. Leukotriene-receptor antagonists are used initially and substituted with leukotriene-synthesis inhibitors if no clinical improvement is seen.
Treatment of CRS and NP	Oral glucocorticoids: Patients with anosmia or persistent nasal blockage should be treated with a 15-day course of oral prednisone. Sinus surgery: Consider if patients fail to respond to oral steroid therapy. Topical glucocorticoids: Mainstay of therapy in patients without anosmia or persistent nasal blockage. LTMAs: Used as an adjunct to topical steroid therapy. Aspirin desensitization and therapy: Consider if all the features of AERD are present and the disease is uncontrolled despite maximal therapy. Antibiotics: Doxycycline may reduce the size of nasal polyps and amount of secretions, but role in therapy is unclear. Antihistamines: Can be used in patients on topical steroid therapy with persistent symptoms; exact role in therapy is unclear.
Avoidance of NSAIDs	Unless desensitized to aspirin, all COX-1–inhibiting NSAIDs should be avoided.
Aspirin desensitization and aspirin therapy	See accompanying text.

AERD, aspirin-exacerbated respiratory disease; COX, cyclooxygenase; CRS, chronic rhinosinusitis; IL, interleukin; LTMAs, leukotriene-modifying agents; NP, nasal polyposis; NSAIDs, nonsteroidal antiinflammatory drugs.

Key Fact

Although other COX-1–inhibiting NSAIDs can be used safely in AERD patients who have been successfully desensitized with aspirin, only subsequent aspirin therapy has been shown to slow the regrowth of nasal polyps and improve asthma symptoms.

ASPIRIN/NSAID DESENSITIZATION AND ASPIRIN THERAPY— Desensitization is the process of inducing tolerance to aspirin/NSAIDs in patients who experience pseudoallergic reactions. A structured protocol is followed where patients are administered gradually increasing doses of an NSAID, generally aspirin, in a monitored setting. Successful desensitization to aspirin can be achieved in nearly all AERD patients.

Indications for aspirin desensitization:

- Worsening of nasal polyposis despite maximal therapy
- Treatment of other conditions that require daily or intermittent use of NSAIDs
- Coronary artery disease and/or other vascular disorders that require the use of aspirin for its antiplatelet effects

Contraindications to challenge testing and desensitization:

- Suboptimal/inadequate control of concurrent cardiopulmonary conditions
- Poor control of underlying asthma

Premedication:

- Leukotriene-modifying agents (LTMAs) reduce the pulmonary manifestations after exposure to aspirin/NSAIDs but do not impact the nasal and ocular manifestations.
- In patients with poor asthma control, systemic glucocorticoids can be used before the test to optimize asthma control.

Symptoms should be managed appropriately as they arise during challenge (Table 3-17).

Table 3-17. Management of Symptoms During Challenge

Condition	Comments
Bronchospasm	Nebulized short-acting bronchodilators as needed
Nasal symptoms	Topical nasal decongestants
Ocular symptoms	Oral antihistamines
Laryngospasm	Nebulized and/or intramuscular epinephrine
Anaphylactic reaction	Systemic glucocorticoids H_1 and H_2 receptor blockers Systemic epinephrine Airway protection, if indicated

Interpretation of test results and ongoing aspirin therapy:

- Negative challenge testing implies that patient does not have pseudoallergic reaction to aspirin/NSAIDs; if suspicion is high, repeat testing without premedication.
- Positive challenge testing confirms the presence of pseudoallergic reaction to aspirin/NSAID use. Proceed with desensitization if indicated.
- A patient who can tolerate a full dose of aspirin (325 mg) is considered successfully desensitized.
- After desensitization, a refractory period of 2–3 days exists before patients again develop reactivity. Initiate daily therapy during this period.
- Post-desensitization, patients should be started on aspirin 650 mg twice daily for at least 3 months, then decrease to 325 mg daily.
- Repeat desensitization is needed in patients with > 5 days of interruption in maintenance therapy.
- Patients taking only 81 mg aspirin daily will tolerate only low doses. High doses should not be administered to such patients. These patients also cannot tolerate other COX-1–inhibiting NSAIDs.
- If patients fail to show any improvement, then either they do not have AERD or they are non-responders to aspirin. In such cases, aspirin therapy should be stopped unless there is any other indication to maintain the desensitized state.
- Despite aspirin therapy, patients can experience acute asthma exacerbations, flares in rhinitis, and upper respiratory tract infections. Patients should be advised to continue aspirin therapy in all these situations.

Key Fact

Successfully desensitized patients should continue taking 325 mg of aspirin or equivalent dose of another COX-1–inhibiting NSAID daily to maintain their desensitized state.

Glucocorticoid-Resistant Asthma (GRA)

In the absence of confounding factors, patients with chronic asthma who fail to show response to high doses of glucocorticoid therapy are labeled as having GRA. In the absence of an acute exacerbation, patients who fail to show improvement in their FEV_1 or peak expiratory flow by at least 15 % from a baseline of < 75% of their predicted values after 1–2 weeks of daily therapy with 40 mg prednisone or the equivalent are termed to have GRA. Such patients might demonstrate glucocorticoid resistance in other tissues also. The optimal treatment for such patients remains unknown. Some of the commonly used treatment strategies include:

- Use of higher doses of systemic steroids for longer durations
- Use of non-glucocorticoid pharmacologic agents
- Use of non-pharmacologic therapies like trigger avoidance and thermoplasty
- Anti-interleukin-5 and anti-interleukin-13 have shown some benefit in such patients

Confounding factors that need to be ruled out before making the diagnosis of GRA include:

- Non-compliance to medications
- Continued exposure to trigger or stimulus including medications like aspirin
- Inappropriate/wrong diagnosis of asthma
- Undiagnosed or inappropriately treated concomitant conditions like COPD, congestive heart failure, GERD, and OSA

CHRONIC MANAGEMENT OF ASTHMA

See Table 3-18.

Table 3-18. General Treatment Principles

	Comments
Goals of Therapy	Reduce impairment: • Limit the number of symptomatic episodes. • Minimize the need to use inhaled rapid-acting ß agonists to ≤ 2 days/week. • Reduce nighttime symptoms causing awakenings to < 2/month. • Maintain/improve quality of life. • Optimize lung function. Reduce risk: • Prevent acute exacerbations requiring hospitalization or emergency care. • Prevent loss of lung function. • Optimize therapy with minimal or no side effects.

Table 3-18. General Treatment Principles, continued

	Comments
Patient Education	Basic understanding of disease Medication use, techniques, and mechanisms Strategies to prevent exacerbations: • Medication compliance (see below) • Identification and avoidance of triggers (see below) • Pre-medication in specific situations like exercise-induced asthma Strategies to identify and manage exacerbations: • Recommend daily home monitoring of PEFR • Introduce the concept of personal best PEFR • Prepare a personalized plan with specific directions for daily management, adjustment of medications, and seeking urgent care in response to decreasing PEFR and/or worsening symptoms
Assessment of Patients With Asthma During Office Visits	For impairment assessment, inquire about the presence of following in last 2–4 weeks: • Nighttime or early morning awakenings • Use of rapid-acting ß agonists to relieve symptoms • Need for urgent or emergency room care for asthma • Change in activity status or quality of life • Changes in PEFR • Side effects from medications For risk assessment, inquire about: • Use of oral steroids in last year • Hospitalization for asthma in last year • Intubation in last 5 years • Current smoking status • Any newly identified triggers including medications like aspirin and/or NSAIDs Check medication use and review the technique for using medication device
Monitoring Pulmonary Function During office Visits	Compare spirometry with patient's old values to check for development or worsening of airflow obstruction, which, if present, predicts the risk for exacerbation In the presence of a normal PEFR, spirometry has greater sensitivity for detecting obstruction.
Optimize Treatment of Coexisting/ Contributing Conditions	Treat GERD, rhinosinusitis, OSA, and COPD appropriately and adequately if present
Pharmacotherapy	See accompanying text

COPD, chronic obstructive pulmonary disease; GERD, gastroesophageal reflux disorder; NSAIDs, nonsteroidal antiinflammatory drugs; OSA, obstructive sleep apnea; PEFR, peak expiratory flow rate.

Role of Medication Compliance in the Management of Asthma

Multiple factors can contribute to nonadherence to asthma therapy, including:

- Lack of knowledge and understanding about the regular need for medication, even in the absence of symptoms
- Complexity of the regimen
- Inability to use the medication device
- Inability to afford the medications
- Misconceptions and/or fear regarding the side effects of the medications
- Sociocultural and religious issues

> ***Key Fact***
>
> It is important for patients to understand that medication use is required to control airway inflammation, even in the absence of symptoms.

Every possible effort should be made to identify and address the factors that contribute to a patient's noncompliance.

Trigger Control in the Management of Asthma

Attempts should be made to identify the agents/allergens or activities that exacerbate asthma symptoms. Once identified, complete avoidance of the trigger is advised (Table 3-19). If this is not possible, efforts should be made to limit the exposure. If exposure cannot be limited, an extra dose of inhaled bronchodilator and an antihistaminic agent can be taken prior to exposure.

Table 3-19. Commonly Identified Asthma Triggers and Steps for Avoidance

	Comments
Respiratory infections	Avoidance of sick contacts Annual vaccination for influenza Pneumococcal vaccination for asthmatic adults
Inhalant Allergens	Animal allergens (dogs, cats, rodents, birds): Advise patient not to keep pets, especially indoors. If pets present, clean aggressively and use HEPA filters. Aggressive pest control for rodent issues. House-dust mites: Use of physical barriers (covers for pillows, mattresses, etc.), minimized use of upholstery and fabric reservoirs, use of vacuums with HEPA filters, humidity control and use of insecticide or allergen-denaturing agents (benzyl benzoate, tannic acid). Measures should be adopted for at least 3–6 months to see clinical benefit. Cockroaches: Use of air filters not helpful. Requires integrated pest management. Indoor fungi: Decrease humidity by increasing ventilation, and increase temperature to reduce humidity. Visible mold can be scrubbed off. Outdoor plant allergens and fungi: Difficult to avoid. Stay indoors during pollen season, and shower before going to bed to avoid contamination of the bed.
Food Allergens	Sulfite-containing food products (wine, vinegar, dry fruits, processed potato products) can cause asthma-like symptoms. Identify food products and avoid exposure.
Occupational Allergens	See section on OA.
Irritants and Cigarette Smoking	Advise smoking cessation and avoidance of secondhand smoke. See section on RADS and IrIA.
Temperature and Weather	Avoid exposure to cold and dry air. Use scarves and masks.
Physical Activity	See section on exercise-induced asthma.
Hormonal Fluctuations	Increase medications if symptom worsening is anticipated during menstruation. Consider trial of antileukotriene agents
Medications	Avoid nonselective ß blockers (including those in topical ophthalmic solutions) if they are found to trigger asthma. Selective ß blockers in high doses can also trigger asthma and should be avoided if found to do so. For aspirin and other NSAIDs, see section on AERD.
Emotional Factors	Manage underlying depression, anxiety, and psychiatric conditions.

AERD, aspirin-exacerbated respiratory disease; HEPA, high-efficiency particulate air; IrIA, irritant-induced asthma; NSAIDs, nonsteroidal antiinflammatory drugs; OA, occupational asthma; RADS, reactive airways dysfunction syndrome.

Key Fact

Never use inhaled long-acting bronchodilators alone in the treatment of asthma. Studies suggest they may increase risk of asthma-related death when not combined with an inhaled corticosteroid.

Classification of Asthma Severity and Treatment Options

See Table 3-20.

Table 3-20. Treatment Options for the Chronic Management of Asthma

	Comments
Short-Acting β_2 Adrenergic Agonists	First-line agents for immediate symptomatic relief of bronchospasm. Increased frequency of use or decreased effectiveness can indicate worsening asthma control. Can cause tachycardia, tremors, palpitations, hypokalemia, lactic acidosis.
Nonselective β_1- and β_2-Adrenergic Agonists	Used for anesthesia-induced bronchospasm.
Short-Acting Anticholinergics	Can be used in patients for immediate relief of symptoms who are intolerant of or do not respond to short-acting ß-agonist therapy. Can also be coadministered with short-acting ß agonists. Can cause adverse cardiovascular events and acute urinary retention in patients with prostatic hypertrophy.
Inhaled Glucocorticoids	Mainstay of anti-inflammatory and maintenance therapy. Dose can be increased in a stepwise manner to achieve better asthma control. Rinse mouth after use to reduce risk of thrush. Can cause skin thinning, adrenal suppression, cataracts, osteoporosis, oral candidiasis, hoarseness of voice, easy bruising, impaired glucose control.
Long-Acting β_2 Agonists	Should not be used as monotherapy due to increased risk of asthma-related death. Have glucocorticoid sparing effect when used in combination with inhaled steroids. Chronic use shown to improve pulmonary function, increase symptom-free days, and decrease the need for rescue therapy. Chronic use has also been associated with rare severe acute asthma exacerbations and increased cardiac- and asthma-related mortality.
Combination Inhalers (Inhaled Glucocorticoids and Long-Acting β_2 Agonists)	First-line controller therapy for moderate-severe persistent asthma.
Systemic Glucocorticoids	Used in severe, persistent asthma uncontrolled with high-dose inhaled steroids. Titrate dose to the minimum required for symptom control.
Cromones	Not known to have bronchodilatory effect. Act by stabilizing airway mast cells and other inflammatory cells, thereby preventing bronchoconstriction. Can be used prophylactically 10–15 minutes prior to exposure to a known trigger. Used as a controller medication in mild persistent asthma in patients who do not want to take inhaled steroids, or in addition to inhaled steroids.

Table 3-20. Treatment Options for the Chronic Management of Asthma, continued

	Comments
Leukotriene Pathway Inhibitors	Can be used as an alternative monotherapy for the treatment of mild-moderate persistent asthma. Not a first-line therapy, as efficacy is lower than inhaled steroids. Can be added to inhaled steroid therapy in patients with moderate or severe persistent asthma whose disease is inadequately controlled, or used for possible steroid sparing effect.
Methylxanthines	Can be used in patients with chronic asthma whose symptoms are uncontrolled on conventional doses of inhaled steroids and in patients who cannot take or are noncompliant with inhaled medications. Needs drug level monitoring.
Long-Acting Anticholinergics	No FDA approval for use in asthma. Can be added to other therapies in severe, persistent asthma to achieve control.

The classification of asthma severity and initiation of treatment in adults with the stepwise approach are outlined in Figure 3-11 and Figure 3-12, respectively.

Components of Severity		Classification of Asthma Severity ≥ 12 years of age			
			Persistent		
		Intermittent	Mild	Moderate	Severe
Impairment Normal FEV_1/FVC: 8-19 yr 85% 20-39 yr 80% 40-59 yr 75% 60-80 yr 70%	Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day
	Nighttime awakenings	≤2 x/month	3-4 x/month	>1x/week but not nightly	Often 7x/week
	Short-acting beta agonist use for symptom control (not prevention of EIB)	≤2 days/week	>2 days/week but not daily, and not more than 1x on any day	Daily	Several times per day
	Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
	Lung function	● Normal FEV_1 between exacerbations ● FEV_1 > 80% predicted ● FEV_1/FVC normal	● FEV_1 > 80% predicted ● FEV_1/FVC normal	● FEV_1 > 60% but <80% predicted ● FEV_1/FVC reduced 5%	● FEV_1 > 60% predicted ● FEV_1/FVC reduced >5%
Risk	Exacerbations requiring oral systemic corticosteroids	0-1/year	>2/year		
		Consider severity and interval since last exacerbation. Frequency and severity may fluctuate over time for patients in any severity category. Relative annual risk of exacerbations may be related to FEV_1.			
Recommended Step for Initiating Treatment		Step 1	Step 2	Step 3	Step 4 or 5
				and consider short course of oral systemic corticosteriods	
		In 2-6 weeks, evaluate level of asthma control that is achieved and adjust therapy accordingly.			

Figure 3-11. Classification of asthma severity and treatment initiation in adults.
FEV_1, forced expiratory volume in one second; FVC, forced vital capacity.
(Reproduced courtesy of National Asthma Education and Prevention Program. Publication No. 07-405.)


Intermittent Asthma
Persistent Asthma: Daily Medication
Consult with asthma specialist if step 4 care or higher is required.
Consider consultation at step 3.
Step 1
Preferred:
SABA PRN
Step 2
Preferred:
Low-dose ICS
Alternative:
Cromolyn, LTRA, Nedocromil, or Theophylline
Step 3
Preferred:
Low-dose ICS + LABA
OR
Medium-dose ICS
Alternative:
Low-dose ICS + either LTRA, Theophylline, or Zileuton
Step 4
Preferred:
Medium-dose ICS + LABA
Alternative:
Medium-dose ICS + either LTRA, Theophylline, or Zileuton
Step 5
Preferred:
High-dose ICS + LABA
AND
Consider Omalizumab for patients who have allergies
Step 6
Preferred:
High-dose ICS + LABA + oral corticosteroid
AND
Consider Omalizumab for patients who have allergies
Step up if needed
(first, check adherence, environmental control, and comorbid conditions)
Assess control
Step down if possible
(and asthma is well controlled at least 3 months)
Each step: Patient education, environmental control, and management of comorbidities.
Steps 2–4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma (see notes).
Quick-Relief Medication for All Patients
• SABA as needed for symptoms. Intensity of treatment depends on severity of symptoms: up to 3 treatments at 20-minute intervals as needed. Short course of oral systemic corticosteroids may be needed.
• Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control and the need to step up treatment.

Figure 3-12. Stepwise approach for asthma therapy in adults.
EIB, exercise-induced bronchospasm; ICS inhaled corticosteroid; LABA, long-acting inhaled β_2 agonist, LTRA, leukotriene receptor antagonist; SABA, inhaled short-acting β_2 agonist.
(Reproduced courtesy of National Asthma Education and Prevention Program. Publication No. 07-405.)

Anti-IgE Therapy in the Management of Asthma

Omalizumab, a recombinant monoclonal antibody, binds IgE with high affinity. It is administered subcutaneously every 2–4 weeks. Dosing is calculated by the patient's body weight and the level of serum IgE. Therapy should not be started during an acute exacerbation and should not be self-administered. In order to prevent local reactions, no more than 150 mg should be administered at a single site. A minimum of 12 weeks of therapy is required prior to determining the effectiveness of therapy. No specific laboratory tests are required to monitor the patients who are clinically improving on anti-IgE therapy. In patients showing clinical response, the optimal duration of therapy has not been established. Adverse effects include injection-site reactions, rash, and urticaria.

Key Fact

Anti-IgE therapy is not a first-line therapy for the majority of asthma patients, but it can be considered in patients with atopic asthma refractory to standard therapy.

Criteria for use include:

- Moderate-to-severe persistent asthma.
- Inadequately controlled symptoms with inhaled steroids.
- Serum IgE level between 30–700 international units/mL; therapy requires presence of enough free IgE to bind to ensure therapeutic effect.

- Presence of allergic sensitization demonstrated through skin testing and/or in vitro testing for allergen-specific IgE. (Allergen should be present year-round.)

A pretreatment eosinophil count > 300 cells/mcL may serve as a predictor of better clinical response.

Bronchial Thermoplasty

Technique of applying heat energy to the airways during bronchoscopy using a specialized catheter. Three separate bronchoscopies are performed over 3 weeks under moderate sedation. The procedure is associated with a modest degree of improvement and lacks data on long-term benefits and effects on airway morphology. It can also result in acute exacerbation requiring hospitalization. Performed only at specialized centers.

Criteria for consideration of bronchial thermoplasty:

- Dependence on systemic steroid therapy (intermittently or continuously)
- $FEV_1 \geq 50\%$ predicted
- No history of life-threatening exacerbations
- Understanding of the risk of asthma worsening or having an acute exacerbation after the procedure

MANAGEMENT OF ACUTE ASTHMA EXACERBATIONS

Risk Factors for Fatal Asthma Attack

Key Fact

A history of severe and/or frequent exacerbations puts patients at increased risk for experiencing a fatal exacerbation.

Risk factors for fatal asthma exacerbation:

- Asthma history:
  - History of severe exacerbation requiring intubation and/or ICU monitoring.
  - History of an exacerbation requiring hospitalization in the previous year.
  - History of ≥ 3 exacerbations requiring emergency care in the previous year.
  - Decrease in peak flow to < 50% of patient's baseline.
- Noncompliance:
  - Noncompliant with medication use, including inhaled steroids.
  - Noncompliant with asthma action plan and regular follow-up.
- Medication dependence:
  - Requiring > 1 canister of rescue therapy per month.
  - Dependent on systemic steroids.
- Patient factors/demographics:
  - History of illicit drug use and/or active smoking.

- Comorbid psychological disorder.
- Poor symptom perception.
- Presence of other cardiovascular and pulmonary co-morbid conditions.
- Low socioeconomic status.
- Non-white.
- Aspirin sensitivity.
- Continued trigger exposure.

Detecting the Onset of an Exacerbation

Patients should be taught to recognize the following indications of an exacerbation.

Symptoms:

- Progressively worsening breathlessness, wheezing, cough, and chest tightness
- Decreased exercise tolerance and fatigue

Peak expiratory flow measurement:

- Baseline peak flow should be established in every patient.
- Decrease in peak flow of > 20% from normal, or from the patient's personal best value, serves as a marker to detect the onset of an acute exacerbation.
- Particularly useful in patients who have poor symptom perception.
- Upon detection of an acute exacerbation, patients should implement their asthma action plan (Figure 3-10).


Asthma Action Plan
For:
Doctor:
Date:
Doctor's Phone Number
Hospital/Emergency Department Phone Number
GREEN ZONE
Doing Well
No cough, wheeze, chest tightness, or shortness of breath during the day or night
Can do usual activities
And, if a peak flow meter is used,
Peak flow: more than
(80 percent or more of my best peak flow)
My best peak flow is:
Take these long-term control medicines each day (include an anti-inflammatory).
Medicine
How much to take
When to take it
Before exercise
2 or 4 puffs
5 minutes before exercise
YELLOW ZONE
Asthma Is Getting Worse
Cough, wheeze, chest tightness, or shortness of breath, or
Waking at night due to asthma, or
Can do some, but not all, usual activities
-Or-
Peak flow: to
(50 to 79 percent of my best peak flow)
First
Add: quick-relief medicine—and keep taking your GREEN ZONE medicine.
(short-acting beta2-agonist)
2 or 4 puffs, every 20 minutes for up to 1 hour
Nebulizer, once
Second
If your symptoms (and peak flow, if used) return to GREEN ZONE after 1 hour of above treatment:
Continue monitoring to be sure you stay in the green zone.
-Or-
If your symptoms (and peak flow, if used) do not return to GREEN ZONE after 1 hour of above treatment:
Take: 2 or 4 puffs or Nebulizer
(short-acting beta2-agonist)
Add: mg per day For (3–10) days
(oral steroid)
Call the doctor before/ within hours after taking the oral steroid.
RED ZONE
Medical Alert!
Very short of breath, or
Quick-relief medicines have not helped, or
Cannot do usual activities, or
Symptoms are same or get worse after 24 hours in Yellow Zone
-Or-
Peak flow: less than
(50 percent of my best peak flow)
Take this medicine:
(short-acting beta2-agonist)
4 or 6 puffs or Nebulizer
(oral steroid)
mg
Then call your doctor NOW. Go to the hospital or call an ambulance if:
You are still in the red zone after 15 minutes AND
You have not reached your doctor.
DANGER SIGNS
Trouble walking and talking due to shortness of breath
Lips or fingernails are blue
Take 4 or 6 puffs of your quick-relief medicine AND
Go to the hospital or call for an ambulance NOW!
(phone)

Figure 3-10. Asthma action plan. The patient's normal PEFR value can be used to construct a personalized asthma action plan.
(Reproduced courtesy of The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.)

Initial Approach and Severity Assessment

On arrival to a healthcare setting, initial approach should focus on assessing hemodynamic stability and the need for intubation. The patient should be evaluated for the presence of alternative diagnoses that might symptomatically present as an acute asthma exacerbation and for the presence of concomitant/coexisting conditions that might lead to an exacerbation (e.g., pneumonia, congestive heart failure, pneumothorax, pulmonary embolism).

INDICATORS OF SEVERITY

Clinical findings:

- The presence of tachypnea, tachycardia (>120 bpm), use of accessory muscles of inspiration, diaphoresis, inability to speak full phrases, inability to lie supine due to breathlessness, and pulsus paradoxus are all suggestive of a severe exacerbation.
- Findings can be present alone or in combination.
- These findings lack sensitivity and might be absent in patients with severe obstruction.

Peak expiratory flow measurements:

- Best method for objective assessment of severity.
- Values < 200 L/min or < 50% of patient's baseline are indicative of severe attack.
- Also used to monitor response to therapy and a predictive marker for the presence of hypercapnia; a decrease in peak expiratory flow to < 25% of patient's baseline is an indirect marker for the presence of hypercapnia.

Arterial blood gas analysis:

- Presence of marked hypoxia (arterial partial pressure of oxygen < 60 mmHg or oxygen saturation < 90%) is suggestive of severe exacerbation.
- Hyperventilation can lead to decreased arterial partial pressure of carbon dioxide ($PaCO_2$); normal or high $PaCO_2$ is indicative of severe airway obstruction.
- Worsening hypercapnia is an indication for intubation.

Imaging studies:

- Presence of hyperinflation is a sign of severe obstruction and air trapping.

Treatment of Acute Asthma Exacerbation (See Table 3-21)

Table 3-21. Treatment of Acute Asthma Exacerbation

	Comments
Goals of Therapy	Rapid reversal of airflow obstruction Maintenance of hemodynamic stability Correction of hypercapnia and/or hypoxemia, if necessary
Supplemental Oxygen	Should be used to maintain oxygen saturation ≥ 90% (> 95% in pregnancy)
Inhaled Short-Acting β2-Agonist Therapy	Mainstay of bronchodilator therapy ≥ 3 treatments need to be given within the first hour Nebulizer therapy is preferred over the use of metered dose inhalers in acutely ill patients and can be administered continuously
Inhaled Anticholinergics	Can be added to inhaled β_2-agonist therapy in the emergency room in the patients with severe obstruction Can also be used in patients who have concomitant COPD or refractory asthma
Systemic Glucocorticoid Therapy	See below
Magnesium Sulfate	Single dose of 2 g infused over 20 minutes in patients with life-threatening exacerbation or in patients with severe exacerbations failing to respond (peak flow < 40% baseline) after 1 hour of intensive therapy with above-mentioned agents Contraindicated in patients with renal failure
Methylxanthines	Not indicated in the routine management of acute asthma exacerbations Can be used in acute exacerbations that fail to respond to conventional therapy (no evidence) For patients on oral therapy prior to admission, maintenance oral therapy is continued during hospital stay Needs drug-level monitoring
Nonstandard Therapies	Anesthetic agents (intravenous ketamine, inhaled halothane) are known to have bronchodilator properties Reported to be used in refractory status asthmaticus Parenteral ß agonists are used in patients suspected of having an anaphylactic reaction leading to exacerbation, patients unable to use inhaled bronchodilators, or in patients with acute respiratory failure secondary to refractory exacerbation Helium-oxygen mixtures: • Low density of helium reduces airflow resistance • Can be used to decrease work of breathing and improve ventilation • Used in patients with refractory severe exacerbations or when significant contribution from upper airway obstruction is suspected. • Conflicting data about efficacy limits routine use
Empiric Antibiotics	No antibiotics to be used routinely unless concomitant bacterial pneumonia, sinusitis, or other bacterial infection is suspected

COPD, chronic obstructive pulmonary disease.

SYSTEMIC GLUCOCORTICOIDS—Essential for exacerbations refractory to intensive bronchodilator therapy.

Indications for early administration of systemic glucocorticoid therapy during an acute exacerbation are as follows:

- Immediate administration in a patient with peak expiratory flow rate < 40% of patient's baseline.
- Early administration recommended in patients with peak expiratory flow rate > 40% of patient's baseline but < 70%.
- Lack of improvement in peak flow after several treatments with rapid-acting bronchodilators.
- Asthma exacerbation in patients who are on current systemic steroid therapy; such patients require steroid supplementation above their baseline dose.

Onset of action:

- Clinically evident ~6 hours after administration.
- Early administration recommended.

Optimal dose:

- Unknown for acute asthma exacerbation.
- Based on expert opinion, patients with life-threatening exacerbations should be given initial dose of 60–80 mg methylprednisolone every 6–12 hours.

Route of administration:

- At comparable doses, the efficacy of systemic steroids administered by oral and IV route remains the same.
- IV steroids should be used in patients who are unable to tolerate oral steroids or who are acutely sick with impending or actual respiratory failure.
- In acutely sick patients, once patient can tolerate and absorb oral medications, transition can be made from IV to oral route.

Duration of therapy:

- The optimal duration of systemic steroid therapy is unknown.
- Routinely, 10–14 days of systemic therapy is recommended.
- Patients can be advised to stop oral therapy earlier if marked improvement in symptoms is noted with improvement in peak flow values (peak expiratory flow > 70% of baseline).
- Tapering steroid therapy is not needed if the total duration of systemic therapy is < 3 weeks.
- However, patients should be placed on inhaled glucocorticoid therapy for maintenance.

AIRWAY MANAGEMENT IN ACUTE ASTHMA EXACERBATION—If intubation difficulty is not anticipated, rapid-sequence intubation is preferred. Nasal intubation is not recommended.

Indications for intubation and mechanical ventilation in acute asthma exacerbation are as follows:

- Decrease in respiratory rate.
- Altered mental status.
- Failure to maintain respiratory effort.
- Worsening acidosis and hypercapnia.
- Hypoxia with oxygen saturation < 95% in the presence of high-flow supplemental oxygen.

Role of noninvasive positive-pressure ventilation has not been well studied in asthma.

Ventilation settings:

- Goal is to adequately oxygenate and ventilate the patient, minimizing the increased airway pressures at the same time.
- Severe bronchoconstriction reduces airflow during expiration; the ventilator settings should provide adequate time for expiration.
- Adequate time for expiration can be achieved by using high inspiratory flow rates (80–100 L/min), low tidal volumes (6–8 mL/kg), and low respiratory rates (10–14 breaths/min).

INDICATIONS FOR HOSPITALIZATION IN ACUTE ASTHMA EXACERBATION

- Patients who fail to show substantial improvement after 4–6 hours of aggressive management with frequent inhaled bronchodilator and systemic glucocorticoid treatment.
- Patients with hemodynamic instability, persistent hypoxemia, hypercarbia, wheezing, presence of concomitant pneumonia, congestive heart failure, and other comorbid conditions.
- Presence of potential trigger in home environment.
- Patients known to be noncompliant with medications or who are unable to care for themselves with lack of social support.
- Presence of risk factors for fatal asthma attack.

PREGNANCY AND ASTHMA

Diagnosis of Asthma during Pregnancy

SPIROMETRY

- Diagnosis can be made by demonstration of reversible airflow obstruction on spirometry.
- FVC, FEV_1, FEV_1/FVC ratio, and peak expiratory flow rates are not significantly changed during normal pregnancy.
- Bronchoprovocation challenge testing is generally avoided.

CLINICAL FEATURES

- One third of patients show improvement in their asthma during pregnancy.
- One third of patients show worsening of their asthma during pregnancy.
- The remaining one third show no change.
- Exacerbations usually occur during the middle trimester.
- Gestational asthma is associated with perinatal mortality, pre-eclampsia, and preterm delivery.

Treatment of Asthma during Pregnancy

GENERAL TREATMENT PRINCIPLES—The general treatment principles for management of acute exacerbations and chronic management of asthma in pregnant patients are the same as non-pregnant individuals. Fetal well-being should also be monitored.

ROLE OF SPECIFIC MEDICATIONS

- Studies on the use of albuterol, metaproterenol, theophylline, and inhaled glucocorticoids, particularly beclomethasone and budesonide, have shown lack of adverse effects on outcomes of human pregnancy.
- Salmeterol, formoterol, ipratropium, nedocromil, zafirlukast, and montelukast have shown reassuring data in animal studies with limited experience in human pregnancies.
- Use of systemic steroids in pregnancy has been associated with slightly increased risk of congenital malformations, low birth weight, pre-eclampsia, and neonatal adrenal insufficiency.
- However, these potential risks outweigh the benefit of using systemic steroid therapy during acute asthma exacerbations during pregnancy.
- Allergen immunotherapy for asthma should not be initiated during pregnancy but can be continued in patients who are already on it and not prone to systemic reactions.

COPD BASIC SCIENCE

COPD is characterized by airflow obstruction that is chronic, progressive, and for the most part, fixed. It is generally divided into emphysema and chronic bronchitis.

- Emphysema is defined as alveolar wall destruction with irreversible enlargement of the air spaces distal to the terminal bronchioles and without evidence of fibrosis.
- Chronic bronchitis is defined as a productive cough that is present for a period of 3 months in each of 2 consecutive years in the absence of another identifiable cause of excessive sputum production.

PATHOPHYSIOLOGY

COPD is characterized by chronic inflammation of the airways, lung tissue, and pulmonary blood vessels. Protease-antiprotease imbalance and oxidative stress are also involved in the pathogenesis of COPD.

Cellular Response and Inflammatory Mediators

Key Fact

Epithelial cells→TGFβ→ small airway fibrosis

Key Fact

Macrophages→LTB4 and IL-8→neutrophil and T-cell chemoattractant→increase d inflammation

- Tobacco smoke and other environmental irritants→activation of epithelial cells and macrophages→release of multiple cytokines like CXC chemokine ligand (CXCL) and CC chemokine ligand (CCL)→recruitment of cytotoxic T cells (T_C1), T_h1 cells, and neutrophils→release of inflammatory mediators and proteases→destruction of lung parenchyma and mucus production. Details are provided in Table 3-21 and Figure 3-13.
  - Chemokines are a group of chemoattractant cytokines secreted by cells and can induce chemotaxis in other leukocytes.
  - Two predominant chemokines involved in the immune response of COPD are CXC chemokines (CXC) and CC chemokines (CC).
- Epithelial cells also secrete TGF→stimulation of fibroblast production→fibrosis of small airways.

Table 3-21. Major Cellular Responses and Mediators in COPD

Cell Types	Inflammatory Mediators
Epithelial cells	TGFβ, CXCL
Macrophages	CXCL, CXC, IL-6, IL-8, LTB4, TNFα, MMP
Neutrophils	MMP, serine proteases
T_h1 cells, T_C cells (CD8+)	Interferons

CXC, CXC chemokine; CXCL, CXC chemokine ligand; IL, interleukin; MMP, metalloproteases; TNF, tumor necrosis factor; TGF, transforming growth factor.



Figure 3-13. Macrophages are activated by cigarette smoke and recruit neutrophils and CD+ lymphocytes to cause elastolysis and emphysema. Similarly, cigarette smoke activates airway epithelium to trigger airway remodeling. Both of these processes result in airflow obstruction.

CXCR3, chemokine CXC receptor 3; CXCR2, chemokine CXC receptor 2; EGF, epidermal growth factor; IL-8, interleukin 8; CXCL, CXC chemokine ligand; CCL, CC chemokine ligand; LTB4, leukotriene B4; MMPs, matrix metalloproteinases; PDGF, platelet-derived growth factor; TGF β, transforming growth factor β.

Flash Card Q4

What are the primary lymphocytes involved in pathogenesis of COPD?

Protease and Antiprotease Imbalance

Increased activity of proteases and decreased activity of antiproteases leads to lung destruction.

- The primary proteases involved are serine proteases, elastases, and matrix metalloproteases (MMP-8, MMP-9, and MMP-12).
- Main antiprotease involved is α_1-antitrypsin.

Oxidative Stress

Oxidative stress due to cigarette smoke and reactive oxygen species produced by inflammatory cells can further accentuate inflammation and protease-antiprotease imbalance, thereby accelerating lung destruction.

PATHOLOGICAL CHANGES IN COPD

Emphysema

Neutrophil elastase and MMP released by the inflammatory cells lead to destruction of alveolar wall and capillaries. In patients with α_1-antitrypsin deficiency, loss of α_1-antitrypsin leads to unopposed breakdown of elastin by elastase (which is released by neutrophils).

Chronic Bronchitis

- Squamous metaplasia and goblet hyperplasia → mucus hypersecretion
- Inflammation → smooth muscle hypertrophy and fibroblast proliferation → peribronchiolar fibrosis
- Smoking → mucociliary dysfunction → mucus buildup → airflow obstruction → air trapping

COMPARISON OF ASTHMA AND COPD

Both asthma and COPD are characterized by airway inflammation. Table 3-23 gives a broad overview of pathogenesis of both the diseases.

Flash Card A4

A: CD8+ cytotoxic T cells

Table 3-23. Overview of Asthma and COPD Pathogenesis

Feature	Asthma	COPD
Inciting factor	Allergen or irritant	Smoking or irritant
Major cell types	Epithelial cells, T_h2 cells (CD4+) Mast cells, eosinophils	T_h1 and T_C1 cells (CD8+) Neutrophils, macrophages
Mediators	IL-4, IL5, IL-13	LTB4, TNFα, IL-8
Airway and parenchymal involvement	Mainly large airway No parenchymal involvement	Small airway fibrosis Parenchymal destruction
Pathological changes	Subepithelial fibrosis Smooth muscle hyperplasia+++ Mucous metaplasia Basement membrane thickening	Peribronchial fibrosis Smooth muscle hyperplasia+ Mucous metaplasia Alveolar destruction
Airflow limitation		

COPD

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as a common, preventable, and treatable disease characterized by persistent airflow limitation that is usually progressive. It associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases.

MECHANISMS OF AIRFLOW LIMITATION

There are two proposed mechanisms of airflow limitation in COPD, and both pathways are the result of the host's modified response to chronic irritants (Table 3-22).

Small airways disease is the result of chronic inflammation leading to thickening and narrowing of the small airways.

Before the development of emphysema and parenchymal destruction, the elastin in the walls of the small airways is destroyed, leading to the disappearance of small airways. The combination of narrowed and lost small airways and mucus occlusion leads to increased peripheral airway resistance.

Parenchymal destruction is the result of chronic inflammation leading to the loss of alveolar attachments to the small airways and decreased elastic recoil. Destruction of the parenchyma also leads to gas exchange abnormalities.

Table 3-22. Mechanisms of Underlying Airflow Limitation

Small Airways Disease	Parenchymal Destruction
Airway inflammation	Loss of alveolar attachments
Narrowing of the small airways	Decreased elastic recoil
Loss of elastin in airway wall	
Disappearance of the small airways	
Luminal plugs	
Increased airway resistance	

Chronic Bronchitis and Emphysema

Chronic bronchitis and emphysema are often used to describe subtypes of COPD but should not be considered COPD unless there is associated airflow obstruction. Figure 3-14 shows the mechanisms of underlying airflow limitation.

Chronic bronchitis is a clinical entity defined as cough or sputum production for at least 3 months in each of 2 consecutive years. It can occur regardless of airflow limitation, and other causes of cough must be ruled out.

Emphysema is a pathological term that describes abnormal enlargement of the airspaces distal to the terminal bronchioles along with the destruction of airspace walls. Emphysema represents one type of structural abnormality in COPD.



Figure 3-14. Mechanism of underlying airflow limitation. Small airways disease is depicted as chronic obstructive bronchiolitis, and parenchymal destruction is depicted as emphysema.

EPIDEMIOLOGY

Burden of COPD

COPD is a global disease with significant morbidity and mortality causing both a social and economic burden. The estimated direct costs of COPD in 2010 were $29.5 billion (largely related to COPD exacerbations), with indirect costs of $20.4 billion (lost earnings for patients and caregivers) in the US alone.

PREVALENCE OF COPD—The World Health Organization (WHO) estimated that 64 million people had COPD worldwide in 2004, but some estimates are as high as 210 million. In the US, the Centers for Disease Control (CDC) reported the prevalence of COPD as 5.1% (11.8 million) from 2007 to 2009, but the National Health and Nutrition Examination Survey (NHANES) III, conducted between 1988 and 1994, estimated that 23.6 million US adults were afflicted with COPD. Overall, the true prevalence is difficult to determine because COPD has a high rate of underdiagnosis. It is estimated that 60–85% of patients with mild-to-moderate COPD are undiagnosed.

Key Fact

The rate of female deaths from COPD is rising and the deaths per year have exceeded that of men since the year 2000.

The prevalence and mortality of COPD in women is higher than in men:

- Women are 37% more likely to have COPD than men (Figure 3-15).
- Mortality in females from COPD has more than quadrupled since 1980.
- Since 2000, more women than men have died from COPD annually.



Figure 3-15. Prevalence of COPD from 1998–2009 in the U.S. was significantly higher among women than men.
(Source: Centers for Disease Control and Prevention/ National Center for Health Statistics Health Data Interactive, National Hospital Discharge Survey, and National Vital Statistics System.)

Prevalence of COPD is higher in older age groups:

- In the Latin American Project for the Investigation of Obstructive Lung Disease:
  - Prevalence of post-bronchodilator obstruction among people > 40 years old was examined in five major Latin American cities.
  - The highest prevalence of COPD was among those ≥ 60 years old.
- Most patients with COPD in the US are > 65 years old (Figure 3-16).



Figure 3-16. Prevalence of COPD in the US 1998–2009 by age and sex.
(Source: Centers for Disease Control and Prevention/ National Center for Health Statistics, Health Data Interactive, National Hospital Discharge Survey, and National Vital Statistics System.)

MORBIDITY AND MORTALITY—COPD is a debilitating disease that impairs sleep, employment, and physical and social activity.

- Associated comorbidities such as cardiovascular disease and diabetes complicate the ability to quantify morbidity in COPD.
- Disability-adjusted life year (DALY) measures the proportion of mortality and disability attributable to major disease and estimates that COPD will be ranked seventh by the year 2030 (compared to 12th in 1990).
- The Global Mortality and Burden of Disease project estimates COPD mortality will rank fourth worldwide and third in middle-income countries by 2030.
- In 2002, COPD was ranked as the fifth-leading cause of death worldwide.
- From 1999–2007, death rates declined for men but did not change significantly for women (Figure 3-17).



Figure 3-17. Hospitalization and death rates in the U.S. for COPD, 1997–2007.
(Source: Centers for Disease Control and Prevention/ National Center for Health Statistics, Health Data Interactive, National Hospital Discharge Survey, and National Vital Statistics System.)

RISK FACTORS FOR COPD

Smoking and Nonsmoking Risk Factors

Cigarette smoking is the single most important risk factor for the development of COPD. However, a significant burden of disease occurs in nonsmokers. Alpha-1antitrypsin deficiency and occupational exposures are implicated as the other major causes of COPD. Other significant causes include outdoor air pollution, secondhand smoke, and biomass smoke.

SMOKING— Nearly 80% of all COPD cases can be attributed to smoking. In a retrospective cohort, smokers were more likely than never smokers to develop COPD over a 25-year span (36% vs. 8%).

Risk of COPD and smoking:

- Cigarette smoking: 15–20% of 1 pack per day (PPD) smokers and 25% of 2 PPD smokers
- Pipe and cigars: Elevated risk, but lower than cigarette smokers
- Passive smoking: Suggestive evidence for secondhand smoke as a risk factor

NONSMOKING—Most data concerning risk factors for nonsmoking COPD were gathered from cross-sectional epidemiologic studies that identified associations rather than cause-and-effect relationships (Table 3-24). In the worldwide Burden of Obstructive Lung Disease (BOLD) survey, the risk in nonsmokers was estimated to be 3–11%.

Table 3-24. Risk of COPD Not Related to Smoking

Risk	Comment
Occupational exposures	Coal miners, hard-rock miners, tunnel workers, cement workers, cotton workers (Table 3-25)
Genetic susceptibility	α_1-antitrypsin deficiency with > 90% caused by homozygous PiZZ phenotype; cutis laxa (emphysema in children); metalloproteinase-12 gene mutation
Asthma/bronchial hyperreactivity	Chronic asthma and hyperreactivity can lead to FEV_1 decline and fixed obstruction in nonsmokers
Biomass smoke	Indoor burning of wood, animal dung, crop residue, and coal in poorly ventilated dwellings (primarily affects women)
Poverty	Strong risk factor but unclear if related to combination of poor nutrition, air pollution, etc.
Poor lung development	Bronchopulmonary dysplasia (neonatal chronic lung disease), low birth weight
Infections	Childhood infections, tuberculosis, HIV (accelerated emphysema in smokers)
Air pollution	Outdoor pollution has been shown to be an independent risk factor for decline in FEV_1

FEV_1, 1-second forced expiratory volume; HIV, human immunodeficiency virus.

Table 3-25. Occupational Irritants That Increase the Risk of COPD

Occupation	Irritant
Agricultural worker	Endotoxin
Coal miner	Coal dust
Concrete worker	Mineral dust
Construction worker	Dust
Gold miner	Silica
Hard rock miner	Mineral dust
Rubber worker	Industrial chemicals

α_1-ANTITRYPSIN (AAT) DEFICIENCY—AAT is a protease inhibitor of the proteolytic enzyme elastase and normally protects the lung from elastin degradation. In AAT deficiency, there is an imbalance favoring degradation of elastin leading to panacinar emphysema. Cigarette smoking increases the risk of emphysema in AAT deficiency and accelerates lung function decline.

Phenotypes and risk for emphysema are listed in Table 3-26.

Table 3-26. α_1-Antitrypsin Deficiency Phenotypes and Emphysema Risk

Phenotype	Risk for Emphysema (%)
MM (normal)	No increase
MZ	Causes intermediate serum level deficiency, but risk of developing emphysema is unclear and controversial
SS	No increase
SZ	Mild increase (20–50%) in smokers; rarely occurs in nonsmokers
ZZ	High risk (80–100%); accelerated age of onset in smokers
Null	High risk (100% by age 30)

The following characteristics differentiate AAT deficiency from smoking-related COPD:

- AAT deficiency has an earlier age of onset; mean age is 46 +/- 11 years in one study and median age is 52 years in another
- Emphysema in a nonsmoker or minimal smoker
- First-degree relative with emphysema
- Characteristic imaging shows bullous changes predominantly at the bases
- Concurrent liver disease/cirrhosis
- Panniculitis (rare skin finding)

Treatment:

- Conventional COPD management, including smoking cessation with nonpharmacologic and pharmacologic therapy, based on GOLD guidelines
- Intravenous α_1-antitrypsin therapy (augmentation) is available for high-risk phenotype patients, typically PiZZ:
  - Increases serum and bronchoalveolar lavage (BAL) fluid levels
  - Eligible patients: nonsmokers, FEV_1 25–80%, plasma AAT level < 11 μmol/L, other therapy optimized
  - Modest effect in slowing lung function decline, but no effect in preventing exacerbations
  - Not recommended for emphysema unrelated to AAT deficiency or patients with normal lung function

Key Fact

AAT deficiency should be suspected in young (<45 years), white nonsmokers with emphysema and imaging showing bullous disease at the lung bases.

NATURAL HISTORY

Pulmonary Function Decline

The natural age-related decline in lung function is accelerated in COPD (Figure 3-18). Patients with COPD often remain asymptomatic for 20–40 years prior to diagnosis. After age 35, nonsmokers can expect to lose up to 30 mL/year in FEV_1, while smokers with COPD lose ~60 mL/year; the most loss occurs in patients with moderate airflow obstruction. Symptoms of dyspnea and wheezing typically occur when FEV_1 is 40–59% of predicted. When a smoker stops smoking, the rate of FEV_1 loss again approximates that of a nonsmoker, but the lost lung function is never fully regained.



Figure 3-18. Lung function decline in smokers and nonsmokers.

DIAGNOSIS

Symptoms

A diagnosis of COPD should be suspected in any patient with dyspnea, chronic cough or sputum production, and a history of exposure to known risk factors. Symptom onset is usually in the fifth decade of life or later and often brought to light by respiratory infections.

ADDITIONAL CLINICAL FEATURES—Other symptoms associated with COPD are important prognostically or may represent other disease processes (e.g., tuberculosis, lung cancer, congestive heart failure).

- Wheezing and chest tightness
- Fatigue
- Weight loss/muscle wasting; inflammatory mediators from the lung may play a role
- Anorexia
- Cough attacks, which may cause rib fractures that are often asymptomatic
- Ankle swelling; may represent cor pulmonale

- Depression/anxiety; associated with an increased risk of exacerbations

Physical Exam

Abnormal physical exam findings are mostly present in severe disease.

CHEST EXAM

- Chest wall hyperinflation; limited diaphragmatic motion on auscultation
- Decreased intensity of breath and/or heart sounds
- Wheezing and prolonged expiratory time
- Pursed-lip breathing and use of accessory respiratory muscles

OTHER

Key Fact

Digital clubbing is not typical in COPD and may reflect other disease processes such as lung cancer or interstitial lung disease.

- Positional relief of dyspnea: leaning forward, arms outstretched with palms or elbows used to bear weight
- Cyanosis
- Digital clubbing is not typical in COPD and may reflect other disease processes (e.g., lung cancer)
- Lower extremity edema may occur with or without cor pulmonale
- Asterixis rare but can be seen with severe hypercapnia

Spirometry

DIAGNOSIS AND SPIROMETRY—In the appropriate clinical context, a diagnosis of COPD is made with spirometry (Figure 3-19).

Key Fact

After age 35, nonsmokers can expect to lose up to 30 mL/year in FEV_1 while smokers lose close to 60 mL/year.

- Post-bronchodilator $FEV_1/FVC < 0.70$ establishes the presence of persistent airflow obstruction (GOLD definition).
- Degree of post-bronchodilator response to FEV_1 is not required for the diagnosis of COPD.
- Up to two thirds of COPD patients can have a significant bronchodilator response despite not having a diagnosis of asthma.
- Presence of a bronchodilator response cannot definitively differentiate COPD from asthma.
- Figure 3-19 illustrates flow-volume loops of a normal lung and in obstructive lung disease.

The lower limit of normal (LLN) for FEV_1/FVC is also used to identify airflow limitation but is not part of the GOLD criteria. Using the LLN is dependent upon the choice of valid reference equations but can help with avoiding overdiagnosis of COPD in the elderly. The fixed FEV_1/FVC threshold can also lead to underdiagnosis in younger patients with COPD.



Figure 3-19. Flow volume loop demonstrating obstruction.

OTHER LUNG FUNCTION FINDINGS

- Elevated total lung capacity (TLC) or functional residual capacity (FRC) > 120% predicted is consistent with hyperinflation.
- Elevated residual volume (RV) > 120% predicted is consistent with air trapping.
- Decreased DLCO, out of proportion to alveolar volume, is seen in emphysema.
- An inspiratory capacity (IC)-to-TLC ratio $\leq$ 25% is an independent predictor of mortality in COPD.

Key Fact

When a smoker stops smoking, the rate of FEV_1 loss again approximates that of a nonsmoker.

Radiography

CHEST X-RAY—Although not useful in the diagnosis of COPD, the chest x-ray can be used to evaluate for other diseases that have similar symptoms (e.g., pulmonary fibrosis, bronchiectasis).

Classic changes on chest x-ray include hyperinflation (flattened diaphragms, increased retrosternal space, teardrop-shaped heart) and hyperlucency of the lung (Figure 3-20).

Figure 3-20. Chest radiograph showing hyperinflation.
(Image courtesy of Wikipedia; permission granted per the GNU Free Documentation License.)

COMPUTED TOMOGRAPHY (CT) OF THE CHEST—Not recommended for routine diagnostic purposes, although it has much better sensitivity and specificity than plain radiographs. If surgery is an option for resection of bullae or lung volume reduction, a chest CT is used to identify the distribution of emphysema (Figure 3-21).

Many patients with COPD will also meet criteria for lung cancer screening with low-dose CT given their older age and extensive smoking histories (see Chapter 12.).



Figure 3-21. CT of the chest showing emphysema.
(Modified and reproduced, with permission, from Matsuoka S, Washko GR, Yamashiro T, et al. Pulmonary Hypertension and Computed Tomography Measurement of Small Pulmonary Vessels in Severe Emphysema. *Am J Respir Crit Care Med* 2010;181(3):218–225. Fig. 1. doi: 10.1164/rccm.200908-1189OC)

Comorbidities

Comorbidities can occur at any stage of disease and directly influence mortality and hospitalization rates. COPD increases the risk of lung cancer, fractures, cardiovascular disease, osteoporosis, and respiratory infections (Figure 3-22).

SYSTEMIC FEATURES—There is growing evidence that inflammatory mediators contribute directly to the worsening of comorbidities. One proposed mechanism describes inflammatory mediators from the lung "spilling over" into the circulation and leading to other disease processes.

MANAGEMENT OF COMORBIDITIES—Comorbidities should be treated independent of COPD severity. In general, the presence of COPD should not interfere with the treatment of other diseases.

- **Cardiovascular disease:** The most frequent coexisting disease and the second most common cause of death in patients with mild-to-moderate COPD.
  - Cardioselective ß blockers should not be discontinued, even in severe COPD.
- **Lung cancer:** The most frequent cause of death in patients with mild COPD.
- **Osteoporosis**, **anxiety/depression**, **metabolic syndrome:** Associated with poor health status and prognosis.



Figure 3-22. Comorbidities of COPD.

ASSESSMENT OF DISEASE

Severity of Disease

SYMPTOMS—There are multiple validated questionnaires to assess symptoms in COPD. GOLD recommends using the Modified British Medical Research Council (mMRC) questionnaire (Figure 3-23) or the COPD Assessment Test (CAT).

PLEASE TICK IN THE BOX THAT APPLIES TO YOU
(ONE BOX ONLY)

mMRC Grade 0. I only get breathless with strenuous exercise. ☐

mMRC Grade 1. I get short of breath when hurrying on the level or walking up a slight hill. ☐

mMRC Grade 2. I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level. ☐

mMRC Grade 3. I stop for breath after walking about 100 meters or after a few minutes on the level. ☐

mMRC Grade 4. I am too breathless to leave the house or I am breathless when dressing or undressing. ☐

Figure 3-23. Modified British Medical Research Council questionnaire.

SEVERITY OF AIRFLOW OBSTRUCTION—Spirometry is used to grade the level of airflow obstruction using FEV_1, but it does not correlate well with symptoms and quality of life assessments. The post-bronchodilator FEV_1 is used to determine GOLD classification (Table 3-27).

Table 3-27. GOLD Classification of Severity of Airflow Limitation in COPD

Severity	FEV_1/FVC[a]	FEV_1 (% Predicted)
I: Mild	<0.70	≥80
II: Moderate	<0.70	50–79
III: Severe	<0.70	30–49
IV: Very severe	<0.70	<30 or chronic respiratory failure

[a]FEV_1/FVC is based on post-bronchodilator response.
FEV_1, 1-second forced expiratory volume; FVC, forced vital capacity.

ASSESSING COPD EXACERBATION RISK—COPD exacerbations are acute events characterized by the worsening of baseline respiratory symptoms (cough, dyspnea, sputum production, etc.) requiring treatment with corticosteroids and/or antibiotics.

Key Fact

GOLD classification uses three ways to identify high-risk patients when categorizing COPD patients: 1) FEV_1 < 50% (GOLD III/IV), 2) >2 exacerbations within the previous 12 months, and 3) one or more hospitalizations for COPD exacerbation.

Mnemonic

Predictor of survival in COPD: **BODE**

Body mass index: Lower BMI is a poor prognostic marker
Obstruction (FEV_1% predicted)
Dyspnea (mMRC)
Exercise (6-minute walk distance)

- The frequency and intensity of exacerbations are variable among individuals.
- Patients are considered high risk for exacerbations if they have more than two exacerbations within the prior year, have been hospitalized for an exacerbation, or have GOLD III or IV airflow limitation.
- GOLD recommends a combined COPD assessment scheme that incorporates airflow limitation, symptoms, and exacerbation risk (Figure 3-24).



Figure 3-24. COPD assessment using symptoms, spirometric classification, and risk of exacerbations. When assessing risk, the highest risk according to GOLD classification or exacerbation history is used.

PREDICTING SURVIVAL—There are multiple variables associated with mortality in COPD including FEV_1, IC/TLC ratio, exercise tolerance (walk distance), peak oxygen consumption, body weight, right heart function, and arterial oxygen tension. The BODE method is a better predictor for survival than any single parameter. BODE is based on a 10-point scale and predicts 4-year mortality.

DIFFERENTIAL DIAGNOSIS OF COPD

See Table 3-28.

Table 3-28. Differential Diagnosis of COPD

Diagnosis	Features
COPD	Onset in midlife. Symptoms slowly progressive. Strong association with tobacco smoking. Largely irreversible airflow limitation.
Asthma	Childhood onset typical but can also present in adulthood. Symptoms may vary from day to day. Symptoms may worsen at night/early morning. Allergy, rhinitis, and/or eczema may also be present. Normalization of airflow limitation after bronchodilator is diagnostic. Positive methacholine challenge is suggestive of asthma.
Congestive heart failure	Basilar crackles on auscultation. Chest radiograph shows dilated heart, pulmonary edema. Pulmonary function tests show restriction, not airflow limitation. Elevated BNP.
Bronchiectasis	Large volumes of purulent sputum. Commonly associated with bacterial infections. Imaging shows bronchial dilation, bronchial wall thickening. Clubbing can be seen.
Tuberculosis	Onset in all ages. Chest radiograph shows lung infiltrate or cavitary lesion. Microbiologic confirmation. Risk factors: endemic areas, incarceration.
Obliterative bronchiolitis	Often associated with rheumatoid arthritis. Inhalation of dusts, fumes, or toxins. Chronic graft-versus-host disease of the lung seen after allogeneic hematopoietic stem cell transplant. Chronic lung transplant rejection. Expiratory HRCT shows mosaicism with hypodense areas representing “trapped” air.
Diffuse panbronchiolitis	Most patients are male nonsmokers of Japanese descent. Almost all have chronic sinusitis. Chest radiograph and CT show diffuse small centrilobular nodular opacities and hyperinflation. Improves with macrolide therapy.

BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; CT, computed tomography; HRCT, high-resolution computed tomography.

Flash Card Q5

A 56-year-old female with COPD describes dyspnea when hurrying on level ground. Post-bronchodilator FEV_1 is 45% predicted with no history of exacerbations within the past year. What is the GOLD combined assessment of this patient?

COPD Versus Asthma

COPD may be difficult to distinguish from asthma, especially in the 30% of longstanding asthma patients that have a fixed component of airflow obstruction. A significant bronchodilator response to short-acting ß agonists (increase of FEV_1 by 200 mL and 12%) can be seen in either COPD or asthma. The major spirometric difference between COPD and asthma is that the pre- and/or post-bronchodilator FEV_1/FVC ratio remains < 0.70 or below the lower limit of normal in COPD. Patients should be treated as having asthma if no clear distinction can be made. Table 3-29 differentiates COPD from asthma.

OTHER FEATURES OF ASTHMA

- Eosinophilia in blood, BAL, and sputum
- Bronchial biopsy showing higher ratios of CD4+/CD8+ cells
- Higher levels of eNO
- Lower emphysema scores on CT
- Higher diffusing capacity

Table 3-29. Differentiating COPD From Asthma

	Asthma	COPD
Key Indicators	Wheezing (especially in children)	Progressive dyspnea or "air hunger" Chronic sputum production Risk factors: tobacco smoke, occupational dusts and chemicals, or smoke from home cooking and heating fuels
Other Factors	Onset generally early in life Intermittent symptoms Environmental triggers Exercise may trigger or worsen symptoms	Highest prevalence rates in adults ≥ 55 years old Progressive disease with chronic symptoms Progressive decline in lung function Smoking history
Spirometry findings	Bronchodilator response FEV_1 ≥ 200 mL and ≥ 12% baseline suggestive of asthma	Postbronchodilator FEV_1/FVC < 0.70

FEV_1, 1-second forced expiratory volume; FVC, forced vital capacity.

Flash Card A5

C. She is GOLD III based on her FEV_1 and scores 1 on the mMRC without a history of exacerbations.

COPD TREATMENT

Smoking Cessation

Smoking cessation will slow FEV_1 decline more than any pharmacologic therapy.

PHARMACOTHERAPIES FOR SMOKING CESSATION—First-line pharmacotherapy includes one of the following: combination nicotine replacement, bupropion, or varenicline (Table 3-30). Therapy should be individualized based on patient preferences, risk factors, and side effects.

Table 3-30. Pharmacotherapy for Smoking Cessation

Therapy	Benefits	Adverse Effects
NRT Modes of delivery: transdermal, gum, lozenge, inhaler, nasal spray	RCTs show NRT is superior to placebo and doubles quit rates. Combination NRT: long-acting (patch) + short-acting (gum, lozenge, inhaler, spray) NRT is most efficacious Duration: 2–3 months Relapse rate is the same for those that used NRT vs. quitting on their own	NRT is safe even in cardiovascular disease Transdermal: Insomnia and vivid dreams if worn at night Gum: Excess nicotine release with vigorous chewing (nausea, vomiting, abdominal pain, constipation, headaches) Local effects: mouth irritation, ulcers, sore throat, rhinitis, bronchospasm, sneezing
E-cigarettes	Electronic system that delivers aerosolized nicotine Amount of nicotine delivered is variable depending on the individual product Further studies required to establish efficacy and safety	Not FDA-approved given safety concerns for potential toxic additives (trace diethylene glycol, nitrosamines) SE: Dry cough, irritation of oropharynx
Bupropion (Zyban, Wellbutrin SR)	Monotherapy doubles the likelihood of smoking cessation compared to placebo Multicenter randomized trial showed improved abstinence for bupropion at 1 year (23% vs 12%) Duration: 7–12 weeks	Serious SE: Reduces seizure threshold; contraindicated in patients with seizure disorder FDA reported “possible association with suicidal events” Common SE: insomnia, agitation, dry mouth, and headache

Table 3-30. Pharmacotherapy for Smoking Cessation, continued

Therapy	Benefits	Adverse Effects
Varenicline	Monotherapy triples the odds of smoking cessation compared to placebo Higher rate of abstinence at both 6 months and 1 year when compared to placebo Superior to Bupropion in 3 RCTs Duration: 12 weeks	Requires dose reduction in moderate renal insufficiency Serious SE: May increase suicide events, cardiovascular events in patients with known CVD, and rates of accidental injuries Common SE: nausea, insomnia, abnormal dreams, syncope, skin reactions
Nortriptyline	Tricyclic antidepressant Modest benefit in RCT compared to placebo	SE: dry mouth and sedation

CVD, cardiovascular disease; FDA, Food and Drug Administration; NRT, nicotine replacement therapy; RCT, randomized control trial; SE, side effects.

COUNSELING FOR SMOKING CESSATION—Smoking cessation counseling is effective and should be offered at each visit with a health care professional. Behavioral therapy is not as effective as pharmacologic therapy alone.

Three types of effective counseling:

- Practical counseling
- Social support as part of treatment
- Social support arranged outside of treatment

Pharmacotherapy for COPD Maintenance

The role of pharmacotherapy is to reduce symptoms, reduce the frequency and severity of exacerbations, and improve exercise tolerance. Mortality and the long-term decline in pulmonary function have not been shown to definitively improve with any pharmacologic agent. Table 3-31 lists inhaled pharmacotherapies for COPD.

Table 3-31. Inhaled Pharmacotherapies

Therapy	Benefits	Adverse Effects
SABA: Albuterol Fenoterol Levalbuterol Salbutamol Terbutaline	Transiently improves FEV_1 and symptoms	Resting sinus tachycardia Exaggerated somatic tremor in older patients
LABA: *Formoterol *Salmeterol *Indacaterol Arformoterol Tulobuterol	*Significantly improves FEV_1 and lung volumes, dyspnea, QOL, and exacerbation rates Salmeterol reduces rate of hospitalizations Indacaterol is once daily and has a similar bronchodilator effect as tiotropium	Resting sinus tachycardia Exaggerated somatic tremor in older patients
SAMA: Ipratropium Oxitropium	Longer lasting than SABA with effects up to 8 hours Blocks M2 and M3 receptors	Bitter metallic taste Acute glaucoma (when used via facemask)
LAMA: Tiotropium Aclidinium bromide Glycopyrronium	Tiotropium works via inhibition of the M3 muscarinic receptors Tiotropium reduces exacerbations and hospitalizations Improves symptoms as well as effectiveness of pulmonary rehabilitation	Dry mouth, constipation, and urinary retention (often in the setting of concurrent BPH)
Combination bronchodilators	Combination SABA/SAMA improves FEV_1 and symptoms better than either one alone Combination LABA/LAMA Ex: indacaterol/glycopyrronium	Same as $ß_2$ agonists and anticholinergics
ICS	Improves symptoms, lung function, QOL, and reduces exacerbations in patients with $FEV_1 < 60\%$ Only approved at fixed doses with LABA	Oral candidiasis, hoarseness, easy bruising Pneumonia
Combination ICS/bronchodilators	In moderate to very severe COPD, ICS/LABA therapy improves lung function and reduces exacerbations Meta-analysis has shown a mortality benefit, but a large prospective trial (TORCH) did not reach statistical significance ICS/LABA + tiotropium improves lung function and QOL	Pneumonia and as above

BPH, benign prostatic hyperplasia; COPD, chronic obstructive pulmonary disease; CV, cardiovascular; FEV_1, 1-second forced expiratory volume; ICS, inhaled corticosteroids; LABA, long-acting ß agonist; LAMA, long-acting muscarinic antagonist; QOL, quality of life; SABA, short-acting ß agonist; SAMA, short-acting muscarinic antagonist.

Flash Card Q6

The TORCH trial revealed all the following findings except:

A. Salmeterol reduced exacerbations
B. Salmeterol-fluticasone combination reduced exacerbations
C. Salmeterol-fluticasone combination reduced mortality
D. Pneumonia was more likely in patients taking fluticasone

Flash Card Q7

The UPLIFT trial revealed that tiotropium was associated with all the following outcomes except:

A. Reduction in exacerbations
B. Reduction in the rate of FEV_1 decline
C. Reduction in hospitalizations related to exacerbations
D. Improved quality of life

TIOTROPIUM AND CARDIOVASCULAR RISK—There is conflicting evidence showing adverse cardiovascular effects with anticholinergic therapy.

- This association was refuted in the UPLIFT trial, which identified no significant safety issues with the use of tiotropium in the HandiHaler dry powder inhaler over a 4-year period.
- There were similar cardiovascular concerns attributed to the Respimat soft-mist inhaler as compared to the HandiHaler. These concerns were refuted in a large randomized trial (TIOSPIR), which revealed no safety issues.

Other Pharmacotherapy

METHYLXANTHINES—Theophylline is considered second-line therapy at low doses. Proposed mechanisms of action include acting as a nonselective phosphodiesterase inhibitor or a nonselective adenosine receptor antagonist.

- Modest bronchodilator and symptomatic effects compared to placebo.
- Recommended as possible add-on therapy in GOLD C or D.
- Combination therapy with salmeterol improves FEV_1 and breathlessness better than salmeterol alone.
- Low doses may reduce exacerbations.
- Toxicity is dose related with a small therapeutic window.
- Adverse effects: atrial and ventricular arrhythmias, seizures, headaches, insomnia, nausea, and vomiting.

PHOSPHODIESTERASE-4 INHIBITOR—Roflumilast reduces moderate-to-severe exacerbations in patients with chronic bronchitis, severe-to-very severe COPD (FEV_1 < 50%) and a history of exacerbations.

- Modest improvement in lung function when added to long-acting ß agonists (LABA).
- Should always be used with a long-acting bronchodilator.
- Avoid in patients with low body mass index (BMI) and depression.
- Adverse effects: Diarrhea, nausea, reduced appetite, abdominal pain, sleep problems, and weight loss.

VACCINES—Influenza and pneumococcal vaccines.

Pneumococcal polysaccharide vaccine:

- Indicated for COPD patients > 65 years old and younger patients with comorbid conditions.
- Reduces community-acquired pneumonia in patients < 65 years old with FEV_1 < 40% predicted.

Influenza vaccine recommended annually:

Flash Card A6

C; salmeterol-fluticasone combination reduced mortality

Flash Card A7

B; reduction in the rate of FEV_1 decline

- Reduces death and lower respiratory tract infections.
- Killed or inactivated virus more effective in elderly patients.

MUCOLYTICS AND ANTIOXIDANTS

- Mucolytics are not universally recommended but can be considered in those with a chronic productive cough.
- Inhaled N-acetylcysteine or carbocysteine may reduce exacerbations in patients not receiving inhaled corticosteroids (ICS), but the effect is very modest.

OPIODS (MORPHINE)—Used to treat dyspnea in very severe disease.

ANTIBIOTICS—In patients with increased risk of acute exacerbations of COPD, azithromycin was shown to reduce exacerbations and improve time to next exacerbation and dyspnea scores when compared to placebo during a 1-year trial.

Other findings:

- No mortality benefit.
- No benefit in the rate of exacerbations requiring hospitalization.
- The treatment group exhibited increased hearing loss.
- FDA has placed a warning for azithromycin causing fatal arrhythmias (QTc prolongation) in patients at risk for cardiovascular death.

ANTITUSSIVES AND VASODILATORS—Not recommended for routine use.

Key Fact

The following inhaled therapies reduce COPD exacerbations: LABA, LAMA, and LABA/ICS

Nonpharmacologic Therapies

Nonpharmacologic therapy includes pulmonary rehabilitation, oxygen therapy, and surgical interventions (See Table 3-32).

Flash Card Q8

What therapy has been shown to slow the rate of FEV_1 decline?
A. LABA
B. LAMA
C. Smoking cessation
D. LAMA + LABA/ICS
E. LAMA + LABA

PULMONARY REHABILITATION—The goal of rehabilitation is to improve symptoms, increase physical activity, and improve quality of life. An effective treatment program typically lasts at least 6 weeks. The longer the treatment program, the longer the benefits last.

Flash Card Q9

Pulmonary rehabilitation improves all of the following except:
A. Dyspnea,
B. Quality of life,
C. FEV_1
D. 6-minute walk distance

Mnemonic

Benefits of pulmonary rehabilitation—**BREATH(e) EASY**

Breathlessness reduction
Recovery after exacerbation
Exercise capacity (6-minute walk, shuttle walk)
Anxiety and depression reduction
Training of respiratory muscles
Hospitalization frequency and days in hospital decreased

Enhanced efficacy of long-acting bronchodilators
Arm function improvement and endurance training of upper limbs
Survival (possible mortality benefit)
Your quality of life improvement

Table 3-32. Non-pharmacologic Therapy

Therapy	Benefit and Patient Population	Notes
Oxygen	Benefit: Long-term oxygen therapy (>15 hours/day) improves survival and exercise tolerance Patient 1: $PaO_2 \leq 55$ mmHg or $SaO_2 \leq 88\%$ +/- hypercapnia Patient 2: PaO_2 56–59 mmHg or $SaO_2 \leq 89\%$ with evidence of pulmonary hypertension or erythrocytosis	Determination of oxygen therapy must use resting blood gas or pulse oximetry confirmed twice over 3-week period Exercise tolerance can improve even in less severe hypoxemia (PaO_2 ~70 mmHg)
Noninvasive ventilation	Benefit: Improves hypercapnia, and in overlap syndrome, CPAP improves survival and decreases hospitalizations Patient 1: severe daytime hypercapnia Patient 2: COPD + concurrent OSA (overlap syndrome)	COPD + OSA (overlap syndrome): one disease does not predispose to the other $\leq$ 15% of COPD patients have OSA
LVRS	Benefit: Improves survival, exercise, and QOL in selected patients Patient 1: Upper lobe-predominant emphysema and poor exercise capacity (<40 W in men, <25 W in women) after pulmonary rehabilitation Patient 2: Upper lobe-predominant emphysema and high exercise capacity have no survival benefit but improve QOL and exercise capacity	Improves elastic recoil, expiratory airflow, and mechanical function of diaphragm Contraindications to LVRS: $FEV_1 \leq 20\%$, DLCO $\leq 20\%$, or diffuse/homogeneous emphysema on CT Combination of diffuse emphysema and high exercise capacity also has increased mortality with LVRS
BLVRS	Benefit: Modest improvement in lung function, exercise tolerance, and symptoms Patient: severe airflow limitation (FEV_1 15–45% predicted), heterogeneous emphysema, and hyperinflation with air trapping (TLC > 100% and RV > 150%)	BLVRS may increase COPD exacerbations, pneumonia, and hemoptysis after implantation More data needed to define optimal technique and ideal patient population
Bullectomy	Benefit: Potential improvement in dyspnea, FEV_1, hypoxemia, and exercise tolerance Patient: select patients with giant bullae occupying 30–50% of hemithorax	Highest risk: $FEV_1 < 40\%$, $PaCO_2 > 45$ mmHg, pulmonary hypertension Contraindications: multiple small bullae, diffuse emphysema, tobacco use

BLVRS, bronchoscopic lung volume reduction surgery; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; CT, computed tomography; DLCO, diffusion lung capacity for carbon monoxide; FEV1, 1-second forced expiratory volume; LVRS, lung volume reduction surgery; OSA, obstructive sleep apnea; QOL, quality of life; RV, residual volume; TLC, total lung capacity.

Flash Card A8

C; smoking cessation

Flash Card A9

C. FEV_1

Palliative care and hospice:

- Prevents and relieves suffering; improves symptoms and quality of life (QOL) for patients and families.
- All COPD patients are eligible for palliation regardless of disease severity.
- COPD patients are much less likely to receive hospice or palliative care than lung cancer patients.
- It is often difficult to predict prognosis in patients with advanced COPD.

Lung transplant:

- Improves QOL and functional capacity, but there is no clear mortality benefit.
- Referral for transplant: BODE Index > 5.
- Transplant listing: BODE Index 7–10 plus additional criteria.
- See lung transplant chapter for detailed criteria for lung transplantation.

COPD TREATMENT BASED ON SEVERITY OF DISEASE

Nonpharmacologic Treatment

Identifying and reducing exposure to risk factors is important in the prevention and treatment of COPD (Figure 3-25). Smoking cessation is essential for all patient groups in the GOLD classification. Pulmonary rehabilitation is recommended for GOLD B, C, and D patients. Physical activity is recommended for all patient groups.



Figure 3-25. Management of stable COPD based on GOLD classification.

Flash Card Q10

A 55-year-old woman with severe emphysema presents for consultation. FEV_1 is 38% predicted, DLCO is 38% predicted, and she is on optimal medical therapy. She has completed pulmonary rehabilitation but still has poor exercise capacity. CT of the chest reveals upper lobe-predominant emphysema. What is the recommended treatment?

A. Bullectomy
B. Lung transplantation
C. Hospice care
D. Lung volume reduction surgery (LVRS)

Flash Card Q11

A 55-year-old women, a 25-pack-year ex-smoker, presents with dyspnea when walking on level ground after a few minutes. Her post-bronchodilator FEV_1/FVC is 0.62. FEV_1 is 59% predicted. She has never been treated for a COPD exacerbation. What should be the initial management of her COPD?

A. ICS + LABA
B. LAMA + LABA
C. LAMA or LABA + pulmonary rehabilitation
D. LAMA only

Flash Card Q12

A 67-year-old male sees you for breathlessness when walking at his own pace on level ground. His post-bronchodilator FEV_1 percent predicted is 55%. He has been treated for a COPD exacerbation twice within the last year. What GOLD classification is he and what is the recommended initial therapy?

Pharmacologic Treatment

After assessing symptoms and risk, patients will fall under four GOLD classifications that determine pharmacologic therapy. Pharmacologic therapy is used to reduce symptoms, reduce frequency and severity of exacerbations, and improve exercise tolerance (Table 3-33).

Table 3-33. Initial Pharmacological Management of COPD

Patient Group	First-Choice Therapy	Second-Choice Therapy
A Low risk Fewer symptoms	SAMA prn or SABA prn	LAMA or LABA or SABA + SAMA
B Low risk More symptoms	LAMA or LABA	LAMA + LABA
C High risk Fewer symptoms	ICS + LABA or LAMA	LAMA + LABA or LAMA + PDE4 inhibitor or LABA + PDE4 inhibitor
D High risk More symptoms	ICS + LABA and/or LAMA	ICS + LAMA or ICS + LABA + LAMA

ICS, inhaled corticosteroids; LABA, long-acting ß agonist; LAMA, long-acting muscarinic antagonist; PDE, phosphodiesterase; SABA, short-acting ß agonist; SAMA, short-acting muscarinic antagonist.

BRONCHODILATORS—Inhaled bronchodilators are preferred over oral bronchodilators. Long-acting $ß_2$ agonists and long-acting muscarinic antagonists are favored over short-acting formulations. If there is no improvement with either $ß_2$ agonists or anticholinergics alone, combined therapy may be warranted.

Flash Card A10

D; lung volume reduction surgery (LVRS)

CORTICOSTEROIDS—Inhaled corticosteroids are indicated as adjunct therapy to long-acting bronchodilators in severe and very severe COPD, especially in patients with a history of exacerbations. There is little evidence to support either monotherapy with ICS or long-term oral corticosteroids for COPD.

Flash Card A11

C; LAMA or LABA + pulmonary rehabilitation

Flash Card A12

GOLD D; ICS + LABA and/or LAMA

Surgery in the COPD Patient

Post-operative pulmonary complications are common in COPD patients. Major post-op respiratory complications include lung infections, atelectasis, increased airflow limitation, and respiratory failure.

NON-LUNG RESECTION SURGERY

- Increased risks of post-operative complications in COPD may vary with disease severity, though there is no known FEV_1 cut-off that would make essential non-lung surgery completely prohibitive.
- Risk increases as surgical site approaches the diaphragm.
- Epidural and spinal anesthesia are favored and considered lower risk than general anesthesia.

ACUTE EXACERBATIONS OF COPD

According to GOLD, an exacerbation of COPD is an acute event characterized by worsening of the patient's respiratory symptoms that is beyond normal day-to-day variations and leads to a change in medication.

> ***Key Fact***
>
> Inhaled corticosteroids are associated with an increased risk of pneumonia in COPD patients.

PRECIPITATING FACTORS—Viral or bacterial respiratory tract infections are the most common cause of COPD exacerbations. In about one third of exacerbations, the etiology is not identified. Other aggravating factors include air pollution or discontinuation of maintenance therapy. Pneumonia, pulmonary embolism, CHF, cardiac arrhythmias, or pleural effusions can both aggravate and resemble a COPD exacerbation and should be considered in the differential diagnosis.

ASSESSMENT AND DIAGNOSIS—An acute COPD exacerbation is characterized by worsening respiratory symptoms, including shortness of breath and sputum production beyond the normal day-to-day variation.

Laboratory findings:

- Arterial blood gas (in hospital): $PaO_2 < 60$ mmHg with or without $PaCO_2 > 50$ mmHg on room air constitutes respiratory failure
- Complete blood count: Identifies polycythemia, anemia, or leukocytosis
- Sputum (often purulent):
  - Empiric antibiotics should be initiated
  - *H influenzae, S pneumoniae,* and *M catarrhalis* are the most common bacteria implicated in acute exacerbations
  - Pseudomonas becomes more common in GOLD III and IV COPD ($FEV_1 < 50\%$)
- Chemistry: Identifies electrolyte abnormalities, diabetes, and poor nutrition

Imaging: Chest radiograph used to evaluate for pneumonia and alternative diagnoses

Pulmonary function tests: Spirometry is not indicated during an acute exacerbation

TREATMENT—Acute COPD exacerbation treatment includes supplemental oxygen, bronchodilators, systemic corticosteroids, and potential use of mechanical ventilation. Careful consideration should be made for hospitalization based on risk factors.

Management of acute exacerbation: See Table 3-34.

Table 3-34. Management of an Acute Exacerbation of COPD

Type	Treatment Details
Oxygen	Target saturation is 88–92%
Bronchodilators	SABA inhaled (MDI or nebulized) with or without SAMA
Systemic corticosteroids	Shortens recovery time, improves FEV_1 and PaO_2 Reduces early relapse, treatment failure, and hospital stay Oral glucocorticoids: Rapidly absorbed and as efficacious as IV administration GOLD guidelines: Equivalent doses of prednisone at 30–40 mg daily, but some clinicians use doses as high as 60–125 mg of methylprednisolone 2–4 times daily Duration varies depending on severity of disease and initial response to therapy but typical course is 5–14 days
Antibiotics	Indication 1: Increased sputum purulence plus either increased dyspnea or sputum production or both Indication 2: Moderate-to-severe exacerbations and those requiring ventilatory support (invasive or noninvasive) Choice of antibiotic: Based on local resistant patterns; should cover likely bacterial pathogens (*H influenzae, M catarrhalis, S pneumoniae*) First-line therapy outpatient: Doxycycline or trimethoprim-sulfamethoxazole First-line therapy inpatient: Respiratory fluoroquinolone or third-generation cephalosporin Antipseudomonas coverage in patients with associated risk factors
Noninvasive ventilation	Decreases mortality, hospital stay, and intubation rate Improves dyspnea, respiratory acidosis, respiratory rate Indications: pH < 7.35 and/or PaCO2 > 45 mmHg and/or severe dyspnea with respiratory muscle fatigue Early NIV after extubation facilitates weaning, prevents re-intubation, and reduces mortality

Table 3-34. Management of an Acute Exacerbation of COPD, continued

Type	Treatment Details
Invasive ventilation	Increased mortality in mechanically ventilated patients with FEV_1 < 30% predicted
Home management	Possible in select patients without respiratory acidosis or comorbidities Includes nursing visits, oxygen therapy, and physical therapy
Hospital discharge follow-up	Patients who are hypoxemic during an exacerbation should be re-evaluated in the next 3 months with arterial blood gas or pulse oximetry; long-term supplemental oxygen should be arranged if the patient remains hypoxemic

FEV_1, 1-second forced expiratory volume; MDI, metered dose inhaler; NIV, noninvasive ventilation; SABA, short-acting ß agonist; SAMA, short-acting muscarinic antagonist.

PREVENTION OF COPD EXACERBATIONS—COPD exacerbations are associated with accelerated disease progression, poorer quality of life, and increased mortality after hospital discharge; thus, efforts should be made to target prevention.

Therapies reducing exacerbations and hospitalization:
- Smoking cessation
- Influenza and pneumococcal vaccines
- Long-acting bronchodilators with or without ICS
- Phosphodiesterase-4 inhibitors (reduce exacerbations only)

Early pulmonary rehabilitation initiated within 1 month of discharge for COPD exacerbation improves dyspnea, exercise capacity, and QOL and decreases repeated exacerbations and hospital readmissions.

Key Fact

Viral or bacterial respiratory tract infections are the most common cause of COPD exacerbations.

Mnemonic

Indications for hospitalization: **COOL FISH**

Comorbidities (e.g., heart failure, new arrhythmia)
Onset of new physical exam findings (e.g., cyanosis, lower extremity edema)
Older age
Lack of home support

Failure to respond to medical management
Increased and severe symptoms (e.g., resting dyspnea, inability to eat or sleep due to symptoms)
Severe COPD
History of frequent exacerbations

Key Fact

The single best predictor of a COPD exacerbation is a history of COPD exacerbations.

BRONCHIECTASIS

Bronchiectasis refers to abnormal and permanent dilatation of bronchi.

ETIOLOGY

The etiology of bronchiectasis is generally divided into infectious and noninfectious causes. Causative factors are summarized in Table 3-35.

Table 3-35. Etiology of Bronchiectasis

	Examples
Infections	Bacterial (e.g., *Staphylococcus*, *Pseudomonas*, *Mycoplasma*)
	Mycobacterial (*Mycobacterium tuberculosis*, MAC)
	Viral
Immune deficiency	Hypogammaglobulinemia
	HIV
	IgG subclass deficiency
Mucociliary clearance defects	PCD
	Cystic fibrosis
	Young's syndrome (bronchiectasis, sinusitis, obstructive azoospermia)
Bronchial obstruction	Endobronchial tumor
	Bronchial compression by lymph node
	Foreign body
	Broncholith
Autoimmune disease	Sjögren's disease
	Rheumatoid arthritis
	Inflammatory bowel disease
	Relapsing polychondritis
	SLE
Congenital disorders	Bronchial atresia
	α_1-antitrypsin deficiency (e.g., in emphysema with liver disease)
	Williams-Campbell syndrome (congenital deficiency of the bronchial cartilage)
	Mounier-Kuhn syndrome (congenital tracheobronchomegaly)
	Tracheal-esophageal fistula
	Yellow nail syndrome
Other	ABPA
	Post radiation
	Post transplant
	Traction bronchiectasis
	Graft-versus-host disease

ABPA, allergic bronchopulmonary aspergillosis; HIV, human immunodeficiency virus; Ig, immunoglobulin; MAC, *Mycobacterium avium* complex; PCD, primary ciliary dyskinesia; SLE, systemic lupus erythematosus.

PATHOGENESIS

The inflammatory response to foreign material and bacteria in the airway causes tissue damage, resulting in bronchiectasis. This condition produces abnormal mucous clearance and further bacterial colonization and inflammation (Figure 3-266).



Figure 3-26. Vicious cycle hypothesis of bronchiectasis pathogenesis.
(Reproduced, with permission, from McShane PJ, et al. Non-Cystic Fibrosis Bronchiectasis *Am J Respir Crit Care Med*. 2013;188(6):647-656. doi:10.1164/rccm.201303-0411CI)

DIAGNOSIS

The diagnosis of bronchiectasis is based on a combination of clinical signs and symptoms, radiological features, and laboratory investigations.

Clinical Manifestations

Bronchiectasis is a chronic illness with a wide range of symptoms. Common signs and symptoms include:

- Chronic cough with thick, foul-smelling mucus
- Hemoptysis
- Dyspnea
- Weight loss
- Recurrent lung infections
- Wheezing (asthma, ABPA)
- Clubbing
- Obstructive pattern on PFTs

ACUTE EXACERBATION OF BRONCHIECTASIS—Acute exacerbations are identified by changes in symptoms, such as worsening dyspnea and worsening cough associated with changes in sputum characteristics (increased volume, thicker consistency, greater purulence, or hemoptysis) unrelated to other causes. Patients may also have fever, chills, reduced exercise tolerance, worsening spirometry, and radiographic changes consistent with infection.

Imaging

All patients suspected of having bronchiectasis should undergo a chest CT. High-resolution computed tomography (HRCT) from thoracic inlet to hemidiaphragms should be performed without contrast, taking 1-mm slices at 10-mm intervals with the patient holding a deep breath. Three distinct radiographic patterns of bronchiectasis have been recognized.

CYLINDRICAL/TUBULAR BRONCHIECTASIS—Characterized by mild, diffuse dilatation of bronchi with thickened wall. Cylindrical bronchiectasis can lead to "tram-track sign" or "signet-ring appearance":

- Tram-track sign: Bronchi have a uniform caliber with parallel walls and lack of bronchial tapering (Figure 3-27).
- Signet-ring appearance: In the axial plane, bronchus is markedly dilated with a diameter at least 1–1.5 times that of the adjacent pulmonary vessel (i.e., bronchoarterial ratio > 1–1.5 (Figure 3-28).



Figure 3-27. CT scan with tram-track sign (*red arrow*).
(Image courtesy of Wikipedia; permission granted per the GNU Free Documentation License.)



Figure 3-28. CT scan showing signet-ring sign and other radiographic signs of bronchiectasis. (A) Bronchus terminating in a cyst. (B) Lack of bronchial tapering as it travels to the periphery of the lung. (C) Signet-ring sign (bronchus is larger than the accompanying vessel). (D) Mucus plug (mucus completely filling the airway lumen).
(Reproduced, with permission, from McShane PJ et al. Non–Cystic Fibrosis Bronchiectasis. *Am J Respir Crit Care Med* 2013;188:647-656. doi:10.1164/rccm.201303-0411CI)

VARICOSE BRONCHIECTSIS—Varicose bronchiectasis is characterized by the beaded appearance of dilated bronchi with interspersed sites of relative narrowing. It is also referred to as "string-of-pearls" appearance (Figure 3-29).



Figure 3-29. Varicose bronchiectasis with string-of-pearls appearance (arrow).

CYSTIC/SACCULAR BRONCIECTASIS—This is the most severe form of bronchiectasis, with cyst-like bronchi that extend to the pleural surface (Figure 3-30). Cysts may contain air-fluid levels.



Figure 3-30. Cystic bronchiectasis.
(Reproduced, with permission, from Parr DG, et al. Prevalence and Impact of Bronchiectasis in α1-Antitrypsin Deficiency. *Am J Respir Crit Care Med.* 2007;176): 1215–1221. Doi: DOI: 10.1164/rccm.200703-489OC)

LOCATION OF BRONCHIECTASIS—The radiographic appearance of bronchiectasis can provide a clue to its etiology and guide further workup (Table 3-36).

Table 3-36. Correlation of Location of Bronchiectasis with Etiology

Disease Location	Possible Etiology
Focal bronchiectasis	Broncholithiasis Endobronchial neoplasm Foreign body Congenital bronchial atresia Mucus plugging
Upper lung	Cystic fibrosis Sarcoidosis Post-tuberculosis bronchiectasis
Central lung	ABPA
Right middle lobe and lingula	Atypical mycobacterial infection (e.g., MAI) Right middle lobe syndrome Immotile cilia syndrome (primary ciliary disease)
Lower lung	Chronic aspiration Usual interstitial pneumonia Hypogammaglobulinemia Recurrent infections α_1-antitrypsin deficiency

ABPA, allergic bronchopulmonary aspergillosis; MAI, mycobacterium avium-intracellulare.

Other Investigations

Once a clinic history and imaging have been obtained, additional investigations are geared towards the suspected underlying etiology (Table 3-37).

Table 3-37. Other Investigations in the Workup of Bronchiectasis

Focal bronchiectasis	Bronchoscopy: tumor, foreign body, BAL Sputum for AFB
Diffuse bronchiectasis	Sputum for AFB CF genotyping, sweat chloride testing Quantitative immunoglobulin testing IgG subclass level α_1-antitrypsin level Ciliary testing for PCD Aspergillus precipitins and total IgE levels Autoimmune workup HIV testing

AFB, acid-fast bacilli; BAL, bronchoalveolar lavage; CF, cystic fibrosis; HIV, human immunodeficiency virus; Ig, immunoglobulin; PCD, primary ciliary dyskinesia.

MANAGEMENT

Objectives of bronchiectasis treatment:

- Manage symptoms
- Treat the underlying etiology
- Limit the progression of disease

A broad overview of management of bronchiectasis can be seen in Figure 3-31.



Figure 3-31. Overview of a comprehensive approach to bronchiectasis management. *A 2-week course is suggested.
AAT, a1-antitrypsin; ATS/IDSA, American Thoracic Society/Infectious Diseases Society of America; IgG, immunoglobulin G; HRCT, high-resolution computed tomography; NTM, nontuberculous mycobacteria. (Reproduced, with permission, from McShane PJ, et al. Non-Cystic Fibrosis Bronchiectasis *Am J Respir Crit Care Med*. 2013;188(6):647-656. doi:10.1164/rccm.201303-0411CI)

Antibiotics

Antibiotics are the cornerstone of treatment. Patients with bronchiectasis are generally colonized with multiple organisms. Common pathogens include *Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus,* and *Pseudomonas aeruginosa.*

Cultures should be obtained during acute exacerbations and used to guide treatment:

- If no old cultures are available, use antipseudomonal fluoroquinolones like ciprofloxacin.
- If cultures are available:
  - *H influenzae*: amoxicillin clavulanate, second/third generation cephalosporin (ceftriaxone), fluoroquinolones, doxycycline, azithromycin
  - *Pseudomonas* sensitive to fluoroquinolones: ciprofloxacin, levofloxacin
  - *Pseudomonas* resistant to fluoroquinolones:
    - Antipseudomonal penicillins: ticarcillin/clavulanate, piperacillin/tazobactam
    - Cephalosporins: ceftazidime, cefepime
    - Monobactam: aztreonam
    - Carbapenems: meropenem, imipenem, doripenem

Duration of treatment: Antibiotics should be administered until the sputum is no longer purulent or for at least 10 days. In cases of *Pseudomonas* infection, treatment should continue for 14–21 days.

Additional therapies:

- Postural drainage/airway clearance: Perform twice daily.
- Bronchodilators may be useful for underlying asthma, COPD, CF, ABPA.
- Corticosteroids and antifungal medications for underlying ABPA
- Treatment of underlying diseases such as *Mycobacterium avium* complex (MAC) and *Mycobacterium* tuberculosis (MTB).

PRIMARY CILIARY DYSKINESIA (PCD)

PCD (also known as immotile cilia syndrome) is an autosomal recessive disease that affects the function of ciliated cells. Structural and functional impairments in the ciliary microtubules leads to defects in the cilia lining the respiratory tract (lower and upper, sinuses, Eustachian tube, middle ear), fallopian tubes, and also impairs the flagella of sperm.

Clinically, PCD presents as rhinosinusitis (present in almost all patients), bronchiectasis, and less often, male sterility. PCD is diagnosed by nasal biopsy with electron microscopic examination of cilia. Treatment is mainly supportive with postural drainage and antibiotics for infections.

The triad of bronchiectasis, rhinosinusitis, and situs inversus (Figure 3-32) is known as Kartagener's syndrome.

Figure 3-32. Chest radiograph with dextrocardia situs inversus showing the cardiac apex facing toward the right.
(Reproduced courtesy of Nevit, Wikimedia Commons, permission granted per the GNU Free Documentation License Version 1.2.)

CYSTIC FIBROSIS (CF)

CF is an autosomal recessive disorder that results in impaired functioning of the chloride channels. Approximately 1000 cases are diagnosed each year in the US.

- The overall prevalence of CF in the US is 1 in 3700 births.
- Cystic fibrosis occurs most commonly among whites of Northern European descent; an estimated 1 in 2500 whites are affected.
- Nearly half of the CF population is age 18 or older. Due to continued research advancement in treatment, the median predicted age of survival for people with CF is in the early 40s.

GENETIC BASIS

- Autosomal recessive disorder with variable penetrance.
- One of the most common genetic disease in the U.S.
- The CF gene, located on the long arm of chromosome 7, encodes for the CF transmembrane regulator (CFTR) protein.
- More than 1500 gene mutations have been identified.

- The most common mutation, ΔF508 mutation (a class II mutation due to deletion of a single phenylalanine residue at position 508), accounts for 70% of CF cases in the US.

CFTR mutations are categorized into six classes as follows (Figure 3-33):

- Class I: Absent protein synthesis
- Class II: Abnormal processing or transport of the protein to the cell membrane
- Class III: Abnormal regulation of CFTR function, inhibiting chloride channel activation
- Class IV: Defective chloride conductance or channel gating
- Class V: Reduced synthesis of fully active CFTR due to promoter or splicing abnormality
- Class VI: Decreased stability of fully processed and functional CFTR



Figure 3-33. CFTR mutation classes and their functional consequences.

PATHOGENESIS

The defective CFTR results in decreased secretion of chloride and increased reabsorption of sodium and water across epithelial cells. This leads to abnormal, viscous secretions in the respiratory tract, pancreas, GI tract, sweat glands, and other exocrine tissues (Figure 3-34).


Defective CFTR
Decreased chloride secretion, increased sodium and water absorption
Increased viscosity of mucus
Decreased mucociliary clearance
Recurrent infection and inflammation
Release of neutrophil elastase, Leukotriene B4, interleukins (IL-8)
Lung damage, bronchiectasis

Figure 3-34. Pathogenesis of cystic fibrosis.

DIAGNOSIS

All states in the U.S. perform newborn screening for CF by IRT (immunoreactive trypsinogen) and/or DNA analysis for common CFTR mutations.

Diagnostic Criteria for CF

Key Fact

Commercially available genotyping can diagnose 20–30 of the most common mutations, which account for > 90% of the most common mutations of CF

Newborns with screening results suggestive of CF need further testing by either sweat chloride or DNA analysis for CFTR gene mutations, if not performed as part of screening. Diagnostic criteria are described in Table 3-38.

Table 3-38. Diagnostic Criteria for CF

Presence of one or more characteristic phenotypic features of CF
or
Sibling with CF
or
Positive newborn-screening test (positive IRT or DNA analysis)
Plus
Laboratory evidence of an abnormality in the CFTR gene or protein (abnormal sweat chloride or presence of CF disease-causing mutation in each copy of the CFTR gene)

Patients with physical findings suggestive of CF, a sibling with CF, or a positive newborn-screening test should have further diagnostic testing starting with sweat chloride testing at 2–4 weeks of life (Figure 3-35).



Figure 3-35. The CF diagnostic process for newborns with positive screening results.

CLINICAL PRESENTATION

CF presents with both pulmonary and extrapulmonary manifestations

Pulmonary Manifestations

- Airway hyperreactivity and wheezing are common in children.
- Bronchiectasis and obstructive lung disease are common in adults.
- Patients with cystic fibrosis get recurrent and chronic infections. *P aeruginosa* infection is most common, followed by *S aureus* (both methicillin-sensitive and methicillin-resistant strains; MSSA and MRSA, respectively), *H influenzae*, *Stenotrophomonas maltophilia*, and *Burkholderia cepacia*.
- Incidence of non-tuberculous mycobacteria (NTM) is higher in CF patients, ranging from 7–24%.
- Noninfectious pulmonary complications include:
  - Spontaneous pneumothorax (3–4%)
  - Massive hemoptysis

Key Fact

Infection with *B cepacia* complex is considered a contraindication for lung transplant in many centers because of increased mortality.

Flash Card Q13

What is the most common mutation in CF?

Flash Card Q14

What gene mutation is targeted by ivacaftor?

SEVERITY OF LUNG DISEASE IN CF—Severity of lung disease is defined by FEV_1% predicted as follows:

- Normal: 90% predicted
- Mildly impaired: 70–89% predicted
- Moderately impaired: 40–69%predicted
- Severely impaired: 40% predicted

Extrapulmonary Manifestations

- Meconium ileus at birth
- Exocrine pancreatic insufficiency→malabsorption→ deficiency of fat-soluble vitamins A, D, E, K (occurs in 90% of CF patients)
- Endocrine pancreatic insufficiency→cystic fibrosis-related diabetes
- Thick biliary secretions→biliary cirrhosis
- 95% of male patients with CF are infertile.
- Female patients with CF have thick cervical mucus but are not infertile.

TREATMENT

Agents to Promote Airway Clearance

- Inhaled DNase I (dornase alfa):
  - Decreases the viscosity of sputum by cleaving denatured DNA released by degenerating neutrophils.
  - Recommended for all patients ≥ 6 years old, especially those with moderate-to-severe disease.
- Inhaled hypertonic saline:
  - Recommended for all patients ≥ 6 years old.
  - 3% or 7% solutions are commonly used.

Flash Card A13

ΔF508 mutation, a class II mutation (due to deletion of a single phenylalanine residue at position 508). It is the most common mutation in CF, affecting 70% of CF patients.

Chest Physiotherapy

Airway clearance therapy is recommended for all patients with CF for clearance of sputum, maintenance of lung function, and improved quality of life.

Flash Card A14

Ivacaftor, a recently approved CFTR-modulating therapy, targets the G551D CFTR mutation (a class III mutation), found in only about 4% of all CF patients.

Bronchodilators

Given to patients with evidence of bronchoreactivity and should be administered prior to inhalation of hypertonic saline or DNase and chest physiotherapy.

Key Fact

Order of inhaled medications: bronchodilator → hypertonic saline → dornase alfa → airway clearance → aerosolized antibiotic.

Antibiotics

Antibiotics play an important role in chronic treatment and during acute exacerbations of CF.

- Surveillance cultures are recommended every 3 months.
- CF patients with airway colonization with *P aeruginosa* have been shown to have improved lung function and quality of life and reduced exacerbations with inhaled antibiotics.

INHALED ANTIBIOTICS—In CF patients ≥ 6 years of age who are colonized with *P aeruginosa*, daily inhaled antipseudomonal agents are recommended. Inhaled aztreonam or inhaled tobramycin can be used.

INTRAVENOUS ANTIBIOTICS—Intravenous antibiotics are used for acute exacerbations. In the absence of cultures, antibiotic coverage should include treatment for both *S aureus* and *Pseudomonas* species.

AZITHROMYCIN—In CF patients ≥ 6 years of age with *P aeruginosa* persistently present in cultures of the airways, chronic use of azithromycin is recommended.

- Inhibits neutrophil migration and elastase production.
- Long-term use of azithromycin is associated with improved lung function and reduction in exacerbations.
- Patients should be screened for NTM before initiating azithromycin and reassessed every 6–12 months.

Newer Treatment (CFTR-Modulating Therapy)

Ivacaftor is a drug approved for CF patients with at least one G551D CFTR mutation. Ivacaftor is a potentiator that activates defective CFTR at the cell surface and increases chloride transport across the cell. Only a small percentage of CF patients have the G551D mutation, but ivacaftor is an important breakthrough as it is the first commercially available, targeted CF therapy.

Flash Card Q15

In patients with CF, chronic infections with what pathogens are associated with accelerated decline in lung functions?

Acute Exacerbations of CF

Acute pulmonary exacerbation of CF is a clinical diagnosis. Clinical features of an exacerbation include increased cough, increased sputum production, shortness of breath, chest pain, loss of appetite, loss of weight, and lung function decline.

- There is a strong association between the frequency of pulmonary exacerbations and subsequent decline in pulmonary function.
- Antibiotics are the mainstay of treatment of acute exacerbations.
- Airway clearance therapies should be increased as part of the treatment of acute exacerbations of pulmonary disease.

Key Fact

Infection with *Burkholderia cepacia* complex is considered a contraindication for lung transplant in many centers because of increased mortality

ANTIBIOTICS FOR ACUTE PULMONARY EXACERBATION

- *P aeruginosa* and *S aureus* are the most common pathogens in CF patients. Thus, antibiotics for an exacerbation must include agents against these pathogens**.**
- Oral antibiotics can be used for a mild exacerbation.
- Intravenous antibiotics are indicated for severe exacerbations, bacterial resistance to orally administered antibiotics, and failure of oral antibiotic therapy to resolve the exacerbation.
- For patient with *P aeruginosa*, two antipseudomonal agents are generally used.

Flash Card A15

P aeruginosa, B cepacia, and MRSA

4 Diffuse Parenchymal Lung Disease

Puneet S. Garcha, MD, Sachin Gupta, MD, & Carlos E. Kummerfeldt, MD

INTERSTITIAL LUNG DISEASE

Definition

Diffuse parenchymal lung disease refers to a group of lung disorders affecting the interstitium. The parenchyma of the lung includes the pulmonary alveolar and capillary endothelium and the spaces between these structures as well as the tissues within the septa comprising the perivascular and perilymphatic tissues. More centrally, it includes the peribronchiolar and peribronchial tissues. Table 4-1 classifies the idiopathic interstitial pneumonias.

Table 4-1. Revised American Thoracic Society/European Respiratory Society Classification of Idiopathic Interstitial Pneumonias

Major Idiopathic Interstitial Pneumonias
Idiopathic pulmonary fibrosis
Idiopathic nonspecific interstitial pneumonia
Respiratory bronchiolitis-interstitial lung disease
Desquamative interstitial pneumonia
Cryptogenic organizing pneumonia
Acute interstitial pneumonia
Rare Idiopathic Interstitial Pneumonias
Idiopathic lymphoid interstitial pneumonia
Idiopathic pleuroparenchymal fibroelastosis
Unclassifiable Idiopathic Interstitial Pneumonias

Table 4-2 shows the lung pathology pattern associated with the individual clinical diagnosis of interstitial lung disease (ILD).

Table 4-2. Clinical Diagnosis and Corresponding Pathology

Clinical Diagnosis	Lung Injury Pattern
Idiopathic pulmonary fibrosis	Usual interstitial pneumonia
Idiopathic nonspecific interstitial pneumonia	Nonspecific interstitial pneumonia
Respiratory bronchiolitis-interstitial lung disease	Respiratory bronchiolitis
Desquamative interstitial pneumonia	Desquamative interstitial pneumonia
Cryptogenic organizing pneumonia	Organizing pneumonia
Acute interstitial pneumonia	Diffuse alveolar damage

Diagnosis

In most idiopathic interstitial pneumonias, a stepwise approach is key to establishing the diagnosis, as shown in Figure 4-1.

IMAGING—Chest x-ray is the initial test. High-resolution computed tomography scan (HRCT) is now a standard diagnostic tool for all patients suspected of having diffuse parenchymal lung disease (DPLD).

BRONCHOSCOPY—Can help to establish the diagnosis but is not essential. It helps to exclude other etiologies, including infection, diffuse alveolar hemorrhage, and eosinophilia and is performed before immunosuppressive therapy is started. Transbronchial biopsy (TBBx) is not recommended as a diagnostic tool because of the small tissue sample size.

Unique bronchoscopic features of idiopathic interstitial pneumonias are shown in Table 4-3.



Figure 4-1. Diagnostic algorithm for interstitial lung disease.
ILD, interstitial lung disease; H&P, history and physical examination PFT, pulmonary function testing; CXR, chest x-ray; HRCT, high-resolution computed tomography scan; BAL, bronchoalveolar lavage; TBBx, transbronchial biopsy; SLB, surgical lung biopsy.

Table 4-3. Bronchoscopic Findings in Idiopathic Interstitial Pneumonia

Idiopathic Interstitial Pneumonia	Finding
Idiopathic nonspecific interstitial pneumonia	BAL shows > 20% lymphocytosis (> 20%) Hypersensitivity pneumonitis and drug-induced lung disease can have similar BAL findings
Cryptogenic organizing pneumonia	BAL shows a characteristic mixed pattern with increased lymphocytes (20–40%), neutrophils (10%), and eosinophils (5%), with some plasma/mast cells. The CD4/CD8 ratio is decreased.
Lymphocytic interstitial pneumonia	Occasionally lymphocytic infiltration is seen on TBBx
Pulmonary Langerhans cell histiocytosis	BAL showing > 5% CD1a-positive cells is virtually diagnostic
Acute eosinophilia pneumonia	BAL eosinophilia (> 20–25%) is characteristic in normal peripheral blood eosinophilia TBBx is not necessary for the diagnosis, but when performed, shows marked eosinophilic infiltration in interstitium and alveoli
Chronic eosinophilic pneumonia	BAL shows eosinophilia TBBx shows eosinophilic microabscesses, low-grade vasculitis, and interstitial fibrosis

BAL, bronchoalveolar lavage; TBBx, transbronchial biopsy

BIOPSY—Surgical lung biopsy (SLB; video-assisted thoracoscopic surgery) is the gold standard investigation to diagnose most idiopathic interstitial pneumonias. It is also helpful in ruling out other etiologies, establishing the pathologic pattern, and establishing a prognosis.

IDIOPATHIC PULMONARY FIBROSIS (IPF)

Definition

IPF is a type of chronic interstitial pneumonia with a characteristic histologic pattern of usual interstitial pneumonia (UIP). However, UIP is not pathognomic of IPF because it can also be seen in other ILDs (connective tissue diseases, asbestosis, drug-induced lung disease, and environmental and occupational exposure).

Clinical Features

- IPF is the most common cause of ILD.
- It affects men in the fifth to sixth decade (male-to-female ratio 2:1).
- Dry cough and dyspnea are the presenting features.
- Cough can be disabling, especially in late-stage disease, causing profound desaturation during a coughing spell.
- Lung auscultation shows dry bibasilar crackles, known as Velcro crackles.
- Digital clubbing can be present.
- Median survival after diagnosis is 3–5 years.

Histopathology

- Basilar and peripheral fibrosis (Figure 4-2)
- Microscopic subpleural and paraseptal fibrosis
- Subpleural microscopic honeycombing
- Fibroblastic foci (Figure 4-3)
- Interspersed normal areas of lung (temporal heterogeneity)

Key Fact

Temporal heterogeneity is the cardinal feature distinguishing UIP from other idiopathic interstitial pneumonias.



Figure 4-2. Usual interstitial pneumonia showing low-magnification patchy interstitial fibrosis with juxtaposition of normal areas of lung with fibrotic and honeycombing changes.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)



Figure 4-3. Usual interstitial pneumonia fibroblastic foci characterized by dome-shaped fibroblastic tissue over collagen fibrosis.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

Diagnosis

IMAGING

- Chest x-ray: Bilateral basal predominant interstitial infiltrates (Figure 4-4).
- HRCT (Figure 4-5):
  - Peripheral reticular opacities
  - Geographic/patchy pattern of subpleural involvement
  - Apicobasal gradient
  - Honeycombing without associated traction bronchiectasis



Figure 4-4. Bilateral reticular opacities are more predominant in peripheral and lower lobes.
(Image courtesy of Puneet Garcha, MD, Cleveland Clinic Foundation.)

BIOPSY—HRCT is replacing SLB as the diagnostic test of choice. However, video-assisted thoracoscopic surgery is the gold standard to diagnose UIP.

Key Fact

SLB is not needed to establish the diagnosis of UIP if HRCT shows characteristic findings (subpleural site, basal predominance, reticular abnormality, honeycombing, and absence of features inconsistent with UIP).

PULMONARY FUNCTION TESTS

- Restrictive lung defect
- Decreased diffusion lung capacity for carbon monoxide (DLCO)
- Exercise-induced desaturation

Figure 4-5. Honeycombing at the lung bases with subpleural reticulation.
(Image courtesy of Puneet Garcha, MD, Cleveland Clinic Foundation.)

Pathogenesis

The exact cause of IPF is unknown. The initial insult in IPF may occur as a repetitive injury to alveolar epithelial cells and the subepithelial basement membrane. Alveolar epithelial cell injury leads to an intense fibroblastic response that results in abnormal wound healing with excessive deposition of collagen and extracellular matrix. The familial variant of IPF occurs in fewer than 5% of cases.

Potential mechanisms of IPF:

- Cigarette smoking
- Gastroesophageal reflux disease
- Occupational and environmental exposures (metal dust, wood dust, sand, stone, and silica)

Acute exacerbation of IPF is characterized by sudden acceleration of the underlying fibroproliferative process. Precipitating factors include infection, gastroesophageal reflux disease, and surgery (hyperinflation). There are no proven therapies, and the mortality rate is high.

Treatment

No treatment stops the progression of IPF. However, there have been promising results from pirfenidone (an antifibrotic agent) in slowing the decline of FVC in patients with mild to moderate forms of the disease.

- Corticosteroids and immunosuppressive agents have no role in management.
- Supplemental oxygen is used for patients with resting and exertional hypoxemia.
- Pulmonary rehabilitation is used to help improve functional status.
- Lung transplantation is recommended for patients with severe IPF. Early referral to a transplant center is prudent. These patients should be considered for transplant listing based on declining functional status and worsening oxygen requirements (forced vital capacity < 60% of predicted; DLCO < 40% of predicted).

NONSPECIFIC INTERSTITIAL PNEUMONIA (NSIP)

This distinct subgroup of idiopathic interstitial pneumonias (absence of typical findings of UIP, desquamative interstitial pneumonia, and cryptogenic organizing pneumonia) is characterized by bronchoalveolar lavage (BAL) findings lymphocytosis, prominent cellular infiltrate on lung biopsy, clinical improvement with corticosteroids, and overall better long-term prognosis compared with IPF.

Clinical Features

- Most common symptoms are dyspnea on exertion and cough.
- Bibasilar crackles are noted.
- Idiopathic NSIP is common in women (nonsmokers) in the fourth or fifth decade.

Histopathology

- NSIP is classified into cellular and fibrotic types based on histology (Table 4-4).
- Temporal uniformity is a key feature distinguishing NSIP from UIP.
- Patients with cellular NSIP (Figure 4-6) have a higher rate of steroid responsiveness and a better prognosis.



Figure 4-6. Cellular nonspecific interstitial pneumonia.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

Table 4-4. Histopathologic Patterns of Nonspecific Interstitial Pneumonia

Cellular (Figure 4-6)	**Fibrotic** (Figure 4-7)
Mild to moderate interstitial chronic inflammation	Dense or loose interstitial fibrosis with uniform appearance
Type II pneumocyte hyperplasia in areas of inflammation	Lung architecture is frequently preserved
	Absence of fibroblastic foci

Flash Card Q1

What are the known genetic associations with pulmonary fibrosis?



Figure 4-7. Fibrotic nonspecific interstitial pneumonia.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

Diagnosis

IMAGING

- Chest x-ray: Bilateral lower lobe interstitial opacities
- HRCT (Figure 4-8):
  - Diffuse ground-glass opacities
  - Reticular opacities
  - Traction bronchiectasis
  - Typically no honeycombing (distinguishing it from UIP, where honeycombing is a cardinal feature)

Flash Card A1

Mutations in *hTERT* and *hTR* are risk factors for pulmonary fibrosis underlying the inheritance in 8–15% of familial cases. In these families, IPF is inherited as an autosomal dominant trait with age-dependent penetrance.



Figure 4-8. Cellular nonspecific interstitial pneumonia showing bibasilar ground-glass opacities.
(Reproduced, with permission, from Martinez FJ. Idiopathic interstitial pneumonias: usual interstitial pneumonia versus nonspecific interstitial pneumonia. *Proc Am Thorac Soc.* 2006; 3: 81-95.)

BRONCHOSCOPY—Lymphocytosis (> 20%) suggests NSIP.

PULMONARY FUNCTION TESTS

- Restrictive lung defect
- Decreased DLCO

Treatment

Immunosuppressive agents form the mainstay of therapy (Table 4-5). Corticosteroids are usually first-line agents. Steroid-sparing cytotoxic agents are used to avoid the significant adverse effects of corticosteroids.

Commonly used treatment regimens:

- Azathioprine and corticosteroids
- Cyclophosphamide and corticosteroids (connective tissue disease–associated ILD with NSIP pattern)
- Mycophenolate and corticosteroids

Table 4-5. Medications Used to Treat Nonspecific Interstitial Pneumonia

Medication	Adverse Effects
Corticosteroids	Hyperglycemia, hypertension, insomnia
Azathioprine	TPMT genotype and TPMT enzyme activity (phenotype) should be screened in all patients with azathioprine Gastrointestinal upset, abnormal liver function test results
Mycophenolate mofetil	Gastrointestinal upset, abnormal liver function test results, leukopenia
Cyclophosphamide	Bladder cancer, neutropenia

Response to therapy is monitored by improvement in symptoms (cough, dyspnea), spirometry, gas exchange, and radiographic findings. If disease progression occurs, change in treatment regimen and/or referral for lung transplantation should be considered.

Prognosis

The overall prognosis for NSIP is believed to be better than that for UIP, based on a retrospective cohort of studies.

CRYTOGENIC ORGANIZING PNEUMONIA/BRONCHIOLITIS OBLITERANS WITH ORGANIZING PNEUMONIA

Clinical Features

- Occurs in the fourth and fifth decades.
- Affects men and women equally.
- More common in nonsmokers.
- Subacute onset of dry cough is typical.
- Dyspnea occurs.
- Patients have fever, weight loss, and malaise.
- Sparse crackles are noted on lung auscultation.

Pathogenesis

Cryptogenic organizing pneumonia is believed to follow an inciting injury that causes lung inflammation that leads to the production of characteristic buds of intra-alveolar granulation tissue. There seems to be an exaggerated response to the inflammatory or injurious stimuli. There is an acute alveolar epithelial injury with cell death and denudation of the basal laminae. The next step is organization into myofibroblasts and fibroinflammatory buds with a loose deposition of matrix (mainly composed of collagen and fibronectin). Progressive fibrosis with concentric layers of myofibroblasts and connective tissues occurs, leading to the characteristic appearance of intra-alveolar buds. The alveolar architecture is well preserved.

Histopathology

- The classic histologic feature is the presence of intra-alveolar buds of granulation tissue made of myofibroblasts, fibroblasts, and loose connective tissue (Figure 4-9). Multinucleated giant cells are seen in approximately 20% of cases.
- Foamy macrophages are conspicuous in empty alveoli.
- All lesions appear to be of similar age.



Figure 4-9. Intraluminal organizing fibrosis.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

Diagnosis

IMAGING

- Chest x-ray: Multiple, migratory patchy alveolar infiltrates are usually peripheral and bilateral in distribution. The size is variable, ranging from a few centimeters to involving the whole lobe.
- HRCT: Density of the infiltrates can vary from ground glass to consolidation. The consolidated areas may have an air bronchogram as well (Figure 4-10).

BRONCHOSCOPY

- BAL shows a characteristic mixed pattern with increased lymphocytes (20–40%), neutrophils (10%), and eosinophils (5%), with some plasma/mast cells.
- The CD4/CD8 ratio is decreased.

BIOPSY—Most patients require SLB before therapy is started because of the patchy nature of the disease, which makes TBBx less reliable.

PULMONARY FUNCTION TESTING

- Mild to moderate restrictive ventilatory defect is seen.
- DLCO can be reduced.



Figure 4-10. Computed tomography image of the chest showing a right lower lobe opacity with air bronchogram.
(Reproduced, with permission, from Pathak V, et al. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. *Ann Am Thorac Soc.* 2014; 11: 87-91. doi: 10.1513/AnnalsATS.201308-261CR.)

Treatment

- Corticosteroids are the mainstay of treatment.
- Optimal dose and duration of treatment are not known.
- Usually, a long course of steroids is required (6–12 months). Monitor for relapse as steroids are tapered.
- Remarkable clinical improvement occurs in 1 week, but radiologic infiltrates take several weeks to show resolution.
- Cytotoxic agents can be used in patients who are intolerant of steroids or have disease progression despite steroid therapy.

ACUTE INTERSTITIAL PNEUMONIA (ACUTE INTERSTITIAL PNEUMONITIS—HAMMAN RICH SYNDROME)

Acute interstitial pneumonitis is a rapidly progressive and histologically unique form of idiopathic interstitial pneumonia.

Clinical Features

- No sex predilection is noted.
- There is no relationship to smoking.
- Patients have acute onset of cough and dyspnea that progresses rapidly to respiratory failure, requiring mechanical ventilation.
- Fever can be present. Up to 50% of patients have a preceding viral prodrome.
- Rapid progression to respiratory failure is key.
- Overall clinical picture is similar to adult respiratory distress syndrome, but unlike adult respiratory distress syndrome, there is no known cause.

Histopathology

Lung biopsy shows diffuse alveolar damage. Two phases are seen: acute and organizing. The acute (exudative) phase is characterized by edema, hyaline membranes, and microvascular thrombi. The organizing phase shows loose organizing fibrosis within alveolar septa and type II pneumocyte.

Diagnosis

IMAGING—Bilateral patchy alveolar opacities are seen, with regions of ground glass along with consolidation (Figure 4-11).



Figure 4-11. Bilateral patchy symmetric ground-glass opacities with consolidation.
(Image courtesy of Joseph Parambil, MD, Cleveland Clinic Foundation.)

BIOPSY—SLB is essential and can establish the histopathologic features of diffuse alveolar damage.

Treatment

- There is no proven treatment.
- High doses of corticosteroids and cytotoxic agents (cyclophosphamide) are often used.

RESPIRATORY BRONCHIOLITIS–ASSOCIATED INTERSTITIAL LUNG DISEASE

Key Fact

Histologically, respiratory bronchiolitis–associated interstitial lung disease is indistinguishable from respiratory bronchiolitis. Respiratory bronchiolitis–associated interstitial lung disease is characterized by clinical evidence of interstitial lung disease (impairment shown on pulmonary function tests and x-rays) and the finding of respiratory bronchiolitis on lung biopsy.

Respiratory bronchiolitis–associated interstitial lung disease is an interstitial and bronchial process that occurs in smokers and is characterized by respiratory bronchiolitis on lung biopsy.

Clinical Features

- Affects smokers.
- Occurs in the fourth and fifth decades.
- No sex predilection is seen.
- Cough and dyspnea occur.
- Crackles can be present on lung auscultation.

Histopathology

- Respiratory bronchiolitis (pigmented alveolar macrophages in and around the respiratory bronchioles and surrounding alveoli) (Figure 4-12)
- No significant fibrosis, interstitial inflammation, or germinal centers



Figure 4-12. Pigmented alveolar macrophages filling the lumen of the respiratory bronchiole and the surrounding airspaces.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

Diagnosis

IMAGING

- Chest x-ray: Bilateral fine reticular or reticulonodular opacities
- HRCT (Figure 4-13):
  - Bronchial wall thickening
  - Fine centrilobular nodules
  - Bilateral, patchy ground-glass opacities in both the upper and lower lung zones
  - Possible emphysematous changes

Figure 4-13. Patchy ground-glass opacities, fine nodules, and bronchial wall thickening.
(Image courtesy of Joseph Parambil, MD, Cleveland Clinic Foundation.)

BIOPSY—SLB is required to establish the diagnosis, but in the setting of epidemiologic, clinical, and radiologic evidence, a clinical diagnosis can be made.

Treatment

- Smoking cessation is key.
- Steroids and other cytotoxic medications are generally ineffective.

Prognosis

Respiratory bronchiolitis-ILD has a good prognosis and mortality is rare.

DESQUAMATIVE INTERSTITIAL PNEUMONIA

Clinical Features

- Occurs predominantly in smokers.
- Nonspecific symptoms include cough and dyspnea.
- Crackles are noted on auscultation.
- Digital clubbing is seen in up to 50% of patients.

PATHOLOGY

Alveolar spaces are filled with pigment-laden macrophages called *smoker's macrophages* because they are associated with smoking and contain a light brown pigment. This occurs in a homogenous pattern, with preserved alveolar architecture and minimal fibrosis or honeycombing (Figure 4-14).



Figure 4-14. Uniform filling of alveolar spaces with eosinophilic macrophages.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

IMAGING

- Chest x-ray: Patchy haziness or interstitial patterns with lower lung predominance
- HRCT (Figure 4-15):
  - Peripheral ground-glass opacities involving bilateral lower lung zones
  - No honeycombing
  - Possible small lung cysts and emphysematous changes



Figure 4-15. High-resolution computed tomography scan of a patient with desquamative interstitial pneumonia showing bilateral ground-glass opacities. (Reproduced courtesy of Professor A. Pesci, University of Parma. Reproduced, with permission, from Caminati A, Harari S. Smoking-related interstitial pneumonias and pulmonary Langerhans cell histiocytosis. *Proc Am Thorac Soc.* 2006; 3: 299-306.)

BIOPSY—SLB is required to establish the diagnosis.

PULMONARY FUNCTION TESTS—Restrictive ventilatory defect with a reduced DLCO is seen in one third of patients.

Treatment

- Smoking cessation is mandatory.
- Most patients receive corticosteroids; however, there are no data showing their effectiveness.
- In patients with progressive disease, lung transplantation is an option. However, desquamative interstitial pneumonia can recur in the transplanted lung.

Prognosis

Overall prognosis is good, with > 90% of patients surviving for > 5 years.

LYMPHOCYTIC INTERSTITIAL PNEUMONIA

Clinical Features

- Can be idiopathic or secondary to lymphoproliferative disorders and immune deficiency states, such as Sjögren syndrome (25% of cases), HIV/AIDS, and common variable immunodeficiency (CVID).
- Most patients are women (2:1 ratio), usually in the fifth decade.
- Cough, dyspnea, fever, and weight loss occur.
- Crackles are noted on lung auscultation.
- The clinical course can vary from resolution without treatment to progressive respiratory failure and death.
- Up to 50% of patients die within 5 years of diagnosis.
- In 5% of cases, the disease transforms to lymphoma.

Pathology

- Interstitial and bronchovascular infiltrate of small lymphocytes and plasma cells is seen (Figure 4-16).
- Poorly formed nonnecrotizing granulomas with multinucleated giant cells are seen in some cases.



Figure 4-16. Diffuse and dense alveolar septal infiltrate consisting of lymphocytes, plasma cells, plasmacytoid cells, and histiocytes.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

Flash Card Q2

Which ILDs are most commonly associated with smoking?

Diagnosis

IMAGING

- Chest x-ray: Bilateral lower lobe reticular or reticulonodular opacities are seen.
- HRCT: Bilateral ground-glass opacities, centrilobular nodules, patchy bronchovascular bundle thickening, interlobular septal thickening, and thin-walled cysts are seen. Ground-glass opacities can be diffuse or may occur predominantly in the lower lobe (Figure 4-17).



Figure 4-17. High-resolution computed tomography scan showing smooth and nodular thickening of bronchovascular bundles, centrilobular and subpleural nodularity, ground-glass opacification, and interlobular septal thickening.
(Reproduced, with permission, from Allen CM, et al. Imaging lung manifestations of HIV/AIDS. *Ann Thorac Med.* 2010; 5: 201-216. doi: 10.4103/1817-1737.69106.)

BIOPSY

- TBBx: Occasional lymphocytic infiltration seen
- SLB: Required for definitive diagnosis

PULMONARY FUNCTION TESTS—Restrictive ventilatory defect with a reduced DLCO

Flash Card A2

Respiratory bronchiolitis–associated interstitial lung disease, desquamative interstitial pneumonia, and pulmonary Langerhans cell histiocytosis. Smoking cessation is a critical component of therapy.

Treatment

Oral corticosteroids are the mainstay of therapy. Response is variable.

CONNECTIVE TISSUE DISEASE–ASSOCIATED ILD

Connective tissue diseases commonly associated with ILD:

- Rheumatoid arthritis
- Systemic sclerosis/scleroderma
- Inflammatory myopathies: polymyositis/dermatomyositis
- Sjögren syndrome
- Systemic lupus erythematosus

Common serologic associations of connective tissue diseases are shown in Table 4-6.

Table 4-6. Serologic Testing

Autoantibody	Type	Connective Tissue Disease Association
ANA	Antinuclear antibody	Can be seen in multiple connective tissue diseases (systemic lupus erythematosus, systemic sclerosis/scleroderma, Sjögren syndrome, polymyositis/dermatomyositis)
dsDNA	Anti-dsDNA antibody	Systemic lupus erythematosus
SSA	Anti-Ro antibody	Systemic lupus erythematosus, SS, myositis
SSB	Anti-La antibody	Sjögren syndrome (~15% in systemic lupus erythematosus)
Scl-70	Anti-DNA topoisomerase 1	Systemic sclerosis
CCP	Anti-CCP antibody	Rheumatoid arthritis
RF	Rheumatoid factor	Rheumatoid arthritis
RNP	Anti-U1 small nuclear RNP	Mixed connective tissue disease
Jo-1, EJ, PL7	Anti-tRNA	Dermatomyositis/polymyositis/antisynthetase syndrome

Rheumatoid Arthritis

Pulmonary disease in rheumatoid arthritis can present as ILD, obstructive airways disease, rheumatoid lung nodules, or pleural involvement. Rheumatoid nodules can occur in the lung and pleura (Figure 4-18). They should be distinguished from granulomatous infection and granulomatosis with polyangiitis. Rheumatoid arthritis-ILD is generally diagnosed in patients with long-standing rheumatoid arthritis, but sometimes ILD is present before the diagnosis of rheumatoid arthritis.

CLINICAL FEATURES

- Cough, progressive dyspnea, pleuritic chest pain, digital clubbing, and dry crackles (known as Velcro crackles) at the lung bases
- Pulmonary hypertension in advanced disease
- Restrictive lung defect and reduced DLCO on pulmonary function tests

PATHOLOGY—Histopathologic patterns:

- UIP (most common)
- Organizing pneumonia
- Follicular bronchiolitis
- Lymphocytic interstitial pneumonia
- Diffuse alveolar damage



Figure 4-18. Rheumatoid nodule showing characteristic cellular palisading.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

DIAGNOSIS—HRCT features of rheumatoid arthritis-ILD:

- Ground-glass opacities
- Reticulation
- Bronchiectasis
- Micronodules

Four common patterns:

- UIP (honeycombing, bibasal subpleural reticular patterns)
- NSIP (lower lobe reticulation, ground-glass opacities, lack of honeycombing)
- Bronchiolitis (centrilobular nodules, bronchiectasis)
- Organizing pneumonia (peripheral airspace consolidation and ground-glass opacities)

TREATMENT

- Corticosteroids
- Cytotoxic drugs (azathioprine, mycophenolate, cyclosporine, cyclophosphamide)
- Biologics: tumor necrosis factor-α inhibitors
- Lung transplantation

Systemic Sclerosis (Scleroderma)

CLINICAL FEATURES—Other than the common symptoms of ILD (cough and dyspnea), systemic symptoms that suggest systemic sclerosis/scleroderma include history of skin thickening, telangiectasias, digital nail pitting, esophageal reflux or food regurgitation, esophageal dysmotility, and dysfunction. Sclerodactyly along with a history of Raynaud phenomenon is suggestive of systemic sclerosis/scleroderma.

PATHOLOGY—Most common histopathologic pattern seen is NSIP. Few patients have the UIP pattern.

Key Fact

Pulmonary arterial hypertension develops in > 15% of patients with systemic sclerosis/ scleroderma. It can be an isolated complication or secondary to ILD. These patients have a high mortality rate. Elevated levels of endothelin-1 cause enhanced vasoconstriction, vascular endothelial cell proliferation, smooth muscle hypertrophy, and irreversible vascular remodeling in the lungs, as shown in Figure 4-19.



Figure 4-19. Arterial remodeling of systemic sclerosis because of elevated levels of endothelin-1.
(Image courtesy of Joseph F. Tomashefski, Jr., MD. Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

PULMONARY FUNCTION TESTS—Restrictive lung defect and reduced DLCO are seen.

DIAGNOSIS

- Imaging: NSIP pattern is common on HRCT. Ground-glass opacities on initial CT scan indicate a progressive pattern.
- Pulmonary function tests: Restrictive lung defect and reduced DLCO are seen.

TREATMENT

- Corticosteroids: Low-dose therapy is used. High-dose steroids cannot be used because of concern about scleroderma renal crisis.
- Cytotoxic drugs: Cyclophosphamide is the most commonly used agent. Azathioprine and mycophenolate are alternatives.
- Lung transplantation: Particular attention is paid to esophageal involvement before lung transplant. Gastroesophageal reflux disease caused by esophageal dysmotility can lead to allograft dysfunction.

Inflammatory Myopathy

Multiple types of inflammatory myopathy are associated with ILD, including polymyositis, dermatomyositis, and anti-synthetase syndrome.

CLINICAL FEATURES—Proximal muscle symptoms include myalgias, muscle weakness, and fatigue. Skin manifestations, such as Gottron's papules (Figure 4-20), heliotrope rash, shawl sign, and mechanic's hands, may occur.

Figure 4-20. Gottron's papules, scaly erythematous eruptions, or red patches overlying the knuckles, elbows, and knees.
(Reproduced Image courtesy of EM Dugan, AM Huber, FW Miller, LG Rider, and the International Myositis Assessment and Clinical Studies (IMACS) Group, CC BY-SA 3.0.)

PATHOLOGY

- NSIP is the most common histopathologic pattern.
- Other patterns seen are usual interstitial pneumonia (UIP), organizing pneumonia (OP), diffuse alveolar damage (DAD).
- SLB usually is not required to establish the diagnosis.

DIAGNOSIS

- Pulmonary function testing:
  - Restrictive ventilatory defect and reduced DLCO.
  - Respiratory muscle insufficiency with reduction in forced vital capacity and total lung capacity (TLC).
- Imaging: HRCT findings are similar to those for other connective tissue disease–associated ILDs. Abnormalities usually seen are ground-glass opacities, reticulation, and alveolar airspace opacities.

TREATMENT

- Despite lack of randomized controlled studies, corticosteroids remain the therapy of choice.
- Azathioprine is the most commonly used cytotoxic agent.
- Cyclophosphamide is reserved for severe, life-threatening disease. Mycophenolate, cyclosporine, methotrexate, intravenous immunoglobulin, and rituximab are also used.
- Lung transplantation is an option for progressive or refractory disease.

Sjögren Syndrome

Sjögren syndrome can be primary or secondary. Secondary Sjögren syndrome is associated with other connective tissue disease–associated ILDs.

CLINICAL FEATURES

- Affects middle-aged women.
- Autoantibodies to Ro (anti-SSA) and/or La (anti-SSB) are seen.
- Cough, dyspnea, wheezing, chest pain, and sicca symptoms (ocular and oral dryness) occur.
- Crackles are noted on auscultation.

PATHOLOGY—Histopathologic patterns include NSIP, lymphocytic interstitial pneumonia, OP, and UIP. Occasionally, primary pulmonary lymphoma and amyloidosis are seen.

DIAGNOSIS—HRCT can show multiple abnormalities, such as large airways and small airways disease or ILD. Thin-walled cysts suggest lymphocytic interstitial pneumonia. Nonresolving consolidation, nodules larger than 1 cm, and lymphadenopathy can suggest lymphoma. These patients should undergo SLB.

TREATMENT—Corticosteroids are initial therapy in most of the cases. Steroid-sparing agents such as azathioprine also can be used.

Systemic Lupus Erythematosus

Most commonly affects young women. This immune-mediated disease causes skin rash, oral ulceration, arthritis, kidney involvement, and hematologic abnormalities. Systemic lupus erythematosus can cause a variety of lung manifestations (Table 4-7).

Table 4-7. Pulmonary Manifestations of Systemic Lupus Erythematosus

Manifestation	Features
Acute lupus pneumonitis	Acute onset of fever, cough, dyspnea, and hypoxia. Can progress to acute respiratory failure. Treat with empiric antibiotics. After infection is ruled out, empiric high-dose steroids are used.

Table 4-7. Pulmonary Manifestations of Systemic Lupus Erythematosus, continued

Manifestation	Features
Diffuse alveolar hemorrhage	Similar presentation to acute lupus pneumonitis. Hemoptysis is not universal. Acute anemia might be suggestive. Bronchoscopy with BAL shows progressive hemorrhagic BAL fluid and hemosiderin-laden macrophages. Treat with empiric antibiotics. High-dose corticosteroids are used in conjunction with cyclophosphamide. Plasmapheresis is also associated with improved survival.
Shrinking lung syndrome	Dyspnea, pleuritic chest pain, small lung volume, and diaphragmatic elevation. Restrictive physiology without parenchymal involvement. Steroids are first-line therapy.
Chronic interstitial lung disease	Seen in older men with insidious onset of cough and dyspnea. Treat with corticosteroids and steroid-sparing agents (azathioprine and MMF). Cyclophosphamide is reserved for refractory cases.

BAL, bronchoalveolar lavage; MMF, mycophenolate mofetil.

PULMONARY LANGERHANS CELL HISTIOCYTOSIS

Pulmonary Langerhans cell histiocytosis is also known as histiocytosis X, pulmonary Langerhans granulomatosis, or pulmonary eosinophilic granuloma.

Clinical Features

- White, younger adults (third or fourth decade)
- No sex predilection
- Strong association with smoking
- Dry cough and dyspnea
- Spontaneous pneumothorax in 10–15% of patients
- Constitutional symptoms, including fever, weight loss, malaise, and anorexia
- Pulmonary hypertension in severe disease, reflecting pulmonary vascular involvement
- Good prognosis in patients who abstain from smoking

Pathogenesis

- Believed to be induced by exposure to cigarette smoke.
- There is accumulation of Langerhans cells in lungs. Approximately 15% of patients have involvement of extrathoracic organ systems.

Pathology

- Predominantly bronchiolocentric stellate lesions with central scarring
- Abundant Langerhans cells in the early phase of disease identified by immunohistochemical staining for CD1a antigen and S-100 protein
- Intracellular inclusions termed *Birbeck granules* in Langerhans cells identified by electron microscopy
- Extensive eosinophilic infiltration in the early phase of disease

Diagnosis

IMAGING

- Chest x-ray: Reticulonodular opacities predominantly in the upper and mid lung zones, with sparing of costophrenic angles
- HRCT: Combination of nodules and cysts seen in the upper lung zones, with relative sparing of lung bases (Figure 4-21)

- **LUNG BIOPSY—**TBBx or SLB is recommended but not required to establish the diagnosis.

- **PULMONARY FUNCTION TESTING—**Variable results are seen (mixed, obstructive, restrictive, or completely normal). DLCO is reduced in most patients. Exercise capacity is limited, reflecting pulmonary vascular involvement.



Figure 4-21. Diffuse thin-walled cysts and lung nodules.
(Image courtesy of Joseph Parambil, MD, Cleveland Clinic Foundation.)

Treatment

- Smoking cessation leads to stabilization of clinical and radiologic abnormalities.
- Corticosteroids are indicated for patients with severe or progressive disease.
- Associated complications (pneumothorax, pulmonary hypertension, and respiratory failure) must be managed.
- Lung transplantation is an option for patients with advanced disease who do not respond to the other treatment modalities.

LYMPHANGIOLEIOMYOMATOSIS

Epidemiology

Exclusively affects premenopausal women and is characterized by hamartomatous proliferation of atypical smooth muscles along lymphatics in the lung, thorax, abdomen, and pelvis.

Key Fact

LAM is associated with tuberous sclerosis complex, which is a multisystem genetic disorder caused by mutation of the *TSC1* or *TSC2* gene.

Clinical Features

- Affects women in the third and fourth decades.
- Dyspnea occurs.
- Recurrent pneumothorax is common (50–80% of patients).
- Hemoptysis is noted.
- Chyloptysis occurs.
- Chylous effusion is noted.
- Most cases progress to end-stage respiratory failure.

Pathogenesis

Lymphangioleiomyomatosis is exclusively a disease of premenopausal women. Estrogen is postulated to play a key role in its pathogenesis. Estrogen (exogenous or endogenous) accelerates disease progression. Lymphangioleiomyomatosis cells are of two types: myofibroblast-like spindle-shaped cells and epithelioid-like polygonal cells. Both cells express melanoma-associated proteins HMB-45 and CD63. Spindle-shaped cells express smooth muscle-specific proteins smooth muscle α actin, vimentin, and desmin.

Flash Card Q3

Which cells are pathognomic of pulmonary Langerhans cell histiocytosis on bronchoalveolar lavage?

Pathology

The finding of multiple lung cysts in the absence of nodule or interstitial fibrosis is pathognomic.

IMMUNOHISTOCHEMISTRY—Muscle-specific actin, desmin, and human melanoma black-45.

Diagnosis

IMAGING

- Chest x-ray:
  - Findings may be normal early in the disease course.
  - Hyperinflated lung fields can be seen with progression of airflow obstruction.
  - Pneumothorax, cystic or reticulonodular opacities, and pleural effusions may occur.
- HRCT:
  - Multiple thin-walled cysts of varying sizes and shapes are seen. Cysts are scattered throughout the lung zones without predilection for central or peripheral regions. Nodules and interstitial fibrosis are not seen (Figure 4-22).
  - Abdominal CT scan can show angiomyolipomas in the kidney, spleen, or pelvic organs or retrocrural or para-aortic lymphadenopathy.
- Ventilation-perfusion lung scan: Speckled pattern may be seen on ventilation lung scan.



Figure 4-22. Multiple cysts of varying sizes and shapes.
(Image courtesy of Puneet Garcha, MD, Cleveland Clinic Foundation.)

Flash Card A3

BAL showing > 5% CD1a-positive cells is virtually diagnostic of pulmonary Langerhans cell histiocytosis.

BRONCHOSCOPY—TBBx can establish the diagnosis.

SLB—Diagnosis can be established without SLB in patients with characteristic HRCT features or any of the following—renal angiomyolipoma, chronic chylous ascites with abdominal lymphadenopathy, or characteristic histopathologic findings on lymph node biopsy.

PULMONARY FUNCTION TESTING—Obstructive ventilatory pattern with air trapping is seen in most patients. DLCO is reduced.

Treatment

- Women should be advised against pregnancy or use of exogenous estrogen.
- Corticosteroids and cytotoxic agents have no role in treatment.
- Sirolimus (mTor inhibitor) suppresses smooth muscle proliferation and DNA synthesis of lymphangioleiomyomatosis cells. In patients with mild to moderate disease, sirolimus decreases the decline in lung function and improves the quality of life. Lung transplantation is an option for patients with end-stage respiratory failure due to lymphangioleiomyomatosis.

ACUTE EOSINOPHILIA PNEUMONIA

Clinical Features

- Multiple risk factors have been identified, including drugs, infections (parasites), heavy metals, toxin inhalation, and cigarette smoking.
- Usually affects men 20–40 years of age.
- Usually presents as acute febrile illness lasting 7–14 days. Can be confused with community-acquired pneumonia or adult respiratory distress syndrome.
- Fever, myalgia, and pleuritic chest pain occur.
- Hypoxic respiratory failure may be seen.
- Prognosis is excellent once the diagnosis is made and therapy is instituted.
- Most patients have no long-term sequelae.

Pathogenesis

Acute cigarette smoke exposure along with other proallergic exposures may facilitate the generation of inflammatory cytokines, leading to massive recruitment and activation of eosinophils in lungs.

Diagnosis

IMAGING

- Chest x-ray: Bilateral alveolar opacities with small pleural effusions are seen.
- HRCT: Patchy alveolar ground-glass and/or consolidative opacities, interlobular septal thickening, and pleural effusions are seen (Figure 4-23).

BRONCHOSCOPY (BAL, TBBx)

- BAL eosinophilia (> 20–25%) is characteristic in normal peripheral blood eosinophilia.
- TBBx is not necessary for diagnosis, but when performed shows marked interstitial and alveolar eosinophilic infiltration.

Figure 4-23. Chest computed tomography scan showing bilateral alveolar opacities and pleural effusions.
(Reproduced, with permission, from Philit F, et al. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. *Am J Respir Crit Care Med*. 2002; 166: 1235-1239. doi: 10.1164/rccm.2112056)

Treatment

Smoking cessation and high doses of corticosteroids usually result in dramatic improvement in 24–48 hours. Total duration of therapy is usually 2–4 weeks.

CHRONIC EOSINOPHILIC PNEUMONIA

Clinical Features

- Affects middle-aged women.
- Symptoms include cough, dyspnea, fever, night sweats, malaise, and weight loss.
- Asthma is present in 50–60% of patients.
- Immunoglobulin E levels are elevated.
- Peripheral blood eosinophilia occurs.
- Prognosis is excellent, but long-term treatment is required.
- Spontaneous resolution is rare.

Diagnosis

IMAGING

- Chest x-ray: Bilateral diffuse peripheral infiltrates are seen. This pattern has been described as the photographic negative of pulmonary edema.
- HRCT: Peripheral infiltrates are seen in all affected lobes.

BRONCHOSCOPY (BAL, TBBx)

- BAL shows eosinophilia.
- TBBx shows eosinophilic microabscesses, low-grade vasculitis, and interstitial fibrosis (Figure 4-24).

Treatment

Corticosteroids are given with a slow taper because relapse can occur.



Figure 4-24. Eosinophilic microabscesses.
(Image courtesy of Joseph F. Tomashefski, Jr., MD, Department of Pathology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio.)

SARCOIDOSIS

Sarcoidosis is a chronic, multisystem, noncaseating granulomatous disease of unknown etiology. A number of diseases appear clinically and histologically similar to sarcoidosis. Therefore, sarcoidosis is in essence a diagnosis of exclusion. Table 4-8 describes its clinicopathologic mimics.

Table 4-8. Histopathologic Mimics of Sarcoidosis

Mimic	Comment
Berylliosis	Affects patients working with circuit boards/electronics. Similar findings on x-ray. Diagnosis made with lymph transfer test on bronchoalveolar lavage.
Interferon therapy	Interferon is used to treat hepatitis C and other conditions and may promote granuloma formation.
World Trade Center responders	Higher incidence of histologically proven pulmonary sarcoidosis is seen in this population.

INTRODUCTION

Table 4-9 shows the demographic features of patients with sarcoidosis.

Table 4-9. Demographic Features of Patients with Sarcoidosis

Age	Sex	Nationality	Genetics	Associations
< 40 y, peak 20–29 y In Scandinavian countries and Japan; second peak incidence in women > 50 y	F > M	Highest prevalence in Sweden, Denmark, and among African Americans	Heredity: 6% in whites, 17% in African Americans No specific gene; major histo-compatibility complex on chromosome 6p most studied	Smoking appears protective Associated HLA subtypes HLA*DRB1*1101 and HLA*DPB1*0101 -HLA DQB1*0201 associated with favorable outcomes

Clinical Presentation

Table 4-10 reveals clinical patterns associated with sarcoidosis.

Table 4-10. Clinical Patterns Associated with Sarcoidosis

Syndrome	Clinical Manifestations	Other Key Facts	Patterns
Pulmonary sarcoidosis	Radiographic stages: Stage 1: Mediastinal and hilar lymphadenopathy Stage 2: Adenopathy with lung disease Stage 3: Lung disease only Stage 4: Fibrosis and honeycombing	Imaging pattern may mimic that seen in other diseases Lung disease in 90% of patients affected	Nodular sarcoidosis has highest rate of spontaneous remission
Löfgren syndrome	Triad: Erythema nodosum, hilar LAD, arthralgias	Strong association with HLA-DQB1*0201 Seen mostly in women	Resolves in 2 y in > 90% of patients
Extrathoracic manifestations	Skin, liver, heart, kidneys, central nervous system, and bone are notable sites	Like pulmonary disease, extrathoracic manifestations may mimic other diseases 2–7% of patients affected	Chronic uveitis: African Americans Lupus pernio: Puerto Ricans Erythema nodosum: Europeans Cardiac and ocular disease: Japanese

Clinical Findings

The clinical presentation and course are heterogeneous. Constitutional symptoms include low-grade fever, night sweats, fatigue, and weight loss. Weight loss is usually limited: 2–6 kg during the 10–12 weeks before presentation.

Pulmonary symptoms can include cough, wheezing, sputum production, and/or pleurisy.

PULMONARY FUNCTION TESTS—Abnormalities are seen in only 20% of patients with stage I disease and 40–70% of patients with stage II–IV disease

- Obstruction or restriction is seen. Occasionally, both are seen.
- Commonly a methacholine challenge test result is positive.
- Forced vital capacity and DLCO are the most predictive long-term markers of disease.

LABORATORY TESTS

- Hypercalcemia occurs in 1–4% of cases, and hypercalciuria occurs in 15–40%.
- Angiotensin-converting enzyme levels are nonspecific for diagnosis, may be used for disease monitoring.
  - Findings may be normal in active disease.
- BAL shows lymphocytosis in > 80% of patients.
- BAL showing CD4/CD8 ratio > 3.5 has sensitivity of 53%, specificity of 94%, positive predictive value of 76%, and negative predictive value of 85%.

IMAGING

- Chest x-ray findings other than bilateral hilar lymphadenopathy are relatively nonspecific.
- Typical chest CT scan findings can vary. Classic findings (Figure 4-25):
  - Widespread small nodules with a bronchovascular and subpleural distribution
  - Thickened interlobular septae
  - Architectural distortion
  - Conglomerate masses
- Radionuclide and positron emission tomography scans are used to evaluate territory of disease.
- Echocardiogram is performed to evaluate cardiac involvement from sarcoidosis or secondary pulmonary hypertension



Figure 4-25. Peribronchovascular disease showing small nodules (*arrows*) and architectural distortion.
(Reproduced, with permission, from Müller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 2. *Am Rev Respir Dis.* 1990; 142 [6 Pt 1]: 1440-1448.)

Pathology

- The diagnosis of sarcoidosis is typically made with bronchoscopy and transbronchial biopsy. This has a diagnostic yield of 60–95%.
- Transbronchial nodal fine-needle aspiration also has high sensitivity.
- Endobronchial disease is seen in > 40% of patients with active disease.

PATHOLOGIC FINDINGS— See Figure 4-26.

- In the lung, about 75% of granulomas are located near or within the connective tissue sheath of bronchioles and subpleural or perilobular spaces (lymphangitic distribution).
- Sarcoid granulomas either resolve or leave fibrotic changes. End-stage sarcoidosis causes parenchymal fibrosis and honeycombing.

Key Fact

Angiotensin-converting enzyme is created by granulomas and can be elevated in any granulomatous disease. Granulomas also produce calcitriol, which can lead to hypercalcemia.

Flash Card Q4

What are normal BAL CD4/CD8 ratios and those in patients with sarcoidosis?

Flash Card Q5

How does the BAL CD4/CD8 ratio differ in HSP and sarcoidosis?

Flash Card Q6

What exposures can mimic sarcoidosis?



Figure 4-26. Noncaseating granulomas.
(Reproduced, with permission, from Dr. Joseph F. Tomashefski, Jr., MetroHealth Medical Center, Case Western Reserve University.)

Treatment

Spontaneous remissions occur and prognosis is based on the initial radiographic stage:

- 55–90% of patients with Stage I disease
- 40–70% with Stage II disease
- 10–20% with Stage III disease
- 0% with Stage IV disease

The course of the disease is usually dictated within 18–24 months of onset. Patients with worsening symptoms, worsening forced vital capacity and/or DLCO, or worsening lung fibrosis should receive therapy. Extrathoracic abnormalities also play a role in deciding whether treatment should be initiated. Table 4-11 reveals the most commonly used therapeutic options.

Overall, respiratory failure is the most common cause of mortality. The directly attributable mortality from sarcoidosis is < 5%.

Flash Card A4

CD4/CD8 ratio 1.5–2.0 = normal
CD4/CD8 ratio >3.5 = suggestive of sarcoidosis

Flash Card A5

CD4/CD8 ratio 1.5–2.0 = normal
CD4/CD8 ratio >3.5 = suggestive of sarcoidosis

Flash Card A6

Nearly identical clinical and pathologic features can be seen in berylliosis, so a detailed exposure history is key.

Table 4-11. Therapeutic Options

Treatment	Comments
None	Monitor symptoms, labs, and pulmonary function tests. Spontaneous remission occurs in up to 40% of patients within the first 6 mo and in 80% within the first 2 y.
Corticosteroids: prednisone/ prednisolone	Cornerstone of therapy; 4–6-wk initial burst with maintenance doses for ~6 mo.
Methotrexate/azathioprine	Used in refractory disease. Methotrexate used early in those with cardiac sarcoidosis.
Chloroquine/hydroxychloroquine	Typically used for skin and central nervous system disease; may stabilize lung function with concurrent steroid use. Requires yearly eye exams because of toxicity.
Infliximab	Used in refractory disease and extrapulmonary manifestations. Limited evidence.
Inhaled corticosteroids	Limited efficacy. Used in mild disease.

PULMONARY ALVEOLAR PROTEINOSIS

Pulmonary alveolar proteinosis is described as lipoproteinaceous material accumulating in alveolar tissue. The disease also increases susceptibility to opportunistic organisms.

INTRODUCTION

Estimated prevalence is 0.36–3.70 cases per 1 million people. Median age at diagnosis is 39 years. Men are mostly affected. The disease is highly associated with smoking tobacco.

The granulocyte-macrophage colony-stimulating factor (GM-CSF) pathway is important in the pathogenesis of both the acquired and congenital forms of pulmonary alveolar proteinosis. Table 4-12 shows the patterns of disease origin.

Flash Card Q7

What causes acquired pulmonary alveolar proteinosis?

Table 4-12. Pathogenesis of Pulmonary Alveolar Proteinosis

Type	Comments
Congenital	Autosomal recessive; caused by mutations on genes for surfactant B, C, or the beta-c chain of the receptor for GM-CSF
Secondary	Most common form; related to conditions that reduce pulmonary macrophages: silica exposure, *Pneumocystis jiroveci* pneumonia, malignancies, certain autoimmune diseases, immune deficiencies, and certain drugs
Acquired	Antibodies against GM-CSF

GM-CSF, granulocyte macrophage colony-stimulating factor.

Clinical Presentation

Typical symptoms include cough and progressive dyspnea. Patients typically present within 10 months of symptom onset. Some patients present with infection. Lung examination shows crackles and occasionally cyanosis and clubbing.

LABORATORY FINDINGS—Findings strongly suggestive of pulmonary alveolar proteinosis:

- Elevated lactate dehydrogenase level
- Possibly elevated carcinoembryonic antigen level
- Cytokeratin 19
- Mucin KL-6
- Surfactant protein-A, B, or D
- Serum or BAL showing GM-CSF antibodies

PULMONARY FUNCTION TESTS

- Restrictive pattern is seen.
- Decrease in DLCO is out of proportion to restriction.

IMAGING

- Chest x-ray: Patchy and asymmetrical consolidation is seen and is more prominent in the perihilar region bilaterally (*batwing appearance*).
- Chest CT scan: Patchy ground-glass opacities or consolidation, with thickening of interlobular septae, resulting in a *crazy paving* pattern (Figure 4-27).

Flash Card A7

Antibodies against GM-CSF



Figure 4-27. Crazy paving pattern on computed tomography scan with pulmonary alveolar proteinosis.
(Reproduced, with permission, from Müller NL, Miller RR. Computed tomography of chronic diffuse infiltrative lung disease. Part 2. *Am Rev Respir Dis.* 1990; 142 [6 Pt 1]: 1440-1448.)

Pathology

The diagnosis is made via bronchoscopy with BAL. Figure 4-28A shows return of milky effluent that shows granular, acellular, eosinophilic, proteinaceous material with foamy macrophages. The finding of lamellar bodies (concentrically laminated phospholipid structures) on electron microscopy is confirmatory.

Periodic acid–Schiff-positive proteinaceous alveolar deposits in the absence of a cellular infiltrate and normal septa are characteristic (Figure 4-28B).

Flash Card Q8

What imaging pattern is strongly suggestive of pulmonary alveolar proteinosis?

A



B

Figure 4-28. (A) Milky findings on bronchoscopy. (B) Periodic acid-Schiff stain in pulmonary alveolar proteinosis.
(Figure A reproduced, with permission, from Garfied JM, Kim V. Dry cough and clubbing in a 45-year-old woman. *ATS Clinical Cases.* Available at http://www.thoracic.org/clinical/ats-clinical-cases/pages/dry-cough-and-clubbing-in-a-45-year-old-woman.php. Figure B reproduced, with permission, from Dr. Joseph F. Tomashefski, Jr., MetroHealth Medical Center, Case Western Reserve University.)

Flash Card A8

Crazy paving pattern

Treatment

Therapies to reduce the development of proteinaceous material were historically lacking, and management was geared toward clearance. More recently, GM-CSF has been used (Table 4-13).

Table 4-13. Treatment Modalities for Pulmonary Alveolar Proteinosis

Modality	Mode	Comments
Sequential whole lung lavage[a]	Up to 3 L saline mixed with non-anti-coagulant or heparin	Average duration of effect: ~15 months. Average patient requires 2 lifetime lavages (range, 1–22).
GM-CSF	Subcutaneous or inhaled	Helpful for acquired pulmonary alveolar proteinosis Proven oxygenation benefit. Some show complete response
Lung transplantation	Typically performed bilaterally	Recurrence has been reported

[a]High level of evidence; standard of therapy.
GM-CSF, granulocyte macrophage colony-stimulating factor.

PROGNOSIS—No major variables predict survival; however, onset at age younger than 5 years is associated with worse prognosis.

- Respiratory failure is the most common case of mortality.
- Infectious complications:
  - Typical CAP organisms
  - Mycobacteria
  - *Aspergillus*—with disseminated disease, seen more often in acquired cases
  - *Nocardia*—with disseminated disease, seen more often in acquired cases
- Survival rate at 10 years is 68%.
- Spontaneous resolution may occur.

Mnemonic

PAP MAN infections:
Pulmonary
Alveolar
Proteinosis
***M**ycobacteria*
***A**spergillus*
***N**ocardia*

PULMONARY AMYLOIDOSIS

Pulmonary amyloid is described as a fibrillar, insoluble, proteinaceous material that deposits within the lungs focally or diffusely.

Clinical Presentation

The disease may present systemically or may be limited to the lungs.

The two most common types of amyloidosis are primary and secondary:
- Primary type is more common and is often associated with multiple myeloma.
- Secondary type is less common and is associated with chronic inflammatory/infectious disorders.

Any organ may be affected. Pulmonary manifestations may be the first sign of disease. Each pattern of pulmonary disease tends to occur independently, and overlap is rare. Table 4-14 shows these patterns of disease.

Table 4-14. Spectrum of Disease with Pulmonary Amyloidosis

Location	Findings
Parenchymal	Cough, sputum production, dyspnea, hemoptysis
Tracheobronchial	Wheezing, dyspnea, cough, hemoptysis
Upper airway	Macroglossia with obstructive sleep apnea symptoms

LABORATORY TESTS—Serum protein electrophoresis or electrophoresis of urine samples may show a monoclonal spike.

PULMONARY FUNCTION TESTS
- Restriction is seen, and obstruction seen with tracheobronchial involvement.
- DLCO is reduced.

IMAGING
- Chest x-ray: Pulmonary nodules are seen with a diffuse interstitial pattern.
- Chest CT scan: Three different patterns are seen:
  - Bilateral reticulonodular or nodular pattern may occur with mediastinal adenopathy.
  - Parenchymal nodules may be cavitated.
  - Diffuse alveolar or tracheobronchial nodules with calcifications (Figure 4-29).

Figure 4-29. Tracheobronchial amyloidosis.
(Reproduced, with permission, from Marchiori E, et al. [Diffuse abnormalities of the trachea: computed tomography findings] [Article in Portuguese]. *J Bras Pneumol.* 2008; 34: 47-54.)

Pathology

- The diagnosis is made by sampling the affected tissue, including fine-needle aspiration (vs. resection) of a nodule or biopsy of lung tissue.
- Bronchoscopy may show focal nodules on the major airways. Endobronchial involvement may appear as focal stenoses with shiny, pale plaques.
- Biopsy (Figure 4-30A) shows characteristic apple-green birefringence with Congo red staining on polarized microscopy. Nodules may also include calcifications. Diffuse alveolar septal amyloid is shown in Figure 4-30B.



A **B**

Figure 4-30. Congo red staining (A). Diffuse alveolar septal amyloid (B).
(Reproduced, with permission, from Dr. Joseph F. Tomashefski, Jr., MetroHealth Medical Center, Case Western Reserve University.)

Flash Card Q9

Is tracheobronchopathia osteochondroplastica associated with amyloid disease?

Treatment

Treatment is centered on therapy for the underlying plasma cell dyscrasia. Focal stenosis within the tracheobronchial tree can be treated with laser therapy. Bevacizumab is used to treat pleural effusions in primary systemic amyloidosis. Median survival is 16 months. Nodular-only disease has a benign course.

BIRT-HOGG-DUBE

DEFINITION—Birt-Hogg-Dube is a rare autosomal dominant disease that causes cystic lung disease and pneumothorax.

This disease was first described as the cutaneous triad of fibrofolliculomas (Figure 4-31), trichodiscomas, and skin tags. It also has a propensity for renal tumors.

ETIOLOGY—It is caused by germline mutations of the *BHD* gene on chromosome 17 that encodes for folliculin, a tumor suppressor.

Figure 4-31. Fibrofolliculomas.
(Reproduced courtesy of Thomas Habif, Dermnet.com, CC BY-SA 3.0.)

Flash Card A9

No, tracheobronchial amyloid is its own disease entity but can present very similarly. Submucosal involvement (posterior wall) is seen only with tracheobronchial amyloid disease.

Clinical Presentation

- Affects patients in the third or fourth decade.
- Patients present with firm, dome-shaped papules on the upper extremities, face, and trunk.
- Renal tumors fall under the pathology of renal cell carcinoma, oncocytic hybrid tumor, or clear cell carcinoma.

PULMONARY MANIFESTATIONS—Can occur in the absence of skin or kidney lesions

- Pneumothorax occurs in 25% of patients.
- Symptoms can include dyspnea and cough.
- Pulmonary function tests show a restrictive pattern.
- Chest x-ray may show cystic lesions in the lung space.
- Chest CT scan shows scattered, thin-walled cysts of various sizes.

Pathology

Features include intraparenchymal air-filled spaces surrounded by normal parenchyma or a thin wall.

Diagnosis is made by open lung biopsy. Biopsy specimens may help to exclude lymphangioleiomyomatosis, lymphocytic interstitial pneumonia, Langerhans cell histiocytosis, and rare forms of malignancy.

Treatment

No specific treatment exists. Usual care is provided for pneumothorax. Family members should be genetically screened. Patients require routine screening for renal malignancy.

Flash Card Q10

What are the causes of noninfectious cystic lung disease?

LIPOID PNEUMONIA

Lipoid pneumonia is divided into endogenous and exogenous forms. Early recognition is key because this condition may mimic infectious pneumonia and lead to incorrect management.

Exogenous lipoid pneumonia is far more commonly reported in the literature than the endogenous form. Table 4-15 shows the differences between endogenous and exogenous lipoid pneumonia.

Table 4-15. Pathogenesis of Lipoid Pneumonia

Type	Comments
Exogenous	Classically seen in chronic laxative users (mineral oil). Also associated with old nasal sprays, aspiration, and bronchography (rarely used today).
Endogenous	Related to proximal airway obstruction with resultant cholesterol-filled macrophages distally. Rarely associated with Niemann-Pick disease.

Clinical Presentation

Cough, wheezing, and dyspnea are common.

LABORATORY TESTS—Non-specific.

BAL—Lipid-laden macrophages are seen.

Flash Card A10

Lymphangioleiomyomatosis, lymphocytic interstitial pneumonia, Langerhans cell histiocytosis, Birt-Hogg-Dube, and rare forms of malignancy

PULMONARY FUNCTION TESTING

- Restriction is noted.
- DLCO is reduced.

IMAGING

- Chest x-ray: Consolidations are seen.
- Chest CT scan: Consolidations are seen, with or without surrounding ground-glass opacities, airspace nodules, and occasional crazy paving pattern when associated with pulmonary alveolar proteinosis. Finding of negative Hounsfield units is diagnostic.

Pathology

New lesions show lipid-laden macrophages in alveolar spaces. With advanced disease, associated inflammatory cell invasion may occur. Over time, these inflammatory cells may cause cell wall destruction and fibrosis.

Staining with Sudan black (Figure 4-32) and oil red O can show lipid-filled vacuoles. Sometimes these are seen with hematoxylin-eosin staining (Figure 4-33).



Figure 4-32. Sudan black stain in lipoid pneumonia.
(Lekka ME, et al. The Impact of Intravenous Fat Emulsion Administration in Acute Lung Injury. *Am J Respir Crit Care Med*. 2004; 169(5): 638-644.Fig 4B. doi: 10.1164/rccm.200305-620OC)

Flash Card Q11

How is infectious pneumonia distinguished from lipoid pneumonia on imaging?



Figure 4-33. Hematoxylin-eosin stain showing characteristic lipoid vacuoles.
(Seif F, Hafez-Khayyata S, Hejal R. A Solitary Pulmonary Nodule Mimicking Lung Cancer. *Am J Respir Crit Care Med*. 2012: 186(3): e4. Fig 1D. doi: 10.1164/rccm.201107-1182IM)

Treatment

The goal of treatment is to avoid reintroduction of exogenous substance. Focal BAL to the site can be attempted and repeated, however little evidence exists to its efficacy.

Prognosis

Prognosis is excellent if detected early and the exogenous source is controlled.

DRUG-INDUCED LUNG DISEASE

Introduction

Drug-induced lung disease encompasses a wide spectrum of disease.

Certain classes of medications have repeatedly been found to cause lung disease. As a whole, drug-induced lung disease should always be included in the differential diagnosis for pulmonary diseases. Unfortunately, the dose and length of exposure do not follow a clear pattern.

Flash Card A11

CT scan shows fewer Hounsfeld units compared with typical infectious consolidations.

In clinical practice, the Web site www.pneumotox.com is helpful for staying up to date on the latest drug-induced lung diseases.

Clinical Presentation

Table 4-16 shows the clinical presentation of drug-associated lung disease and the associated drugs.

Table 4-16. Clinical Associations

Presentation	Associated Drugs
Cough	Angiotensin-converting enzyme inhibitor, rarely angiotensin receptor blockers
Bronchospasm	Beta blockers (including ophthalmic), aspirin/nonsteroidal anti-inflammatory drugs, cetuximab
Noncardiogenic pulmonary edema	Tocolytics, IL-2, aspirin/nonsteroidal anti-inflammatory drugs
Hypersensitivity pneumonitis	Methotrexate, taxanes, penicillin, sulfa drugs
Chronic fibrosis	Bleomycin, Taxol, amiodarone, nitrofurantoin
Venous thromboembolism	Estrogen (and estrogen receptor agonist/antagonists), especially if positive for Factor V Leiden mutation
Lupus	Hydralazine, isoniazid, penicillamine, procainamide, quinidine
Acute lung injury or pleural effusion	Imatinib, dasatinib
Pulmonary hypertension	Dasatinib, methamphetamine

Table 4-17 shows drugs known to cause lung disease. Figure 4-37 shows common lung toxicities.

Table 4-17. Specific Drug Associations

Drug	Presentation	Histopathology	Imaging	Comments
Amiodarone	Older patients; higher risk when dose is > 400 mg/d for > 6 mo	Foamy macrophages with fibrosis, lamellated inclusions	Fibrosis, BOOP, mass lesions with or without cavitation, effusions	Half-life: 30–60 d Trial of steroids > 6 mo
Nitrofurantoin	Acute vs. chronic Women >> men	Acute: hypersensitivity pneumonitis, OP, cellular NSIP Chronic: NSIP	NSIP pattern, no zonal predominance	Steroids used in severe cases

Table 4-17. Specific Drug Associations, continued

Drug	Presentation	Histopathology	Imaging	Comments
5-ASA/ sulfasalazine	Pneumonitis, fever, rash = sulfasalazine	Pulmonary eosinophilia, OP, BO	NSIP, OP pattern	Toxicity: Sulfasalazine > 5-ASA; eosinophilia
Methotrexate	Not related to intensity of therapy Acute vs. subacute vs. chronic presentation	Hypersensitivity pneumonitis, NSIP, OP	OP, NSIP, AIP pattern	Eosinophilia occasionally seen; rarely associated with NHL
Busulfan	Used for CML therapy and HCT induction Subacute vs. chronic presentation	Pneumocyte dysplasia, typical bronchial lining cells	NSIP pattern	Bronchoscopy rarely shows PAP
Bleomycin	Various times of presentation	Hypersensitivity pneumonitis, DAD, NSIP, UIP	Hypersensitivity pneumonitis, ALI, NSIP, UIP	Avoid high O_2 delivery to avoid pulmonary toxicity
Imatinib/ dasatinib	Acute vs. subacute	Noncardiogenic pulmonary edema or AIP	ALI, pleural effusions	Rare PAH from dasatinib
Interferon	Pneumonitis potentially life-threatening	Sarcoidosis, ALI, OP	ALI, pleural effusions, OP	Early discontinuation if evidence of pneumonitis
IVDU	Acute and chronic sequelae	Foreign body granulomatosis, ALI	Septic emboli, DAH, bullae, cardiogenic/non-cardiogenic pulmonary edema	CAP risk increased 10 x PAH risk increased
Radiation therapy	Subacute (4–12 wk) to chronic (6–12 mo).	OP, NSIP	Ground-glass opacities, OP, or NSIP; often confined to a region	Distribution may follow the “radiation port” but not applicable to SBRT, gamma knife, 3D-CRT Steroids in nonfibrotic phase, often over 12 wk

3D-CRT, 3D conformal radiation therapy; 5-ASA, mesalamine; AIP, acute interstitial pneumonitis; ALI, acute lung injury; BO, bronchiolitis obliterans; BOOP, bronchiolitis obliterans with organizing pneumonia; CAP, community-acquired pneumonia; CML, chronic myeloid leukemia; DAD, diffuse alveolar damage; DAH, Diffuse alveolar hemorrhage; HCT, histocompatibility test; IVDU, intravenous drug use; NHL, non-Hodgkin’s lymphoma; NSIP, nonspecific interstitial pneumonia; OP, organizing pneumonia; PAH, pulmonary arterial hypertension; SBRT, stereotactic body radiation therapy; UIP, usual interstitial pneumonia



A B



C

Figure 4-34. Common lung toxicities. (A) Amiodarone toxicity. (B) Bleomycin toxicity. (C) Inhaled cellulose particulate: polarized.
(Reproduced, with permission, from Dr. Joseph F. Tomashefski, Jr., MetroHealth Medical Center, Case Western Reserve University.)

Clinical Findings

Examination findings, labs, pulmonary function test results, and imaging assist with the diagnosis, but the findings are not diagnostic. A high index of suspicion arises with a thorough review of medication exposure history.

Treatment

Treatment is focused on drug discontinuation. Often, this alone leads to resolution of symptoms. Steroids are rarely efficacious.

Occupational and Environmental Lung Diseases

PNEUMOCONIOSES

These diseases are related to mineral dust exposure and are summarized in Table 4-18.

Table 4-18. Clinical Characteristics of the Most Common Pneumoconiosis

Type	Occupations	Presentation	Radiology	Pathology
Silicosis	Sandblasting, tunneling, drill operation, digging, glass manufacturing, hard rock mining, oven-brick making, stone cutting, masonry, foundry work, natural gas extraction via hydraulic fracturing, sandy and dry soil agriculture	**Chronic:** 10–30 y after exposure **Accelerated:** < 10 y after exposure **Acute**: Weeks to 4–5 y after exposure, usually after exposure to high concentrations of fine respirable crystalline silica	**Simple silicosis:** Mid-upper lung zone nodules (< 1 cm) (Fig. 4-35) **Progressive massive fibrosis:** Coalescence of lung nodules (> 1 cm) (eggshell calcification may be seen); upward hilar retraction; lower lobe hyperinflation (Fig. 4-36) **Acute**: Mid-lower lung zone ground-glass opacities with consolidation (batwing distribution). HCRT: Interlobular septal thickening with ground-glass opacities	**Early:** Peribronchovascular, paraseptal, and subpleural dust-laden macrophages **Silicotic nodule:** Concentric collagen fibers around a hyaline center (Fig. 4-37) **Acute:** Alveolar filling with proteinaceous material (phospholipids and surfactant), periodic acid–Schiff positive
Coal workers'	Coal mining	**Chronic bronchitis:** Most common **Simple:** > 20 y after exposure **Accelerated or Complicated**: < 10 y after exposure	**Simple:** Upper-lobe-predominant nodules (< 1 cm) **Progressive massive fibrosis:** Similar to silicosis, with associated lower lobe emphysema	**Coal macule:** Focal collection of coal dust in pigment-laden macrophages **Caplan nodule:** Focal lesion with necrotic center surrounded by lymphocytes and plasma cells **Centrilobular emphysema**

Table 4-18. Clinical Characteristics of the Most Common Pneumoconiosis, continued

Type	Occupations	Presentation	Radiology	Pathology
Asbestosis	Pipefitters, steamfitters, electricians, insulation workers, boilermakers, welders, construction workers and shipbuilders; plastic and rubber manufacturing workers; yarn, thread, or fabric millworkers; truckers and railway workers; and those who work with brakelining or cement	10–40-y latency period. **Pleural disease:** benign asbestos pleural effusion, plaques with calcification	**Chest x-ray:** Lower-lobe-predominant reticular or multinodular opacities (may be normal) (Fig. 4-38) **HRCT:** Subpleural lines; parenchymal and interlobular septal fibrosis; honeycombing; pleural plaques (Fig. 4-39)	**Ferruginous bodies (asbestos bodies):** Large asbestos fibers coated with iron from hemosiderin (Fig. 4-40) **Asbestos fibers:** Small uncoated asbestos fibers of different forms within macrophages (Figs. 4-41 and 4-42)
Beryllium	Aerospace, aircraft, and alloy production; automotive, ceramics, defense, dental and prosthetics, electronics, nuclear, recycling of electronics and computers; and telecommunications	**Acute:** Rare; pneumonitis, tracheobronchitis, nasopharyngitis **Chronic:** Latency period of 3 mo–40 y (average, 10 y). Dyspnea, cough, fever, night sweats, fatigue, weight loss	**Chest x-ray:** Upper-lobe-predominant reticulonodular changes, hilar and mediastinal LAD **HRCT:** Parenchymal nodules, septal thickening, ground-glass, opacities, hilar and mediastinal LAD (Fig. 4-43)	Noncaseating granulomas.

HRCT, high-resolution computed tomography scan; LAD, lymphadenopathy; PAS, periodic acid-Schiff reagent

Flash Card Q12

Which interstitial lung disease resembles acute silicosis histologically and on imaging?

Silicosis

Silicosis includes a spectrum of lung disease caused by inhalation of free crystalline silica (silicon dioxide). It is characterized by progressive development of parenchymal nodules and fibrosis (Figures 4-35 and 4-36) and is the most prevalent chronic occupational lung disease worldwide.

Silicosis increases the risk of several conditions and may be complicated by:

- Mycobacterial and fungal infection, which is suspected if cavitation develops
- Lung cancer, which has been associated with bronchogenic carcinoma
- Chronic bronchitis and airflow obstruction due to airway narrowing and distortion from nodules
- Connective tissue diseases, including scleroderma and rheumatoid arthritis, which are the most common, and also vasculitis



Figure 4-35. Chest x-ray of a patient with silicosis showing upper-lobe-predominant nodular changes with lower lobe hyperinflation.
(Image courtesy of James Ravenel, MD, Medical University of South Carolina.)

Flash Card A12

Secondary pulmonary alveolar proteinosis, which causes alveolar filling with proteinaceous material that consists mostly of phospholipids and surfactant, staining with periodic acid–Schiff reagent (silicoproteinosis). Other exposures with similar findings are aluminum, silica, titanium, cement, insulation, sawdust, paint, varnish, chlorine, nitrogen dioxide, and fertilizer.



Figure 4-36. Chest x-ray of a patient with progressive massive fibrosis caused by silicosis showing coalescence of lung nodules, hilar retraction (*arrow*), and low lung volumes.
(Image courtesy of James Ravenel, MD, Medical University of South Carolina.)



Figure 4-37. Histologic section of a silicotic nodule showing dense collagen (*black arrow*) and several hyaline centers (*red arrow*).
(Reproduced courtesy of Yale Rosen, flikr.com, CC BY-SA 2.0)

Flash Card Q13

Which autoimmune disease is associated with Caplan syndrome?

Flash Card Q14

Which pneumoconiosis is associated with melanoptysis?

Coal Workers' Pneumoconiosis

Key Fact

Anthracosis is the accumulation of coal dust within the lungs. It is often asymptomatic and can be seen in people living in large urban areas where there is significant air pollution.

Also known as *black lung,* coal workers' pneumoconiosis is caused by inhalation and deposition of coal dust. Coal dust is a mixture of carbon, oxygen, nitrogen, crystalline silica, and trace elements, which may include boron, cadmium, nickel, iron, antimony, lead, and zinc. It is formed by the accumulation of vegetable matter subjected to pressure and temperature over the ages.

Asbestosis

Flash Card A13

Rheumatoid arthritis. Caplan syndrome is a nodular reaction that occurs in individuals exposed to coal dust who also have rheumatoid arthritis or who will have rheumatoid arthritis within the next 5–10 years. The nodules can vary in diameter (0.5–5.0 cm) and are usually multiple, bilateral, and peripherally located. They contain a necrotic center surrounded by lymphocytes and plasma cells and a very small amount of coal dust.

Asbestosis is caused by inhalation of asbestos fibers. Asbestos is a naturally occurring hydrated silicate mineral characterized by resistance to heat and degradation. These properties have been exploited in various industries, particularly insulation. Asbestosis is characterized by diffuse interstitial fibrosis, commonly in a symmetrical pattern (Figure 4-38 and 4-39). There are two types of asbestos fibers: serpentine and amphiboles (Table 4-19) (Figures 4-40 through 4-42). There is a long latency period (15–40 years) from initial exposure to development of disease. Pleural involvement distinguishes asbestosis from idiopathic pulmonary fibrosis. The two most commonly associated complications are respiratory failure and malignancy (bronchogenic carcinoma is most common). The most common pleural and pulmonary manifestations of asbestos exposure are summarized in Table 4-20.

Flash Card A14

Coal workers' pneumoconiosis. Melanoptysis is the expectoration of black sputum containing carbonaceous particles. It occurs when a conglomerate of nodules cavitates and ruptures into the airway. Melanoptysis has also been reported with freebase cocaine smoking, malignant melanoma, and aspergilloma caused by *Aspergillus niger*, as well as in progressive massive fibrosis caused by silicosis.

Table 4-19. Characteristics of Asbestos Fibers[a]

Fiber	Shape	Structure	Pathology	Malignancy Risk
Serpentine (chrysotile) (Fig. 4-41)	Curly stranded	Curved	Easily degraded by macrophages	Low
Amphibole (crocidolite, amosite, anthophyllite, tremolite-actinolite) (Fig. 4-42)	Rod-like	Straight	Insoluble, virtually not degradable by macrophages; more durable	High

[a]Long fibers are more carcinogenic than short ones.



Figure 4-38. Chest x-ray of a patient with asbestosis showing lower-lobe-predominant reticulonodular opacities. Notice the pleural plaque on the right diaphragm (*arrow*).
(Image courtesy of James Ravenel, MD, Medical University of South Carolina.)



Figure 4-39. Computed tomography scan of a patient with asbestosis showing lower-lobe-predominant parenchymal and interlobular septal fibrosis. Notice the calcified pleural plaque on the right (*arrow*).
(Image courtesy of James Ravenel, MD, Medical University of South Carolina.)



Figure 4-40. Asbestos (ferruginous) bodies. Notice the large size and the coating with iron.
(Reproduced courtesy of the Ospedale San Polo, Monfalcone, Italy, Wikimedia Commons, CC BY-SA 3.0.)



Figure 4-41. Electron microscopic image of chrysotile asbestos. Notice the curved appearance characteristic of serpentine fibers.
(Image courtesy of the U.S. Geological Survey of the U.S. Department of the Interior. Reproduced from http://usgsprobe.cr.usgs.gov/picts2.html.)

Figure 4-42. Electron microscopic image of anthophyllite asbestos. Asbestos fibers are rarely seen by light microscopy, are smaller than asbestos bodies, and are not coated with iron. Notice the straight, rod-like appearance characteristic of amphiboles.
(Image courtesy of the U.S. Geological Survey of the U.S. Department of the Interior. Reproduced, from http://usgsprobe.cr.usgs.gov/picts2.html.)

Table 4-20. Pleural and Pulmonary Manifestations of Asbestos Exposure

Condition	Latency	Presentation	Radiology	Pathology
Benign asbestos pleural effusion	Shortest of all, < 1 y to > 40 y	Asymptomatic in two thirds; pleurisy and dyspnea	Usually unilateral, costophrenic angle blunting	Exudative effusion; eosinophilic, bloody; can resolve spontaneously; low malignancy risk
Pleural plaques	Most common; found in up to 50% of exposed individuals; 10–40 y	Asymptomatic; incidental finding on imaging	Parietal pleural thickening in the mid-lower ribs and diaphragm; often bilateral; calcification over time	Fibrosis of the parietal pleura; no evidence of malignancy risk
Pleural fibrosis	> 20 y	Asymptomatic; incidental finding on imaging; restriction on pulmonary function testing	Diffuse visceral pleural thickening; usually unilateral	Concomitant with asbestosis; considered direct extension of parenchymal fibrosis
Visceroparietal reactions ("rounded atelectasis")	> 20 y	Asymptomatic; incidental finding on imaging	Pleural-based "mass-like" lesion with hilar structure ("comet tail" sign) (Fig. 4-43)	Local visceral and parietal pleural self-invagination, trapping underlying lung; no evidence of malignancy risk
Asbestosis	10–40 y	Dyspnea; basal crackles	See Table 4-18 .	Asbestos bodies and fibers; lower-lobe-predominant subpleural fibrosis; evidence of malignancy risk (bronchogenic carcinoma)
Bronchogenic carcinoma[a]	10–40 y	Asymptomatic; weight loss, dyspnea, cough	Lung nodule or mass	Induced oncogenic expression leading to abnormal tumor cell proliferation
Mesothelioma[b]	≥ 15 y	Chest pain, dyspnea, cough	Unilateral parietal pleural mass, nodularity, or thickening with pleural effusion; volume loss right > left side	Parietal nodules leading to thickening, visceral pleural coalescence, and lung encasement

[a]Other nonpulmonary malignancies associated with asbestos include laryngeal, pharyngeal, gastric, colorectal, biliary, and renal cancer.

[b]Tumor markers that may be elevated and measured include soluble-mesothelin related peptides (SMRP), fibulin-3, and osteopontin.

Key Fact

There is a multiplicative risk of lung cancer in patients who are exposed to asbestos and smoke cigarettes. The relative risk of cigarette smokers with asbestos exposure is nearly 60.



Figure 4-43. Computed tomography scan of a sheet metal worker showing a left pleural-based mass consistent with rounded atelectasis (*red arrow*). Notice the self-invagination and trapping of lung parenchyma as well as the hilum or "comet tail" (*yellow arrow*).
(Reproduced, with permission, from American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. *Am J Respir Crit Care Med.* 2004; 170: 694. doi: 10.1164/rccm.200310-1436ST.)

Beryllium Disease

Beryllium is a light metal used in many high-technology industries. Exposure causes granulomatous lung disease (Figure 4-44). Beryllium lung disease induces a cell-mediated or delayed hypersensitivity reaction that leads to granulomatous inflammation. Pathologically, chronic beryllium disease and sarcoidosis are almost indistinguishable. Documenting exposure to beryllium is an important clue to distinguish between the two.



Figure 4-44. Computed tomography scan of a patient with berylliosis showing hilar and mediastinal lymphadenopathy (*red arrow*), interlobular septal thickening (*yellow arrow*), subpleural nodules, and nodularity along the bronchovascular bundles (*black arrow*).
(Image courtesy of James Ravenel, MD, Medical University of South Carolina.)

Talcosis

Talcosis results from exposure to hydrated magnesium silicate. Talc is used in the cosmetic, ceramic, chemical, and pharmaceutical industries. Major exposures occur after inhalation of heavy amounts of baby powder or in drug users who inject or inhale crushed tablets.

Chest x-ray may show fibrosis, nodular lung disease, and lower lobe emphysema. Talc granulomas, characterized by multinucleated giant cells, may occur in the interstitium and pulmonary arteries in intravenous drug users. These granulomas may produce pulmonary hypertension and cor pulmonale and show birefringent talc crystals (Figure 4-45).



Figure 4-45. Low-magnification micrograph showing granulomas (*arrow*) in an intravenous drug user with crystals consistent with talc. Talc crystals are birefringent under polarizable light (bright white, not shown).
(Reproduced courtesy of Nephron, Wikimedia Commons, CC BY-SA 3.0.)

Key Fact

Giant odd-appearing multinucleated cells (i.e., cannibalistic cells) can be seen in patients exposed to cobalt. This is also known as giant cell interstitial pneumonitis (Figure 4-49).

Hard Metal Lung Disease

Hard metal lung disease occurs after exposure to hard metals, of which the most common is cobalt. Occupations associated with cobalt exposure include machinist, metal toolmaker, polisher, grinder, saw sharpener, and dental driller. The following may occur:

- Obstructive airways disease
- Acute interstitial pneumonitis
- Diffuse fibrosis

Flash Card Q15

What blood or bronchoalveolar lavage test is used to assist in diagnosing chronic beryllium disease?



Figure 4-46. Histology slide shows peribronchiolar fibrosis (*arrow*) and inflammation, with giant cells in the airspace. Cobalt and tungsten are the most common hard metals associated with giant cell interstitial pneumonia.
(Reproduced courtesy of Yale Rosen, flickr.com, CC BY-SA 2.0)

HYPERSENSITIVITY PNEUMONITIS

Also known as extrinsic allergic alveolitis, hypersensitivity pneumonitis is an immunologic-induced syndrome (believed to be caused by a combined type III and type IV reaction) that results in diffuse mononuclear cell inflammation of the small airways and pulmonary parenchyma after exposure to a wide variety of inhaled antigens (Figures 4-47 and 4-48). These antigens include organic dust (bioaerosols, avian proteins, fungi, thermophilic bacteria) as well as low-molecular-weight volatile and nonvolatile chemical compounds (Table 4-21). The clinical, radiologic, and pathologic findings are similar, despite the wide range of identified antigens.

Flash Card A15

Beryllium lymphocyte proliferation test



Figure 4-47. Low-magnification slide (hematoxylin-eosin-stained) of a patient with chronic hypersensitivity pneumonitis showing an interstitial mononuclear inflammatory infiltrate with airway-centered inflammation. There are two multinucleated giant cells on the left (*arrow*).
(Reproduced courtesy of Mutelysmith, Wikimedia Commons, CC BY-SA 3.0.)

Table 4-21. Examples of Etiologic Agents of Hypersensitivity Pneumonitis

Disease	Antigen	Exposure
Farmer's lung	*Faenia rectivirgula* (bacteria)	Moldy hay, grain, silage
Humidifier lung; air conditioner lung; ventilation pneumonitis	*Thermoactinomyces vulgaris* (bacteria)	Contaminated forced-air systems; water reservoirs
Bagassosis	*T. vulgaris* (bacteria)	Moldy sugar cane (bagasse)
Malt worker's lung	*Aspergillus clavatus* (fungi)	Moldy barley
Maple bark stripper's lung	*Cryptostroma corticale* (bacteria)	Moldy maple bark
Cheese washer's lung	*Penicillium casei* (bacteria)	Moldy cheese
Suberosis	*Thermoactinomyces viridis* (bacteria)	Moldy cork
Paprika slicer's lung	*Mucor stolonifer* (fungi)	Moldy paprika pods
Pigeon breeder's or fancier's disease	Avian droppings, feathers, serum	Parakeets, pigeons, chickens, turkeys



Figure 4-48. High-magnification slide (trichome stain) showing granulomatous inflammation in a patient with hypersensitivity pneumonitis.
(Reproduced courtesy of Nephron, Wikimedia Commons, CC BY-SA 3.0)

Table 4-22 shows the clinical features and classification of hypersensitivity pneumonitis. Pulmonary function tests may show restriction, obstruction, or a mixed pattern with reduced DLCO. Treatment often includes removal from exposure to the offending antigen and in some cases corticosteroids. Cigarette smoking reduces risk**.**

Table 4-22. Clinical Features and Classification of Hypersensitivity Pneumonitis

Type	Onset	Features	Radiology	Pathology
Acute	4–8 h after heavy exposure	Fever, chills, malaise, dyspnea, fine crackles (may be mistaken for viral, atypical, or flu-like illness)	Chest x-ray findings may be normal. HCRT shows diffuse or patchy ground-glass attenuation	Poorly formed, noncaseating granulomas; peribronchial mononuclear cell infiltration
Subacute or intermittent	Gradual or repeated exposure	Cough, dyspnea, fatigue, weight loss, diffuse crackles	Chest x-ray shows micronodular opacities HRCT shows centrilobular ground-glass nodules, focal air trapping (Fig. 4-49)	More well formed, but loose and poorly arranged noncaseating granulomas; bronchiolitis with or without organizing pneumonia
Chronic	Often without a history of acute or subacute episodes	Cough, dyspnea, fatigue	Chest x-ray shows a reticular pattern with honeycombing, fibrosis, and volume loss HRCT shows nodules, ground-glass opacities, and honeycombing (Fig. 4-50)	Loose and poorly arranged noncaseating granulomas with mononuclear alveolitis in the presence of fibrosis with thick alveolar septa

Key Fact

Bronchoalveolar lavage fluid from patients with hypersensitivity pneumonitis is characterized by an elevated percentage of lymphocytes, typically > 50%. There is proliferation of $CD8^+$ T-lymphocytes, resulting in inversion of the CD4/CD8 ratio.



Figure 4-49. Computed tomography scan of a patient with subacute hypersensitivity pneumonitis showing centrilobular ground-glass opacities (*arrows*) in an upper-lobe-predominant distribution.
(Reproduced courtesy of James Ravenel, MD, Medical University of South Carolina.)

Flash Card Q16

What are the characteristic pathologic changes of hypersensitivity pneumonitis?



Figure 4-50. Computed tomography scan of a patient with chronic hypersensitivity pneumonitis showing honeycombing (*red arrow*), ground-glass opacities (*white arrow*), and nodular upper-lobe-predominant changes.
(Reproduced courtesy of James Ravenel, MD, Medical University of South Carolina.)

TOXIC GASES AND FUMES

Inhalation of gases, certain organic antigens, and fumes can result in immediate (hyperacute) cytokine release without consequent lung injury, acute irritant lung injury with or without alveolar damage, or subacute lung parenchymal disease. Exposure to these gases and fumes does not result in hypersensitivity pneumonitis. A summary of these toxic gases and fumes based on mechanism of action is shown in Table 4-23.

Flash Card A16

Cellular bronchiolitis or airway-centered inflammation, an interstitial mononuclear cell infiltrate, and small, poorly formed nonnecrotizing granulomas. Conditions that may appear similar on biopsy include sarcoidosis (well-formed granulomas), other granulomatous infections (i.e., tuberculosis, fungal diseases), UIP, fibrosing NSIP, organizing pneumonia, and drug-induced lung disease.

Table 4-23. Toxic Gases and Fumes

Mechanism	Agent(s)	Related exposure	Presentation	Radiology
Cytokine-mediated reaction with no lung injury (massive inhalation)	Metal fume fever (zinc oxide)	Welding (galvanization), brass work	4–8 h after intense inhalation; flu-like symptoms (fevers, chills, malaise, headache, myalgias), dyspnea and cough; self-limited; resolves in 12–48 h	No radiographic changes
	Organic dust toxic syndrome, thermophilic bacteria, and fungal spores	Contaminated grains, moldy hay, silage, flour, textile materials, wood chips		

Table 4-23. Toxic Gases and Fumes, continued

Mechanism	Agent(s)	Related exposure	Presentation	Radiology
Acute irritant lung injury and diffuse alveolar damage (inorganic, low water solubility)	Chlorine, chloramine	Industrial leaks, transport leaks, swimming pool chemicals, household cleaning products, pulp and paper processing	Mild eye, nose, and throat airway mucosal symptoms; acute dyspnea, respiratory failure; bronchiolitis (with or without obliterans) may develop 2–6 wk later	Airspace opacities; noncardiogenic edema; ground-glass opacities with metals
	Nitrogen dioxide, ozone, acid aerosols, phosgene	Silo filler's disease (nitrogen dioxide), explosive detonations (nitrogen oxides), welding (ozone and phosgene)		
	Metals (cadmium, mercury, nickel carbonyl)	Welding, brazing, flame-cutting (cadmium); equipment electronic recycling (mercury); nickel refining		
Acute irritant lung injury and diffuse alveolar damage (organic, low water solubility)	Fire eater's lung (hydrocarbon)	Flame-blowing performances (ingestion)	Acute dyspnea, respiratory failure; bronchiolitis (with or without obliterans) 2–6 wk later; gastrointestinal symptoms precede pulmonary edema with paraquat (oxygen may worsen paraquat lung injury)	Airspace opacities; noncardiogenic edema
	Paraquat	Ingestion		
	Popcorn worker's lung (diacetyl butanedione)	Flavor industry worker (inhalation)		
Acute irritant lung injury and diffuse alveolar damage (gas mixture, low water solubility)	Smoke inhalation (fire smoke, pyrolysis from plastics, aldehydes acrolein)	Firefighting, incineration, inhalation within a closed or confined space	Eye, nose, and throat irritation; dyspnea, respiratory failure; bronchiolitis	Airspace opacities; noncardiogenic edema

Flash Card Q17

What properties of toxic gases and fumes determine their pattern of lung injury?

Table 4-23. Toxic Gases and Fumes, continued

Mechanism	Agent(s)	Related exposure	Presentation	Radiology
Acute irritant lung injury and diffuse alveolar damage (high water solubility)	Ammonia, chlorine, sulfur dioxide	Farming, refrigeration and cleaning solutions (ammonia); bleaching, disinfectant, plastics (hydrogen chlorine); mining and cement (sulfur dioxide)	Acute eye, nose, and throat irritation; respiratory failure; bronchiolitis (with or without obliterans) 2–6 wk later	Airspace opacities; noncardiogenic edema
Lung parenchymal disease	Flock worker's lung (nylon)	Textile manufacturing	Dyspnea progressing to interstitial lung disease over months to 1 y (usually nonspecific interstitial pneumonia or organizing pneumonia)	Reticulonodular or patchy opacities; peripheral alveolar consolidation and honeycombing
	Ardystil (Acramin FWR/FWN)	Textile printing sprayers		

WORK-RELATED ASTHMA

Work-related asthma is described as asthma that is exacerbated (work-exacerbated asthma) or induced (occupational asthma) by inhalation exposures in the workplace.

Occupational Asthma

Flash Card A17

Water solubility, duration of exposure, and depth of inhalation. For example, more water-soluble gases such as chlorine cause more upper-airway irritation and symptoms than less water-soluble agents such as nitrogen dioxide, which cause more small airways disease and alveolar damage.

Occupational asthma is de novo asthma or recurrence of previously quiescent asthma induced by sensitization to a specific substance or chemical at work (sensitizer-induced asthma) or by exposure to an inhaled irritant at work (irritant-induced asthma). Table 4-24 shows the characteristics that distinguish sensitizer-induced occupational asthma from irritant-induced occupational asthma.

Table 4-24. Occupational Asthma

Characteristic	Sensitizer-Induced Asthma	Irritant-Induced Asthma[a]
Latency period	Present	Absent
Onset	Within months to years	Within minutes or hours (< 24 h)
Causative agents	Complete antigens: Inhaled proteins (high molecular weight > 10 kd). Incomplete antigens (haptens): Chemicals (low molecular weight < 10 kd).	Fumes, gases, smoke, vapors
Examples of causative agents	Complete antigens: Animal and plant proteins, enzymes, flour, and cereals. Incomplete antigens: Isocyanates, anhydrides, metals, drugs, dyes and bleaches, amines, glues and resins, and wood dust.	Chlorine gas, aldehydes, alkaline dusts, bleaching agents, cleaning products (ammonia), accidental spills, smoke from fires
Immunologic response	Yes	No
Diagnosis	Step 1: Confirm asthma diagnosis (spirometry and assessment for airflow reversibility). Perform methacholine challenge test if no airflow reversibility is present (positive if 1-second forced expiratory volume falls > 20% with ≤ 4 mg/mL).	Step 2: Establish occupational relationship (serial peak flows, spirometry, nonspecific bronchoprovocation after workplace exposure, skin tests, immunoassay). Step 3: If diagnosis is still unclear, then consider specific inhalation challenge in a safe and controlled fashion (considered a reference standard, offered in a few specialized centers).
Pathology	Similar to asthma	Acute: Epithelial sloughing and hemorrhage. Chronic: Epithelial cell regeneration; increased basement membrane thickness due to collagen deposition.
Clinical presentation	Symptoms while at work; improvement on weekends or during vacations; rhinoconjunctivitis, contact dermatitis	Precise timing of symptom onset is common. Burning sensation occurs in throat and nose.

[a]The most common form of irritant-induced occupational asthma is reactive airways dysfunction syndrome.

Key Fact

Reactive airways dysfunction syndrome is a type of irritant-induced occupational asthma that occurs after exposure to high doses of a single irritant.

Work-Exacerbated Asthma

Work-exacerbated asthma is triggered by various work-related factors in those with known preexisting or concurrent asthma.

HIGH ALTITUDE AND AIR TRAVEL

High Altitude

With high altitude, barometric pressure and partial pressure of inspired oxygen decrease. Acclimatization is the compensatory response to high altitude and low inspired oxygen that occurs in different organ systems to minimize the effects of hypoxia.

The most important acclimatization changes in the body at high altitude are shown in Table 4-25.

Table 4-25. Physiologic Changes During Acclimatization to High Altitude

Adaptation	Physiologic Change
Ventilation	Hyperventilation, respiratory alkalosis
Brain	Hypoxia-induced vasodilatation Hypocapnia-induced vasoconstriction Constant cerebral blood flow
Kidneys	↑ bicarbonate excretion (normalization of pH); erythropoietin production
Heart	↑ blood pressure; ↑ cardiac output and heart rate (transient); ↓ SV (bicarbonate diuresis and intravascular fluid shift)
Pulmonary vasculature	Hypoxia-induced vasoconstriction (hypertension)
Hematologic	↑ hemoglobin production (increases oxygen-carrying capacity); red cell mass increased in 10–14 d
Oxyhemoglobin dissociation curve	Leftward shift due to alkalosis (improved binding at alveolar-capillary membrane)

HIGH-ALTITUDE ILLNESS—Three conditions occur after rapid ascent to high altitude where there is hypobaric hypoxia: acute mountain sickness, high-altitude pulmonary edema, and high-altitude cerebral edema (Table 4-26). Figure 4-51 shows the altitudes at which these conditions commonly occur.

Table 4-26. Types of High-Altitude Illness

Type	Mechanism	Symptoms	Treatment	Prevention
Acute mountain sickness	Hypoxia-induced cerebral edema	Headache, dizziness, fatigue, malaise, anorexia, nausea, vomiting, insomnia	Mild: Conservative[a] Moderate-severe: Descent, oxygen, hyperbaric therapy, acetazolamide,[b] dexamethasone	Acetazolamide, dexamethasone
High-altitude pulmonary edema	Hypoxic pulmonary vasoconstriction leading to capillary stress fractures; results in noncardiogenic pulmonary edema	Nonproductive cough, progressive dyspnea, pink frothy sputum	Nonpharmacologic: Oxygen, descent, hyperbaric therapy Pharmacologic: Nifedipine, tadalafil, or sildenafil	Nifedipine, tadalafil, sildenafil, dexamethasone, salmeterol
High-altitude cerebral edema	More severe form of hypoxia-induced cerebral edema than acute mountain sickness	Headache, ataxia, confusion, hallucinations, stupor, coma	Descent Other: Dexamethasone, oxygen, hyperbaric therapy	Acetazolamide, dexamethasone

[a]Includes aspirin, acetaminophen, and ibuprofen for headache; promethazine and ondansetron for nausea and vomiting; and avoidance of alcohol or other central nervous system depressants. [b]Contraindicated in patients with known sulfa allergies.

Air Travel

Figure 4-51 shows normal cabin pressure and usual flying altitudes for commercial aircraft. At the usual cabin pressure, the fraction of inspired oxygen is equivalent to 15.1% of the value at sea level.

Contraindications to air travel:

- Recent acute coronary syndrome (within 1–3 weeks) unless low or very low risk
- Coronary artery bypass surgery within 2 weeks
- Stroke within 2 weeks
- Severe sinusitis, large obstructing polyps, or nasal or facial surgery within 1–2 weeks

Flash Card Q18

Which transcription factor is responsible for most of the adaptive changes that occur during acclimatization?

- Any pneumothorax within two weeks
- Hemoptysis
- Unstable chronic obstructive pulmonary disease, asthma, or a sea level oxygen requirement > 4 L/min
- Single, uncomplicated diving within 12 hours, multiple dives, or a dive requiring more than one decompression stop within 2 days
- Retinal detachment surgery with gas bubble

Key Fact

Factors associated with very low risk in patients with coronary artery syndromes include age < 65 years, ejection fraction > 45%, first event, and no complications or further planned interventions. These patients may fly as soon as 3 days after the event. Low-risk patients, those with no symptoms and ejection fraction > 40%, may fly as soon as 10 days after the event.

Most patients already receiving home oxygen supplementation need a higher flow of oxygen at cruising altitude. Several regression equations predict whether PaO_2 will decrease to > 50 mm Hg while flying, but they have not been validated. Another method of predicting in-flight PaO_2 is the hypoxia inhalation test or high-altitude simulation test. A 15.1% oxygen concentration with nitrogen mixture is given via a tight-fitting mask, and pulse oximetry is continuously recorded. An arterial blood gas sample is obtained after 20 minutes. If oxygen saturation remains 88% or greater and PaO_2 is > 55 mm Hg, then no supplemental oxygen is required. If oxygen saturation is < 85% and PaO_2 is < 50 mm Hg, then supplemental oxygen is recommended.

Key Fact

Air travel should be avoided until 7 days after radiographic resolution of pneumothorax.


CABIN PRESSURE – 8,000 ft (2,440 m)
10,000–12,000 ft (3,000–12,200 m)
MOUNT EVEREST – 29,029 ft (8,848 m)
P_aO_2 250 mmHg
> 9,022 ft (2,750 m) HIGH-ALTITUDE CEREBRAL EDEMA
TO REDUCE SYMPTOMS:
DESCEND > 984 ft (> 300 m)
> 8,500 ft (2,590 m) HIGH-ALTITUDE PULMONARY EDEMA
> 8,000 ft (2,440 m) ACUTE MOUNTAIN SICKNESS
SEA LEVEL – 0 ft (0 m)
P_aO_2 760 mmHg
DECOMPRESSION SICKNESS
NITROGEN NARCOSIS, OXYGEN TOXICITY
BAROTRAUMA

Figure 4-51. Air travel, high-altitude, and diving-related conditions.
(Reproduced, with permission, from Isabel Bonenfant.)

Flash Card A18

Hypoxia-inducible factor-1α stimulates vascular endothelial growth factor, which itself stimulates angiogenesis and nitric oxide synthesis. These changes result in greater blood flow and oxygen delivery to tissues.

DIVING

Table 4-27 shows the most common complications of diving. Figure 4-51 shows the complications of barotrauma, nitrogen narcosis, oxygen toxicity, and decompression sickness.

Barotrauma

Barotrauma is the most common diving-related injury. It occurs when air-filled cavities within the body do not equilibrate their pressure with the environment after changes in ambient pressure. It can occur during both descent and ascent.

Decompression Sickness

With descent, tissues become loaded with increased quantities of oxygen and nitrogen. On ascent, the tension of the gases in the tissues may exceed ambient pressure and lead to liberation of free gas from the tissues in the form of bubbles. The bubbles may cause vascular obstruction, rupture vessels, or compress the underlying tissue. This results in inflammation and clotting.

Key Fact

Air travel after diving should be postponed for at least 12 hours in patients who have dived once per day. For those who have dived multiple times or have required decompression stops, flying should be postponed for at least 48 hours.

Nitrogen Narcosis

Nitrogen narcosis results from the increased partial pressure of nitrogen in nervous system tissue, occurring at depths > 100 ft (30.5 m). Alcohol, hypercarbia, hypothermia as a result of cold water, and fatigue increase the risk of nitrogen narcosis. Descent to depths > 300 feet (91 m) can result in loss of consciousness.

Flash Card Q19

In diving medicine, which gas law explains the pathophysiology of most types of barotrauma?

Flash Card Q20

Which gas law explains the pathophysiology behind decompression sickness and nitrogen narcosis?

Table 4-27. Complications of Diving Medicine

Type	Mechanism	Symptoms and Signs	Treatment	Prevention
Extra-alveolar air syndromes (pneumomediastinum, pneumothorax, arterial gas embolism)	Barotrauma (during ascent) as a result of alveolar rupture **Pneumomediastinum:** Gas dissects along the perivascular and then the bronchovascular sheath toward the mediastinum **Pneumothorax*:*** Gas ruptures from the lung parenchyma into the pleural space **Arterial gas embolism:** Gas bubbles into the pulmonary veins and then the systemic circulation	**Pneumomediastinum:** Chest fullness, pleuritic chest pain, hoarseness, dysphagia; crepitation; Hamman's sign[a] **Pneumothorax*:*** Tension with cardiovascular collapse; dyspnea, chest pain, tachycardia, hypotension, neck vein distention, tracheal deviation, hyperresonance to percussion, decreased breath sounds **Arterial gas embolism**: Myocardial infarction, cerebral infarction with motor, sensory, or visual deficits	**Pneumomediastinum*:***100% oxygen to promote reabsorption **Pneumothorax*:*** Needle decompression if tension; chest tube insertion **Arterial gas embolism:**100% oxygen; hyperbaric oxygen therapy	Avoid breath-holding during ascent
Ear and sinus barotrauma	Barotrauma (during descent) **Ear:** Eustachian tube occlusion leading to failure of the middle ear to equilibrate pressure **Sinus:** Mucosal engorgement and edema leading to blocked sinus ostia	Ear ("squeeze"): Pain and pressure, hearing loss, tympanic membrane rupture leading to vertigo, nausea, and disorientation **Sinus:** Headache, epistaxis, sinus pain; pneumocephalus if occurs during ascent	Topical and systemic decongestants, analgesics, antihistamines	**Middle ear pressure equalization maneuvers:** Yawn, swallow, jaw thrust, head tilt

Flash Card A19

Boyle's law. At a constant temperature, the volume of a gas is inversely proportional with the pressure to which it is subjected.

Flash Card A20

Henry's law. At a constant temperature, the amount of a gas dissolved in a liquid is directly proportional to the partial pressure of that gas.

Table 4-27. Complications of Diving Medicine, continued

Type	Mechanism	Symptoms and Signs	Treatment	Prevention
Decompression sickness (*the bends* or *caisson disease*)	Formation of gas bubbles within organs on ascent	Malaise, fatigue, anorexia, headache **Type I (mild):** Musculoskeletal (joint pain), cutaneous (pruritus, erythema), and lymphatic (lymphadenopathy, edema, peau d'orange effect) **Type II (severe):**Neurologic (spinal cord paresthesias, weakness and paralysis, memory loss, ataxia) and pulmonary (chest pain, wheezing, dyspnea, pharyngeal irritation, acute right-sided heart failure)	Hydration, 100% oxygen, left lateral decubitus positioning, mild Trendelenburg, hyperbaric oxygen therapy	Maintain adequate hydration, avoid rapid ascent, avoid alcoholic beverages
Nitrogen narcosis (*rapture of the depths*)	Nitrogen dissolution in central nervous system tissue	Narcotic effects: Impairment of intellectual performance, hallucinations, confusion	Ascent	Avoid alcoholic beverages

[a]Hamman's sign is the auscultation of crackles or crepitation over the heart during systole.

Flash Card Q21

What condition contraindicates hyperbaric oxygen therapy?

HYPERBARIC MEDICINE

Hyperbaric medicine includes hyperbaric oxygen therapy and its uses to treat different conditions. Hyperbaric oxygen therapy is inhalation of 100% oxygen intermittently within a pressure treatment chamber where the pressure is increased to > 1 atmosphere absolute.

Mechanisms

Hyperbaric oxygen therapy:

- Increases oxygen delivery by increasing its dissolution in plasma (Henry's law)
- Reduces the volume of gas bubbles (Boyle's law)
- Replaces nitrogen within bubbles with oxygen, promoting their metabolism within tissues
- Decreases the half-life of carboxyhemoglobin
- Promotes vasoconstriction, ameliorates ischemia-reperfusion inflammation, facilitates angiogenesis and fibroblast proliferation, and increases neutrophil bactericidal activity

Uses

Used to treat:

- Carbon monoxide and cyanide poisoning
- Decompression sickness and air embolism
- Acute traumatic or thermal injury
- Radiation injury
- Nonhealing ulcers, skin grafts, and wounds
- Clostridial myositis or myonecrosis

CARBON MONOXIDE, METHEMOGLOBINEMIA, THERMAL INJURY, CYANIDE, OXYGEN, AND RADIATION TOXICITY

Table 4-28 shows the pathophysiology, clinical manifestations, and treatment of carbon monoxide, methemoglobinemia, thermal injury, cyanide, oxygen, and radiation toxicity.

Flash Card A21

Untreated pneumothorax

Table 4-28. Carbon Monoxide, Methemoglobinemia, Thermal Injury, Cyanide, Oxygen, and Radiation Toxicity

Condition	Mechanism of Injury	Signs and Symptoms	Diagnosis	Treatment
Carbon monoxide exposure (odorless, colorless, tasteless)	> 200 x greater affinity for binding iron in heme portion of hemoglobin than oxygen resulting in leftward shift of oxyhemoglobin curve; impairs tissue oxygen delivery	**Mild:** Headache, malaise, nausea, dizziness **Severe:** Seizures, syncope, coma, myocardial ischemia, arrhythmias, pulmonary edema, lactic acidosis Delayed neuropsychiatric syndrome in up to 40%	Carboxyhemoglobin level > 15% with exposure history	Give high-flow 100% oxygen via nonrebreather mask Give hyperbaric oxygen if: • Unconscious • Mental status changes • Neurologic deficit • End-organ ischemia • CO-Hb > 25% • CO-Hb > 20% in pregnancy
Methemoglobinemia	Ferrous (Fe^{2+}) state of iron in heme converted to ferric (Fe^{3+}) that cannot bind oxygen; leftward shift of oxyhemoglobin curve, impairing delivery **Agents that increase formation of methemoglobinemia:** Dapsone, topical benzocaine or lidocaine, inhaled nitric oxide, nitroglycerin, nitroprusside, chloroquine, metoclopramide sulfonamides, aniline derivatives	Cyanosis, *chocolate brown* blood, saturation gap (difference between pulse oximetry and measured oxygen saturation in blood gas)	Co-oximetry (peak absorbance of methemoglobin at 631 nm)	Discontinue agent; give methylene blue if met-hemoglobin level > 30% Avoid methylene blue in glucose-6-phosphate dehydrogenase deficiency
Thermal injury	Smoke inhalation with resulting epithelial injury, airway edema, and bronchospasm	Cough, stridor, wheezing, hoarseness, carbonaceous sputum, blistering, and oropharyngeal edema	Fiberoptic laryngoscopy and bronchoscopy	Provide airway protection, supplemental oxygen
Cyanide exposure (bitter, almond odor)	Inhibits oxidative phosphorylation by binding to ferric ion of cytochrome oxidase a3; switch from aerobic to anaerobic metabolism, leading to acidosis **Drug most commonly associated:** Nitroprusside	Headache, anxiety, confusion, vertigo, coma, seizures, tachycardia, hypertension, arrhythmias, “cherry-red” color of lips	Lactic acidosis, venous hyperoxia (bright red venous blood)	Give hydroxycobalamin; induce methemoglobinemia (amyl nitrite, sodium nitrite; avoid in concomitant carbon monoxide poisoning), sodium thiosulfate

Table 4-28. Carbon Monoxide, Methemoglobinemia, Thermal Injury, Cyanide, Oxygen, and Radiation Toxicity, continued

Condition	Mechanism of Injury	Signs and Symptoms	Diagnosis	Treatment
Oxygen exposure	Free radical generation (superoxide anion-O_2^-, hydrogen peroxide-H_2O_2, and hydroxyl radical-OH^-) with consequent cell membrane damage and cell apoptosis or necrosis (diffuse alveolar damage, fibrosis) **Drugs that stimulate free radical lung injury:** Bleomycin, amiodarone, nitrofurantoin, mitomycin, and paraquat	Masqueraded by underlying indication for oxygen	No diagnostic testing available	Avoid high oxygen levels; reduce FiO_2 to lowest tolerable limit (≤ 0.5)
Radiation exposure	Cell breakdown leading to free radical generation; type II pneumocyte and endothelial cell death with consequent small vessel and capillary permeability, hyaline membrane formation, and fibrosis	**Predisposing factors:** Volume of lung tissue irradiated; dose (< 30 Gy OK; > 40 Gy radiographic changes; > 50 Gy lung injury); fraction size, previous irradiation, concurrent chemotherapy (bleomycin, doxorubicin, taxanes, gemcitabine, cyclophosphamide, vincristine, mitomycin) or corticosteroids (may mask) **Pneumonitis:** Within 6 mo; dyspnea, dry cough, fever, chest pain **Fibrosis:** 6 mo–2 y; asymptomatic, but if severe then dyspnea, rarely mediastinal fibrosis with superior vena cava syndrome or constrictive pericarditis	**Pneumonitis:** Ground-glass opacities, consolidation; may occur outside radiation field **Fibrosis:** Volume loss, bronchiectasis, pleural thickening, fibrosis	Corticosteroids (pneumonitis)

5 Quality, Safety, and Ethics

Diana H. Yu, MD

ETHICAL CONSIDERATIONS IN PULMONARY AND CRITICAL CARE MEDICINE

Patients with advanced critical illness often lack decision-making capacity. Surrogates are thus involved in making decisions to reflect patient preferences.

SURROGATE DECISION-MAKING

Three Hierarchically Ordered Standards

Standards to follow to guide surrogates to make decisions on behalf of the patient.

KNOWN-WISHES STANDARD—Patient clearly expressed a treatment preference to a specific medical situation.

- Case example: patient completed advance directive that, in the event of respiratory failure, he/she does not wish to receive mechanical ventilation to prolong life

SUBSTITUTED-JUDGMENT STANDARD—Patient's values and preferences are known to the surrogates.

BEST-INTERESTS STANDARD—Patient's values and preferences are not known; surrogate makes decisions to serve patient's best interests.

Flash Card Q1

True or false: A surrogate can change a patient's advanced directive after the patient becomes incapable of making medical decisions, based on the surrogate's own preference.

CONCEPT OF SHARED DECISION-MAKING

Definition

Collaborative process among physicians, patients, and surrogates that serves as the comprehensive ideal for end-of-life care and decisions. The purpose is to focus on shared decision-making rather than the paternalistic approach of unilateral physician decision-making.

Steps of Shared Decision-Making

INFORMATION EXCHANGE—Physician explains to the surrogate the disease process, treatment options and prognosis. Surrogate shares patient's values, interests, and preferences for treatment.

DELIBERATION—Physician and surrogate together deliberate about the best treatment option.

DECISION—Physician and surrogate together arrive at a shared agreement and decision.

Key Fact

In the landmark case of Karen Ann Quinlan, the court affirmed that patients and their surrogates have the right to refuse any unvantd medical reatment, even if life-sustaining. Withdrawal of life-sustaining treatment is not legally considered killing, but rather allowing the patient to die from the underlying illness.

WITHDRAWAL OF LIFE-SUSTAINING TREAMENT

Ethical Principles

Three ethical principles help to shape the current United States consensus around the withdrawal of life-sustaining treatment.

Key Fact

Many states allow for physician-ordered unilateral do not resuscitate (DNR) in conjunction with the local ethics committee. Physicians are **not** ethically obligated to provide treatments that they deem futile.

- Withholding and withdrawing life support are equivalent
  - Both philosophical and legal analyses emphasize no distinction between decisions to withhold or to withdraw.
- There is distinction between euthanasia and allowing death to occur.
- The doctrine of "double effect" provides an ethical rationale for providing relief of pain and other symptoms even when this may have the foreseen (but unintended) consequence of hastening death.

ETHICAL CASE EXAMPLE—Administering high-dose opioids and sedatives prior to ventilator withdrawal to make the patient comfortable may be acceptable even if the medication hastens the unintended effect of death.

Flash Card A1

False

UNETHICAL CASE EXAMPLE—Administering high-dose opioids and sedatives when a patient has no clear signs of pain or distress at the request of family for a quick death.

> ***Key Fact***
>
> Treatments with no beneficial physiologic effect are futile. Treatments with unlikely benefit, beneficial effect with extreme cost and uncertain or controversial benefit are all considered inappropriate and inadvisable but **not** futile.

FUTILE AND POTENTIALLY INAPPROPRIATE TREATMENT

Purpose and Definition

Treatments are defined as futile only when they will not accomplish their intended goal.

FOUR CATEGORIES OF POTENTIALLY INAPPROPRIATE TREATMENT

- Treatments with no beneficial physiologic effect
- Treatments that are extremely unlikely to be beneficial
- Treatments that have a beneficial effect but are extremely costly
- Treatments that are of uncertain or controversial benefit

PRACTICAL ASPECTS OF LIMITING INADVISABLE TREATMENT

- Treatments that offer no physiologic benefit to the patient are futile and should not be offered.
- Treatments with unlikely, uncertain, or controversial benefit should be explored with the patient/surrogate through a collaborative fair process rather than through a unilateral decision by the physician.
- Treatments that have beneficial effects but are extremely costly should be made available in a limited manner, governed by principles of distributive justice (see below).

> ***Flash Card Q2***
>
> True or false: Withdrawal of and withholding life-support measures are ethically equivalent.

> ***Flash Card Q3***
>
> True or false: If a patient is paralyzed, you should reverse the muscle relaxant prior to starting withdrawal of life-sustaining treatments.

BRAIN DEATH AND WITHDRAWAL OF LIFE SUPPORT—Ethical issues surrounding brain death have gathered national headlines recently with families unwilling to accept brain death determined by multiple independent neurologic examinations, including those ordered by the court.

- According to the Uniform Determination of Death Act, which has been adopted in 45 states and recognized in the rest through judicial opinion, if the patient meets neurologic criteria of brain death as defined by loss of the functional activity of the brain stem and cerebral cortex, the patient is legally deemed dead.
- Despite controversy, neither a living will nor family preferences are required to withdraw life support in patients who meet neurologic criteria of brain death, as they are legally dead.

> ***Flash Card Q4***
>
> True or false: Food and fluids can be withheld legally and ethically and withdrawn if congruent with a patient's goals of care.

> ***Flash Card Q5***
>
> True or false: Advance directives are not portable—they are valid only in the state where they were written.

PRINCIPLES OF MEDICAL ETHICS

BASIC PRINCIPLES

Autonomy

Patient has the right to make an informed and uncoerced decision on medical treatment.

INFORMED CONSENT

- Legally, adequate disclosure includes information on
  - Diagnosis
  - Nature and purpose of treatment
  - Risk of treatment
  - Treatment alternatives

LIMITATIONS OF AUTONOMY

- Decision has to be legal
  - If patient requests euthanasia, the right to autonomy is denied, as euthanasia is against the law
- Patient must have capacity to make informed decisions
  - Must be able to communicate, understand relevant information, appreciate situation and consequences, and rationally manipulate information
  - Capacity may be gained or lost, requiring reevaluations as appropriate

Beneficence and Nonmaleficence

Flash Card A2

True

Flash Card A3

True; you always want to be able to assess pain and discomfort

Beneficence refers to actions that promote the well-being of others—physicians should act in the best interest of the patient. The concept of nonmaleficence is embodied by the phrase, "first, do no harm." Conflicts arise when the patient's/surrogate's perception of benefit differs from the physician's view of their own duty to beneficence and nonmaleficence.

Justice

Flash Card A4

True

Flash Card A5

False

Refers to the fair distribution of limited health resources. As the physician's obligation is to advocate for the patient, the principle of distributive justice often does not apply to bedside decision-making.

QUALITY IMPROVEMENT/PATIENT CARE

QUALITY IMPROVEMENT

Quality improvement is the scientific discipline that focuses on the structures, processes, and outcomes of health care delivery. Critical care medicine poses unique challenges to effective health care delivery and thus is an ideal setting for implementing the discipline of quality improvement.

Key Fact

Studies suggest that patients managed in a closed ICU by physicians with critical care training have better outcomes than patients managed in open ICUs by generalists without critical care training.

Understanding Quality in Health Care

Quality health care is defined as care that is safe, timely, effective, efficient, equitable and patient-centered. Three classic quality-of-care components—structure, process, and outcome—serve as a useful framework for understanding and improving the quality of health care.

COMPONENTS OF QUALITY-OF-CARE MODEL

- Structure: how we organize care
  - Example: how the intensive care unit (ICU) is integrated into the hospital, the size of the ICU, and whether the unit is open or closed
- Process: what we do or fail to do for patients and families
  - Requires collaborative efforts of both clinical (data-driven) and nonclinical processes (organizational management)
- Outcome: results we achieve

Flash Card Q6

True or false: Physicians are **not** obligated to continue providing mechanical ventilatory support after brain death.

CHECKLISTS

Medical errors result in significant health care costs and deaths. The goal of checklists is to reduce the frequency of errors. Error reduction correlates directly with improvements in patient outcomes, patient safety, and efficacy of resource utilization.

Flash Card Q7

Obtaining informed consent prior to a procedure is respecting which of the four basic principles of medical ethics?

Flash Card Q8

What is The Belmont Report?

Patient Outcome

EXAMPLES OF STUDIES WITH IMPROVED PATIENT OUTCOMES AND/OR QUALITY OF CARE

- Checklist to assess eligibility criteria for mechanically ventilated patients helped to predict successful weaning from the ventilator
- Intensive Care Delirium Screening Checklist identified patients more likely to develop delirium
- Checklists improved effective transfer of spinal cord injury patients out of the ICU
- Checklist for diagnosis of brain death
- Daily checklists of goals for critical care patients reduced average ICU length of stay and ventilator days
- Checklist for central venous catheter placement and management reduced catheter-related bloodstream infections

SLEEP DEPRIVATION, SHIFT SCHEDULES, AND HANDOFFS

Patient Care and Outcome

Flash Card A6

True

Flash Card A7

Autonomy

Flash Card A8

A statement created by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research that summarizes basic ethical principles and guidelines for research involving human subjects; three core principles identified are respect for persons, beneficence, and justice.

The Harvard Work Hours, Health and Safety Group and others demonstrated that interns working extended hours in traditional schedules demonstrated higher rates of

- Serious medical and diagnostic errors
- Motor vehicle accidents
- Poor performance on clinical and nonclinical tasks, similar to being legally intoxicated
- Needlestick injuries

In 2003, the Accreditation Council for Graduate Medical Education (ACGME) restricted work hours to 80 hours per week for **postgraduate** trainees, and in 2011, interns were restricted to shifts of ≤ 16 hours. Though studies have shown that duty-hour reform reduces medical errors, a mortality benefit has not been shown, and there is increased concern regarding medical errors related to inadequate and frequent handoffs.

The most recent recommendations by the ACGME Joint Commission and the Institute of Medicine require a method to document patient handoff procedures as well as a handoff curriculum during **postgraduate** training.

For example, standardized, computer-assisted sign-outs have been shown to improve continuity of care between inpatient teams.

STAFFING ISSUES

INTENSIVIST: PATIENT RATIO

Substantial indirect evidence from available literature suggests that physician: patient ratios are a significant factor in ensuring quality care, training of future physicians, and maintaining a stable workforce for ICUs.

Society of Critical Care Medicine Taskforce

RECOMMENDATIONS

- Appropriate staffing of ICUs with intensivists impacts the quality of patient care, patient safety, education, and staff well-being
- Caseloads should allow for other activities such as teaching, non-ICU duties,and administration
- Assessment of staff satisfaction, burnout, and stress should be part of the objective data collected to assess appropriateness of ICU staffing
- Teaching institutions should objectively weigh tradeoffs between patient care and education before expanding intensivists' clinical duties
- In academic medical ICUs, a physician:patient ratio < 1:14 has a negative impact on the quality of patient care, education, and workforce stability

NIGHTTIME IN-HOUSE INTENSIVISTS

A recent randomized trial in an academic medical ICU of the effects of nighttime staffing with in-hospital intensivists compared with nighttime coverage by daytime intensivists available for consultation over the phone revealed that nighttime in-hospital intensivist staffing did not improve patient outcomes (length of stay in the ICU, length of stay in the hospital, and in-hospital mortality).

This was in contrast to previous studies showing that ICUs with low-intensity or non-intensivist daytime physician staffing benefited from in-hospital intensivists at night.

PHYSICIAN SUPERVISION OF TRAINEES AND PHYSICIAN EXTENDERS

The supervising attending physician is responsible and liable for the patient care provided by physician extenders, such as nurse practitioners, physician assistants, and resident physicians.

PHYSICIAN WELL-BEING/IMPAIRMENT

PHYSICIAN IMPAIRMENT

Physician impairment by substance abuse continues to be a significant issue for the health care system. It has been identified as a potential source of medical errors and liability, though little research on resident substance abuse has been published. Physicians have legal and ethical obligations to assist and report impaired colleagues.

Research Studies

PUBLISHED DATA

- Favorable prognoses for substance-impaired physicians with early diagnosis and intervention
- Certain risk factors, such as family history of substance abuse, and opioid use with concurrent diagnosis of another psychiatric disease, may predict higher rates of relapse
- In a survey conducted among 3000 American resident physicians with a 60% response rate, heavy substance use patterns were not observed. However, higher rates of alcohol and benzodiazepine use were reported compared to the general population; these were associated with impairment at later stages in the physician's career
- A cross-sectional mail survey of 1000 randomly selected practicing physicians in the U.S. revealed that physicians would be more likely to report physicians involved in substance abuse than to report those who were emotionally or cognitively impaired

6 Epidemiology and Statistics

Nazir Ahmad Lone MD MPH

EPIDEMIOLOGY

Epidemiology is the scientific approach to the distribution and determinants of health, disease, and injury in a population.

Aims of modern epidemiologic research:

- Plan and evaluate the strategies to prevent illness and disease
- Guide disease management
- Identify appropriate public health interventions

Clinical Epidemiology

The study of illness outcomes by observing and comparing events in a group of individuals with shared characteristics. The shared characteristic of a group may be a symptom, sign, illness, diagnoses, prognosis, or treatment. Clinical epidemiology also involves the methodology for evaluating diagnostic tests and therapeutic modalities used in clinical practice. The most common epidemiologic terms and measures of health and disease are ratio, proportion, and rate (Table 6-1).

Clinical epidemiology methods include:

- Measures of disease occurrence: Incidence and prevalence
- Measures of disease outcomes: Mortality and morbidity
- Measures of validity or performance of diagnostic and screening tests: Sensitivity, specificity, predictive values, and likelihood ratios
- Measures of disease association: Odds ratio (OR) and relative risk (RR)

Key Fact

The aim of modern epidemiology is to understand the causal pathways of disease in a population and to identify appropriate public health interventions.

Table 6-1. Common Epidemiologic Terms and Measures of Health and Disease

Term	Definition	Annotation	Properties	Examples
Ratio	Relationship characterized by dividing two numbers	a/b a and b are frequencies of some event	Always more than 0 May or may not have units Numerator and denominator do not have to be mutually exclusive	Odds of disease = p/(1 - p) p = proportion of people with disease; 1 - p = proportion of people without disease OR = odds of disease in population A/odds of disease in population B **OR has no units**
Proportion	Ratio in which the numerator is a subset or part of the denominator	a/(a + b)	Values between 0 and 1 Always a ratio **No units**	Proportionate mortality No. affected/total population No. of deaths due to COPD/total no. of deaths × 100 **Prevalence rate is a proportion**
Rate	Proportion or a ratio, where **time is always in the denominator** Calendar time period is same in both the numerator and denominator	a*/(a + b) a* = frequency of events during a certain time period a + b = no. at risk of the event during that time period	Rate is always a ratio **Those in the denominator are "at risk" of being in the numerator** The denominator is expressed in person-time units such as person-hours or person-years	Percent of all deaths due to COPD = no. of COPD related deaths in calendar year/total no. of deaths in that calendar year × 100 **Incidence is a rate**

COPD, chronic obstructive pulmonary disease; OR, odds ration; RR, relative risk

MEASURES OF DISEASE OCCURRENCE

Incidence and Prevalence

Prevalence is a measurement of all individuals affected by a disease at a particular time, whereas incidence is a measurement of the number of new individuals at risk of developing a disease during a particular period of time (Figure 6-1).



Figure 6-1. Graphic display of dynamics of population distribution in terms of prevalence, incidence, and mortality in a hypothetical population.

INCIDENCE RATE (IR)—Rate at which new cases occur in a calendar year/total population in the same year. Incidence and IR are used interchangeably. The denominator in IRs is usually person-time.

IR = new cases/person-years

Person-years = (no. of subjects) × (years of follow-up per subject)

- Example: Pack-years of smoking = (no. of cigarettes or packs) × (years of smoking)

Key Fact

IRs provide a direct measure of the rate at which new cases occur in the population.

Key Fact

IRs are calculated by dividing the total number of events in a specified time.

PREVALENCE RATE—An estimate of the proportion of individuals in a population who have the outcome or have experienced the event of interest. Prevalence rate at a specific point in time is point prevalence, whereas prevalence rate during a particular time period such as a year is a period prevalence.

Prevalence rate = no. of individuals with disease or health condition/ no. of individuals in that population at a specified time = sick/(sick + well)

- Example: No. of elderly > 75 years of age with asthma/no. of elderly > 75 years at a specified time

PROPERTIES OF PREVALENCE

- Typically derived from cross-sectional surveys
- Describes the burden of illness in a population
- Can be used to gather information about the impact of a disease in a population and help in resource allocation
- Prevalence and incidence are related: Prevalence = incidence ×duration; higher incidence and or longer duration of disease results in higher prevalence (Table 6-2)
    - Example: Upper respiratory tract infection has high incidence but short duration thus has low prevalence, whereas chronic lung disease has low incidence, long duration, and high prevalence

Key Fact

Prevalence = incidence × duration.

Key Fact

Higher prevalence does not necessarily imply an increased risk of the health event or outcome, but rather it may indicate long duration of disease.

Key Fact

Lower prevalence does not necessarily imply low incidence, but rather it may represent a rapidly fatal disease or a short duration of illness.

Table 6-2. Factors Influencing Prevalence Estimate

Increased Prevalence	Decreased Prevalence
Longer duration of disease	Shorter duration of disease
Prolonged survival without cure	High CFR from disease
Increased incidence of new cases	Decreased incidence of disease
Immigration of new cases and susceptible people or out-migration of healthy people	In-migration of healthy people or out-migration of disease
Improved diagnostics and better reporting	Improved cure rate of disease

CFR, case-fatality rate

MEASURES OF DISEASE OUTCOMES

Mortality and Morbidity

Two common measures of disease outcome are mortality and morbidity. All deaths from all causes in 1 year among the entire population in that year is called crude mortality**.** Mortality approximates incidence rate (IR) when case-fatality rate (CFR) is high and or duration of the diseases is short (poor survival).

INDICES OF MORTALITY— Annual mortality rate from all causes (per 1000 population) = d × 1000/N, where d = total number of deaths from all causes in 1 year and N = number of persons in the population at midyear.

Cause-specific mortality rate (per 1000 population) = deaths from a particular disease in a given year × 1000/population at midyear

- Example: Annual mortality from chronic obstructive pulmonary disease (COPD) (per 100 population) = no. of deaths from COPD in 1 year × 1000/no. of persons in the population at midyear

Key Fact

Mortality rate approximates incidence rate when CFR is high and or duration of the diseases is short (e.g., H1N1).

CFR is a proportion and measure of the severity of that disease.

CFR (%) = no. of individuals dying after disease onset or diagnosis during a specified period × 100/no. of individuals with specified disease

Years of potential life lost is a measure of premature mortality and is used to quantify social and economic loss owing to premature death. It is estimated by the average time a person would have lived had he or she not died prematurely.

MORBIDITY—A measure of sickness and refers to a disease, illness, injury, or disability in a population. The main methods for gathering morbidity data are through surveillance systems and sample surveys.

MEASURES OF VALIDITY OR ACCURACY OF DIAGNOSTIC AND SCREENING TESTS

A screening test identifies an occult disease among asymptomatic individuals. A diagnostic test identifies the presence or absence of a disease. Diagnostic tests are generally performed after a positive screening test to establish a definitive diagnosis.

Examples:

- Low-dose computed tomography (CT) scans for detection of lung cancer are screening tests
- Positron emission tomography (PET) CT scans to screen for metastatic disease are also screening tests
- Mediastinoscopy or fine-needle aspiration with endobronchial ultrasound performed after screening imaging are diagnostic tests

Flash Card Q1

In a population of 1000 people in which 50 are sick with H1NI flu illness and 25 die from H1NI in 1 year, what is the mortality rate?

A gold standard test is the best available method, procedure, or measurement that confirms the presence or absence of disease. The performance of a new

test is compared to the gold standard test to determine the sensitivity and specificity of the new test.

Sensitivity and Specificity

SENSITIVITY—The probability that a test result will be positive when the disease is present. It is also described as the ability of the test to identify correctly those who have the disease, or the true positive rate. Using a standard 2 × 2 table, the sensitivity is calculated as a/a + c (Table 6-3).

Table 6-3. Mechanics of 2 × 2

	Disease Present	Disease Absent
Test positive	a = true positives	b = false positives
Test negative	c = false negatives	d = true negatives
	a + c = all individuals with disease	b + d = all individuals without disease

Mnemonic

SnOut —A high **Sen**sitivity test has few false negatives and effectively rules **Out** a disease.

SpIn—A high **Sp**ecificity test has few false positives effectively rules **In** a disease)

SPECIFICITY—The probability that a test result will be negative when the disease is not present. It is also described as the ability of the test to identify correctly those who do not have the disease, or the true negative rate. Using the 2 × 2 table, the specificity is calculated as d/b + d.

Both sensitivity and specificity are fixed characteristics of a test, but changing the positive cutoff value for a test will yield different sensitivities and specificities. Decreasing the cutoff value increases sensitivity (true positives) but also creates more false positives. Increasing the cutoff decreases sensitivity but increases specificity (true negatives) and also results in more false negatives.

As an example, decreasing the cutoff values for d-dimer will increase sensitivity (i.e., identify more true positives [with disease] as well as increase the number of false positives [who do not have disease]).

Flash Card A1

Mortality rate from H1NI in that year = 25/1000 = 0.025 or 2.5%; case rate for H1NI disease = 25/50 = 0.5 or 50%

Predictive Values

POSITIVE PREDICTIVE VALUE (PPV)—Probability that the disease is present when the test is positive. It is also described as the proportion of patients who test positive who actually have the disease.

- Using the 2 × 2 table (Table 6-3), the PPV is calculated as a/a + b

NEGATIVE PREDICTIVE VALUE (NPV)—Probability that the disease is not present when the test is negative. It is also described as the proportion of patients who test negative who are actually free of the disease.

- Using the 2 × 2 table (Table 6-3), the NPV is calculated as d/c + d

RELATIONSHIP OF DISEASE PREVALENCE TO PREDICTIVE VALUE—An increase in disease prevalence increases the PPV of a test. That is, unlike sensitivity and specificity, PPV and NPV are not fixed characteristics of a test.

Key points:

- High disease prevalence increases the PPV of a test
- Low disease prevalence increases the NPV of a test
- Increasing the specificity of a test increases the PPV and NPV of the test
- Changing the sensitivity of a test (assuming no change in the specificity) does not impact the predictive values

Key Fact

A standard 2 × 2 table uses rows to calculate predictive values, and columns for sensitivity and specificity.

Key Fact

Sensitivity and specificity and fixed characteristics of the test. PPV and NPV change based on the prevalence of disease in a given population.

Key Fact

Sensitivity, specificity, PPV, and NPV as well as disease prevalence are expressed as percentages.

Likelihood Ratios

Likelihood ratio is the likelihood that given test result would be expected in a patient with the target disorder compared with likelihood that a same result would be expected in a patient without the target disorder.

POSITIVE LIKELIHOOD RATIO (Lr+)—Ratio between the probability of a positive test result given the presence of the disease and the probability of a positive test result given the absence of the disease.

Lr+ = true positive rate/false positive rate = sensitivity/(1 - specificity)

NEGATIVE LIKELIHOOD RATIO (Lr-)—Ratio between the probability of a negative test result given the presence of the disease and the probability of a negative test result given the absence of the disease.

- Example: LR- = false negative rate/true negative rate = (1 – sensitivity)/ specificity

Other Measures of Performance of Screening and Diagnostic Tests

RECEIVING OPERATOR CHARACTERISTICS (ROC) CURVE

- Used to estimate the discriminative power of a test
- Graphic plot of sensitivity on the y axis against (1 - specificity) on the x axis for varying values of the threshold (Figure 6-2)
- A perfect diagnostic test has an AUC of 1.0, whereas a nondiscriminatory test has an AUC of 0.5

VALIDITY—Ability of a test to detect which individuals have the disease and which do not have the disease.

RELIABILITY/REPEATABILITY—Consistency of results under repeated measurements by the same individuals under the same conditions.

NUMBER NEEDED TO SCREEN—Number of individuals needed to be screened for a given duration to prevent or detect one outcome.



Figure 6-2. Hypothetical ROC curves representing the diagnostic accuracy of the gold standard. Line A, AUC = 1; curve B, AUC = 0.85; and a diagonal line corresponding to random chance (line C, AUC = 0.5). As diagnostic test accuracy improves, the ROC curve moves toward A, and the AUC approaches 1.

Observational Bias in Screening Tests

Screening studies that report survival as an outcome are susceptible to observational bias that undermines the validity of a screening test. Three types of these biases occur when a disease is diagnosed by screening in the asymptomatic period. Introduction of these biases misrepresent that early diagnosis appears to improve survival.

- Lead-time bias
- Length-time bias
- Overdiagnosis bias

LEAD-TIME BIAS—Reflects the observed lengthening of survival time due to earlier diagnosis by a screening test without any actual prolongation of survival. Screening identifies disease during a latent period before it becomes symptomatic. If survival is measured from time of diagnosis, screening will always improve survival, even if treatment is ineffective (Figure 6-3).



Figure 6-3. Lead-time bias reflected by an increased survival time because of early diagnosis by screening test.
(Reproduced courtesy of the National Cancer Institute.)

LENGTH-TIME BIAS—Reflects the increased likelihood of identification of indolent tumors by intermittent screening as compared to fast-growing or aggressive tumors that can be missed due to their rapid progression (Figure 6-4).

Length-time bias occurs because:

- Screening identifies disease-prevalent cases
- Prevalence = incidence × duration
- Slowly growing tumors have greater duration in presymptomatic phase and have greater prevalence; therefore, cases detected by screening will be disproportionately those that are slow growing



Figure 6-4. Length-time bias observed by intermittent screening of indolent tumors that grow more gradually from the detectable stage to the onset of clinical symptoms.
(Reproduced courtesy of the National Cancer Institute.)

OVERDIAGNOSIS BIAS—Reflects the identification of disease by a screening test that does not affect the patient's life in the absence of screening (Figure 6-5). Also called pseudodisease (i.e., condition that looks just like the disease, but never would have concerned the patient).

For example, lung cancer screening may detect lung nodules that would never cause clinical disease.



Figure 6-5. Overdiagnosis bias observed by diagnosing that is not cause of mortality.
(Reproduced courtesy of the National Cancer Institute.)

BIOSTATISTICS

Biostatistics refers to the application of statistical tools and methods to address and analyze problems in health and medicine.

This section will briefly cover:

- Study designs
- Data distribution and types of variables
- Common statistical analytic tools (measures of association)
- Statistical significance
- Issues of interpretation of study results

Study Designs

Two main types of study design are used to determine whether there is an association between an exposure and an outcome (i.e., observational studies and experimental studies). The basic principles and classification of types of clinical study design are shown in Figure 6-6.

In observational studies, the researchers collect information about the sample population but do nothing to alter the exposure, whereas in experimental studies, the researcher alters or manipulates the exposure and studies outcome.

Both observational and experimental studies can be further classified as prospective or retrospective. In prospective studies, data are collected forward in time after the initiation of study, whereas in retrospective studies, data are collected from events that have already occurred from existing sources like hospital records.

The main types of study designs and advantages and disadvantages of each are given in Table 6-4.



Figure 6-6. The basic principles and classification of types of clinical study design. RCT, randomized controlled trial

Table 6-4. Advantages and Disadvantages of Study Designs

Study Design	Advantages	Disadvantages
Case-control studies	Quick and inexpensive Feasible for very rare disorders or those with long lag between exposure and outcome Fewer subjects needed than cross-sectional studies Usually generates OR	Reliance on recall or records to determine exposure status (recall bias) Selection Bias Selection of control groups often is difficult
Cohort study	Ethically safe; easier and cheaper than RCT Matching is possible Can establish timing and directionality of events Eligibility criteria and outcome assessments can be standardized Reduced recall error Useful for generating RR	Difficult to identify controls and blinding is difficult Randomization not present Needs large sample sizes or long follow-up for rare disease Expensive to conduct
Cross-sectional survey	Quick, cheap, simple, and ethically safe Population-based Best for quantifying the prevalence of a disease or risk factor	Establishes association at most, and not causality Recall bias susceptibility Confounders may be unequally distributed
RCT	Unbiased distribution of confounders Usually blinded No bias in the assignment process and randomization facilitates statistical analysis Follow-up usually is complete in both groups	Expensive volunteer bias Ethically problematic Loss of follow-up

OR, odds ratio; RR, relative risk; RCT, randomized controlled trial.

CASE-CONTROL STUDY

- Retrospective
- Certain outcome or disease (cases) and controls (without the outcome or disease) are selected; then information is collected backward to see who has been exposed to the risk factor
- Example: Veterans with and without lung cancer are selected, then data for prior exposure to agent orange are collected

COHORT STUDY

- Prospective
- Considered gold standard in observational epidemiology

- Group of subjects exposed to a risk factor and not exposed to the same risk factor are followed over time; researcher does not allocate the exposure
- Example: A group of fellows enrolled in 2010 are followed to see if there is a reduction in central line complications by using ultrasound for line placement; Framingham Heart Study and Nurses' Health Study are cohort studies

CROSS-SECTIONAL STUDY

- Exposure and outcomes are measured at the same time in a defined population
- Example: A sample of nonsmoking veterans (population) are asked if they were exposed to burn pits (exposure) and have been diagnosed with obstructive lung disease (outcome)

CLINICAL TRIAL/RANDOMIZED CONTROLLED TRIAL (RCT)

- Prospective study
- An experimental design in which subjects are allocated to treatment/intervention or control/placebo groups by a random mechanism called randomization. Researcher does not influence who gets the exposure or treatment.

Types of RCTs:

- Cluster randomized trial: Randomize entire groups rather than individual subjects to treatment
  - Example: A randomize hospitals and intervene with antibiotic cycling to study outcomes of health care–associated infection
- Factorial randomized design: Randomize two or more treatments/ interventions simultaneously in all possible combinations
  - Example: Effect of salmeterol + fluticasone vs. tiotropium + salmeterol + fluticasone vs. salmeterol alone on COPD exacerbations
- Crossover design:
  - Randomly allocate each patient to a sequence that includes each treatment so that each patient can act as their own control for treatment
  - Two or more treatments are given consecutively
  - Can be limited by the potential for carryover of pharmacologic effect that may alter the response to next treatment
  - The washout period may be lengthy and crossover cannot be used for treatments with permanent effects

SYSTEMATIC REVIEW—An evidence-based resource produced after reviewing published and unpublished studies and combining the information of all relevant studies to address a particular clinical question.

META-ANALYSIS—Type of systematic review that uses systematic methods to combine qualitative and quantitative study data from several selected

studies. The meta-analysis has greater statistical power than any single study due to increased sample size and greater diversity among subjects. The results are more generalizable but can be flawed by heterogeneity of study population and skewness of study results secondary to publication bias. Forest plots are diagrammatic representations of meta-analyses.

In evidence-based medicine, a formal hierarchy considers the RCT and collections of RCTs as systematic reviews or meta-analyses as the highest form of evidence, as shown in Figure 6-7.

Figure 6-7. Example of hierarchy of research design as per evidence-based medicine. Review of randomized controlled trials (RCTs) includes systematic reviews with or without meta-analysis.
(Reproduced, with permission, from Concato J. Study Design and Evidence in Patient-oriented Research. *Am J Respir Crit Care Med*. 2013; 187: 1167–72. doi:10.1164/rccm.201303-0521OE)

Key Fact

In observational studies nothing is done to alter the exposure, whereas experimental studies entail manipulation of exposure and randomization of subjects to treatment groups.

DATA DISTRIBUTION AND TYPE OF VARIABLES

The distributions of data in a given population can be symmetric or asymmetric (Figure 6-8).

Symmetric clustering of values around a central location is called the normal distribution and is represented by a bell-shaped curve or the normal curve (Figure 6-8A). Skewness on the other hand refers to asymmetry of the distribution (Figure 6-8B–C).

The distribution with an asymmetric tail extending to the right and a central location to the left is referred to as positively skewed or skewed to the right, whereas a distribution with an asymmetric tail extending to the left and central location to the right is referred to as negatively skewed or skewed to the left.



Figure 6-8. Symmetric (A) or bell-shaped distribution. Asymmetric or skewed distribution (B, C). In positive skewness, mean is greater than median; in negative skewness, mean is less than median.

Measures of Central Tendency

Measures of central tendency denote clustering of observation around the center. The commonly used methods to calculate these characteristics of a frequency distribution are mean, median, and mode.

MEAN—Sum of all observations divided by count of total number of observations. Used for continuous variables. Easily distorted in a skewed data set.

MEDIAN—Middle value among the ordered values above and below which 50% of the observations fall. Used for a continuous variable when the distribution is not normal. Not affected by extreme values so it is robust. If the number of values is odd number, the middle is the median, whereas in even number of values, the median is the average of the middle two numbers.

MODE—Most frequent observation in the data set. Used for discrete variable. Mode is also robust to outliers.

STANDARD DEVIATION (SD)—Measures the spread of distribution values. The SD will be lower if all observed values are tightly grouped, and higher if values are more spread out.

- If values are normally distributed, then68% of values are within 1 SD of the mean
- 95% are within 2 SDs of the mean
- 95% are within ± 1.96 SDs of the mean

> ***Key Fact***
>
> Two-thirds of all observations fall within 1 SD of the mean, and roughly 95% of all observations will fall within ± 2 SD in a normally distributed population.

Variable Types

Variables are measurable quantities that vary among individuals and can be quantitative (numeric) or qualitative (categoric) in nature.

QUANTATIVE (NUMERIC) VARIABLE—Data can take on a whole range of values.

- Continuous variable: No gaps in the values and can be infinite (e.g., weight)
- Discrete: Gaps in the values and take only finite number of values (e.g., number of beds)

> ***Key Fact***
>
> Continuous data can be turned into categoric data (e.g., blood sugar values into normoglycemia, prediabetes, glucose intolerance, and diabetes).

QUALITATIVE (CATEGORIC) VARIABLE—Data fall into few defined categories.

- Ordinal: Have implicit ranking (e.g., Likert scales)
- Nominal: Descriptive and cannot be ordered (e.g., smoker and nonsmoker)

MEASURES OF ASSOCIATIONS

RR and OR

RR (Table 6-5)
- Ratio of risks
- Calculated by risk in exposed divided by risk in nonexposed, or ratio of risk in the treated group to the risk in the control group
- Used in cohort study

$$RR = (a/a + b)/(c/c + d)$$

INTERPRETATION OF RR
- RR = 1 means no association
- RR > 1 means positive association, meaning risk in exposed is greater than in nonexposed
  - Example: Smokers are at high risk of developing lung cancer (harm, causation, association)
- RR < 1 means risk in exposed is less than that in nonexposed
  - Example: Daily exercise protects against heart disease (protective)

OR (Table 6-5)
- Ratio of odds of disease in the exposed group to the odds of disease in nonexposed group
- Used for both cohort and case-control studies

OR CALCULATION
- Odds of disease in exposed = a/b
- Odds of disease in not exposed = c/d
- OR of disease in exposed = a/b/c/d = ad/bc
- OR of exposure in diseased = a/c/b/d = ad/cb

INTERPRETATION OF OR
- OR = 1 means no association of exposure with disease or disease with exposure
- OR > 1 means exposure or disease is positively related (e.g., odds of developing lung cancer is higher in smokers or odds of smoking exposure is higher in lung cancer patients) (harm , causation , association)
- OR < 1 means exposure or disease is negatively related 9 (e.g., odds of developing heart disease is lower in individuals who perform daily exercise) (protective)

OR approximates RR if:
- The cases and controls are representative of the general population (sampled population) with regard to disease and history of the exposure

- If the disease under study is rare and incidence of the disease is low

Table 6-5. 2 ×2 Table for RR and OR

	Diseased	Not Diseased	Total	Incidence/ Risk of Disease	Odds of Disease
Exposure	a	b	a + b	a/(a + b) (incidence in exposed)	a/b (odds of disease in exposed)
No. Exposed	c	d	c + d	c/(c + d) (incidence in nonexposed)	c/d (odds of disease in nonexposed)
Odds of Exposure	a/c	b/d			

Other Commonly Used Statistical Methods

***t*-TEST—**Measure of statistical difference and is used to compare the means from two different samples in a normally distributed data.

- Two-sample unpaired *t*-test: Used to compare the average mean of two independent samples
- One-sample *t*-test: Used to determine if there is a difference between a known population mean and a sample mean
- Paired *t*-test: Used if the individuals in the group are paired

ANALYSIS OF VARIANCE (ANOVA)—Statistical test to determine if there are significant differences between variances of multiple samples. It is similar to the *t*-test for two samples. ANOVA compares the variation within each sample to the variation between the samples.

CHI-SQUARE TEST—Statistical test of the association between two categoric variables from two or more independent groups in the form of 2 × 2 tables. It compares the frequency distribution from observed data to the frequency distribution that would be expected under the null hypothesis of no association.

- Chi-square test tells us the "goodness to fit" between observed and expected data.

CORRELATION AND REGRESSION—Used to study relationship between two random variables.

- Regression analysis is used to estimate the influence of one or more independent variables and predict the value of the dependent variable; allows good control of confounders.
- Types of regression based on the type of data include:

  - Logistic regression for a discrete dependent variable
  - Linear regression for a continuous dependent variable
  - Poisson regression for certain types of count data
  - Survival analysis for a continuous dependent variable that records the time to an event; Kaplan–Meier is a graphic representation of this analysis
- Correlation is a statistical measure of the association between two variables but does not necessarily imply causation; scatter plot is the graphic representation of correlation

PEARSON'S CORRELATION COEFFICIENT—Statistical measure of the association between continuous numeric variables that shows how closely two numeric variables lie in a linear association or straight line. It is denoted by *r*. r can range from -1 to +1.

$r = -1$, perfect negative linear relationship

$r = 1$, perfect positive linear relationship

$r = 0$, no linear relationship or complete absence of relationship

STATICAL SIGNIFICANCE

Hypothesis Testing, *p* values, Confidence Intervals (CIs)

Steps of hypothesis testing:

- State null hypothesis and alternative hypothesis
- Pick a significance level (α) of the test
- Select test procedure, collect data, and calculate *p* value
- If *p* value < α, reject the null hypothesis

NULL AND ALTERNATE HYPOTHESIS—Null hypothesis is a statement of no effect or no association, whereas the alternative hypothesis is a statement of true difference. The goal of research is to reject the null.

> ***Key Fact***
>
> *p*-Values do not indicate the strength or direction of the association, and they depend on sample size and effect size.

***p* VALUES—**Statistical significance is the probability that the results observed in a study may have been just a chance finding and is denoted by *p* value. Statistical significance depends on the sample size and the size of the difference observed (effect size).

- Arbitrarily set at 5%, or $p < 0.05$; or 1% , $p < 0.01$
- The smaller the *p* value the more significant the result, meaning that null hypothesis is unlikely to be true
- *p* Value < 0.05 means only 5% chance of detecting a difference in effect size if there is no actual difference in the population

CI—Range within which the true value of a parameter lies.

- CI is constructed around a parameter that has a specified probability of including the true population value of that parameter
- The specified probability is usually set at 95% and is called the confidence level; a 95% CI indicates 95% certainty that the interval contains the true value of the expected outcome in the entire population
- CIs can be built across many summary statistical estimates like means, proportions, and ORs
- Precision of CI depends on sample size and variation (larger sample sizes and less variation will have narrower CIs, indicating more precision in results and vice versa)

Key Fact

Precision of CI depends on sample size and variation (larger sample sizes and less variation will have narrower CIs, indicating more precision in results and vice versa).

Power and Type of Errors

The outcomes of hypothesis testing have a chance to fall into two types of errors which depends on the power of the study.

TYPE I ERROR AND TYPE II ERROR

- Type I error (α):
  - Rejection of null hypothesis when the null hypothesis is true
  - In diagnostic studies, it is the false positive rate
- Type II error (β):
  - Accepting the null hypothesis when it is false
  - In diagnostic studies, it is the false negative rate

POWER—Probability of finding a true difference when the difference really exists or the probability of correctly rejecting the null hypothesis when it is false

- Calculation: 1 - the probability of a type II error
  - Example: If the probability of a type II error in a study is 5%, the statistical power of the study is 95%
- 80% to 90% power is considered good

Key Fact

Power is directly proportional to sample size. Smaller sample size lead to type II errors.

ISSUES IN INTERPRETATION OF STUDY RESULTS

Causal Associations, Bias, and Confounding

The association of a risk factor could be direct or indirect, and may or may not have cause–effect relationships. The observed results could be influenced by chance, bias, and confounding.

The Bradford-Hill criteria were detailed by Sir Austin Bradford Hill in 1965 to assess evidence of causation.

- Strength: Stronger associations more likely to be causal
- Consistency: Consistent findings on replication studies by different persons in different places with different samples strengthen the likelihood of an effect
- Specificity: Causation is likely if a very specific population at a specific site has disease with no other likely explanation; the more specific an association between a factor and an effect, the bigger the probability of a causal relationship
- Temporality: The exposure has to precede the effect
- Biologic gradient: Dose–response relationship should exist between exposure and outcome; however, in some cases, the mere presence of the factor can trigger the effect, and in other cases, an inverse proportion is observed, where greater exposure leads to lower incidence
- Plausibility: A biologic mechanism consistent with knowledge between cause and effect is helpful
- Coherence: Coherence between epidemiologic and laboratory findings increases the likelihood of an effect
- Reversibility: Effect of removing the exposure should lower risk
- Experiment: Occasionally, it is possible to appeal to experimental evidence
- Analogy or alternate explanations**:** Effect of similar factors may be considered

Key Fact

Bias is a measure of systematic error.

BIAS—Systematic error in the design, conduct, or analysis of a study that results in an erroneous estimate of an association between exposure and outcome.

Types of bias:

- Selection bias: Errors in participant selection or bias in assignment of participant (e.g., nonresponse bias or exclusion bias)
- Information bias: Errors in data collection and poor categorization in exposure or outcome status
- Recall bias: Poor recall or memory of exposure status in case-control studies
- Interviewer bias: Results obtained differently in the diseased vs. control groups by an unblinded interviewers
- Publication bias: Preferential publication of striking results in small studies

CONFOUNDING—Erroneous study results because of a confounder that threatens the internal validity. Confounder is a variable that can cause or prevent the outcome of interest independently and is not an intermediate variable.

Approaches to control confounding:

- During designing of a study:
  - Matching: Potential confounders are assigned equally in both groups
  - Restriction: Individuals with known risk factors for the outcome are excluded from study
- During data analysis and statistical modeling:
  - Stratification: Compares stratum-specific results
  - Adjustment: Direct and indirect adjustment for risk factor
  - Multivariate analysis: Potential confounder is added as an independent variable during modeling

Validity and Reliability

VALIDITY—Degree to which a variable or study intervention measures what it is supposed to measure, and is dependent on the degree of the systematic error.

- Internal validity: Integrity of the experimental design that is dependent on the amount of error in measurements, including exposure, disease, and associations between these variables; high internal validity implies a lack of error in measurement; internal validity is essential for external validity
- External validity: Relevance of study results to a nonstudy individual or populations; also called generalizability

Key Fact

Internal validity is essential for external validity.

RELIABILITY—Reproducible or consistency of the results on repeated measurement. It refers to amount of error that occurs during measurement due to either random or chance variations.

- Intrarater reliability: Agreement between repeated results by the same individual
- Interrater reliability: Agreement between results obtained by different individuals

Efficacy, Effectiveness, and Number Needed to Treat (NNT)

EFFICACY—Measure of the benefit resulting from an intervention under ideal conditions (e.g., RCTs).

EFFECTIVENESS—Measure of the benefit resulting from an intervention under usual conditions of clinical care (e.g., practical world).

INTENTION TO TREAT ANALYSIS—Method for data analysis in a randomized clinical trial in which individual outcomes are analyzed according

Flash Card Q2

241 of 487 patients treated with salmeterol (49.5%) and 210 of 507 patients treated with salmeterol/fluticasone (41.4%) had at least one exacerbation over the 44-week trial. What is the NNT to prevent one exacerbation for salmeterol/fluticasone group?

to the assigned group, even if the study subject never received the treatment. It provides a measure of effectiveness and not the efficacy.

NNT

- Number of patients who need to be treated in order to prevent one clinical outcome of interest or one adverse event.
- Calculated as the inverse of the absolute risk reduction; that is, NNT = 1/ARR = 1/CER - EER, where absolute risk reduction is ARR, control event rate is CER, and experimental event rate is EER.

Flash Card A2

The absolute risk reduction (ARR) of 49.5%–41.4% = 8.1%. NNT with salmeterol/fluticasone (rather than salmeterol alone) to prevent one additional patient from experiencing an exacerbation in 44 weeks = 1/0.081 = 12.3.

7 Anatomy and Physiology of the Respiratory System

Muhammad Nouman Iqbal MD & Sandeep Khosa, MD

STRUCTURE AND FUNCTIONAL RELATIONSHIPS OF THE LUNG

LUNG SEGMENTS

Bronchopulmonary segments describe the anatomic, functional, and surgical units of the lung (Figure 7-1). They divide the first subdivisions of the lobes on each side into 10 segments, each with its own tertiary bronchus and pulmonary artery (separated by connective tissue that contains the pulmonary veins and lymphatics).



Figure 7-1. Lobes and lung segments.

Mnemonic

Right lung—**A PALM** Seed **M**akes **A**nother **L**ittle **P**alm

Anterior
Posterior
Apical
Lateral
Medial
Superior
Medial—basal
Anterior—basal
Lateral—basal
Posterior—basal

Mnemonic

Left lung—**A**ll **A**ttendings **S**at **I**n **S**un **A**nd **P**raised **L**ungs

Apicoposterior
Anterior
Superior—lingular
Inferior—lingular
Superior
Anteromedial—basal
Posterior—basal
Lateral—basal

SECONDARY LOBULE

The secondary lobule of Miller is the smallest anatomic unit that is delineated by connective tissue septa (Figure 7-2). It measures about 10–25 mm and can be described as having three primary components, as summarized in Table 7-1.



Figure 7-2. Normal secondary lobular anatomy.

Pathologic alterations at specific sites of the secondary lobule can be visible on thin-section computed tomography (CT); these alterations have clinical and histopathologic correlations. Description of these patterns is discussed further in the imaging section; in Chapter 8.).

Table 7-1. Secondary Pulmonary Lobule

Anatomic Region	Contents
Interlobular septa	Pulmonary veins and lymphatics; peripheral interstitial fiber system (better defined in the lung periphery)
Centrilobular	Pulmonary artery and bronchiole
Lobular	Lung acini (varies in number, 3–24)

ALVEOLAR–CAPILLARY UNIT

The alveolar–capillary unit is the site of gas exchange in the lung (Figure 7- 3). It is composed of several important structural elements, as summarized in Table 7-2.



Figure 7-3. The alveolar–capillary unit.

Table 7-2. Alveolar–Capillary Unit

Structural Elements	Function/Key Facts
Type I pneumocytes	Squamous epithelial cells Covers 90-95% of alveolar surface area Not capable of multiplying (mitosis)
Type II pneumocytes	Cuboidal epithelial cells Covers about 3% of alveolar surface area (but makes up for most cells in the alveolar unit, more than type I pneumocytes) "Defender of the alveolus" Produce surfactant → reduces surface tension Replicate and replace damaged type I pneumocytes under physiologic and pathologic conditions (takes 2–5 days)
Capillary endothelium	Loose junctions → leaky Converts angiotensin I → angiotensin II Produces adenosine, prostaglandins Inactivates bradykinin Clears serotonin, norepinephrine
Other cells	Fibroblasts, neutrophils, eosinophils, lymphocytes, plasma cells, basophils or mast cells

Surfactant

Formed by type II pneumocytes and functions to keep alveoli open, dry, and clean. Without surfactant to reduce surface tension, smaller alveoli will always have higher tension (and pressures) than larger alveoli. leading to their collapse as described by the law of Laplace (pressure = [2 × tension]/radius). The composition of surfactant and its properties are summarized in Table 7-3.

Key Fact

Dipalmitoylphosphatidylcholine (DPPC) is the primary component of surfactant that lowers the surface tension. About 90% of DPPC is recycled by type II alveolar cells.

Table 7-3. Components of Surfactant

Constituent	Components	Function
Lipids (90%)	Main component is DPPC	Hydrophilic head and hydrophobic tails → reduces surface tension
Proteins (10%)	Surface proteins: SP-A, SP-B, SP-C, and SP-D *ABCA3* (ATP-binding cassette family of proteins) TTF-1	SP-A and SP-D (hydrophilic)—innate immunity of the lung SP-B and SP-C (hydrophobic)—reduces surface tension *ABCA3* (transmembrane protein of lamellar bodies)—role in transport of surfactant TTF-1—role in surfactant regulation

ABCA3, adenosine triphosphate–binding cassette of subfamily A member 3, DPPC, dipalmitoylphosphatidylcholine; TTF-1, thyroid transcription factor 1

Surfactant also has a significant role in the development and maintenance of lung integrity and in pulmonary dysfunction. Several pulmonary disorders relating to surfactant dysfunction have been identified in various age groups and are summarized in Table 7-4.

Key Fact

Autoimmune pulmonary alveolar proteinosis is almost universally found in adults. Antibodies directed against granulocyte–macrophage colony–stimulating factor are present in about 90% of the cases.

Table 7-4. Surfactant Dysfunction Disorders

Age Group	Mechanism	Clinical Presentation
Neonatal/infantile	Preterm delivery (rare mutations in SP-B, SP-C, *ABCA3*, TTF-1)	Respiratory distress syndrome
Children/adults	Genetic mutations (rare, mutations in SP-B, SP-C, *ABCA3*, TTF-1) Acquired forms—autoimmune response (antibodies against GM-CSF found in 90% of the cases)	Pulmonary alveolar proteinosis

ABCA3, ATP-binding cassette subfamily A member 3; GM-CSF, granulocyte–macrophage colony–stimulating factor; SP, surface protein TTF-1 thyroid transcription factor 1

AIRWAYS AND AIRWAY RESISTANCE

Airways

The airways undergo more than 23 generations of dichotomous branching from the trachea to the alveoli, and can be divided up into three zones.

CONDUCTING ZONE—First 16 generations. This constitutes the trachea, bronchi, bronchioles, and terminal bronchioles. It does not participate in gas exchange and constitutes the anatomic dead space.

TRANSITIONAL AND RESPIRATORY ZONES—Last seven generations. Made up of the respiratory bronchioles, alveolar ducts, and alveolar sacs.

Key Fact

The conducting zone contains no alveoli and does not participate in gas exchange. This constitutes the anatomic dead space.

As the airways branch, they go through several changes to their wall structures (summarized in Table 7-5). Due to the close relationship between structure and function of the respiratory system, changes to the airway by disease states affect the airway resistance.

Table 7-5. Airway Structural Properties

Property	Trachea	Bronchi	Bronchioles	Alveolus
Epithelial layer	Ciliated: pseudostratified columnar	Ciliated: pseudostratified columnar	Ciliated: simple cuboidal	Squamous: type I Cuboidal: type II
Smooth muscle	Yes	Yes	Yes	No
Cartilage	Yes: C-shaped	Yes: C-shaped → "plate-like"	No	No
Special cells	Goblet cells	Goblet cells	Clara cells	Type II surfactant–secreting cells

Airway Resistance

The total pulmonary resistance is determined by two factors: airway resistance and pulmonary tissue resistance. The airway resistance itself represents approximately 80% of the total pulmonary resistance and is the most clinically relevant when discussing various disease states.

To simplify the flow of air through the lung, we assume the airways are rigid tubes with columns of air with laminar flow, and use the law of Poiseuille to describe its behavior. According to this law, small changes in the radius can have profound effects on the resistance to air flow.

$$\Delta\text{Pressure} = \text{air flow} \times \text{resistance}$$

$$\text{Resistance} = 8\eta L/\pi r^4$$

η = viscosity of fluid, L =length of tube, r = radius of tube

About a third of the total airway resistance is located in the upper airway, and the rest in the lower airways. In the lower airways, the structures with the highest resistance to air flow are the medium-sized bronchi, rather than the small airways. (This is due to the parallel arrangement of the small airways, reducing their total airway resistance.)

Key Fact

The smallest airway has the smallest radius; therefore, individually it has the highest resistance. However, due to the lungs dichotomous branching, the smallest airways are arranged in parallel (resistances add reciprocally) and their total resistance is significantly reduced. As a result, the airway structures with the highest collective resistance to air flow are the medium-sized bronchi.

Air flow can be laminar, turbulent, or mixed (transitional). Reynolds number, a dimensionless unit, can be used to predict whether flow will be laminar or turbulent.

$$\text{Reynolds number} = (\rho \times Ve \times D)/\eta$$

ρ = density of fluid, Ve = linear velocity of fluid, D = diameter of tube, η = viscosity of fluid

Key Fact

Heliox has the same viscosity of air but has a much lower density. This results in lowering the Reynolds number, and it increases the likelihood of laminar flow. This also will increase the speed of sound through air, and will make you sound like a talking chipmunk.

In general, the greater the velocity of air flow and the larger the diameter of the airway, the higher the likelihood that air flow will be turbulent (Reynolds number exceeds 2000). Because of this, the air flow in the larger upper airways is usually turbulent or mixed, and it is laminar in the smallest airways in normal physiologic state.

In the setting of turbulent air flow, a greater driving pressure is needed to move the same amount of air; as a result, the resistance to air flow becomes influenced more by the density than viscosity of the gas. Under these circumstances, the resistive work of breathing can be decreased with the use of heliox (80% helium, 20% oxygen). Heliox has the same viscosity of air but a much lower density, and increases the probability of laminar flow.

PULMONARY BLOOD FLOW (PBF) AND PULMONARY VASCULAR RESISTANCE (PVR)

Pulmonary Vessels

The lung receives blood from two vascular systems: the pulmonary circulation and the bronchial circulation. A small portion of the bronchial circulation drains into the pulmonary veins and is part of the natural anatomic right-to-left shunt. Compared to the systemic circulation, the pressures within the pulmonary circulation are very low.

PVR

The PVR cannot be directly measured, but the law of Poiseuille can be applied to estimate its value.

$$R = \Delta press/flow$$

For pulmonary circulation: $PVR = (MPAP - MLAP)/PBF$

MLAP = mean left arterial pressure, MPAP = mean pulmonary artery pressure, PBF = pulmonary blood flow

MLAP is approximated using the pulmonary capillary wedge pressure (or pulmonary artery occlusion pressure) measurement by wedging a pulmonary artery catheter. The PBF (or cardiac output) can be measured using either the Fick principle or thermal dilution technique.

Due to low intravascular pressures and highly compliant vessel walls, extravascular factors, such as gravity and lung volume, are significantly influenced by the PVR of the respiratory system. In addition, there are a number of neural and humoral effects on the total PVR and, hence, on PBF. These are summarized in Table 7-6.

Table 7-6. Factors Influencing Total PVR

Factors	Effect
Lung volume	↑LV → compresses alveolar vessels → ↑PVR ↓LV → compression of extraalveolar vessels → ↑PVR
Gravity	Hydrostatic effects lead to alveolar recruitment → ↓PVR in gravity dependent regions
Increased PBV	Alveolar recruitment → ↓PVR
Increased interstitial pressures	Compression of vessels → ↑PVR
Increased blood viscosity	↑Reynolds number → ↑PVR
Positive pressure ventilation	Compression and derecruitment of alveolar vessels (and extraalveolar vessels) → ↑PVR
Alveolar hypoxia	Locally mediated hypoxic vasoconstriction → ↑PVR
Angiotensin, endothelin, histamine, norepinephrine, epinephrine, α-adrenergic agonists	↑PVR
Prostaglandin, prostacyclins	PGE_1 and PGI_2 → ↓PVR $PGE_{2\alpha}$ and PGE_2 → ↑PVR
Bradykinin, acetylcholine, β-adrenergic agonists, nitric oxide	↓PVR
Autonomic nervous system	Stimulation of sympathetic innervation → ↑PVR Stimulation of parasympathetic innervation → ↓PVR

LV, lung volume, PBV, pulmonary blood volume; PG, prostaglandin; PVR, pulmonary vascular resistance

Key Fact

Positive pressure ventilation can cause profound effects on alveolar vessels, extraalveolar vessels, and other very compliant intrathoracic vessels like the vena cava. Clinically, if a patient's circulatory system is already working in overdrive (i.e., sepsis, hypovolemia) and cannot respond to the sudden increase in PVR from mechanical ventilation, an unsafe drop in left ventricular preload and systemic blood pressure can result.

PULMONARY GAS EXCHANGE

Gas Exchange in the Lungs

Using the Dalton law of partial pressures, we can estimate the partial pressure of oxygen in the alveolus (PAO_2) using the following equation:

$$PAO_2 = FiO_2(Pb - PH_20) - PaCO_2/R$$

FiO_2 = fraction of inspired oxygen, Pb = barometric pressure, PH_2O = water vapor partial pressure, $PaCO_2$ = partial pressure of arterial CO_2, R = CO_2 eliminated/O_2 consumed (production of CO_2/production of O_2 [varies based on fuel utilized]).

A useful clinical application of the above equation is the calculation of the alveolar– arterial oxygen difference (A–a gradient= PAO_2 - PaO_2). A– a gradients of larger than normal range (5–15 mm Hg, increases with age) can be seen in shunt-like states, ventilation/perfusion mismatches, and impairments in diffusion. For further discussion of these topics, see hypoxic respiratory failure section in Chapter 2.

CO_2 is removed by the respiratory ventilation at the same rate it is produced. The relationship is inversely proportional:

$$PaCO_2 = VCO_2/VA \times K$$

$PaCO_2$ = partial pressure of arterial CO_2, VCO_2 = CO_2 production, VA = alveolar ventilation, K = a constant

The VA cannot be measured directly but can be calculated if we subtract the dead space ventilation (VD) from the minute ventilation (VE).

$$VA = VE - VD$$

As discussed earlier in this chapter, the VD in normal subjects is attributable to anatomic dead space (conducting zone of the lung). In disease states, there may be development of physiologic dead space (volume of gas that is ventilated but not perfused), and this can be calculated using the Bohr equation.

$$VDCO_2/VT = (PaCO_2 - PECO_2)/PaCO_2$$

$VDCO_2$ = physiologic dead space for CO_2, $PECO_2$ = end-tidal CO_2 ~ alveolar PCO_2

Gas Exchange in the Blood

O_2 delivery to the tissues (DO_2) is determined by the following relationships:

$$DO_2 = CaO_2 \times CO$$

CaO_2 = arterial oxygen content, CO_2 = cardiac output (stroke volume × heart rate)

$$CaO_2 \text{ (mL/dL)} = (\text{Hgb in g/dL} \times 1.34 \times O_2\text{sat\%}) + (0.003 \times PaO_2)$$

It is important to note that all the increases in cardiac output, hemoglobin concentration, O_2 saturation, or partial pressure of oxygen can lead to increases in the arterial blood oxygen content, although to varying degrees.

Ventilation and Perfusion Relationships

In a given lung unit, it is the ratio of ventilation to perfusion that ultimately determines the effectiveness of gas exchange. In normal individuals at rest, this ratio can vary from 0.6 to 3.0 and, in addition to the natural anatomic shunt, also can contribute to differences in A–a gradient. In patients with lung disease, the degree of ventilation/perfusion inequality can have profound effects on gas exchange. Clinically, we can test for distributions of ventilation and perfusion and we can test for their relationships using various techniques.

In greater degrees of inequality (ventilation/perfusion ratios close to 0) or in the presence anatomic shunts, the shunt fraction equation can be applied to quantify the proportion of cardiac output that bypasses oxygenation in the pulmonary capillaries.

$$Qs/Qt = (CcO_2 - CaO_2)/(CcO_2 - CvO_2)$$

Qs/Qt is the shunt fraction, CcO_2 is the end capillary oxygen content, CaO_2 is the arterial oxygen content, and CvO_2 is the mixed venous oxygen content. CaO_2 and CvO_2 are calculated from arterial and mixed venous blood gas measurements, respectively. CcO_2 is estimated from the PAO_2.

To calculate areas of true anatomic shunt, 100% FiO_2 should be applied to the patient for 20 to 30 minutes to saturate the hemoglobin with oxygen in areas that have very low ventilation/perfusion ratios and to eliminate their potential contribution in an estimate.

LUNG ZONES—Ventilation/perfusion mismatches also can result from the effects of gravity, and as a result, this creates pressure differences between the alveolar, arterial, and venous systems of the lung. Experimentally, this has led to the identification of regional pressure relationships based on gravity, known as lung zones.

Flash Card Q1

A patient has a hemoglobin (Hgb) of 6, O_2 saturation of 95%, PaO_2 of 80, and a CO of 3 L. Would an increase in the Hgb to 8 or an increase in the PaO_2 to 100 lead to a larger increase in the delivery of oxygen to the tissues?

Pressure in alveoli (PA), arteries (Pa), and veins (Pv) are in

- Zone 1 = PA > Pa > Pv
- Zone 2 = Pa > PA > Pv
- Zone 3 = Pa > Pv > PA

The boundaries between the lung zones can be altered by body position and lung volume. When dealing with pulmonary artery catheter placement, the catheter tip is theoretically desired to be located in zone 3 to obtain accurate assessment of left atrial pressures at end expiration.

Diffusion

The diffusion of gas through the alveolar–capillary membrane is described by the Fick law of diffusion. The factors that limit gas transfer are based mainly on the diffusion coefficient, alveolar capillary membrane surface area, and the partial pressure of the gas across the membrane.

Volume of gas diffusing (mL/min) = area × diffusion coefficient × partial pressure difference across barrier/ thickness of barrier

Diffusion coefficient is proportional to the solubility of gas in the diffusion barrier and inversely related to its molecular weight.

- The diffusion of gases can be categorized as either
- **Perfusion-limited:** The partial pressure of the gas across the membrane has sufficient time to equilibrate as it passes through pulmonary capillaries; gas transfer is limited by perfusion, or the cardiac output (e.g., nitrous oxide)
- **Diffusion-limited:** The partial pressure of the gas across the membrane does not equilibrate as it passes through the pulmonary capillaries (gas chemically combined to hemoglobin does not contribute) and gradient is maintained; gas transfer is limited by the alveolar–capillary barrier (e.g., carbon monoxide)

Under normal resting conditions, the diffusion of oxygen and carbon dioxide is perfusion-limited; however, in disease states (i.e., pulmonary fibrosis, high altitude), the transfer can become diffusion-limited.

Carbon Monoxide is unique in its properties and is used to determine the ability of a lung to transfer gas. This is discussed further in Chapter 8.

Flash Card A1

Increase in the Hgb to 8 would result in a larger magnitude of increased oxygen delivery to the tissues. This can be determined based on the equation listed at the op of page 345

LUNG MECHANICS AND LUNG VOLUMES

Muscles of Respiration

The diaphragm is the primary muscle of inspiration and is innervated by phrenic nerves emerging from C3–C5. The external intercostals, parasternal intercostals, and scalene muscles (T1–T11 innervation) contract in collaboration with diaphragm and increase the anteroposterior and transverse diameters of chest wall.

It is important to note that the diaphragm plays a larger role during inspiration in the supine position than in the upright posture during normal breathing, and as a result, early diaphragm dysfunction may present with symptoms in the supine position. In the setting of a unilateral paralyzed hemidiaphragm, a rapid inspiratory effort will demonstrate paradoxic movement cephalad of the paralyzed hemidiaphragm (due to the increased negative intrapleural pressure that develops during inspiration). This is the basis of the sniff test. Expiration is normally a passive maneuver, and elastic recoil of the lung causes air to flow out of the lungs.

Compliance

Lung inflation is the result of a pressure gradient between the airway pressure and the pleural pressure, and it has to overcome the elastic recoil of the lung and the airway resistance (discussed earlier in this chapter). Instead of measuring the elastic recoil of the lung, or elasticity, we describe its inverse, or compliance. Compliance is defined as the ease with which the lung is expanded.

$$\text{Compliance} = \Delta\text{volume}/\Delta\text{pressure}$$

Compliance can be used clinically during mechanical ventilation in critical illness, and unless an esophageal balloon is used to estimate the pleural pressure, the total compliance of the respiratory system is measured (chest wall and lung in series). For further details, see Chapter 2, section on mechanical ventilation monitoring.

Lung Volumes

The interactions of the lung, chest wall, and muscles of respiration determine the standard lung volumes and capacities, which are summarized in Table 7-7 and shown in Figure 7-7. Capacities are composed of two or more volumes. The methods of measuring lung volumes and their patterns in respiratory diseases are discussed in Chapter 8. It is important to note that all lung volumes are affected by height, age, race, and sex.

Table 7-7. Lung Volumes and Capacities

Volume/Capacity	Definition	Notes
TV	Volume of gas per breath; determined by respiratory center in brain; normal value ~ 500 mL in a 70-kg adult	TV can increase tremendously during exercise
RV	Volume of gas left in the lungs at the end of forced expiration; normal value ~ 1.5 L in a 70-kg adult	RV is determined by strength of muscles of expiration and elastic recoil of lungs; diseases affecting this can cause a significant increase in RV (e.g., emphysema)
IRV	Volume of gas inhaled during a forceful inspiratory effort, at the end of normal inspiration; normal value ~ 2.5 L in a 70-kg adult	IRV is determined by strength of inspiratory muscles
ERV	Volume of gas exhaled during a forceful expiratory effort, at the end of normal expiration; normal value ~ 1.5 L in a 70-kg adult	Low ERV values can be seen in obesity due to poor expiratory effort
FRC	Volume of gas in the lungs at end of normal expiration (resting volume); normal value ~ 3 L in a 70-kg adult	FRC is volume of gas when inward elastic recoil of lungs is opposite and equal to outward recoil of chest wall
IC	Volume of gas inspired during maximal inspiratory effort, at the end of normal expiration (TV + IRV); normal value ~ 3 L in a 70-kg adult	IC along with spirometry can be helpful in determining degree of obstruction
VC	Volume of gas that can be expelled after a maximal inhalation (IRV + TV + ERV, or TLC - RV)	During a forced VC, the first second of expiration (FEV_1) is most sensitive to changes in airway resistance
TLC	Volume of gas in the lungs at the end of forceful inspiratory effort (RV + TV + IRV + ERV); normal value ~ 6 L in a 70-kg adult	TLC is determined by strength of contraction of inspiratory muscles, compliance of lungs and chest wall

TV, tidal volume; RV, reserve volume; IRV, inspiratory reserve volume; ERV, expiratory reserve volume; FRC, functional residual capacity; IC, inspiratory capacity; VC, vital capacity; FEV_1, forced expiratory volume in 1 second; TLC, total lung capacity



Figure 7-4. Lung volumes and capacities
(Reproduced from Wikimedia Commons, CC BY-SA 3.0.)

RESPIRATORY CONTROL

The ventilator control of respiration is complex and involves multiple sensors, controllers, and effectors. A simplified model is illustrated in Figure 7-5. A group of nuclei in the medullary respiratory center (beneath the floor of the fourth ventricle) is believed to initiate breathing and is surrounded by additional nuclei in the pons that also play a role (Table 7-8). Table 7-9 summarizes clinically relevant receptors and reflexes that modify respiration.



Figure 7-5. Respiratory control model.

Table 7- 8. CENTRAL CONTROL—MEDULLARY RESPIRATORY CENTER

Group	(Location) Nucleus	Function	Afferents	Efferents
DRG	(Medulla) Tractus solitarius	Inspiratory neurons	CN IX, X	Contralateral spinal cord → main input to phrenic nerves
VRG	(Medulla) Nucleus ambiguus Retrofacial: Bötzinge Pre-Bötzinger Para-ambigualis Retro-ambigualis	Inspiratory and expiratory neurons	Collateral fibers from DRG	Pharyngeal, laryngeal, intercostal muscles. **Pre-Bötzinger complex is the "pacemaker" of respiratory system**
Apneustic center	(Lower pons)	Terminates inspiration	CN X	Medullary inspiratory neurons
PRG	(Upper pons) Parabrachialis medialis Kolliker-Fuse	"Fine-tune" breathing pattern	Pulmonary inflation stretch receptors → inhibit PRG	Modulate medullary neurons

DRG, dorsal respiratory group; CN, cranial nerve; VRG, ventral respiratory group; PRG, pontine respiratory group

Table 7- 9. Receptors and Reflex Mechanisms

Reflex	Receptor	Pathway
Hering-Breuer inflation reflex	Slowly adapting pulmonary stretch receptors in airways	Inflation → CN X → cessation/reduced inspiration effort
Hering-Breuer deflation reflex	Stretch, irritant and J receptors	Deflation → CN X → hyperpnea
Paradoxic reflex of Head	Stretch receptors	Inflation → CN X → deep inspiration (sighs)
Cough	Irritant receptors in upper airway	Stimulus → CN X → cough, bronchoconstriction
Sneeze	Irritant receptors in nasal mucosa	Stimulus → trigeminal/olfactory nerves → sneeze, bronchoconstriction
Chemoreceptor reflex	Carotid and aortic bodies	Low PaO_2, high $PaCO_2$, low pH → hypercapnia → CN IX, X → DRG →hyperpnea, bronchoconstriction, bradycardia
Baroreceptor reflex	Carotid sinus and aortic arch stretch receptors	High blood pressure → CN IX, X → apnea, bronchodilation, bradycardia
Pulmonary embolism or vascular congestion	J receptors in pulmonary vessels	Vascular stimulus → CN X → tachypnea

Central chemoreceptors respond to changes in pH or P_{CO_2}, whereas the chemoreceptors respond to changes in pH, P_{CO_2}, or PO_2. In addition, the VA response varies depending on whether the change is P_{CO_2} or PO_2. This is illustrated in Figures 7-6 and 7-7.



Figure 7-6. Effects of hypercapnia on VA.

There is a linear increase in VA when CO_2 rises from 38-50 mmHg

For a given P_{CO_2}, there is a greater increase in VA for lower P_{CO_2} levels.

COPD, sleep, narcotics, and anesthesia can shift the ventilator response curve to the right and decreases the slope.

Metabolic acidosis can shift the ventilator response curve to the left and increases the slope.

Key Fact

Both the central and peripheral chemoreceptors respond to changes in pH and P_{CO_2}; however, only the peripheral chemoreceptors respond to changes in the PO_2. In the setting of eucapnia, PO_2 can drop to levels as low as 40 mm Hg before VA is significantly affected.



Figure 7-7. Effect of hypoxia on VA.

Peripheral chemoreceptors (carotid >> aortic) mediate ventilator response to hypoxia.

In setting of eucapnia, it is only until the PO_2 reaches a level below 40 mmHg is there a significantly in increased ventilator response

In the presence of elevated P_{CO_2} levels, ventilator response increases at higher P_{CO_2}levels

ACID–BASE DISORDERS

The Kassirer–Bleich (KB) equation (modified from the Henderson–Hasselbalch equation) describes a fixed relationship between the $PaCO_2$, pH, and the bicarbonate [HCO_3].

$$pH \propto [HCO_3]/PaCO_2$$

This equation forms the basis of blood gas interpretation. A six step approach to acid–base problems is recommended.

STEP 1—Assess internal validity using a modified version of the above equation. We take advantage of the linear relationship that exists between the hydrogen ion (H^{+}) and pH (holds true within pH ranges of 7.2 to 7.5).

$$H^{+}\,(nmol) = (24 \times PaCO_2)/[HCO_3]$$

$\Delta 1$ nmol ~ $\Delta 0.01$ pH in the opposite direction, and 40 nmol ~ pH = 7.40
(e.g., 30 nmol ~ pH = 7.50, 50 nmol ~ pH = 7.30)

If there is a discrepancy between the calculated H+ and the measured pH, the test may be invalid. Additional errors that may occur can be due to collection methods (venous blood, air in sample, sample > 30 minutes, and not iced) and measuring errors (calibration, leukocyte larceny).

STEP 2—Determine the primary disorder; that is acidemia (pH < 7.40) or alkalemia (pH > 7.40). Generally, a primary disorder can be identified based on the direction of the CO_2 alone, however it is important to note that a disturbance can still be present even in the setting of a normal pH because of the fixed relationship between the HCO_3 and $PaCO_2$. Table 7-10 summarizes the primary disturbances.

Table 7-10. Primary Disturbances

Acidosis/ Alkalosis	Primary Disturbance	Direction of pH	Direction of $PaCO_2$
Acidosis	Respiratory	pH↓	$PaCO_2$↑
Acidosis	Metabolic	pH↓	$PaCO_2$↓
Alkalosis	Respiratory	pH↑	$PaCO_2$↓
Alkalosis	Metabolic	pH↑	$PaCO_2$↑

STEP 3—Determine the appropriateness of compensation for the primary disorder identified using the appropriate equation. The compensation is always in the same direction as the primary disorder in order to normalize the pH (as per the KB equation). If it is not in the correct direction, then there likely is an additional acid–base disorder present. Generally, the compensation is partial rather than complete and does not return the pH to normal (7.40).

- Metabolic acidosis (Winter's formula): $P_{CO_2} = [1.5 \times (\text{serum } HCO_3)] + 8 (\pm 2)$
- Metabolic alkalosis: $\Delta pCO_2 = 0.6 \times \Delta HCO_3 (\pm 2)$
- Respiratory acidosis: ↑ P_{CO_2} by 10, ↑HCO_3 by 1 (acute) or 4 (chronic)
- Respiratory alkalosis: ↓ P_{CO_2} by 10, ↓HCO_3 by 2 (acute) or 4 (chronic)

Key Fact

In the setting of a metabolic acidosis, a useful approximation to estimate the expected P_{CO_2}:: P_{CO_2} ~ last two digits of the pH.

STEP 4—Determine if there is an anion gap (AG) present.

$$AG = Na - (HCO_3 + Cl)$$

In the setting of a normal albumin (4 gm/dL), the normal AG range is 12 +/- 2 mEq/L. For each 1 gm/dl decrease in albumin, the normal AG for that patient will be 2.5 mEq/L lower. An elevated AG can provide significant clinical clues to underlying processes.

Mnemonic

Anion gap metabolic acidosis— **MUDPILES:**
Methanol, metformin
Uremia
Diabetic/alcoholic/starvation ketoacidosis
Paraldehyde
Iron, isoniazid
Lactic acidosis (cyanide, hydrogen sulfide, CO, methemoglobin)
Ethylene glycol
Salicylates

STEP 5—If an AG metabolic acidosis exists, we make an assumption that for each decrease in the HCO_3, there will be proportional increase in the AG. If it does not exist, then there must be an additional acid–base disorder present. This relationship can be calculated using the ΔΔgap.

$$\Delta\Delta gap = \Delta AG/\Delta HCO_3 = (AG - 12^*)/(24 - HCO_3)$$

*assumes albumin= 4.0

If the ratio is between 1 and 2, a pure AG metabolic acidosis is present.

If the ratio is < 1, there is a larger decrease in the HCO_3 that we account for by the given change in the AG, indicating a concomitant nongap AG metabolic acidosis must be present.

A ratio > 2 indicates a smaller decrease in the HCO_3 that we account for by the given change in the AG; thus, a concomitant metabolic alkalosis must be present.

Table 7-11 describes common mixed acid–base disturbances seen in clinical practice.

Flash Card Q2

Identify the following acid–base disorder(s):
A) pH = 7.56,
B) P_{CO_2} = 22 mm Hg
C) P_{O_2} = 90 mm Hg on 35% FiO_2,
D) Na= 127
K= 4.0
Cl= 80
HCO_3= 20
BUN= 35
Cr= 1.5
Albumin= 4.0

Table 7-11. Selected Mixed and Complex Acid–Base Disturbances

Disorder	Characteristics	Selected situations
Respiratory acidosis with metabolic acidosis	↓in pH ↓in HCO_3 ↑in $Paco_2$	Cardiac arrest Intoxications Multi-organ failure
Respiratory alkalosis with metabolic alkalosis	↑ pH ↑HCO_3 ↓$Paco_2$	Cirrhosis with diuretics Pregnancy with vomiting Overventilation of COPD
Respiratory acidosis with metabolic alkalosis	pH in normal range ↑$Paco_2$ ↑HCO_3	COPD with diuretics, vomiting, NG suction Severe hypokalemia
Respiratory alkalosis with metabolic acidosis	pH in normal range ↓$Paco_2$ ↓HCO_3	Sepsis Salicylate toxicity Renal failure with CHF or pneumonia Advanced liver disease
Metabolic acidosis with metabolic alkalosis	pH in normal range HCO_3 normal	Uremia or ketoacidosis with vomiting, NG suction, diuretics, etc.

CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; NG, nasogastric
(Modified, with permission, from Kaufman DA. Interpretation of Arterial Blood Gases (ABGS) American Thoracic Society. http://www.thoracic.org/clinical/critical-care/clinical-education/abgs.php. Accessed August 20, 2014.)

Flash Card A2

A) Triple disorder is present
B) Respiratory alkalosis
C) Metabolic acidosis (anion gap)
D) Metabolic alkalosis

8 Common Respiratory Symptoms, Pulmonary Imaging, & Procedures

Stephanie Young Clough, MD

COMMON RESPIRATORY SYMPTOMS

Common respiratory symptoms include dyspnea and cough. Obtaining a thorough history and physical examination is the first step in evaluating a patient with these complaints. If done properly, the findings generally suggest the correct diagnosis, which can be confirmed by the appropriate diagnostic study.

DYSPNEA

The onset of dyspnea can give a clue to its cause (Table 8-1).

Table 8-1. Causes of Dyspnea Characterized by Onset

Instantaneous	Acute/Subacute (Hours–Days)	Chronic (Months–Years)
Pulmonary embolus Pneumothorax	Asthma COPD exacerbation Upper-airway obstruction Pneumonia Pulmonary edema Acute hypersensitivity pneumonitis Lobar atelectasis Acute interstitial pneumonia Pulmonary hemorrhage Pulmonary embolus Pulmonary vasculitis Pleural effusion Acute myocardial infarction Arrhythmia Valvular disease Tamponade Aortic dissection Metabolic acidosis Hyperventilation syndrome Anxiety Superior vena cava obstruction Anaphylaxis	COPD Asthma Interstitial lung disease Sarcoidosis Bronchiectasis Lymphangitic carcinomatosis Chronic thromboembolic disease Primary pulmonary hypertension Veno-occlusive disease Pleural effusion Hypoventilation: Chest wall deformity Neuromuscular weakness Obesity Anemia Thyrotoxicosis Pregnancy

COPD, chronic obstructive pulmonary disease.

If considering the listed etiologies does not yield a diagnosis, other considerations include carbon monoxide exposure, gastroesophageal reflux disease, and deconditioning.

History

Additional information to obtain from the history:

- Smoking
- Occupational exposure and hobbies
- Use of home humidifier or air conditioning
- Travel
- Rheumatologic disorders/symptoms
- History of malignancy/weight loss
- Immunodeficiency
- Drug use
- New medications

Other important considerations:

- Trepopnea: Dyspnea in a lateral decubitus position suggests unilateral lung disease.
- Platypnea: Dyspnea while upright that is relieved with lying down is associated with hepatopulmonary syndrome secondary to the increase in blood by gravity to intrapulmonary vascular dilations when upright. Although commonly associated with hepatopulmonary syndrome, other causes include intracardiac right-to-left shunt (patent foramen ovale) after pneumonectomy or cardiac abnormality (aortic aneurysm, pericardial effusion) and skeletal deformity as a result of increased streaming of blood from the inferior vena cava to the left atrium caused by mechanical distortion of the interatrial septum.

Key Fact

Platypnea is shortness of breath when upright and is commonly associated with hepatopulmonary syndrome.

Physical Examination

A thorough physical examination is important because many etiologies of dyspnea cause extrapulmonary manifestations.

CLUBBING—Characteristics (Figure 8-1):

- Softening and periungual erythema of the nail beds
- Increase in the normal 165° angle between the nail and cuticle
- Enlargement of the distal phalanx
- Curvature of nails



A

B

C

Figure 8-1. Clubbing. (A) Red line showing the outline of a clubbed nail. (B) Side view of clubbed fingers. (C) Frontal view of clubbed fingers.
(Figure A, B, and C reproduced from Wikimedia Commons, CC BY-SA 3.0.)

Table 8-2 shows conditions associated with clubbing.

Table 8-2. Conditions Associated with Clubbing

Respiratory	Malignancy	Cardiac	Gastrointestinal	Other
Interstitial lung disease: Asbestosis Idiopathic pulmonary fibrosis Collagen vascular disease Langerhans histiocytosis Lipoid pneumonia Chronic infection: Bronchiectasis Tuberculosis Lung abscess Empyema Cystic fibrosis	Bronchogenic lung cancer Pleural tumor Esophageal tumor Lymphoma	Congenital heart disease Subacute bacterial endocarditis Left atrial myxoma Vascular disease (Takayasu arteritis, Behçet disease)	Inflammatory bowel disease Advanced liver disease Celiac disease	Familial Thalassemia Thymoma

Key Fact

Hypertrophic osteoarthropathy is most commonly associated with primary bronchogenic carcinoma, involves the long bones of the upper and lower extremities, and resolves with curative surgery.

When clubbing is associated with subperiosteal formation of new cancellous bone at the distal ends of long bones, it is called hypertrophic osteoarthropathy. This is most commonly caused by lung carcinoma. The proposed pathogenesis includes circulatory bypass of the lung with localized activation of platelet–endothelial cells and subsequent release of fibroblast growth factors or tumor production and release of vascular endothelial growth factor.

Symptomatic Treatment

When dyspnea is not relieved by treatment of the disease, the focus is to relieve the symptom. Considerations include:

- Reducing respiratory effort through breathing technique, nutritional repletion, or overnight "resting" with noninvasive ventilation
- Decreasing respiratory drive with oxygen or inhaled furosemide
- Altering central perception with opiates

There is limited evidence to support their use.

Key Fact

Pulmonary rehabilitation improves symptoms. The greatest effect is found when high-intensity endurance exercises are used in patients with COPD.

Pulmonary rehabilitation has been shown to improve symptoms in patients with chronic obstructive pulmonary disease (COPD). Best outcomes appear to be achieved with high-intensity endurance exercises. Those who have significant dyspnea and cannot tolerate high-intensity exercise can consider interval training and resistance or strength training of the extremities. Neuromuscular electrical stimulation can be used for severely debilitated patients, with some benefit. Inconsistent benefits have been reported with flexibility training, inspiratory muscle training, and anabolic hormonal supplementation as adjuncts to exercise training.

COUGH

The most common cause of acute and subacute cough is viral infection. *Bordetella* can cause persistent cough lasting 3–8 weeks. Cough from the common cold can persist up to 8 weeks because of heightened cough reflex, which can be treated with first-generation antihistamines and decongestants. Newer-generation, nonsedating antihistamines are ineffective. Naproxen may also help in this setting.

Table 8-3 shows the six most common causes of chronic cough and their characteristics.

Table 8-3. Causes of Chronic Cough

Cause	Characteristic
Upper airway cough syndrome	Associated with frequent nasal discharge, sensation of liquid dripping into back of throat, frequent throat clearing
Gastroesophageal reflux	Nonproductive cough that occurs after meals or worsens with lying down; may be accompanied by heartburn, a bitter taste, belching
Asthma	Nocturnal cough; sputum can be thick and mucoid with casts
Chronic bronchitis	Cough productive of sputum on most days for > 3 consecutive months for > 2 years
Bronchiectasis	Cough, with copious, foul, purulent discharge; intermittent blood; influenced by posture
Nonasthmatic eosinophilic bronchitis	Sputum eosinophilia; > 3% of nonsquamous cells induced by nebulized hypertonic saline

Other potential causes:

- Bronchogenic carcinoma
- Metastatic carcinoma
- Mediastinal tumors
- Sarcoidosis
- Chronic aspiration
- Interstitial lung disease
- Left ventricular failure

Figure 8-2 shows a diagnostic algorithm for chronic cough.



Figure 8-2. Evaluation of chronic cough. ACE, angiotensin-converting enzyme; CT, computed tomography; GERD, gastroesophageal reflux disease; HRCT high-resolution computed tomography; PFTs, pulmonary function tests; UACS, upper airway cough syndrome.

HEMOPTYSIS

Table 8-4 shows causes of hemoptysis. Miscellaneous causes include catamenial hemoptysis as a result of endometriosis and cocaine use. Massive hemoptysis is discussed separately in Chapter 2.

Figure 8-3 shows an algorithm for the evaluation of hemoptysis. It is important to first determine the source of the bleed. When a lung source is suspected, chest x-ray is indicated. Depending on the results and risk factors, chest computed tomography (CT) scan or bronchoscopy is warranted.

Table 8-4. Causes of Hemoptysis

Infection	Neoplasm	Vascular	Trauma	Hematologic/ Immunologic
Bronchitis Tuberculosis Fungal infection Pneumonia Lung abscess Bronchiectasis	Bronchogenic carcinoma Bronchial adenoma Kaposi sarcoma	Pulmonary infarction Mitral stenosis Arteriovenous malformation Aortic aneurysm (aortotracheal fistula) Dieulafoy disease (superficial, subepithelial bronchial artery contiguous with bronchial mucosa)	Foreign body Airway trauma	Goodpasture syndrome Granulomatosis with polyangiitis Idiopathic hemosiderosis Lupus pneumonitis Blood dyscrasia Behçet disease



Figure 8-3. Evaluation of hemoptysis.
BUN, blood urea nitrogen; CT, computed tomography; ENT/GI, ear, nose, and throat/gastrointestinal.

PULMONARY IMAGING

CHEST RADIOGRAPHY

Atelectasis

Radiographic findings associated with lobar atelectasis are shown in Table 8-5 and Figure 8-4. Additional general radiographic findings:

- Displacement of hilar/mediastinal structures
- Elevation of the hemidiaphragm
- Decreased distance between ribs
- Compensatory overinflation of the remaining lobes

Table 8-5. Atelectasis and Radiographic Findings

Location of Atelectasis	Posteroanterior/Anteroposterior Radiograph	Lateral Radiograph
Right upper lobe	Wedge-shaped opacity in upper right hemithorax Major fissure displaced anteriorly Minor fissure displaced upward Right upper lobe collapse + central carcinoma = reverse S sign of Golden	Triangular opacity
Left upper lobe	Opacification of left perihilar area with silhouetting of left heart border Luftsichel sign: Lucency next to aortic knob, result of compensatory overinflation of superior segment of left lower lobe	Major fissure displaced forward
Lower lobe	Triangular opacity in lower hemithorax	Opacity over lower thoracic vertebral bodies Loss of posterior hemidiaphragm
Right middle lobe	Opacity with silhouetting of right heart border	Linear or triangular opacity over cardiac silhouette Major fissure displaced superiorly Minor fissure displaced inferiorly



Figure 8-4. Right lower lobe atelectasis.
(Reproduced from Wikimedia Commons, CC BY-SA 3.0.)

CHEST CT SCAN

Chest CT scan produces images based on the different absorption profiles of structures in a cross-sectional plane. The additional use of intravenous contrast helps to delineate vascular from nonvascular structures.

Chest CT scan is helpful in the evaluation of the central airways. Table 8-6 describes pathology of the tracheobronchial tree and associated CT findings.

Table 8-6. Tracheobronchial Tree Abnormalities and Computed Tomography Scan Findings

Abnormality	CT Scan Findings
Tracheal stenosis	1–2 cm narrowing of trachea at thoracic inlet
Tracheobronchomalacia	> 50% decrease in cross-sectional area of lumen on dynamic expiratory images
Saber-sheath trachea	Marked decrease in transverse diameter of intrathoracic trachea associated with increase in sagittal diameter
Tracheobronchopathia osteochondroplastica	Calcified nodules protruding into tracheal lumen and sparing of posterior membrane because of absence of cartilage in this area
Relapsing polychondritis	Thickening of anterolateral tracheal wall with sparing of posterior membrane
Amyloidosis	With involvement of tracheobronchial tree, concentric/nodular thickening of tracheal submucosa
Granulomatosis with polyangiitis	Involvement of tracheobronchial tree rare, usually late in course of disease, with circumferential thickening, ulceration, and luminal narrowing
Mounier-Kuhn syndrome	Thin wall trachea with scalloped/corrugated appearance, diameter > 3 cm, diverticulosis

Key Fact

Tracheobronchial tree abnormalities that spare the posterior membrane are tracheobronchopathia osteochondroplastica and relapsing polychondritis.

CT Angiography

CT angiography has effectively replaced the use of pulmonary angiography and ventilation–perfusion scans for the diagnosis of pulmonary embolus. Aortic abnormalities and pulmonary venous malformations can also be identified. The timing of bolus administration and imaging depends on the possible abnormality being evaluated. Typically, when evaluating for a pulmonary embolus, images are obtained 20 seconds after contrast bolus. Evaluation of an aortic dissection would have a longer delay.

High-Resolution CT Scan

Very thin slices (1 mm versus 7–10 mm with conventional CT) are obtained. The primary indication is identifying interstitial lung disease or bronchiectasis. Table 8-7 shows the various patterns seen on high-resolution CT scan and their associated diagnoses. Dynamic expiratory CT (imaging after a forced vital capacity maneuver) can detect subtle air trapping and tracheobronchomalacia.

Table 8-7. Patterns on High-Resolution Computed Tomography Scan

Pattern	Description	Examples	Image
Linear	Thickening of interlobular septa	Pulmonary edema Lymphangitic spread Sarcoidosis	
Reticular	Mess or net-like appearance	Usual interstitial pneumonia Asbestosis Collagen vascular disorder Drug toxicity	
Nodular	Multiple round opacities < 1 cm in diameter May be: Perilymphatic Centrilobular Random	Perilymphatic sarcoidosis, lymphangitic spread Centrilobular Hypersensitivity pneumonitis, infection Random metastasis, military tuberculosis	

Table 8-7. Patterns on High-Resolution Computed Tomography Scan, continued

Pattern	Description	Examples	Image
Ground-glass opacity	Haziness Preserved bronchovascular markings Represents partial filling of air spaces	*Pneumocystis jiroveci* pneumonia, hemorrhage, bronchioloalveolar carcinoma, lipoid pneumonia, pulmonary edema, hypersensitivity pneumonitis, sarcoidosis Typically represents active disease (also can reflect fibrosis below resolution of high-resolution computed tomography scan) "Crazy paving" (ground-glass opacity + interlobular septal thickening), alveolar proteinosis	
Consolidation	Attenuation with complete obscuring of bronchovascular markings Complete filling of air spaces	Chronic eosinophilic pneumonia Cryptogenic organizing pneumonia	
Cystic	Thin-walled, well-defined air lesions < 1 cm in diameter	Lymphangioleiomyomatosis Langerhans cell histiocytosis Lymphocystic interstitial pneumonia Birt-Hogg-Dubé syndrome (associated with skin tags and renal tumors)	

[a]Tree-in-bud opacities are a form of centrilobular nodules and represent dilated and impacted distal terminal bronchioles. Their presence indicates endobronchial spread of infection. (Figures on row 1 and 6vreproduced, with permission, from Dr. Stephanie Clough, MetroHealth Medical Center; figure on row 2 reproduced, with permission, from Travis WD, et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. *Am J Respir Crit Care Med.* 2013; 188: 733-748; figure on row 3 reproduced, with permission, from Dr. Daniel Monroy Chaves, MetroHealth Medical Center. Figures on rows 4-5 rows reproduced from Wikimedia Commons, CC BY-SA 3.0.)

NUCLEAR MEDICINE TECHNIQUES

Positron Emission Tomography (PET) Scan

PET scans are classically obtained to differentiate between benign and malignant lesions. These scans also can provide information on staging and prognosis and can help to differentiate between recurrence and posttreatment fibrosis. PET scans use 2-[fluorine-18]fluror-2-deoxy-D-glucose (FDG), a D-glucose analog labeled with a positron emitter (fluorine-18). Typically, lung cancers with show uptake of FDG > 2.5.

Key Fact

The cutoff of a standard uptake value of 2.5 is used to distinguish between benign and malignant lesions.

Infectious and inflammatory processes (tuberculosis, histoplasmosis, and rheumatoid nodules) can give false-positive results. False-negative results can occur with carcinoid, adenocarcinoma in situ (formerly bronchioloalveolar carcinoma), and small (< 10 mm) nodules. FDG-PET scan has sensitivity of ~ 90% and specificity of 80%, yielding an overall diagnostic accuracy for nodules of ~ 91%.

Key Fact

Carcinoid, adenocarcinoma in situ, and nodules < 10 mm can cause false-negative findings on PET scan.

Ventilation–Perfusion Scan

Ventilation–perfusion scans are typically used in conjunction with the clinical probability of pulmonary embolus to aid in the diagnosis (see Figure 8-5) and Chapter 10). However, ventilation–perfusion scans can also quantify the magnitude of a right-to-left shunt in patients with pulmonary arteriovenous malformations.

VENTILATION IMAGES—Performed with radiolabeled gas or aerosol (xenon-133 or technetium-99m). Three types of images are obtained:

- Breath hold: Radiolabeled gas/aerosol is administered, the patient takes a deep inspiratory breath and holds, and an image is taken.
- Equilibrium: Patient takes normal tidal breaths for 4 minutes, and images are taken.
- Washout: Patient breathes room air while radiolabeled gas is exhausted and an image is taken.
    - Retained activity in washout images indicates air trapping.

PERFUSION IMAGES—Obtained after intravenous injection of radiolabeled particles (technetium-99m-labeled macroaggregated albumin). The number of particles embolized is proportional to pulmonary arterial blood flow.

Flash Card Q1

For diseases that have a cystic pattern, which ones are predominant in the upper lobe, predominant in the lower lobe, and diffuse?



Figure 8-5. Ventilation–perfusion scan. (A) After the patient inhaled xenon-133 gas, images were obtained in the posterior projection with uniform ventilation to the lungs. (B) After intravenous injection of technetium-99m-labeled macroaggregated albumin, showing decreased activity in the apical segment of the right upper lobe, the anterior segment of the right upper lobe, the superior segment of the right lower lobe, the posterior basal segment of the right lower lobe, the anteromedial basal segment of the left lower lobe, and the lateral basal segment of the left lower lobe.
(Reproduced from Wikimedia Commons, CC BY-SA 3.0.)

ULTRASONOGRAPHY

Ultrasound is nonaudible sound energy that creates waves that undergo attenuation, scatter, refraction, or reflection as they travel through tissue. The reflected waves form the basis of ultrasound images. Fluid appears anechoic (black) or hypoechoic (darker). Soft tissue appears gray (isoechoic). Air appears white (hyperechoic). Bone creates an acoustic shadow that is an anechoic area behind the bony structure.

Randomized trials have found that real-time ultrasound guidance of needle placement of venous cannulation reduces time and risk (Figure 8-6). Ultrasound guidance is also associated with reduced risk of pneumothorax during thoracentesis. See Chapter 13 for an ultrasound image of pleural effusion.

Flash Card A1

Upper lobe: Langerhans cell histiocytosis
Lower lobe: Lymphocystic interstitial pneumonia and Birt-Hogg-Dubé syndrome
Diffuse: Lymphangioleiomyomatosis



Figure 8-6. Ultrasound image of the left internal jugular vein (*red arrow*) and left carotid artery (*white arrow*) for ultrasound guidance of needle placement for venous cannulation.
(Reproduced, with permission, from Sandeep Khosa, MD, MetroHealth Medical Center.)

The use of lung ultrasonography in the evaluation of acute respiratory distress is an emerging field. Definitions and examples are shown in Table 8-8.

Table 8-8. Ultrasound Vocabulary/Image Examples

Ultrasound Vocabulary	Definition/Image
Lung sliding	To-and-fro motion of lung pleura with respiration
Seashore sign	Lung sliding displayed in M mode (motion mode) Reflected energy is shown as areas of brightness traced from left to right on screen with time on *x*-axis 
Stratosphere sign	Absence of lung sliding seen in M mode 

Table 8-8. Ultrasound Vocabulary/Image Examples, continued

Ultrasound Vocabulary	Definition/Image
A lines	Echoes of pleural line indicate air–soft tissue interface 
B lines	Comet tail artifacts that spread all the way to edge of screen without fading represent interstitial thickening 
Lung point	Point where it is possible to see lung sliding and no lung sliding plus A lines in same view
Hepatization	Lung visualized with similar tissue pattern to liver

(Figures on rows 3-5 reproduced, with permission, from Dr. Ziad Shaman, MetroHealth Medical Center. Figure on row 6 reproduced, with permission, from Dr. Stephanie Clough, MetroHealth Medical Center.)

Table 8-9 shows common etiologies and their associated ultrasound findings.

Flash Card Q2

A patient undergoes a difficult central line placement. Ultrasound is used to evaluate the lungs after the procedure. Lung sliding is absent, with an A-line-predominant pattern. What is the likely explanation for the ultrasound finding?

Table 8-9. Ultrasound Findings in Specific Conditions

Condition	Ultrasound Findings
Normal	Lung sliding A lines Seashore sign
Pleural effusion	Anechoic (black) collection bordered by diaphragm, chest wall, and atelectatic lung (Figure 8-7)
Interstitial syndrome	Numerous B lines
Pneumothorax	No lung sliding No B lines Lung point
Consolidation	Hepatization of lung



Figure 8-7. Ultrasound image showing pleural effusion.
(Reproduced, with permission, from Dr. Ziad Shaman, MetroHealth Medical Center.)

Flash Card A2

Pneumothorax

PROCEDURES

PULMONARY FUNCTION TESTS (PFTs)

Clinical indications for PFTs:

- Further evaluate specific respiratory symptoms, signs, or radiographic abnormalities
- Aid in the diagnosis of respiratory disease
- Monitor respiratory disease and response to therapy
- Determine prognosis
- Evaluate for effects of occupational, environmental, or drug exposure
- Evaluate risk before lung resection
- Objectively assess impairment

Reference Values

Important considerations for reference values:

- Lung function values plateau at ~ age 20–35 years.
- 1-second forced expiratory volume (FEV_1) decreases approximately 30 mL/y.
- Vital capacity decreases with age, whereas residual volume increases.
- African-Americans, Asians, and East Indians have lower values than white persons of similar age, height, and sex (if no reference range for these specific populations, use correction factor of 0.88).
- Accurate height and weight are needed (in kyphoscoliosis, arm span estimation of height).

Key Fact

Acceptable spirometry results are extrapolated volume < 5% or FVC of 0.15 L, plateau on volume–time curve, exhalation time > 6 seconds, and no artifacts.

Spirometry

ACCEPTABILITY—Determined by:

- Good start: Sharp takeoff without hesitation, with extrapolated volume < 5% or forced vital capacity (FVC) 0.15 L
- End of test criteria met: Exhalation to residual volume, plateau on volume–time curve, exhalation time > 6 seconds
- Absence of artifact: No cough, glottis closure, air leak, or obstructed mouthpiece

Key Fact

Repeatability criteria are met if the two largest values of FEV_1 and FVC are within 0.15 L of each other.

REPEATABILITY—Determined once acceptability criteria are met, three acceptable spirograms with both FVC and FEV_1 showing the two largest values within 0.15 L of each other.

MAXIUMUM VOLUNTARY VENTILATION (MVV)—Full volume of air a patient can breathe over a specified period, usually 12–15 seconds (MVV= FEV_1 x 40 approximately). It is expressed as liters per minute at body temperature, ambient pressure saturated with water vapor. It is not included in the diagnosis or monitoring of disease; however, it can be useful in certain clinical situations. A disproportional decrease in MVV compared with FEV_1 is seen in neuromuscular disorders and upper-airway obstruction. It is also used to estimate breathing reserve in cardiopulmonary exercise testing; however, its utility in mild to moderate COPD is limited.

MEAN EXPIRATORY FLOW 25–75% of FVC—Not specific but can suggest small airway disease.

BRONCHODILATOR RESPONSE—Defined by the American Thoracic Society/European Respiratory Society task force as an increase in FEV_1 or FVC by 12% and at least 200 mL. To test for bronchodilator response, the patient should avoid using a short-acting bronchodilator at least 4 hours and a long-acting bronchodilator at least 12 hours before testing.

Lung Volume

Lung volume is measured by nitrogen washout, body plethysmography, and inhaled inert gas dilution. The definitions of the different lung volumes are explained in Chapter 7. Table 8-10 compares body plethysmography and gas dilution techniques.

Table 8-10. Lung Volume Determination

Technique	Procedure	Concept	Limitations
Body plethysmography	Patient pants against closed shutter in sealed box Adequate if 3 FRC values agree within 5%	Boyle's law $V_1 \times P_1 = V_2 \times P_2$ Change is pressure that is measured and used to determine lung volumes	Gold standard Expensive, complex, space-consuming Exceeding 1 pant/sec results in overestimation of FRC

Table 8-10. Lung Volume Determination, continued

Technique	Procedure	Concept	Limitations
Gas dilution techniques	Patient inhales known concentration and volume of gas	Measuring exhaled concentration can allow calculation of lung volume	Only measures exhaled gas volume, so air trapping causes underestimation of lung volume
Nitrogen washout	Washout accomplished when nitrogen concentration < 1.5% for ≥ 3 consecutive breaths		
Helium rebreathing	Mixture of 10% helium and 25–30% oxygen inhaled Equilibrium reached when < 0.02% change in concentration occurs for ≥ 30 sec		

FRC, functional residual capacity.

Diffusing Capacity

Diffusing capacity is measured by the rate of carbon monoxide transfer, and values are reported in milliliters per minute per millimeter of mercury. Factors that influence the diffusion of gas across the alveolar–capillary barrier can be explained by Fick's law for diffusion:

Volume of gas diffusing = $A \times D \times (P_1 - P_2)/T$
A = surface area of barrier
D = diffusion coefficient of particular gas
T = thickness of barrier
$P_1 - P_2$ = partial pressure difference of gas across barrier

The most common method to measure diffusion lung capacity for carbon monoxide (DLCO) is the single-breath technique. Others include the steady-state, intrabreath, and rebreathing techniques.

Method:

- Gas inhaled is a mixture of nitrogen, 0.3% CO, helium, and 19–21% oxygen.
- Patient exhales down to the residual volume (exhaled volume is at least 85% of largest vital capacity), and the valve opens.
- Patient rapidly inhales gas to total lung capacity (< 4 seconds).
- Patient holds for 10 seconds (± 2 seconds).
- Patient exhales rapidly (< 4 seconds), and gas is collected.

Factors that affect DLCO are shown in Table 8-11.

Key Fact

Conditions that increase pulmonary capillary blood volume (polycythemia, left-to-right shunt, asthma, Müller's maneuver, exercise, supine position, and obesity) increase DLCO. Those that decrease pulmonary capillary blood volume (anemia, pulmonary vascular disease, Valsalva maneuver) decrease DLCO.

Table 8-11. Conditions that Affect Diffusion Lung Capacity For Carbon Monoxide

Conditions that ↑ DLCO	Conditions that ↓ DLCO
Morning	Evening (↓ by 1–2%/h throughout day)
Premenses (unknown; not related to variation in hemoglobin levels)	Smoking (related to carboxyhemoglobin)
Exercise (secondary to recruitment of capillaries)	After exercise (↓ below pre-exercise levels) Postulated to be related to redistribution of pulmonary capillary blood volume to peripheral muscles
Supine position (secondary to increase in pulmonary capillary blood volume)	Standing
Müller's maneuver (after forced expiration, inspiration is made against closed mouth and nose)	Valsalva maneuver
Pulmonary hemorrhage	Lung resection
Bronchodilator administration (↑ to 6%)	Interstitial lung disease
Left-to-right shunt	Pulmonary vascular disease
Polycythemia	Emphysema
Asthma	
Obesity	

DLCO, diffusion lung capacity for carbon monoxide.

ADJUSTING DLCO—Hemoglobin, supplemental oxygen, altitude, and carboxyhemoglobin can substantially affect the measurement of DLCO. Table 8-12 shows the adjustment equations.

Table 8-12. Adjusting Diffusion Lung Capacity for Carbon Monoxide

Condition	Equation
Adjusting for hemoglobin	Male = DLCO (predicted) × [1.7 Hgb/(10.22 + Hgb)] Female = DLCO (predicted) × [1.7 Hgb/(9.38 + Hgb)]
Supplemental oxygen	Assuming sea level of P_{AO2} of 100 mm Hg DLCO (predicted)/[1.0 + 0.0035(P_{AO2} − 100)]
Altitude	Assuming sea level of P_{AO2} of 150 mm Hg DLCO (predicted)/[1.0 + 0.00311(P_{AO2} − 150)]
Carboxyhemoglobin	DLCO (predicted) × (102% − COHgb%)

DLCO, diffusion lung capacity for carbon monoxide.

DLCO can also be corrected for lung volume. However, the clinical utility is questionable because the relationship between DLCO and lung volume is not linear.

Respiratory Muscle Pressure

Respiratory muscle strength can be measured by obtaining maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP). MIP is obtained by exhaling to residual volume and breathing in as fast as possible for 2 seconds. For MEP, the patient inhales to total lung capacity and exhales as fast as possible. These maneuvers are repeated at least three times with < 10 cm H_2O variability.

There are no definitive reference ranges, but there is a decrease with age and ~ one-third decrease in women compared with men. MIP < one third of normal predicts hypercarbic respiratory failure. MEP < 60 cm H_2O predicts a weak cough and difficultly clearing secretions.

These measurements have a poor positive predicted value. A better alternative in detecting inspiratory muscle weakness is a decrease in FVC from upright to supine, which typically declines by 5–10% in normal subjects. A decrease of > 30% is associated with severe diaphragmatic weakness.

Airway Challenge

Testing for airway hyper-responsiveness can be done by direct (methacholine or histamine) or indirect (exercise, eucapnic voluntary hyperventilation, cold, or mannitol) methods.

Methacholine is the most common method and is accomplished by the tidal breathing method (preferred) or the dosimeter method (sensitivity questioned). It is expressed as the provocation concentration that causes a 20% drop in FEV_1. Table 8-13 shows the American Thoracic Society guidelines for interpretation of methacholine test results.

Table 8-13. Interpretation of Methacholine Test Results

Normal	> 16 mg/mL
Borderline	4–16 mg/mL
Mild airway hyper-responsiveness	1–4 mg/mL
Moderate to severe airway hyper-responsiveness	< 1 mg/mL

False-positive findings can be caused by allergic rhinitis, COPD, smoking, cystic fibrosis, bronchiectasis, bronchiolitis, and recent respiratory tract infection.

False-negative findings are far less common. Most physicians believe that a negative test result effectively rules out asthma in a patient presenting with asthma-like symptoms in the last 2 weeks.

Factors to consider:
- If patient is taking intensive anti-inflammatory medications before testing, this can suppress airway responsiveness.
- If symptoms are related to aeroallergens, the season of exposure may have passed.
- Occasionally, occupational asthma caused by a single antigen may respond only when challenged with that specific agent.

Absolute contraindications to testing:
- Severe airflow limitation (FEV_1 < 50% predicted or < 1.0 L)
- Myocardial infarction or stroke in the last 3 months
- Uncontrolled hypertension (systolic blood pressure > 200 mm Hg or diastolic blood pressure > 100 mm Hg)
- Known aortic aneurysm

Relative contraindications:
- Moderate airflow limitation (FEV_1 < 60% predicted or < 1.5 L)
- Inability to perform acceptable spirometry
- Pregnancy
- Nursing
- Current use of cholinesterase inhibitor medication for myasthenia gravis

Medications withheld before methacholine test:
- Short-acting β_2-agonist: 8 hours
- Short-acting anticholinergic: 24 hours
- Long-acting β_2-agonist: 48 hours
- Long-acting anticholinergic: 7 days
- Short-acting theophylline: 24 hours
- Sustained-release theophylline: 48 hours

Exercise Challenge Testing

MODES OF EXERCISE—Motor-driven treadmill with adjustable speed and grade versus electromagnetically braked cycle ergometer

INHALATE—Dry air < 25°C with a nose clip in place

PROTOCOL—Work rate, speed, and grade for the different modes are determined to target a particular ventilation or heart rate for at least 4 minutes (usually 6–8 minutes total exercise). The primary outcome is FEV_1, and values are obtained at postexercise intervals of 5, 10, 15, 20, and 30 minutes.

INTERPRETATION—Decrease in FEV_1 of 10–15% is abnormal. Positive results have been seen in abnormal posterior motion of the arytenoid region or vocal cord dysfunction. Therefore, it is important to examine the flow–volume curve.

Key Fact

On an exercise challenge test, a decrease in FEV_1 of 10–15% is considered abnormal if it occurs during postexercise intervals of 5, 10, 15, 20, or 30 minutes.

Interpreting PFT Results

Table 8-14 shows the interpretation of PFT test results.

Table 8-14. Pulmonary Function Test Results for Different Disorders

Result	Obstructive	Restrictive	Mixed	Upper Airway Obstruction
Spirometry	$FEV_1/VC \leq LLN$ or $FEV_1/VC \geq LLN$ and $VC \leq LLN$	$FEV_1/VC \geq LLN$ and $VC \leq LLN$	$FEV_1/VC \leq LLN$	$FEV_1/PEF > 8$ in fixed or variable intrathoracic $MIF_{50}/MEF_{50} \sim 1$ for fixed, < 1 variable extrathoracic, > 1 intrathoracic
Lung volume	$TLC \geq LLN$	$TLC < LLN$	$TLC \leq LLN$	Normal
Flow–volume loop	Scooping of expiratory limb	Shortened and shifted to right	Scooping of expiratory limb; shifted to right	Fixed: Flattening of both inspiratory and expiratory limbs Variable extrathoracic: Flattening of inspiratory limb Variable intrathoracic: Flattening of expiratory limb See Figure 8-8
DLCO	Normal in asthma or COPD Decreased in emphysema	Normal in chest wall and neuromuscular disorders Decreased in interstitial lung disease	Variable	Normal

FEV1, 1-second forced expiratory volume; VC, vital capacity; LLN, lower limit of normal; PEF, peak expiratory flow; MIF50, maximum inspiratory flow; at 50% of forced vital capacity; MEF50, maximum expiratory flow at 50% of forced vital capacity; TLC, total lung capacity; DLCO, diffusion lung capacity for carbon monoxide; COPD, chronic obstructive pulmonary disease.

Flash Card Q3

A patient is receiving a long-acting anticholinergic and a methacholine test is ordered for further evaluation. How long should the medication be withheld before testing?



Figure 8-8. Flow-volume loops of upper airway obstructions. (A) Fixed; (B) variable extrathoracic; and (C) variable intrathoracic.
(Reproduced, with permission, from Pellegrino R, et al. Interpretative strategies for lung function tests. *Eur Respir J.* 2005; 26: 948-968. doi: 10.1183/09031936.05.00035205.)

Key Fact

An isolated reduction in DLCO can suggest pulmonary vascular disease or early interstitial lung disease.

Other abnormalities on PFTs and their associated diagnoses:

- Isolated reduction in DLCO: Pulmonary vascular disease or early interstitial lung disease
- Reduction in functional residual capacity (FRC) and expiratory reserve volume (ERV): Likely related to obesity

The severity of the abnormality is determined by the degree of reduction in FEV_1 and is shown in Table 8-15.

To identify worsening lung function, reduction should be > 15%/y in FEV_1, according to the American Thoracic Society/European Respiratory Society recommendations.

Table 8-15. Severity of Abnormality Determined by 1-Second Forced Expiratory Volume According to the American Thoracic Society/European Respiratory Society Task Force Guidelines

Severity	1-Second Forced Expiratory Volume % Predicted
Mild	> 70
Moderate	60–69
Moderately severe	50–59
Severe	35–49
Very severe	< 35

Flash Card A3

Up to 7 days

PFT Results in Pregnancy

Table 8-16 shows changes in PFT results during pregnancy. The major change is the decrease in ERV and residual volume as a result of the enlarging uterus and diaphragmatic elevation.

Table 8-16. Changes in Pulmonary Function Test Results During Pregnancy

Variable	Change
Expiratory reserve volume	↓ by 8–40%
Residual volume	↓ by 7–22%
Functional residual capacity	↓ by 10–25%
Total lung capacity	Mild ↓
Inspiratory capacity	↑
Vital capacity	No change
Tidal volume	↑ by 30–50% (likely secondary to progesterone-mediated ↑ in central respiratory drive)
Respiratory rate	No change or mild ↑
Minute ventilation	↑ by 20–50%
1-second forced expiratory volume	No change
Diffusion capacity	↑ initially in first trimester, then ↓

Key Fact

In pregnancy, ERV, residual volume, and FRC are reduced, whereas total lung capacity is essentially unchanged. Increases in minute ventilation occur almost exclusively as a result of increases in tidal volume caused by a direct progesterone-mediated increase in central respiratory drive and enhancement of hypercapnic ventilatory drive. Tachypnea is an unusual finding and warrants investigation.

CARDIOPULMONARY EXERCISE TESTING

Indications

Commonly, cardiopulmonary exercise testing is the final evaluation of unexplained dyspnea when the methods described earlier do not yield an etiology. It is helpful in identifying a cardiovascular or respiratory cause for limitation of activity.

Other indications:

- Objective assessment of symptoms
- Evaluation of severity of impairment
- Early detection of disease, assessment of response to therapy
- Assessment of disability
- Preoperative risk and transplantation assessment
- Prognosis in certain diseases

Flash Card Q4

A 26-year-old woman is evaluated for dyspnea on exertion. PFTs show FEV_1 84%, total lung capacity 96%, ERV 50%, FRC 76%, and DLCO 119%. These findings are most consistent with what diagnosis?

Protocol

Maximal symptom-limited incremental protocols are usually performed. Endurance exercise protocols continued at a constant work rate can be used to determine response to therapy. A stationary cycle ergometer is more commonly used and offers better direct measurement of work rate, has less potential for artifact, and is typically better tolerated. However, the motorized treadmill yields higher values for peak oxygen consumption (V_{O2}) and is more appropriate for fit normal subjects. Table 8-17 shows common absolute and relative contraindications and indications for terminating cardiopulmonary exercise testing.

Table 8-17. Contraindications and Reasons for Termination of Cardiopulmonary Exercise Testing

Absolute Contraindications	Relative Contraindications	Reasons for Termination
Within 3–5 days of myocardial infarction	Left main coronary stenosis	Chest pain and electrocardiogram changes suggestive of ischemia
Unstable angina	Moderate stenotic valvular heart disease	↓ in systolic pressure > 20 mm Hg
Uncontrolled arrhythmias causing symptoms or hypotension	Severe untreated arterial hypertension	> 250 mm Hg systolic or > 120 mm Hg diastolic
Syncope	High-degree atrioventricular block	Saturation < 80% associated with symptoms and signs of severe hypoxemia
Symptomatic severe aortic stenosis	Hypertrophic cardiomyopathy	Sudden pallor
Uncontrolled heart failure	Significant pulmonary hypertension	Dizziness
Acute pulmonary embolism or infarct	Advanced or complicated pregnancy	
Thrombosis of lower extremities		
Uncontrolled asthma		
Pulmonary edema		
Resting room air saturation ≤ 85%		

Flash Card A4

Obesity can cause a reduction in ERV and FRC and an increase in DLCO.

Cardiovascular and Pulmonary Systems in Exercise

Exercise in a healthy individual is limited by the cardiovascular system.

CARDIAC OUTPUT—Initially increases during exercise through increased stroke volume and heart rate. As work rate is increased, cardiac output increases almost exclusively through increases in heart rate.

BLOOD PRESSURE—Systolic blood pressure typically rises with exercise. Diastolic blood pressure typically remains unchanged or increases slightly.

VENTILATION—Increases in exercise by both tidal volume and respiratory rate. In low-level exercise, it is increased primarily by tidal volume at the expense of inspiratory reserve volume. At ~ 70–80% of peak exercise, increases in ventilation are predominately caused by increases in respiratory rate.

Measurement

V_{O2}—Oxygen uptake is related to oxygen demand and transport. It increases linearly as work rate increases. V_{O2}max (maximal oxygen consumption) occurs when V_{O2} plateaus despite further increases in work rate. This plateau often is not observed. Instead the maximal value of V_{O2} achieved is reported as V_{O2}peak. Normalization for body mass is typically done by V_{O2}/kg, but this may produce low values in obese patients.

ANAEROBIC THRESHOLD (AT)—Estimated at the onset of metabolic acidosis from increases in lactic acid during exercise. It is usually 50–60% of V_{O2}max in healthy individuals and higher in fit individuals. Normal value is 40–80%. It can be measured invasively by arterial lactate (gold standard) or noninvasively by the V-slope method and the ventilator equivalents method. The V-slope method is the most popular and measures the change in slope of the amount of carbon dioxide exhaled from the body per unit of time (V_{CO2}) versus the (V_{O2}) (Figure 8-9). The respiratory exchange ratio (V_{CO2}/V_{O2}) should also be ~ 1 at AT.

HEART RATE RESERVE (HRR)—Difference between age-predicted maximal heart rate (220 − age; may underestimate in the elderly) and maximum heart rate achieved during exercise. Normally, at maximal exercise there is little or no HRR. The slope of heart rate versus V_{O2} is linear. In heart disease, the line shifts to the left with an increase in slope (Figure 8-10). In trained individuals, the line shifts to the right. In lung disease, the predicted maximal heart rate is not achieved.



Figure 8-9. Determination of anaerobic threshold with the V-slope method. STPD, standard temperature and pressure; $V_{CO2,}$ carbon dioxide output; V_{O2}, oxygen uptake.
(Reproduced, with permission, from the ATS/ACCP Statement on Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003; 167: 211-277. doi: 10.1164/rccm.167.2.211. http://www.atsjournals.org/doi/pdf/10.1164/rccm.167.2.211)



Figure 8-10. Cardiovascular response during exercise in cardiomyopathy versus chronic obstructive pulmonary disease. The dashed line represents a normal healthy individual. (A) cardiomyopathy. The slope is shifted to the left, with an increase in slope. (B) Chronic obstructive pulmonary disease. The maximal heart rate is not achieved. HR, heart rate; Max Pred., maximum predicted ; $V_{O2,}$ oxygen uptake.
(Reproduced, with permission, from the ATS/ACCP Statement on Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003; 167: 211-277. doi: 10.1164/rccm.167.2.211. http://www.atsjournals.org/doi/pdf/10.1164/rccm.167.2.211)

OXYGEN PULSE—Ratio of V_{O2} to heart rate and is normally > 80% predicted. It is an indirect measure of stroke volume.

VENTILATORY RESERVE (VR)—Relationship between ventilatory demand and ventilatory capacity. Ventilatory demand is the peak minute ventilation achieved during exercise (V_{Emax}). Ventilatory capacity is typically measured by MVV, although this maneuver has limitations with reproducibility, the breathing strategy during MVV is different than during exercise, and it does not take into account the bronchodilation of exercise. Alternatively, it can be estimated by $FEV_1 \times 37–40$. However, this calculation may not be appropriate for patients with neuromuscular disorders or respiratory weakness. Ventilatory demand is increased and ventilatory capacity is decreased in patients with respiratory disease that results in reduced VR (Figure 8-11).

Reduced VR can be expressed as either:

- High V_{Emax}/MVV
  - Normal: 70%
- Low MVV − V_{Emax}
  - Normal: 15–50%
  - Cyclical fluctuations in minute ventilation (V_E) are seen in patients with congestive heart failure and are related to exercise-associated hemodynamic impairment in patients with congestive heart failure.

Key Fact

Oscillatory breathing response during exercise can be seen in patients with congestive heart failure and is predictive of a poor outcome.



Figure 8-11. Respiratory response during exercise in a healthy person versus a patient with lung disease. (A) In a healthy person, peak V_E (minute ventilation) approaches 70% of maximal value. (B) In a patient with chronic obstructive pulmonary disease, peak V_E exceeds predicted maximal value. V_{O2}, oxygen uptake; V_{CO2}, carbon dioxide output; MVV, maximum voluntary ventilation.
(Reproduced, with permission, from the ATS/ACCP Statement on Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003; 167: 211-277. doi: 10.1164/rccm.167.2.211.)

VENTILATORY EQUIVALENT—For O_2, ventilatory equivalent is the ratio of V_E to V_{O2}. For CO_2, it is the ratio of V_E to V_{CO2}. Normally, V_E/V_{O2} increases at AT and V_E/V_{CO2} has a delayed increase (Figure 8-12). In hyperventilation, the two increase simultaneously. V_E/V_{CO2} is normally < 32–34 at AT.



Figure 8-12. Ventilatory equivalents in a healthy subject. Note the increase at anaerobic threshold of ventilatory equivalent of oxygen (V_E/V_{O2}), before an increase in ventilatory equivalent of carbon dioxide (V_E/V_{CO2}).
(Reproduced, with permission, from the ATS/ACCP Statement on Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003; 167: 211-277. doi: 10.1164/rccm.167.2.211.)

END-TIDAL PARTIAL PRESSURE OF OXYGEN (P_{ETO2}) AND END-TIDAL PARTIAL PRESSURE OF CARBON DIOXIDE (P_{ETCO2})—P_{ETO2} first increases and P_{ETCO2} first remains constant during the isocapnic buffering time. If V_E/V_{CO2} is high and P_{ETCO2} does not decrease, dead space ventilation is suggested.

Table 8-18 shows normal values and typical response patterns in different diseases.

Table 8-18. Cardiopulmonary Exercise Response Patterns

	Normal Values	HD	COPD	ILD	PVD	Obesity	Deconditioned	Poor Effort
V_{O2}max/ peak	≥ 85%	↓	↓	↓	↓	↓ (V_{O2}/kg)	↓	↓
Anaerobic threshold	> 40% Vo_2max	↓	Normal/ ↓/ absent	Normal/ ↓	↓	Normal	Normal/ ↓	Normal or absent
Heart rate reserve	< 15	Normal	↑	↑	Normal	Normal	Normal	↑
Oxygen pulse	> 80%	↓	Normal/ ↓	Normal/ ↓	↓	Normal	↓	↓
V_E/MVV	< 85%	Normal/ ↓	↑	Normal/ ↑	Normal	Normal/ ↑	Normal	↓
V_E/V_{CO2}	< 34	Normal/ ↑	↑	↑	↑	Normal	Normal	Normal
V_D/V_T	< 0.30	↑	↑	↑	↑	Normal	Normal	Normal
P_aO_2	> 80 mm Hg	Normal	Variable	↓	↓	Normal	Normal	Normal
$P_AO_2 - P_aO_2$	< 35 mm Hg	Normal	Variable	↑	↑	Normal	Normal	Normal

COPD, chronic obstructive pulmonary disease; HD, heart disease; ILD, interstitial lung disease; PVD, pulmonary vascular disease;V_{O2}max, maximal oxygen consumption; V_E/MVV, ventilatory reserve; V_E/V_{CO2}, ventilatory equivalent for carbon dioxide; V_D/V_T, ratio of physiologic dead space to tidal volume; P_AO_2, alveolar oxygen pressure.

Interpretation

Figure 8-13 shows the basic strategy for interpretation of cardiopulmonary exercise test results. Typical responses for different diseases are further explained later.

CARDIOVASCULAR DISEASE—Reduced V_{O2}max and AT. Because O_2 pulse is an indirect measure of stroke volume, it is reduced. Cardiac output is maintained exclusively by increases in heart rate. Thus, there typically is no HRR. However, this is variable, depending on the severity of heart disease. With increasing severity, HRR is abnormal because of chronotropic dysfunction. V_D/V_T and V_E/V_{CO2} are increased because of reductions in pulmonary perfusion secondary to the reduction in cardiac output. Reduced VR may indicate a respiratory limitation.

Flash Card Q5

A 70-year-old man who is undergoing cardiopulmonary exercise testing for further evaluation of dyspnea on exertion has a reduced O_2 pulse and an oscillatory pattern of changes on ventilation. What is the most likely diagnosis?



Figure 8-13. Basic strategy for interpretation of cardiopulmonary exercise testing. Abnl., abnormal; AT, anaerobic threshold; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; HRR, heart rate reserve; HR, heart rate; Hyperven., hyperventilation; ILD, interstitial lung disease; P_{ETCO2}, end-tidal partial pressure of carbon dioxide; norm, normal; PFTs, pulmonary function tests; Sao_2, arterial oxygen saturation; V_E, minute ventilation; V_{O2}, oxygen uptake; VR, ventilatory reserve.
(Reproduced, with permission, from the ATS/ACCP Statement on Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med.* 2003; 167: 211-277. doi: 10.1164/rccm.167.2.211.)

Key Fact

The typical pattern of cardiovascular disease is reduced O_2 pulse, variable HRR depending on severity, increase in V_D/V_T and V_E/V_{CO2}, and normal VR.

DECONDITIONING—Typically shows low V_{O2}, low or normal AT, reduced O_2 pulse, and no HRR. It is difficult to distinguish from early or mild cardiovascular disease. Although rare, mitochondrial myopathy produces a similar pattern and is included in the differential diagnosis.

COPD—Produces a spectrum of patterns, depending on severity. Moderate to severe disease has distinguishing reduced VR with significant HRR, signifying an unstressed cardiovascular system. O_2 pulse can be reduced secondary to hypoxemia, deconditioning, or dynamic hyperinflation. Because of increased dead space ventilation, V_D/V_T and V_E/V_{CO2} are increased. Decreases in P_aO_2 and abnormal widening of P_AO_2–P_aO_2 (alveolar-arterial difference for oxygen pressure) are seen in more severe disease.

Flash Card A5

Congestive heart failure

INTERSTITIAL LUNG DISEASE—Produces a similar pattern to COPD, given the ventilatory limitation. AT is typically normal unless there is pulmonary circulatory involvement. Arterial desaturation and abnormal widening of P_AO_2–P_aO_2 are seen.

Key Fact

The typical pattern of lung disease is reduced VR with significant HRR.

Reproducibility

If serial cardiopulmonary exercise testing (CPET) is obtained to determine the response to therapy, generally there should be change > 12–20% of the variables (e.g., $V0_2max$, HRR, VR, etc.) to be considered clinically significant.

BRONCHOSCOPY

Key Fact

There is no firm guideline for the timing of bronchoscopy after myocardial infarction. However, the British Thoracic Society recommends waiting 6 weeks after myocardial infarction, if possible.

Indications

Indications include evaluation of the nodule or mass (lung cancer diagnosis/staging), mediastinal/hilar lymphadenopathy, hemoptysis, suspected airway obstruction, persistent atelectasis/infiltrate, recent history of lung transplantation (rejection or inspection of airway anastomosis), chest trauma, and inhalation injury.

Contraindications to bronchoscopy are shown in Table 8-19.

Table 8-19. Contraindications to Bronchoscopy

Absolute	Relative
Uncorrectable hypoxemia	Severe hypercarbia
Lack of patient cooperation	Uncontrolled asthma
Unstable angina	Uncorrectable coagulopathy
Uncontrolled arrhythmias	Unstable cervical spine

Flash Card Q6

A 78-year-old man who is undergoing cardiopulmonary exercise testing for evaluation of dyspnea has increased ventilator equivalents, increased V_E/MVV ratio, and significant oxygen desaturation. Baseline spirometry results show no obstructive ventilatory impairment. What is the most likely diagnosis?

Diagnostic Bronchoscopy Techniques

BRONCHOALVEOLAR LAVAGE—Used to further evaluate lung abnormalities that suggest infectious, immunologic, or malignant etiology. If disease is diffuse, bronchoalveolar lavage is obtained from the right middle lobe. Otherwise, it is obtained from the area of abnormality. It can be sent for cell count, microbiology, cytology, flow cytometry, polymerase chain reaction, DNA probes, and tissue markers. Serial cell counts can be diagnostic for alveolar hemorrhage.

Bronchoalveolar lavage can be diagnostic in the following situations:

- Opportunistic infection
- Pulmonary alveolar proteinosis
  - Milky or opaque appearance
  - Alveolar macrophages filled with periodic acid-Schiff–positive material
  - Lamellar bodies
- Alveolar hemorrhage
- Malignant infiltrate
- Eosinophilic lung disease
  - > 25% eosinophils
- Chronic beryllium disease
  - Beryllium proliferative test (lymphocytes stimulated with soluble beryllium salts)
- Langerhans cell histocytosis
  - > 4% CD1+ Langerhans cells
- Ventilator-associated pneumonia
  - Quantitative cultures showing $\geq 10^4$ colony-forming units/mL

BRONCHIAL BRUSHES—Available for cytology and microbiology. A protected specimen brush can be sent for quantitative culture for the diagnosis of ventilator-associated pneumonia ($\geq 10^3$ colony-forming units/mL).

ENDOBRONCHIAL BIOPSY—Used to obtain sampling from a visualized lesion. Three biopsy specimens from a suspicious lesion is usually diagnostic in > 97% of cases. Tumors may show false-negative results because of peripheral necrosis. Wang needle sampling deeper in the tissue may be beneficial.

TRANSBRONCHIAL BIOPSY (TBBx)—Most helpful in evaluation of diffuse parenchymal lung disease. Typically, 6–10 specimens are obtained under fluoroscopic guidance. TBBx is diagnostic in lymphangitis carcinomatosis, sarcoidosis, rejection after lung transplantation, hypersensitivity pneumonitis, and mycobacterial and invasive fungal infection.

Flash Card A6

Interstitial lung disease

Complications include pneumothorax and hemorrhage. Pulmonary hypertension increases the risk of hemorrhage. TBBx is safe in patients receiving aspirin, but clopidogrel bisulfate (Plavix) should be withheld 5–7 days before the test.

TRANSBRONCHIAL NEEDLE ASPIRATION—Typically used for staging cancer, evaluating mediastinal or hilar lymphadenopathy, and increasing the yield of peripheral nodules.

ENDOBRONCHIAL ULTRASOUND—Can help to improve the yield of sampling peripheral nodules and guiding transbronchial needle aspiration. See Chapter 13 on specific nodes that can be sampled and the diagnostic yield of the different modalities. There are two types of endobronchial ultrasound: radial and convex probe. Table 8-20 shows a comparison of the two modalities.

Can also help to determine the likelihood of malignancy.

ELECTROMAGNETIC NAVIGATION—Creates an electromagnetic fluid around the chest and superimposes this field on previously acquired CT images. A microsensor is used to determine positioning within the endobronchial tree. It can then guide placement for peripheral lung lesions or mediastinal lymph nodes.

AUTOFLUORESCENCE—Can be used to detect early cancers in the airways (carcinoma in situ and squamous cell carcinoma) by causing a red-brown appearance in the airway. Normal mucosa appears green.

Table 8-20. Radial Versus Convex Probe Endobronchial Ultrasound

Modality	Type of Images	Ideal Applications
Radial	360° image of airway wall and surrounding structure	Used to determine airway tumor invasion Distance and direction of nodule or mass Useful to guide transbronchial biopsy of peripheral nodules
Convex probe	Images parallel to bronchoscope	Real-time sampling

Flash Card Q7

When performing TBBx, how long should Plavix be withheld?

Therapeutic Bronchoscopy Techniques (Table 8-21)

Table 8-21. Therapeutic Bronchoscopy Technique

Method	Mechanism	Indications	Contra-indications	Complications
Electrocautery	Alternating high-frequency current to generate heat to cut, vaporize, or coagulate tissue	Debulking of intraluminal tumor Snare used in pedunculated lesions Knife useful before dilation for tracheal stenosis	Pacemaker Defibrillators High oxygen requirement	Airway perforation Airway fire with high FiO_2
Argon plasma coagulation	Argon gas used to achieve tissue coagulation and hemostasis	Hemorrhage Excess granulation tissue Papillomatosis Postinfectious airway stenosis	Pacemaker	Depth of penetration 2–3 mm (< risk of perforation than laser)
Cryotherapy	Freezing of tissue with either liquid nitrogen, nitrous oxide, or carbon dioxide	Sloughing in 24–48 h so repeat bronchoscopy needed Ideal for foreign bodies with high water content (grapes, vegetables)	None	Postprocedural fever
Laser	Nd:YAG for rapid destruction/vaporization of tissue	Central airway obstruction for exophytic lesion Tracheal stenosis	High oxygen requirement	Depth 10 mm; highest risk of perforation Airway fire Ocular/skin damage
Photo-dynamic therapy	3 steps: Intravenous photosensitizing agent, laser light exposure for activation (after 48 h), “clean up” bronchoscopy	Malignant airway involvement	Tracheal–carinal lesions Postpneumonec-tomy Porphyria	Skin photosensitivity (avoid sunlight 4–6 weeks) Local airway edema Stricture Hemorrhage Fistula formation

Flash Card A7

Plavix should be withheld 5–7 days before TBBx. It is safe to perform TBBx in a patient taking aspirin.

Table 8-21. Therapeutic Bronchoscopy Technique, continued

Method	Mechanism	Indications	Contra-indications	Complications
Brachytherapy	Implantation of radioactive source adjacent to airway lesion	Malignant airway obstruction (intrinsic or extrinsic)	Known fistula involving airway Tumors invading major arteries or mediastinal structures	Intolerance of catheter Radiation bronchitis Airway perforation Massive hemorrhage (if lesion in upper lobes)
Stenting	General anesthesia and rigid bronchoscopy for placement	T-tube in conjunction with tracheostomy for high tracheal stenosis Extrinsic airway compression Tracheobronchomalacia Tracheoesophageal fistula	Metal-covered stents only for malignant compression	Stent migration Bacterial colonization of stent Stent fractures Granulation tissue
Bronchial thermoplasty (still under research)	Thermal energy applied for airway ablation	Asthma	None	None

FiO2, fraction of inspired oxygen

9 Lung Transplantation

Tessy Paul, MD

INDICATIONS AND PATIENT SELECTION

Lung transplantation has become a viable therapeutic option for end-stage lung disease (ESLD) in the last 25 years. Indications for lung transplantation (Figure 9-1) include obstructive disease (i.e., chronic obstructive pulmonary disease [COPD], cystic fibrosis [CF], alpha-1 antitrypsin deficiency, bronchiectasis), restrictive disease (i.e., idiopathic pulmonary fibrosis [IPF] and other interstitial lung diseases), and less commonly, pulmonary vascular disease (pulmonary arterial hypertension [PAH]) and congenital diseases. Table 9-1 shows disease-specific guidelines for lung transplantation in common lung diseases.



Figure 9-1. Indications for adult lung transplantation.
COPD, chronic obstructive pulmonary disease; CF, cystic fibrosis; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary fibrosis; LAM, lipoarabinomannan; OB, obliterative bronchiolitis.

Table 9-1. Disease-Specific Indications

Disease	Indication
COPD and A1AT	BODE Index score of at least 7–10 (**BODE** Index derived from **b**ody mass index, degree of airflow **o**bstruction, **d**yspnea, and **e**xercise capacity measured by 6MWT) or at least one of the following: • Hospitalization for exacerbation with acute $PaCO_2$ > 50 mm Hg • Pulmonary hypertension and/or cor pulmonale despite oxygen therapy • FEV_1 < 20% AND either DLCO < 20% or homogenous distribution of emphysema
Cystic fibrosis	FEV_1 < 30% or rapid decline, especially in young women Exacerbation requiring ICU stay Increased frequency of exacerbations requiring antibiotics Refractory or recurrent pneumothorax Recurrent hemoptysis not controlled with embolization Oxygen-dependent respiratory failure or PaO_2 < 55 mm Hg on room air Hypercapnia with $PaCO_2$ > 50 mm Hg Pulmonary hypertension
Idiopathic pulmonary fibrosis	UIP pattern on CT scan or biopsy with any of the following: • 6MWT desaturation (SpO2 < 89%) • Long-term oxygen therapy • > 10% decline in FVC over 6 months • DLCO < 39% • Honeycombing on high-resolution computed tomography scan (fibrosis score > 2)
Pulmonary arterial hypertension (including congenital heart disease and Eisenmenger syndrome)	Functional class III or IV despite maximal medical therapy (IV epoprostenol or equivalent) Cardiac index < 2 L/min/m^2 Mean RAP > 15 mm Hg Low (< 350 m) or declining 6MWT

A1AT, alpha-1 antitrypsin deficiency; 6MWT, 6-minute walk test; COPD, chronic obstructive pulmonary disease; CT, computer tomography; DLCO, diffusion lung capacity for carbon monoxide; FVC, forced vital capacity; IV, intravenous; FEV_1,1-second forced expiratory volume; $PaCO_2$, partial pressure of carbon dioxide; PaO_2, partial pressure of oxygen, arterial; RAP, right atrial pressure; SpO_2, oxygen saturation; UIP, usual interstitial pneumonia.

Recipient Selection and Contraindications

In general, patients considered for lung transplantation should have:

- ESLD that is either untreatable or is not responding to available therapy.
- No other significant medical diseases.
- Limited life expectancy.
- Psychosocial stability.

Table 9-2 shows absolute and relative contraindications to lung transplantation.

Table 9-2. Contraindications to Lung Transplantation

Relative	Absolute
Age > 65 years	Untreatable advanced dysfunction of another organ (e.g., cirrhosis, end-stage renal disease, congestive heart failure)
Critical or unstable clinical condition (e.g., shock)	Untreatable chronic extrapulmonary infection (e.g., active hepatitis B, hepatitis C)
Severely limited functional status or poor rehabilitation potential	Malignancy in the last 2 years (except non-melanoma skin cancer)
Chronic colonization with highly resistant or virulent organisms (e.g., *Burkholderia cenocepacia, Mycobacterium abscessus,* pan-resistant *Pseudomonas aeruginosa*	Tobacco or other substance abuse within 6 months
Obesity (body mass index > 30 kg/m^2) or poor nutritional status	Significant chest wall or spinal deformity, such as kyphoscoliosis
Severe or symptomatic osteoporosis	Absence of reliable social support system
Mechanical ventilation	History of noncompliance or untreatable psychiatric illness associated with inability to comply with treatment
Extrapulmonary comorbidities without significant end-organ damage (e.g., diabetes mellitus, hypertension, peptic ulcer disease, GERD)	

GERD, gastroesophageal reflux disease.

Choice of Surgical Procedure

BILATERAL LUNG TRANSPLANT (BLT)

- Now performed more often than single-lung transplant (SLT) across all major indications.
- Recipients have improved survival across all major indications, although this advantage is considerably attenuated after adjustment for confounders, particularly in the setting of advanced age and the diagnosis of IPF.
- Also provides improved physiologic function.
- Mandatory for patients with suppurative lung diseases, such as CF and bronchiectasis.
- Preferred in patients with PAH because postoperative insults to the lung may be poorly tolerated after SLT. Complications such as pneumonia may result in severe hypoxemia and V/Q mismatch because of pre-existing severely elevated pulmonary vascular resistance in the native lung.

Key Fact

Suppurative lung diseases, such as CF and bronchiectasis always require BLT rather than SLT.

SINGLE-LUNG TRANSPLANT (SLT)

- Can be performed for nonsuppurative obstructive and restrictive lung diseases.
- Advantages:
  - Reduced operative time and complexity.
  - Reduced ischemic time.
  - Potentially reduced risk of surgical morbidity in some patients.
  - Potentially shorter waiting list time.
- Extends the limited supply of critical donor organs.

Flash Card Q1

Colonization with what organism is a relative contraindication to lung transplantation in patients with CF?

Flash Card Q2

What are the major benefits of SLT vs. BLT?

HEART-LUNG TRANSPLANT (HLT)

- Rarely performed.
- Most frequent indications are Eisenmenger syndrome with a surgically uncorrectable cardiac anomaly or severe ESLD with concurrent severe heart disease.

PRETRANSPLANT EVALUATION

Patients with ESLD should be referred early to transplant centers. Once they are deemed potential candidates, they undergo multiple studies for additional assessment for candidacy.

Laboratory Values

- Renal and liver function tests.
- Infectious serologies (e.g., HIV, viral hepatitis, cytomegalovirus [CMV], Epstein-Barr virus [EBV]).
- Human leukocyte antigen (HLA) typing and screening for pre-existing HLA antibodies.
- Sputum cultures in patients with suppurative lung disease to assist with the postoperative antimicrobial regimen.

Imaging and Other Studies

- Pulmonary function tests: spirometry, lung volume, diffusion capacity.
- Exercise performance with 6MWT.
- Cardiac evaluation: EKG, echocardiogram, cardiac stress test, and coronary angiography for high-risk patients (e.g., age > 40 years, risk factors for coronary artery disease).
- Chest computed tomography (CT) scan to evaluate for nodules not seen on chest x-ray and to evaluate for bronchiectasis if BLT is considered.
- Formal evaluation for GERD and gastroparesis in some high-risk patients (pH probe, manometry, gastric emptying).

Flash Card A1

Burkholderia cenocepacia

Flash Card A2

SLT: shorter ischemia/operative time, possibly shorter waiting list time, and more efficient use of limited organ supply.
BLT: improved long-term outcome and life expectancy.

DONOR SELECTION AND ORGAN ALLOCATION

Most organs are obtained from brain-dead donors; living donor transplantation is rarely performed. Living donor transplantation is primarily done in patients with CF. In this case, two blood group–compatible living donors each provide a lower lobe to the patient.

Donor Selection

Donor selection criteria:

- Age < 55–70 years.
- No significant lung disease or pulmonary infection; no purulent secretions on bronchoscopy.
- Limited smoking history.
- Clear lung fields on chest x-ray; minimal or no evidence of aspiration.
- Adequate gas exchange: PaO_2/FiO_2 >300 mmHg on 5cm H_2O PEEP.
- No active infection, including HIV or hepatitis.
- No history of malignancy.
- Minimal or no chest trauma.

Organ Allocation

Revisions were made to the donor allocation system in 2005. They system is now based on a benefit- and need-based lung allocation score (LAS).

- The LAS is calculated using the transplant benefit measure, which is derived from the difference between the predicted posttransplant survival measure (expected days lived during the first posttransplant year) and waiting list urgency measure (expected days lived during an additional year on the waiting list).
- Each patient receives a normalized score of 0–100. Higher scores represent greater urgency and greater potential for transplant benefit.
- Factors considered in the LAS calculation include diagnosis, age, functional status, use of assisted ventilation, height and weight, presence of diabetes, use of supplemental oxygen, percentage of predicted forced vital capacity (FVC), 6MWT distance, serum creatinine, pulmonary artery pressure, pulmonary capillary wedge pressure, and arterial or venous Pco_2.
- Since the implementation of the LAS system, waiting list mortality and waiting times have improved. However, overall 1-year survival after lung transplant has not significantly changed.

TRANSPLANT IMMUNOSUPPRESSION

Patients are managed with induction immunosuppression immediately postoperatively and typically receive a three-drug maintenance immunosuppressive regimen posttransplant to combat rejection (Table 9-3).

Table 9-3. Transplant Immunosuppression

Agent	Mechanism of Action	Adverse Effects
Induction		
ATG/ALG	Polyclonal antibody against T and B cells	Leukopenia, thrombocytopenia, serum sickness, infusion reactions (cytokine release syndrome, anaphylaxis)
IL-2 receptor antagonists (basiliximab/daclizumab)	Antagonize IL-2–induced T cell proliferation	Relatively well tolerated with rare infusion reactions
Maintenance		
Cyclosporine	Decreases T-cell activation and proliferation via inhibition of calcineurin-dependent induction of IL-2 expression	Nephrotoxic, neurotoxic, TMA, HLD, HTN, hypomagnesemia, hyperkalemia, gastrointestinal disturbance, gingival hyperplasia, hypertrichosis
Tacrolimus	Decreases T-cell activation and proliferation via inhibition of calcineurin-dependent induction of IL-2 expression	Nephrotoxic, neurotoxic, TMA, HLD, HTN, hypomagnesemia, hyperkalemia, gastrointestinal disturbance, hyperglycemia
Azathioprine	Antagonizes purine metabolism and DNA synthesis	Pancytopenia, hepatotoxicity, pancreatitis
Mycophenolate mofetil	Inhibits the de novo pathway of purine synthesis	Pancytopenia, diarrhea, abdominal pain, nausea
Prednisone	Decreases inflammation through multiple mechanisms	Hyperglycemia, weight gain, hyperlipidemia, osteoporosis, myopathy, insomnia, cataracts
Sirolimus	Decreases cell cycle progression via inhibition of mTOR-dependent cyclin D1 synthesis	Pancytopenia, anastomotic dehiscence and poor wound healing, interstitial pneumonitis, HLD, arthralgia, LE edema, acne, stomatitis

ATG, antithymocyte globulin; ALG, antilymphocyte globulin; DNA, deoxyribonucleic acid; HLD, hyperlipidemia; IL-2, Interleukin-2; HTN, hypertension; LE, lower extremity; mTOR, mammalian target of rapamycin; TMA, thrombotic microangiopathy

INDUCTION—Benefit of induction immunosuppression (antithymocyte globulin [ATG]/antilymphocyte globulin [ALG], interleukin-2 [IL-2] receptor antagonists, alemtuzumab) and the choice of agent remain controversial. Approximately half of all recipients receive no induction therapy.

MAINTENANCE—Initial maintenance regimen most commonly includes a combination of a calcineurin inhibitor (tacrolimus or cyclosporine), an antimetabolite (azathioprine or mycophenolate mofetil), and corticosteroids (prednisone).

ALTERNATE REGIMENS—Mammalian target of rapamycin (mTOR) inhibitor–based regimens (sirolimus/everolimus) are used in < 10% of recipients by 1 year, but are avoided in the early postoperative period because of concerns about delayed wound healing and anastomotic dehiscence.

Key Fact

Most transplant recipients eventually have at least some degree of chronic kidney disease attributed to the chronic nephrotoxic effects of calcineurin inhibitor therapy.

COMPLICATIONS AFTER TRANSPLANTATION

EARLY PERIOPERATIVE COMPLICATIONS

Primary Graft Dysfunction (PGD)

PGD, or ischemia-reperfusion injury, develops in the first 72 hours after transplantation and is the leading cause of early death after lung transplantation. PGD shares many features with non–transplant-associated acute lung injury.

FINDINGS—Characterized by new diffuse radiographic opacities and hypoxemia along with decreased lung compliance and increased pulmonary vascular resistance (Figure 9-2 and Table 9-4). The pathologic hallmark of PGD is diffuse alveolar damage. Other postoperative complications, such as rejection, infection, and volume overload, must be ruled out.

Flash Card Q3

Which immunosuppressive agent is most likely to cause poor wound healing and anastomotic dehiscence?

Flash Card Q4

Which immunosuppressive agents are known to cause thrombotic microangiopathy (TMA)?

Flash Card Q5

Which immunosuppressive agent can cause pancreatitis and cholestatic hepatitis?

Flash Card Q6

If the patient shown in Figure 9-2 has 60% Fio_2 with a Pao_2 of 90 on posttransplant day 2, does this patient have PGD?

Table 9-4. Primary Graft Dysfunction

Grade	PaO_2/FiO_2	Radiographic Evidence of Pulmonary Edema
0	> 300	Absent
1	> 300	Present
2	200–300	Present
3	< 200	Present

Pao_2, partial pressure of oxygen, arterial; Fio2, fraction of inspired oxygen.

Figure 9-2. Primary graft dysfunction.
(Courtesy of Dr. Ariss Derhovanessian, David Geffen School of Medicine at UCLA.)

RISK FACTORS

- Donor: age, female sex, African American race, and smoking history
- Recipient: PAH and possibly use of cardiopulmonary bypass

TREATMENT—The mainstay of treatment is supportive care and diuresis. Other therapies, such as protective ventilator strategies, inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO) have been utilized, and retransplantation has been performed in refractory cases.

Flash Card A3

Sirolimus

Airway/Anastomotic Complications

Flash Card A4

Tacrolimus and cyclosporine (calcineurin inhibitors). Neurotoxicity is also common with both agents.

Figure 9-3 shows a normal-appearing transplant anastomosis site. Early airway complications that occur in the first 4–8 weeks and can lead to anastomotic strictures and bronchomalacia include:

Flash Card A5

Azathioprine

- Partial or complete anastomotic dehiscence.
- Fungal anastomotic infection: *Aspergillus* (Figure 9-4) and *Candida*.
- Bacterial anastomotic infection: *Staphylococcus* and *Pseudomonas*.

Flash Card A6

Yes, PGD grade 3



Figure 9-3. Bronchoscopic view of normal transplant anastomosis.
(Courtesy of Dr. David J. Ross, David Geffen School of Medicine at UCLA)



Figure 9-4. (A) and (B) *Aspergillus* infection of an anastomosis site *(arrows)*; (C) bronchoscopic view of *Aspergillus* infection of an anastomosis site.
(Courtesy of Dr. John A. Belperio, David Geffen School of Medicine at UCLA)

PRESENTATION—Usually dyspnea on exertion, cough, wheezing, and worsening obstruction on pulmonary function tests. Bronchial strictures or stenoses (Figure 9-5) are seen on imaging and bronchoscopy. Patients may also have mediastinal emphysema or air adjacent to the anastomosis site on CT scan.



Figure 9-5. Bronchoscopic view of stenosis of the anastomosis site.
(Courtesy of Dr. David J. Ross, David Geffen School of Medicine at UCLA)

TREATMENT—Includes balloon dilatation, stent placement, laser therapy, and surgery along with appropriate antimicrobial treatment for infectious causes.

REJECTION

Transplant rejection is categorized into hyperacute, acute, chronic, and antibody-mediated types based on the timing of the insult and histopathologic findings (Table 9-5).

Acute Rejection (AR)

Despite advances in transplant immunosuppression, more than one third of lung transplant recipients require treatment for AR. AR is the most well-established risk factor for chronic rejection.

TIMING—AR typically occurs in the first 3 months after lung transplant and is rarely seen later than the first year after transplantation.

PRESENTATION AND FINDINGS—Patients may present with cough, shortness of breath, malaise, and fever. However, many episodes are diagnosed in asymptomatic patients undergoing surveillance biopsy.

Physiologic findings include hypoxia and decline in lung function, as seen in FEV_1, $FEF_{25–75\%}$, and VC. Because clinical signs and symptoms are nonspecific, the diagnosis is made histologically with bronchoscopy and transbronchial biopsy.

Pathologically, AR is graded as A0–A4 for perivascular inflammation (Figure 9-6, arrow) and as B0–BX for airway involvement (lymphocytic bronchiolitis).

TREATMENT

- Pulse steroids with methylprednisolone 10–15 mg/kg/day intravenously × 3 days followed by increased maintenance prednisone to 0.5–1.0 mg/kg/day with taper over several weeks.
- Augmentation/alteration of maintenance immunosuppression in appropriate cases.

Resolution of symptoms occurs in days, and histologic resolution should occur in 3–4 weeks.

Table 9-5. Transplant Rejection

Category of Rejection	Grading/ Severity	Findings
Acute cellular rejection A grade	Grade 0	Normal lung
	Grade 1	Small amount of mononuclear perivascular infiltrates
	Grade 2	More frequent mononuclear perivascular infiltrates ± eosinophils
	Grade 3	Dense mononuclear perivascular infiltrates with extension into the interstitium ± endothelialitis, eosinophils, and neutrophils
	Grade 4	Diffuse perivascular, interstitial, and air space mononuclear infiltrates with lung injury and endothelialitis ± neutrophils
Acute cellular rejection B grade	Grade 0	No airway inflammation
	Grade 1R	Scattered mononuclear submucosal and peribronchiolar infiltrates
	Grade 2R	Extensive mononuclear submucosal and peribronchiolar infiltrates with epithelial infiltrates and damage
	Grade X	Ungradable, no bronchiolar tissue available
Chronic airway rejection	0–absent	Normal airways
	1–present	Obliterative bronchiolitis with dense, eosinophilic hyaline fibrosis
Chronic vascular rejection		Accelerated vascular sclerosis of the graft with fibrointimal thickening of pulmonary arteries and veins



Figure 9-6. Lung transplant rejection with perivascular lymphocytic infiltrate (*arrow*).
(Reproduced courtesy of Nephron, Wikimedia Common, CC BY-SA 3.0.)

Chronic Rejection/Bronchiolitis Obliterans Syndrome (BOS)

Chronic allograft rejection is the leading cause of long-term mortality after lung transplantation. It is classically characterized by the histopathologic finding of obliterative bronchiolitis (OB) and its clinical correlate, BOS, which is defined by a progressive, irreversible obstructive ventilatory defect caused by obliteration and fibrosis of terminal respiratory bronchioles.

Key Fact

The most important risk factor for chronic rejection is acute rejection.

POSSIBLE CAUSES/RISK FACTORS—Acute rejection, lymphocytic bronchiolitis, CMV and other infections, *Aspergillus* colonization, GERD, PGD, medication noncompliance, HLA mismatch, donor antigen-specific reactivity, older donor age, and organizing pneumonia.

PRESENTATION—Nonspecific symptoms of cough and progressive dyspnea on exertion with onset that is insidious or abrupt, but is typically more gradual than the onset of AR. Otherwise unexplained progressive airflow obstruction is the physiologic hallmark.

IMAGING—High-resolution CT with hyperinflation, air trapping, cylindrical bronchial dilation, or bronchiectasis.

DIAGNOSIS—Unlike in AR, transbronchial biopsy has low sensitivity for diagnosing OB and is used primarily to exclude other diagnoses.

STAGING—The International Society for Heart and Lung Transplantation (ISHLT) devised a BOS staging system based on FEV_1 with or without pathologic documentation (Table 9-6).

Table 9-6. Staging of Bronchiolitis Obliterans Syndrome

Stage	Pulmonary Function Test Result
0	FEV_1 > 90% baseline and $FEF_{25–75\%}$ > 75%
0-p (potential bronchiolitis obliterans syndrome)	FEV_1 81–90% baseline and/or $FEF_{25–75\%}$ ≤ 75% baseline
1	FEV_1 66–80% baseline
2	FEV_1 51–65% baseline
3	FEV_1 ≤ 50% baseline

FEV_1, forced expiratory volume in 1 second; $FEF_{25–75\%}$, average forced expiratory flow during the mid (25 - 75%) portion of the FVC

.

TREATMENT

- No established treatment regimen exists for BOS, and conventional immunosuppressive strategies have been largely unsuccessful.
- Strategies include alteration of maintenance immunosuppression, high-dose glucocorticoids, cytolytic therapy, and extracorporeal photophoresis, possibly slowing progression of BOS in some cases.
- Azithromycin has shown promise in small clinical trials for treatment and prevention of BOS.
- Aggressive therapy for GERD, including fundoplication, may be considered in patients with confirmed severe refractory GERD.
- Retransplantation is considered for some patients, although overall survival is further reduced compared with first-time transplants.

Antibody Mediated Rejection (AMR)

AMR is suggested by graft dysfunction with new or increasing antibodies to donor HLA or other graft epitopes and histologic findings of acute lung injury with complement deposition and neutrophilic capillaritis. However, these findings are nonspecific. AMR is less well defined in lung transplantation than in other solid organ transplants, and no widely accepted diagnostic criteria exist. Treatment options include combinations of high-dose glucocorticoids, intravenous immunoglobulin, plasmapheresis, anti-CD20 monoclonal antibodies (rituximab), and bortezomib.

Hyperacute rejection is a rare form of AMR that occurs within 24 hours of transplant because of pre-existing donor-specific alloantibodies.

Flash Card Q7

What is the leading cause of posttransplant mortality after the first year?

Flash Card Q8

True or False. BOS can be diagnosed with transbronchial biopsies.

INFECTION

Infection rates are higher in patients with lung transplant compared with other solid organ recipients because of the higher levels of immunosuppression required and the constant exposure of the lung to the environment. Therefore, infection is a leading cause of morbidity and mortality and many also be a risk factor for subsequent chronic rejection. Transplant patients should be given standard vaccinations, but live vaccines should be avoided.

Bacterial Infections

- Up to one fourth of patients have bacterial pneumonia in the first month after transplantation.
- Common organisms include *Pseudomonas aeruginosa* and *Staphylococcus* species.
- Although patients are at risk for opportunistic infection throughout their course, the greatest risk is within the first 6 months.
- At most centers, patients are treated with broad-spectrum empiric antibiotics at the time of transplantation, targeting both donor- and recipient-derived pathogens. The course and choice of agents are tailored to specific culture findings.

Viral Infections

- Viral infections are less common with the use of postoperative prophylactic antiviral agents (ganciclovir or acyclovir).
- The most common viral infection in the first 6 months is CMV. The highest risk is in seronegative recipients with seropositive donors (D+/R−). Patients may be asymptomatic or may present with pneumonitis or, less commonly, gastroenteritis, hepatitis, and colitis. Diagnosis of CMV pneumonia can be made with bronchoscopy with transbronchial biopsy and bronchoalveolar lavage with CMV polymerase chain reaction (PCR) or findings of pathologic hallmark intranuclear inclusions ("owl's eye," as seen in Figure 9-7). Oral valganciclovir and IV ganciclovir are effective in the treatment and prophylaxis of CMV, though resistance has rarely been reported.
- Other less commonly seen viral infections include herpes simplex virus, respiratory syncytial virus, influenza, parainfluenza, human metapneumovirus, and adenovirus.

Key Fact

CMV is the most common viral infection after lung transplantation.

Flash Card A7

Bronchiolitis obliterans syndrome

Flash Card A8

False. Unlike AR, transbronchial biopsy has low sensitivity for diagnosing BOS and is used primarily to exclude other diagnoses.



Figure 9-7. Active cytomegalovirus infection in the lung (*arrow*).
(Reproduced from the CDC Public Health Image Library; content provider, Dr. Edwin P. Ewing, Jr.)

Fungal Infections

- Between 15% and 35% of patients have fungal infections posttransplant.
- Mortality rate may be as high as 80%, particularly for drug-resistant and invasive molds.
- Routine prophylaxis with azoles or aerosolized amphotericin is now used by most centers, although evidence is limited.

ASPERGILLUS—*Aspergillus* species (*A. flavus, A. fumigatus, A. niger, A. terreus*) can colonize the allograft or cause pneumonia; invade blood vessels, causing infarction and hemoptysis; or result in pseudomembranous tracheobronchitis.

- Diagnosis of invasive aspergillosis requires identification of the organism in the tissue or recovery of the organism in the sputum or bronchoalveolar lavage in the appropriate clinical setting.
- Organisms appear as septated hyphae with branching at acute angles (Figure 9-8).
- Voriconazole is the drug of choice. Other azoles (posaconazole and itraconazole, but **not fluconazole**), echinocandins, and amphotericin may also be effective.
- Concurrent reduction in immunosuppression is advisable when feasible.

***CANDIDA* SPECIES—**Can cause wound infection, line sepsis, mucocutaneous disease, and less often, pulmonary involvement. Echinocandins are the treatment of choice, and fluconazole, although active against *Candida albicans,* is less effective against non-albicans species, such as *C. glabrata* and *C. krusei.*

Key Fact

Use of azoles, such as voriconazole, can significantly increase cyclosporine and tacrolimus levels.

Flash Card Q9

What is the most important risk factor for CMV infection in posttransplant patients?



Figure 9-8. Pulmonary aspergillosis.
(Reproduced from the CDC Public Health Image Library and Armed Forces Institute of Pathology [AFIP]; content provider Dr. Hardin.)

***PNEUMOCYSTIS CARINII* PNEUMONIA—**Incidence is now < 1% because of standard prophylaxis with trimethoprim-sulfamethoxazole.

OTHER—Rare fungal infections include *Scedosporium* and *Fusarium* species, mucormycosis, and the endemic mycoses (*Cryptococcus, Histoplasma, Coccidioides,* and *Blastomyces*), with treatment depending on the specific pathogen.

Given their frequent use after lung transplantation, it is important to note the strong interactions between azoles and other transplant medications. In particular, therapy with azoles significantly increases levels of cyclosporine and tacrolimus, uniformly requiring dose reductions for these agents.

Mycobacterial Infections

- Rarely seen in patients with lung transplant.
- *Mycobacterium abscessus* infection is associated with poor outcomes.

Flash Card A9

Donor seropositivity and recipient seronegativity for CMV

POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)

- PTLD is more common in lung transplant recipients compared with other solid organ transplants because of the greater levels of immunosuppression required.
- Most are lymphomas, and the vast majority (76–95%) are associated with EBV and are of B-cell origin. Recipient seronegative EBV status pretransplant significantly increases the risk as acquisition of EBV from the donor leads to persistent viral replication and transformation of B lymphocytes in immunosuppression.
- Estimated incidence is 2–8%.
- Often presents with constitutional symptoms and an infectious mononucleosis-like illness. May be nodal, extranodal, localized, or widely disseminated. Among lung transplant recipients, 69–89% of cases involve the thorax. Imaging shows nodules, infiltrates, or thoracic lymphadenopathy.
- Peak incidence is within the first year after transplantation
- First-line treatment is reduction of immunosuppression. Other modalities include rituximab and consideration for antiviral therapy, chemotherapy, radiation, adaptive immunotherapy, and surgical intervention.

OTHER MALIGNANT COMPLICATIONS

- According to ISHLT registry reports, malignancy develops in 3.5% of 1-year lung transplant survivors and 14.1% of 5-year survivors.
- Skin cancer is most common in patients 5 years posttransplant.
- SLT recipients are also at risk for lung carcinoma in the native lung given their older age, underlying COPD/interstitial lung disease, and frequent smoking history.
- General age- and sex-appropriate cancer screening should be performed with a low threshold to further investigate suspicious findings or lesions.
- In general, treatment involves reduction in immunosuppression in addition to the specific cancer-related therapy.

MISCELLANEOUS POSTTRANSPLANT COMPLICATIONS

- Pleural: effusions, hemothorax, persistent air leak, empyema, and rarely chylothorax.
- Recurrence of primary disease has been reported in those with Langerhans cell histiocytosis, pulmonary alveolar proteinosis, desquamative interstitial

Flash Card Q10

What is the first-line therapy for PTLD?

pneumonitis, lymphangioleiomyomatosis, sarcoidosis, idiopathic hemosiderosis, giant cell interstitial pneumonitis, and diffuse panbronchiolitis.
- GERD and gastroparesis.
- Osteoporosis.
- Thromboembolic disease.
- Some degree of chronic kidney disease in > 50% of patients at 5 years.
- Dyslipidemia, diabetes mellitus, and hypertension.

OUTCOME OF LUNG TRANSPLANTATION

Key Fact

The average 5-year survival rate after lung transplant is about 50%.

Survival after lung transplantation is lower than in other solid organ transplant recipients. The 5-year survival rate is ~53% and is highest in patients with CF and lowest in those with IPF, likely because of the confounding effects of age and accompanying comorbidities.

Table 9-7 shows posttransplant survival over time, and Figure 9-9 shows survival based on diagnosis according to ISHLT registry data.

Table 9-7. Survival After Lung Transplant

Time	3 months	1 year	3 years	5 years	10 years
Survival	88%	79%	64%	53%	30%

Flash Card A10

Reduction in immunosuppression



Figure 9-9. Lung transplant survival by diagnosis.
COPD, chronic obstructive pulmonary disease; CF, cystic fibrosis; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic pulmonary fibrosis.

QUALITY OF LIFE AND PHYSIOLOGIC OUTCOME

- Patients report improvement in quality of life posttransplant, with > 80% reporting no limitations in activity at 1 year.
- The degree of improvement in lung function is gradual and plateaus 3–6 months after transplant.
- Peak posttransplant spirometric index is variable and depends on both the type of transplant and the native lung disease.
- Lung volumes are typically superior after BLT, often yielding normal lung function. These patients also have equal division of ventilation and perfusion.
- After SLT, most ventilation and perfusion is directed toward the transplanted lung, leading to essentially normal gas exchange in most patients.
- Patients with PAH who undergo transplantation have marked improvement in gas exchange, near-normal hemodynamics, and almost complete recovery of right ventricular function. This obviates the need for HLT in most patients with PAH.

MORTALITY

- Early (< 30 day): most often as a result of PGD.
- 30 days to 1 year: most often because of infectious complications.
- Late (> 1 year): most often because of chronic rejection or BOS.

10 Pulmonary Vascular Diseases

Jeffrey Albores, MD, Sachin Gupta, MD, Tessy Paul, MD & Sandeep Sahay, MD

PULMONARY VASCULITIS AND ALVEOLAR HEMORRHAGE SYNDROMES

Vasculitis is the inflammation of blood vessel walls. The Chapel Hill Consensus Conference in 2012 defined the current classification of vasculitic syndromes as shown in Table 10-1.

Idiopathic or primary vasculitis syndromes are a group of immune-mediated diseases of unknown etiology. Secondary vasculitis syndromes are typically secondary to connective tissue disease (e.g., systemic lupus erythematous [SLE]), infection, or drug use (therapeutic or illicit).

Vasculitides can be classified based on the vessel size:

- Small-vessel vasculitis:
  - Immune complex-associated vasculitis
  - Antineutrophilic cytoplasmic antibodies (ANCA)-associated vasculitis
- Medium-vessel vasculitis
- Large-vessel vasculitis

Immune complex small-vessel vasculitis is characterized by immune complex deposits, which are either immunoglobulin G (IgG) or complement and are readily detected in the affected tissues. Small-vessel vasculitides are of utmost importance to the pulmonologist as they tend to involve the small intraparenchymal pulmonary arteries, arterioles, capillaries, and venules. These conditions will be discussed in detail later. Medium arteries and bronchial veins may also be affected.

Table 10-1. Classification of Vasculitis

Primary Vasculitis Syndromes	Small-vessel vasculitis	ANCA-associated vasculitis (pauci-immune): GPA (formerly Wegener's granulomatosis) MPA EGPA (formerly Churg-Strauss syndrome) Immune complex-associated vasculitis: Cryoglobulinemic vasculitis Hypocomplementemic urticarial vasculitis (anti-C1q vasculitis) Anti-GBM disease IgA vasculitis(Henoch-Schönlein)
	Medium-vessel vasculitis	Polyarteritis nodosa Kawasaki disease
	Large-vessel vasculitis	Takayasu arteritis Giant cell (temporal) arteritis
Secondary Vasculitis Syndromes		Lupus vasculitis Rheumatoid vasculitis Sarcoid vasculitis Drug-associated ANCA-associated vasculitis Cancer-associated vasculitis Vasculitis related to hepatitis C and hepatitis B Syphilis-associated aortitis

ANCA, antineutrophilic cytoplasmic antibodies; EGPA, eosinophilic granulomatosis with polyangiitis; GBM, glomerular basement membrane; GPA, granulomatosis with polyangiitis; Ig, immunoglobulin; MPA, microscopic polyangiitis

SMALL-VESSEL VASCULITIS

Mnemonic

The most common causes of pulmonary vasculitides are the AAV diseases: **GME**

Granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis)
Microscopic polyangiitis (MPA)
Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome)

ANCA-Associated Vasculitis (AAV)

ANCA associated vasculitides are characterized by systemic necrotizing small-vessel vasculitis. This group of diseases includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). Frequent occurrence of ANCA is pathognomonic, but not required for diagnosis. More than half of patients with these vasculitides have ANCA positivity as well as predominant pulmonary symptoms.

EPIDEMIOLOGY—AAV can affect patients of any age and gender. GPA is seen more commonly in whites. EGPA does not show any predilection to any race or ethnicity (Table 10-2).

Table 10-2: Comparison of AAV Clinical Features

	GPA	MPA	EGPA
Epidemiology			
Age at diagnosis	Any age	Any age (higher incidence > 50 years)	30–40 years
Gender (M:F)	1:1	1:1	1:1
Race	>90% whites, Northern European descent	Southern European, Mediterranean descent	No predilection
Clinical Features			
Upper airway involvement	90–95%	No	50–60%
Pulmonary parenchymal disease	54–85%	20%	30%
Skin involvement	33–46%	62%	50–60%
Alveolar hemorrhage	5–15%	10–50%	< 3%
Glomerulonephritis	51–80%	60–90%	10–25%
Eye involvement	35–52%	< 5%	< 5%
CNS involvement	20–50%	60–70%	70–80%
GI involvement	< 5%	30%	30–50%
Cardiac involvement	8–16%	10–15%	10–15%
Asthma	No	No	Yes
Type of Inflammation			
Granulomatous	Yes	No	Yes
Inflammatory cell type	Neutrophilic inflammation	Neutrophilic inflammation	Eosinophilic inflammation
Histopathology			
Lung	Capillaritis ± granulomatosis	Capillaritis	Necrotizing eosinophilic granulomatosis (allergic granuloma)
Kidney	Segmental necrosis, crescent	Segmental necrosis, crescent	Necrotizing crescentic glomerulonephritis
Immunofluorescence			
Lung	Negative	Negative	-
Kidney	Pauci-immune	Pauci-immune	Pauci-immune
Serology			
ANCA positivity	90%	70%	50%
Type of ANCA	cANCA[a] (80–90%) (antiproteinase)	pANCA[a] (70–80%) (myeloperoxidase)	pANCA (70–75%) (myeloperoxidase)

[a]20% of patients with GPA or MPA can have alternate ANCA antibodies. ~10% can be ANCA negative.
ANCA, antineutrophilic cytoplasmic antibodies; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CNS, central nervous system; EGPA, eosinophilic granulomatosis with polyangiitis; GI, gastrointestinal; GPA, granulomatosis with polyangiitis; Ig, immunoglobulin; MPA, microscopic polyangiitis; pANCA, perinuclear antineutrophilic cytoplasmic antibodies.

CLINICAL FEATURES—There is a significant overlap in the clinical presentation of the AAV diseases. Table 10-2 highlights the clinical features of the AAVs.

- GPA: Ear, nose, and throat (ENT) symptoms are usually noticed in > 85% of patients with GPA. Cavitary nodules or masses characterize pulmonary involvement in GPA.
- EGPA: Triad of asthma (allergic disease), eosinophilia (blood and tissue; Figure 10-1), and vasculitis (tissue necrosis). Leukotriene inhibitors are

known to unmask EGPA. In EGPA, ANCA follows the vasculitis activity.



Figure 10-1. Micrograph showing an eosinophilic tissue infiltration with necrotizing vasculitis consistent with EGPA (formerly Churg-Strauss syndrome). Hematoxylin and eosin (H&E) stain.
(Reproduced courtesy of Nephron, Wikipedia Commons, permission granted per the GNU Free Documentation License, Version 1.2.)

ANCA TESTING—Cytoplasmic antineutrophil cytoplasmic antibody (cANCA) pattern is characterized by the diffuse cytoplasmic staining (Figure10-2). In cases with cANCA, antibodies are directed against antiproteinase (PR-3); rarely, antibodies against myeloperoxidase (MPO) can also be seen.



Figure 10-2. Immunofluorescence pattern produced by binding of ANCA from a patient with GPA (formerly Wegener's granulomatosis) to ethanol-fixed neutrophils.
(Image courtesy of Wikipedia; permission granted per the GNU Free Documentation License.)

Perinuclear antineutrophil cytoplasmic antibody (pANCA, Figure 10-3) is characterized by perinuclear staining. The responsible antibody is usually directed against MPO, but rarely is also directed against PR-3.



Figure 10-3. Immunofluorescence pattern produced by binding of serum from a patient with MPA to ethanol-fixed neutrophils.
(Image courtesy of Wikipedia; permission granted per the GNU Free Documentation License.)

MANAGEMENT OF AAV—Therapeutic approach for this group of conditions is based on similar principles, as the intent is to induce and maintain remission. Treatment should be individualized based on the extent and the severity of the disease (Table 10-3).

Definition of severe disease: Life-threatening or irreversible loss of an organ; for example, glomerulonephritis, alveolar hemorrhage, eye involvement (except simple episcleritis), and central nervous system (CNS) involvement.

Limited disease: All others who do not have severe disease.

Table 10-3. Treatment of AAV

	GPA	MPA	EGPA
Standard Therapy (Limited Disease)	GCS + MTX	GCS+MTX	GCS ±MTX/AZA
Standard Therapy (Severe Disease)	GCS + CYC or GCS + RTX	GCS+RTX	GCS + CYC or RTX or anti-IL-5
Remission Maintenance (Limited)	MTX or AZA	MTX or AZA	MTX or AZA (after CYC)
Remission Maintenance (Severe)	Following CYC: MTX or AZA Following RTX: unclear	RTX	MTX or AZA or leflunomide (after CYC)
Refractory Disease	GCS + RTX/CYC or plasma exchange	GCS + RTX or RTX alone or plasma exchange	GCS + CYC or RTX Plasma exchange

AZA, azathioprine; CYC, cyclophosphamide; GCS, glucocorticoids; MTX, methotrexate; RTX, rituximab

PROGNOSIS

- GPA or MPA: Untreated patients have mortality rate of 90% in 2 years. Major cause of death is renal or respiratory failure, and less commonly, heart failure.
- EGPA: The 5-year survival rate is 70–90%. Most deaths are due to heart failure or myocardial infarctions.

A five-factor score (FFS) system has been developed to quantify prognosis in EGPA. Each factor is assigned one point:

- Age > 65 years
- Cardiac insufficiency
- Renal insufficiency (creatinine > 1.7 mg/dL)
- Gastrointestinal (GI) involvement

- Absence of ENT manifestations

A score ≥ 1 has been associated with mortality ranging between 25–45% at 5 years. The worst prognosis is seen in older patients (> age 65) with cardiac and GI involvement.

OTHER PULMONARY VASCULITIDES

This group consists of large- and medium-vessel vasculitic conditions that affect the lungs. Table 10-4 highlights their clinical features.

Table 10-4. Clinical Features of Other Pulmonary Vasculitides

Vasculitic Condition	Epidemiology	Clinical Features/ Pulmonary Symptoms	Diagnosis/ Treatment
Giant cell arteritis	25/100,000 per year Scandinavian countries Age > 50 years	Malaise, myalgias, fever, headaches Pulmonary features seen in 25% of patients. Cough, sore throat, hoarseness Lung nodules, interstitial infiltrates, bronchocentric granulomas	Elevated ESR (typically 100 mm/hour or more), elevated CRP Treatment: steroids
Takayasu arteritis	1–3/1 million per year Women < 40 years More common in Asian women	Claudication, mesenteric ischemia, and renal artery stenosis. Pulmonary artery involvement, stenoses, pulmonary hypertension reported as high as 50% of patients.	V/Q scan and MR angiography Treatment: steroids, methotrexate, leflunomide
PAN	2–33/1 million per year Male predominance Usually in 6th decade	Associated with hepatitis B or C infection. Skin, nerves, GI, and kidney commonly involved. Rarely involves bronchial arteries. Alveolar hemorrhage in PAN indicates presence of other disease, as it never causes capillaritis.	Renal arteriography, tissue diagnosis; biopsy shows necrotizing arteritis of medium-sized arteries. Treatment: steroids, methotrexate, CYC in severe cases

Table 10-4. Clinical Features of Other Pulmonary Vasculitides, continued

Vasculitic Condition	Epidemiology	Clinical Features/ Pulmonary Symptoms	Diagnosis/ Treatment
IgA-associated vasculitis (Henoch-Schönlein)	Affects children and young adults (mean age 17 years)	Fever, purpura, large joint arthralgias, abdominal colic, nephritis. Alveolar hemorrhage is extremely rare.	Pathology shows characteristic IgA deposits in skin and kidney. Glomerulonephritis is predominantly proliferative and necrotizing type. Treatment: steroids, NSAIDs
Anti-GBM disease	< 1/1 million per year Patients < 30 years (male predominance) present with Goodpasture's syndrome (DAH) Patients > 50 years (female predominance) usually have isolated renal disease.	Hemoptysis and hematuria. Lungs are affected in 50% of patients with anti-GBM antibodies, causing the clinical presentation of DAH. Renal involvement is seen almost in all cases, and isolated lung involvement is rare.	Anti-GBM antibodies, renal biopsy. Severity of renal disease at diagnosis determines prognosis. Treatment: steroids, plasma exchange, CYC or RTX
Cryoglobulinemic vasculitis	~50% of patients have associated hepatitis C infection	Peripheral nerve and renal involvement are common. Alveolar hemorrhage is seen in 3% but carries a mortality of ~80%.	Diagnosis by tissue biopsy showing cryoglobulin deposition in small vessels, predominantly capillaries, venules, and arterioles. Treatment: RTX

CRP, C-reactive protein; CYC, cyclophosphamide; DAH, diffuse alveolar hemorrhage; ESR, erythrocyte sedimentation rate; GBM, glomerular basement membrane; GI, gastrointestinal; Ig, immunoglobulin; MR, magnetic resonance; NSAID, nonsteroidal antiinflammatory drug; PAN, polyarteritis nodosa; RTX, rituximab; V/Q, ventilation-perfusion

DIFFUSE ALVEOLAR HEMORRHAGE SYNDROMES (DAH)

DAH is characterized by diffuse hemorrhage into the alveolar spaces. Hemoptysis may be absent in up to 30% of patients. Progressive dyspnea and hypoxemia leads to respiratory failure. Chest radiograph typically shows diffuse alveolar infiltrates bilaterally. Reduced and/or declining hemoglobin (iron-deficiency) is also seen. Coagulopathy and thrombocytopenia can predispose to alveolar hemorrhage.

Etiology of DAH is multifactorial. The most common etiologies are listed in Table 10-5.

Table 10-5. Etiology of DAH

DAH associated with pulmonary capillaritis
AAVs (GPA, MPA, EGPA)
Connective tissue disorders (SLE, RA, mixed connective tissue disorders, Behçet disease, polymyositis, IgA-associated vasculitis
DAH with or without capillaritis
Goodpasture's syndrome
SLE
Antiphospholipid syndrome
Drug-induced DAH
DAH without pulmonary capillaritis
Malignancies
Lymphangioleiomyomatosis
Pulmonary veno-occlusive disease
Pulmonary capillary hemangiomatosis
Mitral stenosis
Inhalation toxins (crack cocaine, trimetallic anhydride)
Severe coagulopathy (thrombocytopenia, iatrogenic)
Idiopathic pulmonary hemosiderosis
Drugs (anticoagulation, abciximab, all transretinoic acid, sirolimus)

AAV, ANCA-associated vasculitides; DAH, diffuse alveolar hemorrhage; EGPA, eosinophilic granulomatosis with polyangiitis; GPA, granulomatosis with polyangiitis; Ig, immunoglobulin; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; SLE, systemic lupus erythematous.

DIAGNOSIS

- Determine severity and rate of progression.
- Look for other organ involvement.
- Check complete blood count (CBC) and serial hemoglobin (Hgb) determinations; serum creatinine (> 2.5 mg/dL) and blood urea nitrogen (BUN); urinalysis and urine microscopy. Ruling out coagulopathy is essential.
- Look for specific etiology of the DAH. Autoimmune causes of DAH are listed in Table 10-5. Other causes include bone marrow transplantation, acquired immune deficiency syndrome (AIDS), and idiopathic rapidly progressive glomerulonephritis.

DAH ASSOCIATED WITH BONE MARROW TRANSPLANTATION

- Usually seen within first 30 days.
- Risk is higher with autologous than with allogeneic transplant.
- Risk factors: intensive conditioning, age > 40 years.
- Hemoptysis is often absent—don't be misled.
- Treatment: High-dose steroids, but evidence is not convincing.

ROLE OF BRONCHOSCOPY—DAH from any cause is best confirmed by bronchoalveolar lavage (BAL). The serial lavage aliquots will be gradually more hemorrhagic, confirming the alveolar origin of the blood. Hemosiderin-laden macrophages (demonstrated by Prussian blue staining) are also characteristically found in BAL fluid from patients with DAH, and in the absence of active hemorrhage, > 20% of hemosiderin-laden macrophages in the BAL fluid is

Flash Card Q1

Is DAH more commonly found in autologous or allogenic BMT?

indicative of alveolar hemorrhage. Transbronchial lung biopsy is too small to allow diagnosis and relatively contraindicated in patients on mechanical ventilators. Patients are often too critically ill to tolerate video-assisted thoracoscopic surgery (VATS) or open-lung biopsy (Figure 10-4).

DAH is seen in the variety of autoimmune conditions (Table 10-5). Serological markers, immunofluorescence pattern and the histopathologic findings seen in these conditions is show in Table 10-6.

Table 10-6. Specific Serological Markers and the Pathology of Autoimmune DAH

	Lung Pathology	Immunofluorescence	Serology
GPA	Capillaritis ± granulomatosis	Negative	cANCA (more common)
MPA	Capillaritis	Negative	pANCA or cANCA
SLE	Capillaritis	Granular	ANA
Idiopathic Pulmonary Hemosiderosis	± Capillaritis	Negative	Negative
Goodpasture's Syndrome	± Capillaritis	Linear	ABMA (± pANCA)

ABMA, anti-basement membrane antibody; ANA, antinuclear antibody; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; DAH, diffuse alveolar hemorrhage; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; pANCA, perinuclear antineutrophilic cytoplasmic antibodies; SLE, systemic lupus erythematous.



Figure 10-4. Lung biopsy specimen showing hemosiderin-laden macrophages and blood filling the alveolar spaces. H&E stain.
(Image courtesy of Nephron, Wikimedia commons, CC BY-SA 3.0)

Flash Card A1

Autologous BMT

TREATMENT—Corticosteroids. High-dose pulse dose steroids (500 mg–2g/day in divided doses) for 5 days followed by gradual tapering and maintenance therapy. Cyclophosphamide (CYC) with steroids and plasma exchange have also been tried in refractory cases.

DAH with Antiphospholipid Syndrome (APS)

CLINICAL FEATURES—Presents with rapidly progressing respiratory failure and is associated with high mortality. Subclinical to massive hemoptysis may be absent in 50% of patients. Tissue necrosis from microthrombosis and capillaritis are the mechanisms of alveolar hemorrhage.

TREATMENT—Steroids are helpful. Early plasma exchange along with immunosuppressive therapy should be considered.

Idiopathic Pulmonary Hemosiderosis (IPH)

EPIDEMIOLOGY—Primarily reported in the pediatric population. Exact incidence and prevalence are unknown. There is no definite gender predilection.

CLINICAL FEATURES—Diagnosis of exclusion. It is a disease limited to the lungs. Recurrent hemoptysis and ground-glass infiltrates seen. Iron-deficiency anemia is a hallmark of the disease. Bland-lung histopathology with fibrosis seen in chronic recurrent cases. Predominantly seen in children; 20% of patients are adults (age 20–40 years).

TREATMENT—Immunosuppression, plasma exchange, gluten-free diet.

VENOUS THROMBOEMBOLISM (VTE)

VTE constitutes the spectrum of disease related to deep venous thrombosis (DVT) and pulmonary embolism (PE). About 79% of patients who present with PE also will have concomitant DVT; on the other hand, only ~50% of patients presenting with DVT will have PE. VTE pathogenesis, diagnosis, and therapy are discussed in this chapter.

Flash Card Q2

What is Lane-Hamilton syndrome?

Pathogenesis

Thrombosis is related to one or more of the three factors in Virchow's triad:
1) Disturbed blood flow
2) Endothelial cell injury
3) Hypercoagulability

Table 10-7 discusses the etiologies for hypercoagulability.

Table 10-7. Etiologies for the Hypercoagulable State

Thrombophilia	Etiology
Inherited	Factor V Leiden mutation, protein C or S deficiency, antithrombin III deficiency, prothrombin gene mutation
Acquired	Malignancy, surgery, pregnancy, CVA, hormone replacement, tamoxifen, antiphospholipid syndrome, IBD, nephrotic syndrome, myeloproliferative disorders

CVA, cerebrovascular accident; IBD, inflammatory bowel disease.

DEEP VENOUS THROMBOSIS (DVT)

Diagnosis begins with clinical suspicion. Affected proximal veins include the popliteal, femoral, and iliac; distal veins are those of the calf muscles. Nearly 90% of acute PEs originate from proximal DVTs; these clots more often are related to chronic disease. Workup is therefore geared towards detection of proximal DVT.

For DVT, the clinical signs and symptoms have poor sensitivity and specificity. Therefore, prior to initiating testing it is important to stratify patients with a clinical prediction algorithm. The Wells' prediction rule is presented in Table 10-8.

Flash Card A2

Association of gluten-sensitive sprue (celiac sprue) with idiopathic pulmonary hemosiderosis. Only 18 cases are described in the literature. All IPH patients should be screened for sprue with serologies (antigliadin and antiendomysial antibodies). Gluten-free diet seems key to therapy and prevention of relapses.

Table 10-8. Wells' Prediction Rule for Diagnosing DVT

Clinical Characteristic	Score
Active cancer (patient receiving treatment for cancer within the previous 6 months or currently receiving palliative treatment)	+1
Paralysis, paresis, or recent plaster immobilization of the lower extremities	+1
Recently bedridden for 3 days or more, or major surgery within the previous 4 weeks	+1
Entire leg swollen	+1
Calf swelling—circumference ≥ 3 cm larger than that on the asymptomatic side when measured 10 cm below tibial tuberosity	+1
Pitting edema confined to symptomatic leg	+1
Collateral superficial veins (nonvaricose)	+1
Alternative diagnosis is at least as likely	-2
Clinical Probability of PE	**Sum**
Low	< 1
Intermediate	1–2
High	> 2

Diagnosis

After assigning the patient to low-, moderate-, or high-risk pretest probability, it is appropriate to initiate testing based on risk.

D-Dimer—Use first if Wells' score ≤ 2.

- High sensitivity (88%), poor specificity (40–60%)
- High negative predictive value: 96%
- If negative, DVT has been ruled out.
- If positive, proceed to testing.

Imaging—Refer to Table 10-9 if Wells' score ≥ 2.

Table 10-9. Imaging Studies for Diagnosing DVT

Test	Sensitivity/Specificity	Comments
Noninvasive		
Impedance plethysmography	91%/96%	Rarely used, cumbersome.
Compression ultrasonography	100%/99%	Misses iliac veins; may repeat. Clinical gold standard.
Invasive		
Contrast venography	Reference test	Used when above studies fail, or concern for iliac thrombus.

PULMONARY EMBOLISM (PE)

With treatment, 3-month mortality for PE patients is 8–15%. The formation of chronic thromboemboli is a consequence of inadequate therapy; however, the development of pulmonary hypertension is rare, affecting only 3% of those with acute thromboemboli. Chronic thromboembolic pulmonary hypertension is discussed later in this chapter.

The evaluation of possible PE begins in a similar fashion to DVT. Like DVT, the clinical signs and symptoms have poor sensitivity and specificity. Therefore, before initiating testing, it is important to stratify patients for disease probability with a clinical prediction algorithm. Both the Wells' score and Geneva score have been demonstrated to be efficacious. The Wells' score is most often cited (and tested) and hence presented in Table 10-10.

Table 10-10. Wells' Prediction Rule for Diagnosing PE

Clinical Characteristic	Score
Previous PE or DVT	+1.5
HR > 100 bpm	+1.5
Recent surgery or immobilization in last 30 days	+1.5
Alternative diagnosis less likely than PE	+3
Clinical signs of DVT	+3
Hemoptysis	+1
Cancer (treated within the last 6 months)	+1
Clinical Probability of PE	**Sum**
Low	0–1
Intermediate	2–6
High	≥ 7

DVT, deep venous thrombosis; HR, heart rate; PE, pulmonary embolism.

Diagnosis

After assigning the patient to low-, intermediate-, or high-risk pretest probability, it is appropriate to initiate testing based on risk. The management algorithm is found in Figure 10-5. Features of diagnostic testing are described in Table 10-11.



Figure 10-5. Diagnosis of PE.

Table 10-11. Testing Methods for PE

Test	Sensitivity/ Specificity	Comments
Noninvasive		
D-dimer	96%/40%	Useful if negative in low/intermediate pretest probability only.
V/Q scan	77%/98%	Affected by lung pathology; preferred in cases of renal failure and contrast allergy.
Spiral CTA	83%/96%	Evaluate clot burden, cardiac changes. High NPV.
Extremity ultrasound	29%/97%	Useful when signs/symptoms suggestive of DVT; if + then no further workup necessary.
Invasive		
Pulmonary angiography	Reference test	Morbidity 5%, mortality 2%. Rarely performed.

CTA, computed tomography angiography; DVT, deep venous thrombosis; NPV, negative predictive value; V/Q, ventilation-perfusion.

VTE IN PREGNANCY

PE is associated with a high risk of postpartum morbidity and mortality and is the cause of 20% of maternal mortality in the U.S. (Table 10-12). The management algorithm is shown in Figure 10-6.

Table 10-12. VTE in Pregnancy

Incidence	Timing	Causes	Diagnosis	Comments
10.6 per 100,000	PE most frequently postpartum (up to 6 weeks); DVT most frequently antepartum.	Increased protein C resistance; increased venous stasis from IVC compression and vessel injury during delivery.	See algorithm in Figure 10-6.	D-dimer sensitivity/specificity: 73%/15%; therefore, not used in pregnancy. Left leg DVT more common than right leg because of compression of left iliac vein by right iliac artery when gravid.

DVT, deep venous thrombosis; IVC, inferior vena cava; PE, pulmonary embolism; VTE, venous thromboembolism.



Figure 10-6. Management algorithm for PE in pregnancy.
CTPA, computed-tomographic pulmonary angiography; CUS, compression ultrasound; CXR, chest radiography; PE, pulmonary embolism; V/Q, ventilation–perfusion.
(Reproduced, with permission, from Leung AN, Bull TM , Jaeschke R, et al. An Official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline: Evaluation of Suspected Pulmonary Embolism In Pregnancy. *Am J Respir Crit Care Med.* 2011; 184(10): 1200-1208. Fig. 1.DOI: 10.1164/rccm.201108-1575ST.)

Treatment

Standard pharmacological therapy reduces morbidity and mortality from VTE. Complications of VTE include recurrence of disease, fatal PE, extension of thrombus, post-thrombotic syndrome, and chronic thromboembolic pulmonary hypertension. Table 10-13 details the features of therapies, while Figure 10-7 demonstrates schematically their mechanisms of action. More details on therapies are found in the American College of Chest Physicians (ACCP) guidelines.

Table 10-13. Therapies for VTE

Treatment	Mechanism	Monitoring	Reversal Agent	Comments
Heparin	Binds AT III and factor Xa	PTT levels	Protamine	Can cause Type II HIT when Ab to PF4 form; treat with argatroban.
Enoxaparin	Binds factor Xa >>> AT III	Factor Xa levels	Protamine	Recommended agent in malignancy and pregnancy; monitor levels. Do not use if CrCl < 30 or weight > 150 kg.
Warfarin	Blocks vitamin K epoxide: Slow decrease in factors II, VII, IX, X, and thrombin	INR	Vitamin K, FFP, prothrombin complex	Category X; OK during lactation; multiple drug interactions.
Argatroban	Direct thrombin inhibitor	PTT	None	Primarily used for HIT.
Dabigatran	Oral factor IIa inhibitor	None	None	FDA approved, noninferior to warfarin; lower overall bleeding but increased major bleeding.
Rivaroxaban	Oral factor Xa inhibitor	None	None	FDA approved; equivalent bleeding risk; long-term studies forthcoming.
Thrombolytic therapy: streptokinase, urokinase, tPA	Increased plasminogen increases plasmin, which breaks down fibrin.	None	None	None proven superior; tPA preferred given shortest infusion time. No mortality benefit. Indicated for massive PE.
IVC filter	Placed when a contraindication exists to anticoagulation or if poor cardiopulmonary reserve after PE.		Retrievable or permanent	No short-term or long-term demonstrable mortality benefit. Increased risk of DVT.
Compression stockings	Reduces symptoms of post-thrombotic syndrome.			Pharmacologic therapy for post-thrombotic syndrome not recommended (rutosides, hidrosmin).

Ab, antibodies; AT, antithrombin; CrCl, creatinine clearance; DVT, deep venous thrombosis; FFP, fresh frozen plasma; HIT, heparin-induced thrombocytopenia; IVC, inferior vena cava; PE, pulmonary embolism; PF, platelet factor; PTT, partial thromboplastin time; tPA, tissue plasminogen activator; VTE, venous thromboembolism.

Key Fact

Protamine should be given only when resuscitation techniques and treatment of anaphylactic and anaphylactoid shock are readily available. Reduce the rate of administration in cases of bradycardia, dyspnea, and hypotension. Administration that is too rapid may cause severe hypotension.



Figure 10-7. Coagulation cascade with select VTE therapies.
(Reproduced, with permission, from Gallego P, Roldan V, Lip GYH. Conventional and New Oral Anticoagulants in the Treatment of Chest Disease and Its Complications. *Am J Respir Crit Care Med*. 2013;188(4):413-21. doi: 10.1164/rccm.201301-0141PP)

Mnemonic

Rivaro**X**aban and Api**X**aban are factor **X**a inhibitors

Strepto**K**inase and uro**K**inase are systemic agents

Alte**Plase** is a targeted agent (specific '**plase**')

MASSIVE AND SUBMASSIVE PE

Massive PE is defined by the presence of hypotension and shock, not by the size of the embolism. Submassive PE is less clearly defined in the literature and may be related to increased risk of complications. Management of submassive PE is no different than that for standard PE; however, there may be instances where thrombolytic therapy is considered. Table 10-14 shows mortality rates from PE.

Table 10-14. In-Hospital Mortality Based on Degree of Hemodynamic Compromise

Finding	Mortality
RV dysfunction, no hypotension	8.1%
Hypotension	15.2%
Cardiogenic shock	24.5%
Cardiopulmonary resuscitation	64.8%

RV, right ventricular.

Electrocardiogram (ECG) changes, including S1Q3T3 and T-wave inversions in V1-4, as well as elevated brain natriuretic peptide (BNP) and troponin serve as markers for prognosis in PE (Table 10-15).

Table 10-15. Clinical Markers in PE

Test	Comments
BNP	6x increased mortality when BNP > 100, 16x increased mortality when NT-proBNP > 600
Troponin	Increased risk of short-term mortality (OR 5.24, 95% CI 3.28–8.38) or death due to PE (OR 9.44, 95% CI 4.14–21.49)
RV dysfunction	Incongruent findings on mortality effect in 2 meta-analyses
Concomitant DVT	Correlated with both increased all-cause mortality (adjusted HR 2.05, 95% CI 1.24–3.38) and increased PE-specific mortality (adjusted HR 4.25, 95% CI 1.61-–1.25)

BNP, brain natriuretic peptide; CI, confidence interval; DVT, deep venous thrombosis; HR, hazards ratio; NT, N-terminal; OR, odds ratio; PE, pulmonary embolism; RV, right ventricular.

Figure 10-8 details the management algorithm in the setting of massive PE. Thrombolytic therapy carries a significant risk for massive bleeding. Therefore, its use must be weighed carefully against the risk of complications. Table 10-16 discusses the indications and contraindications for thrombolytic therapy in detail.



Figure 10-8. Management algorithm for massive PE.
BNP, brain natriuretic peptide; IVC, inferior vena cava; IVF, intravenous fluid; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; SK, streptokinase; tPA, tissue plasminogen activator; UFH, unfractionated heparin; UK, urokinase.

Table 10-16. Therapy for Massive VTE

Potential Indications for Therapy	Indications for Therapy	Relative Contraindications to Therapy	Absolute Contraindications to Therapy
Severe hypoxemia	Persistent hypotension	Severe uncontrolled HTN (BP > 180/110)	Previous hemorrhagic stroke at any time; other stroke or cerebrovascular events within 1 year
Large perfusion defect on V/Q scan	Shock	Hx of prior CVA/intracranial disease not covered in absolute contraindications	Known intracranial neoplasm
Extensive embolic burden on CT	Massive proximal LE thrombus associated with severe swelling or limb ischemia	Current use of anticoagulants; known bleeding diathesis	Active internal bleeding
RV dysfunction		Recent trauma (within 2–4 weeks); prolonged CPR (> 10 minutes) or major surgery within 3 weeks	Suspected aortic dissection
Free-floating RA or ventricular thrombus		Noncompressible vascular punctures	
PFO		Recent (2–4 weeks) internal bleeding	
CPR		Pregnancy, PUD	
		For streptokinase: prior exposure (especially within 5 days–2 years) or prior allergic reaction	

BP, blood pressure; CPR, cardiopulmonary resuscitation; CT, computed tomography; CVA, cerebrovascular accident; DVT, deep venous thrombosis; HTN, hypertension; Hx, history; LE, lower extremity; PFO, patent foramen ovale; PUD, peptic ulcer disease; RA, right atrial; RV, right ventricular; V/Q, ventilation-perfusion; VTE, venous thromboembolism.

Length of Treatment

The length of optimal therapy for PE has been studied extensively. The ACCP Antithrombotic Guidelines published in 2012 discuss this issue and are summarized in Table 10-17.

Table 10-17. Length of Treatment for VTE

Event	Duration of Therapy	Comments
First VTE	Provoked: 3 months Unprovoked: at least 3 months	Consider risk/benefit for extended therapy LMWH indicated over VKA if patient has active malignancy Consider D-dimer testing within 4 weeks of discontinuation of therapy
Recurrent VTE	Low bleeding risk: extended (> 1 year) High bleeding risk: 3 months	Consider IVC filter placement if recurrent despite anticoagulation

IVC, inferior vena cava; LMWH, low-molecular-weight heparin; VKA, vitamin K antagonists; VTE, venous thromboembolism.

VTE PREVENTION

VTE prevention is focused entirely on the risk/benefit ratio, factoring potential benefit over harm. Table 10-18 is also based on the ACCP 2012 Antithrombotic Guidelines and summarizes how VTE prevention should be implemented.

Key Fact

For patients undergoing major orthopedic surgery, extend thromboprophylaxis in the outpatient period for up to 35 days (rather than 10–14 days).

Table 10-18. VTE Prevention

Risk	Population	Management
High (> 40% VTE)	Orthopedic surgery, major trauma, spinal cord injury	(LMWH, fondaparinux, rivaroxaban, VKA) + mechanical; mechanical only if increased bleeding risk
Moderate (10–40% VTE)	General medical/surgical patients on bedrest, antepartum with high-risk women	LMWH > UFH; mechanical if increased bleeding risk
Low (< 10% VTE)	Ambulatory patients; includes high-risk patients (e.g., active malignancy) during travel	Early ambulation only

LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; VKA, vitamin K antagonists; VTE, venous thromboembolism.

PULMONARY HYPERTENSION

Pulmonary hypertension is a group of conditions characterized by elevated pressures in the pulmonary vasculature, which can ultimately lead to right heart dysfunction and failure.

The Fifth World Symposium on Pulmonary Hypertension (Nice, 2013) categorized pulmonary hypertension into five groups (Table 10-19).

Group 1 includes patients with pulmonary arterial hypertension (PAH). PAH is defined as a mean pulmonary arterial pressure (mPAP) $\geq$ 25 mm Hg at rest associated with a pulmonary capillary wedge pressure (PCWP) $\leq$ 15 mm Hg and pulmonary vascular resistance (PVR) > 3 Wood units. Group I can be further subdivided into idiopathic PAH (IPAH) or PAH associated with other medical conditions such as connective tissue disease, human immunodeficiency virus (HIV), congenital left-to-right shunts, or liver disease/portal hypertension (portopulmonary hypertension). The term "pulmonary arterial hypertension" is reserved for diseases of the pulmonary artery (classically idiopathic PAH). In contrast, an elevated cardiac output or elevated filling pressures can cause an increase in PAP without an increase in PVR.

Flash Card Q3

How is pulmonary vascular resistance calculated in Wood units?

Flash Card Q4

What is the most common cause of pulmonary hypertension?

Flash Card Q5

What are common drugs/toxins implicated in pulmonary hypertension?

Table 10-19. Updated Fifth World Symposium on Pulmonary Hypertension Classification

Group 1. PAH
- 1.1 Idiopathic PAH
- 1.2 Heritable PAH
- 1.2.1 BMPR2
- 1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
- 1.2.3 Unknown
- 1.3 Drug- and toxin-induced
- 1.4 Associated with:
- 1.4.1 Connective tissue disease
- 1.4.2 HIV infection
- 1.4.3 Portal hypertension
- 1.4.4 Congenital heart diseases
- 1.4.5 Schistosomiasis
- 1' Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
- 1" PPHN

Group 2. Pulmonary hypertension due to left heart disease
- 2.1 Left ventricular systolic dysfunction
- 2.2 Left ventricular diastolic dysfunction
- 2.3 Valvular disease
- 2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies

Group 3. Pulmonary hypertension due to lung diseases and/or hypoxia
- 3.1 Chronic obstructive pulmonary disease
- 3.2 Interstitial lung disease
- 3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
- 3.4 Sleep-disordered breathing
- 3.5 Alveolar hypoventilation disorders
- 3.6 Chronic exposure to high altitude
- 3.7 Developmental lung diseases

Group 4. CTEPH

Group 5. Pulmonary hypertension with unclear multifactorial mechanisms
- 5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
- 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
- 5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
- 5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH

ALK-1, activin receptor-like kinase-1; BMPR-2, bone morphogenetic protein receptor-2; CAV1, caveolin 1; CTEPH, chronic thromboembolic pulmonary hypertension; ENG, endoglin; HIV, human immunodeficiency virus; KCNK3, potassium channel K3; PAH, pulmonary arterial hypertension; PH, pulmonary hypertension; PPHN, persistent pulmonary hypertension of the newborn; SMAD9, Mothers Against Decapentaplegic 9.

Flash Card A3

(mPAP – PCWP) ÷ cardiac output (L/min) = PVR in Wood units

Flash Card A4

Left-sided systolic or diastolic heart disease (WHO Group 2), although this represents pulmonary venous hypertension rather than pulmonary arterial hypertension.

Flash Card A5

Aminorex, fenfluramine, dexfenfluramine, amphetamines, methamphetamines

PULMONARY ARTERIAL HYPERTENSION (PAH)

PAH is a disease with significant morbidity and mortality; its pathogenesis is complex and still poorly understood.

Epidemiology

Based on French registry data, the prevalence of PAH is approximately 15 cases per 1 million adults. The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) is a multicenter, observational, US-based, prospective registry initiated in 2006, which found that the mean age of patients with group 1 PAH was 50 years, with 79% female patients and 73% white patients. Approximately half (47%) of the patients had idiopathic PAH, 3% had heritable PAH, and the remaining 50% had associated PAH, mostly related to connective tissue disease. Heritable PAH patients were less likely to show vasoreactivity during right heart catheterization.

Key Fact

BMPR2 mutations are detected in ~70% of heritable PAH cases and 11–40% of IPAH patients (regardless of family history).

Pathophysiology

The pathogenesis of PAH includes both genetic and environmental factors that alter vascular structure and function in genetically prone individuals (Figure 10-9).

Figure 10-9. Risk factors that trigger PAH in genetically predisposed individuals.

Flash Card Q6

What are the most common mutations seen in heritable PAH?

The vascular changes involve the pulmonary arteriole and are characterized by vasoconstriction, vascular remodeling with intimal and medial proliferation, varying degrees of inflammation, the formation of plexiform lesions, and thrombosis (Figure 10-10). These changes lead to progressive obstruction of flow, increased pulmonary vascular resistance, and eventually, right heart failure and death.

Three pathways are implicated in PAH:

- Prostacyclin (prostaglandin I_2)
- Nitric oxide (NO)-cyclic guanosine monophosphate-phosphodiesterase 5 (cGMP)
- Endothelin-1

An imbalance between the vasoconstrictive (proliferative) endothelin system and the vasodilatory (antiproliferative/anti-thrombotic) NO and prostaglandin I_2 systems is a key factor in the pathogenesis (Figure 10-11). Platelets play an important role as procoagulants by increasing the release of serotonin, vascular endothelial growth factor, and platelet-derived growth factor. Reduced levels of tissue plasminogen activator may also contribute to the procoagulant state.



Figure 10-10. Photomicrograph showing the plexiform lesion in a patient with pulmonary hypertension.
(Reproduced courtesy of Dr. Bulent Celasun, CC BY-SA 2.0)

Flash Card A6

Bone morphogenetic protein mutation type 2 (BMPR2) and activin receptor-like kinase (ALK-1)



Figure 10-11. Flow diagram depicting the mechanisms involved in the pathogenesis of PAH**.**

Clinical Presentation

SYMPTOMS—Dyspnea on exertion, fatigue, and syncope are common symptoms. Patients may also present with chest pain. Hemoptysis is rare but may occur as a consequence of pulmonary vascular rupture.

Disease-specific symptoms are seen in certain patients; for example, Raynaud's phenomenon is a frequent finding in PAH associated with scleroderma.

PHYSICAL EXAMINATION

- Loud P2 component of S2, often with a split S2 that is accentuated with inspiration. A pansystolic left lower sternal border murmur that is louder during inspiration reflects tricuspid regurgitation.
- Jugular venous distension with elevated "a" wave. This finding can be followed serially to assess volume status. Prominent "v" wave is commonly seen with significant tricuspid regurgitation.
- Right ventricular (RV) heave
- RV S3 can indicate elevated right ventricular end-diastolic filling pressure and RV failure. RV S4 can indicate stiffened RV and RV hypertrophy.

Key Fact

As part of the evaluation of PAH, look for signs and symptoms of connective tissue disease and stigmata of liver disease.

Flash Card Q7

Which of the following cellular mechanisms is involved in the development of PAH?

A. Increased prostacyclin synthase
B. Increased NO synthase
C. Increased endothelin levels

In patients with florid right ventricular failure, hepatomegaly, ascites, and extremity edema (even anasarca) can also be seen.

ECG FINDINGS—Right atrial or right ventricular hypertrophy, right-axis deviation, and/or right bundle branch block (RBBB).

IMAGING—Chest radiograph can show an enlarged cardiac silhouette, enlarged R heart border consistent with RV hypertrophy, and enlarged pulmonary arteries in severe cases (Figure 10-12).

CLASSIFICATION—Functional capacity, characterized by the WHO functional classification, is strongly predictive of mortality and helps to guide pharmacologic therapy (Table 10-20).

Figure 10-12. Chest radiograph of a patient with pulmonary hypertension showing enlarged pulmonary arteries and an enlarged cardiac silhouette.
(Reproduced, with permission, from Drs. Sandeep Sahay and Adriano Tonelli.)

Flash Card A7

C. Increased endothelin levels

Table 10-20. WHO Classification of PAH Functional Class	
Class I	Patients with PAH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope.
Class II	Patients with PAH resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
Class III	Patients with PAH resulting in marked limitation of physical activity. These patients are comfortable at rest, but less than ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
Class IV	Patients with PAH resulting in inability to perform any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present at rest, and discomfort is increased by any physical activity.

PAH, pulmonary arterial hypertension; WHO, World Health Organization.

Diagnosis

Patients with risk factors, clinical symptoms, and exam findings suspicious for PAH should be screened. PAH should also be considered in patients with unexplained reduction in diffusing capacity.

ECHOCARDIOGRAM FINDINGS—Transthoracic echocardiogram (TTE) is used initially to estimate RV systolic pressure (a surrogate for pulmonary artery systolic pressure) through the tricuspid regurgitant velocity. It can also determine RV size and function to assess for RV failure. Echo-derived inferior vena cava (IVC) size and respiratory variation can estimate central venous pressure and volume status. Other findings can further characterize RV function: RV akinesis of midventricular free wall but normal apical contraction (McConnell's sign), D-shaped left ventricle, and paradoxical interventricular septal motion (movement of septum away from LV free wall during systole). TTE with agitated saline contrast or "bubble study" can be added to look for intracardiac shunts. Importantly, TTE can assess for evidence of left heart and valvular disease as a cause for pulmonary hypertension (WHO Group 2 PH).

IMAGING AND LABORATORY TESTS—Pulmonary function testing (spirometry, diffusing capacity, arterial blood gas) and a computed tomography (CT) scan of the chest can be performed to exclude underlying respiratory disease and/or hypoxemia. When suggested by history, an overnight polysomnogram can be performed to assess for sleep-disordered breathing.

Blood tests for underlying liver disease or congestive hepatopathy, HIV, and autoimmune disease should be performed in most patients with unexplained PAH, and a ventilation-perfusion (V/Q) scan or chest CT angiography should be performed to evaluate for chronic thromboembolic pulmonary hypertension (CTEPH).

Flash Card Q8

How is a positive vasoreactivity test defined during RHC?

Flash Card Q9

How does one establish a definitive diagnosis of PAH?

Measurement of serum BNP can also be useful in disease monitoring and management.

RIGHT HEART CATHETERIZATION (RHC)—Because TTE can be nonspecific and less sensitive in patients with pulmonary disease, RHC is the gold standard for diagnosis. It is performed to assess hemodynamics (PA pressures, pulmonary capillary wedge pressure, and cardiac output), help exclude WHO Group 2 PH, and diagnose other forms of PH. It is indicated in patients with suspected PAH being considered for PAH-specific therapy. It can be used to assess response to continuous prostanoid therapy or inhaled NO therapy in the setting of critically ill decompensated RV failure due to PAH.

VASOREACTIVITY TESTING—Evaluates the response to selective pulmonary vasodilators (e.g., inhaled NO, intravenous adenosine, or epoprostenol). A positive response to therapy with vasodilators is defined as a fall in mean PAP of > 10 mm Hg to reach a mean PAP of < 40 mm Hg with an increased or unchanged cardiac output.

True responders are uncommon in IPAH, comprising of ~10–12% of all IPAH patients. The usefulness of acute vasoreactivity tests and long-term treatment with calcium channel blockers in patients with other PAH types, such as heritable PAH, connective tissue disease, and HIV patients is less clear than in IPAH.

MEASUREMENT OF EXERCISE CAPACITY—Formal assessment of exercise capacity is an integral part of the evaluation. A 6-minute walk test (6MWT) is usually performed to determine the degree of exercise limitation, as it has been proven to be reproducible and to correlate well with other measures of functional status.

Flash Card A8

A positive response to therapy with vasodilators is defined as a fall in mean PAP of > 10 mm Hg to reach a mean PAP of < 40 mm Hg with an increased or unchanged cardiac output.

Flash Card A9

With RHC showing a mPAP ≥ 25 mm Hg with pulmonary capillary wedge pressure ≤ 15 mm Hg and pulmonary vascular resistance > 3 Wood units (240 dynes/sec/cm^5).

Treatment

There is no cure for PAH and most treatment recommendations are based on clinical data from IPAH and PAH related to connective tissue disease and use of anorexigens.

PHARMACOLOGICAL TREATMENT

- Diuretics are effective in relieving dyspnea and edema and may reduce right ventricular overload in the presence of tricuspid regurgitation.
- Anticoagulation therapy with warfarin is commonly used in IPAH and anorexigen-induced PAH to prevent local thrombosis, but there is insufficient evidence to recommend it routinely.

- Digoxin can lead to modest increases in cardiac output and a reduction in circulating norepinephrine levels in patients with IPAH.
- Oxygen supplementation when indicated.

PAH-SPECIFIC THERAPY—Initiation and intensification of treatment depends on WHO functional class (Figure 10-12 and Table 10-21).



Figure 10-12. PAH-specific drug treatment algorithm.
*ERA's are typically not used for patients in WHO Class IV.

Key Fact

Patients with IPAH who respond to acute vasodilator testing should be treated initially with calcium channel blocker therapy.

Flash Card Q10

Which group of drugs is associated with hepatotoxicity?

Flash Card Q11

Which group of drugs is contraindicated with the use of nitrates?

Flash Card Q12

Which group of drugs causes teratogenicity?

Table 10-21 describes the major pharmacologic agents used in the treatment of PAH.

Table 10-21. Dosage Forms and Side Effects of the PAH-Specific Therapies

Drug Class	Generic	Method of Administration	Adverse Effects
Prostanoids	Epoprostenol	Continuous IV infusion	Flushing, headache, nausea/ vomiting, thrombocytopenia, hypotension, jaw pain
	Iloprost	Aerosol (inhalation)	Flushing, cough, headache, nausea, flu-like illness
	Treprostinil	Continuous IV or SC	Site pain and erythema in SC administration, headache, nausea, diarrhea
	Treprostinil	Inhaled	Cough, headache, throat irritation, nausea, flushing, syncope
ERAs	Bosentan	Oral	Hepatotoxicity (stop if bilirubin 2X ULN, AST/ALT > 3X ULN), peripheral edema, nasopharyngitis, teratogenic
	Ambrisentan	Oral	AST/ALT elevation (stop treatment if > 8X ULN) peripheral edema, headache, nasal congestion, flushing, teratogenic
	Macitentan	Oral	URI, peripheral edema, nasopharyngitis, headache, anemia, AST/ALT elevation, teratogenic
PDE-5 inhibitors	Sildenafil	Oral	Headache, dyspepsia, flushing, epistaxis, optic neuritis (rare), potentiates hypotensive effects of nitrates and alpha blockers
	Tadalafil	Oral	Headache, flushing, respiratory infections, extremity pain Avoid if renal and hepatic impairment
Soluble guanylate cyclase stimulator	Riociguat	Oral	Headache, dyspepsia, nausea, peripheral edema
Calcium channel blockers	Amlodipine, nifedipine	Oral	Peripheral edema, hypotension, bradycardia

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ERA, endothelin receptor antagonist; IV, intravenous; PAH, pulmonary arterial hypertension; PDE, phosphodiesterase; SC, subcutaneous; ULN, upper limit of normal; URI, upper respiratory infection.

Key Fact

Riociguat, a soluble guanylate cyclase stimulator, was recently approved for the treatment of PAH after the PATENT-1 trial showed improvement in exercise capacity/6MWD in patients with Group 1 PAH.

Flash Card A10

Endothelin receptor antagonists (ERAs)

Flash Card A11

Phosphodiestrase-5 (PDE-5) inhibitors

Flash Card A12

Endothelin receptor antagonists (ERAs)

Prognosis

The median duration of survival of patients diagnosed with PAH between 1980–85 was 2.8 years. Since that time, survival has improved and patients without evidence of right ventricular failure may survive > 10 years. Responders to calcium channel blockers have the best prognosis with a 95% 5-year survival rate. Patients with WHO functional classes III–IV treated with epoprostenol have a 5-year survival rate that is twice that of matched control subjects. Patients with evidence of right heart failure have a much lower survival rate. IPAH patients fare better than patients with PAH associated with scleroderma. Overall, patients with PAH associated with congenital heart disease have the best prognosis.

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)

CTEPH is a separate disease entity that causes pulmonary hypertension. It is classified as WHO Group 4.

Epidemiology

Exact incidence is unknown but ranges from 0.5–3.8% of patients after an episode of acute PE and 10% in patients with recurrent PE. It is unclear why only some patients develop CTEPH after an episode of PE.

Pathophysiology

CTEPH is characterized by the obstruction of pulmonary arteries by organizing thrombi, small vessel arteriopathy, and the development of high pulmonary vascular resistance (PVR). Microscopic similarities between CTEPH and other forms of PAH have been demonstrated clearly and with reproducibility on lung biopsy. Pulmonary hypertensive lesions and plexogenic lesions are seen in proximal open vessels exposed to high pressures and in vessels distal to obstructed vessels, suggesting that release of cytokines and other endothelin-derived factors occurs in response to pulmonary hypertension and may contribute to its progression. The progressive nature of pulmonary hypertension in CTEPH patients is related to these resistance changes in small vessels and not necessarily to recurrent pulmonary emboli.

Flash Card Q13

Which of these categories of PAH has the best prognosis?

A. PAH associated with congenital heart disease
B. PAH associated with scleroderma
C. PAH associated with HIV
D. PAH associated with liver disease

Clinical Features

Risk factors for CTEPH:

- PE (recurrent or unprovoked), large perfusion defect
- Pulmonary artery systolic pressure > 50mm Hg at time of initial PE
- Persistently elevated right ventricular systolic pressure (RVSP) 6 months after PE
- Chronic medical conditions (cancer, thyroid disease, splenectomy), or thrombotic factors (lupus anticoagulant, antiphospholipid antibodies, increased factor VIII)
- Genetic factors (ABO blood groups, human leukocyte antigen [HLA] polymorphisms)
- History of splenectomy

Patients with CTEPH have similar clinical presentations to those patients with PAH. Unexplained dyspnea on exertion, dizziness, syncope, and exertional chest pain are all common complaints. Examination findings are similar to other PAH patients: increased jugular venous pressure, loud split S2 with an increased P2 component, RV heave, RV S4 gallop, and tricuspid regurgitation murmur.

Diagnosis

Diagnostic algorithm is similar to PAH. All patients suspected to have CTEPH need right heart catheterization to confirm the presence of pulmonary hypertension. RHC criteria to diagnose PH are the same as previously discussed for PAH.

A V/Q scan is considered the gold standard to diagnose chronic thromboembolic disease as the cause of PH. Several areas or a single area of segmental or subsegmental V/Q mismatch is suggestive of CTEPH. A V/Q scan is more sensitive in diagnosing CTEPH than a CT pulmonary angiography.

Management

CTEPH is the only cause of PH where surgery (pulmonary endarterectomy) can be curative. However, surgery is often difficult, only available at selected centers, and indicated only in carefully selected patients.

Flash Card A13

A. PAH associated with congenital heart disease.

Patients who cannot undergo surgery should be considered for medical management. Recently, the FDA approved the use of riociguat in patients with CTEPH after a recent trial showed improvement in the hemodynamics and 6MWD in patients with CTEPH in WHO functional classes II and III. All patients with CTEPH should be anticoagulated. Evidence regarding the use of other PAH-specific drugs in CTEPH is limited, but experts recommend their use in patients who cannot be considered for surgery.

Prognosis

Prognosis is dependent on the type of management received. Successful surgical candidates have excellent prognosis. Experienced centers have a low 30-day mortality rate of ~4–7%. In patients who have inoperable disease or persistent disease (CTEPH persisting after surgery), medical management improves exercise capacity, functional class, hemodynamics, and symptoms.

PULMONARY VENO-OCCLUSIVE DISEASE (PVOD)

PVOD is a rare cause of pulmonary hypertension. Although it is classified as a subgroup of PAH (WHO Group 1), PVOD involves obstructive vascular remodeling affecting postcapillary pulmonary venules and small veins instead of precapillary arterioles and arteries. Because it is difficult to distinguish from precapillary PAH, its exact incidence is unknown, and many patients are misclassified as IPAH or other precapillary PAH. Compared to IPAH, however, PVOD is associated with a significantly worse prognosis.

Epidemiology

PVOD accounts for ~10% of PAH cases. The estimated annual incidence of PVOD is 0.1–0.2 cases per million worldwide, with a male to female ratio of 1:1 (compared to a female predominance in IPAH). PVOD has been reported in a wide age range, from infants to > 60 years, but it is more commonly seen in children and young adults.

Pathology

In PVOD, fibrotic remodeling of the intima of preseptal pulmonary venules and interlobular septal veins causes flow obstruction, often with intraluminal thrombosis. This is associated with ectasia and proliferation of alveolar capillaries, which become tortuous. These changes can be confused with

Flash Card Q14

What gene plays a role in the pathogenesis of PVOD?

pulmonary capillary hemangiomatosis. Despite predominance of postcapillary disease, pulmonary arterioles are also involved in 50% of cases of PVOD, resulting in similar remodeling as IPAH. Unlike IPAH, PVOD characteristically lacks arteriolar plexiform lesions. Chronic passive congestion can result in occult pulmonary hemorrhage, with hemosiderin loading of macrophages and type II pneumocytes. The disease can affect the lungs diffusely or in a patchy distribution.

Etiology

The etiology of PVOD remains unclear. The rarity of this disease makes to difficult to identify causes. Nevertheless, associations have been described, many of which are shared with etiologic associations of PAH in general. These include bone morphogenetic protein receptor type II (BMPR-2) mutation in familial cases, connective tissue diseases, sarcoidosis, pulmonary Langerhans cell histiocytosis, HIV infection, anorexigen exposure, bleomycin and other chemotherapy agents exposure, tobacco smoking, and hematopoietic stem cell transplant.

Clinical Features

Clinical presentation is very similar to that of heart failure and PAH. Most patients present with exertional dyspnea and fatigue. In late stages, they may present with syncope, edema, orthopnea, or hemoptysis, along with RV failure.

Diagnosis

PVOD requires a diagnosis of PAH. Beyond this, it is very difficult to distinguish precapillary PAH from PVOD. Findings favoring PVOD over precapillary PAH include the following:

- Chest imaging consistent with pulmonary edema, despite low PCWP
- BAL consistent with alveolar hemorrhage
- Development of pulmonary edema with initiation of PAH-specific therapy

The above findings are insensitive to diagnose PVOD. The definitive diagnosis of PVOD requires open lung biopsy, though this procedure may have a high risk for many patients.

IMAGING—Chest imaging, particularly with high-resolution CT, can reveal findings consistent with pulmonary edema, including septal thickening, centrilobular ground glass opacities, and lymph node enlargement. These findings are usually more frequently apparent after pulmonary vasodilator therapy. Nevertheless, normal imaging in PAH should not rule out PVOD.

Flash Card A14

BMPR-2

The V/Q scan is usually normal but occasionally patchy areas of hypoperfusion are seen, which may lead to misclassification of these patients as having CTEPH.

RHC—Diagnosis of PVOD first requires that PAH be diagnosed based on RHC. RHC hemodynamics are not useful to differentiate PVOD from other types of PAH.

Vasoreactivity testing in patients with PVOD can result in acute pulmonary edema, but more commonly it does not. As such, acute vasoreactivity testing does not reliably predict whether a patient with PVOD will develop pulmonary edema with pulmonary vasodilator treatment. Further, positive vasoreactivity testing in patients with PVOD does not predict durable response to calcium channel blockers.

Treatment

CONVENTIONAL TREATMENT—Same in PVOD as in other types of PAH.

PAH-SPECIFIC TREATMENT—Benefits of PAH-specific therapy for PVOD are unclear due to limited data, and evidence supporting its use is based on reported cases of mild improvement or stabilization of disease. Nevertheless, PAH-specific therapy with prostacyclins, PDE-5 inhibitors, and ERAs are still used in PVOD. Calcium channel blockers appear to yield limited durable response, even with a positive vasoreactivity test. Importantly, pulmonary edema is common with all PAH-specific therapies, usually occurring in the first 72 hours of therapy.

Key Fact

Because of the significant risk of pulmonary edema, initiation of PAH-specific therapy in patients with PVOD needs to be carefully monitored, likely in an intensive care unit (ICU) setting, with a slow titration and aggressive use of diuretics.

Lung transplantation should be considered early when PVOD is suspected. Post-transplant survival is similar to that of IPAH.

Prognosis

Prognosis of PVOD is significantly worse than that of IPAH. The 1-year mortality has been reported to be as high as 72%. Time from onset of symptoms to death is found to average 24 months for PVOD, as compared to 58 months for IPAH. Most patients with PVOD die within 2 years of diagnosis.

OTHER PULMONARY VASCULAR DISEASE

PULMONARY COMPLICATIONS OF SICKLE CELL DISEASE

Sickle cell disease (SCD) is an autosomal recessive inherited genetic disorder that produces a myriad of pulmonary complications. Acute chest syndrome and pulmonary hypertension are the leading causes of mortality in this disease.

- Vasoocclusion is the main cause of tissue injury in sickle cell disease (Figure 10-13).
- Hemoglobin SS polymerizes on deoxygenation, assumes a rigid configuration, and adheres to the microvasculature, which impairs blood flow and leads to recurrent hemolysis and vasoocclusive episodes.



Figure 10-13. Vicious cycle of vasoocclusive crisis and acute chest syndrome.
(Modified, with permission, from Miller AC, Gladwin MT. Pulmonary Complications of Sickle Cell Disease. *Am J Respir Crit Care Med.* 2012;185(11): 1154-1165. Fig. 1.doi:10.1164/rccm.201111-2082CI.)

Acute Chest Syndrome

PRESENTATION—An acute lung injury syndrome presenting as chest pain, fever, tachypnea, and cough during a painful crisis.

DIAGNOSIS

- New pulmonary infiltrate on chest radiograph consistent with consolidation involving at least one complete lung segment.
- Pathogenesis multifactorial:
  - Pneumonia or systemic infection
  - Fat embolism
  - Direct pulmonary infarction from hemoglobin-S (HbS)-containing erythrocytes
  - Often idiopathic
- Most common pathogens identified: *Chlamydia pneumoniae, Mycoplasma pneumoniae*, respiratory viruses

Key Fact

Acute chest syndrome is the leading cause of death in patients with sickle cell disease.

TREATMENT—Largely supportive:

- Analgesics
- Hydration
- Supplemental oxygen to prevent sickling
- Blood transfusion (increases Hb oxygen saturation)
- Incentive spirometry
- Empiric antibiotics for pneumonia
- Inhaled β-agonists for associated bronchospasm
- Exchange transfusion in severe or rapidly progressive illness

Fat Emboli Syndrome

- Severe vasoocclusion involving multiple bones results in infarction and necrosis of the marrow compartment. Marrow contents and fat disseminate into the bloodstream, causing diffuse vascular injury and organ dysfunction.
- Fat emboli can cause acute chest syndrome, neurologic dysfunction, renal failure, acute respiratory distress syndrome (ARDS), thrombocytopenia, and petechiae.
- Identification of oil-red-O–positive lipid accumulations within alveolar macrophages on BAL is diagnostic of fat emboli to the lung and has been associated with systemic fat emboli syndrome.

TREATMENT—Mostly supportive; exchange transfusion if severe.

Flash Card Q15

What is the most common pathogen identified in patients with acute chest syndrome?

Pulmonary Hypertension

- Lysed red blood cells release arginase and free hemoglobin, leading to NO dysregulation and vasoconstriction, endothelial dysfunction, and pulmonary hypertension.
- Most patients with pulmonary hypertension from sickle cell disease have mild disease based on hemodynamic data, but the associated mortality rate is extremely high.

TREATMENT

- Large clinical studies are lacking to guide specific therapy of pulmonary hypertension in sickle cell disease; one trial suggests that sildenafil leads to an overall increase in pain crises.
- Current recommendations focus on primary prevention and control of the hematological disease (hydroxyurea, transfusions).

Chronic Lung Disease

Key Fact

The most important predictor of chronic restrictive lung disease in sickle cell disease is the number of prior episodes of acute chest syndrome.

- Develops from recurrent acute chest syndrome.
- Progressive hypoxemia, pulmonary fibrosis, and restrictive lung disease.
- High-resolution CTs usually reveal scattered areas of lung scarring.

HEPATOPULMONARY SYNDROME (HPS)

Definition and Cause

- Pulmonary vascular complication of liver disease causing abnormal gas exchange.
- Thought to be caused by derangement in vasoactive substances (e.g., NO) in the lung, which lead to pulmonary capillary dilation and arteriovenous malformations that cause intrapulmonary shunting (Figure 10-14).
- Seen in up to one third of patients evaluated for liver transplant though often clinically insignificant.

Flash Card A15

Chlamydia pneumoniae



Figure 10-14. (A) Normal oxygenation and (B) hypoxia with HPS.

Signs and Symptoms

- Hypoxia, orthodeoxia: Hypoxia is worse in the upright position compared to supine position because of increased shunting and V/Q mismatch in the upright position, as the vascular abnormalities tend to be worse in the lung bases.
- Dyspnea, platypnea: Dyspnea is worse in the upright position and relieved when supine.
- Other: clubbing, cyanosis, spider angiomas; rarely embolic neurologic complications such as hemorrhage, cerebral abscess, and stroke

Diagnostic Criteria

- Evidence of liver disease
- Alveolar-arterial (A-a) oxygen gradient ≥15 mm Hg OR PaO2 < 80 mm Hg on room air
- Evidence of intrapulmonary vascular dilation (IPVD) by:
  - Contrast transthoracic echo with microbubbles in left atrium 3–6 cycles after administration of agitated saline—preferred method.
  - Radionuclide (technetium-labeled macroaggregated albumin) lung scan with abnormal uptake in brain and kidneys; enables calculation of a shunt fraction.
- Exclude other causes of hypoxia: chest imaging, pulmonary function testing

Flash Card Q16

What molecule is felt to be primarily responsible for the intrapulmonary vascular dilations seen in HPS?

Flash Card Q17

What is the most commonly used method for confirming IPVD in HPS patients?

Flash Card Q18

What intervention has been shown to improve oxygenation and survival in HPS patients?

Treatment and Prognosis

- There is no definitive medical therapy for HPS. Agents such as pentoxifylline and garlic are thought to alter the deranged vasodilator pathways and have been utilized in some patients with modest improvements in PaO2.
- Supplemental O2 can partially correct hypoxemia.
- Rarely, those with large arteriovenous malformations may be amenable to angiographic embolization.
- Pre-liver transplant patients with HPS have worsened quality of life, functional status and survival compared to those without HPS.
- Liver transplantation (LT):
  - Only treatment known to improve survival
  - Generally improves or resolves gas exchange abnormalities within 6–12 months after LT
  - HPS patients with severe hypoxemia (PaO2 < 60) are eligible to receive additional Model for End-Stage Liver Disease (MELD) exception points to decrease their waiting time prior to LT.

Flash Card A16

Nitric oxide

Flash Card A17

Contrast enhanced transthoracic echo

Flash Card A18

Liver transplantation

11 Infections

Ariffin Alam, MD, Sugeet K. Jagpal, MD, Jimmy Johannes, MD, & Naresh Nagella, MD

BRONCHIAL AND BRONCHIOLAR INFECTIONS

ACUTE BRONCHITIS

Self-limited, infectious process in the large and midsized airways not associated with pneumonia on chest x-ray (CXR).

Microbiology

Generally an inflammatory process, mostly of viral etiology, but 10% of cases are bacterial, most commonly *Mycoplasma pneumoniae, Chlamydophila pneumoniae*, and *Bordetella pertussis*.

Winter outbreaks are associated with influenza A and B viruses. Other viral etiologies include parainfluenza virus, coronavirus, rhinovirus, respiratory syncytial virus (RSV), and human metapneumovirus.

The pathogenesis is related to the direct cytopathic effects of the pathogen and the immune response of the host (pro-inflammatory cytokine release).

Clinical Features

Nasal congestion, rhinitis, sore throat, malaise, and low-grade fevers are typical initial symptoms, usually occurring in the winter. Shortly thereafter, a dry or productive cough becomes the dominant complaint. It usually lasts < 3 weeks. Illness severity is affected by factors such as underlying medical conditions, immune status, age, and smoking.

Key Fact

Consider *B. pertussis* in patients presenting with cough of > 4 weeks, even those who have been vaccinated.

Diagnosis

Rapid antigen detection can be helpful for RSV in infants and influenza in all age groups (low sensitivity 40–60%). Reverse-transcription polymerase chain reaction (PCR) assay may be needed to identify other viral pathogens.

B. pertussis can be detected by PCR or serology. Cultures of the posterior nasopharynx can make the diagnosis but are relatively insensitive.

C. pneumoniae can be detected by PCR or serology.

M. pneumoniae can be detected by pathogen-specific immunoglobulin (Ig) M in serum or by PCR.

Generally, these agents do not need to be identified except in outbreaks when antibiotics may help prevent further spread.

Treatment

The goal of treatment is to largely control symptoms: cough, wheezing, and bronchospasm. The Infectious Diseases Society of America (IDSA) does not recommend routine use of antibiotics for uncomplicated cases in normal persons. In the absence of pneumonia, patients with bronchitis due to *M. pneumoniae* or *C. pneumoniae* may not benefit from antibiotics.

Treatment of *B. pertussis* infection with macrolides or tetracyclines is beneficial if these drugs are given within the first week; treatment can be offered later in the course if the goal is to limit transmission.

Influenza should be treated early in its course with neuraminidase inhibitors, such as oseltamivir, to reduce duration of illness. Oseltamivir also can be used for prophylaxis in select patients.

BRONCHIOLITIS

Characterized by infection resulting in inflammation of the bronchioles. It is the most common acute lower respiratory tract illness in children > 2 years of age. The etiology is usually viral, with RSV being the major pathogen. Other pathogens include human metapneumovirus, parainfluenza virus, influenza virus, and rhinovirus.

The virus replicates in the upper respiratory tract and spreads to the lower tract. Inflammation of the bronchial and bronchiolar epithelium results in necrosis and sloughing of the lumen, with subsequent obstruction of the small airways.

Clinical Features/Diagnosis

Upper respiratory tract signs such as fever, cough, and rhinorrhea are common. A prominent cough, tachypnea/increased work of breathing, wheezing, lethargy, and poor feeding signal lower respiratory tract involvement. Acute onset of upper respiratory tract signs followed by lower tract signs in a child < 2 years of age is diagnostic. Bronchiolitis has a seasonal pattern depending on the geography and climate. Complications include apnea, aspiration, and recurrent wheezing. Laboratory evaluation to determine infectious etiology is unnecessary, as it does not change management.

Treatment

Supportive measures include adequate hydration and antipyretics to reduce fever. Bronchodilators, corticosteroids, intravenous (IV) antibiotics, and anticholinergic medications have inconsistent efficacy and are not recommended routinely.

INFECTIOUS COMPLICATIONS OF BRONCHIECTASIS

Mucus-filled airways foster growth of organisms such as *H. influenzae* and *P. aeruginosa*. When compared to other bacteria, presence of *P. aeruginosa* has been shown to correlate with increased disease severity, more frequent exacerbations, worse lung function and decreased quality of life. Other organisms such as Streptococcus and Staphylococcus are less common. Nontuberculous *Mycobacterium*/mycobacteria (NTM) also are common in this patient population.

These bacteria form biofilms that make their eradication difficult for the following reasons:

- Biofilms have zones of anoxia, acidity or nutrient depletion; these can cause bacteria to enter a dormant phase and become resistant to antibiotics.
- Antibiotics do not penetrate biofilms well.
- Antibiotics may become inactivated or diluted by the contents of biofilms.
- Antibiotic-specific efflux pumps in biofilms can make the antibiotics ineffective.
- Bacteria within biofilms are protected from phagocytosis and host antibodies.

Refer to Chapter 3 for further information regarding the pathogenesis and management of bronchiectasis.

FUNGAL INFECTIONS

With increasing numbers of immunocompromised patients, the incidence of fungal infections has dramatically increased over recent years. Based on pathogenicity, fungal infections can be grouped into opportunistic and endemic mycoses (Table 11-1).

Opportunistic mycoses typically cause infections in immunocompromised patients, whereas endemic mycoses affect both healthy hosts and immunocompromised patients. Adequate cell-mediated immunity generally is required for successful clearance of infection by the endemic mycoses.

Fungal pathogens include molds and yeasts. Molds primarily cause pulmonary disease and occasionally involve other organs. In contrast, yeasts typically cause bloodstream infections and sepsis. Fungal infections are associated with significant morbidity and mortality, and recognizing risk factors for fungal disease is crucial for timely management.

Table 11-1. Classification of Pulmonary Fungal Diseases

Opportunistic Mycoses	Endemic Mycoses
Aspergillosis	Histoplasmosis
Candidiasis	Coccidioidomycosis
Cryptococcosis	Blastomycosis
Mucormycosis	Paracoccidioidomycosis
Fusarium species	*Sporothrix schenckii*
Scedosporium species	

DETECTION METHODS

Routine complete blood counts may reveal neutropenia or leukopenia reflecting an immunocompromised state, though leukocytosis or neutrophilia also can be seen. Peripheral eosinophilia has been described with fungal disease, especially coccidioidomycosis.

Direct microscopic examination of sputum studies can reveals fungal elements, whereas cultures can confirm the suspected organism. As oropharyngeal contamination can result in false-positive results, bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial biopsies often are required for a more definitive diagnosis.

Nonculture-based methods are increasingly being utilized to detect fungal infections. The serum Fungitell® assay detects 1,3-β-D-glucan, which is a component of many fungal cell walls. Although nonspecific, this test can be positive in invasive fungal disease prior to overt clinical manifestations. Multiple serologic studies detecting specific fungal antigens or antibodies are routinely used and will be discussed below.

ANTIFUNGAL AGENTS

Table 11-2 describes commonly used antifungal agents.

Table 11-2. Antifungal Agents

Agent	Mechanism of Action	Notes
Flucytosine	Converted to 5-fluorouracil in target cells and inhibits DNA replication through premature chain termination	Used for pathogenic yeasts (*Cryptococcus*) as mostly adjunctive treatment
Polyene antifungal agents: Amphotericin B	Bind to ergosterol, the main sterol in fungal membranes, and cause leakage of cell contents from disturbed cell membrane	Broad-spectrum use given its relative affinity for any fungal cell membrane Nephrotoxicity common but lipid formulations cause less systemic toxicity

Table 11-2. Antifungal Agents, continued

Agent	Mechanism of Action	Notes
Antifungal azoles: Older: Itraconazole Fluconazole Newer: Voriconazole Posaconazole	Inhibit the cytochrome P450–dependent enzyme lanosterol 14α-demethylase in the ergosterol biosynthetic pathway; this causes eventual cell membrane dysfunction	Voriconazole interacts with statins, many immunosuppressants, antiseizure medications, warfarin, and digoxin; requires dose adjustments and close monitoring Posaconazole has emerged as an effective agent for antifungal prophylaxis in at-risk patients and has class-unique activity against mucormycoses
Echinocandins: Caspofungin Micafungin Anidulafungin	Target fungal cell glucan synthesis by inhibiting the enzyme 1,3-ϐ-D-glucan synthase, leading to impaired integrity of the fungal cell wall	Extremely active against Candida species; no activity against endemic mycoses, *Fusarium, Scedosporium* IV formulations only

DNA, deoxyribonucleic acid; IV, intravenous

Key Fact

A false-positive galactomannan enzyme immunoassay can occur from treatment with piperacillin–tazobactam or amoxicillin–clavulanate.

OPPORTUNISTIC MYCOSES

Aspergillus

Key Fact

COPD and critically ill patients in the ICU have been identified recently as at-risk groups for invasive pulmonary aspergillosis despite not having traditional risk factors of overt immunocompromise such as prolonged neutropenia or high-dose steroids.

Aspergillus is ubiquitous in the environment and virtually unavoidable. More than 250 species of *Aspergillus* have been identified, but *A. fumigatus* causes > 50% of infections. Other species commonly associated with invasive disease include *A. flavus, A. niger,* and *A. terreus*.

Aspergillus species cause a wide spectrum of disease ranging from allergic bronchopulmonary aspergillosis (ABPA) to invasive disease (Figures 11-1, 11-2). The severity of disease often correlates with the degree of immunosuppression. The incidence of aspergillosis has been increasing in recent years paralleling a rise in the use of immunosuppression for stem cell and solid organ transplants as well as other disorders. ABPA is discussed in Chapter 3.

Key Fact

A negative culture from a sputum or BAL sample does not rule out invasive aspergillosis.

Aspergillus is a mold with septate hyphae that branch at a V-shaped (45-degree) angle (Figure 11-3). The galactomannan enzyme immunoassay (EIA) tests for a component of the *Aspergillus* cell wall. Sensitivity is reported to be 44–90%, varying depending on the number of samples obtained, severity of infection, underlying immune status, and prior antifungal treatment. It is most reliable in patients with hematologic malignancies and also can be tested in BAL fluid.



Figure 11-1. Host factors and degree of immunosuppression are associated with severity of disease.
ABPA, allergic bronchopulmonary aspergillosis.

Mnemonic

Aspergillus ***terr****eus* is **terr**ibly resistant to ampho**ter**icin.



Figure 11-2. Chest radiograph shows an aspergilloma (fungus ball) in the upper lobe of the right lung.
(Reproduced from the CDC Public Health Image Library [PHIL]; content provider, M. Renz, ID #3955.)

Flash Card Q1

What is the characteristic branching angle when *Aspergillus* is viewed on histopathologic (potassium hydroxide, India ink) stains?

Flash Card Q2

Which antifungal agents have activity against *Aspergillus*?



Figure 11-3. *Aspergillus* with its characteristic 45-degree branching.
(Reproduced from the CDC Public Health Image Library [PHIL] and Armed Forces Institute of Pathology [AFIP]; content provider Dr. Hardin.)

Candidiasis

CHARACTERISTICS—*Candida* species cause a wide spectrum of infections including mucocutaneous infection, invasive disease affecting any organ, and bloodstream infections. Notably, *Candida* found in the upper and lower respiratory tracts is rarely pathogenic and likely a colonizer that does not require treatment. *C. albicans* is the predominant species, but *C. glabrata* and *C. krusei* are emerging pathogens. Candidemia is a rising nosocomial pathogen, particularly in the intensive care unit (ICU). This section focuses on candidemia.

PATHOGENESIS—Disseminates via gastrointestinal (GI) translocation or manipulation of colonized spaces (GI/genitourinary surgery). Risk factors for candidemia include central venous catheters, total parenteral nutrition, renal replacement therapy, prior colonization, neutropenia/immunosuppression, and exposure to antibiotics.

Flash Card A1

45-degree branching with septations; do not confuse with mucormycosis, which is characterized by 90-degree branching without septations

PRESENTATION—Candidemia presents as sepsis. Dissemination also can affect the eye (endophthalmitis), central nervous system (CNS) (meningitis), skin, cardiovascular system (endocarditis), and spleen and liver (hepatosplenic candidiasis).

Flash Card A2

Voriconazole, itraconazole, amphotericin B, and the echinocandins–fluconazole is inactive against *Aspergillus* species

DIAGNOSIS

- Blood cultures are not consistently positive
- Skin manifestations may provide a clinical clue
- Histopathology may be required and reveals yeast with pseudohyphae formation

TREATMENT—Prompt removal of all central venous catheters; antifungal treatment depends on disease severity; for isolated candidemia, antifungal therapy is continued until 2 weeks after the last negative blood culture. Fluconazole is appropriate for infections caused by *C. albicans* or *parapsilosis* and for stable patients without recent azole treatment. Fluconazole has good CNS, eye, and urinary penetration.

- Echinocandins are recommended for critically ill and neutropenic patients; this should be continued if non-*C. albicans* infection is confirmed
- Voriconazole can be used if concomitant coverage for molds is needed
- Liposomal amphotericin B is noninferior to the above options, but its use is limited by side effects; it is primarily used for
  - CNS candidiasis (along with fluconazole)
  - *Candida* endophthalmitis
  - *Candida* endocarditis (along with echinocandins)

PROGNOSIS—Attributable mortality from candidemia varies from 15–47%.

Key Fact

All patients with candidemia require early dilated retinal examination to rule out *Candida* endophthalmitis. Echinocandins do not have good eye penetration.

Cryptococcus neoformans

CHARACTERISTICS—*Cryptococcus neoformans* is budding encapsulated yeast ubiquitously found in the soil, particularly in pigeon excrement. It affects mostly human immunovirus (HIV) and other immunocompromised patients.

PRESENTATION—Meningoencephalitis is the most commonly diagnosed form of cryptococcal infection. Pulmonary manifestations range from colonization (especially in chronic lung disease) to asymptomatic infection to severe pneumonia and respiratory failure. Treatment of HIV can induce an immune reconstitution syndrome (IRIS).

DIAGNOSIS—Meningoencephalitis is diagnosed with serum and cerebrospinal fluid (CSF) cryptococcal antigen and examination of the CSF with India ink. Pulmonary disease is diagnosed with chest imaging and isolation of organism in culture, typically in BAL or lung biopsy specimens. Although serum cryptococcal antigen is sensitive and specific in disseminated disease, it has limited sensitivity in pulmonary disease (25–56%). Staining of BAL fluid with India ink can reveal a characteristic halo appearance (Figure 11-4).

Key Fact

All immunocompromised patients with pulmonary cryptococcal infection require work-up for disseminated disease with serum and CSF cryptococcal antigen and with blood and CSF cultures.

Key Fact

Cryptococcus gattii more often infects immunocompetent hosts and is found in the Northwest United States.

Flash Card Q3

Which antifungal is preferred for treatment of invasive candidiasis in pregnant women?



Figure 11-4. *Cryptococcus neoformans* in India ink. Note the halo from the polysaccharide capsule.
(Reproduced from the CDC Public Health Image Library [PHIL]; ID #14391.)

TREATMENT

- Mild or moderate pulmonary disease or asymptomatic immunocompromised patients:
  - Fluconazole for prolonged course (6–12 months)
- Severe pulmonary disease and/or those with CNS disease:
  - Induction: Amphotericin B and flucytosine (2–4 weeks)
  - Consolidation: Fluconazole 400–800 mg daily (8 weeks)
  - Maintenance: Fluconazole 200 mg daily (6–12 months)

Mucormycosis

CHARACTERISTICS—Mucormycosis is caused by organisms that exist ubiquitously in the environment. Species *Rhizopus*, *Mucor*, and *Rhizomucor,* commonly called zygomyces, are responsible for > 70% of mucormycosis cases. Mucormycosis is the second leading cause of fungal pneumonia after *Aspergillus,* and it typically causes sinopulmonary infections in immunocompromised patients.

PATHOGENESIS—Inhalation of conidia (spores) into the respiratory tract leads to growth of the hyphal form and invasive infection in the immunocompromised host. The disease progresses with extensive angioinvasion with vessel thrombosis, tissue necrosis, and crossing of tissue planes.

Flash Card A3

Systemic amphotericin B; echinocandins and most azoles are category C; flucytosine and voriconazole are contraindicated because of fetal abnormalities in animal studies

Risk factors:
- Immunocompromised state
- Antifungal treatment/prophylaxis for *Aspergillus* (i.e., previous voriconazole use)
- Hyperglycemia/poorly controlled diabetes
- Iron overload states

PRESENTATION—Mucormycosis has a high propensity to develop into sinusitis with necrotic lesions in the nasopharynx and endocranial soft tissues. Pulmonary manifestations are indistinguishable from *Aspergillus* and are otherwise nonspecific with fever, cough, dyspnea, and pleuritic chest pain.

Aggressive angioinvasiveness and ability to cross tissue planes result in rapid dissemination and distal organ involvement:
- Involvement of bronchi, diaphragm, chest wall, pleura, and contralateral lung
  - Necrosis of surrounding parenchyma due to invasion of blood vessels leads to cavitation and hemoptysis, which can be fatal
- Death usually is from disseminated disease before respiratory failure
- Atypical presentations:
  - Chronic infection with constitutional symptoms
  - Multiple mycotic pulmonary artery aneurysms/pseudoaneurysms
  - Bronchial obstruction (usually in diabetic patients)

DIAGNOSIS
- Chest computed tomography (CT):
  - Multiple nodules (> 10) favor mucormycosis over invasive pulmonary aspergillosis (IPA)
  - Pleural effusions weakly favor mucormycosis over IPA
  - Halo and air-crescent signs are less common in mucormycosis than IPA
    - Air-crescent sign in perihilar areas can portend risk of pulmonary artery erosion and massive hemoptysis
- Tissue swabs, sputum, or BAL fluid often nondiagnostic and blood cultures rarely positive
- Tissue samples often required for histologic evidence of *Mucor* species (broad nonseptate hyphae branching at right angles) and evidence of tissue invasion (Figure 11-5)

TREATMENT
- Reversal of underlying predisposing factors if possible
- Surgical debridement of affected tissue
- Antifungal therapy—No guidelines; limited data:
  - Amphotericin B
  - Posaconazole—Provides long-term oral treatment option and possibility for suppressive therapy during continued immunosuppression



Figure 11-5. *Mucor pusillus* in a heart valve. Notice the 90-degree hyphal branching.
(Reproduced from the CDC Public Health Image Library [PHIL]; content provider, L. Ajello, ID #3955.)

PROGNOSIS—Mortality ranges from 50–70% but up to 95% with extrathoracic dissemination.

Uncommon and Emerging Opportunistic Fungal Infections of the Lung

The septate filamentous fungi *Fusarium* and *Scedosporium* species can cause invasive fungal pneumonia in immunosuppressed patients and have clinical presentations similar to IPA, often with a poor prognosis.

FUSARIUM SPECIES

- **Presentation:** Highly angioinvasive with hemorrhagic infarction of tissue, disseminated disease, and fungemia; skin involvement suggests disseminated disease
- **Pathogenesis:** *Fusarium* species enter the immunocompromised host via the lungs, paranasal sinuses, skin breaks, and intravascular catheters
- **Treatment:** Susceptibility to antifungals varies by species; response rates to various antifungal agents limited
- **Prognosis:** Mortality ~ 66% in patients with hematologic malignancy who have disseminated disease 70% of the time

SCEDOSPORIUM SPECIES

- **Presentation:** Typically presents as invasive pulmonary disease; at presentation, ~ 50% of transplant recipients have disseminated disease with skin, CNS, and bloodstream involvement.
- Immunocompetent hosts with the following risk factors can also develop pulmonary disease:
  - Diabetes
  - Heavy exposure during trauma
  - Near-drowning incidents associated with aspiration pneumonia or lung abscesses
- **Treatment and prognosis:** Infections due to *Scedosporium* species are difficult to treat and frequently are fatal; voriconazole has shown variable results, and surgery and reversal of immunosuppression may be the only effective therapeutic options.

ENDEMIC MYCOSES

Histoplasmosis and blastomycosis have some geographic overlap and are seen in the Midwest or the south-central United States. Coccidioidomycosis is seen mostly in the southwestern U.S.

In a subset of patients taking a tumor necrosis factor-α (TNFα) inhibitor who develop an endemic mycosis, discontinuation of the TNFα blocker can lead to a paradoxic worsening of pulmonary symptoms and radiographic findings consistent with an immune reconstitution inflammatory syndrome.

Histoplasmosis

CHARACTERISTICS—*Histoplasma capsulatum* is a dimorphic fungus, existing as a mold in the environment and a yeast in the host. It is endemic in the Midwest and south-central U.S., in the Ohio and Mississippi River valleys. High concentrations are found in caves with bat guano, in chicken coops, decaying trees, and riverbanks.

PATHOGENESIS—Inoculation occurs with inhalation of airborne spores. At body temperature, the yeast form grows before spreading locally and then into hilar and mediastinal lymph nodes. Immunocompromised hosts are at higher risk for severe and disseminated disease.

DIAGNOSIS—Positive culture from sputum, BAL, or tissue biopsy confirms the diagnosis; there is no colonization. Blood cultures can confirm disseminated disease and histopathology reveals caseating granulomas and narrow-based budding yeast.

Urine and serum *Histoplasma* antigen combined have a sensitivity of > 90% for acute pulmonary histoplasmosis. The specificity of the urine *Histoplasma* antigen is nearly 100%. Complement fixation antibodies for *Histoplasma* remain positive for years after an acute infection and high titers correlate with severity of disease.

Key Fact

Urine and serum Histoplasma antigen studies each has a sensitivity of ~60%, but combined they have a sensitivity of >90%.

Imaging can show focal (Figure 11-6), diffuse, or multinodular findings which in general are larger and better defined compared to miliary tuberculosis (TB) (Figure 11-7). Mediastinal lymphadenopathy and calcified granulomas are commonly seen.

Key Fact

Given its clinical and radiographic similarities to sarcoidosis, histoplasmosis must be excluded prior to diagnosing sarcoidosis and starting immunosuppressive treatment.

PRESENTATION/TREATMENT—Disease is typically asymptomatic. In symptomatic cases, the disease can manifest as acute, subacute, and chronic pulmonary histoplasmosis, as well as disseminated histoplasmosis. The severity of disease depends on the inoculum and host immune status. Treatment varies by disease severity.



Figure 11-6. Chest radiograph showing a pulmonary nodule in the left lower lung field (*arrow*) from histoplasmosis, characteristic of a coin lesion.
(Reproduced from the CDC Public Health Image Library [PHIL] and Massachusetts General Hospital Case Records; ID #463.)

ACUTE AND SUBACUTE PULMONARY HISTOPLASMOSIS—Acute (< 1 month of symptoms) and subacute (> 1 month of symptoms) cases present with nonspecific constitutional symptoms (fevers, chills, malaise, myalgias), with cough and pleuritis. Extrapulmonary manifestations include pericarditis, erythema nodosum, and polyarthritis. Mild cases resolve while severe cases can progress to acute respiratory distress syndrome (ARDS).

Other pulmonary complications are:

- Mediastinal granulomas: Cause compression-related symptoms; usually improves slowly
- Broncholithiasis: Calcified lymph nodes erode into airway causing obstructive pneumonia, expectoration of stones, and possibly hemoptysis
- Fibrosing mediastinitis: Caused by *Histoplasma* antigen release and associated with these conditions:
  - Pulmonary hypertension
  - Superior vena cava syndrome
  - Airway constriction
  - Splenic and liver calcifications, which help identify histoplasmosis as the etiology of the mediastinitis
  - Pericarditis, with sterile pericardial effusions

Treatment of acute and subacute pulmonary histoplasmosis:

- Mild-to-moderate acute pulmonary histoplasmosis—if symptoms last > 4 weeks, treat with itraconazole
- Moderately severe or severe acute pulmonary histoplasmosis (diffuse infiltrates and hypoxemia):
  - Amphotericin B for 1–2 weeks, followed by itraconazole
  - Methylprednisolone at 0.5–1 mg/kg daily for 1–2 weeks
- No antifungal therapy recommended for mild mediastinal lymphadenitis, mild mediastinal granulomas, or mediastinal fibrosis

CHRONIC PULMONARY (CAVITARY) HISTOPLASMOSIS—Seen in patients with symptom duration of > 3 months and structurally abnormal lungs, resulting in destruction of proximal normal lung parenchyma with upper lobe predilection and cavitary pulmonary infiltrates. Sputum cultures are most consistently positive in this form of histoplasmosis. It is treated with itraconazole for ≥ 12 months and continued until no further radiographic improvement is seen.

PROGRESSIVE DISSEMINATED HISTOPLASMOSIS—Occurs in the setting of impaired T cell immunity with granuloma formation. Bone marrow and tissue biopsies reveal macrophages full of yeast and can even show necrosis without granuloma formation. Treatment is liposomal amphotericin B for 1–2 weeks followed by prolonged itraconazole. Steroids are recommended for severe cases.

Flash Card Q4

What extrathoracic findings suggest histoplasmosis as the cause of a patient's fibrosing mediastinitis?



Figure 11-7. Chest radiograph shows diffuse pulmonary infiltration due to acute pulmonary histoplasmosis.
(Reproduced from the CDC Public Health Image Library [PHIL]; ID #3954.)

Coccidioidomycosis

CHARACTERISTICS—Typically occurs in the southwestern United States. *Coccidioides immitis* is most common but *Coccidioides posadasii* is also virulent. Usually infects construction, agricultural, or field workers with symptoms appearing 1–4 weeks after exposure (valley fever). *Coccidioides* is listed as a select agent for bioterrorism purposes.

Key Fact

Patients of Korean, Filipino, Japanese, Hispanic, and African-American descent are at increased risk of developing disseminated coccidioidomycosis, even in the absence of immunosuppression.

PRESENTATION—Primary pulmonary infection can present in a variety of forms.

- Localized pneumonia usually heals spontaneously but can rupture into the pleural space
- Diffuse pneumonia occurs after a large exposure and can rarely cause respiratory failure
- Chronic fibrocavitary pneumonia is characterized by pulmonary cavitation and interstitial fibrosis; more common among diabetics and patients with underlying lung disease Disseminated disease occurs in < 1% of cases but is common in immunosuppressed patients, including those with diabetes mellitus (DM); imaging typically shows diffuse reticulonodular or miliary infiltrates; the CNS, bone, joints, and skin are common extrapulmonary sites of infection

Flash Card A4

Splenic and hepatic calcifications

DIAGNOSIS—Affected by the level of exposure, immune status of the patient, and type of infection.

- Peripheral eosinophilia is common
- Serologic tests are positive in 90% of clinically recognized cases, but can be negative in mild illness, immunocompromised states, or early in the course of disease; antibody titers decline to undetectable levels with resolution of disease with or without treatment:
  - Cocci IgG and IgM EIA—screening studies
  - Cocci tube precipitin—specific test that confirms cocci infection
  - Cocci immunodiffusion—specific test that confirms cocci infection
  - Cocci complement fixation—quantifies IgG; the titer predicts active infection and extent of disease with higher titers predicting dissemination
- Cultures of skin or bone lesions are positive in 95% of disseminated cases
- Histopathology revealing the presence of giant spherules with endospores is definitive (Figure 11-8)

Mnemonic

True **P**ositive to **ID** the cocci
Can **F**ollow the titer

Cocci **T**ube **P**recipitin
Cocci **I**mmuno**D**iffusion **ID**
Cocci **C**omplement **F**ixation

TREATMENT—Mandatory for all infections in the immunocompromised host and for diffuse pneumonia and disseminated disease in the normal host. Otherwise treatment of pulmonary infection is reserved for those with enlarging cavities, hemoptysis, or prolonged symptoms (> 3 months).

- Limited pulmonary disease: Fluconazole or itraconazole
- Diffuse pulmonary disease: Amphotericin B until clinical improvement followed by fluconazole or itraconazole for > 1 year
- Meningitis: Lifelong itraconazole or fluconazole plus intrathecal amphotericin B in severe cases



Figure 11-8. Histopathology of coccidioidomycosis of lung. Mature spherule with endospores of *Coccidioides immitis* and intense infiltrate of neutrophils.
(Reproduced from the Centers for Disease Control and Prevention Public Health Image Library [PHIL]; content provider CDC/ Dr. Lucille K. Georg.)

Blastomycosis

CHARACTERISTICS—Blastomycosis is the least common of the endemic mycoses. It is acquired by inhaling soil colonized with *Blastomyces dermatitidis*, typically in the central and southeastern U.S. and in the Mississippi and Ohio River valleys, similar to Histoplasmosis. Like *Histoplasma*, *Blastomyces* is a dimorphic fungus existing as a yeast form in the host.

PRESENTATION—Symptoms can mimic acute bacterial pneumonia with fever and cough or be more indolent with weight loss and night sweats. Asymptomatic disease is common and fibrocavitary disease is rare. Immunocompromised patients can develop ARDS and CNS symptoms and disseminated disease can involve the skin, bone, genitourinary, and central nervous systems. Skin lesions are usually pustules, papules, or subcutaneous nodules seen on the face and extremities.

DIAGNOSIS—Antigen detection is positive in the urine and/or serum in ~ 90% of patients with disseminated or pulmonary blastomycosis.

Key Fact

B*lastomyces dermatitidis* are **b**road-**b**ased **b**udding yeast.

- Antigen titers decline with treatment and increase in relapse, guiding treatment decisions
- Cultures are definitive but slow growing and poorly sensitive
- Wet preparation shows characteristic round broad-based, budding yeast of blastomycosis (Figure 11-9)
- Imaging can show lobar or diffuse infiltrates



Figure 11-9. Grocott methenamine silver-stained biopsy of a section from a human leg lesion shows broad-based budding characteristic of *Blastomyces dermatitidis*.
(Reproduced courtesy of J Scott, Wikimedia Commons, CC0 1.0.)

TREATMENT—Indicated for symptomatic patients with pulmonary disease and for all patients with disseminated disease.

- Itraconazole is first-line therapy for most cases
- Life-threatening severe blastomycosis, ARDS, or meningeal infection requires amphotericin B until clinically improved, followed by long-term itraconazole.

Paracoccidioidomycosis

CHARACTERISTICS—Caused by *Paracoccidioides brasiliensis* and seen in South America, Central America, and southern Mexico, with U.S. cases reported in patients who previously lived in these endemic areas.

PRESENTATION—Respiratory symptoms often are nonspecific and indolent. Skin and mucocutaneous involvement, especially in the oropharynx, is seen with possible dissemination to the lymph nodes, liver, spleen, and bone marrow.

DIAGNOSIS—By culture or direct visualization of fungal elements, typically in a pilot-wheel appearance (Figure 11-10). Chest imaging is nonspecific, but bat-wing distribution of infiltrates (reticular, nodular, or alveolar) are highly characteristic of paracoccidioidomycosis.

TREATMENT—Very sensitive to antifungals and treatment of choice is itraconazole with sulfonamides, azoles, and amphotericin B as alternatives.

Figure 11-10. Histopathology of paracoccidioidomycosis. Budding cells of *Paracoccidioides brasiliensis* in methenamine silver stain.
(Reproduced from the Centers for Disease Control and Prevention Public Health Image Library [PHIL]; content provider Dr. Lucille K. Georg; ID #527.)

Flash Card Q5

Which fungal infection has the classic presentation of a rose gardener injuring his finger with a thorn?

Sporothrix schenckii

S. schenckii is seen in decaying vegetation and soil. It usually is cutaneously inoculated and has the classic presentation of the rose gardener who injures his finger with a thorn.

The lymphocutaneous form is much more common, but pulmonary and disseminated disease can occur with inhalation of *S. schenckii* spores. Pulmonary disease manifests as chronic cavitary fibronodular disease, classically in middle-aged men with risk factors (e.g., alcoholism, chronic obstructive pulmonary disease [COPD]). Outcomes can be poor and often related to delayed diagnosis.

DIAGNOSIS—Culture is the gold standard for diagnosis with histopathology showing a mixed granulomatous and pyogenic inflammatory process.

TREATMENT

- Mild disease: Itraconazole for 12 months
- Severe disease: Amphotericin B with transition to prolonged itraconazole and consideration of surgery for localized pulmonary disease

HIV

Epidemiology

HIV-related diseases have caused the deaths of more than 35 million people since the disease was first recognized in 1981. Heterosexual contact is the predominant mode of transmission worldwide, whereas injection drug users, men who have sex with men, and sex workers are at greatest risk in the developed world.

Immunologic Abnormalities

The degree of immune dysfunction is the primary determinant of the risk of developing specific pulmonary disorders in patients with HIV. When the immune system is not significantly impacted, the pulmonary disorders that occur are similar to those found in the general population. When immune dysfunction is severe, opportunistic infections can occur.

HIV infection leads to the following immunologic abnormalities and alterations in host defenses that increase the risk of pulmonary complications such as:

Flash Card A5

Sporothrix schenckii

- Massive depletion of CD4+ T lymphocytes of the effector memory type from mucosal associated lymphoid tissue
  - Progressive decline of naïve and memory T cell pools
- B cell dysfunction
- Problems with mucociliary clearance and pathogen recognition by alveolar macrophages

Spectrum of Pulmonary Manifestations

The CD4+ lymphocyte count is an excellent indicator of an HIV-infected person's risk of developing a specific infection or neoplasm (Table 11-3).

INFECTIOUS

Bacterial: Despite antiretroviral therapy, bacterial pneumonia is still a significant cause of morbidity and mortality in HIV-infected individuals:

- *Streptococcus pneumoniae* and *H. influenzae* are the most frequent causes of bacterial pneumonia in HIV-infected persons
- *P. aeruginosa* and *Staphylococcus aureus* are the most common causes of bacterial pneumonia in hospitalized patients; these patients tend to have lower CD4+ counts
- Treatment is the same as that for non-HIV-infected hosts
- It is important to vaccinate these patients for *S. pneumoniae*

Table 11-3. CD4+ Count and HIV-Associated Pulmonary Disease

CD4+ Count	Infection or Neoplasm
Any	Bacterial pneumonia, TB, non-Hodgkin lymphoma
< 200 cells/μL	Bacterial pneumonia with bacteremia, disseminated TB, *Pneumocystis* TB, *Cryptococcus neoformans*
< 100 cells/μL	Bacterial pathogens such as *Staphylococcus*, *Pseudomonas*, pulmonary manifestations of Kaposi sarcoma, toxoplasmosis
50–100 cells/μL	Endemic fungi, CMV, MAC, nonendemic fungi

CMV, cytomegalovirus; MAC, *Mycobacterium avium* complex; TB, tuberculosis

Flash Card Q6

Name three risk factors for *Pneumocystis* pneumonia (PCP) among HIV-infected patients.

Flash Card Q7

Name two alternatives to TMP-SMX for PCP prophylaxis.

Mycobacterial: *Mycobacterium tuberculosis* is the most prevalent opportunistic infection in HIV-infected hosts worldwide. It is not clear whether HIV patients are more susceptible to TB than non-HIV hosts; however, once an individual becomes infected, the risk of progression from latent to active disease is much higher.

- HIV-infected persons should be tested for latent TB with either a tuberculin skin test or interferon-y (INFy) assay when HIV is first diagnosed and annually thereafter if they are at risk of continued exposure.
- HIV-infected patients with TB who begin therapy for both infections simultaneously are at increased risk of IRIS and are also at increased risk of drug interactions.

Fungal: *Pneumocystis jirovecii* (also known as pneumocystis) pneumonia (PCP) is the most common acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection, and is a common cause of HIV-associated pneumonia (Figure 11-11).

- Treatment of choice for mild, moderate, or severe PCP remains trimethoprim (TMP)–sulfamethoxazole (SMX) for 21 days; in moderate to severe PCP (defined by a $PaO_2 < 70$ or an alveolar–arterial gradient > 35), adjunctive steroids have been shown to have a benefit in reducing mortality and respiratory failure
- HIV-infected adults with CD4+ < 200 or a history of oropharyngeal candidiasis should receive PCP prophylaxis, usually one double-strength TMP-SMX tablet three times a week



Figure 11-11. Pneumocystis cysts as seen on BL, stained with toluidine blue.
(Reproduced from the Centers for Disease Control and Prevention Public Health Image Library [PHIL].)

Flash Card A6

CD4+ < 200, oropharyngeal candidiasis, and a history of PCP

Flash Card A7

CD4+ < 200, Dapsone 100 mg daily, or aerosolized pentamidine 300 mg once per month

Other fungal diseases seen in HIV-infected hosts include *Cryptococcus neoformans*, *Histoplasma capsulatum*, and *Coccidioides immitis*. Invasive aspergillosis is a life-threatening disease seen in the severely immunosuppressed.

VIRAL—*Cytomegalovirus* (CMV) is an important agent of pulmonary disease in HIV patients, although the most common sites of CMV infection are the retina and GI tract.

Key Fact

Most cases of CMV pneumonia occur in patients with CD4+ < 50.

The diagnosis of CMV pneumonitis cannot be made on BAL alone, as cytopathogenic changes need to be seen; CMV organisms can be shed from respiratory secretions without being diagnostic of pulmonary disease.

Key Fact

The prophylaxis of choice for *T. gondii* is TMP-SMX, the same drug as for PCP.

PARASITES—In general, helminth infections are uncommon in HIV patients. Of the unicellular and multicellular parasites, *T. gondii* is the most frequent cause of disease in HIV patients. It usually manifests as encephalitis, and pulmonary symptoms are nonspecific and hard to distinguish from other pathogens.

HIV patients should be tested for *T. gondii* antibodies, and those who are negative for disease should be instructed to avoid raw, uncooked meat and cat feces

Noninfectious

HIV-infected patients appear to be at increased risk for a number of noninfectious pulmonary diseases, including COPD, lung cancer, and pulmonary arterial hypertension.

MALIGNANCY—HIV-infected patients are at increased risk for Kaposi sarcoma and non-Hodgkin lymphoma, both of which can involve the thorax as isolated pulmonary disease. Non-small cell lung cancer also has a greater incidence in HIV-infected population, although it is difficult to pinpoint HIV as the cause.

- Kaposi sarcoma is the most common HIV-associated malignancy, although rates have declined with antiretroviral therapy; diagnosis can be established via bronchoscopy revealing characteristic endobronchial, flat or slightly raised. red or violaceous lesions (Figure 11-12).
- HIV-associated non-Hodgkin lymphoma tends to be of B cell origin; bilateral, exudative lymphocytic pleural effusions are common; chemotherapy for non-Hodgkin lymphoma often is complicated by opportunistic infections, particularly PCP, so PCP prophylaxis is indicated.

Flash Card Q8

Nonsmokers with signs of emphysema at an early age should be evaluated for what systemic diseases?

Flash Card Q9

What are two treatment options for excessive inflammation in immune reconstitution syndrome?



Figure 11-12. Endobronchial Kaposi sarcoma.
(Reprinted, with permission, from Nagata N, Shimbo T, Yazaki H, Asayama N, Akiyama J, Katsuji T, et al. Predictive clinical factors in the diagnosis of gastrointestinal Kaposi's sarcoma and its endoscopic severity. *PLOS one* 2012; 7(11): e46967. doi:10.1371/journal.pone.0046967. CC BY 2.0)

OBSTRUCTIVE LUNG DISEASE—Obstructive lung disease occurs frequently in the HIV-infected population, but the role of HIV in the pathogenesis of obstruction is unclear.

INTERSTITIAL PNEUMONITIDIES

- HIV-associated lymphocytic interstitial pneumonia is striking for its early age of incidence (children >> adults); diagnosis is confirmed by histology from transbronchial biopsy.
- Nonspecific interstitial pneumonitis has been reported in HIV; its clinical features are indistinguishable from PCP, although it can occur at higher CD4 counts.

OTHER

- **IRIS:** Paradoxic worsening of clinical status temporally related to recovery of the immune system following a period of immunosuppression, or after the initiation of antiretroviral therapy.
  - Infections (mycobacterial, fungal, and viral) are often exacerbated by IRIS.
- **Pulmonary hypertension:**
  - Rare complication of HIV infection and treatment modalities remain experimental
  - Unclear whether antiretroviral therapy improves pulmonary arterial hypertension

Flash Card A8

α_1-antitrypsin deficiency, HIV, connective tissue diseases

Flash Card A9

Nonsteroidal antiinflammatory drugs (NSAIDs) and steroids

PREVENTION AND SCREENING OF HIV AND OPPORTUNISTIC INFECTIONS

Evidence-based guidelines from 2013 for the management of HIV and associated opportunistic infections are summarized here.

- HIV-infected patients should be tested for TB with either a skin test or INFy INFy release assay); those who test positive should be treated for latent TB after active TB has been excluded via a CXR.
- All HIV-infected patients who are *Toxoplasma* seronegative should be counseled on how to avoid new infection.
- Routine testing for MAC and cryptococcal infections is not recommended but can be considered in select patients with CD4 counts < 50.
- Influenza vaccine should be administered annually.
- Pneumococcal vaccine, either heptavalent or tridecavalent, should be administered to all HIV-infected persons.

LUNG ABSCESS

Lung abscesses develop after an infection causes necrotic lung tissue to cavitate (Tables 11-4 and 11-5). Necrotizing pneumonia refers to the formation of multiple small abscesses. Risk factors include seizures, alcoholism, esophageal abnormalities, periodontal disease, and dysphagia. Abscesses commonly are caused by aspiration of oral anaerobes—pneumonitis is followed by necrosis in 1–2 weeks. The differential diagnosis includes noninfectious causes of cavitary lung lesions.

Mnemonic

Noninfectious causes of cavitary lung lesions: **CAVITY**

Cancer
Autoimmune (Wegener's, rheumatoid)
Vascular (bland or septic emboli)
Infection
Trauma (pneumatocele)
Youth (pulmonary sequestration, bronchogenic cyst, congenital pulmonary airway malformation)

Pathophysiology

Small zones of necrosis in consolidated regions of pneumonia form single or multiple abscesses that erode into bronchi, ultimately resulting in fibrosis (Figure 11-13).

Table 11-4. Bacterial Infections That Cause Pulmonary Cavitation

Organism	Radiographic Features	Clinical Presentation/ Diagnosis	Management
Actinomyces (Figs. 11-14, 11-15): Gram + anaerobe Forms sulfur granules Part of normal oral flora GI/vaginal tract	Mass lesion, segmental consolidation, adenopathy, bronchiectasis, ± pleural thickening or effusions/empyema Suspect if you see air bronchograms in the mass lesion and **if it invades or erodes through chest wall**.	Cervicofacial osteomyelitis or abscess in an alcoholic or person with poor dental hygiene (but otherwise **immunocompetent**) with recent dental procedure; pulmonary manifestations (cough, fever, hemoptysis, chest pain) are rare, indolent, and occur through aspiration or direct extension of disease from head, neck, or abdominal cavity Part of normal flora so sputum/ bronchoscopic studies unhelpful unless sulfur granules present; may need transbronchial or open lung biopsy to confirm	**PCN** is drug of choice but can use tetracycline, erythromycin, clindamycin, imipenem 6 weeks of IV therapy followed by 6–12 months of oral therapy
Nocardia (Fig. 11-16): Gram + aerobe Weakly acid fast Found in soil Can be inhaled, ingested, or inoculated directly from trauma	Usually cavitary, bilateral multifocal pneumonia, masses, nodules, effusions/ empyema	**Immunocompromised** patient with underlying lung disease and subacute pulmonary symptoms (most common presentation), hematogenous metastasis (brain, skin, bone, muscle) Bronchoscopy for diagnosis Cultures take weeks to grow	**TMP-SMX** is drug of choice: can use minocycline, third-generation cephalosporins, linezolid 6–12 months

GI, gastrointestinal; PCN, penicillin; IV, intravenous; TMP-SMX, trimethoprim–sulfamethoxazole



Figure 11-13. Lung abscess. Suppuration with central liquefaction surrounded by a thin fibrous capsule.
(Reproduced courtesy of Yale Rosen, flikr.com. CC BY-SA 2.0)

Classification

- Acute (less than 4–6 weeks old) vs. chronic
- Primary (infectious etiology in a healthy host) vs. secondary (due to a preexisting condition such as bronchiectasis, spread from an extrapulmonary site, immunocompromised state)

A



B

Figure 11-14. (A)Patient with actinomycosis on the right side of the face. (B) Fite–Faraco stain with sulfur granule in the middle of the image. These granules represent colonies that macroscopically demonstrate a gross yellow color when unstained.
(Reproduced from the Centers for Disease Control and Prevention Public Health Image Library [PHIL]. Image A content provider, Dr. Thomas F. Sellers/Emory University; image B content provider, Dr. Lucille Georg.)



Figure 11-15. Gram stain shows thin, gram-positive, filamentous *Actinomyces* at the periphery of sulphur granules (*arrow*).
(Reproduced courtesy of Yale Rosen, flickr.com, CC BY-SA 2.0)

Microbiology

- Predominantly anaerobes or a mixture of both anaerobes and aerobes
- Most common anaerobes:
  - *Peptostreptococcus*
  - *Bacteroides*
  - *Fusobacterium*

Mnemonic

NOCARDIA

Nodules seen on imaging
Organ spread
Cavitary lesions
Sulfon**A**mide antibiotic to treat
Respiratory symptoms
Dirt exposure
Immunocompromised
Acid fast (weak)



Figure 11-16. *Nocardia*.
(Reproduced from the Centers for Disease Control and Prevention Public Health Image Library [PHIL]; content provider, Dr. Hardin; ID# 15056.)

Table 11-5 Parasitic Infections That Cause Pulmonary Cavitation

Organism	Radiographic Features	Clinical Presentation/ Diagnosis	Management
Echinococcus: Cestode tapeworm found in the Mediterranean region, Middle East, South America, Australia; infection occurs via ingestion of feces of wolves, dogs, foxes that are hosts	Spherical, round or oval cysts with smooth borders surrounded by normal lung; liver cysts more common than lung.	Can occur in any patient. Often asymptomatic. Can have chronic cough, hemoptysis, fever, chest pain Blood cultures are high yield	Treat with macrolides, rifampin, vancomycin, FQ, AG, or imipenem
Paragonimiasis: Found in Japan, Korea, Philippines, parts of China; infection via ingestion of freshwater crabs, raw boar meat	Cavities and cyst-like lesions with linear or patchy infiltrates, pleural effusion, fibrosis, calcification	Hemoptysis, chest pain, fever, eosinophilia in any patient Diagnosis via microscopy (eggs in sputum, BAL, stool), or serology (serum or CSF)	Treat both symptomatic and asymptomatic patients with antihelminths

AG, aminoglycoside; BAL, bronchoalveolar lavage; CSF, cerebrospinal fluid; FQ, fluoroquinolone

- Other bacteria:
  - Tuberculous mycobacteria and NTM (see below)
- Fungi (see Fungal Infections section):
  - *Aspergillus* species, *Cryptococcus neoformans, Blastomyces dermatitidis, Sporothrix schenckii, Histoplasma, Coccidioides*

Diagnosis

- Indolent symptoms of fevers, cough with putrid sputum, constitutional symptoms for > 2 weeks, and digital clubbing
- Imaging shows infiltrate with cavity, often with air–fluid level; CT helps differentiate empyema from lung abscess (Figures 11-17 and 11-18)
- Bronchoscopy is helpful in excluding TB and malignancy; diagnostic yield for infectious organism is variable
- Complications
  - Empyema
  - Pleural fibrosis
  - Trapped lung
  - Respiratory failure
  - Bronchopleural fistula
  - Pleurocutaneous fistula

Key Fact

CXR shows infiltrates within a cavity, typically in the parts of the lung that are dependent in the recumbent position (superior segment of the lower lobe or posterior segment of the upper lobes).



Figure 11-17. Abscess in right lung; cavitary lesion with an air–fluid level and surrounding consolidation.
(Reproduced courtesy of Yale Rosen, flickr.com, CC BY-SA 2.0.)



Figure 11-18. CT scan of chest shows bilateral pneumonia with abscesses and pleural effusions.
(Reproduced courtesy of Christaras A, Wikimedia Commons, GFDL1.2)

Treatment

- Before era of antibiotics, 1/3 died, 1/3 recovered, 1/3 developed complications such as empyema or bronchiectasis.
- Appropriate therapy results in clinical improvement in 3–4 days; fevers more than 7–10 days may indicate need for further diagnostic tests; recalcitrant cases (e.g., large cavities, resistant organisms such as *P. aeruginosa*, obstructing neoplasm—massive hemorrhage) may require lobectomy or pneumonectomy.
- Empirically cover anaerobes until etiology identified:
  - Clindamycin or β-lactam with β-lactamase inhibitor

Key Fact

The mortality for lung abscess ranges between 5–20%. Larger size is a worse prognostic marker.

Key Fact

Routine bronchoscopy to aspirate lung abscesses is not recommended due to lack of evidence of benefit and potential risk of massive fatal aspiration of abscess contents. If it is performed, requires experienced operator.

Key Fact

Aztreonam, TMP-SMX, aminoglycosides, and ciprofloxacin do not cover anaerobes.

Mycobacterium tuberculosis

History

TB can be caused by any of the mycobacterial pathogens in the *Mycobacterium tuberculosis* complex, the most common of which is *Mycobacterium tuberculosis*. The World Health Organization has estimated that nearly one third of all the people in the world are infected with TB. A resurgence of the disease was noted in the U.S. in the late 1980s and early 1990s because of the epidemic of HIV and the deterioration of public health systems.

Epidemiology

A total of 9945 cases of TB were reported in the U.S. in 2012; the majority (> 60%) of the newly diagnosed cases of TB in U.S. were among foreign-born persons. Annual rates of TB are especially high in immigrants from sub-Saharan Africa and Southeast Asia.

Major challenges to successful control of TB include:

- TB among new immigrants to the U.S.
- Delays in detection and reporting of cases
- Deficiencies in protecting contacts of persons with infectious TB
- Presence of a large reservoir of persons with latent TB
- Difficulty maintaining clinical and public health expertise in an era of declining incidence of TB

Flash Card Q10

What is the most effective mechanism for generating droplet nuclei?

Transmission

Transmission of TB occurs when airborne droplets of secretions (droplet nuclei) containing infectious organisms are expelled into the environment. Transmission rates depend on characteristics of the source case, the exposed person, and the surrounding environment.

SOURCE CASE—Patients with active TB are more likely to transmit the disease if they have:

- A high concentration of acid-fast bacilli in their sputum
- Cavitary disease on chest radiograph
- Frequent and strong cough

EXPOSED PERSON—Only 30–40% of persons with close exposure to a patient with active pulmonary TB become infected. Innate immunity may protect certain persons from infection.

Latent TB may confer protection against subsequent reinfection.

Key Fact

TB is acquired by inhalation of one or more tubercle bacilli contained in an airborne particle small enough (1–5 μm) to reach an alveolus.

ENVIRONMENT—Under standard indoor temperature and humidity conditions, ~ 70% of TB organisms survive 3 hours, ~ 50% survive 6 hours, and ~ 30% survive 9 hours.

Only effective filtration or ultraviolet light can remove TB organisms from the environment.
Crowding and intimacy of contact increase likelihood of transmission of TB.

Pathogenesis

IMMUNOLOGIC RESPONSE TO EXPOSURE—Active TB can develop as a result of early progression from infection to disease or after late progression of latent infection (Figure 11-19). The course of infection likely depends on the immune response of the host.

Flash Card A10

Coughing—a forced expiratory maneuver that involves the sudden acceleration of air and disruption of a liquid surface and therefore aerosolizing of particles; sneezing, yelling, singing, and loud talking are also ways to transmit droplet nuclei

The principal immune response associated with protection against TB is cell-mediated immunity involving T lymphocytes and macrophages.

It is unclear to what extent clinical pulmonary TB can be attributed to new infection by recently inhaled exogenous organisms (i.e., from the environment) as opposed to a reactivation of viable bacilli that have been maintained for many years in a dormant or growth-restricted state within the body.
Current TB control efforts are based on the idea that TB in low-incidence areas is the result of endogenous reactivation.


Exposure of subjects (contacts of TB patients) to droplet nuclei from a source case of sputum smear-positive pulmonary TB
Duration and intensity of exposure
Host immunologic defenses
No infection
Onset of infection
(~50 million people worldwide/year)
Strong protective immune response
Weak protective immune response
Limited initial bacterial growth
Bacterial growth continues
(Primary TB)
Host factors,
Bacterial factors
Bacterial growth arrested
Pathogen eliminated (10%)
(Sterilizing immunity)
Bacterial growth arrested
Some bacilli survive and persist (90%)
(Latent infection, LTBI)
(Total ~2.2 billion people in the world)
Immune response persists, waning of dormant bacilli
Immune response compromised
Clearance of latent infection
Reactivation of latent infection
(Reactivation TB)

Figure 11-19. Events after exposure to smear-positive patient. LTBI, latent tuberculous infection.

(Reproduced, with permission, from Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. *Respir Res*. 2010; 11(1), 169. doi:10.1186/1465-9921-11-169. CC BY 2.0)

Risk Factors

The risk of developing active TB after exposure is related to the host response to infection and the dose of bacilli inoculated in the lungs. Other factors that increase the risk of developing active TB include:

- Time since exposure: The risk is highest during first year after infection.
- HIV infection: Impaired cellular immunity renders patients with HIV susceptible to TB infection, although they may be less infectious to others, because they are less likely to have cavitary lesions.
- Therapies that interfere with cell-mediated immunity, such as TNFα blocking drugs (Figure 11-20).
- Silicosis: Risk thought to be mediated by the detrimental effect of silica on alveolar macrophages.
- Hemodialysis
- Diabetes
- Age: The incidence in children is many times greater than in adults; however, there appears to be a second peak in incidence after age 65, perhaps due to natural decline in host defenses.

Key Fact

In persons with both HIV and latent TB infection, antiretroviral therapy and prophylactic therapy with isoniazid substantially decrease the risk of developing active TB.


1. M. tb infects alveolar macrophages
2.The proinflammatory cytokine TNFα is primarily released by activated monocytes/macrophages in response to M. tb infection. TNFα production is essential for the development and maintenance of the granuloma which compartmentalises tubercle bacilli.
TNFα
Infliximab
3.Anti-TNF agents increase the risk of reactivation of latent tuberculosis infection by binding to TNFα. Infliximab binds to both soluble and transmembrane TNFα.

Figure 11-20. Effect of anti-TNF agents on TB. Binding of TNFα inhibits development and maintenance

TB granulomas. M tb, *Mycobacterium tuberculosis*. (Reproduced, with permission, from Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. *Autoimmun Rev*.2008; December 8(2):147–152. doi: 10.1016/j.autrev.2008.07.011.)

Prevention

In high prevalence countries, vaccination with *Mycobacterium bovis* bacillus Calmette–Guérin (BCG) is routine, although the efficacy has been difficult to document. Vaccination likely protects infants and young children from meningeal and military TB.

Key Fact

BCG should not be given to immunocompromised persons, including those with symptomatic HIV infection and pregnant women.

Diagnosis

More than 70% of new cases of TB involve only the lungs, and diagnosis is centered often on pulmonary symptoms and imaging.

History

- Cough is the most common symptom; early in the course, it is nonproductive, but as tissue necrosis occurs, sputum is produced.
- Hemoptysis can occur from extensive parenchymal involvement or from bronchiectasis as a result of residual disease.
- Systemic features include fever, malaise, and weight loss.

Laboratory Findings

- Hyponatremia can occur because of production of antidiuretic hormone–like substance within affected lung tissue; leukocytosis and anemia also can occur.

Imaging

Radiographic findings of active TB vary, but often demonstrate variable-sized nodules and tree-in-bud opacities (Figure 11-21).

- Primary TB, occurring as a result of recent infection, usually is seen in the middle and lower lung zones with ipsilateral hilar adenopathy.
- TB that develops many years after the original infection (endogenous reactivation) usually involves the upper lobes of one or both lungs; cavitation is common.
- Healing of TB lesions results in development of fibrotic scar, shrinkage of lung parenchyma, and, often, calcification.
- Erosion of a parenchymal focus of TB into a blood or lymph vessel may result in dissemination of the organism and a miliary pattern on the chest film.

Key Fact

In patients with HIV infection, a normal chest radiograph occurs in as many as 11% of patients with positive sputum cultures.



Figure 11-21. Chest x-ray and CT findings of drug-sensitive TB demonstrate common findings of variable-sized nodules (A,B) and tree-in-bud signs (C,D).
(Reproduced with permission, from Cha J, Lee HY, Lee KS, Koh WJ, Kwon OJ, Yi CA, et al. Radiological findings of extensively drug-resistant pulmonary tuberculosis in non-AIDS adults: comparisons with findings of multidrug-resistant and drug-sensitive tuberculosis. Korean J Radiol. 2009; 10(3): 207–216. doi: 10.3348/kjr.2009.10.3.207. Published online April 22,2009.)

Tuberculin Skin Test

- Standard intermediate tuberculin test consists of the intracutaneous injection of 0.1 mL of material, which contains 0.0001 mg of purified protein derivative.
- The reaction size is determined by measuring the diameter of any induration with a ruler 48–72 hours after administration; erythema should not be measured (Figure 11-22).
- Testing does not distinguish between active and latent TB infection.

Induration	Positive in
≥ 15	Everyone
≥ 10	Recent immigrants, high-risk populations (health care professionals), IV drug users, comorbid medical conditions, exposure to index case
≥ 5	Immunosuppressed (including HIV), close contact with active TB, high clinical suspicion

Figure 11-22. A ruler is used to measure induration. Erythema should not be measured.
(Figure reproduced from Wikimedia Commons.)

INFγ Release Assays

INF-γ release assays can be used in place of tuberculin skin tests. Like skin testing, the INFγ release assay cannot distinguish between active and latent infection.

- INFγ release assays have some advantages over skin testing: Only one visit, more specific in the presence of BCG vaccination, less reader variability, and no recall of waned immunity.
- Disadvantages: Must be processed within 12 hours of collection; infection with some NTMs can cause false-positive results (*Mycobacterium szulgai*, *Mycobacterium kansasii, Mycobacterium marinum*).

Bacteriologic Evaluation

A definitive diagnosis of TB is established only by isolation of bacilli in culture or identification of specific nucleic acid sequences from sputum samples, preferably from the first sputum of the day. If sputum cannot be isolated, the next diagnostic step is bronchoscopy with lavage (Table 11-7).

Differential Diagnosis of NTM

- Can present as cavitary disease
- NTM is ubiquitous in the environment; up to 40 species have been documented to cause pulmonary symptoms.
- See NTM section at end of this chapter for additional details

Flash Card Q11

Who should get a screening tuberculin skin test or INFγ assay?

Table 11-7. Diagnostic Testing for Tuberculosis

Type of Test	Value of Test
Acid-fast staining	Finding AFB is very specific for mycobacteria, but it provides no information about species
Mycobacterial culture	Necessary for drug susceptibility testing, which requires isolation of mycobacteria in culture; takes many weeks for final results
Drug-susceptibility testing	Varying techniques; molecular methods are much quicker than other techniques
Genetic polymorphisms	Useful for studying epidemiology and transmission dynamics

AFB, acid-fast bacillus

TREATMENT

Standard Therapy for Active TB

The recommended basic treatment regimen for previously untreated patients with pulmonary TB consists of an initial phase of rifampin, isoniazid, pyrazinamide, and ethambutol (also known as RIPE therapy) given for 2 months, followed by a 4-month continuation phase of isoniazid and rifampin.

Routine measurements of hepatic function, renal function, and platelets are not necessary unless patients have baseline abnormalities or are at increased risk for hepatotoxicity. However, patients should be monitored clinically throughout treatment.

Sputum cultures should be checked monthly until two consecutive negative sputum cultures are obtained.

Figure 11-23 demonstrates treatment algorithms for culture-positive and culture-negative TB.

After 3 months of therapy, more than 90% of patients taking isoniazid and rifampin have negative sputum cultures. If sputum cultures are still positive after 4 months of therapy, a new regimen should be started based on drug susceptibility testing.

Flash Card A11

Contacts of infectious cases, children younger than 17 years, pregnant women, recent immigrants, and health care workers should get a skin test or INFγ assay



A



B.

Figure 11-23. Treatment algorithms for culture-positive (A) and culture-negative (B) TB. CXR, chest x-ray; AFB, acid-fast bacillus; EMB, ethambutol; INH, isoniazid; PZA, pyrazinamide; RIF, rifampin; RPT, rifapentine; Sx, symptoms.

(Reproduced courtesy of the Centers for Disease Control and Prevention. Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of tuberculosis. *MMWR Morb Mortal Wkly Rep.* 2003; 52(11): 6-7.)

Special Cases

HIV—Concerns include drug interactions with antiretrovirals, and the possibility of IRIS. The general recommendation is that antiretrovirals should be started in patients with newly diagnosed TB and a CD4 count < 200. For those with higher CD4 counts, the benefits of antiretrovirals are unclear.

Pregnancy—The risks of active, untreated TB are higher for pregnant women than the risks of treatment. No modification of treatment regimen is needed for pregnant or lactating mothers.

Latent TB

Key Fact

Rifampin can stain urine, saliva, tears, and soft contact lenses orange.

Testing and treatment for latent infection is indicated for patients recently exposed to TB and patients with clinical conditions that increase the risk of progressing from latent infection to active TB. The treatment regimen that is most commonly used is isoniazid and/or rifampin daily for 9 months. Another option for latent TB is rifapentine plus isoniazid for 3 months. Evidence suggests that this regimen is as effective as 9 months of isoniazid alone and has a higher rate of treatment completion.

EXTRAPULMONARY TB

Key Fact

Because of the frequency of extrapulmonary TB in HIV-infected patients, diagnostic specimens from any suspected site of disease should be cultured for mycobacteria.

Although most commonly seen in the lungs, TB can infect all major organ systems. Extrapulmonary TB is seen in up to 50% of HIV patients with TB. Immunosuppression and young age are also risk factors for extrapulmonary TB.

Disseminated TB

- Patients have multiple 1–2mm yellowish nodules that are granulomas on histologic examination – miliary. Figure 11-24 demonstrates miliary TB seen in abdominopelvic organs mimicking ovarian malignancy.

A



B

Figure 11-24. (A) Miliary TB noted on abdominopelvic organs during surgery for suspected ovarian malignancy. (B) Chronic granulomatous inflammation noted on histopathology.
(Reproduced, with permission, from Yassaee F, Farzaneh F. Familial tuberculosis mimicking advanced ovarian cancer. *Infect Dis Obstet Gynecol.* 2009; 2009: 736018. doi: 10.1155/2009/736018.)

Flash Card Q12

What is the value of checking a pleural fluid adenosine deaminase?

Lymphatic TB

- Presents as painless swelling of one or more lymph nodes.
- Diagnosis is established by lymph node biopsy.
- Rate of response to drug therapy is much slower than that of pulmonary TB.
- Corticosteroid treatment has been used to shrink intrathoracic nodes and relieve bronchial obstruction.

Pleural TB

- The pleural space is considered an extrapulmonary site for TB.
- Can be asymptomatic or presents with fever and pleuritic pain; TB empyema requires chest tube drainage.
- Diagnosis is made by analysis of pleural fluid and pleural biopsy.
- See Chapter 13 for a more in-depth discussion of TB pleuritis.

CNS TB

- In TB meningitis, characteristic lumbar puncture results include increased opening pressure, and lymphocytic predominance and elevated protein levels in the CSF.
- Acid-fast bacillus staining and culture is often negative, and the diagnosis generally is made by evidence of disease in another site along with characteristic CSF findings.
- There is reasonable evidence for the use of dexamethasone in TB meningitis and cerebral edema in both children and adults.

Spinal TB

- TB can spread to bones and joints; when it spreads to the spine, it is known as Pott disease; Figure 11-25 demonstrates severe kyphoscoliosis due to childhood TB affecting the spine.

Flash Card A12

Adenosine deaminase has been shown to have high sensitivity (except in HIV patients) but variable specificity in diagnosing TB pleural effusion



Figure 11-25. Childhood TB leading to spinal deformity, which will continue to cause problems as the child grows. (A, B) Increasing curvature as evidenced by X-ray findings despite an attempt at surgical correction. (C) Clinical photograph of the same child (note the surgical scar and significant kyphosis).
(Reproduced, with permission, from Jain AK, Dhammi IK, Jain S, Mishra P. Kyphosis in spinal tuberculosis—prevention and correction. *Indian J Orthop*. 2010; 44(2): 127–36. doi: 10.4103/0019-5413.61893. CC BY 2.0)

PNEUMONIA

COMMUNITY ACQUIRED PNEUMONIA (CAP)

There are about five cases of CAP per 1000 persons per year in the U.S.. The incidence increases with age. Annual all-cause mortality in CAP patients is up to 28%.

Microbiology

In 50% of cases, the etiologic organism responsible for CAP cannot be identified. In the remaining cases, a variety of causative organisms have been identified (Tables 11-8−10). The patient's clinical history can provide clues to the underlying etiology (Table 11-11).

Table 11-8. Organisms Associated with Community Acquired Pneumonia

Outpatient	Inpatient (Non-ICU)	Inpatient (ICU)
Streptococcus pneumoniae *Mycoplasma pneumoniae* *Haemophilus influenzae* *Chlamydophila pneumoniae* Respiratory viruses	Above organisms plus *Legionella* species Aspiration	*Streptococcus pneumoniae* *Staphylococcus aureus* *Legionella* species Gram-negative bacilli *H. influenza*

ICU, intensive care unit

Bacterial

Table 11-9. Typical Bacterial Causes of CAP

Organism	Details
S. pneumoniae	Most common cause (30–60%) of CAP Common etiology in post-influenza pneumonia Severe infections seen in those with functional or anatomic asplenia Vaccination reduces the risk of invasive pneumococcal disease
H. influenzae	At risk patients: Those with underlying lung disease (COPD, cystic fibrosis) Vaccination has decreased the incidence of disease but not for the nontypeable strains
S. aureus	Accounts for 2–5% of CAP More frequent after influenza CA-MRSA in the U.S. has been associated with severe necrotizing pneumonia that has a mortality rate between 29–60%; this may be mediated by the Panton–Valentine leukocidin gene
Gram-negative bacilli (excluding *H. influenzae*)	Generally uncommon, but may require ICU admission for CAP Common organisms: *Klebsiella, Pseudomonas, Enterobacter* species, *E. coli, Serratia* species, *Proteus* species, *Acinetobacter* species Risk factors: Probable aspiration and underlying lung disease

CAP, community acquired pneumonia; COPD, chronic obstructive pulmonary disease; CA-MRSA, community acquired methicillin-resistant *Staphylococcus aureus*; ICU, intensive care unit

Key Fact

Necrotizing/cavitary infiltrates or empyema should raise suspicion for *Staphylococcus aureus.*

Table 11-10. Atypical Organisms

Organism	Details
Mycoplasma pneumoniae	Most common of the atypicals Usually affects healthy individuals in their 20s–30s. Person-to-person transmission via respiratory droplets. Prodrome of upper respiratory tract infection followed by nonproductive cough and extrapulmonary symptoms such as low-grade fever, diarrhea, myalgia, arthralgia, and rash. Severe cases can result in thrombocytopenia, myocarditis, hemolytic anemia (due to cold agglutinins), and transaminitis. Gram stain is usually negative. Diagnosis can be made by culture, PCR, serology with IgM and IgG. CXR usually shows unilateral segmental infiltrate but can have patchy or bilateral interstitial infiltrates
Legionella species	Exposure to aerosols of contaminated water (cooling towers, showers, grocery store mist machines, whirlpool spas, water distribution systems) Cannot be detected by Gram stain Can be associated with high fever, rapid progression on radiographic studies, ICU care, transaminitis, renal failure, GI/neurologic abnormalities
Chlamydophila pneumoniae (formerly *Chlamydia pneumoniae*)	Minimally symptomatic but recovery may be slow (cough/malaise can last weeks to months) Associated with COPD or asthma exacerbations

PCR, polymerase chain reaction; Ig, immunoglobulin; CXR, chest x-ray; ICU, intensive care unit; GI, gastrointestinal; COPD, chronic obstructive pulmonary disease

Key Fact

Atypicals are responsible for 10–20% of cases of community acquired pneumonia and may even cause a coinfection with other typical organisms.

Table 11-11. Organisms Associated With Various Conditions

Condition	Commonly Encountered Pathogen(s)
Alcoholism	*Streptococcus pneumoniae,* oral anaerobes, *Klebsiella pneumoniae, Acinetobacter* species, *Mycobacterium tuberculosis*
COPD and/or smoking	*Haemophilus influenzae, Pseudomonas aeruginosa, Legionella species, Streptococcus pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae*
Aspiration	Gram-negative enteric pathogens, oral anaerobes
Lung abscess	CA-MRSA, oral anaerobes, endemic fungi, *Mycobacterium tuberculosis*, atypical mycobacteria
HIV infection (early)	*S. pneumoniae, H. influenzae, Mycobacterium tuberculosis*
HIV infection (late)	The pathogens listed for early infection plus *Pneumocystis jirovecii, Cryptococcus, Histoplasma, Aspergillus*, atypical mycobacteria
Recently on a cruise ship	*Legionella* species

Key Fact

Diagnostic yield of PCR > culture/antigen detection assays but may overestimate viruses being a cause of community acquired pneumonia since they can be present in the nasopharynx in healthy people.

Flash Card Q13

What causative organism is responsible for pneumonia associated with bat droppings? Birds? Rabbits? Farm animals?

Table 11-11. Organisms Associated With Various Conditions, continued

Condition	Commonly Encountered Pathogen(s)
Southwestern U.S.	*Coccidioides* species, hantavirus
Southeast and East Asia	*Burkholderia pseudomallei*, avian influenza, SARS
Influenza active in community	Influenza, *S. pneumoniae, Staphylococcus aureus, H. influenzae*
Unrelenting cough for weeks	*Bordetella pertussis*
Structural lung disease (e.g., bronchiectasis)	*Pseudomonas aeruginosa, Burkholderia cepacia, Staphylococcus aureus*
Endobronchial obstruction	Anaerobes, *S. pneumoniae, H. influenzae, Staphylococcus aureus*
In context of bioterrorism	*Bacillus anthracis* (anthrax), *Yersinia pestis* (plague), *Francisella tularensis* (tularemia)

COPD, chronic obstructive pulmonary disease; CA-MRSA, community acquired methicillin-resistant *Staphylococcus aureus*; SARS, severe acute respiratory syndrome

Key Fact

Agents such as *Legionella* species, mycobacterial TB, mycobacterial pneumonia, *C. pneumoniae* or *C. psittaci* are rarely ever colonizers and represent true disease. On the other hand, some organisms are virtually never pathogenic: *Candida* species, coagulase-negative *Staphylococcus aureus*, enterococci, gram-positive rods (except *Nocardia*), *H. parainfluenzae*.

Viral

- Influenza, RSVs:
  - The most common viral pathogens, but can be difficult to differentiate from bacterial pneumonia.
- Parainfluenza, adenovirus, RSV
  - Can cause fatal/severe pneumonia in patients who are immunocompromised, including stem cell and solid organ transplant recipients.
- Coronaviruses:
  - Responsible for severe acute respiratory syndrome (SARS) (travel to China, Hong Kong, Singapore; no cases reported since 2004) and Middle East Respiratory Syndrome (MERS) (recent travel to Arabian peninsula or neighboring countries).
- Hantavirus:
  - Can cause a severe respiratory illness. Associated with travel to southwestern U.S., causes an ARDS-like picture.
- Varicella pneumonia:
  - Most frequent complication of varicella infection in healthy adults; fatality rate 10–30%.

Flash Card A13

Bat droppings: *Histoplasma capsulatum*

Birds: *Chlamydophila psittaci* (if poultry, think avian influenza)

Rabbits: *Francisella tularensis*;

Farm animals: *Coxiella burnetii* (Q fever).

Diagnosis

CLINICAL FEATURES—Cough with or without sputum, dyspnea, fever or hypothermia, chest pain, chills. Extrapulmonary symptoms: headache, myalgia, and GI symptoms.

PHYSICAL EXAM—Tachypnea, rales, egophony, increased fremitus, and dullness to percussion.

> ***Key Fact***
>
> Elderly patients may present with confusion, failure to thrive, weakness, or delirium and frequently do not have fever.

Pneumonia within 48 hours of admission to hospital is considered CAP.

IMAGING—CXR showing air space consolidation with air bronchograms strongly suggests bacterial pneumonia. Interstitial infiltrates are not seen with usual bacterial pneumonias. Studies suggest that early CXRs lack sensitivity. In patients whose presentation is suggestive of pneumonia, it may be reasonable to start treatment and repeat imaging in 24–48 hours.

> ***Key Fact***
>
> Follow-up imaging after treatment may not show resolution for up to 12 weeks in certain patients.

LABORATORY TESTS

- Leukocytosis with a left shift; white blood cell count can be depressed in severe shock or normal in the elderly. Leukopenia portends a poor prognosis.
- Sputum cultures optional for outpatients with CAP since they do very well with empiric treatment.
- Per IDSA/ATS 2007 guidelines, investigation for specific pathogens should be done when such pathogens are suspected based on clinical and epidemiologic clues, and the results of such an investigation would change management (Table 11-12 for indications for extensive diagnostic testing).
- Routine serologic testing for *Legionella, Streptococcus pneumoniae*, and *C. pneumoniae* is not recommended.
- Blood cultures are positive in < 10% of patients but are recommended in those ill enough to be hospitalized. Most common isolate is S. pneumoniae.
- Procalcitonin (precursor of calcitonin) is elevated in bacterial infections but decreased in viral infections; a low level (< 0.1 μg) favors a decision to avoid or stop antibiotics; use as an adjunct to clinical judgment.
- Bronchoscopy (BAL, brushing, washing, protected specimen brushing) usually not done unless the pneumonia is severe, or refractory to antibiotic therapy.

> ***Key Fact***
>
> Sputum gram stains represent lower respiratory tract secretions when PMNs > 25 and epithelial cells < 10/lpf.

Table 11-12. Clinical Indications for More Extensive Diagnostic Testing

Indication	Laboratory Test(s)
ICU admission	Blood culture, sputum culture, Legionella UAT, pneumococcal UAT, other[a]
Failure of outpatient antibiotic therapy	Sputum culture, Legionella UAT, pneumococcal UAT
Cavitary infiltrates	Blood culture, sputum culture, other[b]
Leukopenia	Blood culture, pneumococcal UAT
Active alcohol abuse	Blood culture, sputum culture, Legionella UAT, pneumococcal UAT,
Chronic severe liver disease	Blood culture, pneumococcal UAT
Severe obstructive/ structural lung disease	Sputum culture
Asplenia (anatomic or functional)	Blood culture, pneumococcal UAT
Recent travel (within past 2 weeks)	Legionella UAT, other (Table 11-11)
Positive *Legionella* UAT result	Sputum culture[c]
Positive pneumococcal UAT result	Blood culture, sputum culture
Pleural effusion	Blood culture, sputum culture, *Legionella* UAT, pneumococcal UAT, thoracentesis, and pleural fluid cultures

ICU, intensive care unit; UAT, urinary antigen test.
[a]Endotracheal aspirate if intubated, possibly bronchoscopy or nonbronchoscopic BAL
[b] Fungal and TB cultures.
[c]Special medium for *Legionella*

Severity

Many classification systems exist, two of which are shown in Table 11-13. Objective scores should not be used as the sole determinant for hospitalization. Reasons to admit low risk patients: complications of pneumonia, exacerbation of underlying diseases, inability to take oral medications.

IDSA/ATS guidelines recommend direct admission to ICU when 3 minor criteria or 1 major criterion for severe CAP are met (Table 11-14).

Table 11-13. Classification of Severity in Community Acquired Pneumonia

System	Scoring	Interpretation
Pneumonia severity index[a]	Points given based on age, medical conditions (cancer, heart failure, cerebrovascular disease, renal disease, liver disease), physical exam findings (altered mental status, tachycardia, tachypnea, hypotension, hypo- or hyperthermia) and laboratory/radiographic findings.	Points tallied to determine class; 30-day mortality in classes I–III (0.1–0.9%) and IV and V (9.3% and 27%, respectively)
CURB-65 severity score[b]	Confusion, urea > 7, RR > 30, SBP < 90 mm Hg or DBP < 60 mm Hg, age > 65	30-day mortality rate: 0.7% for 0 factors, 2.1% for 1 factor, 9.2% for 2 factors, 14.5% for 3 factors, 40% for 4 factors, and 57% for 5 factors

DBP, diastolic blood pressure; RR, respiratory rate; SBP, systolic blood pressure.
[a]On the basis of mortality rates, classes I and II should be treated as out-patients, class III should have a short observational stay, classes IV and V should be admitted; highly sensitive, well-validated, widely endorsed but cumbersome to use.
[b]Patients with 0–1 factors can be out-patients, those with 2 factors usually warrant hospitalization, and those with 3–5 factors should be assessed for admission to the intensive care unit. Not as extensively studied as the pneumonia severity index, but easier to use; unclear which is superior.

Table 11-14. Criteria for Severe CAP

Minor Criteria[a]	Major Criteria
Tachypnea[b] ≥ 30 breaths/min	Invasive mechanical ventilation
Multilobar infiltrates	Septic shock with the need for vasopressors
Confusion/disorientation	
Uremia (BUN level, ≥ 20 mg/dL)	
Leukopenia[c] (WBC count, < 4000 cells/mm^3)	
Thrombocytopenia (platelet count, < 100,000 cells/mm^3)	
Hypothermia (core temperature, < 36°C)	
Hypotension requiring aggressive fluid resuscitation	

BUN, blood urea nitrogen; CAP, community acquired pneumonia; WBC, white blood cell.
[a]Other criteria to consider include hypoglycemia (in nondiabetic patients). Acute alcoholism/alcoholic withdrawal, hyponatremia, unexplained metabolic acidosis or elevated lactate level, cirrhosis, and asplenia.
[b]A need for noninvasive ventilation can substitute for a respiratory rate > 30 breaths/min or a PAO_2:FiO_2 ratio < 250
[c]As a result of infection alone

Treatment

The appropriate treatment regimen depends on the severity of the disease and the suspicion for particular pathogens (Table 11-15).

Table 11-15. Treatment of Community Acquired Pneumonia

Scenario	Antibiotics	Comments
Outpatient	Macrolide (azithromycin, clarithromycin) **or** doxycycline Alternative: Anti-PNM FQ If risk factors for drug resistance: FQ or anti-PNM BL (high-dose amoxicillin, amoxicillin–clavulanate, cefpodoxime) + macrolide	May need to reserve FQ to prevent FQ-resistant strains. If at risk for *Mycobacterium tuberculosis*, avoid FQ until it has been ruled out. FQ use in out-patients is discouraged unless patients have risk factors for drug resistance or are in a community known to have macrolide-resistant pneumococcus Duration: Minimum of 5 days
Inpatient, non-ICU	FQ (IV or oral) alone **or** Anti-PNM BL (cefotaxime, ceftriaxone, ampicillin–sulbactam) + macrolide If concern for CA-MRSA, add vancomycin or linezolid If structural lung disease, cover PSD	If PCN allergy, use FQ or substitute aztreonam for the β -lactam Doxycycline can be used instead of a macrolide Duration: 5–7 days for typical organisms, 10–14 days for atypical except *Legionella* (21 days); convert to oral from IV therapy when patient improving clinically.
Inpatient, ICU	IV BL (piperacillin–tazobactam, imipenem, meropenem, cefepime) + either an FQ (IV or oral) or a macrolide If concern for CA-MRSA, add vancomycin or linezolid If suspecting PSD or resistant pathogens: BL above plus anti-PSD FQ **or** BL + AG + azithromycin **or** BL + AG + anti-PNM FQ	When covering PSD, use combination treatment to prevent inappropriate initial therapy; adjust therapy once susceptibilities are known. Duration: As above but longer if extrapulmonary infection (meningitis, endocarditis), initial therapy inactive against pathogen identified later, if infected by PSD, *Staphylococcus aureus, Legionella*, unusual/less common pathogens, or if evidence of necrotizing pneumonia, empyema, or lung abscess

AG, aminoglycoside; BL, β-lactam; CA-MRSA, community acquired methicillin-resistant *Staphylococcus aureus*; FQ, fluoroquinolone; IV, intravenous; PNM, pneumococcal; PSD, pseudomonal or *Pseudomonas*; anti-pneumococcal FQ, levofloxacin, moxifloxacin, and gemifloxacin; anti-pseudomonal FQ, ciprofloxacin (400 mg IV every 8 hours or 750 mg by mouth daily) or levofloxacin (750 mg IV by mouth daily)

Key Fact

Both macrolides and fluoroquinolones can cause prolonged QT_c. Use doxycycline instead (unless patient is pregnant).

Risk factors for drug resistant pathogens:

- Age > 65
- Alcoholism
- Significant medical comorbidities (COPD, liver/kidney diseases, cancer, DM, chronic heart disease, immunosuppression)
- Recent (3–6 months) history of β-lactam, macrolide, or FQ use

ASPIRATION PNEUMONIA—Per IDSA/ATS guidelines, anaerobic coverage is indicated in those with a history of loss of consciousness from alcohol/drug overdose or after seizures in people with gingival disease or esophageal motility disorders.

- β-lactam/β-lactamase inhibitor
- Penicillin plus metronidazole (50% failure rate with monotherapy)
- Clindamycin

REFRACTORY PNEUMONIA—Some clinical improvement generally is seen within 48–72 hours of initiating antibiotic therapy; if no improvement within 72 hours, the patient is considered to be a nonresponder (6–15% of hospitalized patients). The median defervescence time is 3 days. Other symptoms may take up to a month to resolve, especially when age > 50 years, severe pneumonia, and comorbid conditions present. Antibiotic changes prior to 72 hours should be considered in only patients who are deteriorating or have new culture data/epidemiologic history.

CAUSES OF TREATMENT FAILURE

- Inadequate or delayed host response.
- Ineffective antibiotic coverage (TB, fungi, *Nocardia, Actinomyces,* resistant pathogens).
- Complications of initial infection: Consider chest CT and thoracentesis to evaluate for effusions, abscess, airway obstruction, and empyema.

Key Fact

20% of nonresolving pneumonia cases are due to noninfectious causes (neoplasm, vasculitis, Bronchiolitis obliterans organizing pneumonia/ cryptogenic organizing pneumonia, eosinophilic pneumonias, drug-induced lung disease, and pulmonary edema/ embolism). In such cases, bronchoscopy with biopsy is useful, especially in young, nonsmokers with diffuse parenchymal involvement.

Prevention

PNEUMOCOCCAL VACCINE—PPSV23 is a capsular polysaccharide from 23 serotypes responsible for 90% of invasive pneumococcal infections; shown to prevent invasive pneumococcal disease.

- Cost-effective in those > 65 years of age in preventing bacteremia
- Who should be vaccinated
  - All immunocompetent patients age > 65
  - Age < 65 and with any of the following: COPD, CHF, DM, alcoholism, cirrhosis, CSF leaks, asplenia, those living in long-term care facilities

Flash Card Q14

What is an appropriate antibiotic regimen for a patient with a prolonged QT and risk factors for drug resistance?

- Efficacy in immunosuppressed unknown but still recommended in: HIV, leukemia/lymphoma, multiple myeloma, organ transplantation, chronic steroid use
- Can be given simultaneously with other vaccines but at a separate site
- Revaccinate once if over age 65 and received the initial vaccine > 5 years prior

PCV13is a pneumococcal protein conjugate polysaccharide vaccine; 39–55% of cases in 2009 were caused by PCV13 serotypes.

- Stimulates good antibody response, mucosal immunity, herd protection and immunologic memory in children and adults
- Vaccination in children has shown to decrease invasive disease in both adult and children
- Not yet recommended for use in healthy adults due to lack of efficacy however some data seem to suggest benefit in immunocompromised patients
- The following patients should receive sequential vaccination with both PCV13 and PPSV23
  - With congenital or acquired immunodeficiency
  - With HIV
  - With chronic renal failure
  - With nephrotic syndrome
  - With leukemia/lymphoma, multiple myeloma, generalized malignancy
  - Solid organ transplant recipients
  - Those who use immunosuppressants

INFLUENZA VACCINE—Influenza infection can result in secondary bacterial pneumonia, commonly by S pneumoniae.

Who should be vaccinated

- Recommended for everyone > 6 months of age
- Particularly important in high-risk groups
  - Persons with increased risk of complications
    - Age > 65
    - Residents of nursing homes or long-term care facilities
    - Those with chronic diseases such as DM, chronic kidney disease, immunosuppression, hemoglobinopathy
  - Persons 50–64 years of age
  - Those who can transmit influenza to those at high risk
    - Health care workers
    - Employees of home health care, nursing homes, long-term care or assisted-living facilities
    - Household members of patients at high risk

Flash Card A14

Monotherapy with a macrolide is NOT recommended due to concern for macrolide-resistant S. pneumoniae. Doxycycline plus β-lactam is a good choice.

NOSOCOMIAL PNEUMONIA

Hospital-acquired pneumonia (HAP): Occurs > 48 hours after admission and not present at the time of admission.

Ventilator-associated pneumonia (VAP): HAP that occurs > 48–72 hours after endotracheal intubation.

Health care–associated pneumonia (HCAP):
- Nonhospitalized patients exposed to a health care setting (home IV therapy, wound care, IV chemotherapy in the past 30 days
- Resident of nursing home or long-term care facility
- Recent hospitalization for 2 or more days in the last 90 days
- Hemodialysis clinic in the past 30 days

Primary route of infection is through microaspiration of colonized organisms of the oropharyngeal or GI tract.

Microbiology

Common pathogens are aerobic gram-negative bacilli (*E. coli, Klebsiella, Enterobacte*r, *Pseudomonas aeruginosa* [PSDA], *Acinetobacter*) and gram-positive cocci *(Staphylococcus, Streptococcus*).

Key Fact

Staphylococcus epidermidis, enterococci, most gram-positive bacilli (except *Actinomyces* and *Nocardia*) are not pathogenic.

Etiology also dependent on risk factors for multidrug-resistance:
- Recent antibiotics within last 90 days
- Current hospitalization of 5 days or more
- High frequency of antibiotic resistance in the community or hospital unit
- Immunosuppression
- Risk factors for HCAP (see above), although some studies report that it may be an overgeneralization to consider all HCAP patients to be at risk for MDR pathogens

Diagnosis

New/progressive infiltrate on imaging plus two of the following: fever, purulent sputum, leukocytosis/leukopenia, or increased oxygen requirements.

Differential diagnoses include aspiration pneumonitis, pulmonary infarction, ARDS, pulmonary hemorrhage/contusion, infiltrative tumor, radiation pneumonitis, pulmonary drug toxicity and cryptogenic organizing pneumonia.

Obtain blood cultures, and thoracentesis, if possible.

Obtain lower respiratory tract samples via tracheobronchial aspiration through endotracheal tube or bronchoscopically via BAL or protected specimen brush (PSB).

Quantitative culture is significant if the value exceeds 1,000,000 colony forming units (CFU)/mL for tracheobronchial aspiration, 10,000 CFU/mL for BAL, or 1000 CFU/mL for samples obtained by PSB. Consider lower thresholds if risk of missing a VAP exceeds risk of unnecessary treatment.

Treatment

Key Fact

Daptomycin does not achieve high concentrations in the lung.

Key Fact

Ceftaroline is approved by FDA for community acquired pneumonia but not if caused by MRSA; not to be used for hospital-acquired pneumonia/ventilator-associated pneumonia/HCAP.

Key Fact

Tigecycline has activity against MRSA but is associated with an increased risk of death, therefore do not use unless other agents are not suitable.

Initial treatment regimen should be selected based on the risk of drug-resistant pathogens (Table 11-16). It can then be tailored when susceptibility data becomes available. If Staphylococcus aureus or gram-negative bacilli (grow easily in culture) are not isolated from good quality sputum specimen, stop coverage for these organisms.

Duration: Generally 7 days, but up to 15 days if pseudomonas is cultured and up to 21 days if MRSA is cultured. Duration can be extended based on clinical course and extent of infection.

Table 11-16. Treatment of Nosocomial Pneumonia

Scenario	Antibiotics	Notes
No known MDR risk factors	Ceftriaxone 2 g IV daily; or ampicillin–sulbactam 3 g IV q6h; or levofloxacin 750 mg IV daily; or moxifloxacin 400 mg IV daily;. or ertapenem 1 g IV daily	If concern for resistant GNB based on institutional data, can start piperacillin–tazobactam, cefepime, or anti-PSD carbapenem as monotherapy
Known MDR risk factors	Cefepime (2 g q8h) or ceftazidime (2 g q8h), **or** Imipenem, meropenem, or doripenem, **or** Piperacillin–tazobactam **AND** Anti-PSD FQ, **or** AG, **or** Colistin **AND** if suspecting MRSA: Linezolid (600 mg q12h IV or oral), **or** Vancomycin (15–20 mg/kg IV q8-12h with target trough 15–20 mg/L)	No conclusive evidence to support combination therapy for gram-negative pathogens such as PSD but commonly done since MDR pathogens that may be resistant to one antibiotic may be susceptible to the other Anti-PSD FQ is preferred if Legionella is likely AG can be stopped in 5–7 days in those who respond Colistin may be appropriate if highly resistant PSD species, *Acinetobacter* species, Enterobacteriaceae family are suspected or established

AG, aminoglycoside (gentamicin, tobramycin, amikacin); anti-PSD FQ, anti-pseudomonal fluoroquinolone, ciprofloxacin (400 mg IV every 8 h or 750 mg PO BID) or levofloxacin (750 mg IV PO daily)FQ, fluoroquinolone; IV, intravenous(ly); GNB, gram-negative bacilli; MDR, multidrug resistance; PSD, pseudomonal or *Pseudomonas*.

Prevention

Hydrogen blockers/proton pump inhibitors are associated with increased risk of HAP. The IDSA recommends avoiding them in patients who are not at high risk for developing stress ulcer or stress gastritis.

The following interventions may reduce the incidence of VAP but have not been shown to change patient outcomes.

- Digestive tract decontamination with oral antiseptics such as chlorhexidine
- Positioning patients in a semirecumbent position with the head of the bed at ≥ 30 degrees
- Silver-coated endotracheal tubes

NTM

Epidemiology

More than 140 NTM have been identified, at least 40 of which are associated with human lung infection. It is difficult to determine the epidemiology of NTM, as reporting is not mandatory, but it appears that the incidence and prevalence are increasing.

Transmission

NTM is ubiquitous in the environment and can be found in natural and drinking water, biofilms, soil, and aerosols. Human-to-human transmission has never been documented. Risk factors for disease include impaired host immunity, impaired lung immunity, and host demographics.

Clinical Presentation

NTM pulmonary disease can present in diverse ways including

- TB-like cavitary disease
- Bronchiectasis
- Hypersensitivity-like lung disease
- Esophageal dysmotility

NTM in AIDS most commonly causes disseminated disease that presents with nonspecific symptoms such as fever, night sweats, diarrhea, abdominal pain, and

Flash Card Q15

What antibiotic can be used to treat nosocomial pneumonia in a patient with a penicillin and/or a cephalosporin allergy?

Flash Card Q16

Describe Lady Windermere syndrome.

lymphadenopathy. In such patients, *Mycobacterium avium* complex (MAC) is the most frequent isolate.

Diagnosis

Clinical, radiographic, and microbiologic criteria must be met to make a diagnosis of NTM infection. Clinical criteria include pulmonary symptoms and exclusion of other diagnoses, and radiographic criteria include nodular or cavitary opacities on chest radiograph or bronchiectasis with small nodules on chest CT. The microbiologic criteria are summarized in Table 11-17.

Table 11-17. Microbiologic Criteria for Diagnosis of NTM Lung Disease

At least 3 sputum results available	2 positive culture results regardless of the results of AFB smear
Single available bronchial wash or lavage	1 positive culture regardless of the results of the AFB smear
Tissue biopsy	Compatible histopathology and a positive biopsy culture ; compatible histopathology and a positive sputum or bronchial wash culture for NTM

AFB, acid-fast bacillus; NTM, nontuberculous *Mycobacterium*/mycobacteria

DIFFERENTIAL DIAGNOSIS—Clinical manifestations of NTM infection include lymphadenitis, and disseminated, skin, soft tissue, and bone diseases. The most important differential is TB lymphadenitis.

Flash Card A15

Aztreonam; if the patient had a severe allergic reaction to ceftazidime in the past, then cross-reactivity is variable, and aztreonam should not be given until the patient is evaluated by an allergy specialist

SLOWLY GROWING *Mycobacterium*

NTM species generally are categorized as slowly growing or rapidly growing organisms. Slowly growing NTM that cause human disease include MAC, *Mycobacterium kansasii*, and *Mycobacterium xenopi*.

Flash Card A16

Thin, postmenopausal women with NTM disease; often associated with right middle lobe and lingular bronchiectasis

MAC

There are three manifestations of pulmonary disease due to MAC—nodular/bronchiectatic disease, cavitary disease, and advanced or previously treated disease.

Recommended duration of treatment is 12 months after documented sputum culture negativity; treatment involves a macrolide, ethambutol, and rifamycins.

Preventive therapy for MAC is recommended for all HIV patients with CD4+ < 50; azithromycin 1200 mg weekly is the preferred agent.

Mycobacterium kansasii

Tap water is the major reservoir, and there is no recommended prophylaxis for disseminated disease.

Recommended regimen for treating pulmonary *M. kansasii* disease is three agents for 12 months of negative sputum cultures: rifampin (600 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).

Mycobacterium xenopi

- Survives in hot water systems and natural hot water reservoirs
- Rarely isolated in the U.S., but often isolated in Canada, United Kingdom, and Europe
- Overall mortality is high
- A number of accepted treatment regimens include clarithromycin, rifampin, and ethambutol ± isoniazid for 12 months

RAPIDLY GROWING *Mycobacterium*

Mycobacterium abscessus

Fulminant, rapidly progressive form of the disease has been seen in patients with gastroesophageal disorders and cystic fibrosis.

- Typically resistant to most of the medications used to treat TB, and therapy usually consists of IV agents such as imipenem or cefoxitin plus amikacin

Key Fact

Mycobacterium abscessus infection in patients with cystic fibrosis who have undergone lung transplantation has been associated with severe and sometimes fatal disease.

Therapy should be continued for at least 2–4 months, although cure with medical therapy alone may be difficult to achieve

PREVENTION OF NTM DISEASE

NTM is ubiquitous in the environment, so complete avoidance is difficult. Transmission of NTM disease in the health care setting has most frequently been linked to tap water exposure. Therefore, it is recommended that tap water not be used in various nosocomial settings. Potent disinfectants have been unsuccessful in eradicating these organisms.

Prophylaxis should be given to adults with AIDS with CD4 counts < 50; azithromycin and clarithromycin have proven efficacy.

12 Lung Neoplasms

Sujith V Cherian MD & Fayez Kheir, MD, MSCR

INTRODUCTION

Lung neoplasms can be classified as benign or malignant. Lung cancer remains the most common cause of cancer-related death in the United States among both men and women. Benign lung tumors are < 5% of all resected lung neoplasms. Most benign lung tumors present as asymptomatic solitary pulmonary nodules, incidentally discovered radiographically. About 50% of benign lung neoplasms are hamartomas.

BENIGN LUNG NEOPLASMS

Benign lung tumors are broadly divided into epithelial and nonepithelial tumors.

EPITHELIAL NEOPLASMS

Types include:
- Papilloma
- Micronodular pneumocyte hyperplasia

Papillomas

SQUAMOUS PAPILLOMA—Most often associated with cigarette smoking and human papilloma virus. Most occur in central large airways.

RECURRENT RESPIRATORY PAPILLOMATOSIS—Also known as juvenile laryngotracheal papillomatosis.

- Associated with human papilloma virus types 11 and 6.
- Surgical excision and laser ablation are the mainstays of treatment.
- Lung involvement occurs in 3% of patients and generally has an aggressive course, with no effective medical therapy.
- Squamous cell carcinoma is the most feared complication and may appear as cavitating nodules or masses (Figures 12-1 and 12-2).

Figure 12-1. Image showing tracheal papillomatosis.
(Reproduced, with permission, from Martin RT, Miller AN. Squamous cell carcinoma arising in recurrent respiratory papillomatosis. *A83. Great Cases: Clinical, Radiologic and Pathologic Correlations by Master Physicians*, 2011; 83: 6466, Fig. 2. DOI: 10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A646610.)



Figure 12-2. (A)Chest computed tomography scan showing presence of cavitary infiltrates in the right lung field, and (B,C) positron emission tomography (PET) scans showing increased fluorodeoxyglucose (FDG) avidity that was diagnosed as squamous cell carcinoma.
(Reproduced, with permission, from Martin RT, Miller AN. Squamous cell carcinoma arising in recurrent respiratory papillomatosis. *A83. Great Cases: Clinical, Radiologic and Pathologic Correlations by Master Physicians*, 2011; 83: 6466. DOI: 10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A646610.)

Micronodular Pneumocyte Hyperplasia

- Characterized by numerous small, well-demarcated parenchymal nodules.
- Classically associated with tuberous sclerosis and/or lymphangioleiomyomatosis.
- Histopathology shows hyperplastic type II pneumocytes.
- Findings are not progressive, so no treatment is indicated.

NONEPITHELIAL NEOPLASMS

Types include:
- Hamartomas
- Solitary fibrous tumors

Hamartomas

- Most common benign lung neoplasm in adults
- More common in men
- Generally discovered incidentally in the sixth or seventh decade
- Parenchymal or endobronchial (10%) nodules with characteristic popcorn calcification (Figure 12-3). Figure 12-4 and 5 demonstrate solitary pulmonary nodules.
- Typically mature hyaline cartilage with fat, fibromyxoid tissue, and/or smooth muscle cells



Figure 12-3. Lung hamartoma with popcorn calcification.
(Reproduced, with permission, from Khan, et al. The calcified lung nodule: What does it mean? *Ann Thorac Med.* 2010; 5: 67-79.)

Flash Card Q1

A 23-year-old man presents with cavitary lung nodules and a vocal polyp. He has a history of hoarseness as a child. What is the diagnosis?



Figure 12-4. Chest x-ray showing a solitary pulmonary nodule (*black box*) in the left upper lobe.
(Reproduced from Wikimedia Commons under the Creative Commons Attribution-Share Alike 3.0 Unported license.)



Figure 12-5. Chest CT scan showing a solitary pulmonary nodule (*arrow*).
(Reproduced from Wikimedia Commons under the Creative Commons Attribution-Share Alike 3.0 Unported license.)

Flash Card A1

Recurrent respiratory papillomatosis with lung involvement, most likely squamous cell cancer

Solitary Fibrous Tumors

- These rare, spindle cell tumors are also referred to as *localized fibrous mesotheliomas*.
- Generally arise from the visceral (most common) or parietal pleura.
- Mean age at diagnosis is the sixth decade.
- Men and women are affected equally.

Key Fact

Hamartomas are the most common benign neoplasms in adults and are generally solitary nodules. Computed tomography scans show a characteristic combination of calcifications and/or fat.

MALIGNANT LUNG NEOPLASMS

Lung cancer is the third most common cancer in the United States (excluding non-melanoma skin cancers). Although breast and prostate cancer are more frequently diagnosed, lung cancer is the most common cause of cancer-related death in both genders.

Predominant types include:

- Non-small cell lung cancer (NSCLC)
- Small cell lung cancer (SCLC)
- Primary pulmonary lymphoma

NON-SMALL CELL LUNG CANCER

NSCLC is the most common form of lung cancer and is divided into the following types:

- Squamous cell carcinoma
- Adenocarcinoma
- Large cell carcinoma
- Carcinoid tumors

Squamous Cell Carcinoma

Squamous cell carcinoma is a malignant epithelial tumor with keratinization and/or intercellular bridges on histopathology (Figure 12-6). Keratinization is most often in the form of squamous pearls.



Figure 12-6. Histopathologic specimen of squamous cell carcinoma of the lung with intercellular bridges *(arrow)*.
(Reproduced courtesy of Yale Rosen, flickr.com, CC BY-SA 2.0.)

- Strongly associated with cigarette smoking (Figure 12-7).
- Occurs predominantly in men.
- Two thirds of cases occur centrally, with involvement of the main stem, lobar, or segmental bronchi.
- Compared with other histologic subtypes, it is more commonly associated with cavitation, Pancoast syndrome, and hypercalcemia.
- Immunohistochemistry: Usually stains positive for p63, cytokeratin 5/6.



Figure 12-7. Incidence of types of lung cancer in smokers and nonsmokers.

Adenocarcinoma

Adenocarcinoma is the most frequently diagnosed histologic type of lung cancer. It is the most common subtype in women and nonsmokers. Most tumors occur in the periphery. Positive immunohistochemical stains include thyroid transcription factor-1, napsin A, and cytokeratin 7.

Common subtypes:

- Acinar: Cuboidal/columnar cells that form acini and tubules (Figure 12-8)
- Papillary: Malignant cells are arranged on the surface of fibrovascular cores.
- Bronchioalveolar carcinoma, now known as *adenocarcinoma in situ*: Characterized by slow lepidic growth
- Solid with mucin production
- Mixed subtype



Figure 12-8. Histopathologic specimen of lung adenocarcinoma showing an acinar pattern.
(Reproduced courtesy of Yale Rosen, flickr.com, CC BY-SA 2.0.)

BRONCHIOLOALVEOLAR CARCINOMA (BAC)—BAC grows in a uniform manner along alveolar walls without evidence of stromal, vascular, or pleural invasion (Figure 12-9). These very slow-growing neoplasms have a 100% 5-year survival rate if the lesion is < 2 cm at the time of resection. They can present radiographically as ground-glass opacities, with or without a solid component, or as diffuse disease (Figure 12-10). Diffuse disease is associated with worse survival.



Figure 12-9. Hematoxylin-eosin-stained lung biopsy specimen showing extensive mucin production.
(Figure reproduced from Wikimedia Commons under the Creative Commons Attribution-Share Alike 3.0 Unported license.)



Figure 12-10. Chest CT scan showing ground-glass opacity, which was shown on biopsy to be bronchioalveolar carcinoma.
(Reproduced courtesy of Wikimedia Commons under the Creative Commons Attribution-Share Alike 3.0 Unported license.)

Large Cell Carcinoma

Undifferentiated malignant epithelial tumors that lack features of small cell carcinoma and glandular or squamous differentiation. They are characterized by large nuclei, prominent nucleoli, and a moderate amount of cytoplasm.

Carcinoid Tumors

Pulmonary carcinoid tumors represent about 1–5% of all lung malignancies. They are mainly of two types, typical and atypical:

- Typical carcinoid: < 2 mitoses per 10 high-power fields and absence of necrosis (Figure 12-11)
- Atypical carcinoid: > 2 mitoses per 10 high-power fields or presence of necrosis

CLINICAL FEATURES

- Usually occur in those who have never smoked.
- About 70% of carcinoids develop in the proximal airways and may be associated with chronic cough, hemoptysis, and bronchial obstruction.
- Peripheral carcinoids are generally asymptomatic.
- Fewer than 2% of cases are associated with carcinoid syndrome.
- Low to moderate activity is seen on PET scan.



Figure 12-11. Histopathologic specimen of lung carcinoid with cells arranged in a trabecular pattern.
((Reproduced courtesy of Yale Rosen, flikr.com, CC BY-SA 2.0.)

TREATMENT—Treatment of carcinoid tumors is different from that of other types of NSCLC:

- Typical carcinoid: Limited resection with segmentectomy and regional lymph node dissection
- Atypical carcinoid: Lobectomy and mediastinal lymph node dissection
- Metastasis: No known benefit to chemotherapy or radiation therapy. Local treatment of metastases may lead to prolonged remission.

Staging of NSCLC

Perhaps the most critical role of the pulmonologist in the management of lung cancer is the diagnostic and staging evaluation of lung cancer. The lung cancer staging system is relatively complex, but accurate staging helps the clinician to estimate prognosis, define the extent of tumor, select treatment options, and report outcomes (Table 12-1).

Five-year survival rates based on the current staging system:

- Stage IA: 73%
- Stage IB: 58%
- Stage IIA: 46%
- Stage IIB: 36%
- Stage IIIA: 24%
- Stage IIIB: 9%
- Stage IV: 13%

Table 12 -1. American Joint Committee on Cancer Staging System for Lung Cancer

Stage	Tumor	Lymph Node	Metastases
IA	T1a or T1b	N0	M0
IB	T2a	N0	M0
IIA	T1a or T1b or T2a	N1	M0
	T2b	N0	M0
IIB	T2b	N1	M0
	T3	N0	M0
IIIA	Any T between T1a and T2b	N2	M0
	T3	N1 or N2	M0
	T4	N0 or N1	M0
IIIB	T4	N2	M0
	Any T between T1a and T4	N3	M0
IV	Any T	Any N	M1a or b

Table 12 -1. American Joint Committee on Cancer Staging System for Lung Cancer, continued

TNM Definitions

T	TX	Positive malignant cell, but primary tumor not visualized by imaging or bronchoscopy
	T0	No evidence of primary tumor
	Tis	Carcinoma in situ
	T1	Tumor ≤ 3 cm, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus T1a- ≤ 2 cm T1b- > 2 cm, but < 3 cm
	T2	Tumor with any of the following features of size or extent: • > 3 cm in greatest dimension, but > 7 cm • Involves main bronchus, ≥ 2 cm distal to the carina • Invades the visceral pleura • Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung T2a- > 3 cm, but < 5 cm T2b- > 5 cm, but < 7 cm
	T3	Tumor of any size that directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus < 2 cm distal to the carina, but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung, or separate tumor nodules in the same lobe
	T4	Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina; or with separate tumor nodule(s) in a different ipsilateral lobe of the lung
N	NX	Regional lymph nodes cannot be assessed
	N0	No regional lymph node metastasis
	N1	Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes involved by direct extension of the primary tumor
	N2	Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s)
	N3	Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)
M	MX	Presence of distant metastasis cannot be assessed
	M0	No distant metastasis
	M1 a M1 b	Contralateral lung nodules, pleural or pericardial nodules, or malignant pleural or pericardial effusion Distant metastasis

Staging of NSCLC

Overall 5-year survival rate is a dismal 14%. Survival curves vary by stage at diagnosis, with early-stage disease associated with much better survival. In general, early-stage disease is surgically managed, locally advanced disease is managed with chemotherapy and radiation therapy, and advanced disease is managed with chemotherapy and supportive care.

PROGNOSTIC FACTORS

- Strongest predictors of survival:
  - Good performance status (Karnofsky scale)
  - Lesser extent of disease
  - Younger age
  - Absence of weight loss
- Other predictors of better survival:
  - Smoking cessation
  - Standard uptake value of the primary tumor on positron emission tomography (PET) scan
- Histologic subtype not considered a predictor of survival.

TREATMENT BY STAGE OF DISEASE

Stage I and II:

- Surgery is first-line treatment. There is no role for chemotherapy or postoperative radiation therapy in stage IA disease. Adjuvant chemotherapy may be useful in selected cases of stage IB disease, especially if the tumor is > 4 cm.
- Stage II disease is treated with surgery followed by adjuvant chemotherapy. Lobectomy is preferred. Sublobar resection is reserved for tumors < 3 cm and patients with severely compromised pulmonary function, advanced age, or extensive comorbidity.
- Radiation therapy is reserved for patients who are poor surgical candidates and those with positive surgical resection margins.

Stage IIIA:

- Most cases are unresectable. Chemotherapy and/or radiation therapy may be used. Some tumors are only definitively staged as IIIA during resection. In these cases, surgery proceeds and is generally followed by adjuvant chemotherapy.

Stage IIIB:

- Combined chemotherapy and radiation therapy is used.

Stage IV:

- Chemotherapy
- Radiation therapy for palliation only

Post-therapy surveillance:

- Follow-up in clinic with chest computed tomography (CT) scans every 4–6 months for the first 2 years and annually thereafter.

CHEMOTHERAPY REGIMENS—Somatic genomic alterations known as *driver mutations* occur in cancer cells that encode for proteins critical to cell growth and survival. Targeted therapy involves agents that target these specific molecular pathways.

If driver mutation is present:

- Epidermal growth factor receptor mutation: Treatment with a single-agent epidermal growth factor receptor tyrosine kinase inhibitor (erlotinib, getinib, afatinib) can be used for initial management. These agents improve progression-free survival compared with traditional chemotherapy. This mutation is most common in female patients of East Asian decent with adenocarcinoma and no history of smoking.
- ALK mutation: Crizotinib is first-line therapy in ALK-positive cases.

SPECIAL CONSIDERATIONS

- *S*uperior sulcus tumor with Pancoast syndrome: Pancoast syndrome is a constellation of symptoms and signs that include shoulder and arm pain along the distribution of the C8, T1, and T2; Horner's syndrome; and weakness and atrophy of the hand. It is seen in one third of patients with superior sulcus tumors. Because of its location, transthoracic need aspiration is diagnostic in > 90% of cases. If the disease is localized, this is one exception where the treatment starts with neoadjuvant chemotherapy and radiation therapy followed by resection.
- Superior vena cava syndrome: Superior vena cava syndrome is usually the result of direct obstruction of the superior vena cava by malignancies. Bronchogenic carcinoma is the most common cause. It is not a medical emergency, and a diagnosis should be obtained before treatment is provided. Bronchoscopy or mediastinoscopy can be safely performed.

Treatment:

- Secondary to SCC: Chemotherapy
- Secondary to NSCLC: Concurrent chemotherapy and radiation therapy

SMALL CELL LUNG CANCER

SCLC is characterized by proliferation of small cells with scant cytoplasm, ill-defined borders, salt and pepper chromatin, frequent nuclear molding, and a high

mitotic count (Figure 12-12). Staining is usually positive for thyroid transcription factor-1,CD 56, synaptophysin, and chromogranin.

Up to 98% of patients with SCLC have a history of smoking. The natural history of SCLC is early metastasis and death. Unlike NSCLC, SCLC is always considered a systemic disease at diagnosis. Liver, bone, bone marrow, and the central nervous system are the most commonly affected extrapulmonary organs.

SCLC shows an excellent response to chemotherapy, but almost always recurs. Median survival for disease confined to the chest is 4–6 months without treatment. For metastatic disease, median survival is 5–9 weeks without treatment.



Figure 12-12. Histopathologic specimen of small cell carcinoma of the lung.
(Reproduced courtesy of Wikimedia Commons under the Creative Commons Attribution-Share Alike 3.0 Unported license.)

Staging of SCLC

Although TNM staging can be used in SCLC, many clinicians prefer a simpler two-stage system. This staging system was originally proposed by the Veterans Administration Lung Study Group and has been found to have prognostic utility:

- Limited stage (25–30% of patients): Disease confined to a single radiation portal or localized to one hemithorax
- Extensive stage (70–75% of patients): Any disease outside of the hemithorax

Chemotherapy

LIMITED DISEASE—Response rate of 70–80% to chemotherapy and thoracic radiation therapy, with a complete clinical response rate of 50–60%. Concurrent radiation therapy begins with the first or second cycle of chemotherapy. No benefit has been shown beyond 4–6 cycles of chemotherapy.

EXTENSIVE DISEASE—Response rate of 60–80% to chemotherapy, with only 20% of patients achieving complete clinical remission. Standard approach is chemotherapy for 4–6 cycles, followed by assessment for progression. Radiation therapy is strictly palliative and can be used for symptomatic control of primary and metastatic lesions.

Prophylactic whole brain radiation is recommended for all patients with a good performance status who have attained remission after induction chemotherapy and radiation therapy.

PRIMARY PULMONARY LYMPHOMA

Primary pulmonary lymphoma is lymphoma affecting one or both lungs, without evidence of extrapulmonary involvement or bone marrow disease at the time of diagnosis and during the subsequent 3 months.
Most frequent subtypes:

- Mucosa-associated lymphoid tissue–type lymphoma
- Lymphomatoid granulomatosis

Mucosa-Associated Lymphoid Tissue–Type Lymphoma

- Accounts for 70–90% of primary pulmonary lymphomas.
- Characterized by diffuse infiltration of small monomorphic lymphoid cells with a typical lymphangitic growth pattern. These cells spread along the bronchovascular bundles and interlobular septa and form solid nodules that fill the alveolar spaces (Figure 12-13A).
- Occurs mainly in patients > 45 years of age, with a slight male preponderance, although it can occur in younger patients, especially those with underlying immunosuppression.
- Most common imaging pattern is pneumonia-like alveolar consolidation with air bronchograms. Sometimes appears as nodular opacities or an “infiltrative” pattern (Figure 12-13B).
- Disease is typically indolent and prognosis is excellent, with 5-year survival rates > 80%.

- Management:
  - Watchful waiting for asymptomatic patients
  - Surgical excision for localized disease
  - Rituximab-based chemotherapy for multifocal or disseminated disease



A



B

Fig 12-13. (A) Histopathologic specimen of the biopsy specimen of the infiltrate showing total replacement of lung parenchyma with lymphocytes (low-power view). (B) Chest x-ray of a patient with persistent right lower lobe infiltrate that was found to be primary pulmonary lymphoma on biopsy.
(Image A mage reproduced, with permission, from Dr. Shakuntala H. Mauzo, University of Texas Health Science Center at Houston.)

Lymphomatoid Granulomatosis

- Malignant B cell angiocentric and angiodestructive lymphoproliferative disorder occurs mainly in 40–50-year-old men. The lung is the most frequent location, although the brain, skin, and central nervous system may be involved.
- Forms multiple and confluent nodules composed of atypical, angiocentric, and polymorphous lymphoid infiltration involving the vascular walls from the subendothelium to the adventitial zones, with focal lumen obliteration.
- Contains mainly CD4 T lymphocytes with scattered atypical B cells infected by Epstein-Barr virus.
- Prognosis is grim, with 5-year survival rate of 30–40%.
- Most common treatment is chemotherapy with high-dose steroids and cyclophosphamide.

TECHNIQUES FOR DIAGNOSIS AND STAGING

A combination of radiographic and invasive techniques is used to diagnose and stage lung cancer. The primary lesion is often identified with computed tomography (CT) and positron emission tomography (PET scans). Extrathoracic scanning can detect metastatic disease at common sites, including the adrenal glands, liver, brain, and skeletal system. Appropriate imaging allows identification of targets for tissue sampling.

RADIOGRAPHIC TECHNIQUES

CT Scan

All patients with lung cancer should have CT scan imaging through the adrenals, with contrast, if possible, to help to distinguish vascular structures from lymph nodes.

PET Scan

More accurate than CT scanning for staging of mediastinum in patients with lung cancer. Sensitivity of 74% and specificity of 85% for identifying mediastinal metastases. Negative findings on PET scan can obviate the need for invasive lymph node sampling. However, if mediastinal nodes are positive on PET scan, invasive sampling is required, given the high false-positive rate.

Flash Card Q2

A 36-year-old patient with unresolving right middle lobe pneumonia of 2 months' duration presents for evaluation. Chest CT scan shows a right middle lobe alveolar infiltrate with air bronchograms. What is the next step?

Magnetic Resonance Imaging (MRI) Scan

Mainly useful for evaluating superior sulcus tumors, especially for possible invasion of the brachial plexus, and for evaluating vertebral invasion.

INVASIVE DIAGNOSTIC AND STAGING TECHNIQUES

Fiberoptic Bronchoscopy

A combination of brushing, endobronchial biopsy, and washing provides a diagnosis in 88% of cases of centrally located lesions. In submucosal and peribronchial lesions, transbronchial needle aspiration has a higher yield (71%) than endobronchial biopsy (55%). Transbronchial needle aspiration can be used to sample lymph nodes that appear to be involved based on CT or PET scan.

Transthoracic Needle Aspiration

Useful for parenchymal lesions that are not accessible by bronchoscopy. Sensitivity and specificity are 90% and 97%, respectively. The main drawback is the risk of pneumothorax, which is 22–45%. Risk is increased with emphysema, smaller lesion size, and greater depth from pleural surface to edge of lesion.

Endobronchial Ultrasound

Endobronchial ultrasound with transbronchial needle aspiration is indicated for assessment of mediastinal and hilar lymph nodes and diagnosis of lung and mediastinal tumors. It is used to access nodes at the following levels (Figure 12-14):

- Highest mediastinal: Station 1
- Upper paratracheal: Stations 2R, 2L
- Lower paratracheal: Stations 4R, 4L
- Subcarinal: Station 7
- Hilar: Station 10
- Interlobar: Station 11

In a patient with a lung mass and lymphadenopathy in the lymph node stations, endobronchial ultrasound with transbronchial needle aspiration is indicated.

Flash Card A2

CT-guided lung biopsy. The biopsy showed complete replacement of lung architecture by monomorphic small lymphoid cells with positive immunohistochemistry for mucosa-associated lymphoid tissue–type lymphoma.



Figure 12-14. Schematic representation of lymph node stations.

Endoscopic Ultrasound

Used to sample the posterior mediastinum through the esophageal wall. Sensitivity is 84% and specificity is 99.5%. Can be used to reach lymph nodes that are not accessible by other techniques (e.g., mediastinoscopy), including the paraesophageal and para-aortic lymph nodes.

Mediastinoscopy

Gold standard for staging the mediastinum in patients with known or suspected lung cancer. It is often done before thoracotomy and is mainly used to sample nodes of the paratracheal (station 4) and anterior subcarinal (station 7) regions. Mediastinoscopy and video-assisted thoracoscopic surgery are the only methods that can access station 5 nodes.

Sensitivity of 78% and specificity of 100% have been reported in nodes that appear to be involved on imaging studies. However, the procedure requires general anesthesia, with a morbidity rate of 2% and a mortality rate of 0.08%.

MEDIASTINAL NEOPLASMS

OVERVIEW

Definition

The mediastinum is defined by the pleural cavities laterally, the thoracic inlet superiorly, and the diaphragm inferiorly (Figure 12-15). Anatomically, it is divided into anterior, middle, and posterior compartments (Figure 12-16).



Figure 12-15. Lateral chest radiograph showing the boundaries of the mediastinum.
(Reproduced, with permission, from Dr. Fayez Kheir.)



Figure 12-16. Lateral chest radiograph showing the compartments of the mediastinum.
(Reproduced, with permission, from Dr. Fayez Kheir.)

Epidemiology

In adults, more than two thirds of mediastinal tumors are benign. Masses in the anterior compartment are more likely to be malignant. Patients with symptoms are more likely to have a malignant neoplasm.

Most common mediastinal masses:

- Thymoma: 15–20%
- Neurogenic neoplasms: 12–21%
- Metastatic disease: 40%
- Lymphoma: 10%

Differential Diagnosis

The differential diagnosis of a mediastinal mass is driven by the anatomic location. Other important factors include patient age, symptoms, and the radiologic characteristics of the mass.

Imaging

CT scan is the most important tool in the evaluation of mediastinal masses. Specific attenuation of air, fat, water, and calcium as well as the anatomic relationships of tumors to adjacent structures can be seen on CT scan. MRI scan adds little information to CT scan but is important in evaluating neurogenic tumors.

ANTERIOR MEDIASTINUM

The anterior mediastinum is located in the retrosternal space, anterior to the heart and great vessels. It contains the thymus, fat, and lymph nodes and can give rise to a variety of neoplasms (Table 12-2).

Table 12-2. Anterior Mediastinal Masses

Neoplasm	Mass	Imaging Features
Thymoma	Soft tissue attenuation Mild to moderate contrast enhancement Round, well-circumscribed lesion Usually homogenous	Patients generally ≥ 40 years old Associated with myasthenia gravis, hypogammaglobulinemia, and pure red cell aplasia
Lymphoma	Mediastinal lymphadenopathy Homogeneous lobulated soft tissue mass	Usually found in young adults Involves mediastinum as part of widespread disease Hodgkin > non-Hodgkin
Teratoma	Well-circumscribed unilocular or multilocular cystic lesion containing fluid, soft tissue, and fat	Usually asymptomatic
Seminoma	Large lobulated homogeneous well-defined mass	Usually symptomatic α-fetoprotein normal
Nonseminoma	Large, irregular, heterogeneous mass with areas of central necrosis, hemorrhage, or cyst formation	Usually symptomatic α-fetoprotein increased
Thyroid goiter	Encapsulated, lobulated, heterogeneous mass	Often discovered incidentally during a physical examination

Mnemonic

Interior mediastinal masses— **four Ts**:

Thymoma
Teratoma
Intrathoracic **T**hyroid
Terrible lymphoma

Thymoma

Most common primary neoplasm of the anterior mediastinum (Figure 12-17).

- Epidemiology: Usually occurs in patients > 40 years of age.
- Presentation: About one third of patients have pressure-induced symptoms.
- Diagnosis: Achieved by CT-guided or surgical biopsy.
  - Imaging:
    - Chest x-ray shows well-defined lobulated masses in the anterosuperior mediastinum.
    - Chest CT scan usually shows homogeneous solid tumors with soft tissue attenuation and well-demarcated borders. Up to one third may have necrotic, hemorrhagic, or cystic components. Calcification may be found in the capsule or throughout the mass.
- Parathymic syndromes, such as myasthenia gravis, hypogammaglobulinemia, and pure red cell aplasia, may develop.
- About 30%–50% of patients with a thymoma have myasthenia gravis, and 10–15% of patients with myasthenia gravis have a thymoma.
- Thymectomy can attenuate symptoms of myasthenia, but the benefit is often delayed for months after surgery.

Figure 12-17. Chest CT scan showing a large necrotic mass in the left anterior mediastinum marked (*red line*). Pathology showed thymoma.
(Reproduced, with permission, from Kurukumbi M, et al. Rare association of thymoma, myasthenia gravis and sarcoidosis : a case report. *J Med Case Reports.* 2008;2:245. doi:10.1186/1752-1947-2-245.)

- Treatment is based on the Masaoka-Koga staging system, which describes the degree of spread of the tumor beyond the capsule.
  - About two thirds of patients have encapsulated disease, which is treated with surgical resection. Five-year survival rate is >75%.
  - About one third of patients have invasive disease, which is treated with surgical resection and adjuvant chemotherapy and radiation therapy. Five-year survival rate is about 50%.
  - Metastatic disease is uncommon and is treated primarily with chemotherapy.

- Prognosis: Other characteristics associated with poor prognosis include:
  - Large tumor (> 10 cm)
  - Tracheal or vascular compression
  - Age < 30 years
  - Epithelial or mixed histologic features
  - Hematologic paraneoplastic syndrome

Lymphoma

Mediastinal lymphoma usually occurs as part of widespread disease. Hodgkin lymphoma (Figure 12-18) accounts for 50–70% of mediastinal lymphomas, whereas non-Hodgkin lymphoma represents 15–25%.



Figure 12-18. Chest CT scan showing a soft tissue mass in the anterior right mediastinum with enlarged nodes. Pathology showed Hodgkin lymphoma.
(Reproduced, with permission, from USMLE-Rx.com.)

Flash Card Q3

What neoplastic syndromes are associated with thymoma?

- Diagnosis:
  - Imaging: Lymphoma appears as a lobulated, homogeneous soft tissue anterior mediastinal mass with mild to moderate contrast enhancement, mediastinal lymphadenopathy, and no vascular involvement. Cystic and necrotic changes may be identified.
  - Diagnosis is usually made by core needle or surgical biopsy.
- Treatment: Hodgkin lymphoma is treated with radiation with or without chemotherapy. Non-Hodgkin lymphoma is treated with radiation plus chemotherapy.
- Prognosis: Overall survival is better for Hodgkin than for non-Hodgkin lymphoma.

Germ Cell Tumors

Germ cell tumors typically occur in young adults. The mediastinum is the most common extragonadal site. Types include teratomas, seminomas, and nonseminomas (embryonal) tumors.

TERATOMAS—Most common type.

Key Fact

Mediastinal teratomas tend to be cystic.

- Epidemiology: Typically seen in children and young adults.
- Presentation: Mature teratomas are usually asymptomatic and represent 60–70% of mediastinal germ cell tumors.
- Usually benign unless they contain fetal or neuroendocrine tissue. These are considered immature and are associated with a poor prognosis.
- Chest x-ray: Benign teratomas are well-circumscribed, round, or lobular masses that may contain fat, cystic changes, or calcification.
- Diagnosis: CT scan usually shows a well-defined uni- or multilocular cystic lesion containing fluid, soft tissue, and fat attenuation.
- Treatment: Complete surgical resection is performed.

SEMINOMAS—Usually occur in men 20–40 years old.

- Presentation: Associated with chest pain, fever, cough, weakness, and weight loss.
- Diagnosis:
  - α-Fetoprotein: Usually normal, but β-human chorionic gonadotropin is elevated in 10–35% of patients.
  - Chest x-ray: Large, lobulated, homogeneous, well-defined mass.
- Treatment: Radiation and chemotherapy because most patients have metastatic disease.
- Prognosis: Overall 5-year survival rate is around 80–90%.

Flash Card A3

Pure red cell aplasia, myasthenia gravis, and hypogammaglobulinemia

NONSEMINOMAS—Heterogeneous group of masses, including embryonal cell carcinomas, endodermal thymus tumors, choriocarcinomas, yolk sac tumors, and mixed germ cell tumors.

- Presentation: Usually occur in young men. Patients are often symptomatic.
- Diagnosis:
  - β-Human chorionic gonadotropin: Elevated in 30% of cases, and α-fetoprotein is elevated in 80% of cases.
  - Chest x-ray: Large, irregular, heterogeneous masses with areas of central necrosis, hemorrhage, or cyst formation.
  - Often invasive and metastatic.
- Treatment: Usually includes cisplatin-based combination chemotherapy, with possible resection of residual tumor.
- Prognosis: Poorer prognosis than seminomas, with a 5-year overall survival rate of 40–50%.

Thyroid Goiter

Usually euthyroid and found incidentally on physical examination.

Chest x-ray: Mediastinal goiters are encapsulated, lobulated heterogeneous masses with tracheal narrowing or deviation.

MIDDLE MEDIASTINUM

Located between the anterior and posterior mediastinum. It contains the heart, pericardium, ascending and transverse aorta, brachiocephalic veins, trachea, bronchi, and lymph nodes (Table 12-3).

Table 12-3. Middle Mediastinal Masses

	Cyst	Imaging Features
Bronchogenic cyst	Well-circumscribed mass with a homogenous density with water attenuation Located paratracheally or in the subcarinal area	Usually asymptomatic
Pericardial cyst	Most commonly located at the right cardiophrenic angle Unilocular, nonenhancing mass with water attenuation	Usually asymptomatic

Bronchogenic Cyst

Approximately 7–15% of mediastinal cysts

- Formed by abnormal branching of the tracheobronchial tree during embryonic development.
- Histology: Lined by respiratory epithelium and cartilaginous plates.
- Presentation: 40% of patients have symptoms (e.g., cough, dyspnea, or chest pain).
- Diagnosis:
  - Chest x-ray: Well-circumscribed mass with a homogenous density and water attenuation (Figure 12-19).
  - Usually located paratracheally or in the subcarinal area.
  - Accomplished by CT-guided or bronchoscopic needle aspiration.
- Treatment: Usually removed surgically or drained by needle aspiration if symptomatic.



Figure 12-19. Computed tomography scan of the chest showing a soft tissue mass (*arrow*) paratracheally with fluid density compatible with a bronchogenic cyst.
(Reproduced, with permission, from Dr. Khalid Alokla.)

Pericardial Cysts

Asymptomatic cysts usually located at the right cardiophrenic angle followed by the left cardiophrenic angle. CT scan shows unilocular, nonenhancing cysts with water attenuation.

OTHER—Other causes of middle mediastinal masses:

- Lymphoma
- Metastatic carcinoma
- Nonmalignant lymphadenopathy, such as sarcoidosis

POSTERIOR MEDIASTINUM

Extends from the posterior border of the heart and trachea to the posterior aspect of the vertebral bodies. It includes the descending thoracic aorta, esophagus, azygous vein, autonomic ganglia and nerves, thoracic lymph nodes, and fat (Table 12-4).

Table 12-4. Posterior Mediastinal Masses

	Imaging Features	Manifestations
Neurogenic tumors	Magnetic resonance imaging is more sensitive than computed tomography scan in delineating intraspinal extension	Schwannoma is the most common type
Extramedullary hematopoiesis	Single or multiple posterior masses adjacent to the vertebrae, ribs, or both	Associated with myeloproliferative diseases or hemolytic anemia

Neurogenic Tumors

Most common cause of posterior mediastinal tumors.

- Derived from neural crest tissue; 70–80% are benign.
- Presentation: Nearly half of patients are asymptomatic. However, compressive or neurologic symptoms may occur.
  - Neurogenic tumors may arise from the peripheral, autonomic, or paraganglionic nervous systems. The former are the most common and include schwannomas.
  - Malignant nerve sheath tumors are painful, heterogeneous masses. Local invasion is treated with complete surgical resection if feasible.

Extramedullary Hematopoiesis

Hematopoiesis occurring outside of the bone marrow.

- Cause: Bone marrow replacement (myeloproliferative disorders) or hemolytic anemia (hemoglobinopathies, chronic anemia)
- Presentation: Usually asymptomatic
- Diagnosis: Chest x-ray: One or more posterior masses adjacent to the vertebrae, ribs, or both (Figure 12-20)

Figure 12-20. Chest computed tomography scan showing multiple posterior masses (*arrows*) in a patient with thalassemia compatible with extramedullary hematopoiesis.
(Reproduced from http://radiopaedia.org/articles/extramedullary-haematopoiesis under the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported licence.)

Other

Other causes of posterior mediastinal masses:
- Diaphragmatic hernia
- Meningocele
- Paravertebral abscess

METASTATIC LUNG TUMORS

The lung is a common site for metastasis of malignant tumors from other organs. Most of these tumors are asymptomatic because most people have a large degree of reserve pulmonary function.

- Nodules caused by metastases from a solid organ primary tumor vary in size and location. They have a proclivity for the lung bases and tend to be subpleural.

- Metastatic lesions are usually round, with sharply demarcated borders.
- Metastases that tend to hemorrhage (e.g., choriocarcinoma, renal cell carcinoma, melanoma, thyroid carcinoma, Kaposi sarcoma) may have indistinct, fuzzy borders and occasionally show a halo of ground-glass opacity.
- Cavitation occurs in < 5% of malignant lesions and is preferentially seen in squamous cell carcinoma.
- The most common malignancies that present as multiple pulmonary nodules include primary neoplasms of the testes, ovaries, and kidneys as well as melanoma and sarcoma.
- Other cancers, such as breast, colorectal, prostate, and thyroid tumors, present with metastatic lung masses after discovery and initial treatment of the primary cancer.

DIAGNOSIS

The diagnosis of metastases is usually made in the setting of a known cancer presenting with multiple pulmonary nodules with smooth borders in the dependent lobes. When a single nodule is the only evidence of metastasis, recognizing it as a metastasis may be difficult.

TREATMENT

The tissue of origin largely dictates treatment of lung metastasis. Curable cancers, such as germ cell tumors, neuroblastoma, lymphoma, and osteosarcoma with lung metastasis, should be treated aggressively, mainly with chemotherapy.

The goal of curative resection of pulmonary metastases is identification and removal of all foci of malignancy, with preservation of a maximal amount of normal lung tissue. The following are the generally accepted criteria for pulmonary metastasectomy.

Absolute criteria:
- Patient is a good candidate for surgery.
- Primary tumor is controlled.
- No extrapulmonary metastases exist.
- Pulmonary metastases are completely resectable.

Relative criteria:

- Pulmonary metastases are symptomatic.
- Tissue is needed for diagnostic reasons.

FACTORS INDICATING POOR PROGNOSIS

- Inability to resect all lesions
- Large number of metastases (> 6)
- Involvement of lymph nodes
- Short disease-free interval after primary tumor treatment

LUNG NODULES

SOLITARY PULMONARY NODULES (SPNs)

SPNs are radiographic opacities ≤ 3 cm in diameter surrounded by lung parenchyma in at least two thirds of the margin (Figure 12-21). Prevalence is 20–51% in high-risk patients. Most are benign, but 1.1–12% are malignant.

Figure 12-21. Chest computed tomography scan showing a solitary pulmonary nodule (*arrow*).
(Reproduced courtesy of Wikipedia under the Creative Commons Attribution-Share Alike 3.0 Unported license.)

Differential Diagnosis

Broad for pulmonary nodules (Table 12-5)

Table 12-5. Differential Diagnosis of Solitary Pulmonary Nodules

Infectious
- Granuloma
- Abscess
- Round pneumonia
- Fungal infection
- Septic embolus

Neoplastic
- Hamartoma
- Metastatic lesion
- Carcinoid tumor
- Carcinoma
- Lymphoma

Vascular
- Arteriovenous malformation
- Hematoma
- Pulmonary aneurysm
- Pulmonary infarct

Lymphatic
- Intrapleural or subpulmonary lymph node

Congenital
- Bronchogenic cyst
- Lung sequestration

Inflammatory
- Rheumatoid lung
- Sarcoidosis
- Granulomatosis with polyangiitis
- Organizing pneumonia

Miscellaneous
- Amyloidosis
- Atelectasis
- Scar
- Mucous impaction

Mnemonic

Differential diagnosis of solitary pulmonary nodules—**CASH PLEAS**e:

Cancer
Abscess
Solitary metastasis
Hamartoma

Pseudotumor
Lymphoma
Echinococcus
Actinomyces
Sequestration

Etiology

It is important to determine the etiology. Early surgical resection of malignant SPNs confers a high cure rate. Avoiding surgery for benign SPNs prevents morbidity.

Radiologic Characteristics

CT images are important for characterizing SPNs. Thin sections with contiguous 1-mm images through nodules are preferred. Both lung and mediastinal windows should be obtained. Comparison with previous chest x-rays and CT scans is key.

GROWTH RATE

- Volumetric doubling of malignant SPNs occurs in 20–400 days and corresponds to a 26% increase in nodule diameter.
- SPNs that double in volume in > 400 days are typically benign, except for slow-growing lung cancers.
- SPNs that double in volume in < 20 days are often caused by an acute inflammatory process.
- In general, a solid SPN with stable volume for 2 years can be considered benign.

SIZE—Likelihood of malignancy increases with nodule diameter.

Radiographic follow-up is often determined by nodule size (Table 12-6).

Table 12-6. Radiographic Follow-up in Solitary Pulmonary Nodule ≤ 8 mm

	Cancer Risk	
Size	**Low**	**High**
≤ 4 mm	No surveillance	Chest CT scan at 12 mo No further follow-up if no change
4–6 mm	Chest CT scan at 12 mo No further follow-up if no change	Chest CT scan at 6–12 mo Chest CT scan at 18–24 mo if no change
> 6–8 mm	Chest CT at 6–12 mo CT chest at 18–24 mo if no change	Chest CT scan at 3–6 mo Chest CT scan at 9–12 month if no change Chest CT scan at 24 mo if no change

CT, computed tomography

MORPHOLOGY

- Defined by edge characteristics, such as smooth, lobulated, irregular, halo or spiculated.
- Smooth edges: Usually benign, but 20–30% of malignant nodules have smooth borders.
- Irregular, lobulated, and spiculated edges often indicate uneven growth and are usually but not exclusively found in malignant tumors.
- SPNs surrounded by a halo of ground-glass opacities can indicate adjacent hemorrhage or lepidic spread.

Key Fact

Hamartomas:
- Benign but can grow slowly
- Fat visible on CT scan in about 60%
- Most often found in men > 50 years of age
- Popcorn calcification seen in about 25%

LOCATION—Malignant SPNs are more common in the upper lobes compared with other lobes.

FAT—CT finding of fat attenuation usually signifies a benign hamartoma or lipoid lesion.

CALCIFICATION—Benign patterns of calcification on chest CT scan:
- Central: Bull's eye
- Diffuse solid: Granulomatous disease
- Laminated: Rings
- Popcorn-like: Chondroid matrix, such as hamartoma

No pattern of calcification is specific for malignancy. Punctuate and eccentric calcifications are often but not exclusively seen in lung cancer.

CAVITATION—Secondary to necrosis. Can be seen in malignant and benign SPNs.

GROUND-GLASS NODULES—Focal nodular areas of increased lung attenuation without obscuring of the lung parenchyma (Figure 12-22)
- Classified into pure ground-glass and partly solid types.

- More solid components are associated with a higher likelihood of malignancy.
- Have a slower growth rate and low metabolic activity, with a doubling time of > 2 years and low or no activity on PET scan.

Figure 12-22. Chest computed tomography scan showing ground-glass nodule (*arrow*).
(Reproduced, with permission, from Ost DE, Gould MK. Decision making in patients with pulmonary nodules. *Am J Respir Crit Care Med.* 2012: 185: 363-372. doi:10.1164/rccm.201104-0679CI)

PET-CT Imaging

- Indicated for nodules > 8–10 mm in diameter. Lower sensitivity for smaller SPNs.
- High metabolic activity (standard uptake value > 2.5) suggests possible malignancy.
- Sensitivity of 96% and specificity of 79% in differentiating benign from malignant lesions in nodules larger than 8–10 mm.
- SPNs with intermediate pretest probability of malignancy should be evaluated.
- Tumors with low metabolic rate, ground-glass nodules, and SPNs < 8–10 mm have higher false-negative rates. Infectious and inflammatory conditions yield higher false-positive rates.
- Whole-body image can detect extrapulmonary tumors and help in lung cancer staging.

Management

Figure 12-23 summarizes an algorithm for management of SPNs.

Flash Card Q4

What is appropriate management when a solitary, pure ground-glass nodule > 5 mm is found on chest CT scan?


Obtain old films
• Assess SPN stability
• Describe whether there is benign pattern or calcification
Yes
No further testing
No
Obtain low-dose chest CT with thin sections through the nodule
• Describe type of SPN (solid versus sub-solid)
Solid SPN
Sub-solid GGN
For SPN > 8mm
Assess pretest probability for lung cancer
• Use either physician prediction based on age, smoking history and radiographic characterstics, or methods such as Bayesian analysis or logistic models
Pure GGn
• For nodule size ≤ 5 mm, no follow up is required.
• For nodule size < 5 mm
• Follow-up CT chest scan in 3 months and if no change, a possible follow-up period of 3 years should be considered (accounting for the slow doubling time of adenocarcinomas)
• Surgical excision should be considered if any change in nodule size or characteristics
• PET-CT scan is of no valuable use in these type of nodules
Partly solid GGN
• Follow-up CT chest scan in 3 months and consider PET-CT scan if solid component >8 mm
• Surgical excision should be considered if any change in nodule size or characteristics
For SPN ≤ 8 mm
• Follow Fleischner society guidelines
Low (<5%)
• Serial CT chest
Negative
Intermediate (5-60%)
• PET-CT
Positive
High (>60%)
• Obtain tissue diagnosis or proceed to surgical resection taking into account patient's preference, and surgical risk as well as center specific expertise

Figure 12-23. Approach to solid pulmonary nodules.
SPN, solitary pulmonary nodule; CT, computed tomography; GGN, ground-glass nodule; PET, positron emission tomography.

Flash Card A4

Initial follow-up at 3 months and then annual surveillance for at least 3 years.

Invasive Diagnostic Evaluation

CT-GUIDED BIOPSY

- Sensitivity is 90%; specificity is 100%.
- Nondiagnostic results are much more common in benign than malignant SPNs.
- Pneumothorax rate is 20–25%, with 4–7% requiring chest tube.

CONVENTIONAL BRONCHOSCOPY

- Safe, well-tolerated procedure.
- Forceps biopsy improves tissue yield.
- Higher accuracy for central versus peripheral lesions.
- Higher diagnostic yield if CT scan shows a bronchus leading to the lesion.

RADIAL ENDOBRONCHIAL ULTRASOUND AND ELECTROMAGNETIC NAVIGATION

- Increase diagnostic yield of peripheral lesions.
- Can be considered with air bronchus sign and pathway to the lesion.

Treatment

SURGERY—Video-assisted thoracic surgery, thoracotomy, or sometimes a combination is indicated to establish a diagnosis when the probability of cancer is high (> 60%). Surgery may also serve as definitive treatment.

RADIATION THERAPY—Patients who are nonsurgical candidates with malignant SPNs may undergo stereotactic radiation therapy.

PARANEOPLASTIC SYNDROMES

Epidemiology

Paraneoplastic syndromes are clinical syndromes caused by underlying malignant disease. Systemic manifestations of paraneoplastic syndromes are mediated by humoral factors excreted by tumor cells or by responses to tumor antigen.

- Associated with many types of lung cancer (Table 12-7).
- Can be the first manifestation of disease or disease recurrence

Flash Card Q5

Which type of lung cancer is most frequently associated with paraneoplastic syndromes?

- About 10% of patients with lung cancer present with a paraneoplastic syndrome.
- Curative cancer treatment not precluded.
- May resolve with treatment of underlying disease.

Table 12-7. Lung Cancer and Common Paraneoplastic Syndromes

Adenocarcinoma	
	Hypertrophic pulmonary osteoarthropathy
Small cell lung cancer	
	Syndrome of inappropriate antidiuretic hormone secretion
	Cushing syndrome
	Carcinoid syndrome
	Neurogenic syndromes
Squamous cell lung cancer	
	Hypercalcemia

HYPERCALCEMIA

Elevated calcium in blood is caused by tumor secretion of parathyroid hormone-related protein, increased active metabolite of vitamin D (calcitriol), and localized osteolytic hypercalcemia.

- Occurs in 10–25% of patients with lung cancer.
- Most commonly associated with squamous cell lung cancer.
- Median survival in patients with lung cancer after diagnosis of hypercalcemia is about 1 month.

Presentation

Clinical symptoms of hypercalcemia depend on calcium level and acuity of onset:

- For patients with mild or moderate hypercalcemia, symptoms include polyuria, polydipsia, nausea, confusion, vomiting, abdominal pain, and myalgia.
- With severe hypercalcemia (serum calcium level > 14.0 mg/dL), symptoms include mental status changes, coma, bradycardia, arrhythmias, and hypotension.
- Hypercalcemia can also cause severe dehydration and acute renal failure.

Flash Card A5

Small cell lung cancer

Diagnosis

Diagnostic evaluation includes assessment of intact parathyroid hormone, parathyroid hormone-related protein, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, calcium, albumin, magnesium, and phosphorus.

Treatment

Fluid resuscitation and bisphosphonate therapy

SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION

Most commonly associated with small cell lung cancer (SCLC).

- ADH is produced by the tumor in an unregulated manner, leading to water retention by reabsorption in renal tubules.
- Manifested as euvolemic hypo-osmolar hyponatremia.

Presentation

Clinical signs and symptoms depend on degree of hyponatremia and acuity of hypo-osmolality. They range from general weakness, headache, and nausea to altered mental status, coma, and seizure.

Diagnosis

Lab findings:

- Urine sodium level > 40 mEq/L
- Urine osmolality > 500 mOsm/kg
- Serum osmolality < 275 mOsm/kg
- Serum uric acid concentration < 4 mg/dL

Treatment

Management of inappropriate antidiuretic hormone secretion–induced hyponatremia:

- Free water restriction for asymptomatic mild hyponatremia
- Administration of hypertonic 3% saline in life-threatening disease

- Cautious use of vasopressin receptor antagonists to avoid overcorrection
- Treatment of the underlying tumor for permanent resolution

CUSHING SYNDROME

Caused by ectopic secretion of adrenocorticotropic hormone. Most commonly associated with SCLC and bronchial carcinoid tumors.

Presentation

Clinical manifestations:
- Weight gain
- Moon facies
- Acne
- Purple striae
- Proximal muscle weakness
- Peripheral edema
- Skin hyperpigmentation

Diagnosis

Diagnostic laboratory tests:
- High plasma adrenocorticotropic hormone
- Nonsuppressed morning cortisol level after high-dose dexamethasone suppression test
- Elevated 24-hour urine free cortisol level

Treatment

Treat underlying disease. Patients with SCLC and Cushing syndrome have a worse response to chemotherapy, shorter survival, and a higher rate of surgical complications.

HYPERCOAGULABLE DISORDERS

Venous thromboembolism occurs within 2 years of diagnosis in 3% of patients with lung cancer.

- Tumor cells directly activate clotting via tissue factor and cancer procoagulant.
- Low-molecular-weight heparin is the preferred treatment.

HYPERTROPHIC PULMONARY OSTEOARTHROPATHY

Characterized by digital clubbing (Figure 12-24), painful symmetrical arthropathy (involving the wrists, elbows, ankles, and knees), and periosteal new bone formation in the distal long bones of the limbs.

Key Fact

Hypertrophic pulmonary osteoarthropathy resolves completely with treatment of the primary cancer.

- Most commonly associated with adenocarcinoma of the lung.
- Histologic features include vascular hyperplasia, edema, and excessive fibroblast and osteoblast proliferation.
- Overexpression of vascular endothelial growth factor may play a role in pathogenesis.
- Treatment of the primary malignancy results in resolution.

Figure 12-24. Digital clubbing is characterized by enlargement of the terminal segments of the fingers.
(Reproduced courtesy of Desherinka, Wikimedia Commons, under the Creative Commons Attribution-Share Alike 3.0 Unported license.)

Flash Card Q6

Which of the following paraneoplastic syndromes is appropriately matched with the corresponding antibodies?

Lambert–Eaton myasthenia syndrome—Anti-Yo antibodies

Cerebellar degeneration—Voltage-gated channel antibodies

Limbic encephalitis—Anti-Hu antibodies

NEUROGENIC SYNDROMES

Paraneoplastic syndromes causing nervous system dysfunction occur almost exclusively in SCLC. They are caused by neuronal autoantibodies resulting in T-cell mediated damage to the central nervous system.

Anti-Hu Syndrome

- Most common paraneoplastic neurologic syndrome associated with lung cancer.
- The presence of anti-Hu antibodies has specificity of 99% and sensitivity of 82% for diagnosing a neurogenic paraneoplastic syndrome, but these antibodies are not themselves pathogenic.
- Symptoms include brain stem encephalitis, opsoclonus-myoclonus, cerebellar degeneration, myelopathy, and peripheral nerve palsy.
- Response to therapy for SCLC helps, but does not cure the disease.

Anti-Yo Syndrome

- Caused by anti-Yo antibodies directed against Purkinje cells in the cerebellum.
- Antibodies have both a diagnostic and a pathogenic role.
- Manifests clinically as cerebellar degeneration.
- Intravenous immunoglobulins may stabilize clinical symptoms if administered early after onset of symptoms.
- Treatment of underlying cancer does not cure the disease.

Lambert–Eaton Myasthenia Syndrome

- Autoantibodies are directed against voltage-gated calcium channel type P/Q.
- Affects the presynaptic neuromuscular junction.
- Manifested clinically as proximal muscle weakness progressing craniocaudally.
- Antibodies have both a diagnostic and a pathogenic role.
- Immunosuppressive therapy improves muscle strength.
- Treatment of the underlying tumor usually leads to resolution of symptoms.

Flash Card A6

Limbic encephalitis—Anti-Hu antibodies

PLEURAL NEOPLASMS

The pleura is composed of a single layer of mesothelial cells overlying a matrix of collagen, elastic fibers, blood vessels, and lymphatics. Primary pleural tumors are rare, but can arise from either the parietal or visceral pleura and can be malignant or benign. Malignant mesothelioma is the most common pleural tumor overall.

DIAGNOSIS

Once a pleural abnormality has been identified, diagnostic work-up includes:

- A detailed clinical history, including environmental and occupational exposures.
- A comprehensive physical examination: Pleural neoplasms often result from metastatic disease, so evaluation for primary tumors is important.
- Appropriate imaging and tissue sampling: Thoracentesis can aid in diagnosis if there is an associated effusion. Video-assisted thoracoscopic surgery has a high diagnostic yield.
- Appropriate histologic and immunohistochemical analyses differentiate malignant from reactive mesothelial cells and mesothelioma from other metastatic disease, including adenocarcinoma.
- Table 12-8 lists the common differential diagnoses for pleural tumors.

Key Fact

The diagnosis of pleural neoplasm is established with proper history, imaging, tissue specimens, and histopathology with immunohistochemical staining.

Table 12-8. Common Differential Diagnoses for Pleural Tumors

Metastatic disease
Pleural plaques
Diffuse pleural thickening
Loculated pleural effusion
Loculated empyema
Loculated hemothorax
Rounded atelectasis
Extramedullary hematopoiesis

MALIGNANT PLEURAL MESOTHELIOMA (MPM)

MPM is an aggressive tumor arising from mesothelial cells. It typically originates in the parietal pleura before spreading into the visceral pleura (Figure 12-25). It can also arise from the pericardium, peritoneum, or tunica vaginalis.

Figure 12-25. Computed tomography scan of the chest in a patient with left-sided mesothelioma showing an extensive pleural mass with contraction of the left hemithorax.
(Reproduced from http://radiopaedia.org/cases/mesothelioma-1, under the Creative Commons Attribution-Share Alike 3.0 Unported license.)

Epidemiology

The incidence of MPM is increasing worldwide. There are 2000–3000 new cases per year in the United States, with a male-to-female ratio of 5:1. The median survival time after diagnosis is 9–17 months. The 5-year survival rate is < 5%. MPM is more frequent with advanced age because of the long latency period between exposure and onset of symptoms.

Etiology

Asbestos exposure is documented in about 85% of patients with MPM. There is no synergistic effect between asbestos and cigarette smoke.

- Other potential etiologies include simian monkey virus 40, radiation, chemical carcinogens, erionite (a mineral found in volcanic ash), and chronic pleural disease.
- MPM is not believed to arise from pleural plaques, although both are associated with asbestos exposure.

Diagnosis

Diagnosis of MPM requires strong clinical suspicion along with appropriate information on the exposure history and knowledge of the latency period from exposure to diagnosis.

SYMPTOMS—Nonspecific. Include shortness of breath, cough, and nonpleuritic chest pain.

IMAGING

- Chest x-ray: Large unilateral pleural effusion obscuring an underlying pleural mass or thickening.
- Chest CT scan: Better defines the extent of pleural disease.
- MRI scan: Sometimes delineates soft tissue planes.
- PET scan: Detects occult metastatic disease in approximately 10% of patients.

BIOPSY—Video-assisted thoracoscopic surgery is recommended to obtain tissue for diagnosis or immunohistochemistry.

- MPM must be differentiated from metastatic adenocarcinoma (Table 12-9).
- No serum biomarkers are useful for diagnostic or screening purposes.

Table 12-9. Immunohistochemical Markers

	Vimentin	Calretinin	Periodic Acid–Schiff	Carcinoembryonic Antigen
Mesothelioma	+	+	-	-
Adenocarcinoma	-	-	+	+

Flash Card Q7

Which of the following statements about MPM is false?

A. There is a synergistic effect between asbestos exposure and smoking.
B. Serum biomarkers are not useful as a screening tool.
C. There is a long latency period between exposure to asbestos and development of symptoms.
D. Treatment is rarely curative.

Treatment

Despite advancement in treating MPM, prognosis remains very poor. Referral to a specialized center is strongly advised.

Key Fact

Treatment of MPM is rarely curative. However, multimodal treatment regimens combining surgery, radiation therapy, and chemotherapy may offer a significant increase in survival for subgroups of patients with mesothelioma.

- For symptomatic effusions, optimal palliative therapy is drainage of fluid with subsequent pleurodesis.
- For bulky intrapleural disease, pleurectomy may provide palliative relief of symptoms.
- Treatment is rarely curative and involves a multimodal approach:
  - Extrapleural pneumonectomy versus pleurectomy/decortications
    - Standard management of surgically resectable patients has yet to be established.
    - Surgical intervention might benefit patients with early-stage disease, good performance status, epithelioid histology, and no mediastinal lymph node involvement.
  - Radiation therapy
  - Adjuvant chemotherapy with pemetrexed and cisplatin

Prognosis

Favorable prognostic signs:

- Good performance status
- Age < 60 years
- Platelet count < 400,000
- Epithelioid histology
- < 5% weight loss
- Tumor confined to ipsilateral pleura

SOLITARY FIBROUS TUMORS

Solitary fibrous tumors are rare spindle cell mesenchymal tumors originating from the pleura (80% visceral and 20% parietal). They account for about 5% of all pleural tumors. Most solitary fibrous tumors (about 80%) are benign.

Flash Card A7

The correct answer is A. There is no synergy between asbestos exposure and smoking in MPM.

Presentation

Most patients are asymptomatic, but may have cough, chest pain, and dyspnea on presentation.

Imaging

Tumors appear as a pleural-based soft tissue masses, with well-defined margins and no associated rib destruction or chest wall abnormality.

Treatment

Treatment for both malignant and benign tumors is complete resection. Long-term follow-up with imaging is needed because of high recurrence rates.

PREOPERATIVE ASSESSMENT

Although surgery is the best curative option for patients with early-stage NSCLC, careful preoperative assessment of individual risk factors is needed to avoid short- and long-term operative complications. Preoperative evaluation allows patients to be counseled appropriately regarding treatment options and risks.

The American College of Chest Physicians has published guidelines for patients with lung cancer that are being considered for possible curative lung resection. Evaluation by a multidisciplinary team consisting of a thoracic surgeon, medical oncologist, radiation oncologist, and pulmonologist is recommended. Smoking cessation is strongly advised because it is associated with short-term perioperative and long-term survival benefits.

- Smokers and former smokers with lung cancer are at increased risk for cardiovascular disease. Thus, a preoperative cardiovascular risk assessment is needed to stratify the risk of major postoperative cardiac complications.
- The thoracic revised cardiac risk index (Table 12-10) is a validated tool for assessing cardiovascular risk factors for patients undergoing lung resection.
- Patients with a score > 1.5, any cardiac condition requiring medication, a newly suspected cardiac condition, or limited exercise tolerance (inability to climb two flights of stairs) should be referred for cardiac consultation.
- Patients at low risk for cardiovascular disease may proceed for further evaluation for possible lung resection (Figure 12-26).

Refer to Table 12-11 for calculation of predictive postoperative forced expiratory volume in 1 second (FEV1) and diffusion capacity for carbon monoxide (DLCO).

Refer to Table 12-12 for definition of risk for lung resection.

Flash Card Q8

Which of the following parameters places the patient at high risk for surgical complications?

A. 77 years old
B. Chronic obstructive pulmonary disease with hypercapnia
C. Able to climb three flight of stairs
D. VO_2 max 30% of predicted

Table 12-10. Thoracic Revised Cardiac Risk Index
Creatinine > 2 mg/dL = 1 point
Pneumonectomy = 1.5 points
Previous cerebrovascular accident or transient ischemic attack = 1.5 points
Previous ischemic heart disease = 1.5 points



Figure 12-26. Algorithm for evaluation of lung resection. (Refer to Table 12-11 for calculation of ppo [FEV_1 and DLCO]).
FEV_1, forced expiratory volume in 1 second; DLCO, diffusing capacity for carbon monoxide; VO_2 max, maximal oxygen uptake.

Flash Card A8

D. VO_2 max < 35% of predicted places the patient at very high risk for surgery.

Table 12-11. Calculation of Predicted Postoperative Forced Expiratory Volume in 1 Second and Diffusing Capacity for Carbon Monoxide

Pneumonectomy	Lobectomy
PPO FEV_1 = preoperative FEV_1 x (1 - fraction of total perfusion for the resected lung) PPO DLCO = preoperative DLCO x (1 - fraction of total perfusion for the resected lung) Quantitative radionuclide perfusion scan performed to measure the fraction of total perfusion for the resected lung	PPO FEV_1 = preoperative FEV 1 x (1 - *y*/*z*) PPO DLCO = preoperative DLCO x (1 - *y*/*z*) *y* = number of functional or unobstructed lung segments to be removed *z* = total number of functional segments Anatomic method used where total number of segments for both lungs is 19 (10 in the right lung and 9 in the left lung)

PPO, predicted postoperative; FEV_1, forced expiratory volume in 1 second; DLCO, diffusing capacity for carbon monoxide.

Key Fact

VO_2 max < 10 mL/kg/min or 35% of predicted indicates a high risk of mortality and long-term disability.

Key Fact

If % PPO FEV_1 and % PPO DLCO values are both > 60%, the patient is considered at low risk for surgical complications and no further tests are indicated.

- Six months after lobectomy:
  - 1-second forced expiratory volume (FEV_1) ~10% < preoperative FEV_1
  - Exercise capacity as measured by maximal oxygen uptake (VO_2 max) 0–13% < preoperative VO_2 max
- Six months after pneumonectomy:
  - FEV_1 34–41% < preoperative FEV_1
  - VO_2 max 20–28% < preoperative VO_2 max

Table 12-12. Definition of Risk for Lung Resection

Low risk	Expected risk of mortality > 1% Major anatomic resection can be safely performed
Moderate risk	Morbidity and mortality rates may vary according to split lung function, exercise tolerance, and extent of resection Risks and benefits of surgery should be thoroughly discussed with patient
High risk	Risk of mortality after standard major anatomic resection may be > 10% Considerable risk of severe cardiopulmonary morbidity and residual functional loss expected Patients should be counseled about alternative surgical (minor resection or minimally invasive surgery) or nonsurgical options

13 Pleural Disease

Jeffrey Albores, MD

PLEURAL EFFUSION

A pleural effusion is excess fluid that accumulates between the parietal and visceral pleura.

THORACENTESIS

One of the first steps to be considered in the management of a patient with a new pleural effusion. It is a procedure to remove fluid from the pleural space for diagnostic and/or therapeutic purposes (Figure 13-1).

Key Fact

The normal pleural space is filled with approximately 7–14 mL of low-protein pleural fluid in a normal adult man and approximately 0.15 mL/kg of fluid is produced hourly by the parietal pleura.


Patient sitting upright and leaning on table
Pleural space filled with excess fluid
Fluid pushes on left lung
Fluid collects in bag or syringe

Figure 13-1. Thoracentesis.
(Reproduced courtesy of the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health & Human Services.)

Supporting Tools

ULTRASOUND—Assists with site selection and increases the safety of pleural procedures.

Key Fact

British Thoracic Society guidelines strongly recommend ultrasound guidance for all pleural procedures used to remove pleural fluid.

PLEURAL MANOMETRY—Measurement of pleural pressures that reflects pleural space elastance.

- Pleural elastance is the change in pleural pressure relative to the volume of pleural fluid (PF) removed ($\Delta P/\Delta V$).
- Manometry may have clinical applications for the diagnosis of trapped and entrapped lung. Serial manometry during a large volume thoracentesis may also be able to predict the development of re-expansion pulmonary edema. However, there are no guidelines at this time recommending the routine use of manometry.

Fluid Removal

AMOUNT OF FLUID TO REMOVE—Fluid removal is stopped at the onset of chest discomfort or when 1000–1500 mL of PF is aspirated.

Key Fact

The symptom most associated with significant drops in pleural pressure is chest discomfort.

RE-EXPANSION PULMONARY EDEMA

- Noncardiogenic pulmonary edema that occurs after rapid re-expansion of atelectatic lung following drainage of a moderate-to-large pleural effusion or pneumothorax (Figure 13-2).
- The condition is usually self-limited and treatment is mainly supportive.



Figure 13-2. Re-expansion pulmonary edema following thoracentesis of a large left pleural effusion.
(Dias OM, Teixeira LR, Vargas FS. Reexpansion pulmonary edema after therapeutic thoracentesis. *Clinics* [serial on the Internet]. 2010; 65(12): 1388. Fig 1. doi.org/10.1590/S1807-59322010001200026. CC-BY-NC 3.0)

PLEURAL FLUID ANALYSIS

A transudative pleural effusion develops when low-protein fluid leaks across an intact capillary barrier because of increased hydrostatic pressure or decreased osmotic pressure.

An exudative pleural effusion develops when fluid leaks across an altered capillary barrier with increased permeability, thus allowing transfer of protein and liquid. It typically represents an inflammatory process of the lung or pleura.

Light's Criteria

Light's criteria characterize PF as a transudate or an exudate that permits significant narrowing of the differential diagnosis (Table 13-1).

Table 13-1. Light's Criteria

Pleural Fluid	Light's Criteria for Exudative Effusions
PF:serum total protein ratio	> 0.5
PF LDH	> 2/3 upper limit of normal
PF:serum LDH ratio	> 0.6

LDH, lactate dehydrogenase; PF, pleural fluid

Pleural Fluid Values

pH—Good correlation between pH and glucose values.

Pitfalls for pH values:
- Air in the syringe increases pH.
- Time increases pH.
- Lidocaine decreases pH.

Table 13-2 lists exudative pleural effusions with low pH.

Flash Card Q1

When should you consider terminating fluid removal during thoracentesis?

Flash Card Q2

Which organism is associated with a complicated parapneumonic pleural effusion that has an elevated pH?

Table 13-2. Exudative Pleural Effusions with Low pH (< 7.3)

Disease	Clinical Pearls
Parapneumonic effusion	Clinical diagnosis of pneumonia Consider chest-tube drainage for PF pH < 7.2 A pH < 7.0 is a poor prognostic indicator
Malignant effusion	~1/3 of patients with malignant pleural effusion have pH < 7.3 Malignant effusions with pH < 7.3 compared to those with pH > 7.3 are associated with greater tumor burden, higher probability of positive PF cytology, and shorter survival
Tuberculous effusion	PF pH < 7.3 in ~20% of cases A low pH is more characteristic of chronic tuberculous empyema than of tuberculous pleural effusion
RA effusion	Typically with pH < 7.3 in contrast to the effusions seen with SLE
Hemothorax	Grossly bloody with PF hematocrit ≥ 50% of the peripheral blood hematocrit
Esophageal rupture	Severe retching or vomiting followed by chest pain and fever Usually, left pneumothorax early and left pleural effusion later Low pH and elevated amylase in effusion
Paragonimiasis	Cough, fever, hemoptysis, chronic asymptomatic pleural effusion Associated with eosinophilia

PF, pleural fluid; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus

GLUCOSE—Low glucose effusions (< 60 mg/dL) are found in the same diagnoses involving exudative pleural effusions with low pH.

PROTEIN, LACTATE DEHYDROGENASE (LDH), AND ALBUMIN

- PF protein and LDH help separate transudative from exudative effusions.
- Elevated PF LDH may be a marker of pleural inflammation when measured serially.
- PF albumin (or protein) gradient is useful in diagnosing false exudates in a congestive heart failure (CHF) patient who has undergone diuresis:
  - Albumin gradient = serum albumin - PF albumin.
  - Albumin gradient > 1.2g/dL is consistent with a transudate.
  - Albumin gradient ≤ 1.2g/dL is consistent with an exudate.
  - Protein gradient > 3.1 g/dL is consistent with a transudate.

Flash Card A1

When a patient complains of chest discomfort or when 1.5L has been removed

Flash Card A2

Proteus. In general, all other complicated parapneumonic effusions will have a low pH.

AMYLASE, CHOLESTEROL, AND TRIGLYCERIDES—See sections on chylothorax, pseudochylothorax, and elevated amylase effusions.

CELL COUNT & DIFFERENTIAL

- In patients with an exudative pleural effusion, the cell count and differential provide diagnostic clues.
- Lymphocytic effusions:
  - Tuberculous pleuritis, post-coronary artery bypass grafting (CABG), rheumatoid arthritis (RA) pleural effusion, yellow nail syndrome, chylothorax (typically > 80% of total nucleated cells)
  - Malignant effusions (typically 50–70% of nucleated cells)
- Eosinophilic effusions > 10% of nucleated cells:
  - Most common: Trauma (pneumothorax, hemothorax, surgery), malignancy
  - Others: Benign asbestos pleural effusion (BAPE), parasitic disease, fungal infection, drug-induced

Key Fact

The most common causes of lymphocytic effusions are tuberculous pleuritis, malignancy, and post-CABG.

Key Fact

Eosinophils in an effusion are nonspecific and usually reflect blood (hemothorax) or air (pneumothorax).

INCIDENCE OF PLEURAL EFFUSION

Approximately 1.5 million pleural effusions are diagnosed in the U.S. each year (Figure 13-3).



Figure 13-3. Annual incidence of pleural effusion in the U.S.

Flash Card Q3

Which pleural effusion most commonly presents with dyspnea out of proportion to pleural effusion size?

Flash Card Q4

A patient with CHF being diuresed has an exudative pleural effusion. What is the best way to evaluate whether this is a false exudate in the setting of diuresis?

TRANSUDATIVE PLEURAL EFFUSIONS

Congestive Heart Failure (CHF)

Key Fact

CHF is the most common cause of a transudative pleural effusion and of pleural effusions in general.

- Due to increased pulmonary capillary pressure
- Diagnosis:
  - Chest x-ray with bilateral pleural effusions, typically with cardiomegaly and pulmonary vascular congestion:
    - Bilateral effusions ~70%
    - Unilateral effusion ~30%, more often seen on the right
  - PF: Transudate with 15–20% presenting as false borderline exudates, often in the setting of diuresis
- Treatment:
  - Optimization of underlying CHF
  - Consider therapeutic thoracentesis if effusion does not respond to optimal diuretic therapy
  - Indwelling pleural catheters (IPCs) or chest-tube pleurodesis may rarely be considered, but only in refractory cases for symptom palliation.

Hepatic Hydrothorax

- Ascites in the chest via diaphragmatic defects driven by pressure gradient from abdomen to pleural space
- Presents with signs and symptoms of cirrhosis and ascites
- Chest x-ray:
  - Unilateral right-sided effusion ~80%
  - Unilateral left-sided effusion ~15%
  - Bilateral effusions rare
- In rare cases, a hydrothorax can exist without ascites due to negative pleural pressures
- Can be superinfected (spontaneous bacterial pleuritis) but often remains transudative
- Treatment:
  - Key to management is optimization of underlying ascites
  - Transjugular intrahepatic portosystemic shunt (TIPS) or liver transplant may be considered in severe refractory cases.
  - Chest-tube drainage is contraindicated and leads to renal failure, protein loss, and cardiovascular collapse.

Flash Card A3

Pleural effusion secondary to CHF

Flash Card A4

Check PF albumin (or protein) gradient

SPONTANEOUS BACTERIAL PLEURITIS

- Diagnosis: Positive PF culture plus neutrophil count > 250 cells/mm^3 **or** > 500 cells/mm^3 with negative PF cultures, in the absence of pneumonia

- Treatment: Treat with antibiotics alone; chest-tube drainage is seldom required.

Nephrotic Syndrome

- Decreased oncotic pressure and increased hydrostatic pressure from salt retention and hypervolemia
- Diagnosis:
  - Chest x-ray typically with bilateral pleural effusions
  - Albumin < 2.0 g/dL in nephrotic syndrome with effusions
- Pulmonary emboli may occur in ~20% of patients with nephrotic syndrome due to acquired protein S deficiency.
- Treatment: Targeted at the underlying protein-losing nephropathy with avoidance of serial thoracenteses to minimize additional protein loss.

Key Fact

PF glucose is elevated and is midway between dialysate and serum values in the setting of an effusion secondary to PD.

Peritoneal Dialysis (PD)

- Movement of fluid through diaphragmatic defects, similar to hepatic hydrothorax
- Most occur within 30 days of initiation of PD, but may occur after > 1 year
- Diagnosis: Chest x-ray with right-sided effusion ~90% of the time
- Treatment: Stop PD for 2–6 weeks; 50% of patients are able to resume PD without recurrence
- Consider pleurodesis or video-assisted thoracoscopic surgery (VATS) to correct diaphragmatic defects and pleurodesis.

Trapped and Entrapped Lung

- Trapped and entrapped lung represent a disease continuum
- Pleural manometry (Figure 13-4):
  - Trapped lung: Abnormally high pleural elastance
  - Entrapped lung: Initial normal elastance that becomes abnormally high as more fluid is removed

ENTRAPPED LUNG—Active inflammation or malignant pleural disease leading to visceral pleural restriction that prevents normal lung expansion.

- May resolve with treatment of the active pleural process.

Flash Card Q5

What is the treatment of choice for spontaneous bacterial pleuritis?

Flash Card Q6

A patient with nephrotic syndrome presents with an exudative pleural effusion. What diagnosis should you suspect?



Figure 13-4. Pleural elastance curves for normal, entrapped, and trapped lungs

Clinical features:

- Typically PF related to the active pleural process is exudative
- Endobronchial lesions leading to obstruction and prevention of lung expansion should be excluded by bronchoscopy if clinically suspected.

Treatment:

- Thoracentesis rarely provides significant symptomatic relief unless there is a significant superimposed process such as a malignant effusion.
- Consider an IPC for patients with malignant effusions who improve symptomatically after a thoracentesis.

TRAPPED LUNG

- Remote pleural inflammatory process
- Irreducible pleural space (Figure 13-5):
  - Fibrous visceral pleural thickening prevents lung re-expansion, leading to a trapped lung
  - Space between visceral and parietal pleura fills with fluid due to an imbalance of hydrostatic pressures.

Flash Card A5

Antibiotics (e.g., cefotaxime), similar to treatment of spontaneous bacterial peritonitis

Clinical features include chronic undiagnosed effusion:

- Can be asymptomatic and diagnosis is often delayed
- Thoracentesis leads to a pneumothorax ex-vacuo due to a lung that does not re-expand, even with chest-tube drainage of the pleural space.
- PF typically transudative or borderline exudative

Flash Card A6

Pulmonary embolus

Causes:

- CABG/cardiac surgery
- Post-cardiac injury syndrome (PCIS)
- Empyema
- Uremic pleuritis
- Hemothorax
- Rheumatoid pleuritis
- Tuberculous pleuritis

Treatment:

- Avoid unnecessary thoracic surgery or repeated thoracenteses.
- Consideration for surgery (decortication) only if dyspnea clearly is due to trapped lung

Figure 13-5. Chest computed tomography (CT) demonstrates large right-sided hydropneumothorax with underlying visceral and parietal pleural thickening and fibrosis (trapped lung).
(Reproduced from Kim YS, Susanto I, Lazar C, et al. Pneumothorax Ex-vacuo or "trapped lung" in the setting of hepatic hydrothorax. *BMC Pulm Med.* 2012, 12:78. Fig 2. doi:10.1186/1471-2466-12-78. CC-BY-NC 3.0.)

Key Fact

A CT scan after thoracentesis showing incomplete lung re-expansion with a thickened visceral pleura suggests either a trapped or an entrapped lung. Chest-tube placement in this scenario is unlikely to lead to lung re-expansion.

Others (Rare)

URINOTHORAX—Presence of urine in the pleural space.

- Due to an obstructive uropathy
- Pleural creatinine: Serum creatinine ratio > 1
- Treatment involves relieving the obstruction

Key Fact

Urinothorax is the only cause of a low pH transudative pleural effusion.

DUROPLEURAL FISTULA/SUBARACHNOID PLEURAL FISTULA—
Cerebrospinal fluid (CSF) leak from the subarachnoid space to the pleural space.

- Positive pressure of the subarachnoid space drives fluid to lower pressure pleural space
- Mostly due to blunt or penetrating trauma or thoracic spinal surgery
- Clear-looking pleural fluid with protein < 1 g/dL
- Detection of pleural fluid beta-2 transferrin level is a specific and sensitive marker to identify CSF leak
- No strong consensus for treatment

HYPOALBUMINEMIA—Decreased oncotic pressure of the blood with increased rate of PF formation, but unclear how frequently hypoalbuminemia truly causes pleural effusions (likely only in severe hypoalbuminemia).

EXUDATIVE PLEURAL EFFUSION

Parapneumonic Effusion and Empyema

Key Fact

Parapneumonic effusion is the most common cause of exudative pleural effusion in the U.S.

PARAPNEUMONIC EFFUSION—Any pleural effusion associated with bacterial pneumonia, lung abscess, or bronchiectasis.

EMPYEMA—An infected pleural space with either pus or thick purulent appearing pleural fluid upon drainage.

Table 13-3 compares parapneumonic effusion and empyema.

Table 13-3. Stages of Parapneumonic Effusion and Empyema

	Simple Parapneumonic Effusion	Complicated Parapneumonic Effusion	Empyema
Stage	Exudative	Fibrinopurulent	Organizing
Appearance	Clear or slightly turbid	Usually cloudy	Pus
pH	≥ 7.20	< 7.20	Usually not measured
Glucose	≥ 60 mg/dL	< 60 mg/dL	Usually not measured
LDH	≤ 1000 U/L	> 1000 U/L	Usually not measured
Gram Stain/ Culture	Negative	May be positive	May be positive
Imaging	Small-to-moderate effusion (> 10 mm thickness but < half the size of the hemithorax) Free-flowing effusion	Effusion occupies > half of the hemithorax Loculated effusion Thickened pleural membrane	Loculated effusion Thickened pleural membrane

LDH, lactate dehydrogenase

Key Fact

MIST-1 study = intrapleural tPA vs. placebo in treatment of empyema with no benefits noted.

MICROBIOLOGY—Community-acquired and hospital-acquired pleural infections exhibit different microbiologic patterns.

- Community-acquired → predominantly *Streptococcus* (50%), anaerobes (20%), and *Staphylococcus* (10%)
- Hospital-acquired → predominantly methicillin-resistant *Staphylococcus aureus* (MRSA) (25%) and gram-negative anaerobes (20%)
- Higher mortality rate with hospital-acquired parapneumonic effusion or empyema

Key Fact

MIST-2 study = intrapleural tPA + DNase superior to either agent alone in treatment of empyema in terms of improved fluid drainage, reduced frequency of surgical referral, and reduced duration of hospital stay.

TREATMENT

- Empiric antibiotics tailored by microbiology, community- vs. hospital-acquired
- Therapeutic thoracentesis
- Chest tube, with current trend toward smaller-bore tubes (10–14 French catheter) for complicated parapneumonic effusions and empyemas
- Consider intrapleural tissue plasminogen activator (tPA) + deoxyribonuclease (DNase) (Multicenter Intrapleural Sepsis Trial [MIST]-2)
- Surgical consultation if persistent sepsis and/or residual pleural collection despite drainage and antibiotics

Flash Card Q7

What are the indications for chest-tube drainage of a parapneumonic effusion?

Pleural Effusion Due to Malignancy

Key Fact

Malignant pleural effusions are the second leading cause of exudative effusions next to parapneumonic effusions.

Figure 13-6 shows the origin of metastatic malignant pleural effusions.

- Dyspnea is the most common symptom
- Most common cause of a massive effusion and a bloody effusion
- Diagnosed by demonstrating malignant cells via PF cytology or pleural biopsy

Key Fact

A new unilateral left-sided pleural effusion in the absence of active infectious symptoms should be considered a malignant pleural effusion until proven otherwise.

TREATMENT (Figure 13-7)

- Observation, if asymptomatic
- Therapeutic thoracenteses
- Chemical pleurodesis with talc using a small-bore chest tube
- Chronic IPC
- VATS with mechanical pleurodesis (pleural abrasion) and/or chemical pleurodesis (talc poudrage)
- Parietal pleurectomy ± decortication
- Pleuroperitoneal shunt (rarely performed)

Key Fact

Talc is the most effective agent for chest-tube pleurodesis.



Figure 13-6. Origin of metastatic malignant pleural effusions.

Flash Card A7

Frankly purulent or turbid/cloudy PF, pH < 7.2, positive Gram stain or culture



Figure 13-7. Management of malignant pleural effusion based on British Thoracic Society 2010 Guidelines.

Pleural Effusion Due to Malignant Mesothelioma

CLINICAL FEATURES

- Pathophysiology related to asbestos exposure
- Chest x-ray: moderate-to-large unilateral pleural effusion or unilateral pleural thickening

Key Fact

Therapeutic Intervention in Malignant Effusion (TIME)-2 Study = IPC vs. chest-tube pleurodesis in management of malignant pleural effusion → no difference in dyspnea at 6 weeks but shorter length of initial hospitalization and less dyspnea at 6 months in IPC group.

PLEURAL FLUID

- PF markers: Exact role of PF and serum markers remain undetermined
  - Soluble mesothelin–related peptide, osteopontin, megakaryocyte potentiating factor
- Cytology yield is generally poor
- Immunohistochemistry with calretinin and cytokeratin favors mesothelioma over adenocarcinoma
- Tissue sampling needed (gold standard)

TREATMENT—Refer to specialized center.

- Best therapeutic approach remains undefined
- Surgery, radiation, chemotherapy, and combination therapies are reported
- For the palliative management of the recurrent pleural effusion, options include thoracenteses, IPC, pleurodesis, or VATS pleurectomy.

Pulmonary Embolism

- 20–50% of patients with pulmonary embolism have an associated pleural effusion
- Related to increased pulmonary capillary permeability
- Effusions usually small and almost always exudative
- Management is treatment of the underlying pulmonary embolism

Key Fact

Presence of a bloody pleural effusion is not a contraindication to the usual management of pulmonary embolism (anticoagulation and/or thrombolytics when indicated).

Pleural Effusion Secondary to Cardiovascular Surgery or Injury

Table 13-4 compares pleural effusions secondary to post-coronary artery bypass graft (CABG) and post-cardiac injury syndrome (PCIS).

Key Fact

Dressler syndrome is a secondary form of pericarditis that occurs after myocardial or pericardial injury and consists of the triad of fever, pleuritis, and pericarditis.

Table 13-4. Post-CABG vs. PCIS

Characteristics	Post-CABG	PCIS[a]
Clinical	Dyspnea	Fever, pleuritic chest pain, pericardial rub
Pathogenesis	Early[b]: due to surgical trauma Late[c]: Unknown	Myocardial or pericardial injury
Imaging	Mostly small unilateral left-sided pleural effusions, ~10% with large effusions	Small effusion, unilateral or bilateral Parenchymal infiltrate
Appearance	Early[b]: bloody Late[c]: clear yellow	Bloody or serosanguineous

Table 13-4. Post-CABG vs. PCIS, continued

Characteristics	Post-CABG	PCIS[a]
Cell count differential	Early[b]: Neutrophilic or eosinophilic Late[c]: Lymphocytic	PMNs or mononuclear cells
pH and glucose	Normal	Normal
Antimyocardial antibody	Absent	High titer
Treatment	Serial thoracentesis	NSAIDs or corticosteroids Colchicine effective in prevention

CABG, coronary artery bypass grafting; NSAIDs, nonsteroidal anti-inflammatory drugs; PCIS, post-cardiac injury syndrome; PMNs, polymorphonuclear neutrophils
[a]PCIS can occur after myocardial infarction, after cardiac surgery, or after trauma
[b]Early post-CABG < 30 days
[c]Late post-CABG > 30 days

Tuberculous Pleuritis

CLINICAL FEATURES

- Due to primary disease (rupture of a parenchymal subpleural caseous focus into the pleural space) or reactivation tuberculosis (TB)
- Primary disease mostly in younger patients, whereas reactivation occurs in older patients
- Mostly present with dry cough, pleuritic chest pain, and fever

PLEURAL FLUID

- PF characteristics: Exudative, low glucose, lymphocytic predominant (though neutrophil predominant ~10% of the time), mesothelial cells < 5%
- Neutrophilic predominant tuberculous pleural effusion: Shorter duration of symptoms and higher adenosine deaminase (ADA) and LDH compared to lymphocytic predominant effusion
- Unilateral, usually small-to-moderate effusion
- Pleural fluid markers: ADA, interferon gamma release assay, polymerase chain reaction, nucleic acid amplification
- Demonstration of an elevated PF ADA level is useful in establishing the diagnosis of tuberculous pleuritis; both sensitivity and specificity ~90%
- Pleural fluid acid-fast bacilli (AFB) smears usually negative unless HIV positive, tuberculous empyema, or neutrophilic predominant
- HIV test should be obtained in all patients with tuberculous pleuritis
- Diagnostic yield approaches 90-100% with pleural biopsy, either closed or via thoracoscopy

TREATMENT—Same as for pulmonary TB, with thoracentesis as needed for symptoms.

Key Fact

Pleural fluid from patients with TB rarely contains >5% mesothelial cells and would strongly argue against tuberculous pleuritis if present.

Key Fact

PF cultures positive in < 40% of patients with tuberculous pleuritis.

Key Fact

Two main diseases other than tuberculous pleuritis that are associated with a high PF ADA are empyema and rheumatoid pleuritis.

Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)

Table 13-5 compares rheumatoid pleural effusion and SLE pleuritis.

Table 13-5. Rheumatoid Pleural Effusion and SLE Pleuritis

Characteristic	RA	SLE
Clinical	Classically in older male patients with RA and subcutaneous nodules Arthritis precedes pleural effusion	Predominantly female in any age group with SLE Pleuritic chest pain, pleural rub, fever, cough, dyspnea
PF	Low glucose (< 40 mg/dL) Low pH (< 7.20) High LDH (> 700 IU/L or 2X upper normal limit) High rheumatoid factor titer (> 1:320)	Glucose > 60 mg/dL pH > 7.35 LDH < 500 IU/L or < 2X upper normal limit Elevated PF ANA (but neither sensitive nor specific for diagnosis)
Chest radiograph	Unilateral, small-to-moderate pleural effusion occupying < 50% of the hemithorax ~25% bilateral effusions	Predominantly small effusions ~50% bilateral effusions
Treatment	Treatment of underlying RA; otherwise non-specific	NSAIDs, steroids

ANA, antinuclear antibodies; LDH, lactate dehydrogenase; NSAIDs, nonsteroidal anti-inflammatory drugs; PF, pleural fluid; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus

Key Fact

The most striking characteristics of the rheumatoid pleural effusion are its low glucose and low pH, helping distinguish it from lupus pleuritis.

Hemothorax

Hemothorax is defined as a bloody effusion with a PF hematocrit of at least 50% of the peripheral blood hematocrit.

TRAUMATIC HEMOTHORAX—Arises predominantly from penetrating or blunt trauma, or can be iatrogenic (i.e., after thoracentesis).

SPONTANEOUS HEMOTHORAX—Relatively uncommon.

TREATMENT—Both are managed with large-bore chest-tube drainage with surgical intervention for severe cases.

Chylothorax and Pseudochylothorax (Cholesterol Effusion)

Table 13-6 differentiates chylothorax from pseudochylothorax (cholesterol effusion).

Table 13-6. Chylothorax vs. Pseudochylothorax

Characteristic	Chylothorax	Cholesterol Effusion/ Pseudochylothorax
Pathogenesis	Lymph fluid accumulates in pleural space due to disruption or obstruction of the thoracic duct	PF contains a high concentration of cholesterol
PF appearance	Milky or opalescent	Milky or opalescent
PF values	Triglyceride > 110 mg/dL Chylomicron-positive even if triglyceride < 110 mg/dL Cholesterol < 220 mg/dL	Cholesterol > 220 mg/dL No chylomicrons
Diagnosis	Look for underlying cause: traumatic (iatrogenic) vs. nontraumatic (rule out malignancy)	Most common etiologies are chronic tuberculous effusion and chronic rheumatoid pleural effusion
Treatment	Address underlying cause Trial of dietary measures in nontraumatic, nonmalignant chylothoraces (high-protein, low-fat diet supplemented with medium-chain triglycerides)	Observation

PF, pleural fluid

Elevated Amylase Effusions

- Acute pancreatitis
- Chronic pancreatitis
- Esophageal rupture
- Malignancy

Key Fact

Effusions secondary to pancreatitis are typically left-sided.

Miscellaneous

BAPE—See Pleural Asbestosis section below.

YELLOW NAIL SYNDROME—Triad of yellow and thickened nails, lymphedema, and pleural effusion. Treatment is primarily supportive.

DRUG-INDUCED—Drugs convincingly incriminated in the development of pleural disease include nitrofurantoin, dantrolene, ergot alkaloids, amiodarone, interleukin-2, procarbazine, methotrexate, and clozapine.

OVARIAN HYPERSTIMULATION SYNDROME (OHS)—Pleural effusions may occur as part of OHS, which is the result of the use of human chorionic gonadotropin hormone for fertility purposes. Treatment is primarily supportive.

MEIGS SYNDROME—Characterized by the presence of ascites and pleural effusions in patients with benign solid ovarian tumors. Ascites and pleural effusions resolve on removal of the ovarian tumor.

ENDOMETRIOSIS—Severe endometriosis can be complicated by massive ascites and pleural effusion.

PLEURAL ASBESTOSIS

BENIGN ASBESTOS PLEURAL EFFUSION (BAPE)

Key Fact

BAPE is typically the first manifestation of asbestos-related disease that occurs after exposure.

- Latency from asbestos exposure to BAPE typically is 15–20 years
- Involves visceral and parietal pleura
- Presentation: Often asymptomatic but can present with pleuritic chest pain, fever, dyspnea
- Variable clinical course:
  - Resolution (rare)
  - Blunted costophrenic angle (most common)
  - Rounded atelectasis
  - Diffuse pleural thickening
- PF: Unilateral, exudative, 1/3 eosinophilic, > 1/2 bloody
- Diagnosis: Exposure history, exclusion of other causes
- Must exclude malignancy and may require VATS for pleural biopsy

Key Fact

BAPE has no clear prognostic implications for the development of pleural plaques or malignancy.

ASBESTOS-INDUCED PLEURAL PLAQUES

- Latency: > 20 years
- High prevalence (>25%) in occupationally exposed workers (e.g., shipyard workers)
- Discrete collagenous material along parietal pleura of the middle-lower ribs and diaphragm
- Plaques serve as a marker of asbestos exposure
- Incidental finding on routine chest radiograph or chest CT (Figure 13-8) with minimal clinical consequence; pulmonary function tests often normal
- Calcify over time, typically > 30 years



Figure 13-8. Chest CT demonstrating circumscribed and calcified, bilateral pleural plaques.
(Reproduced from Miles SE, Sandrini A, Johnson AR, et al. Yates DH. Clinical consequences of asbestos-related diffuse pleural thickening: A review. *J Occup Med Toxicol.*2008, 3:20. Fig..4 doi: 10.1186/1745-6673-3-20. CC BY 2.0)

Key Fact

Pleural plaques serve as a marker of asbestos exposure

ROUNDED ATELECTASIS

- Distinctive comet-tail sign pointing toward the hilum on chest CT scan (Figure 13-9)
- Pleural-based mass that can appear similar to bronchogenic carcinoma
  - Distinguished by asbestos exposure history, stability of the lesion in a 2- to 3-year period, and comet-tail sign
- With progression, pleural fibrosis can trap underlying lung



Figure 13-9. CT scan of the chest demonstrates rounded atelectasis with comet-tail sign (*thick arrows*).
(Reproduced from Anevlavis S, Bouros D. Images in Pneumonology. *PNEUMON* 2013, 26(3):276. Fig 4. CC BY 2.0)

PLEURAL OTHER

PLEURAL IMAGING

Chest Radiography

- First radiographic test for patients with suspected pleural effusion. Different views are able to visualize varying amounts of fluid:
  - Lateral decubitus film, 5–10 mL fluid
  - Lateral film shows blunting of costophrenic sulcus, 25–50 mL fluid
  - Upright posteroanterior film, > 200 mL fluid

Ultrasonography

Figure 13-10 demonstrates ultrasonography of pleural effusion with landmarks.

Detection of pneumothorax:

- Normal lung:
  - Lung sliding on two-dimensional (2-D) mode
  - M-mode demonstrates the seashore sign —motionless portion above the pleural line creating horizontal waves and sliding below it creates granular sand pattern (Figure 13-11A)
- Pneumothorax:
  - Absence of lung sliding on 2-D mode
  - M-mode demonstrates the stratosphere sign—parallel horizontal lines above and below the pleural line resembling a barcode (Figure 13-11B)



Figure 13-10. Ultrasound image of pleural effusion (*red arrows*) and lung (*yellow arrow*).
(Reproduced from Bostantzoglou C, Moschos C, Introduction to transthoracic ultrasound for the pulmonologist. *PNEUMON* 2013, 26(3):223-228. Fig 4. CC BY 2.0)

Flash Card Q8

What are the signs of a pneumothorax on ultrasound?



Figure 13-11. Ultrasonography with M-mode of (A) normal lung and (B) pneumothorax.
(Image courtesy of Dr. Jeffrey Albores, UCLA Division of Pulmonary and Critical Care Medicine)

Chest Computed Tomography (CT)

- Angle—parenchymal vs. pleural:
  - Acute angle suggests parenchymal lesion
  - Obtuse angle suggests pleural process
- Parietal pleural enhancement in empyema or complicated parapneumonic effusion (visualized with intravenous contrast)
- Split-pleura sign of thickened parietal and visceral pleura separated by PF is valuable in differentiating diagnosis of pleural rather than parenchymal disease
- Lung abscess vs. empyema with air-fluid level
- Figure 13-12 demonstrates characteristic features of lung abscess and empyema.

Flash Card A8

Absence of lung sliding on 2-D mode and presence of stratosphere or barcode sign on M-mode



Figure 13-12. Chest radiograph and chest CT demonstrate lung abscess and pleural empyema: top chest CT shows large lung abscess in right upper lobe with relatively thick wall; notice acute angle that abscess makes with posterior chest wall; bottom chest CT shows pleural empyema with enhancement of both visceral and parietal pleura, sign of pleural inflammation that occurs with empyema (split-pleura sign); notice obtuse angle that effusion makes with posterior chest wall.
(Image reproduced from Huang HC, Chen HC, Fang HY, et al. Lung abscess predicts the surgical outcome in patients with pleural empyema. *J Cardiothorac Surg.* 2010 Oct 20;5:88. doi: 10.1186/1749-8090-5-88. Fig. 2. CC BY 2.0)

Magnetic Resonance Imaging and Positron Emission Tomography

Limited value for both in pleural disease.

INVASIVE PLEURAL TESTS

Pleural Biopsy

In a large number of patients, blind pleural biopsies do not provide a definitive diagnosis for pleural pathology.

Thoracoscopy

- Invasive diagnostic test of choice
- Indications: Diagnosis of recurrent or refractory exudative pleural effusions, pleural-based tumors, and pleural thickening
- Advantages: Ease of procedure, high diagnostic accuracy, low cost, and excellent safety record
- Low complication rates, but can include chest wall pain, subcutaneous emphysema, local wound infection, empyema
- Only absolute contraindication is lack of pleural space due to severe and dense pleural adhesions

PNEUMOTHORAX

Pneumothorax is air within the pleural space.

PNEUMOTHORAX CLASSIFICATION

See Figure 13-13 for pneumothorax classification.



Figure 13-13. Pneumothorax classification.

SPONTANEOUS PNEUMOTHORAX

Spontaneous pneumothorax occurs without preceding trauma or an obvious underlying precipitating cause or event.

Classification of Spontaneous Pneumothorax

Diagnosis requires suspicion and confirmation with imaging such as chest radiograph and ultrasonography (emerging role).

PRIMARY SPONTANEOUS PNEUMOTHORAX (PSP)—Occurs in patients without clinically obvious lung disease.

- Risk factors include smoking and ectomorphic body type (tall and thin)
- Male > female

SECONDARY SPONTANEOUS PNEUMOTHORAX (SSP)—Occurs in patients with underlying lung disease.

- Chronic obstructive pulmonary disease most common underlying lung disease but also can see in AIDS or HIV, particularly associated with *Pneumocystis* pneumonia
- Dyspnea more dramatic in SSP compared to PSP due to underlying lung disease
- Mortality greater in SSP compared to PSP

Recurrence Rates in Spontaneous Pneumothorax

Recurrence rates in spontaneous pneumothorax will impact treatment selection.

- ~30% in PSP and ~40% in SSP
- Most recurrences for both PSP and SSP occur in the first 6 months

Management of Spontaneous Pneumothorax

- Treatment options in initial spontaneous pneumothorax include observation or small-bore chest-tube (< 10 French) placement.
- Supplemental oxygen increases the pleural air reabsorption rate.
- Management strategy is based more on the patient's clinical status than the size of the pneumothorax.

Flash Card Q9

When should recurrence prevention be offered for spontaneous pneumothorax?

- Regarding recurrence prevention, the American College of Chest Physicians (ACCP) guidelines propose offering prevention at the time of the second occurrence of a PSP and at the first occurrence of an SSP.
  - When considering recurrence prevention, surgical options are more effective than chemical pleurodesis.
- British Thoracic Society (BTS) guidelines define a large pneumothorax as one with a > 2-cm distance from the visceral to the parietal pleural surface at the level of the hilum (Figure 13-14).

Key Fact

Surgical options are more effective than chemical pleurodesis in pneumothorax recurrence prevention.



Figure 13-14. Measuring the size of a pneumothorax. A=apex to cupola distance per ACCP guidelines. B=interpleural distance at level of the hilum per BTS guidelines.

TRAUMATIC PNEUMOTHORAX

Traumatic pneumothorax results from direct or indirect trauma to the chest, including diagnostic or therapeutic procedures.

Flash Card A9

At the time of the second occurrence of a PSP or the first occurrence of a SSP

Iatrogenic Pneumothorax

Iatrogenic pneumothorax is a traumatic pneumothorax that occurs due to medical interventions (Figure 13-15).



Figure 13-15. Common causes of iatrogenic pneumothorax.

TREATMENT

- Observation may be reasonable in an asymptomatic and stable patient
- Small-bore chest-tube placement if symptoms or if expanding/sizeable pneumothorax; also consider in patients with underlying emphysema who develop a pneumothorax after transthoracic needle aspiration
- Consider bronchopleural fistula in the setting of positive-pressure ventilation

Noniatrogenic Traumatic Pneumothorax

Occurs with trauma such as penetrating or blunt injuries.

TENSION PNEUMOTHORAX

A medical emergency (Figure 13-16).

DIAGNOSIS

- Clinical diagnosis suspected in patients with rapid clinical deterioration, on mechanical ventilation, or who have undergone a procedure known to cause a pneumothorax
- Physical findings are those of any large pneumothorax; additional findings include enlargement of the involved hemithorax relative to the contralateral hemithorax with widened costal interspaces, and contralateral tracheal deviation
- Valuable time should not be wasted on radiologic studies, as the clinical situation and physical findings are often sufficient to establish the diagnosis.

Key Fact

Tension pneumothorax is a medical emergency and urgent needle decompression, or chest tube placement, should not be delayed when the diagnosis is suspected.

TREATMENT—When diagnosis is suspected, perform urgent needle decompression or chest-tube placement.

Figure 13-16. Tension pneumothorax with marked leftward deviation of the trachea, heart, and mediastinum
(Reproduced from Pourmand A, Shokoohi H. Tension Pneumothorax, Pneumoperitoneum, and Cervical Emphysema following a Diagnostic Colonoscopy. *Case Reports in Emergency Medicine*, vol. 2013, Article ID 583287, 2013. doi:10.1155/2013/583287. CC BY 3.0)

ABOUT THE EDITORS

Tao Le, MD, MHS

Dr. Le developed a passion for medical education as a medical student. He currently edits more than 15 titles in the *First Aid* series. In addition, he is the founder of the USMLE-Rx online video and test bank series as well as a cofounder of the *Underground Clinical Vignettes* series. As a medical student, he was editor-in-chief of the University of California, San Francisco (UCSF) Synapse, a university newspaper with a weekly circulation of 9000. Dr. Le earned his medical degree from UCSF in 1996 and completed his residency training in internal medicine at Yale University and fellowship training at Johns Hopkins University. At Yale, he was a regular guest lecturer on the USMLE review courses and an adviser to the Yale University School of Medicine curriculum committee. Dr. Le subsequently went on to cofound Medsn, a medical education technology venture, and served as its chief medical officer. He currently has an interest in medical education and education research at the University of Louisville.

Sandeep Khosa, MD

Dr. Khosa has a love for pulmonary physiology and medical education, receiving numerous teaching awards throughout his training. He is a graduate of Saba University School of Medicine, Netherlands, and completed his Internal Medicine Residency and Chief Residency at Case Western Reserve University (MetroHealth) program. He went on to complete his Fellowship in Pulmonary and Critical Care Medicine at MetroHealth, and currently serves as a Consultant for Pulmonology and Intensive Care at the Mayo Clinic Health System in Mankato, Minnesota. Dr. Khosa has a special interest in Critical Care Ultrasonography and has served as faculty lecturer and instructor for courses at the American College of Chest Physicians, Case Western Reserve University (MetroHealth), and Cleveland Clinic. In addition, Dr Khosa has served as a contributing editor to online resources for quality improvement designed for healthcare professionals.

Susan Pasnick, MD

Dr. Pasnick earned her medical degree at Northwestern University's Feinberg School of Medicine and completed her residency training in internal medicine at Brigham and Women's Hospital in Boston. She recently completed her fellowship in pulmonary and critical care medicine at UCSF. She has a strong commitment to medical education and devoted the research portion of her fellowship to educational scholarship. She is also an alumna of the Harvard Macy Institute Program for Postgraduate Trainees. Particular interests include procedural teaching and the use of novel technologies to streamline and customize content delivery. Dr. Pasnick co-directs the critical care ultrasound course at UCSF and continues her work in postgraduate medical education through the American Thoracic Society.

Tisha Wang, MD

Dr. Wang has a longstanding interest in medical education and board review, and contributed to the *Underground Clinical Vignettes* series while going to medical school in Texas. She earned her medical degree at UTMB Galveston in 2002, and completed her residency training in internal medicine and fellowship training in pulmonary and critical care at UCLA. Dr. Wang is board certified in internal medicine, pulmonary, critical care, and sleep medicine, and has taken a number of leadership roles since joining the UCLA faculty in 2008 as a clinician educator. In 2011, she became program director of a growing pulmonary and critical care fellowship program and was instrumental in the creation of a successful clinician educator track within the training program. In addition, she is director of the liver transplant intensive care unit at UCLA and as of 2014, Dr. Wang was appointed as the Associate Chief of

Inpatient Services for the UCLA Division of Pulmonary, Critical Care, and Sleep Medicine. She regularly publishes review articles, case reports/series, and book chapters and is actively involved in medical education through the American Thoracic Society.